<SEC-DOCUMENT>0001628280-22-012463.txt : 20220506
<SEC-HEADER>0001628280-22-012463.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220505092735
ACCESSION NUMBER:		0001628280-22-012463
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		83
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220505
DATE AS OF CHANGE:		20220505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CROSS COUNTRY HEALTHCARE INC
		CENTRAL INDEX KEY:			0001141103
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HELP SUPPLY SERVICES [7363]
		IRS NUMBER:				134066229
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-33169
		FILM NUMBER:		22894527

	BUSINESS ADDRESS:	
		STREET 1:		6551 PARK OF COMMERCE BOULEVARD, N.W.
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		8003472264

	MAIL ADDRESS:	
		STREET 1:		6551 PARK OF COMMERCE BOULEVARD, N.W.
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROSS COUNTRY INC
		DATE OF NAME CHANGE:	20010521
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ccrn-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:bf6b0e24-63a4-4887-ba98-a744ebcd1084,g:9e05db7a-6f27-4cf3-b67e-d2d201684423,d:1bf462dbbc134b239a7746fda9801e04--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ccrn="http://www.crosscountryhealthcare.com/20220331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ccrn-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80L2ZyYWc6MDNkNGY4YjEyMjFiNGM2NDkyYmNiMDJmNzcyYmRmMDAvdGFibGU6YWFiY2NiMDI2N2U1NGM1YjgyYjA3MDkxMjZiYzg5NGYvdGFibGVyYW5nZTphYWJjY2IwMjY3ZTU0YzViODJiMDcwOTEyNmJjODk0Zl8zLTEtMS0xLTI5MTU4_53b31d86-2ae2-429f-8fc6-1c54d368439d">0001141103</ix:nonNumeric><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80L2ZyYWc6MDNkNGY4YjEyMjFiNGM2NDkyYmNiMDJmNzcyYmRmMDAvdGFibGU6YWFiY2NiMDI2N2U1NGM1YjgyYjA3MDkxMjZiYzg5NGYvdGFibGVyYW5nZTphYWJjY2IwMjY3ZTU0YzViODJiMDcwOTEyNmJjODk0Zl80LTEtMS0xLTI5MTU4_e7b182ff-9936-42ce-86bf-605ed527f7f5">12/31</ix:nonNumeric><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80L2ZyYWc6MDNkNGY4YjEyMjFiNGM2NDkyYmNiMDJmNzcyYmRmMDAvdGFibGU6YWFiY2NiMDI2N2U1NGM1YjgyYjA3MDkxMjZiYzg5NGYvdGFibGVyYW5nZTphYWJjY2IwMjY3ZTU0YzViODJiMDcwOTEyNmJjODk0Zl81LTEtMS0xLTI5MTU4_b2ccf1fb-0b97-4f98-ada9-a3442fa565de">2022</ix:nonNumeric><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80L2ZyYWc6MDNkNGY4YjEyMjFiNGM2NDkyYmNiMDJmNzcyYmRmMDAvdGFibGU6YWFiY2NiMDI2N2U1NGM1YjgyYjA3MDkxMjZiYzg5NGYvdGFibGVyYW5nZTphYWJjY2IwMjY3ZTU0YzViODJiMDcwOTEyNmJjODk0Zl82LTEtMS0xLTI5MTU4_661e49fa-52a0-4058-85ba-06aa7830e52f">Q1</ix:nonNumeric><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80L2ZyYWc6MDNkNGY4YjEyMjFiNGM2NDkyYmNiMDJmNzcyYmRmMDAvdGFibGU6YWFiY2NiMDI2N2U1NGM1YjgyYjA3MDkxMjZiYzg5NGYvdGFibGVyYW5nZTphYWJjY2IwMjY3ZTU0YzViODJiMDcwOTEyNmJjODk0Zl83LTEtMS0xLTI5MTU4_fdfd3078-48ca-461d-a73a-debafab65a69">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfNC0wLTEtMS0yOTE1OA_6dda0d30-5890-4c9f-8681-d8b74b39df62">http://fasb.org/us-gaap/2021-01-31#ServiceMember</ix:nonNumeric><ix:nonNumeric contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfNC0wLTEtMS0yOTE1OA_ba26ef12-921a-472b-ab46-50883adf7edb">http://fasb.org/us-gaap/2021-01-31#ServiceMember</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ccrn-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if611e8a760f3465bbf65e189ed94ebea_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i023808945518453896c9849a64047565_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i798e22e9e3a7404081e3a29a885acc05_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fff72e2c7d84067bc8bb587ed543e9d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied70dd28a73c4c189e455c91623e1d44_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa76515236cd482480f6edceb7a94048_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief163b9f5ac240299549314b12d15ebf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d3c21c3ae5d48b38f7e5a3af77e2ef9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i865e8e69b5b142859c5383ff31f2359e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93c333a1a88c41d393ef6f6edbc2458a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad9600f7c5114b968f1ff06bfc50d97e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4839b02de7646be8e2c4ba6e1e37b8d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa8d7b4e22284c6b95ba3cb021a55a3a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d524f09611145fd86df59fb4e37a8e0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7268129d5164471885e991a61169c5cc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i865ee0b793804235a633da41b19d67ff_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88d0c2f866014453b998a2cb5527a438_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0666e2b0300d466098ae349ea4af461e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i424193d374524b0cb3b883919afb98b6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b2ed9790cf643579bf3f5081650b685_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f999eb4ac1c4a3b8709a282faf39953_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17355322df2d4d97a85fd60c4263a2fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06767ccc204342efa16a4ea58b5982f0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9576d1354b14e038a13830965d5d0a2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2985b0df2b8a4b409d8fe07243d00383_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic731257373c0453aa86943e4ce2a621e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f82736797ee4a15bdf1e4bfe3b7c9e0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iace66efe42844004a2c58ff78aba6bfe_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ffb9692d7734ac0865c2244a805f4d7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide49c6639275478fb68a6d4fecf08904_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2e65fe2c72345ff9fa9e61c8de78784_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i123bae647d194e0aa87a3eeb155cbbc1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i123a8da54abc487d9a3a822dee374164_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f916c87f5844845bdfa58e6b0815916_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bc99217a5124b478bddc5a0566fedaf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8cefece24e942d5a8357106949400d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ccrn:ExitCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c1b8bcd9e5449e8becb131e830d5a44_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff6a7e25073a4b0aabe092d1fa279920_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ccrn:ExitCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6122e323ba5148c68be7d2705dc85e93_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa36abaca6d64d6fb19eca4e3d5f6e6c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ccrn:ExitCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31aa1178ab274d94b1a27d7f903f71ad_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c6b46f3057c41ae9eb9f22f1e50b97d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibda3d097b5e34888bd4ce3a4a893ea70_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c44d67d24f445078de88bbafab90724_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i389a47646ea1490cb51a4d0322234613_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i634a7f36c8c948219ef2af135e76fa0f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f67d3164490454dbd2421830ac30a99_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie35cd3b9be00467fbc0b9f82f0c6c7da_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic536f98865ef4aab8fc1a7e5f5e582c9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99d6ce4715d142a8bc5ce8abc5584a20_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i500ea7c7700c49718811026ceaaeafcd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1921e703c434f25a791d61baf58dc3c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i370fcef443ef4801a10e7a73c103bdf9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5392157ee224225b8abb8f26dbf4fd9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide86e9d4790e48b881466a5c8b847256_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad432390898d40dabc7fcb10fd9dd0ae_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddc9cc886ecc4548a8c7f9a14a4fa974_D20211216-20211216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:SelectedIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-16</xbrli:startDate><xbrli:endDate>2021-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d964a81b82746d29b5d9b48e092bd36_I20211216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:SelectedIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99afbe71598e40ef97034d2edf4c411e_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:WorkforceSolutionsGroupIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93a5acd42c2647e59b5add3dd10a6587_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:WorkforceSolutionsGroupIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:WorkforceSolutionsGroupIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d3157fac8554807a3ac2c4583f90eca_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:WorkforceSolutionsGroupIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c6769ab62314e58bd5be4d34d3bb062_I20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:WorkforceSolutionsGroupIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5ac2467fe50486d918b7f212f790165_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:WorkforceSolutionsGroupIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4c754f48f6947ce94f0c29faed347d7_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:MediscanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>ccrn:installment</xbrli:measure></xbrli:unit><xbrli:context id="idb38d75eba334b9c9661cc92d3d27b1e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:MediscanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i693a80db9468442f89e54f2d5e8f012c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:MediscanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc034a2451eb4ad2a115858bbcbb76a3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:MediscanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70a127889d9c4f5facf6c1e12bc5ef60_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:MediscanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic58e2e7af6004065bc3df5d18eda6a7f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ccrn:ShareBasedPaymentAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a13d2d2a7ff4121984d558f70731480_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ccrn:ShareBasedPaymentAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57ab4d2044634d1997af982de4e6ecf0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DatabasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe98f92bed0843dbbed8160370da0659_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DatabasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfe0db93f1004e008d12e054ef21e25c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55a5b324377c46699174b4a56c307cf9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47c182809d2b46f9a875cd3fd058837d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if89026b691fb4fb7b264f411d8d9b428_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24a8be762a2a4907a7c8cca553b30556_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94654808d0da4588b241ae072d795aa4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i010ea7a8f38b4cb2ad448e4252b0d49d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:A2021TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:A2021TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id40b9c2a2b954b16991ea116d1d59043_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5621975f70784aa29783102660abc224_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b7ceee3e87f40c494783ab3badd4980_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18d296e84536494a9f07c3e749a9af7c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82cd05f641874a9cbbe754810cef2c8a_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:A2021TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96ec9493e07f4d46bfd5d30d2e5c107c_I20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:A2021TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib708536e37a243168ff725de39ebb968_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:A2021TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5020fde8638840f299ef873613611b4e_I20211118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:A2021TermLoanCreditAgreementIncrementalTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcf113a7dd6d430ab8a1df6502e3ce9b_I20211118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57d3f89fcaaa4996af9b46ce7ea8742a_D20211118-20211118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:A2021TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-18</xbrli:startDate><xbrli:endDate>2021-11-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5ea6576089f4784ba8f14453a2b1f66_D20191025-20191025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-25</xbrli:startDate><xbrli:endDate>2019-10-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60d48a75f49947d18289dbf4a324b770_I20191025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b3c8d82e07543fc99205a3c46af08b6_I20191025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ccrn:LineOfCreditSublimitAxis">ccrn:SwingLoansSublimitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74307f2549e54ddd9cd8d5738288941a_I20191025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ccrn:LineOfCreditSublimitAxis">ccrn:StandbyLettersOfCreditSublimitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4338d967d578487f9eb052fd67dd54b1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib19eb57fb973471fb2c67e92a4731b51_I20210308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b42bcc4941c443dae883bd802178090_I20211118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i993410e5ec1b472995349d7ec0413a8c_I20220321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia214024d55344795bd46a7a0c209b921_D20220321-20220321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-21</xbrli:startDate><xbrli:endDate>2022-03-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95b50a07ae9e4b7695f586f6672f3956_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0b6e77d084e4d879d689a6bca85f0e4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9559a9dd705841ba838ccd6ba16e3d37_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa90684f57ec460f92896a283e5a90d3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i495fb315b409472492e63b658e2d1f69_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ccrn:DeferredCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie29a28d5bec04a9a89dd3aad07f2f287_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ccrn:DeferredCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14c7086aa5ac419fb6760c4660fcbb9f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ccrn:DeferredCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5ad89b3e2c34d8baa20d7aaa26a7b15_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ccrn:DeferredCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a52a3cb4a2040cb8b1b261cb0ee596b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56ac23aba6aa4403a0bad0cba4ae5902_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bf46906e48741ed893ff4a25259f391_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03cfea49b0a745c8963d38be107a4c1a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bb29dbc47e244bdab628f989817d591_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8bb48f02ecf42d9aeaca2be048ca7f8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70a1b0b08d174a06886a168bcf0b7dbb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1748aed1a144618a97c5849fa459254_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d432683d3b6435ba0c48c4efd028d04_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9729fca27ba4b91a962fe9441fbd9cc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77d0216a9f1b4205af250d1c80679b15_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id44bfe574f91423a9f3987ed1f01a93a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id106177b91204212b84484a1a875400b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:WorkforceSolutionsGroupIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if502c32883544beda4be6398c9526e3e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:WorkforceSolutionsGroupIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0553a10fc40144f8a768aabc88e29e1a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:WorkforceSolutionsGroupIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i887ee4f6baf748d98a8def4c75aea2d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:WorkforceSolutionsGroupIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29edde64b2264b2aa2d76cb1e65aeb1b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:SelectedIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8cf64a57b224d7c87d32895718dc0f5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:SelectedIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39f100435cf24b988a31207c13a30eb4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:SelectedIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae329d6e3c6a4d0d82b7abd882130b4f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:SelectedIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7193b285bbb7464db035176165d555b2_I20200519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ccrn:OmnibusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9be85c5f345e42d68f473356014730e2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ccrn:OmnibusPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95016a76eb2d4e2bb36c7a7aceb60b64_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib59ced0f2c644556a8fe7a1d5d8f161a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia39ce4bfecff4fc1995df5920a618bf6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34b2f55df92d4cbbb60faf19e1ead3be_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1517da25a84b468e8171eb1381c84236_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00fee55829f24128b87768be086342b2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95f14a36e510429b9814bb8e62be49e0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ccrn:OmnibusPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0518a6d4c63940e7a94abc3ec794e0f8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c0d11239d38482d878be193fb27e8f6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if94c5d761a504a69a0f377a89797162b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50316e467cb343f5859c8c6826909b1c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ccrn:MediscanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id23201d22a6f4efdbb89f5ada9e5702d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001141103</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ccrn:MediscanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1bf462dbbc134b239a7746fda9801e04_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzg1_9357359c-c5ac-41d4-8b4d-bc45cc9e0bbe">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzc5_6cdd5c09-d6b0-4ad3-a52f-40b090fc4517">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;Quarterly Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the Quarterly Period Ended <ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl83Mjc1_43e3320b-600f-43ef-979b-5239fa97b960">March 31, 2022</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Or</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzgw_8eb87418-6921-4b8c-870c-d7fbf80e378f">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;Transition Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the Transition Period From</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> _________ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> _________</span></div><div style="text-align:center"><img src="ccrn-20220331_g1.jpg" alt="ccrn-20220331_g1.jpg" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:249px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzgx_10aa0b81-beb3-4b98-8e67-85cd239ddaa0">CROSS COUNTRY HEALTHCARE, INC</ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.064%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.892%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGFibGU6NGEzZDc2NGJkMTU5NDJkMWJjMWZhNTdhZTA2NjcyN2YvdGFibGVyYW5nZTo0YTNkNzY0YmQxNTk0MmQxYmMxZmE1N2FlMDY2NzI3Zl8wLTAtMS0xLTI5MTU4_346f4f84-8950-4c7f-9125-409ce6381ad4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGFibGU6NGEzZDc2NGJkMTU5NDJkMWJjMWZhNTdhZTA2NjcyN2YvdGFibGVyYW5nZTo0YTNkNzY0YmQxNTk0MmQxYmMxZmE1N2FlMDY2NzI3Zl8wLTEtMS0xLTI5MTU4_d691f72a-4dcb-427b-b848-fb02a3113d17">0-33169</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGFibGU6NGEzZDc2NGJkMTU5NDJkMWJjMWZhNTdhZTA2NjcyN2YvdGFibGVyYW5nZTo0YTNkNzY0YmQxNTk0MmQxYmMxZmE1N2FlMDY2NzI3Zl8wLTItMS0xLTI5MTU4_b75c6cb0-3eb3-4e54-b296-e5e83f22b204">13-4066229</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>Incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Commission<br/>file number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzcx_35cd143d-9883-43f4-a184-4e8ee6f725dd">6551 Park of Commerce Boulevard, N.W.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzc0_b8a83857-905f-499b-a250-fb82480e3af6">Boca Raton</ix:nonNumeric>, <ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzc1_4ca1e5c2-6686-4e3e-b8eb-4afae75717e9">Florida</ix:nonNumeric> <ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzg4_13f51a7a-a802-4813-830f-76d37e43f011">33487</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Address of principal executive offices)(Zip Code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzkx_11467b27-b957-4de1-9da5-c00a600e1d96">561</ix:nonNumeric>) <ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzgy_80cb1e8b-7747-493a-915d-a0b537dcb203">998-2232</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.892%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGFibGU6MjdlOTQ0ZDBjMDkyNGZmOWExYzY4ZGViMDRjMjlmZGEvdGFibGVyYW5nZToyN2U5NDRkMGMwOTI0ZmY5YTFjNjhkZWIwNGMyOWZkYV8xLTAtMS0xLTI5MTU4_57611d0d-7f31-4a80-9cd5-294cf5faa608">Common stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGFibGU6MjdlOTQ0ZDBjMDkyNGZmOWExYzY4ZGViMDRjMjlmZGEvdGFibGVyYW5nZToyN2U5NDRkMGMwOTI0ZmY5YTFjNjhkZWIwNGMyOWZkYV8xLTEtMS0xLTI5MTU4_e721cb22-01f3-4d9c-803a-ff10322bf655">CCRN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGFibGU6MjdlOTQ0ZDBjMDkyNGZmOWExYzY4ZGViMDRjMjlmZGEvdGFibGVyYW5nZToyN2U5NDRkMGMwOTI0ZmY5YTFjNjhkZWIwNGMyOWZkYV8xLTItMS0xLTI5MTU4_0f40e6c1-b1a8-4e9d-af59-86519f62b32a">The Nasdaq Stock Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;<ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzky_2d2ca179-5551-4be2-992b-2e8364518bad">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit and post such files).&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzkz_d6f4bc17-2773-4ba3-923e-e403182c84cf">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;No</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of &#8220;accelerated filer and large accelerated filer&#8221; in Rule&#160;12b-2 of the Exchange Act:</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Large&#160;accelerated filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzc2_186f7bec-ccb3-44c4-8f37-6a440b4b56aa">Accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-accelerated&#160;filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744; </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Smaller reporting company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzg5_d1e1b242-d90e-4930-ab28-76dfde1a7815">&#9744;</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzgz_ad6e0743-3464-4b2e-83f3-f5a84bf4bdfe">&#9744;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl80Mzk4MDQ2NTIwNTAz_d6e0707d-9db4-4390-bd98-78af24021eb1">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The registrant had outstandin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">g <ix:nonFraction unitRef="shares" contextRef="if611e8a760f3465bbf65e189ed94ebea_I20220430" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85MzA2_5c9db77d-5767-4992-8ccf-713b6c41d8cc">38,213,868</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> shares of common stock, par value $0.0001 per share, as of April&#160;30, 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1bf462dbbc134b239a7746fda9801e04_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to historical information, this Quarterly Report on Form&#160;10-Q contains statements relating to our future results (including certain projections and business trends) that are &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), and the Private Securities Litigation Reform Act of 1995, and are subject to the &#8220;safe harbor&#8221; created by those sections. Forward-looking statements consist of statements that are predictive in nature, depend upon or refer to future events. Words such as &#8220;expects&#8221;, &#8220;anticipates&#8221;, &#8220;intends&#8221;, &#8220;plans&#8221;, &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;suggests&#8221;, &#8220;appears&#8221;, &#8220;seeks&#8221;, &#8220;will&#8221;, &#8220;could&#8221;, and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results and performance to be materially different from any future results or performance expressed or implied by these forward-looking statements. These factors include, but are not limited to, the following: the potential impacts of the coronavirus pandemic (COVID-19) on our business, financial condition, and results of operations, our ability to attract and retain qualified nurses, physicians and other healthcare personnel, costs and availability of short-term housing for our travel healthcare professionals, demand for the healthcare services we provide, both nationally and in the regions in which we operate, the functioning of our information systems, the effect of cyber security risks and cyber incidents on our business, the effect of existing or future government regulation and federal and state legislative and enforcement initiatives on our business, our clients&#8217; ability to pay us for our services, our ability to successfully implement our acquisition and development strategies, including our ability to successfully integrate acquired businesses and realize synergies from such acquisitions, the effect of liabilities and other claims asserted against us, the effect of competition in the markets we serve, our ability to successfully defend the Company, its subsidiaries, and its officers and directors on the merits of any lawsuit or determine its potential liability, if any, and other factors set forth in Item 1A. &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2021 (2021 Form 10-K), as filed and updated in our Quarterly Reports on Form&#160;10-Q and other filings with the Securities and Exchange Commission (SEC).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management&#8217;s opinions only as of the date of this filing. There can be no assurance that (i)&#160;we have correctly measured or identified all of the factors affecting our business or the extent of these factors&#8217; likely impact, (ii)&#160;the available information with respect to these factors on which such analysis is based is complete or accurate, (iii)&#160;such analysis is correct or (iv)&#160;our strategy, which is based in part on this analysis, will be successful. Except as may be required by law, the Company undertakes no obligation to update or revise forward-looking statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All references to &#8220;the Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, or &#8220;Cross Country&#8221; in this Quarterly Report on Form&#160;10-Q mean Cross Country Healthcare, Inc., and its consolidated subsidiaries.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1bf462dbbc134b239a7746fda9801e04_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CROSS COUNTRY HEALTHCARE, INC.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2022</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PAGE</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_13">PART I. &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_13">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_16">Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_16">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_19">Condensed Consolidated Balance Sheets (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_19">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_22">Condensed Consolidated Statements of Operations (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_22">2</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_28">Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_28">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_31">Condensed Consolidated Statements of Cash Flows (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_31">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_34">Notes to Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_34">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_88">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_88">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_88">20</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_130">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_130">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_130">29</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_133">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_133">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_133">29</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_136">PART II. &#8211; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_136">30</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_139">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_139">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_139">30</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_142">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_142">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_142">30</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Item 6.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_145">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_145">31</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_148">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bf462dbbc134b239a7746fda9801e04_148">32</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i1bf462dbbc134b239a7746fda9801e04_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I.&#160;FINANCIAL INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div id="i1bf462dbbc134b239a7746fda9801e04_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="i1bf462dbbc134b239a7746fda9801e04_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CROSS COUNTRY HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, amounts in thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNC0xLTEtMS0yOTE1OA_794969b6-9dc8-41cf-a607-7c9b01c0dbbd">1,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNC0zLTEtMS0yOTE1OA_b2bcc68b-844c-4256-9f6c-557e78595a9f">1,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net of allowances of $<ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNS0wLTEtMS0yOTE1OC90ZXh0cmVnaW9uOmU3MDQxOGVhYThlNDRkMzU5ZWE0ZTU0MTEzNjQ5NTg0XzQ3_76cebee4-8616-4c12-ae19-6564c242c6e3">9,141</ix:nonFraction> in 2022 and $<ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNS0wLTEtMS0yOTE1OC90ZXh0cmVnaW9uOmU3MDQxOGVhYThlNDRkMzU5ZWE0ZTU0MTEzNjQ5NTg0XzYz_2c785537-2856-44f9-826d-ace102157932">6,881</ix:nonFraction> in 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNS0xLTEtMS0yOTE1OA_891dd19a-27b6-49a8-9bbf-8b4a243859bf">677,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNS0zLTEtMS0yOTE1OA_4d775b85-4bf5-4255-a140-b0ea29e09e2b">493,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNi0xLTEtMS0yOTE1OA_573bb87a-80a2-40f8-908a-e0829582a3de">7,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNi0zLTEtMS0yOTE1OA_805a9d0c-4270-4a53-976b-16ea6bcba95c">7,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance recovery receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:InsuranceSettlementsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNy0xLTEtMS0yOTE1OA_ac703da3-6b76-4f84-ad5e-e172e8a4af4d">5,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:InsuranceSettlementsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNy0zLTEtMS0yOTE1OA_f4510074-a6cc-4fa9-9202-b6efee4f70a8">5,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfOC0xLTEtMS0yOTE1OA_c95c2940-0c7a-4720-9ca8-f45bff5a3aba">641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfOC0zLTEtMS0yOTE1OA_2fc15305-5c6a-443a-832d-36361aab95ae">638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfOS0xLTEtMS0yOTE1OA_e1042c67-02d0-46ee-b975-53da9fe8d7c8">692,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfOS0zLTEtMS0yOTE1OA_755fbfc3-407d-47bc-9ce1-30dc77715ade">508,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTAtMC0xLTEtMjkxNTgvdGV4dHJlZ2lvbjpkZjhkZmI4NTMxZjA0YzZkYjk2ZjFhYTM2YTg4NGMwMV8xNjQ5MjY3NDQxNzU1_014f6a0e-042c-44ab-a147-61a8076b013c">18,092</ix:nonFraction> in 2022 and $<ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTAtMC0xLTEtMjkxNTgvdGV4dHJlZ2lvbjpkZjhkZmI4NTMxZjA0YzZkYjk2ZjFhYTM2YTg4NGMwMV8xNjQ5MjY3NDQxNzUy_a023a5f3-2e87-4005-b8df-914f9701bcbb">17,729</ix:nonFraction>  in 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTAtMS0xLTEtMjkxNTg_37fd1375-ea1b-4cca-8023-87a6a44f9e64">16,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTAtMy0xLTEtMjkxNTg_626fb72a-8bde-4eeb-abdc-e1bb86e9d3f2">15,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTEtMS0xLTEtMjkxNTg_e41d2eb2-c697-4bb6-b5e5-e70efd11003d">5,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTEtMy0xLTEtMjkxNTg_9b2ccf8b-da3d-4721-9c4f-e6daaa263b2a">7,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTItMS0xLTEtMjkxNTg_81a7b4fc-3379-43e5-88e1-e86881864443">119,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTItMy0xLTEtMjkxNTg_854bba10-9f59-4959-8410-7e6d45ba2b39">119,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade names, indefinite-lived</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:IndefiniteLivedTradeNames" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTMtMS0xLTEtMjkxNTg_24dab7ad-fe21-432b-9489-34f85154f627">5,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:IndefiniteLivedTradeNames" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTMtMy0xLTEtMjkxNTg_7d2d3c64-0d09-4d39-be9d-3c39b73c5854">5,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTQtMS0xLTEtMjkxNTg_d1b04310-1273-4608-9ec2-d7a5cf4836a9">40,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTQtMy0xLTEtMjkxNTg_4d635149-a268-4750-bcc5-11381dc3f126">42,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTUtMS0xLTEtMzIxMzI_6c79acfb-3e67-4e88-95a9-87ccb2df8379">9,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTUtMy0xLTEtMzIxMzI_3ad0a21b-ca0d-4164-af4d-a423006c1a58">11,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTUtMS0xLTEtMjkxNTg_be89089c-e92e-49a5-87ca-ce97ec161ef6">26,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTUtMy0xLTEtMjkxNTg_6dcb67f2-5aaf-4016-b4c5-6b91d4408d0d">21,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTYtMS0xLTEtMjkxNTg_858070fc-a507-4f58-b867-708728214496">916,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTYtMy0xLTEtMjkxNTg_3be7d6be-a606-4705-9989-0151e8c339c4">732,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjAtMS0xLTEtMjkxNTg_54cb512a-b6d5-473d-9455-5923ccb6c56a">164,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjAtMy0xLTEtMjkxNTg_0d588d0b-8e65-41e7-af36-251eb40b2370">109,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjEtMS0xLTEtMjkxNTg_de30d4c7-1efe-41f9-853f-4b66b75aa7aa">74,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjEtMy0xLTEtMjkxNTg_0d5f85a2-8546-4bbf-8471-a0ca7cb030d6">65,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjItMS0xLTEtMjkxNTg_cae04602-7c62-4ffa-8a6e-60cef5986955">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjItMy0xLTEtMjkxNTg_9e2b648e-2387-438d-957b-b3b7d7dad65b">4,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjMtMS0xLTEtMjkxNTg_4c10032b-3140-4954-98d4-2c51027dfb5e">4,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjMtMy0xLTEtMjkxNTg_63b18203-e058-4194-9ae7-fb06020483f4">4,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjUtMS0xLTEtMzIxNDM_5c188a2e-6147-4453-ace8-02d6e989b5f9">29,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjUtMy0xLTEtMzIxNDM_5dae2c57-351d-4917-9217-f1c6e1f96afb">7,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of earnout liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjQtMS0xLTEtMjkxNTg_9138c97d-b808-44bd-a1fa-bf824e89dc22">8,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjQtMy0xLTEtMjkxNTg_0fd728ff-6968-42ab-b1c2-a0df7a072c2e">7,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjUtMS0xLTEtMjkxNTg_dec2d693-5486-435e-9fd0-d19a956f36b8">1,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjUtMy0xLTEtMjkxNTg_91f33308-7991-46db-bae7-bff7607a4dcf">1,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjYtMS0xLTEtMjkxNTg_cad3dd81-fa34-4454-af27-9a28a4cf8e28">283,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjYtMy0xLTEtMjkxNTg_d41e6b50-c35c-40c5-9144-8cbd7eee3400">199,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:OtherLongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjctMS0xLTEtMjkxNTg_e62af5e7-29dd-4b4f-af56-5ee5687136c1">218,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:OtherLongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjctMy0xLTEtMjkxNTg_f0ea74f4-3946-4b9e-be3a-de7acb8e49c9">176,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities - non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjgtMS0xLTEtMjkxNTg_a08a5177-14b4-4efb-900c-45fb5f721756">9,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjgtMy0xLTEtMjkxNTg_5fe13b3d-6383-4c49-8565-f5671011e6e8">10,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjktMS0xLTEtMjkxNTg_dbefa421-03f6-45c0-ab12-fc9e44542737">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjktMy0xLTEtMjkxNTg_76d6ce81-ad34-40a6-b88e-63b7b44c769d">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term accrued claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzAtMS0xLTEtMjkxNTg_7075e72f-6417-4f35-9bac-327776a4197c">26,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzAtMy0xLTEtMjkxNTg_f7013942-d793-4253-a5a8-d3e3c9fdbc34">25,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current earnout liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzEtMS0xLTEtMjkxNTg_0cd4dda6-5649-409c-8792-405ceab27cd6">8,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzEtMy0xLTEtMjkxNTg_f3035dba-2392-4db3-9321-3250883946d4">9,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzItMS0xLTEtMjkxNTg_b867e760-646b-4133-8cd1-e3e8f87d9e93">14,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzItMy0xLTEtMjkxNTg_7d2872a7-7a5d-4cc5-a5a2-ecd58470c295">13,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzMtMS0xLTEtMjkxNTg_97041cd6-c14d-46d4-aa3f-79e01eaae9d4">560,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzMtMy0xLTEtMjkxNTg_a0f75c26-0af9-4948-be9c-31e55328e355">435,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzUtMS0xLTEtMjkxNTg_c8354567-fbeb-4cc4-8021-ef05d0818ab8"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzUtMy0xLTEtMjkxNTg_80ca81b3-04a4-4a1a-9e65-68b35c929c3e"></ix:nonFraction></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzgtMS0xLTEtMjkxNTg_7d33a462-2cab-4db1-9e46-592d19ccca30">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzgtMy0xLTEtMjkxNTg_541ffa6e-b465-44a1-884f-0bae570f60da">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzktMS0xLTEtMjkxNTg_479a97b4-bd7e-4315-b573-c53e515d3c21">318,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzktMy0xLTEtMjkxNTg_b19fb58d-99aa-49fc-8a8c-03ffc808f5dd">321,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNDAtMS0xLTEtMjkxNTg_8301d9a7-b948-4087-b5ab-8d92da758be2">1,304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNDAtMy0xLTEtMjkxNTg_f4ce58ae-9ba7-4f8b-8a25-ef817a0db42b">1,293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings (accumulated deficit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNDEtMS0xLTEtMjkxNTg_0ff1e621-2b19-447a-a42b-222b657f6655">39,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNDEtMy0xLTEtMjkxNTg_5e3aa7b4-6269-47a6-b145-19c71a9fa649">22,735</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNDQtMS0xLTEtMjkxNTg_13bf172a-0291-4c31-952d-d75d2be9bc08">356,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNDQtMy0xLTEtMjkxNTg_d1130ba6-2820-4814-a6f8-716bb98e77da">297,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNDUtMS0xLTEtMjkxNTg_9f71fbf7-9768-4d86-9e47-2995365fed4f">916,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNDUtMy0xLTEtMjkxNTg_d3fba70e-808e-49b6-9be6-869e3f137745">732,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                     </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i1bf462dbbc134b239a7746fda9801e04_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CROSS COUNTRY HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, amounts in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.452%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfNC0wLTEtMS0yOTE1OA_6dda0d30-5890-4c9f-8681-d8b74b39df62"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfNC0wLTEtMS0yOTE1OA_ba26ef12-921a-472b-ab46-50883adf7edb">Revenue from services</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfNC0xLTEtMS0yOTE1OA_b68a049e-eb64-42aa-a54d-7409a2cacf6c">788,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfNC0zLTEtMS0yOTE1OA_e22305dd-2a61-473b-a09f-79af41673e1a">329,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:DirectOperatingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfNi0xLTEtMS0yOTE1OA_fe6c2b19-056e-4b50-a561-bc40302000d7">613,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:DirectOperatingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfNi0zLTEtMS0yOTE1OA_4d676f75-f698-4978-8f4e-281ea441a72a">257,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfNy0xLTEtMS0yOTE1OA_b1fb26f6-ff5a-4b7d-983c-f109cd5dfca5">76,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfNy0zLTEtMS0yOTE1OA_1cf05beb-1881-47ab-919d-f19e6d7c1edf">46,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfOC0xLTEtMS0yOTE1OA_fbf859ff-c5c4-4972-baea-9b4d457cba31">2,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfOC0zLTEtMS0yOTE1OA_af99e25d-7e23-4c3f-82ca-51b6ae8ed09c">504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfOS0xLTEtMS0yOTE1OA_de4e9cbc-2759-413a-ac05-5cd2d0886411">2,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfOS0zLTEtMS0yOTE1OA_11c0de07-f4d2-4cc4-9ef7-641fa492de3b">2,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration-related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="ccrn:AcquisitionAndIntegrationRelatedCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTAtMS0xLTEtMjkxNTg_36f4cbf9-ad6e-41fa-8c86-01676e0b0821">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="ccrn:AcquisitionAndIntegrationRelatedCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTAtMy0xLTEtMjkxNTg_37941326-f7dc-496c-afab-eb38ef72afff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTEtMS0xLTEtMjkxNTg_409d9fe3-66e5-4313-b4e0-6bfe42c5e99c">480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTEtMy0xLTEtMjkxNTg_60254c99-2626-4d5e-bf04-e9c403ecd96d">1,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTItMS0xLTEtMjkxNTg_1d0fc2d2-8bc8-461d-8908-bc3dc505cbf2">1,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTItMy0xLTEtMjkxNTg_b1411083-c016-4bf8-9668-597f1ecfea9a">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTMtMS0xLTEtMjkxNTg_0a00b429-5f94-49c8-80e8-99387d18a35a">698,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTMtMy0xLTEtMjkxNTg_3dcf3f7b-6fd4-47ff-bc83-12f459926a94">308,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTQtMS0xLTEtMjkxNTg_302285c3-1e22-48d9-965f-21a99fa50edb">90,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTQtMy0xLTEtMjkxNTg_9fc58c9a-7ba8-4374-bee3-8cc987368438">20,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses (income):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTYtMS0xLTEtMjkxNTg_147b74fb-c920-4205-a08a-8f685b750f7a">3,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTYtMy0xLTEtMjkxNTg_0d852673-bbec-4577-9c4e-363be80b42ba">671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTctMS0xLTEtMjkxNTg_a807185d-fb56-4e50-922f-3eab1a1c0c5c">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTctMy0xLTEtMjkxNTg_990a9cc7-4c3b-4d17-ac94-e48bbc7c57e9">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTgtMS0xLTEtMjkxNTg_7d63e522-9f69-4fd1-baf2-e8a87e5d5b96">87,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTgtMy0xLTEtMjkxNTg_2d8be03c-51f7-48fa-8c22-8407a0232ccd">20,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTktMS0xLTEtMjkxNTg_d204518c-0fc4-4ab7-859d-e7d62bdd8ded">25,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTktMy0xLTEtMjkxNTg_41ce910b-50eb-4637-b619-4647eb5cd384">912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjItMS0xLTEtMjkxNTg_37d00c1d-ae6d-4299-9147-53f285ccbabc">61,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjItMy0xLTEtMjkxNTg_fffa8766-b7fb-49b2-bf0d-6242e5236c1c">19,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized foreign currency translation loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjUtMS0xLTEtMzI3Njg_f0609260-96f4-4496-90ff-5f99d2a252bd">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjUtMy0xLTEtMzI3NjA_c0e9de15-9b35-435e-bb33-9e8012add9b8">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjYtMS0xLTEtMzI3ODA_e4f2d81c-6b93-4427-b468-ac31248b85f6">61,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjYtMy0xLTEtMzI3NzQ_898d1ec4-0cc5-4b76-b4bc-c27d45d64239">19,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to common stockholders - Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjQtMS0xLTEtMjkxNTg_ac2aad56-e2b6-4f42-80a9-93b9f50687e1">1.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjQtMy0xLTEtMjkxNTg_6caa8afd-1883-4acf-a368-7929a8d6f596">0.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to common stockholders - Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjYtMS0xLTEtMjkxNTg_fd85843b-1ed6-4437-a8a4-09f42884024d">1.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjYtMy0xLTEtMjkxNTg_ff72e80c-9a75-45dc-a52e-5c74b90065b2">0.53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjktMS0xLTEtMjkxNTg_c78aab41-3bb6-4a73-be26-c74d9b4e0941">37,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjktMy0xLTEtMjkxNTg_10f88dc3-5903-4235-97a8-e6052488cb8d">36,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMzAtMS0xLTEtMjkxNTg_c4ae6181-c02d-4f44-9b71-6dd1ef05fba7">37,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMzAtMy0xLTEtMjkxNTg_4c247fc0-f27f-4836-84d1-f6e3a0ea3cb8">37,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i1bf462dbbc134b239a7746fda9801e04_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CROSS COUNTRY HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2022 and 2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, amounts in thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Additional<br/>Paid-In Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Accumulated Other <br/>Comprehensive Loss, net</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(Accumulated Deficit) Retained Earnings</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Noncontrolling Interest in Subsidiary</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Stockholders&#8217; Equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Dollars</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balances at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i798e22e9e3a7404081e3a29a885acc05_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMi0xLTEtMS0yOTE1OA_5b376691-5009-4ca0-97b2-4dee5847b226">37,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i798e22e9e3a7404081e3a29a885acc05_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMi0zLTEtMS0yOTE1OA_cec1d3d5-4400-459e-a655-bf314c4935f5">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fff72e2c7d84067bc8bb587ed543e9d_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMi01LTEtMS0yOTE1OA_7b87ed21-96fc-4a19-bb15-159e2676f937">321,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied70dd28a73c4c189e455c91623e1d44_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMi03LTEtMS0yOTE1OA_42dc6aa2-2f6a-4f8d-9134-f0a26ac89347">1,293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa76515236cd482480f6edceb7a94048_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMi05LTEtMS0yOTE1OA_34e82771-49b3-4e32-9da4-af4ce9fd0d12">22,735</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief163b9f5ac240299549314b12d15ebf_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMi0xMS0xLTEtMjkxNTg_d7275fc1-f11c-48db-a7b0-84841b0f11b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMi0xMy0xLTEtMjkxNTg_19e90ca6-ff4d-46d0-aa5e-485ddab2052c">297,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Vesting of restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d3c21c3ae5d48b38f7e5a3af77e2ef9_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMy0xLTEtMS0yOTE1OA_22774c73-474f-4843-8e55-37c46fe06124">419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i865e8e69b5b142859c5383ff31f2359e_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMy01LTEtMS0yOTE1OA_76057cd4-22e5-451c-ba5d-48654b82068b">5,028</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMy0xMy0xLTEtMjkxNTg_1d2aba6c-347b-4ea6-af3b-e81a65d20c97">5,028</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i865e8e69b5b142859c5383ff31f2359e_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfNC01LTEtMS0yOTE1OA_f6e49a78-118a-447d-b343-4434202b6497">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfNC0xMy0xLTEtMjkxNTg_9b6ea6a3-85ff-41d4-a9bf-7967a8126c31">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Foreign currency translation adjustment, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93c333a1a88c41d393ef6f6edbc2458a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfNS03LTEtMS0yOTE1OA_006edf2e-174a-4b4a-ac5d-06702de8c2d3">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfNS0xMy0xLTEtMjkxNTg_39c358c0-aa99-4387-a3bd-7c1c50596843">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad9600f7c5114b968f1ff06bfc50d97e_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfOC05LTEtMS0yOTE1OA_38cbd0be-5612-425a-b042-ac4d7f055d51">61,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfOC0xMy0xLTEtMjkxNTg_71e603d0-966f-4bb9-90cc-293bcc34792a">61,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balances at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4839b02de7646be8e2c4ba6e1e37b8d_I20220331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfOS0xLTEtMS0yOTE1OA_f4e3ca22-7f09-410e-90db-fdbafec5fbad">37,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4839b02de7646be8e2c4ba6e1e37b8d_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfOS0zLTEtMS0yOTE1OA_c23739f2-3578-44d3-8b31-21d4cad07db7">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa8d7b4e22284c6b95ba3cb021a55a3a_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfOS01LTEtMS0yOTE1OA_961e421d-9554-4cf6-9fb8-51247bfb6fd4">318,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d524f09611145fd86df59fb4e37a8e0_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfOS03LTEtMS0yOTE1OA_af5f23bf-133a-4584-9d30-3452a1675d84">1,304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7268129d5164471885e991a61169c5cc_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfOS05LTEtMS0yOTE1OA_77e737fe-97d1-4fd0-8c01-27168e7c8bd0">39,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i865ee0b793804235a633da41b19d67ff_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfOS0xMS0xLTEtMjkxNTg_d2ad1d3f-3921-4ca1-901b-8fb66e1f729d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfOS0xMy0xLTEtMjkxNTg_f7b60c06-73b3-4aa6-8c3c-08738ae8b8e2">356,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Additional<br/>Paid-In Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Accumulated Other <br/>Comprehensive Loss, net</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Noncontrolling Interest in Subsidiary</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Stockholders&#8217; Equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Dollars</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balances at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88d0c2f866014453b998a2cb5527a438_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTMtMS0xLTEtMjkxNTg_f2f8d2c8-8c7a-4dda-9717-ee06d69f443a">36,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88d0c2f866014453b998a2cb5527a438_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTMtMy0xLTEtMjkxNTg_77531302-1ea9-4ea1-8929-9055b0c300e2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0666e2b0300d466098ae349ea4af461e_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTMtNS0xLTEtMjkxNTg_052e5790-0a1b-46f8-81d4-bce8265a5735">310,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i424193d374524b0cb3b883919afb98b6_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTMtNy0xLTEtMjkxNTg_a5abcd34-4627-426f-910c-6e00c6c07d56">1,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b2ed9790cf643579bf3f5081650b685_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTMtOS0xLTEtMjkxNTg_157b08df-2cc7-44f3-b6ea-ac21b5c7061e">154,737</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f999eb4ac1c4a3b8709a282faf39953_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTMtMTEtMS0xLTI5MTU4_e3151e57-983e-451d-8f84-2e2761da70b4">534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17355322df2d4d97a85fd60c4263a2fc_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTMtMTMtMS0xLTI5MTU4_82c0b49c-cf3e-4bba-8149-47f402fbf61a">154,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Vesting of restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06767ccc204342efa16a4ea58b5982f0_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTQtMS0xLTEtMjkxNTg_7bd39d12-95b3-41c5-b53f-497d3076eb88">318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9576d1354b14e038a13830965d5d0a2_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTQtNS0xLTEtMjkxNTg_f4ec7375-3056-4f4a-806a-25e87707078f">2,026</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTQtMTMtMS0xLTI5MTU4_693ba2cd-3465-4031-9645-d5491559a28e">2,026</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9576d1354b14e038a13830965d5d0a2_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTUtNS0xLTEtMjkxNTg_1029367a-5452-4261-901e-ccd0e31e6ac0">1,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTUtMTMtMS0xLTI5MTU4_e3315471-7188-40fc-8216-22ca6e1f4bc1">1,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Foreign currency translation adjustment, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2985b0df2b8a4b409d8fe07243d00383_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTYtNy0xLTEtMjkxNTg_4fa24d48-1ce2-48f3-8327-a002bbd352f6">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTYtMTMtMS0xLTI5MTU4_d3ba781d-7918-40c8-89ce-4ee3d6164b37">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic731257373c0453aa86943e4ce2a621e_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTgtOS0xLTEtMjkxNTg_929bbea4-b2bc-4fee-afde-83bfa9f8a92c">19,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTgtMTMtMS0xLTI5MTU4_c261e007-f0f4-4372-a489-6314de4bc910">19,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balances at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f82736797ee4a15bdf1e4bfe3b7c9e0_I20210331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTktMS0xLTEtMjkxNTg_2202c118-7d5c-4579-9fb8-1c0fe30c621a">36,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f82736797ee4a15bdf1e4bfe3b7c9e0_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTktMy0xLTEtMjkxNTg_e370cd26-4971-45c7-addb-b2b80e54a5a8">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iace66efe42844004a2c58ff78aba6bfe_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTktNS0xLTEtMjkxNTg_ec94bf02-e6f4-4fdb-b9ac-ed84eac54beb">309,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ffb9692d7734ac0865c2244a805f4d7_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTktNy0xLTEtMjkxNTg_9a2a91a2-02fd-4bd3-969c-c57493dc5f54">1,286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide49c6639275478fb68a6d4fecf08904_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTktOS0xLTEtMjkxNTg_eaa5a4d4-da57-41da-bb30-784227bcd40f">135,289</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e65fe2c72345ff9fa9e61c8de78784_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTktMTEtMS0xLTI5MTU4_a264cff1-3cdb-4a89-a3a6-a1e653d4f557">534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i123bae647d194e0aa87a3eeb155cbbc1_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTktMTMtMS0xLTI5MTU4_02a23b69-730c-456f-a6fd-78642b40ab88">173,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i1bf462dbbc134b239a7746fda9801e04_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CROSS COUNTRY HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, amounts in thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfNC0xLTEtMS0yOTE1OA_46f317cb-ee8f-4313-9c62-1d6b6b9c8e28">61,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfNC0zLTEtMS0yOTE1OA_1e86f1a9-9ad9-400b-8615-0885e6a7fdee">19,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfNi0xLTEtMS0yOTE1OA_79d739ec-57f0-4c63-8693-eb1e2d5a912d">2,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfNi0zLTEtMS0yOTE1OA_cd17788c-bbea-4bb3-bb69-3898e0e833a9">2,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="ccrn:ProvisionForDoubtfulAccountsAndOtherAllowances" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfNy0xLTEtMS0yOTE1OA_1832df05-fede-4f10-ab12-5b152f21d975">3,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="ccrn:ProvisionForDoubtfulAccountsAndOtherAllowances" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfNy0zLTEtMS0yOTE1OA_ea562490-bb76-4c43-812e-d2a5638da3ce">1,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfOC0xLTEtMS0yOTE1OA_6892dd66-3a66-446f-95e7-95c1b1ceec0d">2,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfOC0zLTEtMS0yOTE1OA_b630dfab-d626-4b58-bbb4-4ffa63c89d33">266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="ccrn:OperatingLeaseExpenseNonCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfOS0xLTEtMS0yOTE1OA_775bd6a3-0057-4d80-a557-5f32d8e88634">567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="ccrn:OperatingLeaseExpenseNonCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfOS0zLTEtMS0yOTE1OA_211d344e-f629-4c73-af99-fdd2be65cfaa">622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTAtMS0xLTEtMjkxNTg_88b26b9f-a834-4acd-988c-742d77525c59">1,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTAtMy0xLTEtMjkxNTg_5ffdfdd6-e96e-4881-8535-aeabdc0853d3">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTEtMS0xLTEtMjkxNTg_c691d365-8dee-4512-9014-e86f405bcb7e">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTEtMy0xLTEtMjkxNTg_33250f83-d2d4-4dd7-b6f8-6e0e3441d152">1,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:OtherNoncashExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTItMS0xLTEtMjkxNTg_080a889c-bd47-4e3d-a1a5-dc907024f703">446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:OtherNoncashExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTItMy0xLTEtMjkxNTg_93273c53-c556-475f-b884-46d986bf941b">214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTQtMS0xLTEtMjkxNTg_b3daf1fe-90cb-47d5-8588-3b349f3134fb">186,701</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTQtMy0xLTEtMjkxNTg_c0bc1ed3-8f02-4507-8b8e-6706e8bf3a55">76,581</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTUtMS0xLTEtMjkxNTg_10d3328c-7246-408a-a94c-cb7787fc151f">557</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTUtMy0xLTEtMjkxNTg_318f9801-6332-4f33-879e-359c45acb1de">568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTYtMS0xLTEtMzc1NjU_071fe692-6731-41db-a8fe-12d74233266b">22,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTYtMy0xLTEtMzc1NzI_bbd42685-88ae-4d8a-9a33-287daf56b996">617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTYtMS0xLTEtMjkxNTg_56dcd33e-ec27-4cc9-9318-8554fd224d9f">62,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTYtMy0xLTEtMjkxNTg_9f148f0d-74f1-42c3-a043-cc264e0b7b0e">26,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" sign="-" name="ccrn:IncreaseDecreaseInOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTctMS0xLTEtMjkxNTg_6a825cd5-70df-4477-a5a1-251f077c8291">1,273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" sign="-" name="ccrn:IncreaseDecreaseInOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTctMy0xLTEtMjkxNTg_08c3e546-bf2a-4845-9d06-073e062f661e">1,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTgtMS0xLTEtMjkxNTg_b4a22d2a-2a72-4a73-ba2b-1210c9aefd8e">200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTgtMy0xLTEtMjkxNTg_39470ba5-ec55-4a9a-839a-08c1d72deb42">319</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTktMS0xLTEtMjkxNTg_feb015ec-ef62-4a05-9248-8c07cdfefbaf">29,038</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTktMy0xLTEtMjkxNTg_14c560d1-f385-4538-8f35-0a9a0811b471">24,927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMjMtMS0xLTEtMjkxNTg_aeb7e0b5-89ac-4011-b54f-125aa793d041">2,096</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMjMtMy0xLTEtMjkxNTg_bd4bdde6-2198-4fab-9cc9-7c2ae26cad72">1,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMjQtMS0xLTEtMjkxNTg_94d29a12-1372-4c8c-96c4-ce80e26d9881">2,096</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMjQtMy0xLTEtMjkxNTg_e6883498-1693-4386-a647-a3242660a7c5">1,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments on term loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMjgtMS0xLTEtMjkxNTg_48a33f9f-1686-45d9-9548-a74d1e923085">437</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMjgtMy0xLTEtMjkxNTg_9291068d-33bb-4551-b77a-0b10c80e2ee4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMjktMS0xLTEtMjkxNTg_f3c924a2-756d-444e-b859-7066e803c0aa">3,092</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMjktMy0xLTEtMjkxNTg_018ffaef-82c1-4c44-b24d-25a8c7eb5c9b">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings under Senior Secured Asset-Based revolving credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzAtMS0xLTEtMjkxNTg_7b768368-9692-4fe0-b267-11e953ed5b0b">415,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzAtMy0xLTEtMjkxNTg_03b0a398-1c38-42bd-992a-ed7757c06894">148,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments on Senior Secured Asset-Based revolving credit facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzEtMS0xLTEtMjkxNTg_f7ac4429-7090-4b95-bf91-e2f8095b3e49">372,874</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzEtMy0xLTEtMjkxNTg_a9a143d8-c8e3-4e8f-a256-1af4220db07e">105,400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for shares withheld for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzItMS0xLTEtMjkxNTg_c6bb72fb-6c21-49a7-99f6-93d67e85e78a">5,028</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzItMy0xLTEtMjkxNTg_5f227f91-e569-44bb-bf2c-fe5bc00224a0">2,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments on note payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzMtMS0xLTEtMjkxNTg_8f2ba99d-ef30-415e-9ed5-ab89f814b516">2,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzMtMy0xLTEtMjkxNTg_ad75674e-f8eb-4c01-afc8-7f84b79c1ee1">2,425</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzUtMS0xLTEtMjkxNTg_c119e578-d82c-4127-96b7-67bdeab7fbf1">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzUtMy0xLTEtMjkxNTg_df6b44a7-509e-4627-8c0c-305c548d1c1f">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzYtMS0xLTEtMjkxNTg_3d8dafc1-e661-41e5-8af8-9baefcb76e07">31,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzYtMy0xLTEtMjkxNTg_64e2f414-3479-4ec3-a74d-2ed0703cef7f">38,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzgtMS0xLTEtMjkxNTg_8532487e-1c8e-4aca-80e3-4f01458b021f">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzgtMy0xLTEtMjkxNTg_a6c47789-5169-431e-b707-8cf7e21e980f">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzktMS0xLTEtMjkxNTg_9f5fa508-80fe-4704-a087-fd5174c883d3">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzktMy0xLTEtMjkxNTg_7eff9486-2da0-438a-97be-9abaaf56cf20">11,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfNDAtMS0xLTEtMjkxNTg_c8708602-3cf9-4ef0-bd43-e028ab09589a">1,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17355322df2d4d97a85fd60c4263a2fc_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfNDAtMy0xLTEtMjkxNTg_11c92ae3-eff6-450a-919a-5caab6bb6803">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfNDEtMS0xLTEtMjkxNTg_b75c2a03-e781-4c24-8e66-23561aef03f4">1,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i123bae647d194e0aa87a3eeb155cbbc1_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfNDEtMy0xLTEtMjkxNTg_4be730ef-1867-4bd8-958a-0d680399cce3">13,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                      </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i1bf462dbbc134b239a7746fda9801e04_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CROSS COUNTRY HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)</span></div><div style="text-align:justify"><span><br/></span></div><div id="i1bf462dbbc134b239a7746fda9801e04_37"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zNy9mcmFnOmQwYzBmMmRlYjY0ZjRlMGE5ODkwZjdhZDFlOTNjNWRiL3RleHRyZWdpb246ZDBjMGYyZGViNjRmNGUwYTk4OTBmN2FkMWU5M2M1ZGJfMjE1Nw_ebfc4021-8043-411b-bc3a-09838906d39c" continuedAt="i5e069c84afa247fbb4a436ebabd2d119" escape="true">ORGANIZATION AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i5e069c84afa247fbb4a436ebabd2d119"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zNy9mcmFnOmQwYzBmMmRlYjY0ZjRlMGE5ODkwZjdhZDFlOTNjNWRiL3RleHRyZWdpb246ZDBjMGYyZGViNjRmNGUwYTk4OTBmN2FkMWU5M2M1ZGJfMjE0OQ_60e90b93-9c0a-41ca-ac77-1110243d550f" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nature of Business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of Cross Country Healthcare, Inc. and its direct and indirect wholly-owned subsidiaries (collectively, the Company). In the opinion of management, all adjustments necessary for a fair presentation of such unaudited condensed consolidated financial statements have been included. All such adjustments consisted of all normal recurring items, including the elimination of all intercompany transactions and balances.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zNy9mcmFnOmQwYzBmMmRlYjY0ZjRlMGE5ODkwZjdhZDFlOTNjNWRiL3RleHRyZWdpb246ZDBjMGYyZGViNjRmNGUwYTk4OTBmN2FkMWU5M2M1ZGJfMjE0NQ_fc3b3b7b-84d0-48d6-acca-fd94736b2323" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form&#160;10-Q and Article 10 of Regulation&#160;S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These operating results are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2021 included in the Company&#8217;s Annual Report on Form&#160;10-K as filed with the SEC on February 28, 2022 (2021 Form 10-K). The December&#160;31, 2021 condensed consolidated balance sheet included herein was derived from the December&#160;31, 2021 audited consolidated balance sheet included in the 2021 Form&#160;10-K.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to the current year presentation. See the condensed consolidated statements of cash flows.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i1bf462dbbc134b239a7746fda9801e04_40"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfODA3MA_c60afccc-caa7-4d34-ab63-6e7aa6438ecb" continuedAt="id33a5b90dcf24b668dc42dcba8a7024a" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="id33a5b90dcf24b668dc42dcba8a7024a" continuedAt="i1eec6153785d4132abc16d93f9938dc3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfODA3OA_a2d72451-295b-4a1f-a562-52ecf5f3dd68" continuedAt="i7631174237bc497aa0974f9cff9def4d" escape="true">Use of Estimates</ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:continuation id="i7631174237bc497aa0974f9cff9def4d" continuedAt="ic9728b804bc64951a59553fb461a24b0"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Management has assessed various accounting estimates and other matters, including those that require consideration of forecasted financial information, in context of the unknown future impacts of the global </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 (COVID)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic9728b804bc64951a59553fb461a24b0"> pandemic using information that is reasonably available to the Company at the time. Significant estimates and assumptions are used for, but not limited to: (i) the valuation of accounts receivable; (ii) goodwill, trade names, and other intangible assets; (iii) other long-lived assets; (iv) revenue recognition; (v) accruals for health, workers&#8217; compensation, and professional liability claims; (vi) valuation of deferred tax assets; (vii) legal contingencies; and (viii) income taxes. Accrued insurance claims and reserves include estimated settlements from known claims and actuarial estimates for claims incurred but not reported. As additional information becomes available to the Company, its future assessment of these estimates, including management's expectations at the time regarding the duration, scope and severity of the pandemic, as well as other factors, could materially and adversely impact the Company's consolidated financial statements in future reporting periods. Actual results could differ from those estimates.</ix:continuation>  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prioritizes the mental health and well-being of its employees, especially in response to the COVID pandemic. While operating primarily through a remote workforce, the Company's offices remain open with stringent safety guidelines and procedures in place. Business travel, including visits to healthcare clients, continues to be somewhat limited at the request of the Company's clients who are continuing to cope with the pandemic twenty-four hours a day/seven days a week.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022, average bill rates rose slightly as the Company continued to experience higher demand across a wide range of specialties. Investments in people and technology, along with other improvements the Company has made during the pandemic, have allowed it to quickly respond to high demand levels that it is continuing to see across a wide range of specialties, including operating room, emergency room, pediatrics, labor and delivery, and medical and surgical services, not all of which are directly related to COVID needs.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1eec6153785d4132abc16d93f9938dc3" continuedAt="i6106ac139b784030b41d335978f77e88"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, the Company worked collaboratively with clients on adjusting bill rates in order to adapt to the rapidly changing market conditions. One of the Company's core values is to act ethically and responsibly, and it has been especially important during this pandemic to be transparent and build trust with its clients to re-enforce long-lasting relationships as both demand and bill rates increased to unprecedented levels.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfODA2NA_982dab38-6f47-4fd6-adc9-94c85e842db0" continuedAt="ic0b7d663c7954ab69d56f7f8372728a1" escape="true"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable, net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The timing of revenue recognition, billings, and collections results in billed and unbilled accounts receivable from customers, which are classified as accounts receivable on the condensed consolidated balance sheets and are presented net of allowances for doubtful accounts and sales allowances. Estimated revenue for the Company employees', subcontracted employees', and independent contractors&#8217; time worked but not yet billed at March 31, 2022 and December 31, 2021 totaled $<ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-5" name="us-gaap:UnbilledContractsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfNDE2Mw_f1da3a81-e5fd-422b-9460-e0d1dc873d7a">249.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-5" name="us-gaap:UnbilledContractsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfNDE3MA_f24ea75e-2a99-4da4-8a71-2dc09b8040d0">140.0</ix:nonFraction>&#160;million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally does not require collateral and mitigates its credit risk by performing credit evaluations and monitoring at-risk accounts. The allowance for doubtful accounts is established for losses expected to be incurred on accounts receivable balances. Accounts receivable are written off against the allowance for doubtful accounts when the Company determines amounts are no longer collectible. Judgment is required in the estimation of the allowance and the Company evaluates the collectability of its accounts receivable and contract assets based on a combination of factors. The Company bases its allowance for doubtful account estimates on its historical write-off experience, current conditions, an analysis of the aging of outstanding receivable and customer payment patterns, and specific reserves for customers in adverse condition adjusted for current expectations for the customers or industry. Based on the information currently available, the Company also considered current expectations of future economic conditions, including the impact of COVID, when estimating its allowance for doubtful accounts.</span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfODA4Nw_24e6c580-ee7f-47c3-a545-87447b70f8d1" escape="true"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjVkMWQyZGNiNWQ5YjRkYTBhMWYyZTFjYmE4NThiMTBhL3RhYmxlcmFuZ2U6NWQxZDJkY2I1ZDliNGRhMGExZjJlMWNiYTg1OGIxMGFfNC0xLTEtMS0yOTE1OA_eec503df-2df2-4721-9ca9-1544ba453f90">6,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17355322df2d4d97a85fd60c4263a2fc_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjVkMWQyZGNiNWQ5YjRkYTBhMWYyZTFjYmE4NThiMTBhL3RhYmxlcmFuZ2U6NWQxZDJkY2I1ZDliNGRhMGExZjJlMWNiYTg1OGIxMGFfNC0zLTEtMS0yOTE1OA_2d5625bf-3510-487c-8dd4-e7721eb2aa6a">3,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad Debt Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjVkMWQyZGNiNWQ5YjRkYTBhMWYyZTFjYmE4NThiMTBhL3RhYmxlcmFuZ2U6NWQxZDJkY2I1ZDliNGRhMGExZjJlMWNiYTg1OGIxMGFfNS0xLTEtMS0yOTE1OA_91ac00d7-a5bf-4678-8d7b-75c99e217900">2,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjVkMWQyZGNiNWQ5YjRkYTBhMWYyZTFjYmE4NThiMTBhL3RhYmxlcmFuZ2U6NWQxZDJkY2I1ZDliNGRhMGExZjJlMWNiYTg1OGIxMGFfNS0zLTEtMS0yOTE1OA_9dc1dde0-908f-4c7e-87b6-40e70861aba1">504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-Offs, net of Recoveries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjVkMWQyZGNiNWQ5YjRkYTBhMWYyZTFjYmE4NThiMTBhL3RhYmxlcmFuZ2U6NWQxZDJkY2I1ZDliNGRhMGExZjJlMWNiYTg1OGIxMGFfNi0xLTEtMS0yOTE1OA_8dfe0c4a-434d-4659-bf9c-24b07e50253a">365</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjVkMWQyZGNiNWQ5YjRkYTBhMWYyZTFjYmE4NThiMTBhL3RhYmxlcmFuZ2U6NWQxZDJkY2I1ZDliNGRhMGExZjJlMWNiYTg1OGIxMGFfNi0zLTEtMS0yOTE1OA_0019d961-08b0-4feb-86a8-8fafca6fc614">699</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjVkMWQyZGNiNWQ5YjRkYTBhMWYyZTFjYmE4NThiMTBhL3RhYmxlcmFuZ2U6NWQxZDJkY2I1ZDliNGRhMGExZjJlMWNiYTg1OGIxMGFfNy0xLTEtMS0yOTE1OA_34e058e4-d020-4b77-98c3-3169e582353c">8,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i123bae647d194e0aa87a3eeb155cbbc1_I20210331" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjVkMWQyZGNiNWQ5YjRkYTBhMWYyZTFjYmE4NThiMTBhL3RhYmxlcmFuZ2U6NWQxZDJkY2I1ZDliNGRhMGExZjJlMWNiYTg1OGIxMGFfNy0zLTEtMS0yOTE1OA_e77fd4ef-b813-43bb-b5d8-54dced10d033">3,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the allowance for doubtful accounts, the Company maintains a sales allowance for billing-related adjustments which may arise in the ordinary course of business and adjustments to the reserve are recorded as contra-revenue. The balance of this allowance as of March 31, 2022 and December 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-5" name="ccrn:SalesAllowanceBillingRelatedAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfNTc3Nw_8ff1d91f-81e1-4eff-8465-1cab99979427">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-5" name="ccrn:SalesAllowanceBillingRelatedAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfNTc4NA_bcca6826-d60d-4d63-8785-fdb65d6ee3b6">0.8</ix:nonFraction>&#160;million, respectively.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic0b7d663c7954ab69d56f7f8372728a1">The Company&#8217;s contract terms typically require payment between <ix:nonNumeric contextRef="i123a8da54abc487d9a3a822dee374164_D20220101-20220331" name="ccrn:ThresholdPeriodPastDueForPaymentOfServicesProvided" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfNTg2Ng_573c7350-adae-41a7-93c2-63df297e8b44">30</ix:nonNumeric> to <ix:nonNumeric contextRef="i6f916c87f5844845bdfa58e6b0815916_D20220101-20220331" name="ccrn:ThresholdPeriodPastDueForPaymentOfServicesProvided" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfNTg3Mg_42d88196-b99f-4dd9-9e83-fdd17f112ed6">60</ix:nonNumeric> days from the date of invoice and are considered past due based on the particular negotiated contract terms. The majority of the Company's customers are U.S. based healthcare systems with a significant percentage in acute-care facilities.</ix:continuation> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No single customer accounted for more than 10% of the Company&#8217;s revenue for the three months ended March 31, 2022 and 2021, or the accounts receivable balance as of March 31, 2022 and December 31, 2021.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfODA5MA_7efbfb95-61bf-43f7-939f-63b0422d4a67" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers restructuring activities to be programs whereby it fundamentally changes its operations, such as closing and consolidating facilities, reducing headcount, and realigning operations in response to changing market conditions. As a result, restructuring costs on the condensed consolidated statements of operations primarily include employee termination costs and lease-related exit costs.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6106ac139b784030b41d335978f77e88"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfODA5Nw_109b4ecc-c3a4-4e9e-a9b7-1a38e7cd97dc" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliation of the employee termination costs and lease-related exit costs beginning and ending liability balance is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee Termination Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease-Related Exit Costs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bc99217a5124b478bddc5a0566fedaf_I20211231" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjlmYWFiMmRhNzFhNzRjYzQ4ODViMTQ1NjM3ZjBmMWUwL3RhYmxlcmFuZ2U6OWZhYWIyZGE3MWE3NGNjNDg4NWIxNDU2MzdmMGYxZTBfMy0xLTEtMS0yOTE1OA_77fb7f8e-ab4a-4153-9d0b-b0a1841a2faf">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8cefece24e942d5a8357106949400d3_I20211231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjlmYWFiMmRhNzFhNzRjYzQ4ODViMTQ1NjM3ZjBmMWUwL3RhYmxlcmFuZ2U6OWZhYWIyZGE3MWE3NGNjNDg4NWIxNDU2MzdmMGYxZTBfMy0zLTEtMS0yOTE1OA_c0cf36e4-8913-45ea-ba55-06c6c25f7c14">2,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to restructuring costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c1b8bcd9e5449e8becb131e830d5a44_D20220101-20220331" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjlmYWFiMmRhNzFhNzRjYzQ4ODViMTQ1NjM3ZjBmMWUwL3RhYmxlcmFuZ2U6OWZhYWIyZGE3MWE3NGNjNDg4NWIxNDU2MzdmMGYxZTBfNC0xLTEtMS0yOTE1OA_c692e820-86e6-4d5a-af55-bbb990aba9eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff6a7e25073a4b0aabe092d1fa279920_D20220101-20220331" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjlmYWFiMmRhNzFhNzRjYzQ4ODViMTQ1NjM3ZjBmMWUwL3RhYmxlcmFuZ2U6OWZhYWIyZGE3MWE3NGNjNDg4NWIxNDU2MzdmMGYxZTBfNC0zLTEtMS0yOTE1OA_9ad6cba2-7415-4fd7-a10f-c56cf3e4021f">389</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c1b8bcd9e5449e8becb131e830d5a44_D20220101-20220331" decimals="-3" name="ccrn:PaymentsForRestructuringAndAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjlmYWFiMmRhNzFhNzRjYzQ4ODViMTQ1NjM3ZjBmMWUwL3RhYmxlcmFuZ2U6OWZhYWIyZGE3MWE3NGNjNDg4NWIxNDU2MzdmMGYxZTBfNS0xLTEtMS0yOTE1OA_651a82b8-b440-4376-996d-308ea609ad13">160</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff6a7e25073a4b0aabe092d1fa279920_D20220101-20220331" decimals="-3" name="ccrn:PaymentsForRestructuringAndAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjlmYWFiMmRhNzFhNzRjYzQ4ODViMTQ1NjM3ZjBmMWUwL3RhYmxlcmFuZ2U6OWZhYWIyZGE3MWE3NGNjNDg4NWIxNDU2MzdmMGYxZTBfNS0zLTEtMS0yOTE1OA_eebfe1ff-ac54-4171-ab3b-4a3c50446943">192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6122e323ba5148c68be7d2705dc85e93_I20220331" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjlmYWFiMmRhNzFhNzRjYzQ4ODViMTQ1NjM3ZjBmMWUwL3RhYmxlcmFuZ2U6OWZhYWIyZGE3MWE3NGNjNDg4NWIxNDU2MzdmMGYxZTBfNi0xLTEtMS0yOTE1OA_84be9e69-d5e1-40a8-b912-8cf85160cb97">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa36abaca6d64d6fb19eca4e3d5f6e6c_I20220331" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjlmYWFiMmRhNzFhNzRjYzQ4ODViMTQ1NjM3ZjBmMWUwL3RhYmxlcmFuZ2U6OWZhYWIyZGE3MWE3NGNjNDg4NWIxNDU2MzdmMGYxZTBfNi0zLTEtMS0yOTE1OA_50b90b64-12b9-493c-bc80-67824eddf9a8">2,620</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Restructuring costs in the condensed consolidated statements of operations for the three months ended March 31, 2022 include an immaterial amount of ongoing lease costs related to the Company's strategic reduction in its real estate footprint, which are included as operating lease liabilities - current and non-current in our condensed consolidated balance sheets. Other costs were immaterial for the three months ended March 31, 2022.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i1bf462dbbc134b239a7746fda9801e04_43"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RleHRyZWdpb246MmI1MzY3MTgzNDRkNDUzMjlmZDZiOWZkNDgwMmUwODVfODIx_8924a251-2515-4671-bbcb-f6f2fc367f26" continuedAt="ic3ded7f7ec5d4b25b85b6a94fdcd88c8" escape="true">REVENUE RECOGNITION</ix:nonNumeric></span></div><ix:continuation id="ic3ded7f7ec5d4b25b85b6a94fdcd88c8" continuedAt="i356848f25da540678fac60c25084adf4"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RleHRyZWdpb246MmI1MzY3MTgzNDRkNDUzMjlmZDZiOWZkNDgwMmUwODVfODI0_e6b4597a-8c0e-4214-820a-678f47e5964e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenues from customer contracts are generated from temporary staffing services and other services. Revenue is disaggregated by segment in the following table. Sales and usage-based taxes are excluded from revenue.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nurse<br/>And Allied<br/>Staffing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Physician<br/>Staffing</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Segments</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary Staffing Services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31aa1178ab274d94b1a27d7f903f71ad_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMy0xLTEtMS0yOTE1OA_e7d00163-1085-4e1f-999e-5582c2ed3644">749,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c6b46f3057c41ae9eb9f22f1e50b97d_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMy0zLTEtMS0yOTE1OA_b3b67d98-4314-4f25-9174-68189d09c3c3">22,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibda3d097b5e34888bd4ce3a4a893ea70_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMy03LTEtMS0yOTE1OA_35c02285-fc35-4ac6-925f-909aaec82ec3">771,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c44d67d24f445078de88bbafab90724_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfNC0xLTEtMS0yOTE1OA_4717b3c5-1a80-435b-9dbf-082e7786e1d8">16,133</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i389a47646ea1490cb51a4d0322234613_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfNC0zLTEtMS0yOTE1OA_9e804a99-1e6d-4f15-b454-853c9de47ffa">1,048</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634a7f36c8c948219ef2af135e76fa0f_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfNC03LTEtMS0yOTE1OA_e4da5880-34a5-43f3-bf00-9582aefee591">17,181</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f67d3164490454dbd2421830ac30a99_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfNS0xLTEtMS0yOTE1OA_e169ef26-f9ed-4b69-9296-0471bf735e99">765,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie35cd3b9be00467fbc0b9f82f0c6c7da_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfNS0zLTEtMS0yOTE1OA_ca749508-a8e4-4059-aba7-ffbbb6bdbc1d">23,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfNS03LTEtMS0yOTE1OA_e7a921e3-a247-430a-9076-535f5343c215">788,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nurse<br/>And Allied<br/>Staffing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Physician<br/>Staffing</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Segments</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary Staffing Services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic536f98865ef4aab8fc1a7e5f5e582c9_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMTAtMS0xLTEtMjkxNTg_e291db7d-fa7a-48b1-8df4-eef30e003e5d">305,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99d6ce4715d142a8bc5ce8abc5584a20_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMTAtMy0xLTEtMjkxNTg_969d2553-66b0-4657-8742-2b39bd51f2dd">15,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i500ea7c7700c49718811026ceaaeafcd_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMTAtNy0xLTEtMjkxNTg_a92f7903-70f6-43e4-89a9-43d25a11240e">321,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1921e703c434f25a791d61baf58dc3c_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMTEtMS0xLTEtMjkxNTg_cef51be9-a3df-4b33-b4b9-71ac5d6f77d2">7,033</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i370fcef443ef4801a10e7a73c103bdf9_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMTEtMy0xLTEtMjkxNTg_09e843e8-c949-40d3-9289-51e9579d5808">827</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5392157ee224225b8abb8f26dbf4fd9_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMTEtNy0xLTEtMjkxNTg_c9e06875-8076-45dd-89db-f014f90cbb5d">7,860</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide86e9d4790e48b881466a5c8b847256_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMTItMS0xLTEtMjkxNTg_e085f5e2-1847-412e-a557-f69da6bb2398">313,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad432390898d40dabc7fcb10fd9dd0ae_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMTItMy0xLTEtMjkxNTg_20082648-8a66-4b20-8d91-2b71afbfda7b">16,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMTItNy0xLTEtMjkxNTg_c903ac52-eac8-43f1-94ba-c4cdf43b1a63">329,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i356848f25da540678fac60c25084adf4">See Note 12 - Segment Data.</ix:continuation>                                                                                                </span></div><div><span><br/></span></div><div id="i1bf462dbbc134b239a7746fda9801e04_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMjczOQ_3c8780fe-125a-47d6-84ac-2d314b9de267" continuedAt="ib769cb0ecdee4eb0a9d11ec822082331" escape="true">ACQUISITIONS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ib769cb0ecdee4eb0a9d11ec822082331" continuedAt="i216840d68be744daad0da0a40cbf8a01"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selected</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2021, the Company purchased and acquired substantially all of the assets and assumed certain liabilities of Selected, Inc. (Selected) for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="iddc9cc886ecc4548a8c7f9a14a4fa974_D20211216-20211216" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMTA5OTUxMTYzNjEzMw_e7c8b84f-e4b2-4062-84ed-165fd255eaa3">3.5</ix:nonFraction>&#160;million in cash, subject to adjustment, and $<ix:nonFraction unitRef="usd" contextRef="iddc9cc886ecc4548a8c7f9a14a4fa974_D20211216-20211216" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMTA5OTUxMTYzNjE0Nw_92c1f151-1b2a-488f-8963-eb3ea708b222">1.5</ix:nonFraction>&#160;million in shares (or <ix:nonFraction unitRef="shares" contextRef="iddc9cc886ecc4548a8c7f9a14a4fa974_D20211216-20211216" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMTA5OTUxMTYzNjE2MQ_d3119505-c5fb-4c05-b718-58c14a1aae1a">59,429</ix:nonFraction> shares) of the Company's common stock. The transaction was treated as a purchase of assets for income tax purposes. As of March 31, 2022, the acquisition has not been fully integrated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sellers are also eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="i7d964a81b82746d29b5d9b48e092bd36_I20211216" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMTA5OTUxMTYzNjE4NA_dab8d622-19ca-426d-b261-6edf00a711f6">1.5</ix:nonFraction>&#160;million in earnout cash consideration, based on Selected's revenues for each of the twelve-month periods ending on the first and second anniversaries of the first day after the closing date. See Note 10 - Fair Value Measurements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was not significant and has been accounted for using the acquisition method of accounting. The Company has not completed its valuation of assets acquired and liabilities assumed. Any necessary adjustments will be finalized within one </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i216840d68be744daad0da0a40cbf8a01"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year from the date of acquisition. As a result, $<ix:nonFraction unitRef="usd" contextRef="i7d964a81b82746d29b5d9b48e092bd36_I20211216" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMTA5OTUxMTYzNzk4Mg_a65a331a-6b7b-486d-be10-704e9cb75342">6.5</ix:nonFraction>&#160;million has been recorded as goodwill on the Company's condensed consolidated balance sheets. See Note 7 - Goodwill, Trade Names, and Other Intangible Assets. Associated acquisition-related costs incurred have been included in acquisition and integration-related costs on the Company's condensed consolidated statements of operations for the three months ended March 31, 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cross Country Workforce Solutions Group (CCWSG)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, the Company purchased and acquired substantially all of the assets and assumed certain liabilities of Workforce Solutions Group, Inc. (WSG) for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i99afbe71598e40ef97034d2edf4c411e_D20210608-20210608" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMjM3_3668b6f3-c379-438b-9bf4-a2f516849dae">25.0</ix:nonFraction>&#160;million in cash and $<ix:nonFraction unitRef="usd" contextRef="i99afbe71598e40ef97034d2edf4c411e_D20210608-20210608" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMzE2_1afb64f8-d40e-4433-b232-eef26d35c69a">5.0</ix:nonFraction>&#160;million in shares (or <ix:nonFraction unitRef="shares" contextRef="i99afbe71598e40ef97034d2edf4c411e_D20210608-20210608" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMzMz_dea2d21e-d3dd-4763-9eb1-df14562c9f3c">307,730</ix:nonFraction> shares) of the Company's common stock. The parties agreed to a final net working capital reduction of $<ix:nonFraction unitRef="usd" contextRef="i93a5acd42c2647e59b5add3dd10a6587_D20211001-20211231" decimals="-5" name="ccrn:BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMTA5OTUxMTY0MjkxNQ_b6b5b17b-f714-4808-b818-1d83a599ece9">1.1</ix:nonFraction>&#160;million which was received in the fourth quarter of 2021.The transaction was treated as a purchase of assets for income tax purposes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sellers are also eligible to receive an earnout based on the business' performance through <ix:nonNumeric contextRef="i99afbe71598e40ef97034d2edf4c411e_D20210608-20210608" name="ccrn:BusinessCombinationContingentConsiderationTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfNTQ4_5e9f0cb6-02fe-404c-aca7-c045bea8c696">three years</ix:nonNumeric> after the acquisition date that could provide up to an additional $<ix:nonFraction unitRef="usd" contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfNjE3_a81e2a3e-4bad-4db9-b9f4-392ca5456640">15.0</ix:nonFraction>&#160;million in cash. The current portion of the liability of $<ix:nonFraction unitRef="usd" contextRef="i6d3157fac8554807a3ac2c4583f90eca_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfNjY5_8760bc7d-8c98-488d-a5a7-e577cd792467">7.5</ix:nonFraction>&#160;million is included in current portion of earnout liability and the non-current portion of $<ix:nonFraction unitRef="usd" contextRef="i6d3157fac8554807a3ac2c4583f90eca_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfNzU1_fae3f54c-8acd-4c3b-bfab-f88b010d0f6a">7.5</ix:nonFraction>&#160;million is included in non-current earnout liability on the condensed consolidated balance sheets. See Note 10 - Fair Value Measurements.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMjc0MA_4e18ebb2-ea2e-4dfb-95c7-1cc27594e4d4" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of the assets acquired and liabilities assumed on June 8, 2021:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfMS0xLTEtMS0yOTE1OA_f92e3889-9cd4-4177-b5c3-24d6e8b0b3d7">957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfMi0xLTEtMS0yOTE1OA_a032eb42-f33c-463d-a9e9-a90e91bbc5d0">11,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfMy0xLTEtMS0yOTE1OA_ae61efdb-ef8c-45d8-b60c-5ca1ccf6c579">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfNC0xLTEtMS0yOTE1OA_30dd469b-25ff-4b64-b3aa-7ca584aebfe6">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608" decimals="-3" name="ccrn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfNS0xLTEtMS0zNjQ0NQ_ec828296-1677-4822-8861-5ad3e1d4b1ae">1,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfNS0xLTEtMS0yOTE1OA_340e4cbe-0f34-485f-bd7e-6e00ef00ca20">22,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfNi0xLTEtMS0yOTE1OA_15ae9184-9c53-4e1f-af17-f18e087f74bc">14,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608" decimals="-3" name="ccrn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfNy0xLTEtMS0yOTE1OA_a75380b5-47a8-4b1b-acb5-f4c9d70cc83c">50,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfOC0xLTEtMS0yOTE1OA_46787b87-0d05-432c-a4b9-0369c94f7d9c">3,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608" decimals="-3" name="ccrn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfOS0xLTEtMS0yOTE1OA_dee8a54b-8446-47d8-8ddf-6c35e06a9f08">1,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608" decimals="-3" name="ccrn:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfMTEtMS0xLTEtMzY0NTI_bc347e2e-b67e-4502-a0c9-b632d8439afb">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability - non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608" decimals="-3" name="ccrn:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfMTItMS0xLTEtMzY0NTI_4496bb23-a6a7-485a-ba63-b1bb8cb103fd">762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnout liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfMTAtMS0xLTEtMjkxNTg_5d52130c-7060-4b7c-a590-f5732b3a176b">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfMTEtMS0xLTEtMjkxNTg_59377d2f-68a0-426c-ac29-e1cb5ab5e200">21,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfMTItMS0xLTEtMjkxNTg_cf3191e0-d283-4a32-9ed9-9679b9b5c3dd">29,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assigned a value to other identifiable intangible assets of $<ix:nonFraction unitRef="usd" contextRef="i7c6769ab62314e58bd5be4d34d3bb062_I20210608" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMTUwOQ_45470e3c-3aa5-4a2b-bace-fa97c1add698">14.2</ix:nonFraction>&#160;million in customer relationships with a weighted average estimated useful life of <ix:nonNumeric contextRef="id5ac2467fe50486d918b7f212f790165_D20210608-20210608" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMTU4Nw_ade074e8-f907-49b3-a08b-249b448ec23c">11.5</ix:nonNumeric> years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining excess purchase price over the fair value of net assets acquired of $<ix:nonFraction unitRef="usd" contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMTc2MQ_ea2cda0d-e13f-42af-bd80-97d81bc6f394">22.1</ix:nonFraction>&#160;million was recorded as goodwill on the Company's condensed consolidated balance sheets. See Note 7 - Goodwill, Trade Names, and Other Intangible Assets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was not significant and has been accounted for using the acquisition method of accounting. The pro-forma impact on the Company's consolidated revenue from services and net income, including the pro forma effect of events that are directly attributable to the acquisition, was not significant. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mediscan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, the Company entered into a note payable of $<ix:nonFraction unitRef="usd" contextRef="ib4c754f48f6947ce94f0c29faed347d7_I20200331" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMTA5OTUxMTY0MTgzNA_075fb178-d46c-4bad-8c39-a74b9244dedc">7.3</ix:nonFraction>&#160;million related to contingent consideration assumed as part of the Mediscan acquisition, payable in <ix:nonFraction unitRef="installment" contextRef="ib4c754f48f6947ce94f0c29faed347d7_I20200331" decimals="INF" name="ccrn:NotePayableNumberOfPaymentInstallments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMzg0ODI5MDcxMjY2Mw_ac53bd64-a43d-43cc-a7cc-ef2c02fc6054">three</ix:nonFraction> installments. The first <ix:nonFraction unitRef="installment" contextRef="idb38d75eba334b9c9661cc92d3d27b1e_I20210331" decimals="INF" name="ccrn:NotePayableNumberOfInstallmentsPaid" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMTA5OTUxMTY0MTkyNg_d6ece42f-2dcd-4575-a40c-eb9a112873e1">two</ix:nonFraction> installments of $<ix:nonFraction unitRef="usd" contextRef="i693a80db9468442f89e54f2d5e8f012c_D20200401-20200630" decimals="-5" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMzg0ODI5MDcxMjY2Nw_b3026ad5-dc8f-4a3e-8678-88a38c001d73"><ix:nonFraction unitRef="usd" contextRef="ifc034a2451eb4ad2a115858bbcbb76a3_D20210101-20210331" decimals="-5" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMzg0ODI5MDcxMjY2Nw_e2559305-7eb4-4fe0-b847-5bb3ed1985d1">2.4</ix:nonFraction></ix:nonFraction>&#160;million each were paid in the second quarter of 2020 and in the first quarter of 2021, respectively. The third and final installment of $<ix:nonFraction unitRef="usd" contextRef="i70a127889d9c4f5facf6c1e12bc5ef60_D20220101-20220331" decimals="-5" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMzg0ODI5MDcxMjY3MQ_0e1d8e8b-62bc-4bd7-a9a3-5fed86c4cbd8">2.6</ix:nonFraction>&#160;million, including interest, was paid in the first quarter of 2022.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i1bf462dbbc134b239a7746fda9801e04_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80OS9mcmFnOmM0NGY3MzBkYzU0MzRmZmY4NGQxYjM5MWE2MjkxMGM2L3RleHRyZWdpb246YzQ0ZjczMGRjNTQzNGZmZjg0ZDFiMzkxYTYyOTEwYzZfOTg0_1cc429d6-b1d0-4d20-9dec-6313f87721da" continuedAt="i3a9f738874344904aac5b90b6df70f5e" escape="true">COMPREHENSIVE INCOME</ix:nonNumeric></span></div><ix:continuation id="i3a9f738874344904aac5b90b6df70f5e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total comprehensive income includes net income or loss and foreign currency translation adjustments, net of any related deferred taxes, and is included within the accompanying condensed consolidated statements of operations. Certain of the Company&#8217;s foreign subsidiaries use their respective local currency as their functional currency. Assets and liabilities of these operations are translated at the exchange rates in effect on the balance sheet date. Income statement items are translated at the average exchange rates for the period. The cumulative impact of currency fluctuations related to the balance sheet translation is included in accumulated other comprehensive loss in the accompanying condensed consolidated balance sheets and was an unrealized loss of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-5" sign="-" name="ccrn:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80OS9mcmFnOmM0NGY3MzBkYzU0MzRmZmY4NGQxYjM5MWE2MjkxMGM2L3RleHRyZWdpb246YzQ0ZjczMGRjNTQzNGZmZjg0ZDFiMzkxYTYyOTEwYzZfMTA5OTUxMTYyOTA3Mw_febb1d0d-80ce-4fb3-a709-eb05a1f227b9">1.4</ix:nonFraction>&#160;million at March 31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-5" sign="-" name="ccrn:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80OS9mcmFnOmM0NGY3MzBkYzU0MzRmZmY4NGQxYjM5MWE2MjkxMGM2L3RleHRyZWdpb246YzQ0ZjczMGRjNTQzNGZmZjg0ZDFiMzkxYTYyOTEwYzZfNzkz_8defc148-7545-4892-91a8-b5e73ee9cc70">1.3</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at December&#160;31, 2021.</span></div></ix:continuation><div><span><br/></span></div><div id="i1bf462dbbc134b239a7746fda9801e04_52"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RleHRyZWdpb246NThkMTVkNzIyYWUzNDhlZTg2OWRmNzAyZTMyNDM1MmVfNDA1_5ef214f7-90d4-40cd-b247-ff4ddb66876c" continuedAt="i14ba62e9b41d44f187249b6ecdb92268" escape="true">EARNINGS PER SHARE</ix:nonNumeric></span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><ix:continuation id="i14ba62e9b41d44f187249b6ecdb92268"><div><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RleHRyZWdpb246NThkMTVkNzIyYWUzNDhlZTg2OWRmNzAyZTMyNDM1MmVfNDAy_94664a6d-b386-4e8e-a5c9-2d3920bdfdf7" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the numerator and denominator for the computation of the basic and diluted earnings per share:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(amounts in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to common stockholders - Basic and Diluted</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfNS0xLTEtMS0yOTE1OA_b0162f79-bfdb-4c25-8b59-e7e1b1ab38ac"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfNS0xLTEtMS0yOTE1OA_da6b6529-eb88-4411-a616-e6f1df28885e">61,983</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfNS0zLTEtMS0yOTE1OA_8a202ec9-689f-4e58-bc35-2210125f8c50"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfNS0zLTEtMS0yOTE1OA_8b5583e9-376d-47e2-8cde-d6dc33fd7cc4">19,448</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares - Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfOC0xLTEtMS0yOTE1OA_f99de772-2fa0-42d3-a5f6-1ea0ed9e0e7a">37,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfOC0zLTEtMS0yOTE1OA_a685c58d-041c-4a7e-ad60-74116a89abcc">36,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of diluted shares:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Share-based awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfMTAtMS0xLTEtMjkxNTg_cc413781-f9ce-44dc-9cc7-d09ef4eed39c">945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfMTAtMy0xLTEtMjkxNTg_95226b53-6c18-42a1-bec2-dded92a0b09c">853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares - Diluted</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfMTEtMS0xLTEtMjkxNTg_eae4d3b6-289a-4410-9ba7-74ab6e2c4939">37,973</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfMTEtMy0xLTEtMjkxNTg_40a1c77c-79d2-4bbe-9326-cb692b5ace2e">37,034</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to common stockholders - Basic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfMTMtMS0xLTEtMjkxNTg_5cb0ab01-673b-496b-9588-2d05d315a7ac">1.67</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfMTMtMy0xLTEtMjkxNTg_34cefbc8-50ea-471d-aa63-e308c9eb077d">0.54</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to common stockholders - Diluted</span></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfMTUtMS0xLTEtMjkxNTg_181a39de-e6b0-4601-a0b9-0138a792c3ce">1.63</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfMTUtMy0xLTEtMjkxNTg_ec24cdc4-bfce-42dc-b6c3-a492111a522e">0.53</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, there were <ix:nonFraction unitRef="shares" contextRef="ic58e2e7af6004065bc3df5d18eda6a7f_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RleHRyZWdpb246NThkMTVkNzIyYWUzNDhlZTg2OWRmNzAyZTMyNDM1MmVfMTA5OTUxMTYyODkyMQ_670101ad-5d59-4aa0-ab61-9adf49506775">4,276</ix:nonFraction> share-based awards that could potentially dilute net income per share attributable to common stockholders in the future that were not included in the computation of diluted net income per share attributable to common stockholders because to do so would have been anti-dilutive for that period. There were <ix:nonFraction unitRef="shares" contextRef="i1a13d2d2a7ff4121984d558f70731480_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RleHRyZWdpb246NThkMTVkNzIyYWUzNDhlZTg2OWRmNzAyZTMyNDM1MmVfMTA5OTUxMTYyODkyNw_587d1a86-a934-40fd-bc27-c1e7d5013a08">no</ix:nonFraction> such share-based awards for the three months ended March 31, 2022.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i1bf462dbbc134b239a7746fda9801e04_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RleHRyZWdpb246ZGE4NDhmYTcxMjJkNGE5Nzg2NGI3MmNkNjdkNWIwM2NfNDMyMw_f960f133-e4c8-4220-9abf-9eb31bcd2477" continuedAt="i40011ac13a8246179bc8f5d4eb957b29" escape="true">GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i40011ac13a8246179bc8f5d4eb957b29" continuedAt="i7eec7fa196f4409382706d6cff8ac30a"><div><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RleHRyZWdpb246ZGE4NDhmYTcxMjJkNGE5Nzg2NGI3MmNkNjdkNWIwM2NfNDMzMw_16b89e71-e5fe-487e-98b3-c6f417a40edb" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had the following acquired intangible assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets subject to amortization:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Databases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ab4d2044634d1997af982de4e6ecf0_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNC0xLTEtMS0yOTE1OA_ab610927-427f-48b5-aefc-9e0da4f1ddb5">30,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ab4d2044634d1997af982de4e6ecf0_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNC0zLTEtMS0yOTE1OA_eb88b524-9fdb-4294-8b56-d37b7c3bd790">19,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ab4d2044634d1997af982de4e6ecf0_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNC01LTEtMS0yOTE1OA_cd7a6e0c-1873-4317-ba37-bc5f75603c3c">11,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe98f92bed0843dbbed8160370da0659_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNC03LTEtMS0yOTE1OA_69ce716c-a7bd-42fa-bf84-5f502a784d32">30,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe98f92bed0843dbbed8160370da0659_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNC05LTEtMS0yOTE1OA_a05984ea-63eb-4e22-be07-e11038beacac">18,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe98f92bed0843dbbed8160370da0659_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNC0xMS0xLTEtMjkxNTg_ddf277ae-5069-477f-b34b-61339eaf21f3">12,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfe0db93f1004e008d12e054ef21e25c_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNS0xLTEtMS0yOTE1OA_c8ec48ba-c9a0-425b-bd83-58b5873e5d81">47,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfe0db93f1004e008d12e054ef21e25c_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNS0zLTEtMS0yOTE1OA_a539d7ba-ca7c-4b78-be14-dd1d950ebbcd">18,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfe0db93f1004e008d12e054ef21e25c_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNS01LTEtMS0yOTE1OA_fc78bf44-0e70-4d70-9f42-5930f390d1d6">29,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55a5b324377c46699174b4a56c307cf9_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNS03LTEtMS0yOTE1OA_c2fb53e7-6715-405e-92b8-ec2400040d18">47,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55a5b324377c46699174b4a56c307cf9_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNS05LTEtMS0yOTE1OA_a2bee017-a7ed-486f-af4b-22404c70957d">17,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55a5b324377c46699174b4a56c307cf9_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNS0xMS0xLTEtMjkxNTg_574790aa-2ad6-46bd-9ee6-fb396ff567c4">30,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c182809d2b46f9a875cd3fd058837d_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNi0xLTEtMS0yOTE1OA_8bf2731f-9045-436e-b468-22a0b1d4e221">304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c182809d2b46f9a875cd3fd058837d_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNi0zLTEtMS0yOTE1OA_5e606afa-a932-4a74-93ea-9b1441d2b21b">288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c182809d2b46f9a875cd3fd058837d_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNi01LTEtMS0yOTE1OA_7a2daeb0-b6e5-47f5-bc04-66a8883aef35">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if89026b691fb4fb7b264f411d8d9b428_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNi03LTEtMS0yOTE1OA_2892ee68-d0d4-4bd0-bf9f-69cf68a51351">304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if89026b691fb4fb7b264f411d8d9b428_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNi05LTEtMS0yOTE1OA_28acbd8d-6a4a-41a3-b012-c533ef9d9ba1">272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if89026b691fb4fb7b264f411d8d9b428_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNi0xMS0xLTEtMjkxNTg_6174b63b-4ab8-4fa2-826e-1f6a9d1c86db">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNy0xLTEtMS0yOTE1OA_4336fcae-11f4-4aff-a888-c9a8f950a495">78,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNy0zLTEtMS0yOTE1OA_5a20afe0-58c1-48fa-bb53-c70f7d283477">38,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNy01LTEtMS0yOTE1OA_46af9022-7748-494b-8122-20c843aaac20">40,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNy03LTEtMS0yOTE1OA_6c6bac8a-60bd-483c-9fb1-dfe97ee3825b">78,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNy05LTEtMS0yOTE1OA_89809a19-3a52-49ac-aa94-0e888a2638ef">36,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNy0xMS0xLTEtMjkxNTg_59b16482-4408-4b69-b870-d4db6eb96b96">42,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets not subject to amortization:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names, indefinite-lived</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:IndefiniteLivedTradeNames" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfMTAtNS0xLTEtMjkxNTg_98d7b65b-16f8-4fbd-944c-7585066082cd">5,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:IndefiniteLivedTradeNames" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfMTAtMTEtMS0xLTI5MTU4_86ad37e9-00bb-44de-9188-f03a73227b8f">5,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RleHRyZWdpb246ZGE4NDhmYTcxMjJkNGE5Nzg2NGI3MmNkNjdkNWIwM2NfNDMzNQ_2c3719d3-c4ea-401a-b608-2f96edec5301" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, estimated annual amortization expense is as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:80.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December&#160;31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOjU3ZGQ1Y2E5NTljYjRlNmNhYWQ5NGZiZDlkMzM2ZjVlL3RhYmxlcmFuZ2U6NTdkZDVjYTk1OWNiNGU2Y2FhZDk0ZmJkOWQzMzZmNWVfMS0xLTEtMS0yOTE1OA_c4c867db-1a86-4b3a-96bd-c12e6757eaa1">5,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOjU3ZGQ1Y2E5NTljYjRlNmNhYWQ5NGZiZDlkMzM2ZjVlL3RhYmxlcmFuZ2U6NTdkZDVjYTk1OWNiNGU2Y2FhZDk0ZmJkOWQzMzZmNWVfMi0xLTEtMS0yOTE1OA_5383db97-a1a5-4105-a298-ee20d7a0c555">7,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOjU3ZGQ1Y2E5NTljYjRlNmNhYWQ5NGZiZDlkMzM2ZjVlL3RhYmxlcmFuZ2U6NTdkZDVjYTk1OWNiNGU2Y2FhZDk0ZmJkOWQzMzZmNWVfMy0xLTEtMS0yOTE1OA_620d0b87-f293-4e71-b560-90c9f79b9072">6,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOjU3ZGQ1Y2E5NTljYjRlNmNhYWQ5NGZiZDlkMzM2ZjVlL3RhYmxlcmFuZ2U6NTdkZDVjYTk1OWNiNGU2Y2FhZDk0ZmJkOWQzMzZmNWVfNC0xLTEtMS0yOTE1OA_8ac75a2c-e622-453e-b9f2-b657dd3166a1">5,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOjU3ZGQ1Y2E5NTljYjRlNmNhYWQ5NGZiZDlkMzM2ZjVlL3RhYmxlcmFuZ2U6NTdkZDVjYTk1OWNiNGU2Y2FhZDk0ZmJkOWQzMzZmNWVfNS0xLTEtMS0yOTE1OA_90329f19-f102-4209-aa90-2adce5a18e5c">4,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="ccrn:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOjU3ZGQ1Y2E5NTljYjRlNmNhYWQ5NGZiZDlkMzM2ZjVlL3RhYmxlcmFuZ2U6NTdkZDVjYTk1OWNiNGU2Y2FhZDk0ZmJkOWQzMzZmNWVfNi0xLTEtMS0yOTE1OA_a90cdb34-a27a-4435-9074-4b479f4f0697">10,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOjU3ZGQ1Y2E5NTljYjRlNmNhYWQ5NGZiZDlkMzM2ZjVlL3RhYmxlcmFuZ2U6NTdkZDVjYTk1OWNiNGU2Y2FhZDk0ZmJkOWQzMzZmNWVfNy0xLTEtMS0yOTE1OA_7da4e9ee-b53b-4e63-b7a0-ceb656f8f621">40,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Goodwill, Trade Names, and Other Intangible Assets Impairment </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests reporting units&#8217; goodwill and intangible assets with indefinite lives for impairment annually during the fourth quarter and more frequently if impairment indicators exist. The Company performs quarterly qualitative assessments of significant events and circumstances such as reporting units&#8217; historical and current results, assumptions regarding future performance, strategic initiatives and overall economic factors, including COVID, and macro-economic developments, to determine the existence of potential indicators of impairment and assess if it is more likely than not that the fair value of reporting units or intangible assets is less than their carrying value. If indicators of impairments are identified a quantitative impairment test is performed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the Company performed a qualitative assessment of each of its reporting units and determined it was not more likely than not that the fair value of its reporting units dropped below their carrying value. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lthough management believes that the Company's current estimates and assumptions utilized in its qualitative testing are reasonable and supportable, including its assumptions on the impact and timing related to COVID, there can be no assurance that the estimates and assumptions management used for purposes of its qualitative assessment as of March 31, 2022 will prove to be accurate predictions of future performance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, goodwill by reporting segment was: $<ix:nonFraction unitRef="usd" contextRef="i24a8be762a2a4907a7c8cca553b30556_I20220331" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RleHRyZWdpb246ZGE4NDhmYTcxMjJkNGE5Nzg2NGI3MmNkNjdkNWIwM2NfMTA5OTUxMTYzNDE5MQ_53f946a7-5b42-4937-a89b-ebc3df6c6712">116.7</ix:nonFraction>&#160;million for Nurse and Allied Staffing and $<ix:nonFraction unitRef="usd" contextRef="i94654808d0da4588b241ae072d795aa4_I20220331" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RleHRyZWdpb246ZGE4NDhmYTcxMjJkNGE5Nzg2NGI3MmNkNjdkNWIwM2NfMTA5OTUxMTYzNDIwNw_49142779-5bd3-4152-8878-de0bcef4325d">2.8</ix:nonFraction>&#160;million for Physician Staffing, for a total of $<ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RleHRyZWdpb246ZGE4NDhmYTcxMjJkNGE5Nzg2NGI3MmNkNjdkNWIwM2NfMTA5OTUxMTYzNDIyMQ_c43f4b57-e133-4e0f-b1fd-e7a9fc8cb285">119.5</ix:nonFraction>&#160;million. Goodwill includes amounts acquired from the acquisitions of WSG and Selected, calculated as the excess of the fair value of consideration exchanged as compared to the fair value of identifiable net assets acquired. See Note 4 - Acquisitions. During the measurement period, which is not to exceed one year from the acquisition date, the Company may record adjustments to the assets acquired or liabilities assumed, with a corresponding offset to goodwill. Upon conclusion of the measurement period, any subsequent adjustments would be recorded to earnings.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7eec7fa196f4409382706d6cff8ac30a">For its long-lived assets and definite-lived intangible assets, the Company reviews for impairment whenever events or changes in circumstances indicate the carrying amount may not be recoverable. As of March 31, 2022, the Company performed a qualitative assessment of its trade names and other intangible assets and determined it was not more likely than not that their carrying value may not be recoverable. During the three months ended March 31, 2021, the Company wrote off a discontinued software development project, resulting in an immaterial impairment charge.</ix:continuation></span></div><div><span><br/></span></div><div id="i1bf462dbbc134b239a7746fda9801e04_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfODQ3Nw_afdf7267-3b56-4a65-b04a-63fbec2ec20c" continuedAt="ideb348766c964f5dacab5e345c597dd8" escape="true">DEBT</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ideb348766c964f5dacab5e345c597dd8" continuedAt="i10f6c0306e3a43ff908c81522f4f945e"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfODQ4MQ_74d2996e-3a70-42b2-bc32-7f1461cac13a" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's long-term debt consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan, interest of <ix:nonFraction unitRef="number" contextRef="i010ea7a8f38b4cb2ad448e4252b0d49d_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfMy0wLTEtMS0yOTE1OC90ZXh0cmVnaW9uOmE4MDgyYjJkMGFhYTRmNzNhZDlhMzkyZjkyMjIwZjZiXzI3_4fa15427-88fd-46ce-8b9e-589d37340d2b"><ix:nonFraction unitRef="number" contextRef="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfMy0wLTEtMS0yOTE1OC90ZXh0cmVnaW9uOmE4MDgyYjJkMGFhYTRmNzNhZDlhMzkyZjkyMjIwZjZiXzI3_7ddc6aa0-6a63-4de4-ab7d-552063d3a2dd">6.50</ix:nonFraction></ix:nonFraction>% at March 31, 2022 and December 31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfMy0xLTEtMS0yOTE1OA_1209fb0d-119e-4a25-9e79-dce4abec1d4f">173,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfMy0zLTEtMS0yOTE1OA_b7a92633-9ab3-4b42-8624-2219f719625b">5,151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i010ea7a8f38b4cb2ad448e4252b0d49d_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfMy01LTEtMS0yOTE1OA_ea894b07-318e-46e4-aa34-32d736dee4ad">174,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i010ea7a8f38b4cb2ad448e4252b0d49d_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfMy03LTEtMS0yOTE1OA_2809196a-874f-4732-bdc7-c78d90e707ab">5,396</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Secured Asset-Based Loan, interest of <ix:nonFraction unitRef="number" contextRef="id40b9c2a2b954b16991ea116d1d59043_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNC0wLTEtMS0yOTE1OC90ZXh0cmVnaW9uOmE5YzIyOWY4ZDk0ZTRiYjI4ZTQ3YmRlMmRkNTRkMzg1XzQ5_02c52fea-32d4-4f0b-accc-fe88c924c674">1.88</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i5621975f70784aa29783102660abc224_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNC0wLTEtMS0yOTE1OC90ZXh0cmVnaW9uOmE5YzIyOWY4ZDk0ZTRiYjI4ZTQ3YmRlMmRkNTRkMzg1XzU2_4f76a5db-c06c-4d96-852f-a5eb62f50759">1.60</ix:nonFraction>% at March 31, 2022 and December 31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40b9c2a2b954b16991ea116d1d59043_I20220331" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNC0xLTEtMS0yOTE1OA_94d3b622-d99c-4740-b6d9-c1816e3494ec">51,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id40b9c2a2b954b16991ea116d1d59043_I20220331" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNC0zLTEtMS0yOTE1OA_c2a4a120-7710-400e-99dc-3aa912e9adc8">3,990</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5621975f70784aa29783102660abc224_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNC01LTEtMS0yOTE1OA_a733b3de-6f12-4547-9014-7885f9120bf8">9,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5621975f70784aa29783102660abc224_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNC03LTEtMS0yOTE1OA_635268b5-b0e7-406c-8a99-0686359a7ec1">991</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note Payable, interest of <ix:nonFraction unitRef="number" contextRef="i5b7ceee3e87f40c494783ab3badd4980_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNS0wLTEtMS0yOTE1OC90ZXh0cmVnaW9uOjYwNWM3N2VkNzkzMjQ1YWM4YTk3NmFjMDU1NjU1OWIyXzMw_758c76bc-160d-4da1-a6ac-e6f8fc82f6a5">2.00</ix:nonFraction>% per annum at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18d296e84536494a9f07c3e749a9af7c_I20220331" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNS0xLTEtMS0yOTE1OA_581ef7a7-400e-45ff-8652-56b12f49b4ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18d296e84536494a9f07c3e749a9af7c_I20220331" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNS0zLTEtMS0yOTE1OA_72803e3d-ccba-4e72-8651-a4eb54db38b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b7ceee3e87f40c494783ab3badd4980_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNS01LTEtMS0yOTE1OA_8328d648-4401-40c8-bce5-4cb9c8fb72fd">2,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b7ceee3e87f40c494783ab3badd4980_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNS03LTEtMS0yOTE1OA_1c946d7b-450c-4735-868d-6f2ffd668a31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNi0xLTEtMS0yOTE1OA_ef41249b-d7b0-42dc-bb52-76019259e2c2">225,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNi0zLTEtMS0yOTE1OA_b8abcb1c-a9ad-4df1-ac43-1ba3fdc1f4e9">9,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNi01LTEtMS0yOTE1OA_e74ba88d-5e91-4dd4-9a3a-1236bb48ee8d">185,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNi03LTEtMS0yOTE1OA_6d72b390-23f7-4a2c-b4e4-4934271c71a4">6,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion - note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18d296e84536494a9f07c3e749a9af7c_I20220331" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNy0xLTEtMS0yOTE1OA_e0efc99b-08a4-4d07-8f89-28bd810a5651">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b7ceee3e87f40c494783ab3badd4980_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNy01LTEtMS0yOTE1OA_1654c957-022d-468f-a98e-f9a51204b93b">2,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion - term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfOC0xLTEtMS0yOTE1OA_4713d71e-3ff4-40f5-b2b0-3b4820d3de8b">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i010ea7a8f38b4cb2ad448e4252b0d49d_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfOC01LTEtMS0yOTE1OA_dde97bf0-49c3-4418-9738-798704141810">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfOS0xLTEtMS0yOTE1OA_2c458e3a-32ac-4d68-af91-51f8f8329ea3">223,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfOS0zLTEtMS0yOTE1OA_f87566a6-9790-4a12-84b5-ec5ced2fe8d8">9,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfOS01LTEtMS0yOTE1OA_5b3a2bd8-7bf4-4f25-9968-523e299edc0c">181,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfOS03LTEtMS0yOTE1OA_521e9ca0-addd-48ff-a626-579b55c04511">6,387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, the current portion of the term loan is included in current portion of debt on the condensed consolidated balance sheets. In addition, the current portion of the note payable as of December 31, 2021 is included in current portion of debt on the condensed consolidated balance sheets. The Company has elected to present the debt issuance costs associated with its revolving line-of-credit as an asset, which is included in other non-current assets on the condensed consolidated balance sheets. As a result, the long-term debt in the above table will not agree to long-term debt, net of current portion on the condensed consolidated balance sheets herein.</span></div><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfODQ4NA_878bf812-623b-4200-b378-e008212b4125" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the aggregate schedule for maturities of debt are as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term Loan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Secured Asset-Based Loan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Through Years Ending December&#160;31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfMy0xLTEtMS0yOTE1OA_552982b2-6a81-4483-8826-355094bca66a">1,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40b9c2a2b954b16991ea116d1d59043_I20220331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfMy0zLTEtMS0yOTE1OA_86256b30-0c7d-4461-b837-3daa997b6d43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfNC0xLTEtMS0yOTE1OA_20f8974c-3d1c-47bc-b21a-9a1c9c201f4b">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40b9c2a2b954b16991ea116d1d59043_I20220331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfNC0zLTEtMS0yOTE1OA_3afb4f15-bd2f-4a22-8de7-40f72757e3e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfNS0xLTEtMS0yOTE1OA_9673b29d-efce-4ae1-a477-74ac9713841d">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40b9c2a2b954b16991ea116d1d59043_I20220331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfNS0zLTEtMS0yOTE1OA_0dd840a6-d85b-49e7-be58-b9d5e6238029">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfNi0xLTEtMS0yOTE1OA_99a23e0c-3a28-48ab-8105-0e2d8e234081">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40b9c2a2b954b16991ea116d1d59043_I20220331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfNi0zLTEtMS0yOTE1OA_bbe409c0-2798-458a-91c6-a2ee351c75da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfNy0xLTEtMS0yOTE1OA_83671746-9f43-4896-9cdf-937f249e5688">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40b9c2a2b954b16991ea116d1d59043_I20220331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfNy0zLTEtMS0yOTE1OA_cc04981c-0d8f-4e64-8e78-e49870b8e27e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331" decimals="-3" name="ccrn:LongTermDebtMaturityAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfOC0xLTEtMS0yOTE1OA_be902e87-d9ca-4c6e-8060-bb5b18f6cff9">165,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40b9c2a2b954b16991ea116d1d59043_I20220331" decimals="-3" name="ccrn:LongTermDebtMaturityAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfOC0zLTEtMS0yOTE1OA_7f72a51c-6de9-4f6e-92b9-7c6aa0f18068">51,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfOS0xLTEtMS0yOTE1OA_4fa94845-8c28-4b18-ab39-0d085d8a839d">173,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40b9c2a2b954b16991ea116d1d59043_I20220331" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfOS0zLTEtMS0yOTE1OA_e3526fa5-ffce-427b-852c-b9c87b2b4068">51,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Term Loan Credit Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 8, 2021, the Company entered into a Term Loan Credit Agreement (Term Loan Agreement) with</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> certain lenders identified therein (collectively, the Lenders) and Wilmington Trust</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, National Association as administrative agent and collateral agent, pursuant to which the Lenders extended to the Company a <ix:nonNumeric contextRef="i82cd05f641874a9cbbe754810cef2c8a_D20210608-20210608" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfODQ4Mg_9744a90a-543f-4438-85ed-46888a34ec5d">six-year</ix:nonNumeric> second lien subordinated term loan in the amount of $<ix:nonFraction unitRef="usd" contextRef="i96ec9493e07f4d46bfd5d30d2e5c107c_I20210608" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMTI5NA_d1489a96-af28-46d9-84d1-9846c97d95f1">100.0</ix:nonFraction>&#160;million (term loan). The term loan has an interest rate of one-month London Inter-Bank Offered Rate (LIBOR) plus <ix:nonFraction unitRef="number" contextRef="ib708536e37a243168ff725de39ebb968_D20210608-20210608" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMTQwMg_59762908-7ea6-4ae9-9353-3b2ddf759e2c">5.75</ix:nonFraction>% per annum, subject to a <ix:nonFraction unitRef="number" contextRef="ib708536e37a243168ff725de39ebb968_D20210608-20210608" decimals="INF" name="ccrn:DebtInstrumentVariableInterestRateFloor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMTQyOQ_3ea58b83-58b1-4bc9-8a3d-0e545c866f4a">0.75</ix:nonFraction>% LIBOR floor. The term loan was used to pay the cash consideration, as well as any costs, fees, and expenses in connection with the WSG acquisition (see Note 4 - Acquisitions), with the remainder used to pay down a </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i10f6c0306e3a43ff908c81522f4f945e" continuedAt="i234f5e1509b443cf9c5522903edf9b85"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">portion of the asset based credit facility. Fees paid in connection with the Term Loan Agreement have been included as debt issuance costs and as a reduction to the carrying amount of the term loan and are expected to be amortized to interest expense over the term of the Term Loan Agreement.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The borrowings under the Term Loan Agreement generally bear interest at a variable rate based on either LIBOR or Base Rate (as defined in the Term Loan Agreement) and are subject to mandatory prepayments of principal payable in quarterly installments, commencing on September 30, 2021, with each installment being in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i82cd05f641874a9cbbe754810cef2c8a_D20210608-20210608" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMjI5MA_6683629d-1fb5-401d-ad10-948d32dbe813">0.3</ix:nonFraction> million (subject to adjustment as a result of prepayments) provided that, to the extent not previously paid, the aggregate unpaid principal balance would be due and payable on the maturity date. The Term Loan Agreement contains various restrictions and covenants applicable to the Company and its subsidiaries, including a covenant to maintain a minimum net leverage ratio. The Company was in compliance with this covenant as of March 31, 2022. Obligations under the Term Loan Agreement are secured by substantially all the assets of the borrowers and guarantors under the Term Loan Agreement, subject to customary exceptions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2021, the Company amended its Term Loan Agreement (Term Loan First Amendment), which provided the Company an incremental term loan in an aggregate amount equal to $<ix:nonFraction unitRef="usd" contextRef="i5020fde8638840f299ef873613611b4e_I20211118" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMTA5OTUxMTYzOTgxNA_5995b743-0331-4201-a33e-6087f7ee9859">75.0</ix:nonFraction>&#160;million. Additionally, the Term Loan First Amendment increased the aggregate amount of all increases (as defined in the Term Loan Agreement) to be no greater than $<ix:nonFraction unitRef="usd" contextRef="idcf113a7dd6d430ab8a1df6502e3ce9b_I20211118" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMTA5OTUxMTYzOTgyOQ_2c809929-2b1b-439b-9793-545027998579">115.0</ix:nonFraction>&#160;million. The borrowings will be used primarily to fund organic growth. Commencing on December 31, 2021, installments of the mandatory prepayments will be in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i57d3f89fcaaa4996af9b46ce7ea8742a_D20211118-20211118" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMTA5OTUxMTYzOTg0NQ_34c294b9-bb9f-4e26-961f-3dc9bcc16488">0.4</ix:nonFraction>&#160;million. All other terms, conditions, covenants, and pricing of the Term Loan Agreement remain the same. In conjunction with the Term Loan First Amendment, the Company entered into the Term Loan First Amendment to the Intercreditor Agreement, effective as of November 18, 2021, which sets forth the lien priority, relative rights, and other creditors&#8217; rights issues in respect of the collateral lenders.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term loan is secured by a second-priority security interest in the collateral as defined in the ABL Credit Agreement (Loan Agreement) (as described below), and Wells Fargo Bank, National Association as agent, as amended by the First Amendment, Second Amendment, Third Amendment, Fourth Amendment, and Fifth Amendment to the Loan Agreement (as described below). The lien priority, relative rights, and other creditors&#8217; rights issues in respect of the collateral lenders are set forth in the Intercreditor Agreement, by and among Wells Fargo Bank, National Association, as first lien agent, and Wilmington Trust, National Association, as second lien agent, as amended, restated, amended and restated, supplemented or otherwise modified from time to time in accordance with the terms thereof dated June 8, 2021 (Intercreditor Agreement).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Loan Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective October 25, 2019, the Company terminated its commitments under its prior senior credit facility entered into in August 2017 and entered into a Loan Agreement, by and among the Company and certain of its domestic subsidiaries, as borrowers or guarantors, Wells Fargo, PNC Bank N.A., as well as other Lenders (as defined) from time to time parties thereto. The Loan Agreement provides for a <ix:nonNumeric contextRef="if5ea6576089f4784ba8f14453a2b1f66_D20191025-20191025" name="us-gaap:LineOfCreditFacilityExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfODQ4NQ_53b599e2-0b0e-424b-92c5-7a021664ee8c">five-year</ix:nonNumeric> revolving senior secured asset-based credit facility (ABL) in the aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i60d48a75f49947d18289dbf4a324b770_I20191025" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNDYwMw_f78906a6-0ad0-4577-967f-342ed1d750e7">120.0</ix:nonFraction>&#160;million (as described below), including a sublimit for swing loans up to $<ix:nonFraction unitRef="usd" contextRef="i8b3c8d82e07543fc99205a3c46af08b6_I20191025" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNDY3MQ_c748fc35-0c98-4faf-a931-3cb46f077337">15.0</ix:nonFraction>&#160;million and a $<ix:nonFraction unitRef="usd" contextRef="i74307f2549e54ddd9cd8d5738288941a_I20191025" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNDY4MA_7dead3a9-8802-47ca-a5e4-500fdbe32171">35.0</ix:nonFraction>&#160;million sublimit for standby letters of credit.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2020, the Company amended its Loan Agreement (First Amendment), which increased the current aggregate committed size of the ABL from $<ix:nonFraction unitRef="usd" contextRef="i60d48a75f49947d18289dbf4a324b770_I20191025" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNDg2OA_14e9fcbc-7f07-48ff-9a4d-07404b28e43c">120.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i4338d967d578487f9eb052fd67dd54b1_I20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNDg3NA_418dd0b9-3d29-4eaf-a96e-544a3c891cf2">130.0</ix:nonFraction>&#160;million. All other terms, conditions, covenants, and pricing of the Loan Agreement remained the same. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2021, the Company amended its Loan Agreement (Second Amendment), which increased the current aggregate committed size of the ABL from $<ix:nonFraction unitRef="usd" contextRef="i4338d967d578487f9eb052fd67dd54b1_I20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNTExOA_3805706e-4b7b-46e5-8989-a0386b251f52">130.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="ib19eb57fb973471fb2c67e92a4731b51_I20210308" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNTEyNA_741cdc85-97ed-46e3-a582-631d467e09be">150.0</ix:nonFraction>&#160;million, increased certain borrowing base sub-limits, and decreased both the cash dominion event and financial reporting triggers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, the Company amended its Loan Agreement (Third Amendment), which permits the incurrence of indebtedness and grant of security as set forth in the Loan Agreement and in accordance with the Intercreditor Agreement, and provides mechanics relating to a transition away from LIBOR as a benchmark interest rate to a replacement alternative benchmark rate or mechanism for loans made in U.S. dollars.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2021, the Company amended its Loan Agreement (Fourth Amendment), whereby the permitted indebtedness (as defined in the Loan Agreement), was increased to $<ix:nonFraction unitRef="usd" contextRef="i8b42bcc4941c443dae883bd802178090_I20211118" decimals="INF" name="ccrn:LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMTY0OTI2NzQ1MDc0NQ_711294f9-9c82-4e49-97fe-c1437f3db6e9">175.0</ix:nonFraction> million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 21, 2022, the Company amended its Loan Agreement (Fifth Amendment), which increased the current aggregate committed size of the ABL from $<ix:nonFraction unitRef="usd" contextRef="ib19eb57fb973471fb2c67e92a4731b51_I20210308" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMTY0OTI2NzQ1MTQ1NA_ced723da-6b8e-4ead-9b83-3878a1feea55">150.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i993410e5ec1b472995349d7ec0413a8c_I20220321" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMTY0OTI2NzQ1MTQ2Mg_58d359ea-1ffe-4808-b4fe-dac50a27e7ab">300.0</ix:nonFraction> million, extended the credit facility for an additional <ix:nonNumeric contextRef="ia214024d55344795bd46a7a0c209b921_D20220321-20220321" name="us-gaap:LineOfCreditFacilityExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMTA5OTUxMTY0MjA3OA_503b4fe8-8fb7-460f-9561-cb0e5d8bdd17">five years</ix:nonNumeric>, and increased certain borrowing base sub-limits. In addition, the agreement provides the option for all or a portion of the borrowings to bear interest at a rate based on the Secured Overnight Financing Rate (SOFR) or Base Rate, at the election of the borrowers, plus an applicable margin. The applicable margin will increase <ix:nonFraction unitRef="number" contextRef="ia214024d55344795bd46a7a0c209b921_D20220321-20220321" decimals="INF" name="ccrn:LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMTA5OTUxMTY0MjA3NA_0db30749-d76a-4eaf-aedd-8898aef85df5">10</ix:nonFraction> basis points due to the credit spread associated with the transition to SOFR.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i234f5e1509b443cf9c5522903edf9b85"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These amendments were treated as modifications of debt and, as a result, the associated fees and costs were included in debt issuance costs and will be amortized ratably over the remaining term of the Loan Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Availability of the ABL commitments is subject to a borrowing base of up to <ix:nonFraction unitRef="number" contextRef="i60d48a75f49947d18289dbf4a324b770_I20191025" decimals="INF" name="ccrn:LineOfCreditBorrowingBasePercentageOfAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNTk1NA_b2f7657f-e3fb-4ecf-9eaa-33ddb55844d4">85</ix:nonFraction>% of secured eligible accounts receivable, subject to adjustment at certain quality levels, minus customary reserves and subject to customary adjustments. Revolving loans and letters of credit issued under the Loan Agreement reduce availability under the ABL on a dollar-for-dollar basis. Availability under the ABL will be used for general corporate purposes. At March 31, 2022, borrowing base availability under the ABL was $<ix:nonFraction unitRef="usd" contextRef="i95b50a07ae9e4b7695f586f6672f3956_I20220331" decimals="INF" name="ccrn:LineOfCreditFacilityBorrowingBaseAvailability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNjUyMg_4fe52437-96e6-45c6-95dc-feb7271eb392">300.0</ix:nonFraction>&#160;million and the Company had $<ix:nonFraction unitRef="usd" contextRef="i95b50a07ae9e4b7695f586f6672f3956_I20220331" decimals="-5" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNjU0NQ_30c7ea49-17cc-415a-870a-db82a49de71d">51.5</ix:nonFraction>&#160;million of borrowings drawn, as well as $<ix:nonFraction unitRef="usd" contextRef="i95b50a07ae9e4b7695f586f6672f3956_I20220331" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNjU4MA_23179574-09c8-40d8-9d40-79ebc2f7b9ca">17.5</ix:nonFraction>&#160;million of letters of credit outstanding related to workers' compensation and professional liability policies, leaving $<ix:nonFraction unitRef="usd" contextRef="i95b50a07ae9e4b7695f586f6672f3956_I20220331" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNjY5NA_41300356-5e48-454c-905e-dde354fe7af1">231.0</ix:nonFraction>&#160;million of excess availability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the interest rate spreads and fees under the Loan Agreement were based on SOFR plus <ix:nonFraction unitRef="number" contextRef="id0b6e77d084e4d879d689a6bca85f0e4_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNjgzMw_c901e690-63bb-4537-b65e-fceb2c6e139b">1.85</ix:nonFraction>% for the revolving portion of the borrowing base. The Base Rate (as defined by the Loan Agreement) margin would have been <ix:nonFraction unitRef="number" contextRef="i9559a9dd705841ba838ccd6ba16e3d37_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNzAwOQ_6360ebea-3fd3-4dfc-8d63-06ec66ebaf85">0.75</ix:nonFraction>%  for the revolving portion</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The SOFR and Base Rate margins are subject to monthly pricing adjustments, pursuant to a pricing matrix based on the Company&#8217;s excess availability under the revolving credit facility. In addition, the facility is subject to an unused line fee, letter of credit fees, and an administrative fee. The unused line fee is <ix:nonFraction unitRef="number" contextRef="ifa90684f57ec460f92896a283e5a90d3_D20220101-20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNzQwOA_4a1797a2-57dc-48f8-94e0-43aebb673372">0.375</ix:nonFraction>% of the average daily unused portion of the revolving credit facility.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement contains various restrictions and covenants applicable to the Company and its subsidiaries, including a covenant to maintain a minimum fixed charge coverage ratio. The Company was in compliance with this covenant as of March 31, 2022. Obligations under the ABL are secured by substantially all the assets of the borrowers and guarantors, subject to customary exceptions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note Payable</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, the Company entered into a note payable of $<ix:nonFraction unitRef="usd" contextRef="ib4c754f48f6947ce94f0c29faed347d7_I20200331" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNzk2MQ_6bfa1db3-1663-45d4-81b0-1e80e3697f2a">7.3</ix:nonFraction>&#160;million related to contingent consideration assumed as part of a prior period acquisition, payable in <ix:nonFraction unitRef="installment" contextRef="ib4c754f48f6947ce94f0c29faed347d7_I20200331" decimals="INF" name="ccrn:NotePayableNumberOfPaymentInstallments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMzg0ODI5MDcwODI2Ng_ac53bd64-a43d-43cc-a7cc-ef2c02fc6054">three</ix:nonFraction> installments. The first <ix:nonFraction unitRef="installment" contextRef="idb38d75eba334b9c9661cc92d3d27b1e_I20210331" decimals="INF" name="ccrn:NotePayableNumberOfInstallmentsPaid" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMzg0ODI5MDcwODI2Mg_408550fb-1b56-4496-8864-c7f68ea61d92">two</ix:nonFraction> installments of $<ix:nonFraction unitRef="usd" contextRef="i693a80db9468442f89e54f2d5e8f012c_D20200401-20200630" decimals="-5" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMzg0ODI5MDcwODI3MA_b3026ad5-dc8f-4a3e-8678-88a38c001d73"><ix:nonFraction unitRef="usd" contextRef="ifc034a2451eb4ad2a115858bbcbb76a3_D20210101-20210331" decimals="-5" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMzg0ODI5MDcwODI3MA_e2559305-7eb4-4fe0-b847-5bb3ed1985d1">2.4</ix:nonFraction></ix:nonFraction>&#160;million each were paid in the second quarter of 2020 and in the first quarter of 2021, respectively. The third and final installment of $<ix:nonFraction unitRef="usd" contextRef="i70a127889d9c4f5facf6c1e12bc5ef60_D20220101-20220331" decimals="-5" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMzg0ODI5MDcwODI3Ng_0e1d8e8b-62bc-4bd7-a9a3-5fed86c4cbd8">2.6</ix:nonFraction>&#160;million, including interest, was paid in the first quarter of 2022.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i1bf462dbbc134b239a7746fda9801e04_61"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RleHRyZWdpb246ZjM0ZjBiODJlZTNjNDdlYzg5Y2E4YWE2ZWJkYjVjNWZfMzY5NQ_0a8b8ee3-b9ef-42bd-a1ac-05e216bf3125" continuedAt="i95788344ccdf4b208795c1e270f1d1cf" escape="true">LEASES</ix:nonNumeric></span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><ix:continuation id="i95788344ccdf4b208795c1e270f1d1cf" continuedAt="i1fe4a743509a4d389cee66d056ba8818"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease population of its right-of-use asset and lease liabilities is substantially related to the rental of office space. The Company enters into lease agreements as a lessee that may include options to extend or terminate early. Some of these real estate leases require variable payments of property taxes, insurance, and common area maintenance, in addition to base rent. Certain of the leases have provisions for free rent months during the lease term and/or escalating rent payments and, particularly for the Company&#8217;s longer-term leases for its corporate offices, it has received incentives to enter into the leases, such as receiving up to a specified dollar amount to construct tenant improvements. These leases do not include residual value guarantees, covenants, or other restrictions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the second quarter of 2020, in connection with the continuing developments from COVID, the Company expedited restructuring plans and either reduced or fully vacated leased office space. The Company is in the process of seeking to sublet some of the space where possible. The decision and change in the use of space resulted in a right-of-use asset impairment charge of $<ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RleHRyZWdpb246ZjM0ZjBiODJlZTNjNDdlYzg5Y2E4YWE2ZWJkYjVjNWZfMTI0OQ_e3fd6ed6-1ac1-4e2e-b406-af138b405e55">1.5</ix:nonFraction>&#160;million for the three months ended March 31, 2022. This loss was determined by comparing the fair value of the impacted right-of-use assets to the carrying value of the assets as of the impairment measurement date. The fair value of the right-of-use assets was based on the estimated sublease income for the space taking into consideration the time period it will take to obtain a subtenant, the applicable discount rate, and the sublease rate. For the three months ended March 31, 2022, the Company wrote off an immaterial amount of leasehold improvements and other property and equipment related to these locations. The Company did not record any lease-related impairment charges for the three months ended March 31, 2021. The measurement of the right-of-use asset impairments, using the assumptions described, is a Level 3 fair value measurement. See Note 10 - Fair Value Measurements for a description of Level 3 inputs.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1fe4a743509a4d389cee66d056ba8818" continuedAt="id6c96c55e37e40458e487e0ae600b178"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="ccrn:AssetsAndLiabilitiesLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RleHRyZWdpb246ZjM0ZjBiODJlZTNjNDdlYzg5Y2E4YWE2ZWJkYjVjNWZfMzY5Ng_e18267ca-0505-46a2-aec2-158fa964f437" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the lease-related assets and liabilities included on the condensed consolidated balance sheets:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification on Condensed Consolidated Balance Sheets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOmY1ZDM4N2I0MGRhNTQyZDdiOTA3YzIyZWZhODhmYjIxL3RhYmxlcmFuZ2U6ZjVkMzg3YjQwZGE1NDJkN2I5MDdjMjJlZmE4OGZiMjFfMi0xLTEtMS0yOTE1OA_e41d2eb2-c697-4bb6-b5e5-e70efd11003d">5,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOmY1ZDM4N2I0MGRhNTQyZDdiOTA3YzIyZWZhODhmYjIxL3RhYmxlcmFuZ2U6ZjVkMzg3YjQwZGE1NDJkN2I5MDdjMjJlZmE4OGZiMjFfMi0zLTEtMS0yOTE1OA_ff2c2e25-8968-41a4-b78d-4e490befd885">7,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOmY1ZDM4N2I0MGRhNTQyZDdiOTA3YzIyZWZhODhmYjIxL3RhYmxlcmFuZ2U6ZjVkMzg3YjQwZGE1NDJkN2I5MDdjMjJlZmE4OGZiMjFfMy0xLTEtMS0yOTE1OA_4c10032b-3140-4954-98d4-2c51027dfb5e">4,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOmY1ZDM4N2I0MGRhNTQyZDdiOTA3YzIyZWZhODhmYjIxL3RhYmxlcmFuZ2U6ZjVkMzg3YjQwZGE1NDJkN2I5MDdjMjJlZmE4OGZiMjFfMy0zLTEtMS0yOTE1OA_6fc3ca3d-66ae-4d8e-aed7-007a6fe0b108">4,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - non-current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOmY1ZDM4N2I0MGRhNTQyZDdiOTA3YzIyZWZhODhmYjIxL3RhYmxlcmFuZ2U6ZjVkMzg3YjQwZGE1NDJkN2I5MDdjMjJlZmE4OGZiMjFfNC0xLTEtMS0yOTE1OA_a08a5177-14b4-4efb-900c-45fb5f721756">9,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOmY1ZDM4N2I0MGRhNTQyZDdiOTA3YzIyZWZhODhmYjIxL3RhYmxlcmFuZ2U6ZjVkMzg3YjQwZGE1NDJkN2I5MDdjMjJlZmE4OGZiMjFfNC0zLTEtMS0yOTE1OA_cf6baad2-1abe-4616-bf22-75657f97051e">10,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjdjZDYxMDU0MWViYjRiYTNhZTBmNjBjNWVmNWUxNjk5L3RhYmxlcmFuZ2U6N2NkNjEwNTQxZWJiNGJhM2FlMGY2MGM1ZWY1ZTE2OTlfMS0xLTEtMS0yOTE1OA_19068705-52e4-4238-88eb-b1e657b1f3ff">3.2</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i023808945518453896c9849a64047565_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjdjZDYxMDU0MWViYjRiYTNhZTBmNjBjNWVmNWUxNjk5L3RhYmxlcmFuZ2U6N2NkNjEwNTQxZWJiNGJhM2FlMGY2MGM1ZWY1ZTE2OTlfMS0zLTEtMS0yOTE1OA_d3c6627f-559e-49d0-8835-1185c72c4835">3.4</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjdjZDYxMDU0MWViYjRiYTNhZTBmNjBjNWVmNWUxNjk5L3RhYmxlcmFuZ2U6N2NkNjEwNTQxZWJiNGJhM2FlMGY2MGM1ZWY1ZTE2OTlfMi0xLTEtMS0yOTE1OA_5537702c-38b1-4fdc-9ed0-162c6f56062b">6.41</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i023808945518453896c9849a64047565_I20211231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjdjZDYxMDU0MWViYjRiYTNhZTBmNjBjNWVmNWUxNjk5L3RhYmxlcmFuZ2U6N2NkNjEwNTQxZWJiNGJhM2FlMGY2MGM1ZWY1ZTE2OTlfMi0zLTEtMS0yOTE1OA_dc3ea5b6-0667-4b67-9f52-3aa3dae768ca">6.39</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RleHRyZWdpb246ZjM0ZjBiODJlZTNjNDdlYzg5Y2E4YWE2ZWJkYjVjNWZfMzY5OA_434e5500-d3aa-45e3-93e5-6c078526e842" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reconciles the undiscounted cash flows for each of, and total of, the remaining years to the operating lease liabilities (which do not include short-term leases) recorded on the condensed consolidated balance sheets as of March 31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:75.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December&#160;31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjczODlhM2ZiMDUxOTQxOGRiYzYyNzM3NDEyNmUxNjk4L3RhYmxlcmFuZ2U6NzM4OWEzZmIwNTE5NDE4ZGJjNjI3Mzc0MTI2ZTE2OThfMS0xLTEtMS0yOTE1OA_0e8eed5a-46bc-42f8-8974-a51cefa09ace">3,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjczODlhM2ZiMDUxOTQxOGRiYzYyNzM3NDEyNmUxNjk4L3RhYmxlcmFuZ2U6NzM4OWEzZmIwNTE5NDE4ZGJjNjI3Mzc0MTI2ZTE2OThfMi0xLTEtMS0yOTE1OA_0fe53a9b-0502-4a2a-9277-3de29eb0acc6">4,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjczODlhM2ZiMDUxOTQxOGRiYzYyNzM3NDEyNmUxNjk4L3RhYmxlcmFuZ2U6NzM4OWEzZmIwNTE5NDE4ZGJjNjI3Mzc0MTI2ZTE2OThfMy0xLTEtMS0yOTE1OA_4298378b-fd62-453b-bc8e-6d6f227dd825">3,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjczODlhM2ZiMDUxOTQxOGRiYzYyNzM3NDEyNmUxNjk4L3RhYmxlcmFuZ2U6NzM4OWEzZmIwNTE5NDE4ZGJjNjI3Mzc0MTI2ZTE2OThfNC0xLTEtMS0yOTE1OA_ce2693ef-7e74-496f-b4c8-87d4200490bd">2,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjczODlhM2ZiMDUxOTQxOGRiYzYyNzM3NDEyNmUxNjk4L3RhYmxlcmFuZ2U6NzM4OWEzZmIwNTE5NDE4ZGJjNjI3Mzc0MTI2ZTE2OThfNi0xLTEtMS0yOTE1OA_0a3dda89-923c-40b9-aa86-c22e4adcb963">15,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjczODlhM2ZiMDUxOTQxOGRiYzYyNzM3NDEyNmUxNjk4L3RhYmxlcmFuZ2U6NzM4OWEzZmIwNTE5NDE4ZGJjNjI3Mzc0MTI2ZTE2OThfNy0xLTEtMS0yOTE1OA_33ac78a6-7591-4c54-974f-195d8de9399b">1,482</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjczODlhM2ZiMDUxOTQxOGRiYzYyNzM3NDEyNmUxNjk4L3RhYmxlcmFuZ2U6NzM4OWEzZmIwNTE5NDE4ZGJjNjI3Mzc0MTI2ZTE2OThfOC0xLTEtMS0yOTE1OA_abf57638-ef17-424a-8f77-390e9b6cfc0e">13,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: operating lease liabilities - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjczODlhM2ZiMDUxOTQxOGRiYzYyNzM3NDEyNmUxNjk4L3RhYmxlcmFuZ2U6NzM4OWEzZmIwNTE5NDE4ZGJjNjI3Mzc0MTI2ZTE2OThfOS0xLTEtMS0yOTE1OA_d058f248-921e-45db-8c18-cfb8efc2062a">4,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - non-current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjczODlhM2ZiMDUxOTQxOGRiYzYyNzM3NDEyNmUxNjk4L3RhYmxlcmFuZ2U6NzM4OWEzZmIwNTE5NDE4ZGJjNjI3Mzc0MTI2ZTE2OThfMTAtMS0xLTEtMjkxNTg_72c3f0de-b9fb-4bab-8e51-6081104e3b04">9,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Information</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RleHRyZWdpb246ZjM0ZjBiODJlZTNjNDdlYzg5Y2E4YWE2ZWJkYjVjNWZfMzcwMA_a576f39f-70b9-4a24-9cb4-fa346232fff1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding supplemental cash flows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOmIwOTI2YmNmZTJmMDQwMzc5OWZkZjliMzgzNWM0ZGRjL3RhYmxlcmFuZ2U6YjA5MjZiY2ZlMmYwNDAzNzk5ZmRmOWIzODM1YzRkZGNfNS0xLTEtMS0yOTE1OA_d866a96f-29d4-4d13-9f5a-ada02224c361">1,383</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOmIwOTI2YmNmZTJmMDQwMzc5OWZkZjliMzgzNWM0ZGRjL3RhYmxlcmFuZ2U6YjA5MjZiY2ZlMmYwNDAzNzk5ZmRmOWIzODM1YzRkZGNfNS0zLTEtMS0yOTE1OA_de3d0326-4409-47a3-b248-9fd7ff232e2a">1,637</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets acquired under operating lease</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOmIwOTI2YmNmZTJmMDQwMzc5OWZkZjliMzgzNWM0ZGRjL3RhYmxlcmFuZ2U6YjA5MjZiY2ZlMmYwNDAzNzk5ZmRmOWIzODM1YzRkZGNfNi0xLTEtMS0yOTE1OA_a85709eb-a157-4e2e-b435-257581c08955">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOmIwOTI2YmNmZTJmMDQwMzc5OWZkZjliMzgzNWM0ZGRjL3RhYmxlcmFuZ2U6YjA5MjZiY2ZlMmYwNDAzNzk5ZmRmOWIzODM1YzRkZGNfNi0zLTEtMS0yOTE1OA_0b43ab92-2766-4602-aced-375d3e90fce6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Included in Condensed Consolidated Statements of Operations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjk5Mzk1ZjY5NTE5YTQyMjY4MDFkNjQzM2MzNTQ5OTI4L3RhYmxlcmFuZ2U6OTkzOTVmNjk1MTlhNDIyNjgwMWQ2NDMzYzM1NDk5MjhfNS0xLTEtMS0yOTE1OA_02c637ac-96aa-41ec-b6fe-8db5975de28d">802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjk5Mzk1ZjY5NTE5YTQyMjY4MDFkNjQzM2MzNTQ5OTI4L3RhYmxlcmFuZ2U6OTkzOTVmNjk1MTlhNDIyNjgwMWQ2NDMzYzM1NDk5MjhfNS0zLTEtMS0yOTE1OA_6462a25f-9fea-47e7-98eb-c390b96e99d7">914</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjk5Mzk1ZjY5NTE5YTQyMjY4MDFkNjQzM2MzNTQ5OTI4L3RhYmxlcmFuZ2U6OTkzOTVmNjk1MTlhNDIyNjgwMWQ2NDMzYzM1NDk5MjhfNi0xLTEtMS0yOTE1OA_5b4daa5d-3ad1-4bd0-98da-4a6d83819e81">1,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjk5Mzk1ZjY5NTE5YTQyMjY4MDFkNjQzM2MzNTQ5OTI4L3RhYmxlcmFuZ2U6OTkzOTVmNjk1MTlhNDIyNjgwMWQ2NDMzYzM1NDk5MjhfNi0zLTEtMS0yOTE1OA_456dd94e-3036-43c9-859b-860f4b73a5b5">849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable and other lease costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjk5Mzk1ZjY5NTE5YTQyMjY4MDFkNjQzM2MzNTQ5OTI4L3RhYmxlcmFuZ2U6OTkzOTVmNjk1MTlhNDIyNjgwMWQ2NDMzYzM1NDk5MjhfNy0xLTEtMS0yOTE1OA_e92a8fff-6878-4f6e-ac96-b347ecd4a565">757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjk5Mzk1ZjY5NTE5YTQyMjY4MDFkNjQzM2MzNTQ5OTI4L3RhYmxlcmFuZ2U6OTkzOTVmNjk1MTlhNDIyNjgwMWQ2NDMzYzM1NDk5MjhfNy0zLTEtMS0yOTE1OA_43a5a3c0-302f-48d1-8c00-4e926eec00a2">468</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id6c96c55e37e40458e487e0ae600b178"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense, short-term lease expense, and variable and other lease costs are included in selling, general and administrative expenses, direct operating expenses, and restructuring costs in the condensed consolidated statements of operations, depending on the nature of the leased asset. Operating lease expense is reported net of sublease income, which is not material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the Company does not have any material operating leases which have not yet commenced. The Company has an immaterial</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amount of finance lease contracts related to other equipment rentals which are not included in the above disclosures.</span></div></ix:continuation><div><span><br/></span></div><div id="i1bf462dbbc134b239a7746fda9801e04_64"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RleHRyZWdpb246N2Q1MTdiOTdkZTYzNGM4ZTljZmRjYjE4MWI3ZjNiNTdfNTIwMQ_f418c3f5-9b8a-441f-801e-3b9f99137f9c" continuedAt="i63f9e4f964f64120ac068ce13a1bf05a" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i63f9e4f964f64120ac068ce13a1bf05a" continuedAt="i41415020427942c89721f8bc478ca62c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy was established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Items Measured at Fair Value on a Recurring Basis:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial assets/liabilities required to be measured on a recurring basis were its: (i) deferred compensation asset included in other non-current assets; and (ii) deferred compensation liability included in other long-term liabilities on its condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company utilizes Level 1 inputs to value its deferred compensation assets and liabilities. The Company&#8217;s deferred compensation assets and liabilities are measured using publicly available indices, as per the plan documents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RleHRyZWdpb246N2Q1MTdiOTdkZTYzNGM4ZTljZmRjYjE4MWI3ZjNiNTdfNTE5NQ_3a294061-b8c0-4fc2-8bc9-e4d1aa8bf6ec" continuedAt="i102c2fcf19a3436a9c89186d4e75374f" escape="true">The estimated fair value of the Company&#8217;s financial assets and liabilities measured on a recurring basis is as follows:&#160;</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:center"><ix:continuation id="i102c2fcf19a3436a9c89186d4e75374f"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:58.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation asset</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i495fb315b409472492e63b658e2d1f69_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOjhmOWU2YzBhY2UyYjQ4ZDk5YmJhMGE1M2Y5Mjk0ZGM0L3RhYmxlcmFuZ2U6OGY5ZTZjMGFjZTJiNDhkOTliYmEwYTUzZjkyOTRkYzRfNC0xLTEtMS0yOTE1OA_0e869822-0719-40c9-8f57-388df3f013bd">1,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie29a28d5bec04a9a89dd3aad07f2f287_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOjhmOWU2YzBhY2UyYjQ4ZDk5YmJhMGE1M2Y5Mjk0ZGM0L3RhYmxlcmFuZ2U6OGY5ZTZjMGFjZTJiNDhkOTliYmEwYTUzZjkyOTRkYzRfNC0zLTEtMS0yOTE1OA_d7fd73f5-7bd4-4e84-a8ea-884a335038e3">1,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities:</span></td><td colspan="9" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14c7086aa5ac419fb6760c4660fcbb9f_I20220331" decimals="-3" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOjhmOWU2YzBhY2UyYjQ4ZDk5YmJhMGE1M2Y5Mjk0ZGM0L3RhYmxlcmFuZ2U6OGY5ZTZjMGFjZTJiNDhkOTliYmEwYTUzZjkyOTRkYzRfNy0xLTEtMS0yOTE1OA_96b7961e-58e1-4212-b9fd-e032e00b524a">2,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ad89b3e2c34d8baa20d7aaa26a7b15_I20211231" decimals="-3" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOjhmOWU2YzBhY2UyYjQ4ZDk5YmJhMGE1M2Y5Mjk0ZGM0L3RhYmxlcmFuZ2U6OGY5ZTZjMGFjZTJiNDhkOTliYmEwYTUzZjkyOTRkYzRfNy0zLTEtMS0yOTE1OA_90d0c418-9b80-4644-a1c2-7cbdc228df7e">2,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Items Measured at Fair Value on a Non-Recurring Basis:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's non-financial assets, such as goodwill, trade names, other intangible assets, right-of-use assets, and property and equipment, are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized. </span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i41415020427942c89721f8bc478ca62c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three months ended March 31, 2022 included impairment charges to right-of-use assets along with related property and equipment in connection with leases that were vacated. Accordingly, as of March 31, 2022, these assets were recorded at fair value using Level 3 inputs. See Note 9 - Leases for more information about these fair value measurements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments not measured or recorded at fair value in the condensed consolidated balance sheets consist of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses. The estimated fair value of accounts receivable and accounts payable and&#160;accrued expenses approximate their carrying amount due to the short-term nature of these instruments. Other financial instruments not measured or recorded at fair value include: (i) note payable, (ii) ABL, (iii) term loan, and (iv) and (v) earnout liabilities, as discussed below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(i) The Company paid the third and final installment on its note payable in the first quarter of 2022. Due to its relatively short-term nature, the carrying value of the note payable approximated its fair value. (ii) The carrying amount of the Company's ABL approximates fair value because the interest rates are variable and reflective of market rates. (iii) The estimated fair value of the Company's term loan was calculated applying an interest rate lattice model using Level 2 inputs from available market information. (iv) Potential earnout payments related to the WSG acquisition are contingent upon meeting certain performance requirements based on 2021 through 2023 performance. The Company performed an analysis using multiple forecasted scenarios to determine the fair value of the earnout liability. The earnout liability's carrying amount approximates fair value and is included in current portion of earnout liability and non-current earnout liability on the condensed consolidated balance sheets. (v) Potential earnout payments related to the Selected acquisition are contingent upon meeting certain performance requirements based on 2022 and 2023 revenues. The earnout liability's carrying amount approximates fair value and is included in current portion of earnout liability and non-current earnout liability on the condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RleHRyZWdpb246N2Q1MTdiOTdkZTYzNGM4ZTljZmRjYjE4MWI3ZjNiNTdfNTIxNg_77b8d5b2-16cc-45db-8671-5b3caa7f9742" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and estimated fair value of the Company&#8217;s significant financial instruments that were not measured at fair value are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.108%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note Payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a52a3cb4a2040cb8b1b261cb0ee596b_I20220331" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNC0xLTEtMS0yOTE1OA_1f7f7429-4d7b-4896-8657-5b1d2f9334ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ac23aba6aa4403a0bad0cba4ae5902_I20220331" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNC0zLTEtMS0yOTE1OA_d983a2c6-dffe-42a1-93b6-bd9054525ce8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf46906e48741ed893ff4a25259f391_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNC01LTEtMS0yOTE1OA_6f1f2ae2-06ee-41a1-973b-46f832d633b3">2,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03cfea49b0a745c8963d38be107a4c1a_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNC03LTEtMS0yOTE1OA_d1276f5e-c111-42d3-bf75-46ee255c0a36">2,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Secured Asset-Based Loan</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb29dbc47e244bdab628f989817d591_I20220331" decimals="-3" name="us-gaap:LinesOfCreditFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNS0xLTEtMS0yOTE1OA_3f5623e8-0a04-4e6f-ba2e-42adf3f29715">51,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8bb48f02ecf42d9aeaca2be048ca7f8_I20220331" decimals="-3" name="us-gaap:LinesOfCreditFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNS0zLTEtMS0yOTE1OA_ac0e91da-6cb0-46fa-b82e-54d5c8deec75">51,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70a1b0b08d174a06886a168bcf0b7dbb_I20211231" decimals="-3" name="us-gaap:LinesOfCreditFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNS01LTEtMS0yOTE1OA_71059074-3f4f-4033-9c4e-bb6436d4b649">9,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1748aed1a144618a97c5849fa459254_I20211231" decimals="-3" name="us-gaap:LinesOfCreditFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNS03LTEtMS0yOTE1OA_85d2fa1e-4a66-4ffd-b8fe-4dcbe42157b1">9,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan, net</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d432683d3b6435ba0c48c4efd028d04_I20220331" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNi0xLTEtMS0yOTE1OA_b9e641e3-9748-4ddf-9ec2-d607c3f3a944">173,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9729fca27ba4b91a962fe9441fbd9cc_I20220331" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNi0zLTEtMS0yOTE1OA_0a1a5210-1afe-4db6-b22a-dc2981479de3">174,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77d0216a9f1b4205af250d1c80679b15_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNi01LTEtMS0yOTE1OA_f90db467-15cd-410a-a7f8-637c57eadb97">174,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id44bfe574f91423a9f3987ed1f01a93a_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNi03LTEtMS0yOTE1OA_e30ab461-27e9-4871-857b-3db38a7ae5fb">174,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnout Liability (WSG)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id106177b91204212b84484a1a875400b_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNy0xLTEtMS0zMjQyNw_8d6d2591-60f1-4eb1-bb3c-5faf28f32a79">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if502c32883544beda4be6398c9526e3e_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNy0zLTEtMS0zMjQyNw_f4110304-dc1b-45ec-bb69-242386e7269e">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553a10fc40144f8a768aabc88e29e1a_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNy01LTEtMS0zMjQyNw_9b05bc97-02dd-4bd0-8eda-7ca72d2f83dc">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i887ee4f6baf748d98a8def4c75aea2d2_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNy03LTEtMS0zMjQyNw_55d6c938-f57f-4cb7-9a6f-09a419de0cbe">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnout Liability (Selected)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29edde64b2264b2aa2d76cb1e65aeb1b_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNy0xLTEtMS0yOTE1OA_3041b0a6-826c-447e-bae5-71251eb2e811">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8cf64a57b224d7c87d32895718dc0f5_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNy0zLTEtMS0yOTE1OA_e12c1f4c-ba84-48c3-b800-fc900267f342">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39f100435cf24b988a31207c13a30eb4_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNy01LTEtMS0yOTE1OA_f9705464-b0eb-4e57-9471-dcc3581f1a6f">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae329d6e3c6a4d0d82b7abd882130b4f_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNy03LTEtMS0yOTE1OA_550dbc14-0517-4f58-ad24-65794a7b596c">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk:</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See discussion of credit losses and allowance for doubtful accounts in Note 2 - Summary of Significant Accounting Policies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, based on the large number of customers in differing geographic areas, primarily throughout the United States and its territories, the Company believes the concentration of credit risk is limited.</span></div></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1bf462dbbc134b239a7746fda9801e04_67"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMzIyMw_f28b7409-6555-4640-9e59-8dabd455513c" continuedAt="i13edd31d5d6d4c1fbce3bffd0ea23490" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i13edd31d5d6d4c1fbce3bffd0ea23490" continuedAt="i556a85490de84f09bbdd940a91efb7d6"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Repurchase Program</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022 and 2021, the Company did <ix:nonFraction unitRef="shares" contextRef="i06767ccc204342efa16a4ea58b5982f0_D20210101-20210331" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMTMy_41c2d8e0-d5f7-4aa1-9d6b-c890d65c2b4f"><ix:nonFraction unitRef="shares" contextRef="i2d3c21c3ae5d48b38f7e5a3af77e2ef9_D20220101-20220331" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMTMy_8f5335b4-e6b6-4135-a54b-b63ec3713294">no</ix:nonFraction></ix:nonFraction>t repurchase any shares of its common stock. As of March&#160;31, 2022, the Company has <ix:nonFraction unitRef="shares" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="INF" name="us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMjA0_8a7e18b8-74bf-4a4e-8567-3308820b4c21">510,004</ix:nonFraction> shares of common stock under the current share repurchase program available to repurchase, subject to certain conditions in the Company's Loan Agreement and Term Loan Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Payments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 19, 2020, the Company's stockholders approved the Cross Country Healthcare, Inc. 2020 Omnibus Incentive Plan (2020 Plan), which replaced the 2017 Omnibus Incentive Plan (2017 Plan), and applies to awards granted after May 19, 2020. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i556a85490de84f09bbdd940a91efb7d6"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining shares available for grant under the 2017 Plan were cancelled and no further awards will be granted under that plan. The 2020 Plan generally mirrors the terms of the 2017 Plan and includes the following provisions: (i) an aggregate share reserve of <ix:nonFraction unitRef="shares" contextRef="i7193b285bbb7464db035176165d555b2_I20200519" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfOTE2_6f8be641-b23c-4138-b0d3-bec40ff30ae7">3,000,000</ix:nonFraction> shares; (2) annual dollar and share limits of awards granted to employees and consultants, as well as non-employee directors, based on type of award; (3) awards granted generally will be subject to a minimum <ix:nonNumeric contextRef="i9be85c5f345e42d68f473356014730e2_D20220101-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMzIyMQ_6eefd626-5347-420a-afbf-91a67883dc33">one-year</ix:nonNumeric> vesting schedule; and (4) awards may be granted under the 2020 Plan until March 24, 2030.</span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMzIxNQ_19a08ff5-bf24-4f11-8f0b-4dda8936d0a1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock awards and performance stock awards activity issued under the 2017 Plan and the 2020 Plan (Plans) for the three months ended March&#160;31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Stock Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance Stock Awards</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Target <br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock awards, January&#160;1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i95016a76eb2d4e2bb36c7a7aceb60b64_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfMi0xLTEtMS0yOTE1OA_febd175e-86c8-479e-9eb8-0e1f5a0000f3">1,039,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i95016a76eb2d4e2bb36c7a7aceb60b64_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfMi0zLTEtMS0yOTE1OA_f119b2ef-8f55-460c-96d4-54634d702f1b">9.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib59ced0f2c644556a8fe7a1d5d8f161a_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfMi01LTEtMS0yOTE1OA_9b378c9f-4b7f-4062-af20-c934d682712d">522,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib59ced0f2c644556a8fe7a1d5d8f161a_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfMi03LTEtMS0yOTE1OA_c662e000-8edf-4056-a6f0-ca074be537bf">8.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia39ce4bfecff4fc1995df5920a618bf6_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfMy0xLTEtMS0yOTE1OA_3a78637c-69ca-4b8c-8442-fb99e700f3a9">215,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia39ce4bfecff4fc1995df5920a618bf6_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfMy0zLTEtMS0yOTE1OA_c074fdb2-73cf-4757-a552-b132de1f59d1">21.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34b2f55df92d4cbbb60faf19e1ead3be_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfMy01LTEtMS0yOTE1OA_d513ee55-4774-4158-b5af-f84027007189">154,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i34b2f55df92d4cbbb60faf19e1ead3be_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfMy03LTEtMS0yOTE1OA_b8b8eda7-7371-4d16-b481-38d931e855bf">18.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia39ce4bfecff4fc1995df5920a618bf6_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNC0xLTEtMS0yOTE1OA_3921600c-b8d7-4839-844a-fa058c19ff72">481,231</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia39ce4bfecff4fc1995df5920a618bf6_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNC0zLTEtMS0yOTE1OA_cfb0b987-2248-4587-8ebf-084d042f30f5">8.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i34b2f55df92d4cbbb60faf19e1ead3be_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNC01LTEtMS0yOTE1OA_84ca2268-51e0-4a68-96b9-314aac123834">170,278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i34b2f55df92d4cbbb60faf19e1ead3be_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNC03LTEtMS0yOTE1OA_7ceb9ad4-b38d-4e33-b36d-bcc937f63984">7.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia39ce4bfecff4fc1995df5920a618bf6_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNS0xLTEtMS0yOTE1OA_1c3a9aea-7a5b-477c-8d3f-24815e467f1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia39ce4bfecff4fc1995df5920a618bf6_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNS0zLTEtMS0yOTE1OA_83fb6751-714a-43d6-a011-fa5842f4cadc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34b2f55df92d4cbbb60faf19e1ead3be_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNS01LTEtMS0yOTE1OA_ef6bc877-06ce-422d-8d63-d09d98131c11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i34b2f55df92d4cbbb60faf19e1ead3be_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNS03LTEtMS0yOTE1OA_75b8d55e-4d0d-496c-9e6d-b2db397d290c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock awards, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1517da25a84b468e8171eb1381c84236_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNi0xLTEtMS0yOTE1OA_06b1f656-9e5d-4f7c-ade9-cfc03688c18e">773,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1517da25a84b468e8171eb1381c84236_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNi0zLTEtMS0yOTE1OA_569a7109-a2fd-4750-87bc-c368d9857f4f">13.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00fee55829f24128b87768be086342b2_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNi01LTEtMS0yOTE1OA_e9c68be4-568d-4ac3-8d33-44f85b06b998">506,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i00fee55829f24128b87768be086342b2_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNi03LTEtMS0yOTE1OA_0c435937-a42b-4443-a0d2-46420f3fd1e7">12.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards granted under the Company&#8217;s Plans entitle the holder to receive, at the end of a vesting period, a specified number of shares of the Company&#8217;s common stock. Share-based compensation expense is measured by the market value of the Company&#8217;s stock on the date of grant. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards granted to non-employee directors under the 2017 Plan, prior to the adoption of the 2020 Plan, vest in <ix:nonFraction unitRef="installment" contextRef="i95f14a36e510429b9814bb8e62be49e0_D20220101-20220331" decimals="INF" name="ccrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMTgwNQ_2ef77b09-8e36-4295-9bb5-f855b56ab1c3">three</ix:nonFraction> equal installments on the first, second and third anniversaries of the grant date, while restricted shares granted under the 2020 Plan on and subsequent to June 2020 will vest on the first anniversary of such grant date, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or earlier subject to retirement eligibility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, effective in the three months ended June 30, 2020, the Company implemented modified guidelines that provide for accelerated vesting of restricted stock grants on the last date of service when a retirement-eligible director retires.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Plans, the number of target shares that are issued for performance-based stock awards are determined based on the level of attainment of the targets. During the first quarter of 2022, the Company's Compensation Committee of the Board of Directors approved a <ix:nonFraction unitRef="number" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="INF" name="ccrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMTA5OTUxMTYzMjA2OA_d26d2ca2-0db8-4e28-8d9b-e540e80fe011">120</ix:nonFraction>% level of attainment for the 2019 performance-based share awards, resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="i34b2f55df92d4cbbb60faf19e1ead3be_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMTA5OTUxMTYzMjA3NA_4363d75a-cb56-4365-ad73-a0472d22d5d5">170,278</ix:nonFraction> performance shares that vested on March 31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March 31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i0518a6d4c63940e7a94abc3ec794e0f8_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMjcwNg_1132d110-d86c-48f7-927d-f461d2e5ad48">1.6</ix:nonFraction> million was included in selling, general and administrative expenses related to share-based payments, and a net of <ix:nonFraction unitRef="shares" contextRef="ia39ce4bfecff4fc1995df5920a618bf6_D20220101-20220331" decimals="INF" name="ccrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMjgzOA_e7c8ea22-6352-4f24-8b62-0fbbe278e0bf">419,500</ix:nonFraction> shares of common stock were issued upon the vesting of restricted and performance stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i2c0d11239d38482d878be193fb27e8f6_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMjk4NA_96ea3832-b134-4d43-a63a-84016c988e3e">1.3</ix:nonFraction> million was included in selling, general and administrative expenses related to share-based payments, and a net of <ix:nonFraction unitRef="shares" contextRef="if94c5d761a504a69a0f377a89797162b_D20210101-20210331" decimals="INF" name="ccrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMzExNg_22109e6b-40c5-434b-bd6f-8cf5844315e3">317,605</ix:nonFraction> shares of common stock were issued upon the vesting of restricted stock.</span></div></ix:continuation><div><span><br/></span></div><div id="i1bf462dbbc134b239a7746fda9801e04_70"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RleHRyZWdpb246ODAyYWIwZWEwNjVkNDZkZWE0NDQzNTk1NTg2YjYwNDVfMzU2OA_8f146f2d-5cd9-41df-98ec-665ac5ca544b" continuedAt="i9c8572d69a4d42779cd1e18d7402fa38" escape="true">SEGMENT DATA</ix:nonNumeric></span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><ix:continuation id="i9c8572d69a4d42779cd1e18d7402fa38" continuedAt="i478990b88d21438281b8c4336013b860"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s segments offer services to its customers as described below:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9679;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nurse and Allied Staffing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Nurse and Allied Staffing provides traditional staffing, recruiting, and value-added total talent solutions including: temporary and permanent placement of travel and local nurse and allied professionals, managed services programs (MSP) services, education healthcare services, in-home care services, and outsourcing services. In addition, Nurse and Allied Staffing provides retained search services for healthcare professionals, as well as contingent search and recruitment process outsourcing services. Its clients include: public and private acute-care and non-acute care hospitals, government facilities, local and national healthcare plans, managed care providers, public schools and charter schools, outpatient clinics, ambulatory care facilities, physician practice groups, and many other healthcare providers throughout the United States.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9679;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Physician Staffing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Physician Staffing provides physicians in many specialties, as well as certified registered nurse anesthetists, nurse practitioners, and physician assistants as independent contractors on temporary assignments </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i478990b88d21438281b8c4336013b860"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">throughout the United States at various healthcare facilities, such as acute and non-acute care facilities, medical group practices, government facilities, and managed care organizations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates performance of each segment primarily based on revenue and contribution income. The Company defines contribution income as income (loss) from operations before depreciation and amortization, acquisition and integration-related costs, restructuring costs, legal settlement charges, impairment charges, and corporate overhead. The Company does not evaluate, manage, or measure performance of segments using asset information; accordingly, total asset information by segment is not prepared or disclosed. The information in the following table is derived from the segments&#8217; internal financial information as used for corporate management purposes. Certain corporate expenses are not allocated to and/or among the operating segments.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RleHRyZWdpb246ODAyYWIwZWEwNjVkNDZkZWE0NDQzNTk1NTg2YjYwNDVfMzU2NA_17743470-6a96-4f22-84d0-8ba2eb7bfe08" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on operating segments and a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reconciliation to income from operations for the periods indicated are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from services:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nurse and Allied Staffing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f67d3164490454dbd2421830ac30a99_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfNS0xLTEtMS0yOTE1OA_28f3d93e-1cf6-4164-a506-0640121fcdfd">765,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide86e9d4790e48b881466a5c8b847256_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfNS0zLTEtMS0yOTE1OA_7c5ff0c1-2e50-4082-9774-09775eea6d69">313,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physician Staffing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie35cd3b9be00467fbc0b9f82f0c6c7da_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfNi0xLTEtMS0yOTE1OA_6c11becb-3b14-4e9c-b120-21cd7c38a24f">23,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad432390898d40dabc7fcb10fd9dd0ae_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfNi0zLTEtMS0yOTE1OA_f5785474-3bde-4e02-b4b0-2230bf358eab">16,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfNy0xLTEtMS0yOTE1OA_718ff009-c7e4-4509-9112-c8f0793e63f1">788,732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfNy0zLTEtMS0yOTE1OA_d16aa131-59cb-4956-ae9b-95a00402d63d">329,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nurse and Allied Staffing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f67d3164490454dbd2421830ac30a99_D20220101-20220331" decimals="-3" name="ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTAtMS0xLTEtMjkxNTg_930211ad-a9f2-490b-988d-70c146ceddaf">110,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide86e9d4790e48b881466a5c8b847256_D20210101-20210331" decimals="-3" name="ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTAtMy0xLTEtMjkxNTg_d9821eab-4322-478e-b7c3-2bc7e54d0c37">37,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physician Staffing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie35cd3b9be00467fbc0b9f82f0c6c7da_D20220101-20220331" decimals="-3" name="ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTEtMS0xLTEtMjkxNTg_0c589c77-e102-4fe0-b0e8-ccc953ff90c9">1,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad432390898d40dabc7fcb10fd9dd0ae_D20210101-20210331" decimals="-3" name="ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTEtMy0xLTEtMjkxNTg_4466d9c2-9e71-440d-b9ca-26944330ff79">1,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTItMS0xLTEtMjkxNTg_fd170f26-9268-469d-bac9-169aed84d133">111,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTItMy0xLTEtMjkxNTg_96a5fbdc-86f0-48bd-a252-e06cf1cc764b">38,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate overhead </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="ccrn:SegmentReportingUnallocatedCorporateExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTQtMS0xLTEtMjkxNTg_41ef2cf8-9685-4c20-a8d0-2bd5f96319c4">16,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="ccrn:SegmentReportingUnallocatedCorporateExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTQtMy0xLTEtMjkxNTg_be59c291-db8d-4206-8add-5bcc46b59e08">14,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTUtMS0xLTEtMjkxNTg_f0819776-f115-439f-b8b2-8a739e8e5acc">2,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTUtMy0xLTEtMjkxNTg_8c93bcd7-1c63-4b77-b74e-9697063418bf">2,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration-related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="ccrn:AcquisitionAndIntegrationRelatedCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTYtMS0xLTEtMjkxNTg_df8ce719-848e-48b0-abf9-4ca6c8b40e28">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="ccrn:AcquisitionAndIntegrationRelatedCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTYtMy0xLTEtMjkxNTg_218b063f-3dba-4359-9fd1-8019100ca37c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTctMS0xLTEtMjkxNTg_6885145f-03e8-4ba1-9355-512300efb6d3">480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTctMy0xLTEtMjkxNTg_c20a6871-776c-4e69-a133-c68c83e1171b">1,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTgtMS0xLTEtMjkxNTg_e0169b01-cb5e-44b0-9100-1a8ea387136d">1,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTgtMy0xLTEtMjkxNTg_308931de-2bbb-42fa-a4be-a2542ffe0c8f">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTktMS0xLTEtMjkxNTg_cc883229-c33e-4549-a656-81f00b84a3da">90,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTktMy0xLTEtMjkxNTg_ccac4972-3410-413b-b66b-81c03b554b2a">20,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives).</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i1bf462dbbc134b239a7746fda9801e04_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83My9mcmFnOjBmMjIwY2RlMDUwNzRmZTZiMjhhZjRkNzg1NmMyNzQ0L3RleHRyZWdpb246MGYyMjBjZGUwNTA3NGZlNmIyOGFmNGQ3ODU2YzI3NDRfMzE2NQ_5e4a6d2a-feca-4dc1-b69a-e579434ffa34" continuedAt="i6a215fc209584a599eb0cfbefd346299" escape="true">CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i6a215fc209584a599eb0cfbefd346299" continuedAt="i639c4f380a164a7c84a7b2e6b8199afa"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various litigation, claims, investigations, and other proceedings that arise in the ordinary course of its business. These matters primarily relate to employee-related matters that include individual and collective claims, professional liability, tax, and payroll practices. The Company establishes reserves when available information indicates that a loss is probable and an amount or range of loss can be reasonably estimated. These assessments are performed at least quarterly and are based on the information available to management at the time and involve significant management judgment to determine the probability and estimated amount of potential losses, if any. Based on the available information considered in its reviews, the Company adjusts its loss contingency accruals and its disclosures as may be required. Actual outcomes or losses may differ materially from those estimated by the Company's current assessments, including available insurance recoveries, which would impact the Company's profitability. Adverse developments in existing litigation claims or legal proceedings involving the Company or new claims could require management to establish or increase litigation reserves or enter into unfavorable settlements or satisfy judgments for monetary damages for amounts in excess of current reserves, which could adversely affect the Company's financial results. The Company believes the outcome of any outstanding loss contingencies as of March 31, 2022 will not have a material adverse effect on its business, financial condition, results of operations, or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales and Other State Non-Income Tax Liabilities </span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i639c4f380a164a7c84a7b2e6b8199afa">The Company's sales and other state non-income tax filings are subject to routine audits by authorities in the jurisdictions where it conducts business in the United States which may result in assessments of additional taxes. The Company accrues sales and other non-income tax liabilities based on the Company's best estimate of its probable liability utilizing currently available information and interpretation of relevant tax regulations. Given the nature of the Company's business, significant subjectivity exists as to both whether sales and other state non-income taxes can be assessed on its activity and how the sales tax will ultimately be measured by the relevant jurisdictions. The Company makes a determination for each reporting period whether the estimates for sales and other non-income taxes in certain states should be revised. The expense is included in selling, general and administrative expenses in the Company's condensed consolidated statements of operations and the liability is reflected in sales tax payable within other current liabilities in its condensed consolidated balance sheets.</ix:continuation> </span></div><div><span><br/></span></div><div id="i1bf462dbbc134b239a7746fda9801e04_76"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83Ni9mcmFnOmQ2ZTQ0NDQ1MDdjNzRlNzk5MTFmMzM1OWU3ODFhODYzL3RleHRyZWdpb246ZDZlNDQ0NDUwN2M3NGU3OTkxMWYzMzU5ZTc4MWE4NjNfMjM1Ng_8e6a0dbc-3b3f-46e9-ac85-d1333b2b38bd" continuedAt="ifb13b1e8fc1547f581819c29f1315ad3" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="ifb13b1e8fc1547f581819c29f1315ad3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three-month period ended March 31, 2022, the Company calculated its effective tax rate estimating its annual effective tax rate as opposed to the quarter ended March 31, 2021, whereby the Company calculated its effective tax rate based on year-to-date results. The Company&#8217;s effective tax rate for the three months ended March 31, 2022 and 2021 was <ix:nonFraction unitRef="number" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83Ni9mcmFnOmQ2ZTQ0NDQ1MDdjNzRlNzk5MTFmMzM1OWU3ODFhODYzL3RleHRyZWdpb246ZDZlNDQ0NDUwN2M3NGU3OTkxMWYzMzU5ZTc4MWE4NjNfMzEw_8648e57c-8f01-4e44-ab81-09c089f5b82a">28.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83Ni9mcmFnOmQ2ZTQ0NDQ1MDdjNzRlNzk5MTFmMzM1OWU3ODFhODYzL3RleHRyZWdpb246ZDZlNDQ0NDUwN2M3NGU3OTkxMWYzMzU5ZTc4MWE4NjNfMzE3_ad05ec03-d8a5-494f-b315-4764edb00101">4.5</ix:nonFraction>%, respectively, including the impact of discrete items. Excluding discrete items, the Company's effective tax rate for the three months ended March 31, 2022 and 2021 was <ix:nonFraction unitRef="number" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="3" name="ccrn:EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83Ni9mcmFnOmQ2ZTQ0NDQ1MDdjNzRlNzk5MTFmMzM1OWU3ODFhODYzL3RleHRyZWdpb246ZDZlNDQ0NDUwN2M3NGU3OTkxMWYzMzU5ZTc4MWE4NjNfMzc5_65c303e9-eeb1-48e3-84b2-84204c001bda">30.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331" decimals="3" name="ccrn:EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83Ni9mcmFnOmQ2ZTQ0NDQ1MDdjNzRlNzk5MTFmMzM1OWU3ODFhODYzL3RleHRyZWdpb246ZDZlNDQ0NDUwN2M3NGU3OTkxMWYzMzU5ZTc4MWE4NjNfMzg2_c8915b63-eaca-4cc9-ab7c-f6ac3f6d54a0">4.5</ix:nonFraction>%, respectively. The effective tax rate for the first quarter of 2022 was primarily impacted by federal and state taxes. Income tax expense for the three months ended March 31, 2021 was primarily impacted by international and state taxes as a result of the Company's valuation allowance on substantially all of its domestic deferred tax assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2021, the Company concluded that it was more likely than not that a benefit from a substantial portion of its United States federal and state deferred tax assets would be realized and released the majority of its valuation allowance. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, the Company had an immaterial amount of valuation allowance on its deferred tax assets related to state net operating losses not expected to be realized before expiration.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83Ni9mcmFnOmQ2ZTQ0NDQ1MDdjNzRlNzk5MTFmMzM1OWU3ODFhODYzL3RleHRyZWdpb246ZDZlNDQ0NDUwN2M3NGU3OTkxMWYzMzU5ZTc4MWE4NjNfMTg5OA_02941c86-8c93-4e68-ae56-0c10ee927f01">9.2</ix:nonFraction> million of unrecognized tax benefits included in other long-term liabilities, $<ix:nonFraction unitRef="usd" contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83Ni9mcmFnOmQ2ZTQ0NDQ1MDdjNzRlNzk5MTFmMzM1OWU3ODFhODYzL3RleHRyZWdpb246ZDZlNDQ0NDUwN2M3NGU3OTkxMWYzMzU5ZTc4MWE4NjNfMTk3MQ_681b950b-de65-40d3-b2e6-0e96a75ccbf5">9.4</ix:nonFraction> million, net of deferred taxes, which would impact the effective tax rate if recognized. During the three months ended March&#160;31, 2022, the Company had net increases of $<ix:nonFraction unitRef="usd" contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83Ni9mcmFnOmQ2ZTQ0NDQ1MDdjNzRlNzk5MTFmMzM1OWU3ODFhODYzL3RleHRyZWdpb246ZDZlNDQ0NDUwN2M3NGU3OTkxMWYzMzU5ZTc4MWE4NjNfMjEyNA_38b14005-f0d1-478d-8a41-29ad471e9092">0.3</ix:nonFraction>&#160;million to its current year unrecognized tax benefits related to federal and state tax provisions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax years 2012 through 2021 remain open to examination by certain taxing jurisdictions to which the Company is subject to tax, other than certain states in which the statute of limitations has been extended.</span></div></ix:continuation><div><span><br/></span></div><div id="i1bf462dbbc134b239a7746fda9801e04_79"></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83OS9mcmFnOmFiMmUwZGQ2NDhhODQwMmVhZWNjNzQxZGE0MTc1ZjNiL3RleHRyZWdpb246YWIyZTBkZDY0OGE4NDAyZWFlY2M3NDFkYTQxNzVmM2JfMzMxMg_90ae777b-acf0-4f0f-80e3-e93cb27f54be" continuedAt="i256450bd9b444eeea3ded0f6fcad2542" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i256450bd9b444eeea3ded0f6fcad2542"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into an arrangement for digital marketing services provided by a firm that is related to Mr. Clark, the Company's Co-Founder &amp; Chief Executive Officer through March 31, 2022. Mr. Clark is a minority shareholder in the firm's parent company and is a member of the parent company's Board of Directors. Management believes the terms of the arrangement are equivalent to those prevailing in an arm's-length transaction and have been approved by the Company through its related party process. The digital marketing firm manages a limited number of digital publishers covering various Company brands for a monthly management fee. During the three months ended March 31, 2022 and 2021, the Company incurred an immaterial amount in expenses. The Company had an immaterial payable balance at March 31, 2022 and December 31, 2021.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides services to entities which are affiliated with certain members of the Company&#8217;s Board of Directors. Management believes the services were conducted on terms equivalent to those prevailing in an arm's-length transaction. Revenue related to these transactions was immaterial for the three months ended March 31, 2022. The Company had no revenue related to these transactions for the three months ended March 31, 2021. Accounts receivable due from these entities was an immaterial amount at March 31, 2022 and December 31, 2021.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the WSG acquisition on June 8, 2021, the Company continues to rent WSG's headquarters. The Chief Executive Officer and Founder of WSG, and currently a business unit president with the Company, is an agent of the lessor. The lease term is from January 1, 2020 through December 31, 2024. The Company paid an immaterial amount in rent expense for these premises for the three months ended March 31, 2022, and had an immaterial payable balance at March 31, 2022 and no payable balance at December 31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, the Company entered into a note payable of $<ix:nonFraction unitRef="usd" contextRef="i50316e467cb343f5859c8c6826909b1c_I20200331" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83OS9mcmFnOmFiMmUwZGQ2NDhhODQwMmVhZWNjNzQxZGE0MTc1ZjNiL3RleHRyZWdpb246YWIyZTBkZDY0OGE4NDAyZWFlY2M3NDFkYTQxNzVmM2JfMjk2MQ_4c77bbcd-abf2-43db-8dd6-34150a317775">7.3</ix:nonFraction>&#160;million related to contingent consideration assumed as part of a prior period acquisition, payable in <ix:nonFraction unitRef="installment" contextRef="i50316e467cb343f5859c8c6826909b1c_I20200331" decimals="INF" name="ccrn:NotePayableNumberOfPaymentInstallments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83OS9mcmFnOmFiMmUwZGQ2NDhhODQwMmVhZWNjNzQxZGE0MTc1ZjNiL3RleHRyZWdpb246YWIyZTBkZDY0OGE4NDAyZWFlY2M3NDFkYTQxNzVmM2JfMzA1OA_89ac02e4-bcc4-42e6-9d1e-9f0a8c6b635e">three</ix:nonFraction> equal installments. The payees of the note are controlled by an employee of the sellers who remained with the Company. The third and final installment of $<ix:nonFraction unitRef="usd" contextRef="id23201d22a6f4efdbb89f5ada9e5702d_D20220101-20220331" decimals="-5" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83OS9mcmFnOmFiMmUwZGQ2NDhhODQwMmVhZWNjNzQxZGE0MTc1ZjNiL3RleHRyZWdpb246YWIyZTBkZDY0OGE4NDAyZWFlY2M3NDFkYTQxNzVmM2JfMTA5OTUxMTYzMzMzMw_3b38867e-6f4b-46e2-843c-222abd7d1e6a">2.6</ix:nonFraction>&#160;million, including interest, was paid in the first quarter of 2022.</span></div></ix:continuation><div><span><br/></span></div><div id="i1bf462dbbc134b239a7746fda9801e04_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF84NS9mcmFnOjIzOWM5MzdmNDNlZDQyYzVhZGQxOGY3MWU3YmU5ZDhkL3RleHRyZWdpb246MjM5YzkzN2Y0M2VkNDJjNWFkZDE4ZjcxZTdiZTlkOGRfMTIxNQ_9916cc37-557e-459b-90ca-048038c04b3a" continuedAt="i27be1c74317a4813bf0ad9b867503fe9" escape="true">RECENT ACCOUNTING PRONOUNCEMENTS</ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:continuation id="i27be1c74317a4813bf0ad9b867503fe9"><ix:nonNumeric contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF84NS9mcmFnOjIzOWM5MzdmNDNlZDQyYzVhZGQxOGY3MWU3YmU5ZDhkL3RleHRyZWdpb246MjM5YzkzN2Y0M2VkNDJjNWFkZDE4ZjcxZTdiZTlkOGRfNzY5NjU4MTM5ODExNA_cc0a2308-16cd-4ef5-9acb-188d73ef2833" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2021, the FASB issued ASU No. 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires contract assets and contract liabilities such as deferred revenue acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. Generally, this amendment will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. Historically such amounts were recognized by the acquirer at fair value in acquisition accounting. This guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The amendments should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The Company is currently in the process of evaluating this standard and expects to adopt this standard in its first quarter of 2023.</span></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div id="i1bf462dbbc134b239a7746fda9801e04_88"></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the following Management&#8217;s Discussion and Analysis (MD&amp;A) is to help facilitate the understanding of significant factors influencing the quarterly operating results, financial condition, and cash flows of the Company. Additionally, MD&amp;A also conveys our current expectations of the potential impact of known trends, events, or uncertainties that may impact future results. MD&amp;A is provided as a supplement to, and should be read in conjunction with, our 2021 Form 10-K (including Part I, Item 1A, "Risk Factors"), our financial statements and the accompanying notes to our financial statements, as well as the Risk Factors contained herein.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1bf462dbbc134b239a7746fda9801e04_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We provide total talent management services, including strategic workforce solutions, contingent staffing, permanent placement, and consultative services for healthcare customers across the continuum of care, by recruiting and placing highly qualified healthcare professionals in virtually every specialty and area of expertise. In addition to clinical roles such as school nurses, speech language, and behavioral therapists, we place non-clinical professionals such as teachers, substitute teachers, and other education specialties at educational facilities across the nation. Our diverse customer base includes both public and private acute care and non-acute care hospitals, outpatient clinics, ambulatory care facilities, single- and multi-specialty physician practices, rehabilitation facilities, Program of All-Inclusive Care for the Elderly (PACE) programs, urgent care centers, local </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and national healthcare systems, managed care providers, public and charter schools, correctional facilities, government facilities, pharmacies, and many other healthcare providers. Through our national staffing teams, we offer our workforce solutions and place clinicians on travel and per diem assignments, local short-term contracts, and permanent positions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our workforce solutions include managed service programs (MSPs), recruitment process outsourcing (RPO), project management, and other outsourcing and consultative services as described in Item 1. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Business</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">in our 2021 Form 10-K. By utilizing the solutions we offer, customers are able to better plan their personnel needs, optimize their talent acquisition and management processes, strategically flex and balance their workforce, have access to quality healthcare personnel, and provide continuity of care for improved patient outcomes. We have a history of investing in diversity, equality, and inclusion as a key component of the organization&#8217;s overall corporate social responsibility program, closely aligned with our core values to create a better future for our people, communities, and our stockholders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating results of our business segments are regularly reviewed by the chief operating decision maker.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9679;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nurse and Allied Staffing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Nurse and Allied Staffing represented approximately 97% of our total revenue in the first quarter of 2022. The Nurse and Allied Staffing segment provides workforce solutions and traditional staffing, including temporary and permanent placement of travel nurses and allied professionals, as well as per diem and contract nurses and allied personnel. We also provide clinical and non-clinical professionals on short-term and long-term assignments to clients such as local and national healthcare plans, managed care providers, public and charter schools, correctional facilities, skilled nursing facilities, and other non-acute settings. In addition, Nurse and Allied Staffing provides retained search services for healthcare professionals, as well as contingent search and recruitment process outsourcing services. We provide flexible workforce solutions to our healthcare customers through diversified offerings designed to meet their unique needs, including: MSP, RPO, and consulting services.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9679;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Physician Staffing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Physician Staffing represented approximately 3% of our total revenue in the first quarter of 2022. Physician Staffing provides physicians in many specialties, as well as certified registered nurse anesthetists, nurse practitioners, and physician assistants as independent contractors on temporary assignments throughout the United States.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Summary of Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the quarter ended March 31, 2022, revenue from services increased 140% year-over-year to $788.7 million, due to continued growth in both our Nurse and Allied Staffing and our Physician Staffing segments. The majority of this growth was driven by an increasing number of professionals on assignment. Revenue increased 23% sequentially, with a relatively small impact coming from bill rates. As a result of our investment in people and technology, we expanded the number of professionals on assignment, with a majority due solely to organic growth, thereby significantly improving our operating leverage. Throughout the pandemic, we worked collaboratively with clients on adjusting bill rates in order to adapt to the rapidly changing market conditions. Net income attributable to common stockholders in the first quarter of 2022 was $62.0 million, as compared to $19.4 million in the prior year.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the second quarter of 2022, average travel bill rates are anticipated to experience a low double-digit decline sequentially. While demand has retreated from the peak of the first quarter, the growing supply and demand imbalance is still supporting higher rates. We expect continued sequential growth in headcount and professionals on assignment across all lines of business. Looking beyond the second quarter, we anticipate further market share gains despite potential headwinds from changing bill rates or demand from certain specialties. We remain committed to investing in our people and our tech enabled digital platform by doubling our IT project budget for 2022, versus 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 21, 2022, we amended the ABL Credit Agreement (Loan Agreement) (Fifth Amendment), which increased the current aggregate committed size of the ABL from $150.0 million to $300.0 million and extended the credit facility for an additional five years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, cash flow used in operating activities was $29.0 million, with net borrowings of $42.3 million on our senior-secured asset-based credit facility (ABL), and an increase in working capital stemming from the strong sequential growth in our business. As of March 31, 2022, we had $1.2 million of cash and cash equivalents, with a principal balance of $173.9 million outstanding on our term loan. Borrowing base availability under the ABL was $300.0 million, with $51.5 million of borrowings drawn under our ABL, and $17.5 million of undrawn letters of credit outstanding, leaving $231.0 million of excess availability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Results of Operations, Segment Results, and Liquidity and Capital Resources sections that follow for further information.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating Metrics</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our financial condition by tracking operating metrics and financial results specific to each of our segments. Key operating metrics include hours worked, days filled, number of contract personnel on a full-time equivalent (FTE) basis, revenue per FTE, and revenue per day filled. Other operating metrics include number of open orders, candidate applications, contract bookings, length of assignment, bill and pay rates, and renewal and fill rates, number of active searches, and number of placements. These operating metrics are representative of trends that assist management in evaluating business performance. Due to the timing of our business process and other factors, certain of these operating metrics may not necessarily correlate to the reported U.S. GAAP results for the periods presented. Some of the segment financial results analyzed include revenue, operating expenses, and contribution income. In addition, we monitor cash flow, as well as operating and leverage ratios, to help us assess our liquidity needs.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.952%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Business Segment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Business Measurement</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nurse and Allied Staffing </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FTEs represent the average number of Nurse and Allied Staffing contract personnel on a full-time equivalent basis.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average revenue per FTE per day is calculated by dividing the Nurse and Allied Staffing revenue, excluding permanent placement, per FTE by the number of days worked in the respective periods.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Physician Staffing</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Days filled is calculated by dividing the total hours invoiced during the period, including an estimate for the impact of accrued revenue,  by eight hours.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per day filled is calculated by dividing revenue as reported by days filled for the period presented.</span></td></tr></table></div><div><span><br/></span></div><div id="i1bf462dbbc134b239a7746fda9801e04_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Results of Operations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, for the periods indicated, selected condensed consolidated statements of operations data expressed as a&#160;percentage of revenue. Our historical results of operations are not necessarily indicative of future operating results.&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.485%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to common stockholders</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i1bf462dbbc134b239a7746fda9801e04_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Comparison of Results for the Three Months Ended March 31, 2022 compared to the Three Months Ended March 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct operating expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,938&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,162&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,865&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(758)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,638&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,119&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,360&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,759&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to common stockholders</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,983&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,448&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,535&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NM - Not meaningful</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from services</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Revenue from services increased 139.6% to $788.7 million for the three months ended March&#160;31, 2022, as compared to $329.2 million for the three months ended March&#160;31, 2021, due to strong performance in both our Nurse and Allied and Physician Staffing segments, both resulting from an increase in volume, and higher bill rates in Nurse and Allied. The increase in bill rates is a result of the continued high level of demand for our services due to the overall tight supply for clinicians and professionals. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">See further discussion in Segment Results. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Direct operating expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct operating expenses are comprised primarily of field employee compensation and independent contractor expenses, housing expenses, travel expenses, and related insurance expenses. Direct operating expenses increased $356.2 million, or 138.2%, to $613.9 million for the three months ended March&#160;31, 2022, as compared to $257.8 million for the three months ended March&#160;31, 2021, as a result of revenue increases. As a percentage of total revenue, direct operating expenses decreased to 77.8% compared to 78.3% in the prior year period.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, general and administrative expenses</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased 65.8% to $76.8 million for the three months ended March&#160;31, 2022, as compared to $46.3 million for the three months ended March&#160;31, 2021, primarily </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due to increases in compensation and benefit expense, as well as marketing and consulting expense and computer subscription fees, partially offset by decreases in legal expenses. As a&#160;percentage of total revenue, selling, general and administrative expenses decreased to 9.7% for the three months ended March&#160;31, 2022, as compared to 14.1% for the three months ended March&#160;31, 2021.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and amortization expense</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense&#160;for the three months ended March&#160;31, 2022 was $2.7 million, as compared to $2.3 million for the three months ended March&#160;31, 2021. The increase is primarily due to the additional amortization of other intangible assets from the Workforce Solutions Group (WSG) acquisition. See Note 7 - Goodwill, Trade Names, and Other Intangible Assets to our condensed consolidated financial statements. As a percentage of revenue, depreciation and amortization expense was 0.4% for the three months ended March&#160;31, 2022 and 0.7% for the three months ended March&#160;31, 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs for the three months ended March&#160;31, 2022 were primarily comprised of ongoing lease costs related to the Company's strategic reduction of its real estate footprint and totaled $0.5 million. Restructuring costs for the three months ended March 31, 2021 were primarily comprised of employee termination costs and ongoing lease costs related to office closures. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment charges</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash impairment charges totaled $1.7 million for the three months ended March 31, 2022 and related to real estate restructuring activities. For the three months ended March 31, 2021, non-cash impairment charges related to the write-off of a discontinued software development project. See Note 7 - Goodwill, Trade Names, and Other Intangible Assets and Note 9 - Leases to our condensed consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest expense</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $3.5 million for the three months ended March&#160;31, 2022, as compared to $0.7 million for the three months ended March&#160;31, 2021, due to higher average borrowings and a higher effective interest rate. The effective interest rate on our borrowings was 6.4% and 2.9% for the three months ended March&#160;31, 2022 and 2021, respectively. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income tax expense</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense totaled $25.1 million for the three months ended March&#160;31, 2022, compared to $0.9 million for the three months ended March&#160;31, 2021. The effective tax rate for the first quarter of 2022 was primarily impacted by federal and state taxes. Income tax expense for the three months ended March 31, 2021 was primarily impacted by international and state taxes as a result of the valuation allowance on substantially all of our domestic deferred tax assets. See Note 14 - Income Taxes to our condensed consolidated financial statements.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i1bf462dbbc134b239a7746fda9801e04_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Segment Results</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on operating segments and a reconciliation to income from operations for the periods indicated are as follows:  </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from services:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nurse and Allied Staffing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physician Staffing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,732&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nurse and Allied Staffing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physician Staffing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,845&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate overhead</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration-related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,632&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,994&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 12 - Segment Data to our condensed consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain statistical data for our business segments for the periods indicated are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:44.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.686%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Nurse and Allied Staffing statistical data:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FTEs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,454&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,614&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,840&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average Nurse and Allied Staffing revenue per FTE per day </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Physician Staffing statistical data:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Days filled </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,068&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,469&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,599&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue per day filled </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See definition of Business Measurements under the Operating Metrics section of our MD&amp;A.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Segment Comparison - Three Months Ended March 31, 2022 compared to the Three Months Ended March 31, 2021</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Nurse and Allied Staffing</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue increased $452.6 million, or 144.6%, to $765.6 million for the three months ended March&#160;31, 2022, compared to $313.0 million for the three months ended March&#160;31, 2021, through strong performance driven by volume increases and higher bill rates</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contribution income increased $72.7 million, or 194.3%, to $110.1 million for the three months ended March&#160;31, 2022, compared to $37.4 million for the three months ended March&#160;31, 2021, driven by increased revenue. As a&#160;percentage of segment revenue, contribution income margin was 14.4% for the three months ended March&#160;31, 2022, compared to 12.0% for the three months ended March&#160;31, 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average number of FTEs on contract during the three months ended March&#160;31, 2022 increased 103.4% from the three months ended March&#160;31, 2021, primarily due to headcount growth in travel nurse and allied, as well as additional headcount resulting from the WSG acquisition. The average revenue per FTE per day increased 20.3%, due to the increase in the average bill rates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Physician Staffing</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased $7.0 million, or 42.6%, to $23.2 million for the three months ended March&#160;31, 2022, compared to $16.2 million for the three months ended March&#160;31, 2021, primarily due to an increase in volume in both primary care physicians and certified registered nurse anesthetists.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contribution income was $1.8 million for the three months ended March&#160;31, 2022, compared to $1.4 million for the three months ended March&#160;31, 2021. As a&#160;percentage of segment revenue, contribution income was 7.6% for the three months ended March&#160;31, 2022, compared to 8.8% for the three months ended March&#160;31, 2021, driven by higher revenue, partially offset by higher direct costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total days filled for the three months ended March 31, 2022 were 13,068, as compared with 9,469 in the prior year. Revenue per day filled was $1,772 as compared with $1,714 in the prior year due to a shift in the mix of business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Overhead</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects. Corporate overhead increased to $16.3 million for the three months ended March 31, 2022, from $14.2 million for the three months ended March 31, 2021, primarily </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due to increases in compensation and benefit expense, as well as equity compensation expense, and IT and consulting expense, partially offset by decreases in legal and accounting expense.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As a percentage of consolidated revenue, corporate overhead was 2.1% for the three months ended March 31, 2022 and 4.3% for the three months ended March 31, 2021.</span></div><div><span><br/></span></div><div id="i1bf462dbbc134b239a7746fda9801e04_112"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Transactions with Related Parties</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 15 - Related Party Transactions to our condensed consolidated financial statements.</span></div><div><span><br/></span></div><div id="i1bf462dbbc134b239a7746fda9801e04_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Liquidity and Capital Resources</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, we reported $1.2 million in cash and cash equivalents, $173.9 million of term loan outstanding, at par, and $51.5 million of borrowings drawn under our ABL. Working capital increased by $100.6 million to $409.1 million as of March&#160;31, 2022, compared to $308.5 million as of December&#160;31, 2021, primarily due to strong sequential growth, partially offset by the timing of disbursements. As of March 31, 2022, our days' sales outstanding, net of amounts owed to subcontractors, was 62 days, up</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 6 days year-over-year and 4 days since the beginning of the current year, primarily due to the timing of revenue recognized throughout the quarter given the monthly sequential growth through the first quarter.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of March 31, 2022, we do not have any off-balance sheet arrangements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating cash flow constitutes our primary source of liquidity and, historically, has been sufficient to fund our working capital, capital expenditures, internal business expansion, and debt service. This includes our commitments, both short-term and long-term, of interest expense on our debt and operating lease commitments, as well as any settlements on uncertain tax positions, and future principal payments on our term loan and our ABL credit facility.&#160;We expect to meet our future needs from a combination of cash on hand, operating cash flows, and funds available through the ABL. See debt discussion which follows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an effective &#8220;shelf&#8221; registration statement on Form S-3 on file with the SEC that enables us, in one or more offerings, to sell up to an aggregate of 5,000,000 shares of common stock. Although we do not have any current plans to use the shelf registration statement, the proceeds from any offering could be used for working capital and other general corporate purposes, or to fund acquisitions of businesses, products, and technologies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $29.0 million in the three months ended March&#160;31, 2022, compared to $24.9 million in the three months ended March&#160;31, 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily due to the investment in net working capital associated with the continued revenue growth in our business, which resulted in a $186.7 million increase in receivables since the start of the year.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $2.1 million in the three months ended March&#160;31, 2022, compared to $1.2 million in the three months ended March&#160;31, 2021. Net cash used in both periods was for capital expenditures, primarily related to multiple IT projects. Expenditures in the three months ended March 31, 2022 also included computer replacements, and in the three months ended March 31, 2021 also included the build-out of our corporate office.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities during the three months ended March&#160;31, 2022 was $31.3 million, compared to $38.0 million during the three months ended March&#160;31, 2021. During the three months ended March 31, 2022, we reported net borrowings of $41.9 million on our debt, and used cash to pay $2.4 million on our note payable, $5.0 million for income taxes on share-based compensation, $3.1 million in debt issuance costs, and an immaterial amount for other financing activities. During the three months ended March 31, 2021, we reported net borrowings of $42.6 million on our ABL, and used cash to pay $2.4 million on our note payable, $2.0 million for income taxes on share-based compensation, and an immaterial amount for other financing activities. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1bf462dbbc134b239a7746fda9801e04_118"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Debt</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Term Loan Credit Agreement</span></div><div style="margin-top:3pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As more fully described in Note 8 - Debt to our condensed consolidated financial statements, on June 8, 2021, we entered into a Term Loan Credit Agreement (Term Loan Agreement), which provides for a six-year second lien subordinated term loan in the amount of $100.0&#160;million (term loan). The term loan has an interest rate of one-month LIBOR plus 5.75% per annum, subject to a 0.75% LIBOR floor. The term loan was used to pay the cash consideration, as well as any costs, fees, and expenses in connection with the WSG acquisition (see Note 4 - Acquisitions to our condensed consolidated financial statements), with the remainder used to pay down a portion of the asset-based credit facility.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The borrowings under the Term Loan Agreement generally bear interest at a variable rate based on either LIBOR or Base Rate (as defined in the Term Loan Agreement) and are subject to mandatory prepayments of principal payable in quarterly installments, commencing on September 30, 2021, with each installment being in the aggregate principal amount of $0.3 million (subject to adjustment as a result of prepayments) provided that, to the extent not previously paid, the aggregate unpaid principal balance would be due and payable on the maturity date. The Term Loan Agreement contains various restrictions and covenants applicable to the Company and its subsidiaries, including a covenant to maintain a minimum net leverage ratio. The Company was in compliance with this covenant as of March 31, 2022. Obligations under the Term Loan Agreement are secured by substantially all the assets of the borrowers and guarantors under the Term Loan Agreement, subject to customary exceptions.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2021, we amended the Term Loan Agreement (Term Loan First Amendment), which provided the Company an incremental term loan in an aggregate amount equal to $75.0 million. Additionally, the Term Loan First Amendment increased the aggregate amount of all increases (as defined in the Term Loan Agreement) to be no greater than $115.0 million. The borrowings will be used primarily to fund organic growth. Commencing on December 31, 2021, installments of the mandatory prepayments will be in the aggregate principal amount of $0.4 million. All other terms, conditions, covenants, and pricing of the Term Loan Agreement remain the same.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Loan Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective October 25, 2019, our prior senior credit facility entered into in August 2017 was replaced by a $120.0&#160;million Loan Agreement, which provides for a five-year senior secured revolving credit facility. On June 30, 2020, we amended the Loan Agreement (First Amendment), which increased the current aggregate committed size of the ABL from $120.0&#160;million to $130.0&#160;million. All other terms, conditions, covenants, and pricing of the Loan Agreement remained the same. On March 8, 2021, we amended the Loan Agreement (Second Amendment), which increased the current aggregate committed size of the ABL from $130.0&#160;million to $150.0&#160;million, increased certain borrowing base sub-limits, and decreased both the cash dominion event and financial reporting triggers. On June 8, 2021, we amended the Loan Agreement (Third Amendment), which permits the incurrence of indebtedness and grant of security as set forth in the Loan Agreement and in accordance with the Intercreditor Agreement, and provides mechanics relating to a transition away from LIBOR as a benchmark interest rate to a replacement alternative benchmark rate or mechanism for loans made in U.S. dollars. On November 18, 2021, we amended the Loan Agreement (Fourth Amendment), whereby the permitted indebtedness (as defined in the Loan Agreement) was increased to $175.0 million. On March 21, 2022, we amended the Loan Agreement (Fifth Amendment), which increased the current aggregate committed size of the ABL from $150.0 million to $300.0 million, extended the credit facility for an additional five years, increased certain borrowing base sub-limits, and provided the option for all or a portion of the borrowings to bear interest at a rate based on the Secured Overnight Financing Rate (SOFR) or Base Rate, at the election of the borrowers, plus an </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable margin.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the interest rate spreads and fees under the Loan Agreement were based on SOFR plus 1.85% for the revolving portion of the borrowing base. The Base Rate (as defined by the Loan Agreement) margin would have been 0.75%  for the revolving portion</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The SOFR and Base Rate margins are subject to monthly pricing adjustments, pursuant to a pricing matrix based on the Company&#8217;s excess availability under the revolving credit facility. In addition, the facility is subject to an unused line fee, letter of credit fees, and an administrative fee. The Loan Agreement contains various restrictions and covenants, including a covenant to maintain a minimum fixed charge coverage ratio. We were in compliance with the fixed charge coverage ratio covenant as of March 31, 2022. Borrowing base availability under the ABL was was $300.0&#160;million at March 31, 2022, with $51.5&#160;million of borrowings drawn as well as $17.5&#160;million of letters of credit outstanding, leaving $231.0&#160;million of excess availability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note Payable</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The third and final installment of the subordinated promissory note payable, made in connection with the Mediscan acquisition, was paid in the amount of $2.6&#160;million, including interest, in the first quarter of 2022. See Note 4 - Acquisitions to our condensed consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8 - Debt to our condensed consolidated financial statements.</span></div><div><span><br/></span></div><div id="i1bf462dbbc134b239a7746fda9801e04_121"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Stockholders&#8217; Equity</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 11 - Stockholders' Equity to our condensed consolidated financial statements.</span></div><div><span><br/></span></div><div id="i1bf462dbbc134b239a7746fda9801e04_124"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Critical Accounting Policies and Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting policies and estimates remain consistent with those reported in our 2021 Form 10-K.</span></div><div><span><br/></span></div><div id="i1bf462dbbc134b239a7746fda9801e04_127"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 16 - Recent Accounting Pronouncements to our condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i1bf462dbbc134b239a7746fda9801e04_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to variable interest rate risk associated with our Term Loan Agreement entered into on June 8, 2021 and our Loan Agreement entered into on October 25, 2019. These agreements charge interest at a rate based on either SOFR, LIBOR, or Base Rate (as defined in the agreements) plus an applicable margin.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A 1% change in interest rates would have resulted in interest expense fluctuating approximately $0.5 million and $0.2 million for the three months ended March 31, 2022 and 2021, respectively. See Note 8 - Debt to our condensed consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to our 2021 Form 10-K Item 1A. Risk Factors under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"The interest rates under our Term Loan Agreement and our ABL Credit Agreement may be impacted by the phase-out of the London Interbank Offered Rate (LIBOR)"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for discussion of the interest rate risk related to the potential phase-out of LIBOR in 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Risks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our other exposures as disclosed in our 2021 Form&#160;10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i1bf462dbbc134b239a7746fda9801e04_133"></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our &#8220;disclosure controls and procedures&#8221; (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act), as of the end of the period covered by this report. Based upon the evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective. Disclosure controls and procedures are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized, communicated to management, including the Chief Executive Officer and the Chief Financial Officer, and reported within the time periods specified in the SEC&#8217;s rules and forms. The disclosure controls and procedures are designed to ensure that information required to be disclosed by us in reports required under the Exchange Act of 1934, as amended, is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, in order to allow timely decisions regarding any required disclosure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting as defined in Exchange Act Rules&#160;13a-15(f) that occurred during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not experienced any material impact to our internal controls over financial reporting despite the fact that most of our employees are working remotely due to the COVID pandemic.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i1bf462dbbc134b239a7746fda9801e04_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. &#8211; OTHER INFORMATION</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1bf462dbbc134b239a7746fda9801e04_139"></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to certain legal proceedings is included in Part I, Item 1, Note 13 - Contingencies - </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Quarterly Report on Form 10-Q, and is incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i1bf462dbbc134b239a7746fda9801e04_142"></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are no material changes to our Risk Factors as previously disclosed in our 2021 Form 10-K.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i1bf462dbbc134b239a7746fda9801e04_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.265%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1141103/000115752322000358/a52612995ex10_1.htm">Amendment No. 5 to ABL Credit Agreement and Amendment No. 2 to Guaranty and Security Agreement, dated as of March 21, 2022, by and among Cross Country Healthcare, Inc. and certain of its domestic subsidiaries as borrowers or guarantors, and Wells Fargo Bank N.A., as administrative agent, collateral agent, and lender (Previously filed as an exhibit to the Company's Form 8-K </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1141103/000115752322000358/a52612995ex10_1.htm">fil</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1141103/000115752322000358/a52612995ex10_1.htm">ed</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1141103/000115752322000358/a52612995ex10_1.htm"> on</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1141103/000115752322000358/a52612995ex10_1.htm"> March 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1141103/000115752322000358/a52612995ex10_1.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1141103/000115752322000358/a52612995ex10_1.htm">, 2022 and incorporated by reference herein)</a></span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.2 #</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ccrn20220331-10qex10x2.htm">Offer Letter by and between Cross Country Healthcare, Inc. and Daniel J. White, dated as of April 5, 2022</a></span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 #</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1141103/000115752322000069/a52564385ex10_1.htm">Letter Agreement, by and between Cross Country Healthcare, Inc. and Kevin C. Clark, dated as of January 14, 2022 (Previously filed as an exhibit to the Company's Form 8-K filed on January 19, 2022 and incorporated by reference herein)</a></span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 #</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1141103/000115752322000069/a52564385ex10_2.htm">Employment Agreement, by and between Cross Country Healthcare, Inc. and John A. Martins, dated as of January 14, 2022 (Previously filed as an exhibit to the Company's Form 8-K filed on January 19, 2022 and incorporated by reference herein)</a></span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ccrn20220331-10qex31x1.htm">Certification pursuant to Rule&#160;13a-14(a) and Rule&#160;15d-14(a) by </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ccrn20220331-10qex31x1.htm">John A. Martins</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ccrn20220331-10qex31x1.htm">,&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ccrn20220331-10qex31x1.htm">President</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ccrn20220331-10qex31x1.htm">, Chief Executive Officer, Director (Principal Executive Officer)</a></span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ccrn20220331-10qex31x2.htm">Certification pursuant to Rule 13a-14(a) and Rule 15d-14(a) by William J. Burns, Executive Vice President, Chief Financial Officer (Principal Accounting and Financial Officer)</a></span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ccrn20220331-10qex32x1.htm">Certification pursuant to 18 U.S.C. Section&#160;1350 by </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ccrn20220331-10qex32x1.htm">John A. Martins</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ccrn20220331-10qex32x1.htm">,&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ccrn20220331-10qex32x1.htm">President</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ccrn20220331-10qex32x1.htm">, Chief Executive Officer, Director (Principal Executive Officer)</a></span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**32.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ccrn20220331-10qex32x2.htm">Certification pursuant to 18 U.S.C. Section&#160;1350 by William J. Burns, Executive Vice President, Chief Financial Officer (Principal Accounting and Financial Officer)</a></span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Represents a management contract or compensatory plan or arrangement</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith</span></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i1bf462dbbc134b239a7746fda9801e04_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CROSS&#160;COUNTRY&#160;HEALTHCARE,&#160;INC.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May&#160;5, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ William J. Burns</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William J. Burns<br/>Executive Vice President &amp; Chief&#160;Financial&#160;Officer                         (Principal Accounting and Financial Officer)</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>ccrn20220331-10qex10x2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic5fb9be4e1344ab4aa8ecf22a37616a4_1"></div><div style="min-height:87.12pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:68px;margin-bottom:5pt;vertical-align:text-bottom;width:260px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.378%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DocuSign Envelope ID&#58; 5D460804-F0D8-45E9-B87E-4C4792986401</font></div></td></tr></table></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">April 5, 2022</font></div><div><font><br></font></div><div style="padding-left:5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Daniel J. White</font></div><div style="padding-left:5pt;padding-right:344.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5815 Loma Verde Drive PO Box 1137</font></div><div style="padding-left:5pt;padding-right:333.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:232%">Rancho Santa Fe, CA 92067 Dear Dan,</font></div><div style="margin-top:3.8pt;padding-left:5pt;padding-right:12.05pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:118%">We are pleased to confirm our offer of employment to join Cross Country Healthcare Services, Inc. (the &#8220;Company&#8221;) as Chief Commercial Officer (CCO). You will report to John Martins, Chief Executive Officer (CEO). Your start date will be April 5, 2022.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:118%">In your role as Chief Commercial Officer (CCO), your responsibilities with be to lead client marketing, sales, sales support, solution design, implementation, strategic accounts &#47; program management, RPO and strategic partnerships&#47;relationships with third parties and any other responsibilities that may be directed, from time to time, by the CEO.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">You will be compensated for all services rendered by you under this Agreement at the rate of</font></div><div style="padding-left:5pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$450,000.00 per annum, payable in a manner that is consistent with the Company&#8217;s payroll practices for executive employees. At least annually, the Company&#8217;s Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;) will review and consider in its sole discretion whether to modify the base salary payable to you hereunder. Your annual rate of base salary as determined herein from time to time is hereinafter referred to as the &#8220;Base Salary&#8221;. Applicable payroll deductions as required by State and Federal law will be withheld from your paycheck, along with any voluntary deductions that you authorize.</font></div><div style="margin-top:6.05pt;padding-left:5pt;padding-right:11.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:103%">For each calendar year, while employed by the Company, you will participate in the Company&#8217;s short-term incentive bonus plan approved by the Company at opportunity levels to be defined by the Compensation Committee in its discretion, with a target annual bonus amount of 100% of your Base Salary (&#8220;STI Target Percentage&#8221;).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">For each calendar year, while employed by the Company, you will participate in the Company&#8217;s long-term incentive plan as approved by the Company and receive awards thereunder on an annual basis with a target value of 85% of your Base Salary (&#8220;LTI Target Percentage&#8221;). Such award shall be upon terms and conditions determined at the discretion of the Compensation Committee in its sole discretion, which grant for 2022 shall made based on the closing price of the Company&#8217;s common stock on April 18, 2022.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:68px;margin-bottom:5pt;vertical-align:text-bottom;width:260px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.378%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DocuSign Envelope ID&#58; 5D460804-F0D8-45E9-B87E-4C4792986401</font></div></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Your compensation package will include the following&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:65.35pt;padding-right:29.4pt;text-indent:-17.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:13.7pt">Medical, Vision, Dental, Life Insurance&#8212;basic and supplemental, eligible 1st of the month following your hire date.</font></div><div style="margin-top:0.5pt;padding-left:65.35pt;text-indent:-17.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:13.95pt">Disability Insurance&#8212;short-term and long-term</font></div><div style="margin-top:1.3pt;padding-left:65.6pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.2pt">Tuition Assistance</font></div><div style="margin-top:1pt;padding-left:65.35pt;text-indent:-17.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:13.95pt">Vacation Time&#8212;20 days per year</font></div><div style="margin-top:0.75pt;padding-left:65.6pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.2pt">Sick Time&#8212;6 days per year</font></div><div style="margin-top:0.6pt;padding-left:65.35pt;text-indent:-17.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:13.95pt">Personal Time&#8212;3 days per year</font></div><div style="margin-top:0.9pt;padding-left:65.35pt;text-indent:-17.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:13.95pt">Holidays&#8212;eligible for all Company paid holidays following hire date.</font></div><div style="margin-top:0.95pt;padding-left:65.35pt;text-indent:-17.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:13.95pt">Participation in other benefits generally offered to the Company</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:10.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Change of Control Severance&#58;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:10.65pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Upon signing a Participation Agreement and subject to approval by the Compensation Committee in its discretion, you will be entitled to participate in the Company's Executive Severance Agreement Amended and Restated as of May 28, 2010 pursuant to which you will be entitled to receive a 1-year payout and other benefits upon a change of control (pursuant to the terms and conditions in the Executive Severance Agreement at that time).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:10.65pt;padding-right:5.55pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This offer of employment is contingent upon satisfactory references, verification of your eligibility to work in the United States, background screen, pre-employment drug testing, and the signing of an agreement containing certain covenants required by the Company. This is at- will employment, and you have the right to terminate the employment at any time, as does the Company.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:10.65pt;padding-right:11.7pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:119%">Dan, on behalf of the Company, we wish to convey our enthusiasm for inviting you to join us as a team member. We are confident that you will find your employment to be a rewarding opportunity and one which will contribute to your growth as well as that of the Company.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:10.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sincerely,</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:10.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-style:italic;font-weight:700;line-height:100%">Colin McDonald</font></div><div style="margin-top:12.55pt;padding-left:10.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Colin McDonald</font></div><div style="padding-left:10.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Chief Human Resources Officer</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:10.65pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cc&#58; John Martins, Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.4pt;padding-left:10.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:108%">I acknowledge and understand the terms of this offer letter&#58;</font></div><div style="padding-left:10.2pt;text-align:justify"><img alt="image_1.jpg" src="image_1.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:140px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:364%">&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:364%">April 5, 2022</font></div><div style="padding-left:10.65pt"><img alt="image_2.jpg" src="image_2.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:311px"></div><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Daniel J. White (Signature)&#160;&#160;&#160;&#160;Date</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ccrn20220331-10qex31x1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i824610cf7a4b4a419cb707dda2e21275_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John A. Martins, certify that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form&#160;10-Q of Cross Country Healthcare, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John A. Martins</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John A. Martins<br>President &#38; Chief&#160;Executive Officer<br>(Principal&#160;Executive&#160;Officer)</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ccrn20220331-10qex31x2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6b08051dc9964e1da9d4a5ff48811492_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, William J. Burns, certify that&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form&#160;10-Q of Cross Country Healthcare, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; William J. Burns</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William J. Burns<br>Executive Vice President &#38; Chief&#160;Financial&#160;Officer                                                                                    (Principal Accounting and Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ccrn20220331-10qex32x1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia755863b4f2d41da977bb8a8e92b74c3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the accompanying Quarterly Report on Form&#160;10-Q of Cross Country Healthcare, Inc. (the Company) for the quarterly period ended March&#160;31, 2022, (the &#34;Periodic Report&#34;), I, John A. Martins, President and Chief Executive Officer of the Company, hereby certify pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge the Periodic Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John A. Martins</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John A. Martins<br>President &#38; Chief&#160;Executive Officer<br>(Principal&#160;Executive&#160;Officer)</font></td></tr></table></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section&#160;906, has been provided to Cross Country Healthcare, Inc. and will be retained by Cross Country Healthcare, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is provided solely for purposes of complying with the provisions of Section&#160;906 of the Sarbanes-Oxley Act of 2002.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>ccrn20220331-10qex32x2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i802b3c25376e4e19910fd9ec9e476791_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the accompanying Quarterly Report on Form&#160;10-Q of Cross Country Healthcare, Inc. (the &#34;Company&#34;) for the quarterly period ended March&#160;31, 2022, (the &#34;Periodic Report&#34;), I, William J. Burns, Executive Vice President and Chief Financial Officer of the Company, hereby certify pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge the Periodic Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; William J. Burns</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William J. Burns<br>Executive Vice President &#38; Chief&#160;Financial&#160;Officer                                                                                    (Principal Accounting and Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section&#160;906, has been provided to Cross Country Healthcare, Inc. and will be retained by Cross Country Healthcare, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is provided solely for purposes of complying with the provisions of Section&#160;906 of the Sarbanes-Oxley Act of 2002.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ccrn-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:bf6b0e24-63a4-4887-ba98-a744ebcd1084,g:9e05db7a-6f27-4cf3-b67e-d2d201684423-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ccrn="http://www.crosscountryhealthcare.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.crosscountryhealthcare.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ccrn-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ccrn-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ccrn-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ccrn-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.crosscountryhealthcare.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDBASISOFPRESENTATION" roleURI="http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATION">
        <link:definition>2101101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2102102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2203201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>2304301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails">
        <link:definition>2405401 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAllowanceforDoubtfulAccountsDetails" roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAllowanceforDoubtfulAccountsDetails">
        <link:definition>2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Allowance for Doubtful Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringCostsDetails" roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringCostsDetails">
        <link:definition>2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restructuring Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITION" roleURI="http://www.crosscountryhealthcare.com/role/REVENUERECOGNITION">
        <link:definition>2108103 - Disclosure - REVENUE RECOGNITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONTables" roleURI="http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONTables">
        <link:definition>2309302 - Disclosure - REVENUE RECOGNITION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONDetails" roleURI="http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails">
        <link:definition>2410404 - Disclosure - REVENUE RECOGNITION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONS" roleURI="http://www.crosscountryhealthcare.com/role/ACQUISITIONS">
        <link:definition>2111104 - Disclosure - ACQUISITIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSTables" roleURI="http://www.crosscountryhealthcare.com/role/ACQUISITIONSTables">
        <link:definition>2312303 - Disclosure - ACQUISITIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSAdditionalInformationDetails" roleURI="http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails">
        <link:definition>2413405 - Disclosure - ACQUISITIONS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>2414406 - Disclosure - ACQUISITIONS - Recognized Identified Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMPREHENSIVEINCOME" roleURI="http://www.crosscountryhealthcare.com/role/COMPREHENSIVEINCOME">
        <link:definition>2115105 - Disclosure - COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMPREHENSIVEINCOMEDetails" roleURI="http://www.crosscountryhealthcare.com/role/COMPREHENSIVEINCOMEDetails">
        <link:definition>2416407 - Disclosure - COMPREHENSIVE INCOME (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERSHARE" roleURI="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARE">
        <link:definition>2117106 - Disclosure - EARNINGS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERSHARETables" roleURI="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARETables">
        <link:definition>2318304 - Disclosure - EARNINGS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails" roleURI="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails">
        <link:definition>2419408 - Disclosure - EARNINGS PER SHARE - Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERSHAREAdditionalInformationDetails" roleURI="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAdditionalInformationDetails">
        <link:definition>2420409 - Disclosure - EARNINGS PER SHARE - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETS" roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETS">
        <link:definition>2121107 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSTables" roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSTables">
        <link:definition>2322305 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails" roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails">
        <link:definition>2423410 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Acquired Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails" roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails">
        <link:definition>2424411 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Estimated Annual Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails" roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails">
        <link:definition>2425412 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT" roleURI="http://www.crosscountryhealthcare.com/role/DEBT">
        <link:definition>2126108 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTTables" roleURI="http://www.crosscountryhealthcare.com/role/DEBTTables">
        <link:definition>2327306 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTLongtermDebtDetails" roleURI="http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails">
        <link:definition>2428413 - Disclosure - DEBT - Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTMaturitiesofDebtDetails" roleURI="http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails">
        <link:definition>2429414 - Disclosure - DEBT - Maturities of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT2021TermLoanCreditAgreementDetails" roleURI="http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails">
        <link:definition>2430415 - Disclosure - DEBT - 2021 Term Loan Credit Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT2019LoanAgreementDetails" roleURI="http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails">
        <link:definition>2431416 - Disclosure - DEBT - 2019 Loan Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTNotePayableDetails" roleURI="http://www.crosscountryhealthcare.com/role/DEBTNotePayableDetails">
        <link:definition>2432417 - Disclosure - DEBT - Note Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.crosscountryhealthcare.com/role/LEASES">
        <link:definition>2133109 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.crosscountryhealthcare.com/role/LEASESTables">
        <link:definition>2334307 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESAdditionalInformationDetails" roleURI="http://www.crosscountryhealthcare.com/role/LEASESAdditionalInformationDetails">
        <link:definition>2435418 - Disclosure - LEASES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESSupplementalBalanceSheetInformationDetails" roleURI="http://www.crosscountryhealthcare.com/role/LEASESSupplementalBalanceSheetInformationDetails">
        <link:definition>2436419 - Disclosure - LEASES - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESOperatingLeaseMaturityDetails" roleURI="http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails">
        <link:definition>2437420 - Disclosure - LEASES - Operating Lease Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESOperatingLeaseMaturityDetails_1" roleURI="http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails_1">
        <link:definition>2437420 - Disclosure - LEASES - Operating Lease Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseCostsDetails" roleURI="http://www.crosscountryhealthcare.com/role/LEASESLeaseCostsDetails">
        <link:definition>2438421 - Disclosure - LEASES - Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>2139110 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>2340308 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" roleURI="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
        <link:definition>2441422 - Disclosure - FAIR VALUE MEASUREMENTS - Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails" roleURI="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails">
        <link:definition>2442423 - Disclosure - FAIR VALUE MEASUREMENTS - Carrying Amounts and Estimated Fair Values of Significant Financial Instrument that were not Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITY">
        <link:definition>2143111 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>2344309 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYAdditionalInformationDetails" roleURI="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails">
        <link:definition>2445424 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYRestrictedStockActivityDetails" roleURI="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails">
        <link:definition>2446425 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTDATA" roleURI="http://www.crosscountryhealthcare.com/role/SEGMENTDATA">
        <link:definition>2147112 - Disclosure - SEGMENT DATA</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTDATATables" roleURI="http://www.crosscountryhealthcare.com/role/SEGMENTDATATables">
        <link:definition>2348310 - Disclosure - SEGMENT DATA (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTDATADetails" roleURI="http://www.crosscountryhealthcare.com/role/SEGMENTDATADetails">
        <link:definition>2449426 - Disclosure - SEGMENT DATA (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONTINGENCIES" roleURI="http://www.crosscountryhealthcare.com/role/CONTINGENCIES">
        <link:definition>2150113 - Disclosure - CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.crosscountryhealthcare.com/role/INCOMETAXES">
        <link:definition>2151114 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESDetails" roleURI="http://www.crosscountryhealthcare.com/role/INCOMETAXESDetails">
        <link:definition>2452427 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>2153115 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSDetails" roleURI="http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails">
        <link:definition>2454428 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECENTACCOUNTINGPRONOUNCEMENTS" roleURI="http://www.crosscountryhealthcare.com/role/RECENTACCOUNTINGPRONOUNCEMENTS">
        <link:definition>2155116 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax" abstract="false" name="AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_AssetsAndLiabilitiesLeasesTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided" abstract="false" name="ThresholdPeriodPastDueForPaymentOfServicesProvided" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ccrn_LineOfCreditBorrowingBasePercentageOfAssets" abstract="false" name="LineOfCreditBorrowingBasePercentageOfAssets" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_SeniorSecuredAssetBasedLoanMember" abstract="true" name="SeniorSecuredAssetBasedLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ccrn_A2021TermLoanCreditAgreementIncrementalTermLoanMember" abstract="true" name="A2021TermLoanCreditAgreementIncrementalTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ccrn_LineOfCreditFacilityBorrowingBaseAvailability" abstract="false" name="LineOfCreditFacilityBorrowingBaseAvailability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_SwingLoansSublimitMember" abstract="true" name="SwingLoansSublimitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ccrn_AcquisitionAndIntegrationRelatedCosts" abstract="false" name="AcquisitionAndIntegrationRelatedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_ExitCostsMember" abstract="true" name="ExitCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances" abstract="false" name="ProvisionForDoubtfulAccountsAndOtherAllowances" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_DeferredCompensationMember" abstract="true" name="DeferredCompensationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ccrn_DebtInstrumentVariableInterestRateFloor" abstract="false" name="DebtInstrumentVariableInterestRateFloor" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ccrn_A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember" abstract="true" name="A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ccrn_LineOfCreditSublimitAxis" abstract="true" name="LineOfCreditSublimitAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ccrn_A2021TermLoanCreditAgreementMember" abstract="true" name="A2021TermLoanCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ccrn_OperatingLeaseExpenseNonCash" abstract="false" name="OperatingLeaseExpenseNonCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_OtherServicesMember" abstract="true" name="OtherServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ccrn_TemporaryStaffingServicesMember" abstract="true" name="TemporaryStaffingServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ccrn_LineOfCreditSublimitDomain" abstract="true" name="LineOfCreditSublimitDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable" abstract="true" name="ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ccrn_BusinessCombinationContingentConsiderationTerm" abstract="false" name="BusinessCombinationContingentConsiderationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ccrn_BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment" abstract="false" name="BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_MediscanMember" abstract="true" name="MediscanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ccrn_EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems" abstract="false" name="EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ccrn_NurseAndAlliedStaffingMember" abstract="true" name="NurseAndAlliedStaffingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ccrn_SalesAllowanceBillingRelatedAdjustments" abstract="false" name="SalesAllowanceBillingRelatedAdjustments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources" abstract="false" name="LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_ShareBasedPaymentAwardsMember" abstract="true" name="ShareBasedPaymentAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ccrn_OmnibusPlanMember" abstract="true" name="OmnibusPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard" abstract="false" name="OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_EarnoutNotesPayableMember" abstract="true" name="EarnoutNotesPayableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ccrn_NotePayableNumberOfInstallmentsPaid" abstract="false" name="NotePayableNumberOfInstallmentsPaid" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" abstract="true" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ccrn_WorkforceSolutionsGroupIncMember" abstract="true" name="WorkforceSolutionsGroupIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ccrn_LongTermDebtMaturityAfterYearFour" abstract="false" name="LongTermDebtMaturityAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_PaymentsForRestructuringAndAdjustments" abstract="false" name="PaymentsForRestructuringAndAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_SegmentReportingUnallocatedCorporateExpenses" abstract="false" name="SegmentReportingUnallocatedCorporateExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_NotePayableNumberOfPaymentInstallments" abstract="false" name="NotePayableNumberOfPaymentInstallments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ccrn_LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR" abstract="false" name="LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ccrn_PhysicianStaffingMember" abstract="true" name="PhysicianStaffingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_SelectedIncMember" abstract="true" name="SelectedIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ccrn_StandbyLettersOfCreditSublimitMember" abstract="true" name="StandbyLettersOfCreditSublimitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ccrn-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:bf6b0e24-63a4-4887-ba98-a744ebcd1084,g:9e05db7a-6f27-4cf3-b67e-d2d201684423-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ccrn-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f2de93bc-976f-48b7-b963-d8e099c0a59c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_86f2332e-25cc-4329-bc42-9afd3a79041c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f2de93bc-976f-48b7-b963-d8e099c0a59c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_86f2332e-25cc-4329-bc42-9afd3a79041c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_c613ad58-9218-4041-9c9b-b471883bca7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f2de93bc-976f-48b7-b963-d8e099c0a59c" xlink:to="loc_us-gaap_TaxesPayableCurrent_c613ad58-9218-4041-9c9b-b471883bca7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_4f06a0a5-ae6f-4e21-b176-0669025b553a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f2de93bc-976f-48b7-b963-d8e099c0a59c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_4f06a0a5-ae6f-4e21-b176-0669025b553a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_ea1d6719-49c2-48cf-b6b6-2dd311351965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f2de93bc-976f-48b7-b963-d8e099c0a59c" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_ea1d6719-49c2-48cf-b6b6-2dd311351965" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_429b647b-d82a-4ab3-89f1-a6f585858ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f2de93bc-976f-48b7-b963-d8e099c0a59c" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_429b647b-d82a-4ab3-89f1-a6f585858ad6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b450920d-1e8c-4656-8526-3e484c329dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f2de93bc-976f-48b7-b963-d8e099c0a59c" xlink:to="loc_us-gaap_LongTermDebtCurrent_b450920d-1e8c-4656-8526-3e484c329dca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d155e87f-e48d-48bc-9b78-3e39729251af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f2de93bc-976f-48b7-b963-d8e099c0a59c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d155e87f-e48d-48bc-9b78-3e39729251af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_183e0bf8-a6f3-4b07-8423-9a7b9d5ff0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7a3e051f-fde4-4c67-9fe2-9f238762964d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_183e0bf8-a6f3-4b07-8423-9a7b9d5ff0ce" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7a3e051f-fde4-4c67-9fe2-9f238762964d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_731d08fb-f2d6-436a-a243-3ef233a32b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_183e0bf8-a6f3-4b07-8423-9a7b9d5ff0ce" xlink:to="loc_us-gaap_CommonStockValue_731d08fb-f2d6-436a-a243-3ef233a32b6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a8bff1ce-c2e7-4cfb-a7d3-7a1d423d42fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_183e0bf8-a6f3-4b07-8423-9a7b9d5ff0ce" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a8bff1ce-c2e7-4cfb-a7d3-7a1d423d42fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8726f157-eb15-438b-9a3a-234f35416733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_183e0bf8-a6f3-4b07-8423-9a7b9d5ff0ce" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8726f157-eb15-438b-9a3a-234f35416733" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9bcdb135-237a-4779-ad09-e9c6fe148201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9703ecf2-8595-45ab-9b9d-feee5086b5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9bcdb135-237a-4779-ad09-e9c6fe148201" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9703ecf2-8595-45ab-9b9d-feee5086b5d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_def40da0-19a6-4c93-b567-a670febb9679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9bcdb135-237a-4779-ad09-e9c6fe148201" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_def40da0-19a6-4c93-b567-a670febb9679" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ab19aa2c-1d72-4fe0-9d69-001ea71c623f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9bcdb135-237a-4779-ad09-e9c6fe148201" xlink:to="loc_us-gaap_LiabilitiesCurrent_ab19aa2c-1d72-4fe0-9d69-001ea71c623f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_451c705f-c0a8-42f5-9e74-8e5a49b949a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9bcdb135-237a-4779-ad09-e9c6fe148201" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_451c705f-c0a8-42f5-9e74-8e5a49b949a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f0fef789-ef63-4c5b-a1ba-c8edddb6f94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9bcdb135-237a-4779-ad09-e9c6fe148201" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f0fef789-ef63-4c5b-a1ba-c8edddb6f94f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent_5ec7abc0-0cbc-4113-98ed-709d3ebf1aff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermDebtNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9bcdb135-237a-4779-ad09-e9c6fe148201" xlink:to="loc_us-gaap_OtherLongTermDebtNoncurrent_5ec7abc0-0cbc-4113-98ed-709d3ebf1aff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c598e04e-a620-4e65-903c-bc85ff03885b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9bcdb135-237a-4779-ad09-e9c6fe148201" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c598e04e-a620-4e65-903c-bc85ff03885b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_bcb4db39-fbd7-4530-a800-50a3913439ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_87a9bcd0-9026-4438-bcd7-b73c54e24163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_bcb4db39-fbd7-4530-a800-50a3913439ef" xlink:to="loc_us-gaap_CommitmentsAndContingencies_87a9bcd0-9026-4438-bcd7-b73c54e24163" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ffb99bcc-8590-42ae-a8cd-61a10909e975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_bcb4db39-fbd7-4530-a800-50a3913439ef" xlink:to="loc_us-gaap_StockholdersEquity_ffb99bcc-8590-42ae-a8cd-61a10909e975" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_edd79489-ef83-47bf-9c08-0b287dd866c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_bcb4db39-fbd7-4530-a800-50a3913439ef" xlink:to="loc_us-gaap_Liabilities_edd79489-ef83-47bf-9c08-0b287dd866c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_452cea67-4044-4191-bc52-fe1a4a5db9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4fc71ecb-2fce-49c4-ab92-0ef8024b071d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_452cea67-4044-4191-bc52-fe1a4a5db9f5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4fc71ecb-2fce-49c4-ab92-0ef8024b071d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_eee05d12-9402-452c-ae14-51b26ca6bb63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_452cea67-4044-4191-bc52-fe1a4a5db9f5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_eee05d12-9402-452c-ae14-51b26ca6bb63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_5e4c7db4-daef-45b7-994f-d70bd2f6cbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_452cea67-4044-4191-bc52-fe1a4a5db9f5" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_5e4c7db4-daef-45b7-994f-d70bd2f6cbcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceSettlementsReceivableCurrent_8f591e5e-d8bb-4dc5-9db6-594226d36b89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceSettlementsReceivableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_452cea67-4044-4191-bc52-fe1a4a5db9f5" xlink:to="loc_us-gaap_InsuranceSettlementsReceivableCurrent_8f591e5e-d8bb-4dc5-9db6-594226d36b89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_e6d3ab30-83a6-40e3-9358-4ac572fba07c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_452cea67-4044-4191-bc52-fe1a4a5db9f5" xlink:to="loc_us-gaap_OtherAssetsCurrent_e6d3ab30-83a6-40e3-9358-4ac572fba07c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ff040c97-16f0-4d5f-bdc2-e1fe00d7bfa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e6b6d3d7-ef02-4411-9cfd-21498922209f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff040c97-16f0-4d5f-bdc2-e1fe00d7bfa3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e6b6d3d7-ef02-4411-9cfd-21498922209f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_b8cbb4d3-7a6d-47dc-a385-1be509f8d125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff040c97-16f0-4d5f-bdc2-e1fe00d7bfa3" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_b8cbb4d3-7a6d-47dc-a385-1be509f8d125" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0d3cba7c-b620-40de-bfa9-2cbe35aef62a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff040c97-16f0-4d5f-bdc2-e1fe00d7bfa3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0d3cba7c-b620-40de-bfa9-2cbe35aef62a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_25e841dc-f528-44a9-aacc-a759a335033b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff040c97-16f0-4d5f-bdc2-e1fe00d7bfa3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_25e841dc-f528-44a9-aacc-a759a335033b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6ece8800-f671-458e-bc69-68cc3735e002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff040c97-16f0-4d5f-bdc2-e1fe00d7bfa3" xlink:to="loc_us-gaap_Goodwill_6ece8800-f671-458e-bc69-68cc3735e002" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bd0b6a6d-3c46-42fe-ab6f-560cc6358a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff040c97-16f0-4d5f-bdc2-e1fe00d7bfa3" xlink:to="loc_us-gaap_AssetsCurrent_bd0b6a6d-3c46-42fe-ab6f-560cc6358a6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b9292ddb-d732-48f6-9ccd-22cf4d8363e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff040c97-16f0-4d5f-bdc2-e1fe00d7bfa3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b9292ddb-d732-48f6-9ccd-22cf4d8363e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedTradeNames_b6491b8e-3760-4f54-ade0-cb3b7de36513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedTradeNames"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff040c97-16f0-4d5f-bdc2-e1fe00d7bfa3" xlink:to="loc_us-gaap_IndefiniteLivedTradeNames_b6491b8e-3760-4f54-ade0-cb3b7de36513" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="ccrn-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_098f503e-16ab-4079-8089-615326107db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d24c8796-8fb5-4b59-9032-d1e78bbe7980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_098f503e-16ab-4079-8089-615326107db1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d24c8796-8fb5-4b59-9032-d1e78bbe7980" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d0aaa493-e22d-4c2a-9751-765d1bc7ef75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_098f503e-16ab-4079-8089-615326107db1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d0aaa493-e22d-4c2a-9751-765d1bc7ef75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9c26c0ac-8b1b-4f96-bb29-2bc1eb0bfd93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_62d81556-7252-4071-96b4-ac8ca5375cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9c26c0ac-8b1b-4f96-bb29-2bc1eb0bfd93" xlink:to="loc_us-gaap_CostsAndExpenses_62d81556-7252-4071-96b4-ac8ca5375cea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c0344dec-cffa-40a4-9a72-4dec18cd2bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9c26c0ac-8b1b-4f96-bb29-2bc1eb0bfd93" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c0344dec-cffa-40a4-9a72-4dec18cd2bdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ac5e0b44-fdb8-4116-af3d-54f53deee5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_f9d5fef6-1727-459c-8e2d-9033124a1456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ac5e0b44-fdb8-4116-af3d-54f53deee5bb" xlink:to="loc_us-gaap_AssetImpairmentCharges_f9d5fef6-1727-459c-8e2d-9033124a1456" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6a3feb03-7720-4826-8ff0-1771bd33c069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ac5e0b44-fdb8-4116-af3d-54f53deee5bb" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6a3feb03-7720-4826-8ff0-1771bd33c069" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_422ae33f-b8f3-419e-a541-c16ff006dadc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ac5e0b44-fdb8-4116-af3d-54f53deee5bb" xlink:to="loc_us-gaap_RestructuringCharges_422ae33f-b8f3-419e-a541-c16ff006dadc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AcquisitionAndIntegrationRelatedCosts_66155234-9bbc-424d-92b8-a2d87b34600c" xlink:href="ccrn-20220331.xsd#ccrn_AcquisitionAndIntegrationRelatedCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ac5e0b44-fdb8-4116-af3d-54f53deee5bb" xlink:to="loc_ccrn_AcquisitionAndIntegrationRelatedCosts_66155234-9bbc-424d-92b8-a2d87b34600c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_00222551-87cf-403a-9cd9-58baf90e5113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ac5e0b44-fdb8-4116-af3d-54f53deee5bb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_00222551-87cf-403a-9cd9-58baf90e5113" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_01c1c49e-9a8f-4b18-a558-7adb88064fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ac5e0b44-fdb8-4116-af3d-54f53deee5bb" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_01c1c49e-9a8f-4b18-a558-7adb88064fc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectOperatingCosts_614e0b47-c21e-4c0b-92a9-da9003a09f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DirectOperatingCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ac5e0b44-fdb8-4116-af3d-54f53deee5bb" xlink:to="loc_us-gaap_DirectOperatingCosts_614e0b47-c21e-4c0b-92a9-da9003a09f0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7df46767-b7e4-4c0c-923e-bd6b7aec0a25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1ca97068-8488-4bf9-b8ac-178d34c217a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7df46767-b7e4-4c0c-923e-bd6b7aec0a25" xlink:to="loc_us-gaap_NetIncomeLoss_1ca97068-8488-4bf9-b8ac-178d34c217a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_87c026a4-a94c-4d4a-8d25-1754690d5d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7df46767-b7e4-4c0c-923e-bd6b7aec0a25" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_87c026a4-a94c-4d4a-8d25-1754690d5d3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_04732277-9e54-4bce-83d8-01bcf71a180f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bea312c8-8616-4209-b707-0cb5602527c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_04732277-9e54-4bce-83d8-01bcf71a180f" xlink:to="loc_us-gaap_OperatingIncomeLoss_bea312c8-8616-4209-b707-0cb5602527c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b7ebcfae-798a-4999-a6cb-66c624fac633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_04732277-9e54-4bce-83d8-01bcf71a180f" xlink:to="loc_us-gaap_InterestExpense_b7ebcfae-798a-4999-a6cb-66c624fac633" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_db3e62f6-aac7-4934-ada6-5d88c0599bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_04732277-9e54-4bce-83d8-01bcf71a180f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_db3e62f6-aac7-4934-ada6-5d88c0599bfd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ccrn-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_611ea2da-3b4e-4e17-bc07-c317147ef433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fc5a709e-e2ed-4d99-9eed-6edac9bfea42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_611ea2da-3b4e-4e17-bc07-c317147ef433" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fc5a709e-e2ed-4d99-9eed-6edac9bfea42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b7d9ff2a-704d-4730-99fa-58b1832d1e42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b2c2b538-7fd0-4ac3-a64a-ff04a142ba6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b7d9ff2a-704d-4730-99fa-58b1832d1e42" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b2c2b538-7fd0-4ac3-a64a-ff04a142ba6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_02251cd8-2aa2-4098-8df2-f56249d5ef31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b7d9ff2a-704d-4730-99fa-58b1832d1e42" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_02251cd8-2aa2-4098-8df2-f56249d5ef31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d70c0f1e-2b51-4dd1-a2ed-b032980fbbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b7d9ff2a-704d-4730-99fa-58b1832d1e42" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d70c0f1e-2b51-4dd1-a2ed-b032980fbbd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_77010572-67c0-4ddd-9cc4-5fd233c238f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b7d9ff2a-704d-4730-99fa-58b1832d1e42" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_77010572-67c0-4ddd-9cc4-5fd233c238f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ce3d695-9b38-484d-90fc-f6f2cc83d8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances_6e8dc618-a8a8-4288-b05e-2693e3b2f3ad" xlink:href="ccrn-20220331.xsd#ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ce3d695-9b38-484d-90fc-f6f2cc83d8e1" xlink:to="loc_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances_6e8dc618-a8a8-4288-b05e-2693e3b2f3ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2c905fef-4682-45e1-aaf4-7c14b64a3ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ce3d695-9b38-484d-90fc-f6f2cc83d8e1" xlink:to="loc_us-gaap_NetIncomeLoss_2c905fef-4682-45e1-aaf4-7c14b64a3ae7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_d43f79e1-5912-4496-a21f-9c9c8c44dceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ce3d695-9b38-484d-90fc-f6f2cc83d8e1" xlink:to="loc_us-gaap_OtherNoncashExpense_d43f79e1-5912-4496-a21f-9c9c8c44dceb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_834466eb-6e1f-4c74-8aaa-b4c1582d40ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ce3d695-9b38-484d-90fc-f6f2cc83d8e1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_834466eb-6e1f-4c74-8aaa-b4c1582d40ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_da85b617-6835-4a36-b835-082e924f2018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ce3d695-9b38-484d-90fc-f6f2cc83d8e1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_da85b617-6835-4a36-b835-082e924f2018" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1e58b3a7-fad3-491c-98f4-8eee61cb454f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ce3d695-9b38-484d-90fc-f6f2cc83d8e1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1e58b3a7-fad3-491c-98f4-8eee61cb454f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_fb3e34b2-b976-4e38-95d0-271651c287a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ce3d695-9b38-484d-90fc-f6f2cc83d8e1" xlink:to="loc_us-gaap_ShareBasedCompensation_fb3e34b2-b976-4e38-95d0-271651c287a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities_c6afde59-8d2c-42c6-865f-1318c9e9dbf2" xlink:href="ccrn-20220331.xsd#ccrn_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ce3d695-9b38-484d-90fc-f6f2cc83d8e1" xlink:to="loc_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities_c6afde59-8d2c-42c6-865f-1318c9e9dbf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_512e8b4b-e753-4253-a21d-5acf74ac3cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ce3d695-9b38-484d-90fc-f6f2cc83d8e1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_512e8b4b-e753-4253-a21d-5acf74ac3cc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_874c4ec8-f38a-4e3d-9afa-ac1577886e25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ce3d695-9b38-484d-90fc-f6f2cc83d8e1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_874c4ec8-f38a-4e3d-9afa-ac1577886e25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_5079308d-1c22-4c1c-ab9c-e2964cfac6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ce3d695-9b38-484d-90fc-f6f2cc83d8e1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_5079308d-1c22-4c1c-ab9c-e2964cfac6cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_53b595a1-8ad2-493d-ad65-7c0b448e36aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ce3d695-9b38-484d-90fc-f6f2cc83d8e1" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_53b595a1-8ad2-493d-ad65-7c0b448e36aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OperatingLeaseExpenseNonCash_43d4c959-8f7f-435f-8c82-1321bd29d519" xlink:href="ccrn-20220331.xsd#ccrn_OperatingLeaseExpenseNonCash"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ce3d695-9b38-484d-90fc-f6f2cc83d8e1" xlink:to="loc_ccrn_OperatingLeaseExpenseNonCash_43d4c959-8f7f-435f-8c82-1321bd29d519" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_7f67aacd-8ea0-459f-8c40-9113363a859a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ce3d695-9b38-484d-90fc-f6f2cc83d8e1" xlink:to="loc_us-gaap_AssetImpairmentCharges_7f67aacd-8ea0-459f-8c40-9113363a859a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4f29854c-22e1-42c1-9eea-f6b5e2c0d7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_a6089014-1a8a-4214-bbb9-3ce846643c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4f29854c-22e1-42c1-9eea-f6b5e2c0d7e8" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_a6089014-1a8a-4214-bbb9-3ce846643c3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_03536a33-cd48-4fe8-b65a-4b20a1432ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4f29854c-22e1-42c1-9eea-f6b5e2c0d7e8" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_03536a33-cd48-4fe8-b65a-4b20a1432ae7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_9d102457-3663-43a0-bd04-c8f055862ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4f29854c-22e1-42c1-9eea-f6b5e2c0d7e8" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_9d102457-3663-43a0-bd04-c8f055862ea7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9cd93285-9cd0-462b-a57d-2dc4a495165b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4f29854c-22e1-42c1-9eea-f6b5e2c0d7e8" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9cd93285-9cd0-462b-a57d-2dc4a495165b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_61c0b9c5-43e1-474c-b005-58f654249d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4f29854c-22e1-42c1-9eea-f6b5e2c0d7e8" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_61c0b9c5-43e1-474c-b005-58f654249d8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_ab42bfa9-f936-467f-a5c3-0e72a149807c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4f29854c-22e1-42c1-9eea-f6b5e2c0d7e8" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_ab42bfa9-f936-467f-a5c3-0e72a149807c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_f5e977ff-6c36-4642-b47b-6fcf30efa843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4f29854c-22e1-42c1-9eea-f6b5e2c0d7e8" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_f5e977ff-6c36-4642-b47b-6fcf30efa843" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_9094f14c-92e2-4c3b-b954-73ffe2c4e5e1" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_302bb7e0-6079-4811-9d6d-d3a1b6e1f35d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_9094f14c-92e2-4c3b-b954-73ffe2c4e5e1" xlink:to="loc_us-gaap_Goodwill_302bb7e0-6079-4811-9d6d-d3a1b6e1f35d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_cbbaa28f-8e99-4032-a027-d4fc8f7c72ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_9094f14c-92e2-4c3b-b954-73ffe2c4e5e1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_cbbaa28f-8e99-4032-a027-d4fc8f7c72ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_1ddd98a3-0ecf-405f-9114-b9997e6e82a3" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_9094f14c-92e2-4c3b-b954-73ffe2c4e5e1" xlink:to="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_1ddd98a3-0ecf-405f-9114-b9997e6e82a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_d5feb1d2-5d9d-4836-a0ce-decbfa1f397c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_9094f14c-92e2-4c3b-b954-73ffe2c4e5e1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_d5feb1d2-5d9d-4836-a0ce-decbfa1f397c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_1c8a3865-8f70-44fc-91d0-db681d858384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_9094f14c-92e2-4c3b-b954-73ffe2c4e5e1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_1c8a3865-8f70-44fc-91d0-db681d858384" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_97ed6112-7dff-4974-a3e0-c7e85f5d7717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_9094f14c-92e2-4c3b-b954-73ffe2c4e5e1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_97ed6112-7dff-4974-a3e0-c7e85f5d7717" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_f18825c5-8d3a-4aac-8ca4-35e8144230e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_9094f14c-92e2-4c3b-b954-73ffe2c4e5e1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_f18825c5-8d3a-4aac-8ca4-35e8144230e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3d971eb2-76f6-4917-a42f-5c6796e96074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_fe6e59fa-d21f-41e6-b253-9cb450bd593c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3d971eb2-76f6-4917-a42f-5c6796e96074" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_fe6e59fa-d21f-41e6-b253-9cb450bd593c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent_76c550e1-fc5b-46c4-a360-7bdc4c7dacba" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3d971eb2-76f6-4917-a42f-5c6796e96074" xlink:to="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent_76c550e1-fc5b-46c4-a360-7bdc4c7dacba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits_10f2ccfd-ecfa-49c5-8817-fb462c39e947" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3d971eb2-76f6-4917-a42f-5c6796e96074" xlink:to="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits_10f2ccfd-ecfa-49c5-8817-fb462c39e947" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_7059cd10-fff9-491d-b783-a00a9e2a960b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3d971eb2-76f6-4917-a42f-5c6796e96074" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_7059cd10-fff9-491d-b783-a00a9e2a960b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent_7eb87f5e-8914-4a9a-b816-6746166f05dc" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3d971eb2-76f6-4917-a42f-5c6796e96074" xlink:to="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent_7eb87f5e-8914-4a9a-b816-6746166f05dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5985d259-a7b4-4558-993f-7c999694e67a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_67416bb8-f0d1-430c-81c6-adeef6e5d18b" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5985d259-a7b4-4558-993f-7c999694e67a" xlink:to="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_67416bb8-f0d1-430c-81c6-adeef6e5d18b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_59f12318-bb83-4d5a-a817-6e218d4faf58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5985d259-a7b4-4558-993f-7c999694e67a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_59f12318-bb83-4d5a-a817-6e218d4faf58" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_07311ccc-4712-4990-8445-d59d20f683f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cab5f8b8-ed5b-472e-9ac8-255a4da0dd4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_07311ccc-4712-4990-8445-d59d20f683f2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cab5f8b8-ed5b-472e-9ac8-255a4da0dd4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_69e247f3-2706-4c54-a464-2cee90bd5729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_07311ccc-4712-4990-8445-d59d20f683f2" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_69e247f3-2706-4c54-a464-2cee90bd5729" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_93508842-3f14-4629-bf0c-a2d9b33b5b73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_17344c16-a833-43d6-9e9c-3c8e6e5f3a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_93508842-3f14-4629-bf0c-a2d9b33b5b73" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_17344c16-a833-43d6-9e9c-3c8e6e5f3a7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0c93f39c-6971-4fe8-a52e-884dbb12ac61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_93508842-3f14-4629-bf0c-a2d9b33b5b73" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0c93f39c-6971-4fe8-a52e-884dbb12ac61" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5df5b8d9-3953-42a5-8fef-25a6e718c4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_1b43286a-8c44-41d5-9461-cd7b01367f50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5df5b8d9-3953-42a5-8fef-25a6e718c4ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_1b43286a-8c44-41d5-9461-cd7b01367f50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1b29605c-5963-4dd9-9983-3bb70ad8ba5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5df5b8d9-3953-42a5-8fef-25a6e718c4ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1b29605c-5963-4dd9-9983-3bb70ad8ba5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_34475847-4de9-4621-b026-db41d1d279bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5df5b8d9-3953-42a5-8fef-25a6e718c4ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_34475847-4de9-4621-b026-db41d1d279bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4240aac6-1e62-4772-9cff-71d7546db329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5df5b8d9-3953-42a5-8fef-25a6e718c4ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4240aac6-1e62-4772-9cff-71d7546db329" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_5e937f91-afda-42b0-80ad-ce1cb3c212f0" xlink:href="ccrn-20220331.xsd#ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5df5b8d9-3953-42a5-8fef-25a6e718c4ab" xlink:to="loc_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_5e937f91-afda-42b0-80ad-ce1cb3c212f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d57c9551-5c03-42a4-98fc-1798235e7a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5df5b8d9-3953-42a5-8fef-25a6e718c4ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d57c9551-5c03-42a4-98fc-1798235e7a6f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#DEBTLongtermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_2dc8f930-ac73-4125-b6a4-06253e222f31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f270b6f1-cfea-440c-ab7e-607b83c5e850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2dc8f930-ac73-4125-b6a4-06253e222f31" xlink:to="loc_us-gaap_LongTermDebtCurrent_f270b6f1-cfea-440c-ab7e-607b83c5e850" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_651af7c4-eb11-4289-aefc-25eec2c3d790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2dc8f930-ac73-4125-b6a4-06253e222f31" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_651af7c4-eb11-4289-aefc-25eec2c3d790" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#DEBTMaturitiesofDebtDetails"/>
  <link:calculationLink xlink:role="http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0c82188f-bd42-4626-a39f-b1cf08d57423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c4aa2e08-d9d2-452e-85d7-704c25ebe56c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0c82188f-bd42-4626-a39f-b1cf08d57423" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c4aa2e08-d9d2-452e-85d7-704c25ebe56c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_081ecd81-543a-4cda-8639-a9a0e83a0117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0c82188f-bd42-4626-a39f-b1cf08d57423" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_081ecd81-543a-4cda-8639-a9a0e83a0117" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_1d358a41-0f94-4c68-a4b7-7ad59d063484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0c82188f-bd42-4626-a39f-b1cf08d57423" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_1d358a41-0f94-4c68-a4b7-7ad59d063484" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LongTermDebtMaturityAfterYearFour_f80f276f-07d2-4907-9907-b0c94bcab8a5" xlink:href="ccrn-20220331.xsd#ccrn_LongTermDebtMaturityAfterYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0c82188f-bd42-4626-a39f-b1cf08d57423" xlink:to="loc_ccrn_LongTermDebtMaturityAfterYearFour_f80f276f-07d2-4907-9907-b0c94bcab8a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ed4a21f3-9ec8-48a4-bd09-df10640fd58f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0c82188f-bd42-4626-a39f-b1cf08d57423" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ed4a21f3-9ec8-48a4-bd09-df10640fd58f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d261e75b-3ea5-4eeb-a5cf-c2051c1c41ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0c82188f-bd42-4626-a39f-b1cf08d57423" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d261e75b-3ea5-4eeb-a5cf-c2051c1c41ff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#LEASESOperatingLeaseMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3990c2fb-2333-4ea2-977f-a7780d40bfd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1466d7cd-83c6-4fda-84d0-06d6a8315d47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3990c2fb-2333-4ea2-977f-a7780d40bfd8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1466d7cd-83c6-4fda-84d0-06d6a8315d47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7a9b7451-659e-4d82-85a4-63027ed8aaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3990c2fb-2333-4ea2-977f-a7780d40bfd8" xlink:to="loc_us-gaap_OperatingLeaseLiability_7a9b7451-659e-4d82-85a4-63027ed8aaf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b30cae82-1ddb-4143-a39f-ad2b1f9be70c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9701e2d7-4340-48f2-801d-e248ddf20acd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b30cae82-1ddb-4143-a39f-ad2b1f9be70c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9701e2d7-4340-48f2-801d-e248ddf20acd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_239e1dae-bffa-41fe-8992-5cf1cc634e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b30cae82-1ddb-4143-a39f-ad2b1f9be70c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_239e1dae-bffa-41fe-8992-5cf1cc634e40" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails_1" xlink:type="simple" xlink:href="ccrn-20220331.xsd#LEASESOperatingLeaseMaturityDetails_1"/>
  <link:calculationLink xlink:role="http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6099d9e9-54a1-497e-9267-1b2908735446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a979b490-8927-4a5c-a8e0-5ae8845fb063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6099d9e9-54a1-497e-9267-1b2908735446" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a979b490-8927-4a5c-a8e0-5ae8845fb063" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_090b311e-956f-4a23-92e6-b2f357ebd649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6099d9e9-54a1-497e-9267-1b2908735446" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_090b311e-956f-4a23-92e6-b2f357ebd649" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0d34fdb1-fb3f-433a-b315-b0aeb422c207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6099d9e9-54a1-497e-9267-1b2908735446" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0d34fdb1-fb3f-433a-b315-b0aeb422c207" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_48cdcc71-fd7e-455c-8890-2eda9e5f9d57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6099d9e9-54a1-497e-9267-1b2908735446" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_48cdcc71-fd7e-455c-8890-2eda9e5f9d57" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>ccrn-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:bf6b0e24-63a4-4887-ba98-a744ebcd1084,g:9e05db7a-6f27-4cf3-b67e-d2d201684423-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ccrn-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i04fe6a8c39e546078d84930752fd44ff_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_72c1451e-e60b-4815-aeb5-157f6b8302a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_277ba291-ec80-4262-842a-18848db97be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72c1451e-e60b-4815-aeb5-157f6b8302a1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_277ba291-ec80-4262-842a-18848db97be8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_8ddde697-7d90-49cf-811e-ec3c99b0a6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_277ba291-ec80-4262-842a-18848db97be8" xlink:to="loc_us-gaap_SharesOutstanding_8ddde697-7d90-49cf-811e-ec3c99b0a6ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f151e666-7e9d-4599-8c0b-80de184acf75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_277ba291-ec80-4262-842a-18848db97be8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f151e666-7e9d-4599-8c0b-80de184acf75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c7f97412-90bb-499d-ab6e-a42c3bbf4d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_277ba291-ec80-4262-842a-18848db97be8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c7f97412-90bb-499d-ab6e-a42c3bbf4d4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a047c7c1-3287-4e8d-9b2d-7f6c338469fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_277ba291-ec80-4262-842a-18848db97be8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a047c7c1-3287-4e8d-9b2d-7f6c338469fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_baa0f66c-dc09-428b-a118-57b117769f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_277ba291-ec80-4262-842a-18848db97be8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_baa0f66c-dc09-428b-a118-57b117769f9b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_618fdb02-bb17-4750-ba95-c60c1306b437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_277ba291-ec80-4262-842a-18848db97be8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_618fdb02-bb17-4750-ba95-c60c1306b437" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c7267a43-310a-434a-a8b5-12c26fa3ddd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_277ba291-ec80-4262-842a-18848db97be8" xlink:to="loc_us-gaap_NetIncomeLoss_c7267a43-310a-434a-a8b5-12c26fa3ddd3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d1f7092d-a8b6-45b5-a1fb-3a6a8689019a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f678beea-0698-497f-ac79-5df9e7e3c593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d0dd4fdd-74f6-4966-b1a3-7c54817ae87a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_72c1451e-e60b-4815-aeb5-157f6b8302a1" xlink:to="loc_us-gaap_StatementTable_d0dd4fdd-74f6-4966-b1a3-7c54817ae87a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_772926a3-fa5a-421f-9b3c-d24448711d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d0dd4fdd-74f6-4966-b1a3-7c54817ae87a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_772926a3-fa5a-421f-9b3c-d24448711d5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_772926a3-fa5a-421f-9b3c-d24448711d5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_772926a3-fa5a-421f-9b3c-d24448711d5a" xlink:to="loc_us-gaap_EquityComponentDomain_772926a3-fa5a-421f-9b3c-d24448711d5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_25ec9992-3ba1-453a-9798-fe86af337bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_772926a3-fa5a-421f-9b3c-d24448711d5a" xlink:to="loc_us-gaap_EquityComponentDomain_25ec9992-3ba1-453a-9798-fe86af337bc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_dde0f825-54aa-45d3-9e48-3dfb448f3a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_25ec9992-3ba1-453a-9798-fe86af337bc9" xlink:to="loc_us-gaap_CommonStockMember_dde0f825-54aa-45d3-9e48-3dfb448f3a16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cd1c7783-e44a-4d35-99cb-cb201c8826aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_25ec9992-3ba1-453a-9798-fe86af337bc9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cd1c7783-e44a-4d35-99cb-cb201c8826aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f1333c8-0caa-4ea3-a9bd-91601a7d6db3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_25ec9992-3ba1-453a-9798-fe86af337bc9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f1333c8-0caa-4ea3-a9bd-91601a7d6db3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2b7cb24d-7e50-46c4-9f05-0147d174520c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_25ec9992-3ba1-453a-9798-fe86af337bc9" xlink:to="loc_us-gaap_RetainedEarningsMember_2b7cb24d-7e50-46c4-9f05-0147d174520c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_257092cd-6178-42a1-8f98-3af950b133fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_25ec9992-3ba1-453a-9798-fe86af337bc9" xlink:to="loc_us-gaap_NoncontrollingInterestMember_257092cd-6178-42a1-8f98-3af950b133fa" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="extended" id="i3557ed7d5ca14af983482083ccc1a007_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_98343c2e-7e88-44f6-9c5c-fae3d0ad5348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_712a7b5b-eda5-431c-99f8-b180446bf905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_98343c2e-7e88-44f6-9c5c-fae3d0ad5348" xlink:to="loc_us-gaap_UnbilledContractsReceivable_712a7b5b-eda5-431c-99f8-b180446bf905" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SalesAllowanceBillingRelatedAdjustments_177138f2-71b5-4c1d-a88c-9ce7229ea5d5" xlink:href="ccrn-20220331.xsd#ccrn_SalesAllowanceBillingRelatedAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_98343c2e-7e88-44f6-9c5c-fae3d0ad5348" xlink:to="loc_ccrn_SalesAllowanceBillingRelatedAdjustments_177138f2-71b5-4c1d-a88c-9ce7229ea5d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided_dbba19ce-eac0-48c7-82e8-d08d7502b1fe" xlink:href="ccrn-20220331.xsd#ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_98343c2e-7e88-44f6-9c5c-fae3d0ad5348" xlink:to="loc_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided_dbba19ce-eac0-48c7-82e8-d08d7502b1fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0476c760-d54d-4c58-856e-8c9b8b6122fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_98343c2e-7e88-44f6-9c5c-fae3d0ad5348" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0476c760-d54d-4c58-856e-8c9b8b6122fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_272340ef-f12b-473f-a330-89bf6a61e5c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0476c760-d54d-4c58-856e-8c9b8b6122fc" xlink:to="loc_srt_RangeAxis_272340ef-f12b-473f-a330-89bf6a61e5c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_272340ef-f12b-473f-a330-89bf6a61e5c3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_272340ef-f12b-473f-a330-89bf6a61e5c3" xlink:to="loc_srt_RangeMember_272340ef-f12b-473f-a330-89bf6a61e5c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1c9910f6-d30c-479a-81c1-ec100b897cc8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_272340ef-f12b-473f-a330-89bf6a61e5c3" xlink:to="loc_srt_RangeMember_1c9910f6-d30c-479a-81c1-ec100b897cc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6bef987c-6118-4390-92da-ab8bdb8d6194" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1c9910f6-d30c-479a-81c1-ec100b897cc8" xlink:to="loc_srt_MinimumMember_6bef987c-6118-4390-92da-ab8bdb8d6194" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a0202dc7-58ab-4aef-949f-8b351a91365e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1c9910f6-d30c-479a-81c1-ec100b897cc8" xlink:to="loc_srt_MaximumMember_a0202dc7-58ab-4aef-949f-8b351a91365e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringCostsDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringCostsDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringCostsDetails" xlink:type="extended" id="idd60ccb9b61c486db3232d9417a8eaae_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringCostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_db59cc9b-7e1d-463d-8cff-d3726a81bf51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_c8d13a6e-98a6-4a49-be89-694b7a6a87c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_db59cc9b-7e1d-463d-8cff-d3726a81bf51" xlink:to="loc_us-gaap_RestructuringReserveRollForward_c8d13a6e-98a6-4a49-be89-694b7a6a87c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_4d46f57b-c37a-4133-ba49-926137a83a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c8d13a6e-98a6-4a49-be89-694b7a6a87c8" xlink:to="loc_us-gaap_RestructuringReserve_4d46f57b-c37a-4133-ba49-926137a83a3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_af79bd77-1d8b-4a5c-bfbb-abea4f6e523d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c8d13a6e-98a6-4a49-be89-694b7a6a87c8" xlink:to="loc_us-gaap_RestructuringCharges_af79bd77-1d8b-4a5c-bfbb-abea4f6e523d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_PaymentsForRestructuringAndAdjustments_3923df69-2cb4-45c8-8f70-007e2105ec4c" xlink:href="ccrn-20220331.xsd#ccrn_PaymentsForRestructuringAndAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c8d13a6e-98a6-4a49-be89-694b7a6a87c8" xlink:to="loc_ccrn_PaymentsForRestructuringAndAdjustments_3923df69-2cb4-45c8-8f70-007e2105ec4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_6c57f751-32b2-44af-9cbc-c65971943eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4989ed8f-edab-443d-b06c-30f8632281fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_db59cc9b-7e1d-463d-8cff-d3726a81bf51" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4989ed8f-edab-443d-b06c-30f8632281fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1307265f-db45-4791-92b0-5ef4fb7b8d54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4989ed8f-edab-443d-b06c-30f8632281fd" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1307265f-db45-4791-92b0-5ef4fb7b8d54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1307265f-db45-4791-92b0-5ef4fb7b8d54_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1307265f-db45-4791-92b0-5ef4fb7b8d54" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1307265f-db45-4791-92b0-5ef4fb7b8d54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_de0fd2c7-d804-410d-a95c-f5f3bd4089f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1307265f-db45-4791-92b0-5ef4fb7b8d54" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_de0fd2c7-d804-410d-a95c-f5f3bd4089f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_b07bc6b1-e0e0-45c7-9908-bd5ee91cf06d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_de0fd2c7-d804-410d-a95c-f5f3bd4089f5" xlink:to="loc_us-gaap_EmployeeSeveranceMember_b07bc6b1-e0e0-45c7-9908-bd5ee91cf06d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ExitCostsMember_43b1d9b0-ba53-4e32-876f-95a92f7952db" xlink:href="ccrn-20220331.xsd#ccrn_ExitCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_de0fd2c7-d804-410d-a95c-f5f3bd4089f5" xlink:to="loc_ccrn_ExitCostsMember_43b1d9b0-ba53-4e32-876f-95a92f7952db" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#REVENUERECOGNITIONDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails" xlink:type="extended" id="ia4e99814859e4c68a7465ce741726fcc_REVENUERECOGNITIONDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_515c9487-81f8-4095-876d-dc2058b9e309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e8cd2861-938b-4a15-9b19-6d7baa450821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_515c9487-81f8-4095-876d-dc2058b9e309" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e8cd2861-938b-4a15-9b19-6d7baa450821" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_8ad51106-7808-45bb-8392-cc2596c8a36f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_515c9487-81f8-4095-876d-dc2058b9e309" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_8ad51106-7808-45bb-8392-cc2596c8a36f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3397fc6e-02fd-4646-8df9-b01362853989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8ad51106-7808-45bb-8392-cc2596c8a36f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3397fc6e-02fd-4646-8df9-b01362853989" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3397fc6e-02fd-4646-8df9-b01362853989_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3397fc6e-02fd-4646-8df9-b01362853989" xlink:to="loc_us-gaap_SegmentDomain_3397fc6e-02fd-4646-8df9-b01362853989_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d803d0c9-0ee1-4b3a-a551-ce3d90c28121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3397fc6e-02fd-4646-8df9-b01362853989" xlink:to="loc_us-gaap_SegmentDomain_d803d0c9-0ee1-4b3a-a551-ce3d90c28121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NurseAndAlliedStaffingMember_de820d37-e081-49cf-922d-a7ed901968de" xlink:href="ccrn-20220331.xsd#ccrn_NurseAndAlliedStaffingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d803d0c9-0ee1-4b3a-a551-ce3d90c28121" xlink:to="loc_ccrn_NurseAndAlliedStaffingMember_de820d37-e081-49cf-922d-a7ed901968de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_PhysicianStaffingMember_943cc010-3e30-44d3-b9ef-e06997da0031" xlink:href="ccrn-20220331.xsd#ccrn_PhysicianStaffingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d803d0c9-0ee1-4b3a-a551-ce3d90c28121" xlink:to="loc_ccrn_PhysicianStaffingMember_943cc010-3e30-44d3-b9ef-e06997da0031" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5151b80e-c395-462b-aa18-76fef703a8c2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8ad51106-7808-45bb-8392-cc2596c8a36f" xlink:to="loc_srt_ProductOrServiceAxis_5151b80e-c395-462b-aa18-76fef703a8c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5151b80e-c395-462b-aa18-76fef703a8c2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5151b80e-c395-462b-aa18-76fef703a8c2" xlink:to="loc_srt_ProductsAndServicesDomain_5151b80e-c395-462b-aa18-76fef703a8c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_87b7461c-2fd8-438e-aa62-6697cbf880f3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5151b80e-c395-462b-aa18-76fef703a8c2" xlink:to="loc_srt_ProductsAndServicesDomain_87b7461c-2fd8-438e-aa62-6697cbf880f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_TemporaryStaffingServicesMember_274b90c4-4de2-44e5-87b6-c7e2e4c5fb6e" xlink:href="ccrn-20220331.xsd#ccrn_TemporaryStaffingServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_87b7461c-2fd8-438e-aa62-6697cbf880f3" xlink:to="loc_ccrn_TemporaryStaffingServicesMember_274b90c4-4de2-44e5-87b6-c7e2e4c5fb6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OtherServicesMember_3eff6412-d3ea-4eda-98c5-416022b0bb3e" xlink:href="ccrn-20220331.xsd#ccrn_OtherServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_87b7461c-2fd8-438e-aa62-6697cbf880f3" xlink:to="loc_ccrn_OtherServicesMember_3eff6412-d3ea-4eda-98c5-416022b0bb3e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#ACQUISITIONSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails" xlink:type="extended" id="i7f8ccd72856541b885a280de031ba392_ACQUISITIONSAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_962e10c6-3116-40d3-980c-4f2782d58774" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_962e10c6-3116-40d3-980c-4f2782d58774" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_acc50c1f-c6b6-48dd-8c4a-6d08a1e3c397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_acc50c1f-c6b6-48dd-8c4a-6d08a1e3c397" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0f96d9ff-0c91-41dc-a971-fb8bcf25196d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0f96d9ff-0c91-41dc-a971-fb8bcf25196d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_268a6a7a-9767-4dc6-8c79-d95db05afd60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_268a6a7a-9767-4dc6-8c79-d95db05afd60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_36e5a841-f531-4ca1-9d96-b38cdb0918dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_us-gaap_Goodwill_36e5a841-f531-4ca1-9d96-b38cdb0918dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment_e57775a9-159f-4a1d-b562-3190d4a28c40" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_ccrn_BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment_e57775a9-159f-4a1d-b562-3190d4a28c40" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationContingentConsiderationTerm_c54004bd-5ee7-4856-921d-4011bf832f9b" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationContingentConsiderationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_ccrn_BusinessCombinationContingentConsiderationTerm_c54004bd-5ee7-4856-921d-4011bf832f9b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0049cd21-bf90-45c5-9006-f517b048c3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0049cd21-bf90-45c5-9006-f517b048c3a8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_ddf8e812-ce34-4c27-8945-226f9f92981b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_ddf8e812-ce34-4c27-8945-226f9f92981b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_57bf0c6b-0316-414e-bcd2-e790f44bf4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_57bf0c6b-0316-414e-bcd2-e790f44bf4c1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8eff5799-7a77-42e4-8c05-737cf996e726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8eff5799-7a77-42e4-8c05-737cf996e726" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_ad0b6d84-70a9-4210-ad01-323e3351ca25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_us-gaap_NotesPayable_ad0b6d84-70a9-4210-ad01-323e3351ca25" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NotePayableNumberOfPaymentInstallments_f1fd6189-f54d-456d-b12a-370119071e4e" xlink:href="ccrn-20220331.xsd#ccrn_NotePayableNumberOfPaymentInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_ccrn_NotePayableNumberOfPaymentInstallments_f1fd6189-f54d-456d-b12a-370119071e4e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NotePayableNumberOfInstallmentsPaid_069b24b6-8edf-4479-b4bf-85e9a2f76f1f" xlink:href="ccrn-20220331.xsd#ccrn_NotePayableNumberOfInstallmentsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_ccrn_NotePayableNumberOfInstallmentsPaid_069b24b6-8edf-4479-b4bf-85e9a2f76f1f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_b5d004ad-648d-486a-92de-d756f05ec4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_b5d004ad-648d-486a-92de-d756f05ec4a6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2311a09a-9dcd-4907-bc9d-7a2350b23d27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2311a09a-9dcd-4907-bc9d-7a2350b23d27" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a910a12c-adb1-4dfa-bbda-9cff9df00ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2311a09a-9dcd-4907-bc9d-7a2350b23d27" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a910a12c-adb1-4dfa-bbda-9cff9df00ca1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a910a12c-adb1-4dfa-bbda-9cff9df00ca1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a910a12c-adb1-4dfa-bbda-9cff9df00ca1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a910a12c-adb1-4dfa-bbda-9cff9df00ca1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_386a0db8-e86c-4fec-a52c-24fcbc08c7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a910a12c-adb1-4dfa-bbda-9cff9df00ca1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_386a0db8-e86c-4fec-a52c-24fcbc08c7ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SelectedIncMember_b9b7ff5c-291b-4791-9a04-a52a40514aa3" xlink:href="ccrn-20220331.xsd#ccrn_SelectedIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_386a0db8-e86c-4fec-a52c-24fcbc08c7ae" xlink:to="loc_ccrn_SelectedIncMember_b9b7ff5c-291b-4791-9a04-a52a40514aa3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_WorkforceSolutionsGroupIncMember_42f8451f-7c07-4bfa-aaf8-c47745c5a63e" xlink:href="ccrn-20220331.xsd#ccrn_WorkforceSolutionsGroupIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_386a0db8-e86c-4fec-a52c-24fcbc08c7ae" xlink:to="loc_ccrn_WorkforceSolutionsGroupIncMember_42f8451f-7c07-4bfa-aaf8-c47745c5a63e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_MediscanMember_3b5d57c4-2bed-45f5-b924-566fc88da6d3" xlink:href="ccrn-20220331.xsd#ccrn_MediscanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_386a0db8-e86c-4fec-a52c-24fcbc08c7ae" xlink:to="loc_ccrn_MediscanMember_3b5d57c4-2bed-45f5-b924-566fc88da6d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_35bf8445-7b7a-482e-a3e6-6b25b0279853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2311a09a-9dcd-4907-bc9d-7a2350b23d27" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_35bf8445-7b7a-482e-a3e6-6b25b0279853" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_35bf8445-7b7a-482e-a3e6-6b25b0279853_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_35bf8445-7b7a-482e-a3e6-6b25b0279853" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_35bf8445-7b7a-482e-a3e6-6b25b0279853_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a139f510-6dfc-4b23-8a03-e4049b098b78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_35bf8445-7b7a-482e-a3e6-6b25b0279853" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a139f510-6dfc-4b23-8a03-e4049b098b78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_82091444-d5d8-43e0-a271-b56f87eaa53a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a139f510-6dfc-4b23-8a03-e4049b098b78" xlink:to="loc_us-gaap_CustomerRelationshipsMember_82091444-d5d8-43e0-a271-b56f87eaa53a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b1d352d4-035a-4a0d-becf-321f07470912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2311a09a-9dcd-4907-bc9d-7a2350b23d27" xlink:to="loc_us-gaap_DebtInstrumentAxis_b1d352d4-035a-4a0d-becf-321f07470912" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b1d352d4-035a-4a0d-becf-321f07470912_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1d352d4-035a-4a0d-becf-321f07470912" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b1d352d4-035a-4a0d-becf-321f07470912_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_97bb2fef-e116-4dc1-95fb-e12d357af202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1d352d4-035a-4a0d-becf-321f07470912" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_97bb2fef-e116-4dc1-95fb-e12d357af202" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_EarnoutNotesPayableMember_879057c3-ed0c-4a93-bbb9-1358df207c7a" xlink:href="ccrn-20220331.xsd#ccrn_EarnoutNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_97bb2fef-e116-4dc1-95fb-e12d357af202" xlink:to="loc_ccrn_EarnoutNotesPayableMember_879057c3-ed0c-4a93-bbb9-1358df207c7a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="i056f6d1ce2fb4142ace20bd6b128f9dc_ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_9846b4d7-285d-4b3b-a6d8-c861d7bbff9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_9846b4d7-285d-4b3b-a6d8-c861d7bbff9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_cb1d21e2-8137-451d-aec7-9495f1f01367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_cb1d21e2-8137-451d-aec7-9495f1f01367" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_62d5028d-19dd-4a10-88d3-7cb69a52246a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_62d5028d-19dd-4a10-88d3-7cb69a52246a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a7bb3e97-9af4-4f46-8213-10cba508573c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a7bb3e97-9af4-4f46-8213-10cba508573c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_6c20f634-2308-456c-86b8-6b230a59bcef" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_6c20f634-2308-456c-86b8-6b230a59bcef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dff18bcf-1e19-4f63-be2d-50b0a7e637ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_us-gaap_Goodwill_dff18bcf-1e19-4f63-be2d-50b0a7e637ed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_a804666a-dfdf-415c-8633-3958c811b7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_a804666a-dfdf-415c-8633-3958c811b7e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_b8ad88b8-82a2-4b8e-ab02-e01fbec90522" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_b8ad88b8-82a2-4b8e-ab02-e01fbec90522" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_437654e7-33af-40ab-97e6-c2a3ea765d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_437654e7-33af-40ab-97e6-c2a3ea765d5c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits_5517014c-baa5-41ff-8f86-a026de3808df" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits_5517014c-baa5-41ff-8f86-a026de3808df" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent_07d03d61-e64f-4264-9cd7-dc9e6c99df43" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent_07d03d61-e64f-4264-9cd7-dc9e6c99df43" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent_9cfafcd3-e666-4673-bfce-839ddcc9542d" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent_9cfafcd3-e666-4673-bfce-839ddcc9542d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_a854a71f-b457-4721-9da1-f5af334510d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_a854a71f-b457-4721-9da1-f5af334510d1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_d7e45078-84a6-4c6a-86a4-32145682ff88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_d7e45078-84a6-4c6a-86a4-32145682ff88" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_619368ea-cae8-4bd8-8e4b-61ef1ba70ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_619368ea-cae8-4bd8-8e4b-61ef1ba70ebe" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ffa84dd5-c110-4a15-94ce-888c90e82da8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ffa84dd5-c110-4a15-94ce-888c90e82da8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ec487327-e2cf-4a9d-a8fd-d918691942d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ffa84dd5-c110-4a15-94ce-888c90e82da8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ec487327-e2cf-4a9d-a8fd-d918691942d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec487327-e2cf-4a9d-a8fd-d918691942d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ec487327-e2cf-4a9d-a8fd-d918691942d4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec487327-e2cf-4a9d-a8fd-d918691942d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96d1792d-3cbd-4a94-b9f7-61210e813610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ec487327-e2cf-4a9d-a8fd-d918691942d4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96d1792d-3cbd-4a94-b9f7-61210e813610" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_WorkforceSolutionsGroupIncMember_db34c296-c69f-4456-af4b-f5fac1e525dc" xlink:href="ccrn-20220331.xsd#ccrn_WorkforceSolutionsGroupIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96d1792d-3cbd-4a94-b9f7-61210e813610" xlink:to="loc_ccrn_WorkforceSolutionsGroupIncMember_db34c296-c69f-4456-af4b-f5fac1e525dc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAdditionalInformationDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#EARNINGSPERSHAREAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAdditionalInformationDetails" xlink:type="extended" id="if391cd26d1e442f5946b31aacb54746e_EARNINGSPERSHAREAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4c6abd8a-9ca8-4212-a6ad-150e7a8596aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bb230fbc-4537-445b-a7f5-96181b84d14e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4c6abd8a-9ca8-4212-a6ad-150e7a8596aa" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bb230fbc-4537-445b-a7f5-96181b84d14e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_32dfa663-3a2f-44b5-b8b2-70fde141adb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4c6abd8a-9ca8-4212-a6ad-150e7a8596aa" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_32dfa663-3a2f-44b5-b8b2-70fde141adb8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7be2cf7e-590b-4370-a045-e4e913c0ec26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_32dfa663-3a2f-44b5-b8b2-70fde141adb8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7be2cf7e-590b-4370-a045-e4e913c0ec26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7be2cf7e-590b-4370-a045-e4e913c0ec26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7be2cf7e-590b-4370-a045-e4e913c0ec26" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7be2cf7e-590b-4370-a045-e4e913c0ec26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_61b35b3e-9203-4c48-849a-bf8f2b6b3e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7be2cf7e-590b-4370-a045-e4e913c0ec26" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_61b35b3e-9203-4c48-849a-bf8f2b6b3e69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ShareBasedPaymentAwardsMember_91fa179f-9a94-49c9-bb52-8c5da6791eae" xlink:href="ccrn-20220331.xsd#ccrn_ShareBasedPaymentAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_61b35b3e-9203-4c48-849a-bf8f2b6b3e69" xlink:to="loc_ccrn_ShareBasedPaymentAwardsMember_91fa179f-9a94-49c9-bb52-8c5da6791eae" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails" xlink:type="extended" id="i5233eab2e5d0490099f5d6da5db2397a_GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e5b37eb3-e426-418d-8286-e016a6c91a78" xlink:href="ccrn-20220331.xsd#ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d4334c3d-5685-4d54-87dc-34b266f56f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e5b37eb3-e426-418d-8286-e016a6c91a78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d4334c3d-5685-4d54-87dc-34b266f56f6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a7490920-b031-45a6-a74e-062a8b620306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e5b37eb3-e426-418d-8286-e016a6c91a78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a7490920-b031-45a6-a74e-062a8b620306" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_009cad77-a92e-42d3-98d9-4709c9b25c36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e5b37eb3-e426-418d-8286-e016a6c91a78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_009cad77-a92e-42d3-98d9-4709c9b25c36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedTradeNames_a2f81bc4-8c95-46b5-8c7a-246f827ddf05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedTradeNames"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e5b37eb3-e426-418d-8286-e016a6c91a78" xlink:to="loc_us-gaap_IndefiniteLivedTradeNames_a2f81bc4-8c95-46b5-8c7a-246f827ddf05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable_ea741ae6-2fa5-49f8-8b00-9c9b7eef5618" xlink:href="ccrn-20220331.xsd#ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e5b37eb3-e426-418d-8286-e016a6c91a78" xlink:to="loc_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable_ea741ae6-2fa5-49f8-8b00-9c9b7eef5618" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1ab3d22-98a4-4cde-9ecb-6b4cd5ed757f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable_ea741ae6-2fa5-49f8-8b00-9c9b7eef5618" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1ab3d22-98a4-4cde-9ecb-6b4cd5ed757f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a1ab3d22-98a4-4cde-9ecb-6b4cd5ed757f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1ab3d22-98a4-4cde-9ecb-6b4cd5ed757f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a1ab3d22-98a4-4cde-9ecb-6b4cd5ed757f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c59943a6-ce03-422e-a2d6-44571cfaa61b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1ab3d22-98a4-4cde-9ecb-6b4cd5ed757f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c59943a6-ce03-422e-a2d6-44571cfaa61b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DatabasesMember_0f0aec8c-568c-4b8c-ae13-40ccd4637a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DatabasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c59943a6-ce03-422e-a2d6-44571cfaa61b" xlink:to="loc_us-gaap_DatabasesMember_0f0aec8c-568c-4b8c-ae13-40ccd4637a9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_e7239ab5-28ed-4e41-b352-85188ef2b550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c59943a6-ce03-422e-a2d6-44571cfaa61b" xlink:to="loc_us-gaap_CustomerRelationshipsMember_e7239ab5-28ed-4e41-b352-85188ef2b550" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_12ec3daf-d976-460a-a5fa-775bb4c708da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c59943a6-ce03-422e-a2d6-44571cfaa61b" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_12ec3daf-d976-460a-a5fa-775bb4c708da" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails" xlink:type="extended" id="ifa32ed3dfa8b478985d4e20d52bf89ba_GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_7de9579a-ec7b-4852-a402-89e2887a3b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e18d8583-15ed-4b87-bf86-6f978bd887e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_7de9579a-ec7b-4852-a402-89e2887a3b5a" xlink:to="loc_us-gaap_Goodwill_e18d8583-15ed-4b87-bf86-6f978bd887e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_3f798ee1-9bdd-4eab-94e5-458a28f7335c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_7de9579a-ec7b-4852-a402-89e2887a3b5a" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_3f798ee1-9bdd-4eab-94e5-458a28f7335c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e7a3febf-2f09-4126-aaa2-36b7b144a233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3f798ee1-9bdd-4eab-94e5-458a28f7335c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e7a3febf-2f09-4126-aaa2-36b7b144a233" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e7a3febf-2f09-4126-aaa2-36b7b144a233_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e7a3febf-2f09-4126-aaa2-36b7b144a233" xlink:to="loc_us-gaap_SegmentDomain_e7a3febf-2f09-4126-aaa2-36b7b144a233_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5775d41a-3cf3-49a5-8d3b-fd084419b229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e7a3febf-2f09-4126-aaa2-36b7b144a233" xlink:to="loc_us-gaap_SegmentDomain_5775d41a-3cf3-49a5-8d3b-fd084419b229" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NurseAndAlliedStaffingMember_2a32ec75-5f28-4f12-a729-9fb13a93ee45" xlink:href="ccrn-20220331.xsd#ccrn_NurseAndAlliedStaffingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5775d41a-3cf3-49a5-8d3b-fd084419b229" xlink:to="loc_ccrn_NurseAndAlliedStaffingMember_2a32ec75-5f28-4f12-a729-9fb13a93ee45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_PhysicianStaffingMember_fc19bb1b-cfd8-44e0-8699-7b31ad748aff" xlink:href="ccrn-20220331.xsd#ccrn_PhysicianStaffingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5775d41a-3cf3-49a5-8d3b-fd084419b229" xlink:to="loc_ccrn_PhysicianStaffingMember_fc19bb1b-cfd8-44e0-8699-7b31ad748aff" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#DEBTLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails" xlink:type="extended" id="i5a602c4ebe8c49dcae8fb0692b73a37d_DEBTLongtermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4e6e3cda-47d6-4500-a4df-eafd4f6c93f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_45f348ca-578e-4fb5-9a34-6781459e7a42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e6e3cda-47d6-4500-a4df-eafd4f6c93f8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_45f348ca-578e-4fb5-9a34-6781459e7a42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cb5fb57d-c9b3-4be2-bae6-54259892e11d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e6e3cda-47d6-4500-a4df-eafd4f6c93f8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cb5fb57d-c9b3-4be2-bae6-54259892e11d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_8f1de0a8-caef-46ee-9d47-65710b9b4d33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e6e3cda-47d6-4500-a4df-eafd4f6c93f8" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_8f1de0a8-caef-46ee-9d47-65710b9b4d33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_05a5cbdc-4143-444d-905f-78d4462f115c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e6e3cda-47d6-4500-a4df-eafd4f6c93f8" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_05a5cbdc-4143-444d-905f-78d4462f115c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7b5a58cc-b774-4641-abf9-222159de43a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e6e3cda-47d6-4500-a4df-eafd4f6c93f8" xlink:to="loc_us-gaap_LongTermDebtCurrent_7b5a58cc-b774-4641-abf9-222159de43a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3769b13e-4229-45a1-a001-5b952b5ad5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e6e3cda-47d6-4500-a4df-eafd4f6c93f8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3769b13e-4229-45a1-a001-5b952b5ad5a7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c9c8e4be-1de3-466c-82a6-cfcde635c86f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e6e3cda-47d6-4500-a4df-eafd4f6c93f8" xlink:to="loc_us-gaap_DebtInstrumentTable_c9c8e4be-1de3-466c-82a6-cfcde635c86f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2387fdae-ecf5-41b3-a531-b899539e70cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c9c8e4be-1de3-466c-82a6-cfcde635c86f" xlink:to="loc_us-gaap_DebtInstrumentAxis_2387fdae-ecf5-41b3-a531-b899539e70cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2387fdae-ecf5-41b3-a531-b899539e70cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2387fdae-ecf5-41b3-a531-b899539e70cf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2387fdae-ecf5-41b3-a531-b899539e70cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b8b1bcda-b0b8-48a5-966d-d32b1065ddeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2387fdae-ecf5-41b3-a531-b899539e70cf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b8b1bcda-b0b8-48a5-966d-d32b1065ddeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_A2021TermLoanCreditAgreementMember_39d466e2-9f05-4777-ba6d-6a36cc4e0c42" xlink:href="ccrn-20220331.xsd#ccrn_A2021TermLoanCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b8b1bcda-b0b8-48a5-966d-d32b1065ddeb" xlink:to="loc_ccrn_A2021TermLoanCreditAgreementMember_39d466e2-9f05-4777-ba6d-6a36cc4e0c42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_EarnoutNotesPayableMember_378e990e-e99b-47e7-831f-6dc027fbdc3c" xlink:href="ccrn-20220331.xsd#ccrn_EarnoutNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b8b1bcda-b0b8-48a5-966d-d32b1065ddeb" xlink:to="loc_ccrn_EarnoutNotesPayableMember_378e990e-e99b-47e7-831f-6dc027fbdc3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f22300e7-ff2d-40fa-87a8-22498a01e3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c9c8e4be-1de3-466c-82a6-cfcde635c86f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f22300e7-ff2d-40fa-87a8-22498a01e3fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f22300e7-ff2d-40fa-87a8-22498a01e3fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f22300e7-ff2d-40fa-87a8-22498a01e3fe" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f22300e7-ff2d-40fa-87a8-22498a01e3fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dfacb9a2-eb53-4fcc-a8dd-a63e11acf66b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f22300e7-ff2d-40fa-87a8-22498a01e3fe" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dfacb9a2-eb53-4fcc-a8dd-a63e11acf66b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_b7f568b7-d1a5-4a47-b501-ee8e345bffc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dfacb9a2-eb53-4fcc-a8dd-a63e11acf66b" xlink:to="loc_us-gaap_SecuredDebtMember_b7f568b7-d1a5-4a47-b501-ee8e345bffc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_3203e8eb-7468-4a22-b904-d5beac12e0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dfacb9a2-eb53-4fcc-a8dd-a63e11acf66b" xlink:to="loc_us-gaap_LineOfCreditMember_3203e8eb-7468-4a22-b904-d5beac12e0ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_0d96fe72-9fee-4d35-8960-88f28e5eb3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dfacb9a2-eb53-4fcc-a8dd-a63e11acf66b" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_0d96fe72-9fee-4d35-8960-88f28e5eb3ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_99cbe146-6265-4f55-b569-473e8f9c2f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c9c8e4be-1de3-466c-82a6-cfcde635c86f" xlink:to="loc_us-gaap_CreditFacilityAxis_99cbe146-6265-4f55-b569-473e8f9c2f2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_99cbe146-6265-4f55-b569-473e8f9c2f2d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_99cbe146-6265-4f55-b569-473e8f9c2f2d" xlink:to="loc_us-gaap_CreditFacilityDomain_99cbe146-6265-4f55-b569-473e8f9c2f2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9c5f3219-48d7-42a9-93e5-015d9e0e0076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_99cbe146-6265-4f55-b569-473e8f9c2f2d" xlink:to="loc_us-gaap_CreditFacilityDomain_9c5f3219-48d7-42a9-93e5-015d9e0e0076" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SeniorSecuredAssetBasedLoanMember_861c06bc-2d5c-4f31-a313-dc01007c76c2" xlink:href="ccrn-20220331.xsd#ccrn_SeniorSecuredAssetBasedLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_9c5f3219-48d7-42a9-93e5-015d9e0e0076" xlink:to="loc_ccrn_SeniorSecuredAssetBasedLoanMember_861c06bc-2d5c-4f31-a313-dc01007c76c2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#DEBTMaturitiesofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails" xlink:type="extended" id="i0569d3a2e2694d86a08cab8c4b14b3bf_DEBTMaturitiesofDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fc638272-a376-4c9e-bd08-cde61b2293c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_44d09d5a-c186-47e9-8dc3-896b52280c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fc638272-a376-4c9e-bd08-cde61b2293c7" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_44d09d5a-c186-47e9-8dc3-896b52280c49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_d28f2f98-63b3-4e16-9b7e-813bba31a756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_44d09d5a-c186-47e9-8dc3-896b52280c49" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_d28f2f98-63b3-4e16-9b7e-813bba31a756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e2c5482a-eb08-4ea8-9628-db79abb82694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_44d09d5a-c186-47e9-8dc3-896b52280c49" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e2c5482a-eb08-4ea8-9628-db79abb82694" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_82868e8f-a57b-42e2-966b-9efa555cd577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_44d09d5a-c186-47e9-8dc3-896b52280c49" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_82868e8f-a57b-42e2-966b-9efa555cd577" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f957c7a1-32ff-45ce-bbc8-b564f552346a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_44d09d5a-c186-47e9-8dc3-896b52280c49" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f957c7a1-32ff-45ce-bbc8-b564f552346a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_5e9d6350-816b-4349-961a-f7e1da74c168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_44d09d5a-c186-47e9-8dc3-896b52280c49" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_5e9d6350-816b-4349-961a-f7e1da74c168" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LongTermDebtMaturityAfterYearFour_7437ce38-d3e6-4dce-9054-0b7d7b49c7db" xlink:href="ccrn-20220331.xsd#ccrn_LongTermDebtMaturityAfterYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_44d09d5a-c186-47e9-8dc3-896b52280c49" xlink:to="loc_ccrn_LongTermDebtMaturityAfterYearFour_7437ce38-d3e6-4dce-9054-0b7d7b49c7db" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_40ba8b2f-9d39-42f8-8810-e91ca4d8ff47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_44d09d5a-c186-47e9-8dc3-896b52280c49" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_40ba8b2f-9d39-42f8-8810-e91ca4d8ff47" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1d15df77-7199-483b-8073-d22f95b6f872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fc638272-a376-4c9e-bd08-cde61b2293c7" xlink:to="loc_us-gaap_DebtInstrumentTable_1d15df77-7199-483b-8073-d22f95b6f872" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e66ec56b-f7e3-4b52-aea4-0ad2f2a8a5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1d15df77-7199-483b-8073-d22f95b6f872" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e66ec56b-f7e3-4b52-aea4-0ad2f2a8a5e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e66ec56b-f7e3-4b52-aea4-0ad2f2a8a5e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e66ec56b-f7e3-4b52-aea4-0ad2f2a8a5e9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e66ec56b-f7e3-4b52-aea4-0ad2f2a8a5e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b8db39ea-99a3-4477-80c4-aae04bfbdd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e66ec56b-f7e3-4b52-aea4-0ad2f2a8a5e9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b8db39ea-99a3-4477-80c4-aae04bfbdd5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_c28c0bc9-e88c-4724-a213-807a17baf48b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b8db39ea-99a3-4477-80c4-aae04bfbdd5e" xlink:to="loc_us-gaap_SecuredDebtMember_c28c0bc9-e88c-4724-a213-807a17baf48b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_91cc6a20-15f2-49e7-b88d-f01be2a62e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b8db39ea-99a3-4477-80c4-aae04bfbdd5e" xlink:to="loc_us-gaap_LineOfCreditMember_91cc6a20-15f2-49e7-b88d-f01be2a62e8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_30cee963-e1cf-46cb-bb43-b0235542afcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b8db39ea-99a3-4477-80c4-aae04bfbdd5e" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_30cee963-e1cf-46cb-bb43-b0235542afcc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d4b3fb6b-d1e4-4f7f-ba50-c253969ccb57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1d15df77-7199-483b-8073-d22f95b6f872" xlink:to="loc_us-gaap_DebtInstrumentAxis_d4b3fb6b-d1e4-4f7f-ba50-c253969ccb57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d4b3fb6b-d1e4-4f7f-ba50-c253969ccb57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d4b3fb6b-d1e4-4f7f-ba50-c253969ccb57" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d4b3fb6b-d1e4-4f7f-ba50-c253969ccb57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9ca953b7-1fce-4221-9fb1-b6d1002a409e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d4b3fb6b-d1e4-4f7f-ba50-c253969ccb57" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9ca953b7-1fce-4221-9fb1-b6d1002a409e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_A2021TermLoanCreditAgreementMember_ceeb9bde-2d60-475a-97c8-a14bd69a3d95" xlink:href="ccrn-20220331.xsd#ccrn_A2021TermLoanCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9ca953b7-1fce-4221-9fb1-b6d1002a409e" xlink:to="loc_ccrn_A2021TermLoanCreditAgreementMember_ceeb9bde-2d60-475a-97c8-a14bd69a3d95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_EarnoutNotesPayableMember_2c4f039e-5926-473e-9dd0-4a217141a8ee" xlink:href="ccrn-20220331.xsd#ccrn_EarnoutNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9ca953b7-1fce-4221-9fb1-b6d1002a409e" xlink:to="loc_ccrn_EarnoutNotesPayableMember_2c4f039e-5926-473e-9dd0-4a217141a8ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_67fe94f0-1845-4598-949b-af02cfccf5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1d15df77-7199-483b-8073-d22f95b6f872" xlink:to="loc_us-gaap_CreditFacilityAxis_67fe94f0-1845-4598-949b-af02cfccf5ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_67fe94f0-1845-4598-949b-af02cfccf5ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_67fe94f0-1845-4598-949b-af02cfccf5ab" xlink:to="loc_us-gaap_CreditFacilityDomain_67fe94f0-1845-4598-949b-af02cfccf5ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2f516a64-7bbc-401e-999e-d92fa50f59f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_67fe94f0-1845-4598-949b-af02cfccf5ab" xlink:to="loc_us-gaap_CreditFacilityDomain_2f516a64-7bbc-401e-999e-d92fa50f59f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SeniorSecuredAssetBasedLoanMember_3c227fa2-373b-45e9-b59d-21a70f2c0e83" xlink:href="ccrn-20220331.xsd#ccrn_SeniorSecuredAssetBasedLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2f516a64-7bbc-401e-999e-d92fa50f59f9" xlink:to="loc_ccrn_SeniorSecuredAssetBasedLoanMember_3c227fa2-373b-45e9-b59d-21a70f2c0e83" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#DEBT2021TermLoanCreditAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails" xlink:type="extended" id="i6ae9bdd199c74b598d54a091e3137f58_DEBT2021TermLoanCreditAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_30908520-14b1-4d78-82b6-d38f83caaa78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_8f5d9e3a-fdcd-4fe1-a12d-f3d77227aef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_30908520-14b1-4d78-82b6-d38f83caaa78" xlink:to="loc_us-gaap_DebtInstrumentTerm_8f5d9e3a-fdcd-4fe1-a12d-f3d77227aef7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_3603dd42-5a08-472d-bd12-f251d42b5481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_30908520-14b1-4d78-82b6-d38f83caaa78" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_3603dd42-5a08-472d-bd12-f251d42b5481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6d2a3405-0cc0-46a1-bf5e-d48be7d92588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_30908520-14b1-4d78-82b6-d38f83caaa78" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6d2a3405-0cc0-46a1-bf5e-d48be7d92588" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_DebtInstrumentVariableInterestRateFloor_0251d538-f9ab-4680-a1c7-72eca47d6e2a" xlink:href="ccrn-20220331.xsd#ccrn_DebtInstrumentVariableInterestRateFloor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_30908520-14b1-4d78-82b6-d38f83caaa78" xlink:to="loc_ccrn_DebtInstrumentVariableInterestRateFloor_0251d538-f9ab-4680-a1c7-72eca47d6e2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_e94ea8b7-8389-42f3-8fec-ff1f45fba6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_30908520-14b1-4d78-82b6-d38f83caaa78" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_e94ea8b7-8389-42f3-8fec-ff1f45fba6eb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_22eccbf3-c958-467d-a38c-c64036fe9e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_30908520-14b1-4d78-82b6-d38f83caaa78" xlink:to="loc_us-gaap_DebtInstrumentTable_22eccbf3-c958-467d-a38c-c64036fe9e6d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e4a73b83-f939-4295-b259-abf59e4f64e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_22eccbf3-c958-467d-a38c-c64036fe9e6d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e4a73b83-f939-4295-b259-abf59e4f64e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e4a73b83-f939-4295-b259-abf59e4f64e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e4a73b83-f939-4295-b259-abf59e4f64e2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e4a73b83-f939-4295-b259-abf59e4f64e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ff0f1289-a52c-452d-915d-c386d04e0c18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e4a73b83-f939-4295-b259-abf59e4f64e2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ff0f1289-a52c-452d-915d-c386d04e0c18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_289055e8-a207-49b2-962a-36429a98d93f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ff0f1289-a52c-452d-915d-c386d04e0c18" xlink:to="loc_us-gaap_SecuredDebtMember_289055e8-a207-49b2-962a-36429a98d93f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f9230d1d-86a8-43e9-bf79-5dd0f3958394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_22eccbf3-c958-467d-a38c-c64036fe9e6d" xlink:to="loc_us-gaap_DebtInstrumentAxis_f9230d1d-86a8-43e9-bf79-5dd0f3958394" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f9230d1d-86a8-43e9-bf79-5dd0f3958394_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f9230d1d-86a8-43e9-bf79-5dd0f3958394" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f9230d1d-86a8-43e9-bf79-5dd0f3958394_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0091ce56-8bc3-46cd-951c-7346c940c8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f9230d1d-86a8-43e9-bf79-5dd0f3958394" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0091ce56-8bc3-46cd-951c-7346c940c8a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_A2021TermLoanCreditAgreementMember_09f972d3-e8f4-43a3-b0f5-9f2d001f4006" xlink:href="ccrn-20220331.xsd#ccrn_A2021TermLoanCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0091ce56-8bc3-46cd-951c-7346c940c8a3" xlink:to="loc_ccrn_A2021TermLoanCreditAgreementMember_09f972d3-e8f4-43a3-b0f5-9f2d001f4006" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember_ee600720-4505-4b34-b4a6-c5d7694b7e03" xlink:href="ccrn-20220331.xsd#ccrn_A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ccrn_A2021TermLoanCreditAgreementMember_09f972d3-e8f4-43a3-b0f5-9f2d001f4006" xlink:to="loc_ccrn_A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember_ee600720-4505-4b34-b4a6-c5d7694b7e03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_A2021TermLoanCreditAgreementIncrementalTermLoanMember_23e32039-fcbb-4092-8afb-8b73cab5c6ce" xlink:href="ccrn-20220331.xsd#ccrn_A2021TermLoanCreditAgreementIncrementalTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ccrn_A2021TermLoanCreditAgreementMember_09f972d3-e8f4-43a3-b0f5-9f2d001f4006" xlink:to="loc_ccrn_A2021TermLoanCreditAgreementIncrementalTermLoanMember_23e32039-fcbb-4092-8afb-8b73cab5c6ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_c2a92939-7bea-402f-8047-da9d7da5ee47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_22eccbf3-c958-467d-a38c-c64036fe9e6d" xlink:to="loc_us-gaap_VariableRateAxis_c2a92939-7bea-402f-8047-da9d7da5ee47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_c2a92939-7bea-402f-8047-da9d7da5ee47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_c2a92939-7bea-402f-8047-da9d7da5ee47" xlink:to="loc_us-gaap_VariableRateDomain_c2a92939-7bea-402f-8047-da9d7da5ee47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4c7237d4-a4e2-4407-aa6a-de6ac18d5a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_c2a92939-7bea-402f-8047-da9d7da5ee47" xlink:to="loc_us-gaap_VariableRateDomain_4c7237d4-a4e2-4407-aa6a-de6ac18d5a9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_9fa15d14-3068-49b7-8dd2-e7275931d688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_4c7237d4-a4e2-4407-aa6a-de6ac18d5a9e" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_9fa15d14-3068-49b7-8dd2-e7275931d688" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#DEBT2019LoanAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails" xlink:type="extended" id="ie3ee749a97544d0f9313f7fbbaf405e2_DEBT2019LoanAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_02cb6cf5-9987-456d-8c53-982c9f2e3ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_02cb6cf5-9987-456d-8c53-982c9f2e3ea4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dfd7d960-efbf-4f75-9b3c-9e91c609c1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dfd7d960-efbf-4f75-9b3c-9e91c609c1bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources_59ec3d63-d8a6-458f-91f9-37da95f8e837" xlink:href="ccrn-20220331.xsd#ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:to="loc_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources_59ec3d63-d8a6-458f-91f9-37da95f8e837" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR_19b27aa0-0798-46bc-ad21-cc0667bd7781" xlink:href="ccrn-20220331.xsd#ccrn_LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:to="loc_ccrn_LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR_19b27aa0-0798-46bc-ad21-cc0667bd7781" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditBorrowingBasePercentageOfAssets_8549f715-8f0d-436d-ab7f-b55a6c24a116" xlink:href="ccrn-20220331.xsd#ccrn_LineOfCreditBorrowingBasePercentageOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:to="loc_ccrn_LineOfCreditBorrowingBasePercentageOfAssets_8549f715-8f0d-436d-ab7f-b55a6c24a116" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditFacilityBorrowingBaseAvailability_d475321c-ecda-45d6-be71-538b5bfc6fd8" xlink:href="ccrn-20220331.xsd#ccrn_LineOfCreditFacilityBorrowingBaseAvailability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:to="loc_ccrn_LineOfCreditFacilityBorrowingBaseAvailability_d475321c-ecda-45d6-be71-538b5bfc6fd8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_f5c23b58-2a54-40ed-abe5-9a2d04158892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:to="loc_us-gaap_LineOfCredit_f5c23b58-2a54-40ed-abe5-9a2d04158892" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_5f5cf4cd-d2bb-4dbd-b05e-be53f2bb7817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_5f5cf4cd-d2bb-4dbd-b05e-be53f2bb7817" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_7ca3e677-f0a3-40ed-a41a-8f8498bd48ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_7ca3e677-f0a3-40ed-a41a-8f8498bd48ca" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_28dc64b1-fb86-4fcc-9c35-5e43bff486ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_28dc64b1-fb86-4fcc-9c35-5e43bff486ed" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_be707969-9535-40c8-9931-de935c6435e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_be707969-9535-40c8-9931-de935c6435e5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_0e3ad474-dc18-4dae-85b0-ae9762f3a9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_0e3ad474-dc18-4dae-85b0-ae9762f3a9ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_0df09974-4156-4566-a4a4-425055e8a353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_0e3ad474-dc18-4dae-85b0-ae9762f3a9ad" xlink:to="loc_us-gaap_CreditFacilityAxis_0df09974-4156-4566-a4a4-425055e8a353" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0df09974-4156-4566-a4a4-425055e8a353_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_0df09974-4156-4566-a4a4-425055e8a353" xlink:to="loc_us-gaap_CreditFacilityDomain_0df09974-4156-4566-a4a4-425055e8a353_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_cfd933df-557a-4293-8771-0c0debe22b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_0df09974-4156-4566-a4a4-425055e8a353" xlink:to="loc_us-gaap_CreditFacilityDomain_cfd933df-557a-4293-8771-0c0debe22b49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SeniorSecuredAssetBasedLoanMember_6beba02c-26d9-4927-ae63-106839f84fb5" xlink:href="ccrn-20220331.xsd#ccrn_SeniorSecuredAssetBasedLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_cfd933df-557a-4293-8771-0c0debe22b49" xlink:to="loc_ccrn_SeniorSecuredAssetBasedLoanMember_6beba02c-26d9-4927-ae63-106839f84fb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditSublimitAxis_d3b78ba4-4b9f-44c2-a615-496c11c3a0a8" xlink:href="ccrn-20220331.xsd#ccrn_LineOfCreditSublimitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_0e3ad474-dc18-4dae-85b0-ae9762f3a9ad" xlink:to="loc_ccrn_LineOfCreditSublimitAxis_d3b78ba4-4b9f-44c2-a615-496c11c3a0a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditSublimitDomain_d3b78ba4-4b9f-44c2-a615-496c11c3a0a8_default" xlink:href="ccrn-20220331.xsd#ccrn_LineOfCreditSublimitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ccrn_LineOfCreditSublimitAxis_d3b78ba4-4b9f-44c2-a615-496c11c3a0a8" xlink:to="loc_ccrn_LineOfCreditSublimitDomain_d3b78ba4-4b9f-44c2-a615-496c11c3a0a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditSublimitDomain_d905a5d3-cf74-4574-a72c-7d1f8c3634d7" xlink:href="ccrn-20220331.xsd#ccrn_LineOfCreditSublimitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ccrn_LineOfCreditSublimitAxis_d3b78ba4-4b9f-44c2-a615-496c11c3a0a8" xlink:to="loc_ccrn_LineOfCreditSublimitDomain_d905a5d3-cf74-4574-a72c-7d1f8c3634d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SwingLoansSublimitMember_7849089b-d1e3-4233-b0dc-d1134da0b919" xlink:href="ccrn-20220331.xsd#ccrn_SwingLoansSublimitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ccrn_LineOfCreditSublimitDomain_d905a5d3-cf74-4574-a72c-7d1f8c3634d7" xlink:to="loc_ccrn_SwingLoansSublimitMember_7849089b-d1e3-4233-b0dc-d1134da0b919" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_StandbyLettersOfCreditSublimitMember_3a59cd5d-dcc3-4d47-8695-5cd163cec105" xlink:href="ccrn-20220331.xsd#ccrn_StandbyLettersOfCreditSublimitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ccrn_LineOfCreditSublimitDomain_d905a5d3-cf74-4574-a72c-7d1f8c3634d7" xlink:to="loc_ccrn_StandbyLettersOfCreditSublimitMember_3a59cd5d-dcc3-4d47-8695-5cd163cec105" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_125c65a0-a6a4-4c61-bd38-6dfb9bb898be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_0e3ad474-dc18-4dae-85b0-ae9762f3a9ad" xlink:to="loc_us-gaap_VariableRateAxis_125c65a0-a6a4-4c61-bd38-6dfb9bb898be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_125c65a0-a6a4-4c61-bd38-6dfb9bb898be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_125c65a0-a6a4-4c61-bd38-6dfb9bb898be" xlink:to="loc_us-gaap_VariableRateDomain_125c65a0-a6a4-4c61-bd38-6dfb9bb898be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ebe7c7c1-984c-4343-9dbb-a7b56ae9e878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_125c65a0-a6a4-4c61-bd38-6dfb9bb898be" xlink:to="loc_us-gaap_VariableRateDomain_ebe7c7c1-984c-4343-9dbb-a7b56ae9e878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_9e3d1b49-da58-4e8b-afca-f65deca5723c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_ebe7c7c1-984c-4343-9dbb-a7b56ae9e878" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_9e3d1b49-da58-4e8b-afca-f65deca5723c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_63838c10-b916-4be3-a826-9762ba98c85b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_ebe7c7c1-984c-4343-9dbb-a7b56ae9e878" xlink:to="loc_us-gaap_BaseRateMember_63838c10-b916-4be3-a826-9762ba98c85b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/DEBTNotePayableDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#DEBTNotePayableDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/DEBTNotePayableDetails" xlink:type="extended" id="ic798bdd310fd49ebad3bba1f5bdc38c9_DEBTNotePayableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f4d0a278-6e2f-413d-8619-c34bdf8d97f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_ee82d034-f8d9-4198-ba3d-9f96759c771b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d0a278-6e2f-413d-8619-c34bdf8d97f9" xlink:to="loc_us-gaap_NotesPayable_ee82d034-f8d9-4198-ba3d-9f96759c771b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NotePayableNumberOfPaymentInstallments_e27c5655-73b9-4d9a-b4fd-aebbe956c5b5" xlink:href="ccrn-20220331.xsd#ccrn_NotePayableNumberOfPaymentInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d0a278-6e2f-413d-8619-c34bdf8d97f9" xlink:to="loc_ccrn_NotePayableNumberOfPaymentInstallments_e27c5655-73b9-4d9a-b4fd-aebbe956c5b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NotePayableNumberOfInstallmentsPaid_76941ca0-27ee-4990-adac-aa93c1484ebb" xlink:href="ccrn-20220331.xsd#ccrn_NotePayableNumberOfInstallmentsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d0a278-6e2f-413d-8619-c34bdf8d97f9" xlink:to="loc_ccrn_NotePayableNumberOfInstallmentsPaid_76941ca0-27ee-4990-adac-aa93c1484ebb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_31c334b1-fca3-4642-8ba3-83eafe1c4b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d0a278-6e2f-413d-8619-c34bdf8d97f9" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_31c334b1-fca3-4642-8ba3-83eafe1c4b51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1edb6063-b9db-48ac-b9f9-7b4da5b73e50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d0a278-6e2f-413d-8619-c34bdf8d97f9" xlink:to="loc_us-gaap_DebtInstrumentTable_1edb6063-b9db-48ac-b9f9-7b4da5b73e50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_60b5ebef-87f4-43ed-8c3d-174a0a49c7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1edb6063-b9db-48ac-b9f9-7b4da5b73e50" xlink:to="loc_us-gaap_DebtInstrumentAxis_60b5ebef-87f4-43ed-8c3d-174a0a49c7d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_60b5ebef-87f4-43ed-8c3d-174a0a49c7d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_60b5ebef-87f4-43ed-8c3d-174a0a49c7d9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_60b5ebef-87f4-43ed-8c3d-174a0a49c7d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_72df4157-c839-440e-a6f4-95e612c297fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_60b5ebef-87f4-43ed-8c3d-174a0a49c7d9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_72df4157-c839-440e-a6f4-95e612c297fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_EarnoutNotesPayableMember_a545fd2a-ab72-427d-b5a5-dcf764bef53f" xlink:href="ccrn-20220331.xsd#ccrn_EarnoutNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_72df4157-c839-440e-a6f4-95e612c297fe" xlink:to="loc_ccrn_EarnoutNotesPayableMember_a545fd2a-ab72-427d-b5a5-dcf764bef53f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b8e05722-ac1f-437d-8f38-a15072fe892b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1edb6063-b9db-48ac-b9f9-7b4da5b73e50" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b8e05722-ac1f-437d-8f38-a15072fe892b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8e05722-ac1f-437d-8f38-a15072fe892b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b8e05722-ac1f-437d-8f38-a15072fe892b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8e05722-ac1f-437d-8f38-a15072fe892b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ea48c03-2905-45e1-ac1a-84fabdac8223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b8e05722-ac1f-437d-8f38-a15072fe892b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ea48c03-2905-45e1-ac1a-84fabdac8223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_MediscanMember_c2c1d7cd-4ebb-4bf1-a83e-31d83277805c" xlink:href="ccrn-20220331.xsd#ccrn_MediscanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ea48c03-2905-45e1-ac1a-84fabdac8223" xlink:to="loc_ccrn_MediscanMember_c2c1d7cd-4ebb-4bf1-a83e-31d83277805c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended" id="id267de4b5f204076a98df7decbd4c271_FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_35b4000a-d40c-46a0-8a68-20b9adaec7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_885c0e57-0e1a-4289-a0e5-3743b36f123d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_35b4000a-d40c-46a0-8a68-20b9adaec7dc" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_885c0e57-0e1a-4289-a0e5-3743b36f123d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_e8b57afb-4198-4348-b7d0-aa17c6adef4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_35b4000a-d40c-46a0-8a68-20b9adaec7dc" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_e8b57afb-4198-4348-b7d0-aa17c6adef4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c473ff2e-c76e-4dc6-822b-9d05aa835304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_35b4000a-d40c-46a0-8a68-20b9adaec7dc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c473ff2e-c76e-4dc6-822b-9d05aa835304" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_666c2f81-0905-4342-9502-b16e94ed6bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c473ff2e-c76e-4dc6-822b-9d05aa835304" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_666c2f81-0905-4342-9502-b16e94ed6bf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_666c2f81-0905-4342-9502-b16e94ed6bf0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_666c2f81-0905-4342-9502-b16e94ed6bf0" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_666c2f81-0905-4342-9502-b16e94ed6bf0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e3a57112-32d7-4fd5-8212-95892a306758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_666c2f81-0905-4342-9502-b16e94ed6bf0" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e3a57112-32d7-4fd5-8212-95892a306758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_DeferredCompensationMember_3e9e8a8b-e65b-4af7-829b-59951d9c47d1" xlink:href="ccrn-20220331.xsd#ccrn_DeferredCompensationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e3a57112-32d7-4fd5-8212-95892a306758" xlink:to="loc_ccrn_DeferredCompensationMember_3e9e8a8b-e65b-4af7-829b-59951d9c47d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_ee1bbb72-19ba-44fe-af07-1bb0b0539029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c473ff2e-c76e-4dc6-822b-9d05aa835304" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_ee1bbb72-19ba-44fe-af07-1bb0b0539029" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ee1bbb72-19ba-44fe-af07-1bb0b0539029_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_ee1bbb72-19ba-44fe-af07-1bb0b0539029" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ee1bbb72-19ba-44fe-af07-1bb0b0539029_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d5a476cd-7ce2-4fc5-a1e8-84319c2f6fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_ee1bbb72-19ba-44fe-af07-1bb0b0539029" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d5a476cd-7ce2-4fc5-a1e8-84319c2f6fb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_DeferredCompensationMember_b96439e5-6c28-450d-8b49-2abe342e0fd4" xlink:href="ccrn-20220331.xsd#ccrn_DeferredCompensationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d5a476cd-7ce2-4fc5-a1e8-84319c2f6fb3" xlink:to="loc_ccrn_DeferredCompensationMember_b96439e5-6c28-450d-8b49-2abe342e0fd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2f9b924d-1352-4172-a35a-2bfa08a39a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c473ff2e-c76e-4dc6-822b-9d05aa835304" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2f9b924d-1352-4172-a35a-2bfa08a39a9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2f9b924d-1352-4172-a35a-2bfa08a39a9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2f9b924d-1352-4172-a35a-2bfa08a39a9a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2f9b924d-1352-4172-a35a-2bfa08a39a9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4956cdb1-2ad1-4208-aa7d-77de90b6f2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2f9b924d-1352-4172-a35a-2bfa08a39a9a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4956cdb1-2ad1-4208-aa7d-77de90b6f2b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_255ca8a2-c7d6-464c-bf9e-308ec479d282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4956cdb1-2ad1-4208-aa7d-77de90b6f2b0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_255ca8a2-c7d6-464c-bf9e-308ec479d282" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails" xlink:type="extended" id="i12b4deb3bf6c4bc8bee0492afdaf5c82_FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_addce8dd-fff0-476b-b265-37fb0e6d09cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_d52d9341-6abd-43cc-a95b-0fe8a117cae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_addce8dd-fff0-476b-b265-37fb0e6d09cc" xlink:to="loc_us-gaap_DebtInstrumentFairValue_d52d9341-6abd-43cc-a95b-0fe8a117cae3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditFairValueDisclosure_bbdd34c0-3e42-466c-a3fd-0b4b398ed401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LinesOfCreditFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_addce8dd-fff0-476b-b265-37fb0e6d09cc" xlink:to="loc_us-gaap_LinesOfCreditFairValueDisclosure_bbdd34c0-3e42-466c-a3fd-0b4b398ed401" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_43a3b0be-e309-415d-b5a1-2e1100e21c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_addce8dd-fff0-476b-b265-37fb0e6d09cc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_43a3b0be-e309-415d-b5a1-2e1100e21c8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_c365f61d-8655-4e01-9f8f-75678181cdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_addce8dd-fff0-476b-b265-37fb0e6d09cc" xlink:to="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_c365f61d-8655-4e01-9f8f-75678181cdfa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7948d4c0-d981-4222-b8eb-1ba06bb58cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_c365f61d-8655-4e01-9f8f-75678181cdfa" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7948d4c0-d981-4222-b8eb-1ba06bb58cdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7948d4c0-d981-4222-b8eb-1ba06bb58cdd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7948d4c0-d981-4222-b8eb-1ba06bb58cdd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7948d4c0-d981-4222-b8eb-1ba06bb58cdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_65a284d0-b4c0-47c5-9a7e-07ed392901be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7948d4c0-d981-4222-b8eb-1ba06bb58cdd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_65a284d0-b4c0-47c5-9a7e-07ed392901be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_99f63125-71c9-4806-a93b-fc6c2ad6fa33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_65a284d0-b4c0-47c5-9a7e-07ed392901be" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_99f63125-71c9-4806-a93b-fc6c2ad6fa33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_416a7085-b686-4c08-bfdd-bee2bd380f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_c365f61d-8655-4e01-9f8f-75678181cdfa" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_416a7085-b686-4c08-bfdd-bee2bd380f0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_416a7085-b686-4c08-bfdd-bee2bd380f0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_416a7085-b686-4c08-bfdd-bee2bd380f0b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_416a7085-b686-4c08-bfdd-bee2bd380f0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9c46c91f-a215-45a0-88ef-b97bd82e6c80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_416a7085-b686-4c08-bfdd-bee2bd380f0b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9c46c91f-a215-45a0-88ef-b97bd82e6c80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_EarnoutNotesPayableMember_65b374e5-1635-49b6-a449-1ab897284bb9" xlink:href="ccrn-20220331.xsd#ccrn_EarnoutNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9c46c91f-a215-45a0-88ef-b97bd82e6c80" xlink:to="loc_ccrn_EarnoutNotesPayableMember_65b374e5-1635-49b6-a449-1ab897284bb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_6e666595-9ff7-4e06-bbc7-6a18ed59c0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9c46c91f-a215-45a0-88ef-b97bd82e6c80" xlink:to="loc_us-gaap_SecuredDebtMember_6e666595-9ff7-4e06-bbc7-6a18ed59c0e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_95dba209-14b7-46aa-8f88-68f7e2f8d750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_c365f61d-8655-4e01-9f8f-75678181cdfa" xlink:to="loc_us-gaap_CreditFacilityAxis_95dba209-14b7-46aa-8f88-68f7e2f8d750" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_95dba209-14b7-46aa-8f88-68f7e2f8d750_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_95dba209-14b7-46aa-8f88-68f7e2f8d750" xlink:to="loc_us-gaap_CreditFacilityDomain_95dba209-14b7-46aa-8f88-68f7e2f8d750_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_97dc675b-9ce7-488f-9750-c563dae61472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_95dba209-14b7-46aa-8f88-68f7e2f8d750" xlink:to="loc_us-gaap_CreditFacilityDomain_97dc675b-9ce7-488f-9750-c563dae61472" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SeniorSecuredAssetBasedLoanMember_e3e28afe-2500-427a-8ddd-8d27f129f423" xlink:href="ccrn-20220331.xsd#ccrn_SeniorSecuredAssetBasedLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_97dc675b-9ce7-488f-9750-c563dae61472" xlink:to="loc_ccrn_SeniorSecuredAssetBasedLoanMember_e3e28afe-2500-427a-8ddd-8d27f129f423" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_878624b3-675f-4e02-b4bc-fb90cd9e4ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_c365f61d-8655-4e01-9f8f-75678181cdfa" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_878624b3-675f-4e02-b4bc-fb90cd9e4ec5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_878624b3-675f-4e02-b4bc-fb90cd9e4ec5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_878624b3-675f-4e02-b4bc-fb90cd9e4ec5" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_878624b3-675f-4e02-b4bc-fb90cd9e4ec5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_519df301-8247-4f23-ae52-c58d392f6c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_878624b3-675f-4e02-b4bc-fb90cd9e4ec5" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_519df301-8247-4f23-ae52-c58d392f6c59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_8370d536-33aa-4dc1-b1ea-2350955c2a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_519df301-8247-4f23-ae52-c58d392f6c59" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_8370d536-33aa-4dc1-b1ea-2350955c2a5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_2685a4ae-09fe-47f9-a8fd-c42e61284021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_519df301-8247-4f23-ae52-c58d392f6c59" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_2685a4ae-09fe-47f9-a8fd-c42e61284021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c48f4b46-1058-40cf-9bc5-720cb0d95576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_519df301-8247-4f23-ae52-c58d392f6c59" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c48f4b46-1058-40cf-9bc5-720cb0d95576" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_93aea921-bd9f-446f-9d76-dc44021715b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_c365f61d-8655-4e01-9f8f-75678181cdfa" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_93aea921-bd9f-446f-9d76-dc44021715b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93aea921-bd9f-446f-9d76-dc44021715b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_93aea921-bd9f-446f-9d76-dc44021715b9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93aea921-bd9f-446f-9d76-dc44021715b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_450e4cb1-39d5-425c-bdb6-f961b12addde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_93aea921-bd9f-446f-9d76-dc44021715b9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_450e4cb1-39d5-425c-bdb6-f961b12addde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_WorkforceSolutionsGroupIncMember_7c69677a-a803-4da7-9dd7-641638b3ebba" xlink:href="ccrn-20220331.xsd#ccrn_WorkforceSolutionsGroupIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_450e4cb1-39d5-425c-bdb6-f961b12addde" xlink:to="loc_ccrn_WorkforceSolutionsGroupIncMember_7c69677a-a803-4da7-9dd7-641638b3ebba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SelectedIncMember_5b9105d6-2b4a-4904-bd40-ae9962acb088" xlink:href="ccrn-20220331.xsd#ccrn_SelectedIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_450e4cb1-39d5-425c-bdb6-f961b12addde" xlink:to="loc_ccrn_SelectedIncMember_5b9105d6-2b4a-4904-bd40-ae9962acb088" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#STOCKHOLDERSEQUITYAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="extended" id="id6f1374a47d741d39651a6a9f87d6c35_STOCKHOLDERSEQUITYAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba8f9a7e-6b1f-4550-8040-5c463e34fad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_71ab1c59-c551-4331-9f0b-8513ff542e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba8f9a7e-6b1f-4550-8040-5c463e34fad3" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_71ab1c59-c551-4331-9f0b-8513ff542e1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_474d9f61-edf4-4827-a7ca-a3947b6fd1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba8f9a7e-6b1f-4550-8040-5c463e34fad3" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_474d9f61-edf4-4827-a7ca-a3947b6fd1ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c2392c52-e0cf-45c9-b55b-c14c67385cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba8f9a7e-6b1f-4550-8040-5c463e34fad3" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c2392c52-e0cf-45c9-b55b-c14c67385cfe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f08b8bd8-4d8b-455b-bf01-ec7a8330b0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba8f9a7e-6b1f-4550-8040-5c463e34fad3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f08b8bd8-4d8b-455b-bf01-ec7a8330b0e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a5e9a903-f2dd-4f7c-ac75-91cb460c90ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba8f9a7e-6b1f-4550-8040-5c463e34fad3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a5e9a903-f2dd-4f7c-ac75-91cb460c90ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage_df9dadc4-330f-4f4f-96ec-373851e11304" xlink:href="ccrn-20220331.xsd#ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba8f9a7e-6b1f-4550-8040-5c463e34fad3" xlink:to="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage_df9dadc4-330f-4f4f-96ec-373851e11304" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_13d58c18-48ae-4afc-a936-31f38016c96e" xlink:href="ccrn-20220331.xsd#ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba8f9a7e-6b1f-4550-8040-5c463e34fad3" xlink:to="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_13d58c18-48ae-4afc-a936-31f38016c96e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c56264f3-c502-4c2e-9e9d-970b90dc4cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba8f9a7e-6b1f-4550-8040-5c463e34fad3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c56264f3-c502-4c2e-9e9d-970b90dc4cfb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet_f516b2cd-bd11-430f-a246-bbe3b99fdfad" xlink:href="ccrn-20220331.xsd#ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba8f9a7e-6b1f-4550-8040-5c463e34fad3" xlink:to="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet_f516b2cd-bd11-430f-a246-bbe3b99fdfad" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_029191d5-9fab-4f18-b5be-ba27a2d3fe73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba8f9a7e-6b1f-4550-8040-5c463e34fad3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_029191d5-9fab-4f18-b5be-ba27a2d3fe73" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1ef1dcaa-93bd-4ad6-a0c8-46615ac938ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_029191d5-9fab-4f18-b5be-ba27a2d3fe73" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1ef1dcaa-93bd-4ad6-a0c8-46615ac938ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1ef1dcaa-93bd-4ad6-a0c8-46615ac938ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1ef1dcaa-93bd-4ad6-a0c8-46615ac938ee" xlink:to="loc_us-gaap_EquityComponentDomain_1ef1dcaa-93bd-4ad6-a0c8-46615ac938ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4b9093c8-0d4b-476f-a21e-f069a2f4c4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1ef1dcaa-93bd-4ad6-a0c8-46615ac938ee" xlink:to="loc_us-gaap_EquityComponentDomain_4b9093c8-0d4b-476f-a21e-f069a2f4c4a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f43f463b-ddcc-41c0-980d-b33e4ecbca10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4b9093c8-0d4b-476f-a21e-f069a2f4c4a3" xlink:to="loc_us-gaap_CommonStockMember_f43f463b-ddcc-41c0-980d-b33e4ecbca10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_28f763ca-2dbb-4fc4-80c9-258c76109ced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_029191d5-9fab-4f18-b5be-ba27a2d3fe73" xlink:to="loc_us-gaap_PlanNameAxis_28f763ca-2dbb-4fc4-80c9-258c76109ced" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_28f763ca-2dbb-4fc4-80c9-258c76109ced_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_28f763ca-2dbb-4fc4-80c9-258c76109ced" xlink:to="loc_us-gaap_PlanNameDomain_28f763ca-2dbb-4fc4-80c9-258c76109ced_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_021d37f3-faea-44ad-a483-6c0dd43fa4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_28f763ca-2dbb-4fc4-80c9-258c76109ced" xlink:to="loc_us-gaap_PlanNameDomain_021d37f3-faea-44ad-a483-6c0dd43fa4ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OmnibusPlanMember_665296c2-4f40-4768-8237-c9761cdcb06f" xlink:href="ccrn-20220331.xsd#ccrn_OmnibusPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_021d37f3-faea-44ad-a483-6c0dd43fa4ee" xlink:to="loc_ccrn_OmnibusPlanMember_665296c2-4f40-4768-8237-c9761cdcb06f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eb9023b1-7ace-475a-9ba5-34242706b407" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_029191d5-9fab-4f18-b5be-ba27a2d3fe73" xlink:to="loc_srt_RangeAxis_eb9023b1-7ace-475a-9ba5-34242706b407" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eb9023b1-7ace-475a-9ba5-34242706b407_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_eb9023b1-7ace-475a-9ba5-34242706b407" xlink:to="loc_srt_RangeMember_eb9023b1-7ace-475a-9ba5-34242706b407_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b244b55b-a2e7-43ed-8dc0-fca6447c5cf5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_eb9023b1-7ace-475a-9ba5-34242706b407" xlink:to="loc_srt_RangeMember_b244b55b-a2e7-43ed-8dc0-fca6447c5cf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7a947f61-c935-4542-8b39-6ef2f01f4a46" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b244b55b-a2e7-43ed-8dc0-fca6447c5cf5" xlink:to="loc_srt_MinimumMember_7a947f61-c935-4542-8b39-6ef2f01f4a46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_a0cc932c-0fbe-4528-a9a1-298a0a9c686b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_029191d5-9fab-4f18-b5be-ba27a2d3fe73" xlink:to="loc_srt_TitleOfIndividualAxis_a0cc932c-0fbe-4528-a9a1-298a0a9c686b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a0cc932c-0fbe-4528-a9a1-298a0a9c686b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_a0cc932c-0fbe-4528-a9a1-298a0a9c686b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a0cc932c-0fbe-4528-a9a1-298a0a9c686b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3297a411-7ac5-4417-8b7f-268968eaef72" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_a0cc932c-0fbe-4528-a9a1-298a0a9c686b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3297a411-7ac5-4417-8b7f-268968eaef72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_b643bdb6-edc4-4ee4-8c0d-4907545a8e53" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3297a411-7ac5-4417-8b7f-268968eaef72" xlink:to="loc_srt_DirectorMember_b643bdb6-edc4-4ee4-8c0d-4907545a8e53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_edfa468f-0e02-4d67-a5e7-aa3214536175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_029191d5-9fab-4f18-b5be-ba27a2d3fe73" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_edfa468f-0e02-4d67-a5e7-aa3214536175" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_edfa468f-0e02-4d67-a5e7-aa3214536175_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_edfa468f-0e02-4d67-a5e7-aa3214536175" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_edfa468f-0e02-4d67-a5e7-aa3214536175_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_74cc10dd-6f6d-4789-8ff9-8126ec8fd577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_edfa468f-0e02-4d67-a5e7-aa3214536175" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_74cc10dd-6f6d-4789-8ff9-8126ec8fd577" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f717a33a-ef6d-4e5a-b3da-5d77f79efcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_74cc10dd-6f6d-4789-8ff9-8126ec8fd577" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f717a33a-ef6d-4e5a-b3da-5d77f79efcbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_24e1bc0a-c056-4989-9c6f-70bcf47078b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_029191d5-9fab-4f18-b5be-ba27a2d3fe73" xlink:to="loc_us-gaap_AwardTypeAxis_24e1bc0a-c056-4989-9c6f-70bcf47078b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24e1bc0a-c056-4989-9c6f-70bcf47078b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_24e1bc0a-c056-4989-9c6f-70bcf47078b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24e1bc0a-c056-4989-9c6f-70bcf47078b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab0ef765-6ec8-4b79-8a03-0ca6e97b474f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_24e1bc0a-c056-4989-9c6f-70bcf47078b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab0ef765-6ec8-4b79-8a03-0ca6e97b474f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b041426a-99f2-4bbb-9b32-68534456ef75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab0ef765-6ec8-4b79-8a03-0ca6e97b474f" xlink:to="loc_us-gaap_RestrictedStockMember_b041426a-99f2-4bbb-9b32-68534456ef75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_5ee45d6c-54ff-40e7-852f-ecd131a707fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab0ef765-6ec8-4b79-8a03-0ca6e97b474f" xlink:to="loc_us-gaap_PerformanceSharesMember_5ee45d6c-54ff-40e7-852f-ecd131a707fc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#STOCKHOLDERSEQUITYRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails" xlink:type="extended" id="i440a4cb3562c4992ba735ef50fdf5f1a_STOCKHOLDERSEQUITYRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84d0d2ca-4549-4e99-b3d1-0e6875da9c05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06871a7c-1b17-4f30-b7f5-207eaf452dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84d0d2ca-4549-4e99-b3d1-0e6875da9c05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06871a7c-1b17-4f30-b7f5-207eaf452dd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_df94ace6-234a-48cc-8e21-47c922bd62e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06871a7c-1b17-4f30-b7f5-207eaf452dd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_df94ace6-234a-48cc-8e21-47c922bd62e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0d7b4a19-44ab-41b7-aa9c-8bd293895e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06871a7c-1b17-4f30-b7f5-207eaf452dd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0d7b4a19-44ab-41b7-aa9c-8bd293895e7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_84d1ac43-2812-4b0f-99b4-c61cc9a05dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06871a7c-1b17-4f30-b7f5-207eaf452dd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_84d1ac43-2812-4b0f-99b4-c61cc9a05dda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d720712b-3f3b-42a3-8847-9821eb1e842a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06871a7c-1b17-4f30-b7f5-207eaf452dd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d720712b-3f3b-42a3-8847-9821eb1e842a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_55c22213-c0ea-49b9-aa1f-8c48a2301e86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6f363edf-f3f3-4ca2-97f8-88815193288d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84d0d2ca-4549-4e99-b3d1-0e6875da9c05" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6f363edf-f3f3-4ca2-97f8-88815193288d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_39d47990-7d4c-44a4-84fc-6177c2c677b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6f363edf-f3f3-4ca2-97f8-88815193288d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_39d47990-7d4c-44a4-84fc-6177c2c677b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ea3dcc32-5ab3-4e4a-afbc-b0f42da17511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6f363edf-f3f3-4ca2-97f8-88815193288d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ea3dcc32-5ab3-4e4a-afbc-b0f42da17511" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_39857cb1-ca1c-4ff5-9667-a7bded2dc505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6f363edf-f3f3-4ca2-97f8-88815193288d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_39857cb1-ca1c-4ff5-9667-a7bded2dc505" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_cd6a49c8-5540-4ab5-b650-455849a07e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6f363edf-f3f3-4ca2-97f8-88815193288d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_cd6a49c8-5540-4ab5-b650-455849a07e5e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_216b7711-07f5-43a7-9f9e-0a2819db1c20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2acd185-7624-4eb7-b05b-a24a4a16f4af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84d0d2ca-4549-4e99-b3d1-0e6875da9c05" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2acd185-7624-4eb7-b05b-a24a4a16f4af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_417e27b7-32b6-482d-a0aa-f16284125fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2acd185-7624-4eb7-b05b-a24a4a16f4af" xlink:to="loc_us-gaap_AwardTypeAxis_417e27b7-32b6-482d-a0aa-f16284125fb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_417e27b7-32b6-482d-a0aa-f16284125fb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_417e27b7-32b6-482d-a0aa-f16284125fb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_417e27b7-32b6-482d-a0aa-f16284125fb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90efd7a4-0381-4eb2-ad77-efb4422c3d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_417e27b7-32b6-482d-a0aa-f16284125fb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90efd7a4-0381-4eb2-ad77-efb4422c3d6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_3cbac5c8-b776-4047-8857-c5a55d577e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90efd7a4-0381-4eb2-ad77-efb4422c3d6a" xlink:to="loc_us-gaap_RestrictedStockMember_3cbac5c8-b776-4047-8857-c5a55d577e8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_b295b4bd-708f-4124-8604-61164b0c15a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90efd7a4-0381-4eb2-ad77-efb4422c3d6a" xlink:to="loc_us-gaap_PerformanceSharesMember_b295b4bd-708f-4124-8604-61164b0c15a6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SEGMENTDATADetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#SEGMENTDATADetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/SEGMENTDATADetails" xlink:type="extended" id="i19fc0a7de26d4d20af18bc76b2c516ee_SEGMENTDATADetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_012f56a5-ff19-42f1-b2e2-001fc58bf132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7a854113-11a0-42dc-93e1-aeb183798ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_012f56a5-ff19-42f1-b2e2-001fc58bf132" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7a854113-11a0-42dc-93e1-aeb183798ca7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard_77970edd-251c-42af-8ac8-2439c26dd53a" xlink:href="ccrn-20220331.xsd#ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_012f56a5-ff19-42f1-b2e2-001fc58bf132" xlink:to="loc_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard_77970edd-251c-42af-8ac8-2439c26dd53a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SegmentReportingUnallocatedCorporateExpenses_1c3150d8-d9e6-478e-a795-dfbe5b1d0cb0" xlink:href="ccrn-20220331.xsd#ccrn_SegmentReportingUnallocatedCorporateExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_012f56a5-ff19-42f1-b2e2-001fc58bf132" xlink:to="loc_ccrn_SegmentReportingUnallocatedCorporateExpenses_1c3150d8-d9e6-478e-a795-dfbe5b1d0cb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ad218491-4bc4-49dc-a015-63cc4e8cf136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_012f56a5-ff19-42f1-b2e2-001fc58bf132" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ad218491-4bc4-49dc-a015-63cc4e8cf136" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AcquisitionAndIntegrationRelatedCosts_2cfc6cf0-c0e8-4e8c-9775-134b41483eb6" xlink:href="ccrn-20220331.xsd#ccrn_AcquisitionAndIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_012f56a5-ff19-42f1-b2e2-001fc58bf132" xlink:to="loc_ccrn_AcquisitionAndIntegrationRelatedCosts_2cfc6cf0-c0e8-4e8c-9775-134b41483eb6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_a0232d6e-5398-4be7-b4d0-869cb800c2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_012f56a5-ff19-42f1-b2e2-001fc58bf132" xlink:to="loc_us-gaap_RestructuringCharges_a0232d6e-5398-4be7-b4d0-869cb800c2fc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_fe7e61a2-8ece-42fd-b168-e38135c7aa1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_012f56a5-ff19-42f1-b2e2-001fc58bf132" xlink:to="loc_us-gaap_AssetImpairmentCharges_fe7e61a2-8ece-42fd-b168-e38135c7aa1b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_08b1e063-0706-4900-95e3-b9acf78d9cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_012f56a5-ff19-42f1-b2e2-001fc58bf132" xlink:to="loc_us-gaap_OperatingIncomeLoss_08b1e063-0706-4900-95e3-b9acf78d9cc4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_3105eb6e-9510-48eb-ad5f-1bc65017b032" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_012f56a5-ff19-42f1-b2e2-001fc58bf132" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_3105eb6e-9510-48eb-ad5f-1bc65017b032" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3777df38-17ea-48d5-82c5-5cdc176f0891" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_3105eb6e-9510-48eb-ad5f-1bc65017b032" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3777df38-17ea-48d5-82c5-5cdc176f0891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3777df38-17ea-48d5-82c5-5cdc176f0891_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3777df38-17ea-48d5-82c5-5cdc176f0891" xlink:to="loc_us-gaap_SegmentDomain_3777df38-17ea-48d5-82c5-5cdc176f0891_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_47fbf36d-09b6-4edf-8c1e-7400848b6ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3777df38-17ea-48d5-82c5-5cdc176f0891" xlink:to="loc_us-gaap_SegmentDomain_47fbf36d-09b6-4edf-8c1e-7400848b6ed6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NurseAndAlliedStaffingMember_63e688fc-fba4-4b58-9c68-d5ad6a2893bf" xlink:href="ccrn-20220331.xsd#ccrn_NurseAndAlliedStaffingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_47fbf36d-09b6-4edf-8c1e-7400848b6ed6" xlink:to="loc_ccrn_NurseAndAlliedStaffingMember_63e688fc-fba4-4b58-9c68-d5ad6a2893bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_PhysicianStaffingMember_2bf420a5-5167-4a30-bca7-14a2965ad0ba" xlink:href="ccrn-20220331.xsd#ccrn_PhysicianStaffingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_47fbf36d-09b6-4edf-8c1e-7400848b6ed6" xlink:to="loc_ccrn_PhysicianStaffingMember_2bf420a5-5167-4a30-bca7-14a2965ad0ba" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:definitionLink xlink:role="http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended" id="ib5789530309c41b8813382f4e1c0e8e0_RELATEDPARTYTRANSACTIONSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_988428c1-0a0a-4a40-8cd3-be9375b578e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_41bd95f2-5e9f-4137-9e06-ff49272127c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_988428c1-0a0a-4a40-8cd3-be9375b578e0" xlink:to="loc_us-gaap_NotesPayable_41bd95f2-5e9f-4137-9e06-ff49272127c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NotePayableNumberOfPaymentInstallments_4576e1bf-2d4b-4014-95b4-6943632859d3" xlink:href="ccrn-20220331.xsd#ccrn_NotePayableNumberOfPaymentInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_988428c1-0a0a-4a40-8cd3-be9375b578e0" xlink:to="loc_ccrn_NotePayableNumberOfPaymentInstallments_4576e1bf-2d4b-4014-95b4-6943632859d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_fe65964b-ca91-41a2-9799-cfbd72e7443d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_988428c1-0a0a-4a40-8cd3-be9375b578e0" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_fe65964b-ca91-41a2-9799-cfbd72e7443d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b7bde243-71a8-40d4-af1c-d0acf10f2ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_988428c1-0a0a-4a40-8cd3-be9375b578e0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b7bde243-71a8-40d4-af1c-d0acf10f2ad1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7d755cd3-b40c-4613-88a8-482bb7e2d58b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b7bde243-71a8-40d4-af1c-d0acf10f2ad1" xlink:to="loc_us-gaap_DebtInstrumentAxis_7d755cd3-b40c-4613-88a8-482bb7e2d58b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7d755cd3-b40c-4613-88a8-482bb7e2d58b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7d755cd3-b40c-4613-88a8-482bb7e2d58b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7d755cd3-b40c-4613-88a8-482bb7e2d58b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_80e4fbc7-4c9c-4e39-a819-4d8c29843e60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7d755cd3-b40c-4613-88a8-482bb7e2d58b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_80e4fbc7-4c9c-4e39-a819-4d8c29843e60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_EarnoutNotesPayableMember_c693976e-6fc3-4327-a307-9e503c801e71" xlink:href="ccrn-20220331.xsd#ccrn_EarnoutNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80e4fbc7-4c9c-4e39-a819-4d8c29843e60" xlink:to="loc_ccrn_EarnoutNotesPayableMember_c693976e-6fc3-4327-a307-9e503c801e71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f7459cea-3a64-4d3d-a4ae-0b09d740f527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b7bde243-71a8-40d4-af1c-d0acf10f2ad1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f7459cea-3a64-4d3d-a4ae-0b09d740f527" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f7459cea-3a64-4d3d-a4ae-0b09d740f527_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f7459cea-3a64-4d3d-a4ae-0b09d740f527" xlink:to="loc_us-gaap_RelatedPartyDomain_f7459cea-3a64-4d3d-a4ae-0b09d740f527_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4888a43e-5c4a-44dd-bcb5-16c47bd13d97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f7459cea-3a64-4d3d-a4ae-0b09d740f527" xlink:to="loc_us-gaap_RelatedPartyDomain_4888a43e-5c4a-44dd-bcb5-16c47bd13d97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_MediscanMember_23b305e4-2e54-4bba-b647-8492c8331ecf" xlink:href="ccrn-20220331.xsd#ccrn_MediscanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4888a43e-5c4a-44dd-bcb5-16c47bd13d97" xlink:to="loc_ccrn_MediscanMember_23b305e4-2e54-4bba-b647-8492c8331ecf" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>ccrn-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:bf6b0e24-63a4-4887-ba98-a744ebcd1084,g:9e05db7a-6f27-4cf3-b67e-d2d201684423-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ccrn_NotePayableNumberOfPaymentInstallments_146bfe44-e828-4a4e-abbd-84002590b205_terseLabel_en-US" xlink:label="lab_ccrn_NotePayableNumberOfPaymentInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of installments</link:label>
    <link:label id="lab_ccrn_NotePayableNumberOfPaymentInstallments_label_en-US" xlink:label="lab_ccrn_NotePayableNumberOfPaymentInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Payable, Number Of Payment Installments</link:label>
    <link:label id="lab_ccrn_NotePayableNumberOfPaymentInstallments_documentation_en-US" xlink:label="lab_ccrn_NotePayableNumberOfPaymentInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Payable, Number Of Payment Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NotePayableNumberOfPaymentInstallments" xlink:href="ccrn-20220331.xsd#ccrn_NotePayableNumberOfPaymentInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_NotePayableNumberOfPaymentInstallments" xlink:to="lab_ccrn_NotePayableNumberOfPaymentInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember_f7691924-f956-42aa-8d92-2d67f44f14b4_terseLabel_en-US" xlink:label="lab_ccrn_A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Term Loan Credit Agreement, Aggregate Amount of All Possible Increases</link:label>
    <link:label id="lab_ccrn_A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember_label_en-US" xlink:label="lab_ccrn_A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Term Loan Credit Agreement, Aggregate Amount Of All Possible Increases [Member]</link:label>
    <link:label id="lab_ccrn_A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember_documentation_en-US" xlink:label="lab_ccrn_A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Term Loan Credit Agreement, Aggregate Amount Of All Possible Increases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember" xlink:href="ccrn-20220331.xsd#ccrn_A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember" xlink:to="lab_ccrn_A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedTradeNames_a75abe03-b387-4c6a-aa73-f51c43834b9b_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedTradeNames" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade names, indefinite-lived</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedTradeNames_2a2d284d-216f-4aba-a62a-f9676726ea15_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedTradeNames" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade names, indefinite-lived</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedTradeNames_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedTradeNames" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Trade Names</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedTradeNames" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedTradeNames"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedTradeNames" xlink:to="lab_us-gaap_IndefiniteLivedTradeNames" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_fd1d54ab-3a11-4098-981e-24a10b9dc2e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7ad571c7-1283-4e5d-9b4e-5a82279cbb0f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_BusinessCombinationContingentConsiderationTerm_03486dd7-531e-4560-bbc5-d79a3eca8595_terseLabel_en-US" xlink:label="lab_ccrn_BusinessCombinationContingentConsiderationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability, term</link:label>
    <link:label id="lab_ccrn_BusinessCombinationContingentConsiderationTerm_label_en-US" xlink:label="lab_ccrn_BusinessCombinationContingentConsiderationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Term</link:label>
    <link:label id="lab_ccrn_BusinessCombinationContingentConsiderationTerm_documentation_en-US" xlink:label="lab_ccrn_BusinessCombinationContingentConsiderationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationContingentConsiderationTerm" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationContingentConsiderationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_BusinessCombinationContingentConsiderationTerm" xlink:to="lab_ccrn_BusinessCombinationContingentConsiderationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_09cd5695-fced-4c9d-b6d4-6d64965eea53_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_cbb834a6-11c0-4369-bf13-c3d9498f7335_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b56d76ef-1636-4d7c-970b-f8cc8f3a6da7_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_5da9d3dc-57fc-4f81-907a-4ec4dd2fc546_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnout liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_96eaa5e6-3070-4dc0-b90f-5492f5271c50_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_d9ea7f67-59c6-477e-bc5d-4ae9eede8ab4_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_f046531e-dcb7-4b1a-a34f-f50db0539233_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_c9d0c776-d004-498f-8dec-77b4d37510cd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c88b5c23-4c3a-4ddc-807f-2d4fa122c5e1_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_0df68988-72e1-490d-b9a9-f58ab92cd252_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR_000a721e-f99b-484e-8cb3-5c00671af177_terseLabel_en-US" xlink:label="lab_ccrn_LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate, additional credit spread associated with SOFR</link:label>
    <link:label id="lab_ccrn_LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR_label_en-US" xlink:label="lab_ccrn_LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Basis Spread On Variable Rate, Additional Credit Spread Associated With SOFR</link:label>
    <link:label id="lab_ccrn_LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR_documentation_en-US" xlink:label="lab_ccrn_LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Basis Spread On Variable Rate, Additional Credit Spread Associated With SOFR</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR" xlink:href="ccrn-20220331.xsd#ccrn_LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR" xlink:to="lab_ccrn_LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_9eb3dcb2-398d-4c65-b581-e65a26b5ebf4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Aggregate Scheduled Maturities of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_DeferredCompensationMember_39c09119-6005-4655-b25e-5370b380a196_terseLabel_en-US" xlink:label="lab_ccrn_DeferredCompensationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation</link:label>
    <link:label id="lab_ccrn_DeferredCompensationMember_label_en-US" xlink:label="lab_ccrn_DeferredCompensationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation [Member]</link:label>
    <link:label id="lab_ccrn_DeferredCompensationMember_documentation_en-US" xlink:label="lab_ccrn_DeferredCompensationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_DeferredCompensationMember" xlink:href="ccrn-20220331.xsd#ccrn_DeferredCompensationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_DeferredCompensationMember" xlink:to="lab_ccrn_DeferredCompensationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6f15557b-dcd8-40b6-92bf-7814c01c56c5_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8d1f237a-4932-4b6d-a218-447e380d6851_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_87537125-4a80-44cb-834c-dde50bc41a94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_cb025d28-9f59-481f-92f5-921d8cbc2b75_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_bccbaa45-3328-4184-8d90-5e321350a18a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_fcf041da-65ca-4884-b88a-94454c640586_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5ac5843c-0dfe-452f-bc1e-8ae5049ae1ae_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_39069b50-3ffc-4743-8563-8a0fb546de38_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_d799a13e-da59-4d66-ac1f-e2ce1d9510fc_terseLabel_en-US" xlink:label="lab_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived And Indefinite Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:href="ccrn-20220331.xsd#ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="lab_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a876d229-2019-4634-8663-6bbaf1376184_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_9b6faee4-4721-498f-a071-df8d0af1c09f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_8f00c0dc-dca5-4311-8c93-6d990779ffb9_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Segments</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fdbc56da-34df-4e1b-9711-e89dab3c626d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_SelectedIncMember_3db08da6-5e79-470e-93be-0ce100bdfdb4_terseLabel_en-US" xlink:label="lab_ccrn_SelectedIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected, Inc</link:label>
    <link:label id="lab_ccrn_SelectedIncMember_label_en-US" xlink:label="lab_ccrn_SelectedIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected, Inc [Member]</link:label>
    <link:label id="lab_ccrn_SelectedIncMember_documentation_en-US" xlink:label="lab_ccrn_SelectedIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SelectedIncMember" xlink:href="ccrn-20220331.xsd#ccrn_SelectedIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_SelectedIncMember" xlink:to="lab_ccrn_SelectedIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0c3df598-6bdc-487e-8c43-b8fa384e9c72_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_4b89d0f9-1a9e-44ff-b150-6d0cced470ca_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50dc2cce-57d6-4b95-abc8-aee262f79530_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_c0f121aa-71a4-4e87-81f6-0e99cf76a0aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_SwingLoansSublimitMember_853dae99-54ac-4d2f-9285-2df1a072b83f_terseLabel_en-US" xlink:label="lab_ccrn_SwingLoansSublimitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swingline Sublimit</link:label>
    <link:label id="lab_ccrn_SwingLoansSublimitMember_label_en-US" xlink:label="lab_ccrn_SwingLoansSublimitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Loans Sublimit [Member]</link:label>
    <link:label id="lab_ccrn_SwingLoansSublimitMember_documentation_en-US" xlink:label="lab_ccrn_SwingLoansSublimitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Loans Sublimit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SwingLoansSublimitMember" xlink:href="ccrn-20220331.xsd#ccrn_SwingLoansSublimitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_SwingLoansSublimitMember" xlink:to="lab_ccrn_SwingLoansSublimitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_680558db-bc3b-4901-b60c-8e08f580012c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1b895cd0-4433-49bc-8628-0afb70a38643_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_e744c155-2531-4517-b299-8defa204bfff_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_9ca5fd44-9643-4c74-9d8d-c3955b5f52bd_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable and other lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_559ad145-9cfc-4860-8a41-11d387415be4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1fca5eae-b3a2-4a5e-9664-7a95afa1f365_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares excluded from diluted weighted average shares (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_e3f57cf2-8cfa-43e0-ad8a-afd5d808ef60_totalLabel_en-US" xlink:label="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets acquired</link:label>
    <link:label id="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_label_en-US" xlink:label="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill</link:label>
    <link:label id="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_documentation_en-US" xlink:label="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill" xlink:to="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_dc98943e-f927-42f5-919c-11a35fc842ee_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_93a4f52e-aa95-43e2-90e3-1d10095d6021_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_1a428dd3-b7b6-4578-967f-c8b7bc61fc15_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_d1a5e314-92c5-49e8-be70-cccd25e63876_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_b08f2792-b4ca-41b7-a1e4-c521d3f37643_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6061af2b-dbe1-4b8b-959c-129ac0132f22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_NotePayableNumberOfInstallmentsPaid_048376ae-7188-4bb0-97ed-46045c8e78ac_terseLabel_en-US" xlink:label="lab_ccrn_NotePayableNumberOfInstallmentsPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of installments paid</link:label>
    <link:label id="lab_ccrn_NotePayableNumberOfInstallmentsPaid_label_en-US" xlink:label="lab_ccrn_NotePayableNumberOfInstallmentsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Payable, Number Of Installments Paid</link:label>
    <link:label id="lab_ccrn_NotePayableNumberOfInstallmentsPaid_documentation_en-US" xlink:label="lab_ccrn_NotePayableNumberOfInstallmentsPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Payable, Number Of Installments Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NotePayableNumberOfInstallmentsPaid" xlink:href="ccrn-20220331.xsd#ccrn_NotePayableNumberOfInstallmentsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_NotePayableNumberOfInstallmentsPaid" xlink:to="lab_ccrn_NotePayableNumberOfInstallmentsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_6a602ecd-df8f-4466-8972-04c20441f770_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_fe8ac53d-5fc5-40de-8270-7454e9211e50_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_5ae6f0b7-6de6-49f3-8106-1794d5002582_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_a28f5adf-0434-41c5-9321-178f5246e9d5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_13685f36-f291-4663-804d-b4cb34b59099_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DirectOperatingCosts_6f1e073e-3fa5-4758-94dc-878fda871bc2_terseLabel_en-US" xlink:label="lab_us-gaap_DirectOperatingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct operating expenses</link:label>
    <link:label id="lab_us-gaap_DirectOperatingCosts_label_en-US" xlink:label="lab_us-gaap_DirectOperatingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct Operating Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectOperatingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DirectOperatingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectOperatingCosts" xlink:to="lab_us-gaap_DirectOperatingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_bc178f5f-0aa7-4e0a-b1ef-2e076c11916b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1ece41a2-7e84-439c-b609-e9bce1979642_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_WorkforceSolutionsGroupIncMember_87ce1b55-a5e3-4c6e-b602-746d111bcc47_terseLabel_en-US" xlink:label="lab_ccrn_WorkforceSolutionsGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workforce Solutions Group, Inc.</link:label>
    <link:label id="lab_ccrn_WorkforceSolutionsGroupIncMember_label_en-US" xlink:label="lab_ccrn_WorkforceSolutionsGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workforce Solutions Group, Inc. [Member]</link:label>
    <link:label id="lab_ccrn_WorkforceSolutionsGroupIncMember_documentation_en-US" xlink:label="lab_ccrn_WorkforceSolutionsGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workforce Solutions Group, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_WorkforceSolutionsGroupIncMember" xlink:href="ccrn-20220331.xsd#ccrn_WorkforceSolutionsGroupIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_WorkforceSolutionsGroupIncMember" xlink:to="lab_ccrn_WorkforceSolutionsGroupIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_bfc3cd78-786e-47ca-80dc-d0286a076a26_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_52a3e1be-f89a-4180-bad8-ef3277088fc3_terseLabel_en-US" xlink:label="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_label_en-US" xlink:label="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-Of-Use Assets</link:label>
    <link:label id="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_documentation_en-US" xlink:label="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:to="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_SegmentReportingUnallocatedCorporateExpenses_b040dece-8eb2-45f7-8ba6-aa0293ac1245_terseLabel_en-US" xlink:label="lab_ccrn_SegmentReportingUnallocatedCorporateExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate overhead</link:label>
    <link:label id="lab_ccrn_SegmentReportingUnallocatedCorporateExpenses_label_en-US" xlink:label="lab_ccrn_SegmentReportingUnallocatedCorporateExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Unallocated Corporate Expenses</link:label>
    <link:label id="lab_ccrn_SegmentReportingUnallocatedCorporateExpenses_documentation_en-US" xlink:label="lab_ccrn_SegmentReportingUnallocatedCorporateExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Unallocated Corporate Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SegmentReportingUnallocatedCorporateExpenses" xlink:href="ccrn-20220331.xsd#ccrn_SegmentReportingUnallocatedCorporateExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_SegmentReportingUnallocatedCorporateExpenses" xlink:to="lab_ccrn_SegmentReportingUnallocatedCorporateExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_MediscanMember_8facc55f-53ed-449e-a0da-ed1b3a93abb8_terseLabel_en-US" xlink:label="lab_ccrn_MediscanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mediscan</link:label>
    <link:label id="lab_ccrn_MediscanMember_label_en-US" xlink:label="lab_ccrn_MediscanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mediscan [Member]</link:label>
    <link:label id="lab_ccrn_MediscanMember_documentation_en-US" xlink:label="lab_ccrn_MediscanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mediscan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_MediscanMember" xlink:href="ccrn-20220331.xsd#ccrn_MediscanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_MediscanMember" xlink:to="lab_ccrn_MediscanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_2987eca4-890d-44b0-ba00-982f3f387753_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Accumulated Deficit) Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_a2b9471f-97c2-4f72-a67a-0af50ee4bbc9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_cebca692-b5cd-4b01-b823-1ea8b878c15f_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note payable, fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_af4e059b-7a8a-4f22-8056-7c6988de5a14_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ad08f77d-4cc2-43de-82c5-798ca077b21e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d579311f-1100-4800-a3e8-63f0a1576f19_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_c63e27d4-b74f-4734-9e4e-7ba220a3b434_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_4b338c79-55f1-4e17-ae24-fbe15f17adb3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_8abdba17-fcc9-4081-946d-ca27c0fa53a8_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets acquired under operating lease</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_85116c53-89d0-4b04-9f33-f4124fdf3403_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares left remaining to repurchase under the plan (up to) (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_92d3b4e7-73bd-4422-b9a6-dbbbf5e419d9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard_034505fa-bc12-4dac-993e-7d6e35282b2a_terseLabel_en-US" xlink:label="lab_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution income</link:label>
    <link:label id="lab_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard_label_en-US" xlink:label="lab_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income Loss Before D And A Acquisition And Integration Contingent Consideration Restructuring Legal Impairment And Corporate Overheard</link:label>
    <link:label id="lab_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard_documentation_en-US" xlink:label="lab_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income Loss Before D And A Acquisition And Integration Contingent Consideration Restructuring Legal Impairment And Corporate Overheard</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard" xlink:href="ccrn-20220331.xsd#ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard" xlink:to="lab_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_510aa2a9-9210-479e-a492-75e906d7b193_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing availability</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_184d1f0a-f1c3-4bc1-a770-e7508f79879d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share attributable to common stockholders - Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_6bfb1a94-4478-4907-b5b1-46bab2a2bfab_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of earnout liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_6367c8f4-dac1-49cb-9a98-b5dedc45698f_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of earnout liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0cc260f1-dc8c-4105-a3f7-a9158f769169_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_d2d9a63c-79cb-4839-94e0-e324cf857e48_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUE RECOGNITION</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bb74a0e3-0f88-43cf-a205-6ee07103bed7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock awards, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f145736b-9d44-44a5-a5a4-5e5d3d5cd206_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock awards, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_fc8aca2d-b3c3-44a3-8609-0c44283c5053_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_c3590834-20b3-4046-9efe-5bb166d02530_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_7b80785c-5388-4e56-b807-f4ad1e04a839_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_08fd78b5-5752-48c4-860b-30d0100340f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_ffb9e39a-25c4-44a5-8f78-ded3031a9915_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_57c2af3d-0f6d-45b2-8613-32fec32f1d56_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c25f9266-0247-4f21-a329-358d78d3c424_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock_6094ac27-cd57-4546-89dc-dbf32f9a25bb_terseLabel_en-US" xlink:label="lab_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock_label_en-US" xlink:label="lab_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Leases [Table Text Block]</link:label>
    <link:label id="lab_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock_documentation_en-US" xlink:label="lab_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock" xlink:href="ccrn-20220331.xsd#ccrn_AssetsAndLiabilitiesLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock" xlink:to="lab_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_99caeb4a-c32b-4d43-882e-8dcdad57541e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet_83ba3dcf-9127-4f7c-995f-5796760ec053_terseLabel_en-US" xlink:label="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested in period, net (in shares)</link:label>
    <link:label id="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet_label_en-US" xlink:label="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other than Options, Vested In Period, Net</link:label>
    <link:label id="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet_documentation_en-US" xlink:label="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other than Options, Vested In Period, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet" xlink:href="ccrn-20220331.xsd#ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet" xlink:to="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_7620f620-4477-4c9f-a74d-82e4fb905460_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_f62c895b-c825-4555-9851-0f9cc2ef713e_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bad debt expense</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_7c4be4a1-f2bf-48a9-af29-b20ba7891eb8_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bad Debt Expense</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_5148abc3-3450-40a1-a7c2-b272fe2c9473_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_EarnoutNotesPayableMember_1fb49bfb-dd17-4938-81d4-4c778511d227_terseLabel_en-US" xlink:label="lab_ccrn_EarnoutNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnout Notes Payable</link:label>
    <link:label id="lab_ccrn_EarnoutNotesPayableMember_label_en-US" xlink:label="lab_ccrn_EarnoutNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnout Notes Payable [Member]</link:label>
    <link:label id="lab_ccrn_EarnoutNotesPayableMember_documentation_en-US" xlink:label="lab_ccrn_EarnoutNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnout Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_EarnoutNotesPayableMember" xlink:href="ccrn-20220331.xsd#ccrn_EarnoutNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_EarnoutNotesPayableMember" xlink:to="lab_ccrn_EarnoutNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_435aa597-5841-4393-8d7f-48980fada972_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Option, Quantitative Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Option, Quantitative Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_769ac0e3-6f85-44e6-8a8c-3137154bd048_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_b4d9d6fb-ca19-4236-83e3-c67783c024c6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation asset</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_cb2db200-5eb0-46fc-8015-5f891f8a0595_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_853908e9-01c9-46e0-9a97-57644b327099_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ada0e804-3f4d-44ad-a8d1-7c6feeb5b8ef_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_A2021TermLoanCreditAgreementIncrementalTermLoanMember_31df4e8b-1b4f-49ff-a025-4da48710828b_terseLabel_en-US" xlink:label="lab_ccrn_A2021TermLoanCreditAgreementIncrementalTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Term Loan Credit Agreement, Incremental Term Loan</link:label>
    <link:label id="lab_ccrn_A2021TermLoanCreditAgreementIncrementalTermLoanMember_label_en-US" xlink:label="lab_ccrn_A2021TermLoanCreditAgreementIncrementalTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Term Loan Credit Agreement, Incremental Term Loan [Member]</link:label>
    <link:label id="lab_ccrn_A2021TermLoanCreditAgreementIncrementalTermLoanMember_documentation_en-US" xlink:label="lab_ccrn_A2021TermLoanCreditAgreementIncrementalTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Term Loan Credit Agreement, Incremental Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_A2021TermLoanCreditAgreementIncrementalTermLoanMember" xlink:href="ccrn-20220331.xsd#ccrn_A2021TermLoanCreditAgreementIncrementalTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_A2021TermLoanCreditAgreementIncrementalTermLoanMember" xlink:to="lab_ccrn_A2021TermLoanCreditAgreementIncrementalTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_90319c24-120f-4468-861c-10f701eda3ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_1ecfa199-333a-48b3-81c8-9b4c125eda6a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_4a81f4a0-dd3e-4d6f-a7b9-367ef32ef689_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_12bd5513-c087-47fd-b078-843f11357d1c_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross increase to current year unrecognized tax benefits related to federal and state tax issues</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_7eb971e8-95ed-4261-8e89-cb5bd9a0b459_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_95ff1b24-8e10-43d8-86e8-f3ab91681e9b_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-compete agreements</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_04c9e158-4400-4860-8c10-6ddb803cb5af_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_3f1717f5-1b39-4562-bbf7-d03da7baf1a2_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_a13cc2ea-9042-4523-9319-92c16dc0f876_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_ShareBasedPaymentAwardsMember_3f75ab7d-a21b-4282-8789-b41cbd0baacb_terseLabel_en-US" xlink:label="lab_ccrn_ShareBasedPaymentAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Awards</link:label>
    <link:label id="lab_ccrn_ShareBasedPaymentAwardsMember_label_en-US" xlink:label="lab_ccrn_ShareBasedPaymentAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Awards [Member]</link:label>
    <link:label id="lab_ccrn_ShareBasedPaymentAwardsMember_documentation_en-US" xlink:label="lab_ccrn_ShareBasedPaymentAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Awards [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ShareBasedPaymentAwardsMember" xlink:href="ccrn-20220331.xsd#ccrn_ShareBasedPaymentAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_ShareBasedPaymentAwardsMember" xlink:to="lab_ccrn_ShareBasedPaymentAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable_3f4c3dde-86f7-4bd6-803d-b630d5f52928_terseLabel_en-US" xlink:label="lab_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Indefinite Lived And Finite Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Indefinite Lived And Finite Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable_documentation_en-US" xlink:label="lab_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Indefinite Lived And Finite Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable" xlink:href="ccrn-20220331.xsd#ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable" xlink:to="lab_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_927f93e4-8d7f-4526-9d3c-a8556a20d2b1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, impairment loss</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_e46d3767-125a-48d8-9259-9155f5a440d3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_6c04ef56-88d9-44e6-af15-3448f82ef273_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_ebaea818-ada2-43a2-822f-8b3b0bc210dd_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_b5c8451b-3f27-4c6c-9b09-8398fe2dab0b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermDebtNoncurrent_ec9aa0e5-86ae-4968-88a3-f2cd5c74fb05_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, less current portion</link:label>
    <link:label id="lab_us-gaap_OtherLongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermDebtNoncurrent" xlink:to="lab_us-gaap_OtherLongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_3a4e363b-c5c6-4884-8110-0604322b0087_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_59835de6-c7a5-47d7-8bfc-b3ee74e151f3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7cdda515-6d87-4d1a-bc10-dac9e6dc927f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_eb6e8802-5a95-4e6b-978b-dc084dde68d0_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, carrying amount</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52b72bb1-f7e7-41dc-adb6-6f2fe5c70278_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_LineOfCreditSublimitAxis_f7a9e6c6-906a-43a4-9bdd-c006f21d6313_terseLabel_en-US" xlink:label="lab_ccrn_LineOfCreditSublimitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Sublimit [Axis]</link:label>
    <link:label id="lab_ccrn_LineOfCreditSublimitAxis_label_en-US" xlink:label="lab_ccrn_LineOfCreditSublimitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Sublimit [Axis]</link:label>
    <link:label id="lab_ccrn_LineOfCreditSublimitAxis_documentation_en-US" xlink:label="lab_ccrn_LineOfCreditSublimitAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Sublimit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditSublimitAxis" xlink:href="ccrn-20220331.xsd#ccrn_LineOfCreditSublimitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_LineOfCreditSublimitAxis" xlink:to="lab_ccrn_LineOfCreditSublimitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_62ccdf94-4bdf-432b-9d85-78c48a327f75_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_98841271-0d3a-4c60-9a55-86ca712c281f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_442fd03b-460d-42d8-bd75-ad7ae5853a7f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_8e73ec75-0744-4640-8f96-d0a8d3fd149a_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_3a43b784-da17-4bf4-a41b-7b06fa0e293f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_8fdb1e6b-0aaa-4a9a-bbe2-0068b6b6dd30_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_0bc8f7b2-d22a-40e7-9918-327f6a235702_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_b44c3286-669d-4946-a927-93585ed6a0e4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_283dc99e-68bd-48bc-a101-ca6c27a44d8c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_7c4ced00-f6da-4f96-8c4a-28db50a64099_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_PhysicianStaffingMember_7a5ddac5-a182-44e6-bb6d-43e1a88cca91_terseLabel_en-US" xlink:label="lab_ccrn_PhysicianStaffingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physician Staffing</link:label>
    <link:label id="lab_ccrn_PhysicianStaffingMember_label_en-US" xlink:label="lab_ccrn_PhysicianStaffingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physician Staffing [Member]</link:label>
    <link:label id="lab_ccrn_PhysicianStaffingMember_documentation_en-US" xlink:label="lab_ccrn_PhysicianStaffingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physician staffing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_PhysicianStaffingMember" xlink:href="ccrn-20220331.xsd#ccrn_PhysicianStaffingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_PhysicianStaffingMember" xlink:to="lab_ccrn_PhysicianStaffingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_6eca871c-9c6d-41bc-91ff-dcbf944f4c56_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_9800727d-5f3b-4153-8f5a-1318a9e43977_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_5f651b36-e2ce-4239-b9b9-1370273f7617_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_2688d6a8-9b97-4d37-85a4-7fd072782cb9_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Asset-Based Loan</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_e232095e-605c-4836-9191-c4324af9259b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent_8e553e2f-c4d1-41f7-9e16-ec071c49b3a8_terseLabel_en-US" xlink:label="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability - non-current</link:label>
    <link:label id="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent_label_en-US" xlink:label="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation, Noncurrent</link:label>
    <link:label id="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent_documentation_en-US" xlink:label="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent" xlink:to="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_5e45b67d-3794-4f21-b244-87f5eb380bb2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_a7dc109f-ffa2-43b2-890e-2a812fd9a6a4_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of credit outstanding</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_39de194e-b8b1-4658-b6ad-263b1878d47a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2900649d-5e00-4321-872d-73b473f21e30_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_ccdc1c3a-ff84-45b1-9f58-a8baf6fd22d0_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7a3200c6-ee6b-40de-847d-2b6c502efcec_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock awards, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_91470bc2-9ee0-451b-b00c-a6f86e14c149_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock awards, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8e7943c6-8a24-4f17-90e1-c82ad7f4815e_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_9bc058d9-eb3c-4249-b25d-ca6931cfec03_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Awards</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_dd77e25a-bc56-4e8f-81c9-7653ce10a0bd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_d72903a5-ddc0-4b8a-923a-98f3f5a5a205_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_730c09cd-1249-4f22-bca5-3e644350b2ec_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_99c32ebf-e2d5-4199-bb26-674ef1db32de_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_ed7360c0-5ce1-4108-857b-ba228c7a132f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Amounts and Estimated Fair Values of Significant Financial Instrument that were not Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_0a47d049-43fe-4795-ae81-62aa3767fee3_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2fdcb97a-be0c-4adc-9f75-126ecc378051_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b9ce2854-e90e-4c7a-a1c6-d704056c02db_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_01a64288-f94a-447a-846d-57effbdb0de7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITIONS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_eda4f338-bdcd-4961-b012-7ee2e08e8b58_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_94fa4766-b318-4c79-877b-03df5ec0e493_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_86e0ae6f-f9ab-4bfb-8cd9-1020cb584f9d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_4055b4b0-18af-437c-b3d7-32bcb6c87da0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly installment amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8a00980c-bdcc-4bb7-a27e-0dce30b023a7_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based awards (shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_4f68f348-bff7-4956-8c0b-2df8b35b3be4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_29833e76-4c72-4cf1-a13b-ee26308e4e82_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_aa127e30-a9e7-4159-a196-f781f67c2130_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_055863e4-c534-4416-b081-a37fc0674b45_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: amount of lease payments representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax_e5dbf32d-8d21-4691-b937-b68626720af9_negatedTerseLabel_en-US" xlink:label="lab_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on currency fluctuations</link:label>
    <link:label id="lab_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax_label_en-US" xlink:label="lab_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Before Tax</link:label>
    <link:label id="lab_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax_documentation_en-US" xlink:label="lab_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax" xlink:href="ccrn-20220331.xsd#ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax" xlink:to="lab_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b25a19f0-657b-4e2b-bc28-e6ab0b9e8d8c_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_eec54af7-7858-4b20-8ce8-db393887cefb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity consideration for acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ed1f3ce9-01be-47d8-bc5a-eb5f59eb3750_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from services</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_TemporaryStaffingServicesMember_a72a419f-1941-4a7c-915f-2870c9f677c6_terseLabel_en-US" xlink:label="lab_ccrn_TemporaryStaffingServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Staffing Services</link:label>
    <link:label id="lab_ccrn_TemporaryStaffingServicesMember_label_en-US" xlink:label="lab_ccrn_TemporaryStaffingServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Staffing Services [Member]</link:label>
    <link:label id="lab_ccrn_TemporaryStaffingServicesMember_documentation_en-US" xlink:label="lab_ccrn_TemporaryStaffingServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Staffing Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_TemporaryStaffingServicesMember" xlink:href="ccrn-20220331.xsd#ccrn_TemporaryStaffingServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_TemporaryStaffingServicesMember" xlink:to="lab_ccrn_TemporaryStaffingServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems_6cfaa1a1-c735-416a-bfd2-3756d7072b59_terseLabel_en-US" xlink:label="lab_ccrn_EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate, excluding discrete items</link:label>
    <link:label id="lab_ccrn_EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems_label_en-US" xlink:label="lab_ccrn_EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate, Continuing Operations, Excluding Discrete Items</link:label>
    <link:label id="lab_ccrn_EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems_documentation_en-US" xlink:label="lab_ccrn_EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate, Continuing Operations, Excluding Discrete Items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems" xlink:href="ccrn-20220331.xsd#ccrn_EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems" xlink:to="lab_ccrn_EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_dcc79523-c6c3-4749-9d38-cdd9e7c08625_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_75e53650-8b51-44bd-876b-2446cbb99732_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_04480047-4320-4757-ac22-16de5416e30b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_b3ef1ed9-267d-4f42-b8e0-c8eb6c0c2fa3_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_08cbee47-217d-465b-8f9d-274da15d24a3_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_fdab4163-89f1-4877-b0ee-74e54bc73045_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_42ab618b-a585-41fb-83ba-b7075d9130ac_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_4df10f3a-0ea5-423b-b15a-0fc68a301c25_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENT DATA</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_8bdf5d14-4a09-46c5-85a2-548df7819e67_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_6127f6c9-040c-4245-a27b-5468b8bd510d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_35655a7b-fed1-4bc3-bf1c-23e3a468f735_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_2d9a8ba6-ebd0-43c8-8823-4dd114ed54c5_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: operating lease liabilities - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1a78c453-918e-41c4-a486-ed1d392fc840_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_07ba7079-4691-4ac0-96da-923377d83e7f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_9f277b39-248e-41e4-beda-f8c10fdeb06b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_8dea0925-9388-4425-af19-173faec30ba6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_a4ed05c0-7e69-41d4-8ef0-8a6427483e42_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_ccf38f32-40d0-4f2f-aff7-88275411d367_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_37717f37-31bf-4169-ab9e-c8081ccafa52_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LinesOfCreditFairValueDisclosure_e90ea5f1-2855-4892-9431-dc5c83456f8b_terseLabel_en-US" xlink:label="lab_us-gaap_LinesOfCreditFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Asset-Based Loan</link:label>
    <link:label id="lab_us-gaap_LinesOfCreditFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LinesOfCreditFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lines of Credit, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LinesOfCreditFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LinesOfCreditFairValueDisclosure" xlink:to="lab_us-gaap_LinesOfCreditFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities_9dd496a9-7764-430d-a791-eb2b63467e56_terseLabel_en-US" xlink:label="lab_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:label id="lab_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="ccrn-20220331.xsd#ccrn_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_916f71d0-fd61-4ddc-8e3a-49169c061d84_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_effbb770-9f72-4852-939d-28734fcf7196_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_52a3e293-aacf-472a-8796-5ae5d12f8430_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_90679fef-5074-434b-9853-83047aa6a306_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_7a367012-b655-446e-b91a-14d00dc99f73_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased and retired (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7e084b27-a46f-42ca-8be2-030e27391f24_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_89873026-d34a-4e05-aa73-fd620f81f28c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_38458d4b-fd1a-4751-a2a8-5e12741c76e8_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_dd7ff597-94b5-448b-9e55-af5e5d959e37_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_5534db84-574f-487f-b3f1-619e9c9a4ea5_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2505168b-edfc-43a6-ab83-0c3d7fb12181_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_50df6821-9a92-4dc1-ba03-06ba66f4b282_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fb30cc63-d67c-4d99-bb8e-e5de127aa25d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_80642b89-9d78-4903-9bc1-5655fb524f6b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_3f424caa-711d-4b14-8437-a38a27bb2fdf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligations, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0038179d-e378-4f7c-a0b8-ae132a4b6ecb_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5a838483-a839-41e5-ab39-070a53cc675f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8870de5e-8498-4dfd-8be7-af15ea6b96af_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f5d47eed-5781-44f5-b833-48ac2da08208_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_LineOfCreditFacilityBorrowingBaseAvailability_ad2329d4-0ead-4508-954c-62411330ca7d_terseLabel_en-US" xlink:label="lab_ccrn_LineOfCreditFacilityBorrowingBaseAvailability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing base availability</link:label>
    <link:label id="lab_ccrn_LineOfCreditFacilityBorrowingBaseAvailability_label_en-US" xlink:label="lab_ccrn_LineOfCreditFacilityBorrowingBaseAvailability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Borrowing Base Availability</link:label>
    <link:label id="lab_ccrn_LineOfCreditFacilityBorrowingBaseAvailability_documentation_en-US" xlink:label="lab_ccrn_LineOfCreditFacilityBorrowingBaseAvailability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Borrowing Base Availability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditFacilityBorrowingBaseAvailability" xlink:href="ccrn-20220331.xsd#ccrn_LineOfCreditFacilityBorrowingBaseAvailability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_LineOfCreditFacilityBorrowingBaseAvailability" xlink:to="lab_ccrn_LineOfCreditFacilityBorrowingBaseAvailability" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_LineOfCreditSublimitDomain_af8d8232-b739-4041-9e4d-a6a2d878b1c8_terseLabel_en-US" xlink:label="lab_ccrn_LineOfCreditSublimitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Sublimit [Domain]</link:label>
    <link:label id="lab_ccrn_LineOfCreditSublimitDomain_label_en-US" xlink:label="lab_ccrn_LineOfCreditSublimitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Sublimit [Domain]</link:label>
    <link:label id="lab_ccrn_LineOfCreditSublimitDomain_documentation_en-US" xlink:label="lab_ccrn_LineOfCreditSublimitDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Line Of Credit Sublimit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditSublimitDomain" xlink:href="ccrn-20220331.xsd#ccrn_LineOfCreditSublimitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_LineOfCreditSublimitDomain" xlink:to="lab_ccrn_LineOfCreditSublimitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_LongTermDebtMaturityAfterYearFour_2b872d6e-6d17-4d05-b91a-487e1dae883e_terseLabel_en-US" xlink:label="lab_ccrn_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ccrn_LongTermDebtMaturityAfterYearFour_label_en-US" xlink:label="lab_ccrn_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, After Year Four</link:label>
    <link:label id="lab_ccrn_LongTermDebtMaturityAfterYearFour_documentation_en-US" xlink:label="lab_ccrn_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LongTermDebtMaturityAfterYearFour" xlink:href="ccrn-20220331.xsd#ccrn_LongTermDebtMaturityAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_LongTermDebtMaturityAfterYearFour" xlink:to="lab_ccrn_LongTermDebtMaturityAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_aeb2a94b-637c-4bfa-b6f3-5c4476b5b16c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_3472b421-b353-410a-ac85-44d90367d149_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMPREHENSIVE INCOME</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_097426d5-a816-4de4-8676-21c4623c5ec9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a7598fc1-c1c4-4245-b3a7-d5dd30c1157a_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_179b3df5-d838-4228-96cb-faf9c7533f06_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_76ce6cba-d845-4046-b782-a8d42c9090f5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_OperatingLeaseExpenseNonCash_3b083048-dff0-41a3-93fd-02c096af8565_terseLabel_en-US" xlink:label="lab_ccrn_OperatingLeaseExpenseNonCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_ccrn_OperatingLeaseExpenseNonCash_label_en-US" xlink:label="lab_ccrn_OperatingLeaseExpenseNonCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Expense, Non-Cash</link:label>
    <link:label id="lab_ccrn_OperatingLeaseExpenseNonCash_documentation_en-US" xlink:label="lab_ccrn_OperatingLeaseExpenseNonCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Expense, Non-Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OperatingLeaseExpenseNonCash" xlink:href="ccrn-20220331.xsd#ccrn_OperatingLeaseExpenseNonCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_OperatingLeaseExpenseNonCash" xlink:to="lab_ccrn_OperatingLeaseExpenseNonCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0b612fdb-0242-498e-8370-2bd3e0550845_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate at period end (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_77e6edee-9d9e-4c49-b00e-ebdfaa32f92d_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_d4431e72-ce00-427e-8682-59c4b0df13e4_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_49d42811-e183-4715-a4f6-3da0f8ce92fe_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible List]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_c4295aaf-db57-421a-bbbb-20a22b99badd_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly commitment fee on the average daily unused portion (percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_6ae6a889-c322-441f-912a-c9a64e52d682_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_DebtInstrumentVariableInterestRateFloor_9c1a31f5-db8f-4903-9898-5cf7f0ca20b4_terseLabel_en-US" xlink:label="lab_ccrn_DebtInstrumentVariableInterestRateFloor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest margin floor (percent)</link:label>
    <link:label id="lab_ccrn_DebtInstrumentVariableInterestRateFloor_label_en-US" xlink:label="lab_ccrn_DebtInstrumentVariableInterestRateFloor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Variable Interest Rate Floor</link:label>
    <link:label id="lab_ccrn_DebtInstrumentVariableInterestRateFloor_documentation_en-US" xlink:label="lab_ccrn_DebtInstrumentVariableInterestRateFloor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Variable Interest Rate Floor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_DebtInstrumentVariableInterestRateFloor" xlink:href="ccrn-20220331.xsd#ccrn_DebtInstrumentVariableInterestRateFloor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_DebtInstrumentVariableInterestRateFloor" xlink:to="lab_ccrn_DebtInstrumentVariableInterestRateFloor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_becbdeaf-d22b-49af-a5cd-80e6668f2076_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d593d78d-0691-40fd-8fd9-f9e89576826f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_666cf772-091a-4479-8b1c-6065d02c58e7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_8acc6ad3-1e86-4a04-92c8-eb2189ee791a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_d3f08a41-c8af-4593-b8cf-ec58a078ff47_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_e9ca01a2-6bc1-474d-98bb-49b71ad7e2cf_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_1d8976e1-2abb-46cc-8306-09e58296a854_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5ab2706a-13a7-4b99-a1a4-bd9aa92fd865_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_105e1ae7-a9f9-4fc0-ac07-67c950ef9276_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_b05f4e1e-bdc5-46b3-9907-b815d070c4b6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage_493d27f9-3297-4791-8790-020b92ba7646_terseLabel_en-US" xlink:label="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance attainment percentage</link:label>
    <link:label id="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage_label_en-US" xlink:label="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Attainment Percentage</link:label>
    <link:label id="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage_documentation_en-US" xlink:label="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Target Attainment Level, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage" xlink:href="ccrn-20220331.xsd#ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage" xlink:to="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances_6b903620-51d6-45bb-a68a-fb7a973c2fc9_verboseLabel_en-US" xlink:label="lab_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for allowances</link:label>
    <link:label id="lab_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances_label_en-US" xlink:label="lab_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Doubtful Accounts And Other Allowances</link:label>
    <link:label id="lab_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances_documentation_en-US" xlink:label="lab_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Doubtful Accounts And Other Allowances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances" xlink:href="ccrn-20220331.xsd#ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances" xlink:to="lab_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_591661a5-7e99-4d35-9d0a-451a9f3c57e4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ab0c2b4e-7558-42ed-be97-7aa87dd81e7d_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4c3a0f83-7af0-41c7-b8b1-ef532fa697f6_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_46e88b59-2c7f-4a1f-b783-70c122003da0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_bbd37394-23d1-47fe-90cd-9925919b4ac7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowances of $9,141 in 2022 and $6,881 in 2021</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_4f19d75a-c5f4-4d5e-922e-97d9e77cb810_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_f3b60dfb-c0fe-4aba-92d6-83a2322344d5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_10316c33-45c3-4d78-a7e2-7ec8cb2909a4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_e20b0117-cf91-4557-b8ba-e0e47ecaf9cb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ae611d4a-fe09-4c64-82f6-5159427f7728_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_394025d2-21d2-4f85-9a1e-869414f8ddb8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c919e10c-0f92-41c0-9e53-f16c2ce3d32d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fdd3d261-2504-4308-992e-ea5cc2816ca7_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_4a888242-a86b-4834-aa11-bad7c557b7c0_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_89fab731-ad8d-4e32-8065-388a9b3280d6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6d313af8-6d3c-4677-a612-cfae65516192_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6b9c589e-f372-41a8-ba69-89a6314d40d1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_cedbaa89-0bf4-43f7-a845-f1c2818f04c4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_62b1ce95-17cd-4a18-b8ad-a79e0e942181_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized foreign currency translation loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_d3b03460-85ae-4b99-842b-2e628cd169b9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current earnout liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_0588119c-f892-4ed6-a757-2ebfa2061fce_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_190ecaf0-e287-45d4-b41b-a9ec193e2923_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_f9d25fa9-307e-4924-9ba3-dd9ead38ba40_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_00c772c4-3ec0-4906-929f-c9e5e794aa42_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable_e1783810-c40a-4b26-8e40-1ebb0d9a5fd5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Option, Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Option, Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_503be706-00d1-42b3-aa2b-ee7bea53f493_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Abstract]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_c01326f7-1700-49ff-aeb4-0ae29fee640d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_1e5fc275-d817-4e7b-a649-af88cd3e02eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease expense</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_794a6776-36a5-424a-91f7-213f8b011249_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7257ee9c-9611-4eff-a091-b54fd75504c5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f95d0c63-3108-4c47-a9fe-8a410eb3afeb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment, net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_SeniorSecuredAssetBasedLoanMember_0112168d-e5f7-4892-ad8c-eb3ba42e9fbc_terseLabel_en-US" xlink:label="lab_ccrn_SeniorSecuredAssetBasedLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Asset-Based Loan</link:label>
    <link:label id="lab_ccrn_SeniorSecuredAssetBasedLoanMember_label_en-US" xlink:label="lab_ccrn_SeniorSecuredAssetBasedLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Asset-Based Loan [Member]</link:label>
    <link:label id="lab_ccrn_SeniorSecuredAssetBasedLoanMember_documentation_en-US" xlink:label="lab_ccrn_SeniorSecuredAssetBasedLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Asset-Based Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SeniorSecuredAssetBasedLoanMember" xlink:href="ccrn-20220331.xsd#ccrn_SeniorSecuredAssetBasedLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_SeniorSecuredAssetBasedLoanMember" xlink:to="lab_ccrn_SeniorSecuredAssetBasedLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_e1811551-22fc-4a0c-8a0f-de8d1c197b8c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d164752e-8764-4a28-853d-57c8449563b6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity consideration for acquisition, value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_b0d3fbca-71b4-410e-a364-184df41184e2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_SalesAllowanceBillingRelatedAdjustments_cbe4beee-f93d-4747-a541-e38ced348235_terseLabel_en-US" xlink:label="lab_ccrn_SalesAllowanceBillingRelatedAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales allowance, billing-related adjustments</link:label>
    <link:label id="lab_ccrn_SalesAllowanceBillingRelatedAdjustments_label_en-US" xlink:label="lab_ccrn_SalesAllowanceBillingRelatedAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Allowance, Billing-Related Adjustments</link:label>
    <link:label id="lab_ccrn_SalesAllowanceBillingRelatedAdjustments_documentation_en-US" xlink:label="lab_ccrn_SalesAllowanceBillingRelatedAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Allowance, Billing-Related Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SalesAllowanceBillingRelatedAdjustments" xlink:href="ccrn-20220331.xsd#ccrn_SalesAllowanceBillingRelatedAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_SalesAllowanceBillingRelatedAdjustments" xlink:to="lab_ccrn_SalesAllowanceBillingRelatedAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9c40d62f-317e-4af8-b4c7-27aa4cc01779_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_4795466b-e4a9-4d92-897e-50895a1186fd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f7529846-ff90-4cb9-95d9-9d8b3485ba08_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_b8615754-2d32-43df-8494-d5a932657ab1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_139e22ca-c811-4454-8d3b-889540be10c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_932c0926-e267-49df-9acc-b67bfda65997_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_0e9b02af-1cb5-449b-b8aa-473edd8ce0f9_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_1c88f644-c6e1-4c82-9c9d-8bb6ba768423_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_87664309-1d9e-4bf5-a1f3-80caaa85e2ea_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7c54627f-7644-4b6d-b434-a44c5919b75a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_55cd7c8b-2349-40a5-b6da-d3698d3659c7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_1999db97-c79a-4c12-8c1a-7b3f5cd47a31_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3074ebd1-2033-41f7-9cb3-0cb1d227b88a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_1b896ca2-99b0-4e23-a3ea-af507e1d3ba2_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_b8822407-fbf3-46f0-b87c-6c58554665ca_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member of the Board of Directors</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_06b31d14-c459-46c0-b691-82880bc68f23_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_f52890a0-2478-489c-a4a4-4e1eb3082f44_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to common stockholders - Basic and Diluted - Diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided_fb6e41af-5b71-4a7f-8230-3ce1d011a48a_terseLabel_en-US" xlink:label="lab_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold period, past due for payment of services provided</link:label>
    <link:label id="lab_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided_label_en-US" xlink:label="lab_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold Period, Past Due For Payment Of Services Provided</link:label>
    <link:label id="lab_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided_documentation_en-US" xlink:label="lab_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold Period, Past Due For Payment Of Services Provided</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided" xlink:href="ccrn-20220331.xsd#ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided" xlink:to="lab_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_7966afe1-7c6a-4952-ae0c-ded84dc541b6_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on term loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_3b9fb15b-9f10-490e-b5e3-92df2d6b219e_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9c0c3476-a469-4ae6-9dda-4752daa1953e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to common stockholders - Basic and Diluted - Basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_23685745-429e-42b1-b5e6-0e4e30c81a93_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on note payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_3f21d607-017e-4e52-bfa4-a5baf3f857be_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of notes payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4dc93465-3f3a-4bb1-bf82-502079bf6a60_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_74e9aa63-2d0c-4a4d-a6cb-a9c034db2ef8_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_cfe0b468-e28f-4e65-96c4-1b9880fc6913_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest in Subsidiary</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_6e866aa8-a128-41d8-91de-69c88ca670f6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_fc90b6ba-9dfd-43f7-9db6-9576ddfe0b60_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnout liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6bfa2f1-2525-47fc-bacd-d4069b184559_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_8f7d221f-7907-41d0-8075-9f00ef40da42_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6db6f17d-c6a0-4386-a91f-243d64e9ade0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_0940d46c-37e6-4782-adf3-8396a75cb4c3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c2d5178a-b4b3-4e44-b281-a345c94aab7b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_b16bcdd9-c741-407a-881d-8fcb1e599b98_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_aea40275-ce5a-4258-8720-eafdb81b3e0e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_99459aca-b511-474c-a3d7-d8c053180cc5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_972119c8-3290-4332-b7ce-1322c07ead05_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares - Basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_ed53aea3-916f-438c-aed6-a629409b1af1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share attributable to common stockholders - Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_942bff55-497b-4ac9-b762-d2da23be0149_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of diluted shares:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_9b7bc999-031f-4520-aeb8-1c5de29059bb_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_76ec63cb-a5d2-464f-9473-53d566826a5b_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_ec254627-17c7-4a41-8c71-32946d9784d1_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments on Senior Secured Asset-Based revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_a016e0e5-fe1e-4cd3-a882-8f1864e3999c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit term</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1045edd5-20e2-4d1f-a64d-d180875d367d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_30f93ba4-37e9-4909-942d-1f4f343927ad_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled contracts receivable</link:label>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_label_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledContractsReceivable" xlink:to="lab_us-gaap_UnbilledContractsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9cbb27ef-3998-47e4-8115-e187abfe3b64_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DatabasesMember_f621bae8-7c49-4834-a1e9-e5054da3e693_terseLabel_en-US" xlink:label="lab_us-gaap_DatabasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Databases</link:label>
    <link:label id="lab_us-gaap_DatabasesMember_label_en-US" xlink:label="lab_us-gaap_DatabasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Database Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DatabasesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DatabasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DatabasesMember" xlink:to="lab_us-gaap_DatabasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_ce3a6aaf-226b-4a76-a8a3-9c8eff450549_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Termination Costs</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef082b22-c26a-4084-bdac-5f3b17909aa1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_d20a8530-49cf-4e95-b9d7-948478164248_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_73b1eb86-92e9-4614-bebf-9660b004007e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_2116d689-58b7-4196-834d-92edea09061b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_50d086a4-9cf2-4db1-bc93-157fea60d276_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_44041975-2561-470e-97c2-76a926400488_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_83c1295e-8aac-49ee-a079-967961d8490f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_c12b4768-b053-48f5-b098-00a747eb8fb7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_dc67c1df-8a55-4ae6-9e4a-6358c55021ee_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_10f98768-154f-422d-82a7-0bec6a256b7c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_7e7cf6fa-7e2d-4207-8117-868cc312b5cb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_942d3e5f-71b7-4e31-8104-18c246843a2b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_58266df9-25fa-4f42-ae5c-347f604019f9_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged to restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_PaymentsForRestructuringAndAdjustments_7984dbae-0fac-4fba-bdeb-0996f0cf8232_negatedTerseLabel_en-US" xlink:label="lab_ccrn_PaymentsForRestructuringAndAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and adjustments</link:label>
    <link:label id="lab_ccrn_PaymentsForRestructuringAndAdjustments_label_en-US" xlink:label="lab_ccrn_PaymentsForRestructuringAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Restructuring And Adjustments</link:label>
    <link:label id="lab_ccrn_PaymentsForRestructuringAndAdjustments_documentation_en-US" xlink:label="lab_ccrn_PaymentsForRestructuringAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Restructuring And Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_PaymentsForRestructuringAndAdjustments" xlink:href="ccrn-20220331.xsd#ccrn_PaymentsForRestructuringAndAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_PaymentsForRestructuringAndAdjustments" xlink:to="lab_ccrn_PaymentsForRestructuringAndAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashExpense_55b6414e-5c94-4301-8c43-63c576256009_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash costs</link:label>
    <link:label id="lab_us-gaap_OtherNoncashExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashExpense" xlink:to="lab_us-gaap_OtherNoncashExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_782fb006-676c-4d8e-8c5c-b2170632d246_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d23887b7-e6d7-4df1-9ae7-4f9b9b82c6ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b596904c-da22-4ef3-9216-8955318a3da5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_beb49392-deb2-43dd-9e50-98caa7f8c9cf_terseLabel_en-US" xlink:label="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of vesting installments</link:label>
    <link:label id="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_label_en-US" xlink:label="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number Of Vesting Installments</link:label>
    <link:label id="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_documentation_en-US" xlink:label="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number Of Vesting Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" xlink:href="ccrn-20220331.xsd#ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" xlink:to="lab_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_0260a742-4567-42c4-b561-715be6d91995_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings under Senior Secured Asset-Based revolving credit facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8b1071dc-907b-4995-a12d-fcd9fbc76655_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss, net</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_c00103be-072f-48a2-b63d-96c3583312b6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_3add27fc-6e66-48e3-bf1d-dbb647545aed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_8d07e725-0004-48c7-b527-59051cbe8ed9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_6033e161-88b6-4df4-adca-1a0c4448adad_terseLabel_en-US" xlink:label="lab_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="ccrn-20220331.xsd#ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6e1136e6-1577-47f9-a5c7-45de70acfa7a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_NurseAndAlliedStaffingMember_c60759a1-27c1-494a-9cd0-1ca7fa3549cb_verboseLabel_en-US" xlink:label="lab_ccrn_NurseAndAlliedStaffingMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nurse And Allied Staffing</link:label>
    <link:label id="lab_ccrn_NurseAndAlliedStaffingMember_label_en-US" xlink:label="lab_ccrn_NurseAndAlliedStaffingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nurse And Allied Staffing [Member]</link:label>
    <link:label id="lab_ccrn_NurseAndAlliedStaffingMember_documentation_en-US" xlink:label="lab_ccrn_NurseAndAlliedStaffingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nurse and allied staffing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NurseAndAlliedStaffingMember" xlink:href="ccrn-20220331.xsd#ccrn_NurseAndAlliedStaffingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_NurseAndAlliedStaffingMember" xlink:to="lab_ccrn_NurseAndAlliedStaffingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_35515604-68f1-4740-808d-5ccfd5b241be_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cdf09336-1f15-4678-98ec-728157609055_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_4f295370-6210-41d0-9a0b-fda3719ed3db_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_b2339984-eb56-4aa9-9af3-95bb3e001935_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt term (in years)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_70c77338-5856-4cda-b0c1-5f514d6152d3_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d4f6af0d-02f5-47f7-bac8-6d2d4cc5a48b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $18,092 in 2022 and $17,729 in 2021</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_6b8a95eb-298c-4882-861d-9c023fe3f791_terseLabel_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity and Share-based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_cb0f093a-af84-4e39-88a8-36870828cbc5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_f8481a0e-4a94-438e-b22e-64f14a100edf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_4cc29315-ca4f-4d68-a0a8-5ed1bd8b3634_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Annual Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_30ffd9e6-141d-417c-bd09-8e43a98c6801_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2d34205d-924c-4ddb-a668-aab02c0d1f98_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_e972daa0-8fea-460d-a9e3-bdcb8c725e68_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_StandbyLettersOfCreditSublimitMember_9d8a4e01-a13e-4e63-83c9-6b71a2c5776d_terseLabel_en-US" xlink:label="lab_ccrn_StandbyLettersOfCreditSublimitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters Of Credit Sublimit</link:label>
    <link:label id="lab_ccrn_StandbyLettersOfCreditSublimitMember_label_en-US" xlink:label="lab_ccrn_StandbyLettersOfCreditSublimitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters Of Credit Sublimit [Member]</link:label>
    <link:label id="lab_ccrn_StandbyLettersOfCreditSublimitMember_documentation_en-US" xlink:label="lab_ccrn_StandbyLettersOfCreditSublimitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters Of Credit Sublimit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_StandbyLettersOfCreditSublimitMember" xlink:href="ccrn-20220331.xsd#ccrn_StandbyLettersOfCreditSublimitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_StandbyLettersOfCreditSublimitMember" xlink:to="lab_ccrn_StandbyLettersOfCreditSublimitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_c41c0e0d-06e4-4282-9b70-b96b163ff48b_periodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_6e9b7b75-cb03-4f63-b212-c7618666cbc7_periodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0d296816-0099-4494-ba1a-0f868959137b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_e73e2e0b-4fd1-4e93-8a6d-bcf5ef8bd31c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources_e5c8fc1e-363b-4c7c-8aa8-f1c3d0716c1f_terseLabel_en-US" xlink:label="lab_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of indebtedness permitted from other sources</link:label>
    <link:label id="lab_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources_label_en-US" xlink:label="lab_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit, Amount Of Indebtedness Permitted By Senior Secured Asset Based Loan To Be Borrowed From Other Sources</link:label>
    <link:label id="lab_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources_documentation_en-US" xlink:label="lab_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit, Amount Of Indebtedness Permitted By Senior Secured Asset Based Loan To Be Borrowed From Other Sources</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources" xlink:href="ccrn-20220331.xsd#ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources" xlink:to="lab_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_12063e85-7ea8-4b8a-b24e-d70db359127b_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_ExitCostsMember_cf5794df-43ab-41d6-b9b7-25f54f9f0342_terseLabel_en-US" xlink:label="lab_ccrn_ExitCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease-Related Exit Costs</link:label>
    <link:label id="lab_ccrn_ExitCostsMember_label_en-US" xlink:label="lab_ccrn_ExitCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Costs [Member]</link:label>
    <link:label id="lab_ccrn_ExitCostsMember_documentation_en-US" xlink:label="lab_ccrn_ExitCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ExitCostsMember" xlink:href="ccrn-20220331.xsd#ccrn_ExitCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_ExitCostsMember" xlink:to="lab_ccrn_ExitCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_11d3333e-622f-4468-9f10-deedc5fa75ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_72be2161-c641-4b88-83d7-92995e10b867_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6b55a698-7f6e-49fa-9f0e-bd1eac8625db_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent_f75a7e2d-e218-4bf1-b52a-0a94f29dd7e2_terseLabel_en-US" xlink:label="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability - current</link:label>
    <link:label id="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent_label_en-US" xlink:label="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation, Current</link:label>
    <link:label id="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent_documentation_en-US" xlink:label="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent" xlink:to="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5709d5f3-0c12-452c-83c5-2098c7b887f6_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_OtherServicesMember_c0120205-2887-4582-a408-ad9d3cc7c6e7_terseLabel_en-US" xlink:label="lab_ccrn_OtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Services</link:label>
    <link:label id="lab_ccrn_OtherServicesMember_label_en-US" xlink:label="lab_ccrn_OtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Services [Member]</link:label>
    <link:label id="lab_ccrn_OtherServicesMember_documentation_en-US" xlink:label="lab_ccrn_OtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OtherServicesMember" xlink:href="ccrn-20220331.xsd#ccrn_OtherServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_OtherServicesMember" xlink:to="lab_ccrn_OtherServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits_843393d8-b086-44f8-8043-ad9a6b11335d_terseLabel_en-US" xlink:label="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits_label_en-US" xlink:label="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Compensation And Benefits</link:label>
    <link:label id="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits_documentation_en-US" xlink:label="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Compensation And Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits" xlink:to="lab_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f7c0df69-1806-47b2-9a9d-683a8bc3b535_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_354c5dd8-398a-4e25-812c-4d6f612d38f0_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44c14f0d-98dc-4a4c-8dfd-965a5722b2dc_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_12790538-647a-4450-b174-580f81ba2a8e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_09221b18-f88f-4bbb-b775-73b4591fcab0_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_60cc0ae9-4b72-4ed1-bb6b-c76631b7f486_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_1d1da7b0-16ab-4ec9-9de8-9430db5f18d9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_4c0cedc0-af2f-4756-92f9-acec6e306228_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_40be6bc2-3e6e-48c4-a05d-104a533fd57d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for share-based payments (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_531666f0-7320-4b57-8d26-043557cb8f60_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_0f92de73-2d46-4853-b7fa-55cffaa0d396_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_OmnibusPlanMember_58bee38f-c244-4a35-9c64-6132638493c5_terseLabel_en-US" xlink:label="lab_ccrn_OmnibusPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Plan</link:label>
    <link:label id="lab_ccrn_OmnibusPlanMember_label_en-US" xlink:label="lab_ccrn_OmnibusPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Plan [Member]</link:label>
    <link:label id="lab_ccrn_OmnibusPlanMember_documentation_en-US" xlink:label="lab_ccrn_OmnibusPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OmnibusPlanMember" xlink:href="ccrn-20220331.xsd#ccrn_OmnibusPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_OmnibusPlanMember" xlink:to="lab_ccrn_OmnibusPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_c131822f-5f48-4d42-996a-ecd4a220b536_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term accrued claims</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_aec44793-b3de-4d00-87c7-cb86225130d8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4e15bac0-4eaa-49e2-a5e3-07d61ae94b91_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ce07f8b1-4d40-42db-8e04-13d67dbfd73f_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares - Diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_c942b8b5-1fa6-4ab5-a5b3-0ceb48339aaa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment_f4f2e492-e6a7-4b2d-848a-4b45d54ccb7f_terseLabel_en-US" xlink:label="lab_ccrn_BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net working capital adjustment</link:label>
    <link:label id="lab_ccrn_BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment_label_en-US" xlink:label="lab_ccrn_BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Net Working Capital Adjustment</link:label>
    <link:label id="lab_ccrn_BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment_documentation_en-US" xlink:label="lab_ccrn_BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Net Working Capital Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment" xlink:to="lab_ccrn_BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_350ea102-0f2a-4799-b604-7961274407d6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_30affef0-b39e-406f-abc6-41af1092412d_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8a3b1304-63bc-4903-b33d-3d9f37decc3b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest margin (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_786e00d0-105d-4c09-a77d-c3e416433bd6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-Offs, net of Recoveries</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_e0ae0149-5e6e-48b4-8671-457d5d559d71_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_7d0b8bbb-46e6-4270-8c9d-ba32e67b2416_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_eae5650f-c9b3-4911-9dd1-d225848b8277_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses (income):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_AcquisitionAndIntegrationRelatedCosts_6c61231d-cc4e-4786-9463-5804584d7016_terseLabel_en-US" xlink:label="lab_ccrn_AcquisitionAndIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition and integration-related costs</link:label>
    <link:label id="lab_ccrn_AcquisitionAndIntegrationRelatedCosts_label_en-US" xlink:label="lab_ccrn_AcquisitionAndIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition And Integration-Related Costs</link:label>
    <link:label id="lab_ccrn_AcquisitionAndIntegrationRelatedCosts_documentation_en-US" xlink:label="lab_ccrn_AcquisitionAndIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition and integration-related costs include costs for prior acquisitions, costs incurred for potential transactions, and accretion and valuation adjustments on contingent consideration liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AcquisitionAndIntegrationRelatedCosts" xlink:href="ccrn-20220331.xsd#ccrn_AcquisitionAndIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_AcquisitionAndIntegrationRelatedCosts" xlink:to="lab_ccrn_AcquisitionAndIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_LineOfCreditBorrowingBasePercentageOfAssets_e719543d-655e-47b0-9dc1-3fd91786dc11_terseLabel_en-US" xlink:label="lab_ccrn_LineOfCreditBorrowingBasePercentageOfAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing base, percentage of assets</link:label>
    <link:label id="lab_ccrn_LineOfCreditBorrowingBasePercentageOfAssets_label_en-US" xlink:label="lab_ccrn_LineOfCreditBorrowingBasePercentageOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit, Borrowing Base, Percentage Of Assets</link:label>
    <link:label id="lab_ccrn_LineOfCreditBorrowingBasePercentageOfAssets_documentation_en-US" xlink:label="lab_ccrn_LineOfCreditBorrowingBasePercentageOfAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit, Borrowing Base, Percentage Of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditBorrowingBasePercentageOfAssets" xlink:href="ccrn-20220331.xsd#ccrn_LineOfCreditBorrowingBasePercentageOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_LineOfCreditBorrowingBasePercentageOfAssets" xlink:to="lab_ccrn_LineOfCreditBorrowingBasePercentageOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_e392db22-c704-48c7-8c17-239a35e738e2_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3dbfb79a-4632-4053-a6af-7253efb7ca45_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a26aa056-3f17-4e9e-89fe-f424673c8e48_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_ce928036-3355-4c29-8c33-8485b461f35d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_1511b26a-1e81-4bff-a865-89b12e20d3d9_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Information on Operating Segments and Reconciliation to Loss From Operations</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_b344baae-d852-4b39-9220-d3064c7fedd8_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c0e6c426-6990-4052-ad30-0713d72408c9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5738f9fd-cf35-4f9b-8b0f-746702b1c27d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_a9f214f7-02a7-47f2-9b0c-bb02871ce296_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f338d90c-b5f7-44a4-a277-970638721429_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5c0e753c-afeb-46af-b602-ad7d4d65a892_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_699c43df-017f-4247-99d6-22e2acc585fb_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_4e50a1af-6552-4722-8410-4b3232d6e999_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_5da4aaca-4675-4f05-a96e-22409a1b74fe_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_45443a27-9177-4d8b-9451-c5251980aa02_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for shares withheld for taxes</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_01a84934-1030-4a7f-a886-ab4183fff133_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration, gross</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_533f2743-c0a7-4e91-b5e5-76319b991fac_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_dddaf082-a36c-4034-ab13-b4a1fc8a0ca5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_937d4cf6-229a-4e6b-93e3-1a1be4af0fbc_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_39df9adf-dfc5-47f7-abfb-5f96e68b598b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_665b6617-785b-4a43-999b-dcf658af5f7f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_1d61b1ac-3998-44cc-9905-c3792bda282e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_aff2a22a-d07c-46e8-a16f-4a4eb8aac0e7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f4fcb8ba-0d65-468c-8ffb-9e70d3966451_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Accounting Pronouncement</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_de500f8e-b7c8-4b82-8eab-c0a6af0edb0b_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_e583b7b1-8728-4827-9361-d5a95edfa0f8_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, net</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_30e29d8e-fa03-408b-aae1-e7d68f5c08b1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_0e3578a9-b9e1-4466-b410-1f7ca06b4c9f_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_2fc34744-59f1-45df-bc05-a02697128e7d_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cdac8e2e-e48c-49b3-a84f-df3066d2ccbe_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_43273e99-f3a8-43ef-a1a4-c7e558e3968a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_00d02197-c64f-415d-b735-4c87b717a980_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ccrn_A2021TermLoanCreditAgreementMember_00889468-f81e-48e5-bc2f-d9abe28dcfdd_terseLabel_en-US" xlink:label="lab_ccrn_A2021TermLoanCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Term Loan Credit Agreement</link:label>
    <link:label id="lab_ccrn_A2021TermLoanCreditAgreementMember_label_en-US" xlink:label="lab_ccrn_A2021TermLoanCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Term Loan Credit Agreement [Member]</link:label>
    <link:label id="lab_ccrn_A2021TermLoanCreditAgreementMember_documentation_en-US" xlink:label="lab_ccrn_A2021TermLoanCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Term Loan Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_A2021TermLoanCreditAgreementMember" xlink:href="ccrn-20220331.xsd#ccrn_A2021TermLoanCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ccrn_A2021TermLoanCreditAgreementMember" xlink:to="lab_ccrn_A2021TermLoanCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_bfa7956c-228e-40aa-b35e-6fa3ab7feca9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_b5aee689-bfda-486e-ba8a-af172d793128_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allowance for Doubtful Accounts</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_a453f549-4c9c-4ec8-aaa4-f709941b2f99_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceSettlementsReceivableCurrent_6be0ce80-20c5-4034-8a59-0476688052e4_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceSettlementsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance recovery receivable</link:label>
    <link:label id="lab_us-gaap_InsuranceSettlementsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InsuranceSettlementsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Settlements Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceSettlementsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceSettlementsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceSettlementsReceivableCurrent" xlink:to="lab_us-gaap_InsuranceSettlementsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>ccrn-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:bf6b0e24-63a4-4887-ba98-a744ebcd1084,g:9e05db7a-6f27-4cf3-b67e-d2d201684423-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/Cover" xlink:type="simple" xlink:href="ccrn-20220331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f990aaf3-43c3-4874-97d6-5d390f964e5c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_DocumentType_f990aaf3-43c3-4874-97d6-5d390f964e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_680911d3-5bea-45d9-9bd6-886f875e2505" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_DocumentQuarterlyReport_680911d3-5bea-45d9-9bd6-886f875e2505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c516f87b-9676-4008-8014-5bdd3b24746f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_DocumentPeriodEndDate_c516f87b-9676-4008-8014-5bdd3b24746f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_6e210075-9265-4c6b-8aaa-87d03fe91efc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_DocumentTransitionReport_6e210075-9265-4c6b-8aaa-87d03fe91efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_eefe0361-a0ec-41a5-a132-8187edbd00ab" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_EntityRegistrantName_eefe0361-a0ec-41a5-a132-8187edbd00ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_328328ef-3e8b-42e2-963b-b1998875c472" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_EntityIncorporationStateCountryCode_328328ef-3e8b-42e2-963b-b1998875c472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a7feac8c-4028-428f-b611-22eb53ecf73f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_EntityFileNumber_a7feac8c-4028-428f-b611-22eb53ecf73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_0f85f23f-b510-46ab-aae2-cf121e77efd0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_EntityTaxIdentificationNumber_0f85f23f-b510-46ab-aae2-cf121e77efd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_fc47e216-fa32-47a2-ae01-e892adfdaad0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_EntityAddressAddressLine1_fc47e216-fa32-47a2-ae01-e892adfdaad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_86161ab7-4d83-411a-97d7-1439208a06dd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_EntityAddressCityOrTown_86161ab7-4d83-411a-97d7-1439208a06dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6bcaccd9-228b-4f56-90fc-49b25cea46ee" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_EntityAddressStateOrProvince_6bcaccd9-228b-4f56-90fc-49b25cea46ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4980b6f9-095c-4f8b-8c5a-08ca41692f5d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_EntityAddressPostalZipCode_4980b6f9-095c-4f8b-8c5a-08ca41692f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_43a155c5-b56c-4be5-9d5b-8abf588549a0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_CityAreaCode_43a155c5-b56c-4be5-9d5b-8abf588549a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_bd48ceaf-a820-4dbd-8f71-ce7ee6feba1c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_LocalPhoneNumber_bd48ceaf-a820-4dbd-8f71-ce7ee6feba1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3a8f1430-9a4e-41e0-981f-13885bef4dbc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_Security12bTitle_3a8f1430-9a4e-41e0-981f-13885bef4dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a93f765f-6445-4297-b24c-929151818849" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_TradingSymbol_a93f765f-6445-4297-b24c-929151818849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2283c3dc-1989-483e-90ea-37a8569370ed" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_SecurityExchangeName_2283c3dc-1989-483e-90ea-37a8569370ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_f1cb1d2e-ae3c-4728-9158-9005c07168c2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_EntityCurrentReportingStatus_f1cb1d2e-ae3c-4728-9158-9005c07168c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_395abe0b-1907-42f6-bd60-b681a0924e15" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_EntityInteractiveDataCurrent_395abe0b-1907-42f6-bd60-b681a0924e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d28542ca-f73d-472a-9106-341902fddaa3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_EntityFilerCategory_d28542ca-f73d-472a-9106-341902fddaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_175c7c44-6f47-4a59-9fc3-9e03c954ead8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_EntitySmallBusiness_175c7c44-6f47-4a59-9fc3-9e03c954ead8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_791fc699-7491-461d-a445-d2cbea38c7a5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_EntityEmergingGrowthCompany_791fc699-7491-461d-a445-d2cbea38c7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_6a872767-22ef-4d7b-af3a-9e1069f1e108" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_EntityShellCompany_6a872767-22ef-4d7b-af3a-9e1069f1e108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d4ecaab9-d491-4113-99f7-1a0d2ee7c7e6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d4ecaab9-d491-4113-99f7-1a0d2ee7c7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7d565a61-bf62-404c-8571-91fde472c09a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_EntityCentralIndexKey_7d565a61-bf62-404c-8571-91fde472c09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_490fcadb-f69e-437e-9db2-137f9e5dd536" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_CurrentFiscalYearEndDate_490fcadb-f69e-437e-9db2-137f9e5dd536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_bf4e77fb-5d66-47db-bf5b-e2bbc7af0726" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_DocumentFiscalYearFocus_bf4e77fb-5d66-47db-bf5b-e2bbc7af0726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_63abaac6-3b9e-4d0a-9391-2a8bcebd3423" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_DocumentFiscalPeriodFocus_63abaac6-3b9e-4d0a-9391-2a8bcebd3423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1e120886-aa4c-4a8a-8d66-885dcea36ae8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_da47e50a-7d0b-4a4e-9a88-54368a093456" xlink:to="loc_dei_AmendmentFlag_1e120886-aa4c-4a8a-8d66-885dcea36ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ccrn-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b445d639-04d7-4926-bf7c-965677855c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_7ae7e826-e5a5-4bb9-bb1d-708d4749f264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b445d639-04d7-4926-bf7c-965677855c3e" xlink:to="loc_us-gaap_AssetsAbstract_7ae7e826-e5a5-4bb9-bb1d-708d4749f264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_296a2e2d-f641-4c35-b348-d20a52d1d90f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7ae7e826-e5a5-4bb9-bb1d-708d4749f264" xlink:to="loc_us-gaap_AssetsCurrentAbstract_296a2e2d-f641-4c35-b348-d20a52d1d90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8bd7fadd-62ed-4976-bdb7-ffecfb338c91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_296a2e2d-f641-4c35-b348-d20a52d1d90f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8bd7fadd-62ed-4976-bdb7-ffecfb338c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dce2b386-c66b-466c-9cab-f6dc0063389c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_296a2e2d-f641-4c35-b348-d20a52d1d90f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dce2b386-c66b-466c-9cab-f6dc0063389c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_017125b0-adff-469d-a1d5-c361bb4bf4af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_296a2e2d-f641-4c35-b348-d20a52d1d90f" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_017125b0-adff-469d-a1d5-c361bb4bf4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceSettlementsReceivableCurrent_5312008d-935c-46aa-bb03-f5cb345e78f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceSettlementsReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_296a2e2d-f641-4c35-b348-d20a52d1d90f" xlink:to="loc_us-gaap_InsuranceSettlementsReceivableCurrent_5312008d-935c-46aa-bb03-f5cb345e78f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_a255e1b9-0b82-41ec-b749-3a5e34a8b474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_296a2e2d-f641-4c35-b348-d20a52d1d90f" xlink:to="loc_us-gaap_OtherAssetsCurrent_a255e1b9-0b82-41ec-b749-3a5e34a8b474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a9cf856b-d2b2-4b1f-ab19-74bf0eb0ce23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_296a2e2d-f641-4c35-b348-d20a52d1d90f" xlink:to="loc_us-gaap_AssetsCurrent_a9cf856b-d2b2-4b1f-ab19-74bf0eb0ce23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_09597d87-2e35-4a6b-add7-003cfc363a12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7ae7e826-e5a5-4bb9-bb1d-708d4749f264" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_09597d87-2e35-4a6b-add7-003cfc363a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_fd694a0b-6b7c-4a07-8387-d19910b47cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7ae7e826-e5a5-4bb9-bb1d-708d4749f264" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_fd694a0b-6b7c-4a07-8387-d19910b47cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a035bbd9-ee0a-49ec-9ad4-e6d589085328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7ae7e826-e5a5-4bb9-bb1d-708d4749f264" xlink:to="loc_us-gaap_Goodwill_a035bbd9-ee0a-49ec-9ad4-e6d589085328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedTradeNames_36357671-c72a-4469-a22d-18c59c22c49c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedTradeNames"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7ae7e826-e5a5-4bb9-bb1d-708d4749f264" xlink:to="loc_us-gaap_IndefiniteLivedTradeNames_36357671-c72a-4469-a22d-18c59c22c49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2d0164d6-61be-4ed7-a44d-2611872a0f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7ae7e826-e5a5-4bb9-bb1d-708d4749f264" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2d0164d6-61be-4ed7-a44d-2611872a0f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_61eac5ea-befc-46a3-94c4-71b532f4a048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7ae7e826-e5a5-4bb9-bb1d-708d4749f264" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_61eac5ea-befc-46a3-94c4-71b532f4a048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4253b902-5c7e-4717-98f1-1bed54cb542f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7ae7e826-e5a5-4bb9-bb1d-708d4749f264" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4253b902-5c7e-4717-98f1-1bed54cb542f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0e4cea0c-1607-4883-af35-b0e12412e69b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7ae7e826-e5a5-4bb9-bb1d-708d4749f264" xlink:to="loc_us-gaap_Assets_0e4cea0c-1607-4883-af35-b0e12412e69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62abbaa2-2d01-4870-82db-1334621b6101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b445d639-04d7-4926-bf7c-965677855c3e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62abbaa2-2d01-4870-82db-1334621b6101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8e4cfac5-c982-4189-97ee-5f9562a36ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62abbaa2-2d01-4870-82db-1334621b6101" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_8e4cfac5-c982-4189-97ee-5f9562a36ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_3f7eb645-a156-4487-8297-44ea435925dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8e4cfac5-c982-4189-97ee-5f9562a36ceb" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_3f7eb645-a156-4487-8297-44ea435925dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9a5e3869-3a00-4b6b-aa38-2a2a8ffb28e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8e4cfac5-c982-4189-97ee-5f9562a36ceb" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9a5e3869-3a00-4b6b-aa38-2a2a8ffb28e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c8b88526-184c-4c9b-8944-14fff124ef63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8e4cfac5-c982-4189-97ee-5f9562a36ceb" xlink:to="loc_us-gaap_LongTermDebtCurrent_c8b88526-184c-4c9b-8944-14fff124ef63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6ea2061e-0a0c-492b-9a4f-f65289fff179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8e4cfac5-c982-4189-97ee-5f9562a36ceb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6ea2061e-0a0c-492b-9a4f-f65289fff179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_9cbad22e-5273-42e4-85c4-8de99da0a638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8e4cfac5-c982-4189-97ee-5f9562a36ceb" xlink:to="loc_us-gaap_TaxesPayableCurrent_9cbad22e-5273-42e4-85c4-8de99da0a638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_895a088d-f673-4fb2-a9ce-f1b187abe6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8e4cfac5-c982-4189-97ee-5f9562a36ceb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_895a088d-f673-4fb2-a9ce-f1b187abe6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_26cc500c-0d37-4995-b5f9-b9da609087ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8e4cfac5-c982-4189-97ee-5f9562a36ceb" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_26cc500c-0d37-4995-b5f9-b9da609087ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_19db3916-bfde-4dcf-8ffd-76027557abcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8e4cfac5-c982-4189-97ee-5f9562a36ceb" xlink:to="loc_us-gaap_LiabilitiesCurrent_19db3916-bfde-4dcf-8ffd-76027557abcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent_2876bcf8-2183-4bec-b28c-a65c00159554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62abbaa2-2d01-4870-82db-1334621b6101" xlink:to="loc_us-gaap_OtherLongTermDebtNoncurrent_2876bcf8-2183-4bec-b28c-a65c00159554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e29fd1d5-748c-45c3-a92c-c99e97d43406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62abbaa2-2d01-4870-82db-1334621b6101" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e29fd1d5-748c-45c3-a92c-c99e97d43406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ea0efe4f-9447-4735-b1ab-e377f74dc4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62abbaa2-2d01-4870-82db-1334621b6101" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ea0efe4f-9447-4735-b1ab-e377f74dc4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_601229de-595c-4112-8200-13bc5badc07f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62abbaa2-2d01-4870-82db-1334621b6101" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_601229de-595c-4112-8200-13bc5badc07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_0468cb94-f3d0-4ada-9028-a91cd7440965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62abbaa2-2d01-4870-82db-1334621b6101" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_0468cb94-f3d0-4ada-9028-a91cd7440965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_34e5cefe-1fc1-4514-9869-d956e3b3b6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62abbaa2-2d01-4870-82db-1334621b6101" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_34e5cefe-1fc1-4514-9869-d956e3b3b6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8d2adb81-8037-466e-afa1-cbf72a809154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62abbaa2-2d01-4870-82db-1334621b6101" xlink:to="loc_us-gaap_Liabilities_8d2adb81-8037-466e-afa1-cbf72a809154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b1040f50-0871-48c4-9e03-a673b93cca5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62abbaa2-2d01-4870-82db-1334621b6101" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b1040f50-0871-48c4-9e03-a673b93cca5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4a283cea-363c-4bb8-a8f4-140afd7cb3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62abbaa2-2d01-4870-82db-1334621b6101" xlink:to="loc_us-gaap_StockholdersEquityAbstract_4a283cea-363c-4bb8-a8f4-140afd7cb3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_95fd67c0-590b-4d72-8d5d-1cdfe7f797b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4a283cea-363c-4bb8-a8f4-140afd7cb3f6" xlink:to="loc_us-gaap_CommonStockValue_95fd67c0-590b-4d72-8d5d-1cdfe7f797b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ae1b73fb-23ec-4f0f-844a-e986ed8afcfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4a283cea-363c-4bb8-a8f4-140afd7cb3f6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ae1b73fb-23ec-4f0f-844a-e986ed8afcfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6866466d-5a60-4e38-ba0a-3398b897f846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4a283cea-363c-4bb8-a8f4-140afd7cb3f6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6866466d-5a60-4e38-ba0a-3398b897f846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2d856da2-2d9b-40ba-9bd9-1dc702ccc1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4a283cea-363c-4bb8-a8f4-140afd7cb3f6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2d856da2-2d9b-40ba-9bd9-1dc702ccc1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4e160ee3-df7b-41af-8f20-5d0e4a032d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4a283cea-363c-4bb8-a8f4-140afd7cb3f6" xlink:to="loc_us-gaap_StockholdersEquity_4e160ee3-df7b-41af-8f20-5d0e4a032d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ef9f1929-c0e9-4c2d-94aa-d8f35161c7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62abbaa2-2d01-4870-82db-1334621b6101" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ef9f1929-c0e9-4c2d-94aa-d8f35161c7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="ccrn-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3f0ed22d-43e5-4363-a88d-65315a776ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_aaa97090-dbb2-4da3-a2a2-6d7550d84f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3f0ed22d-43e5-4363-a88d-65315a776ae0" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_aaa97090-dbb2-4da3-a2a2-6d7550d84f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c390115f-a8f1-4bc3-9e2e-a7bf14ae61ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3f0ed22d-43e5-4363-a88d-65315a776ae0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c390115f-a8f1-4bc3-9e2e-a7bf14ae61ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="ccrn-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_88b28f04-35bf-4d39-92d2-c9ab37b3b487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_37733d3b-678e-493f-8855-6248ce2b7564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88b28f04-35bf-4d39-92d2-c9ab37b3b487" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_37733d3b-678e-493f-8855-6248ce2b7564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f8e71cf7-5bec-49b9-ac10-00e5d70dc768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88b28f04-35bf-4d39-92d2-c9ab37b3b487" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f8e71cf7-5bec-49b9-ac10-00e5d70dc768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d09664ff-21fe-4983-8dac-848f3ddb6e03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88b28f04-35bf-4d39-92d2-c9ab37b3b487" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d09664ff-21fe-4983-8dac-848f3ddb6e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectOperatingCosts_7387ed5f-ab22-4b25-90dd-c1839f3c98da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DirectOperatingCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d09664ff-21fe-4983-8dac-848f3ddb6e03" xlink:to="loc_us-gaap_DirectOperatingCosts_7387ed5f-ab22-4b25-90dd-c1839f3c98da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ae4af4bb-85bc-4273-85b0-f4ec44cebd9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d09664ff-21fe-4983-8dac-848f3ddb6e03" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ae4af4bb-85bc-4273-85b0-f4ec44cebd9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_f9473746-8b8c-4168-aa74-cb6bb0b2db30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d09664ff-21fe-4983-8dac-848f3ddb6e03" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_f9473746-8b8c-4168-aa74-cb6bb0b2db30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_04f910dc-bb2c-4756-a7a7-f7a9f6f16ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d09664ff-21fe-4983-8dac-848f3ddb6e03" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_04f910dc-bb2c-4756-a7a7-f7a9f6f16ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AcquisitionAndIntegrationRelatedCosts_ba4b6099-442e-448f-8e51-ebd20b03e46a" xlink:href="ccrn-20220331.xsd#ccrn_AcquisitionAndIntegrationRelatedCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d09664ff-21fe-4983-8dac-848f3ddb6e03" xlink:to="loc_ccrn_AcquisitionAndIntegrationRelatedCosts_ba4b6099-442e-448f-8e51-ebd20b03e46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_b6c95e7b-ec41-4995-b87a-84f69180e5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d09664ff-21fe-4983-8dac-848f3ddb6e03" xlink:to="loc_us-gaap_RestructuringCharges_b6c95e7b-ec41-4995-b87a-84f69180e5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_8a4f2401-a9fa-4170-a188-b02e5ea8bb37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d09664ff-21fe-4983-8dac-848f3ddb6e03" xlink:to="loc_us-gaap_AssetImpairmentCharges_8a4f2401-a9fa-4170-a188-b02e5ea8bb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_dde4fc16-4d38-4b6d-af18-f811fff4223f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d09664ff-21fe-4983-8dac-848f3ddb6e03" xlink:to="loc_us-gaap_CostsAndExpenses_dde4fc16-4d38-4b6d-af18-f811fff4223f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fc01e21a-476a-465c-8269-5f31bd4582d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88b28f04-35bf-4d39-92d2-c9ab37b3b487" xlink:to="loc_us-gaap_OperatingIncomeLoss_fc01e21a-476a-465c-8269-5f31bd4582d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a7da4dac-1151-4a36-a0ff-8ee1ed6e533c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88b28f04-35bf-4d39-92d2-c9ab37b3b487" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a7da4dac-1151-4a36-a0ff-8ee1ed6e533c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0cf3d199-bc6d-47e3-90f0-31d8f143e6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a7da4dac-1151-4a36-a0ff-8ee1ed6e533c" xlink:to="loc_us-gaap_InterestExpense_0cf3d199-bc6d-47e3-90f0-31d8f143e6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c2766f12-3e6d-4803-bd3b-8731e9d6fd98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a7da4dac-1151-4a36-a0ff-8ee1ed6e533c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c2766f12-3e6d-4803-bd3b-8731e9d6fd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bb9c0829-dff0-485a-a051-36b47c4f482c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88b28f04-35bf-4d39-92d2-c9ab37b3b487" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bb9c0829-dff0-485a-a051-36b47c4f482c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cc288f21-ec9c-4233-9c2c-9ddaa423a65c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88b28f04-35bf-4d39-92d2-c9ab37b3b487" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_cc288f21-ec9c-4233-9c2c-9ddaa423a65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_caaee353-8b4a-4b00-8fbb-54ae7b3b22b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88b28f04-35bf-4d39-92d2-c9ab37b3b487" xlink:to="loc_us-gaap_NetIncomeLoss_caaee353-8b4a-4b00-8fbb-54ae7b3b22b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9702fdcb-7302-4ef6-98d4-53e03bfc7759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88b28f04-35bf-4d39-92d2-c9ab37b3b487" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9702fdcb-7302-4ef6-98d4-53e03bfc7759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_dd6bd6a4-1c9a-45a7-b50a-aa54666ce440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9702fdcb-7302-4ef6-98d4-53e03bfc7759" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_dd6bd6a4-1c9a-45a7-b50a-aa54666ce440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6502edaa-3760-4ef3-aa85-d27ae3aaac99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9702fdcb-7302-4ef6-98d4-53e03bfc7759" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6502edaa-3760-4ef3-aa85-d27ae3aaac99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_13ad15a9-1ff3-4466-ae7e-f5371de9f05a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88b28f04-35bf-4d39-92d2-c9ab37b3b487" xlink:to="loc_us-gaap_EarningsPerShareBasic_13ad15a9-1ff3-4466-ae7e-f5371de9f05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f027afb9-fa62-4a63-9310-8a570f1cf34f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88b28f04-35bf-4d39-92d2-c9ab37b3b487" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f027afb9-fa62-4a63-9310-8a570f1cf34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e80d2a47-5f48-4616-a033-1ce8f172a09e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88b28f04-35bf-4d39-92d2-c9ab37b3b487" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e80d2a47-5f48-4616-a033-1ce8f172a09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7bb61ed1-a08d-45f4-b48b-9b012a54ccc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e80d2a47-5f48-4616-a033-1ce8f172a09e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7bb61ed1-a08d-45f4-b48b-9b012a54ccc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a416eb5f-66a0-4e97-8426-83c62035b712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e80d2a47-5f48-4616-a033-1ce8f172a09e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a416eb5f-66a0-4e97-8426-83c62035b712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ccrn-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_02ab3020-f7e9-4e46-bdb5-2f38f356bcca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d0dd4fdd-74f6-4966-b1a3-7c54817ae87a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_02ab3020-f7e9-4e46-bdb5-2f38f356bcca" xlink:to="loc_us-gaap_StatementTable_d0dd4fdd-74f6-4966-b1a3-7c54817ae87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_772926a3-fa5a-421f-9b3c-d24448711d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d0dd4fdd-74f6-4966-b1a3-7c54817ae87a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_772926a3-fa5a-421f-9b3c-d24448711d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_25ec9992-3ba1-453a-9798-fe86af337bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_772926a3-fa5a-421f-9b3c-d24448711d5a" xlink:to="loc_us-gaap_EquityComponentDomain_25ec9992-3ba1-453a-9798-fe86af337bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_dde0f825-54aa-45d3-9e48-3dfb448f3a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_25ec9992-3ba1-453a-9798-fe86af337bc9" xlink:to="loc_us-gaap_CommonStockMember_dde0f825-54aa-45d3-9e48-3dfb448f3a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cd1c7783-e44a-4d35-99cb-cb201c8826aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_25ec9992-3ba1-453a-9798-fe86af337bc9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cd1c7783-e44a-4d35-99cb-cb201c8826aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f1333c8-0caa-4ea3-a9bd-91601a7d6db3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_25ec9992-3ba1-453a-9798-fe86af337bc9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f1333c8-0caa-4ea3-a9bd-91601a7d6db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2b7cb24d-7e50-46c4-9f05-0147d174520c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_25ec9992-3ba1-453a-9798-fe86af337bc9" xlink:to="loc_us-gaap_RetainedEarningsMember_2b7cb24d-7e50-46c4-9f05-0147d174520c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_257092cd-6178-42a1-8f98-3af950b133fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_25ec9992-3ba1-453a-9798-fe86af337bc9" xlink:to="loc_us-gaap_NoncontrollingInterestMember_257092cd-6178-42a1-8f98-3af950b133fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_72c1451e-e60b-4815-aeb5-157f6b8302a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d0dd4fdd-74f6-4966-b1a3-7c54817ae87a" xlink:to="loc_us-gaap_StatementLineItems_72c1451e-e60b-4815-aeb5-157f6b8302a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_277ba291-ec80-4262-842a-18848db97be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72c1451e-e60b-4815-aeb5-157f6b8302a1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_277ba291-ec80-4262-842a-18848db97be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_8ddde697-7d90-49cf-811e-ec3c99b0a6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_277ba291-ec80-4262-842a-18848db97be8" xlink:to="loc_us-gaap_SharesOutstanding_8ddde697-7d90-49cf-811e-ec3c99b0a6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f151e666-7e9d-4599-8c0b-80de184acf75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_277ba291-ec80-4262-842a-18848db97be8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f151e666-7e9d-4599-8c0b-80de184acf75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c7f97412-90bb-499d-ab6e-a42c3bbf4d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_277ba291-ec80-4262-842a-18848db97be8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c7f97412-90bb-499d-ab6e-a42c3bbf4d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a047c7c1-3287-4e8d-9b2d-7f6c338469fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_277ba291-ec80-4262-842a-18848db97be8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a047c7c1-3287-4e8d-9b2d-7f6c338469fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_baa0f66c-dc09-428b-a118-57b117769f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_277ba291-ec80-4262-842a-18848db97be8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_baa0f66c-dc09-428b-a118-57b117769f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_618fdb02-bb17-4750-ba95-c60c1306b437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_277ba291-ec80-4262-842a-18848db97be8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_618fdb02-bb17-4750-ba95-c60c1306b437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c7267a43-310a-434a-a8b5-12c26fa3ddd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_277ba291-ec80-4262-842a-18848db97be8" xlink:to="loc_us-gaap_NetIncomeLoss_c7267a43-310a-434a-a8b5-12c26fa3ddd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d1f7092d-a8b6-45b5-a1fb-3a6a8689019a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_277ba291-ec80-4262-842a-18848db97be8" xlink:to="loc_us-gaap_SharesOutstanding_d1f7092d-a8b6-45b5-a1fb-3a6a8689019a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f678beea-0698-497f-ac79-5df9e7e3c593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_277ba291-ec80-4262-842a-18848db97be8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f678beea-0698-497f-ac79-5df9e7e3c593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ccrn-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_33fab41c-3985-4bd2-9fb2-cbabed0c7554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ef60b4bd-057a-4dd2-95a8-6773e7df3b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_33fab41c-3985-4bd2-9fb2-cbabed0c7554" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ef60b4bd-057a-4dd2-95a8-6773e7df3b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2214207e-38a2-4e78-9651-a28a401bdff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ef60b4bd-057a-4dd2-95a8-6773e7df3b7e" xlink:to="loc_us-gaap_NetIncomeLoss_2214207e-38a2-4e78-9651-a28a401bdff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80af6d17-77d9-44c7-86ee-a85b02b49558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ef60b4bd-057a-4dd2-95a8-6773e7df3b7e" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80af6d17-77d9-44c7-86ee-a85b02b49558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b24ce096-e292-4b01-b1a2-32b60942fc45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80af6d17-77d9-44c7-86ee-a85b02b49558" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b24ce096-e292-4b01-b1a2-32b60942fc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances_916be082-f470-4096-9242-dcee2b86d574" xlink:href="ccrn-20220331.xsd#ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80af6d17-77d9-44c7-86ee-a85b02b49558" xlink:to="loc_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances_916be082-f470-4096-9242-dcee2b86d574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_63db140b-dfa2-4a2e-be76-db322b209c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80af6d17-77d9-44c7-86ee-a85b02b49558" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_63db140b-dfa2-4a2e-be76-db322b209c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OperatingLeaseExpenseNonCash_97b81643-4dc6-4c45-8add-3b821bac2b3f" xlink:href="ccrn-20220331.xsd#ccrn_OperatingLeaseExpenseNonCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80af6d17-77d9-44c7-86ee-a85b02b49558" xlink:to="loc_ccrn_OperatingLeaseExpenseNonCash_97b81643-4dc6-4c45-8add-3b821bac2b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_0497f7af-8e17-4f4c-a3db-6bb0b86f2409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80af6d17-77d9-44c7-86ee-a85b02b49558" xlink:to="loc_us-gaap_AssetImpairmentCharges_0497f7af-8e17-4f4c-a3db-6bb0b86f2409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e5d6018d-6e46-479f-8bcc-de10d2e17f70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80af6d17-77d9-44c7-86ee-a85b02b49558" xlink:to="loc_us-gaap_ShareBasedCompensation_e5d6018d-6e46-479f-8bcc-de10d2e17f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_53e7c963-2f90-4015-b288-7d58c64ff01e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80af6d17-77d9-44c7-86ee-a85b02b49558" xlink:to="loc_us-gaap_OtherNoncashExpense_53e7c963-2f90-4015-b288-7d58c64ff01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae0a482f-db61-40af-b31a-63fc5464d47b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80af6d17-77d9-44c7-86ee-a85b02b49558" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae0a482f-db61-40af-b31a-63fc5464d47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_560ed914-b313-4f43-af5d-46878d1a2cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae0a482f-db61-40af-b31a-63fc5464d47b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_560ed914-b313-4f43-af5d-46878d1a2cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0b3ca654-b68e-4a0f-b61c-b96ead91a1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae0a482f-db61-40af-b31a-63fc5464d47b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0b3ca654-b68e-4a0f-b61c-b96ead91a1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_947ae3f9-467b-4bb9-91b4-c3871cbaa581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae0a482f-db61-40af-b31a-63fc5464d47b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_947ae3f9-467b-4bb9-91b4-c3871cbaa581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a44028da-35a0-41d2-b260-980dc09d052d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae0a482f-db61-40af-b31a-63fc5464d47b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a44028da-35a0-41d2-b260-980dc09d052d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities_fe6fa8ea-1c44-4f18-a931-82fd7afa7e4a" xlink:href="ccrn-20220331.xsd#ccrn_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae0a482f-db61-40af-b31a-63fc5464d47b" xlink:to="loc_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities_fe6fa8ea-1c44-4f18-a931-82fd7afa7e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_507cc92f-2ffa-4cd2-aa7a-085ef59de70b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae0a482f-db61-40af-b31a-63fc5464d47b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_507cc92f-2ffa-4cd2-aa7a-085ef59de70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fded6a0a-cec0-4831-82fd-64a064b00733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ef60b4bd-057a-4dd2-95a8-6773e7df3b7e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fded6a0a-cec0-4831-82fd-64a064b00733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_657b613e-0977-451a-8f63-7caebb9439dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_33fab41c-3985-4bd2-9fb2-cbabed0c7554" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_657b613e-0977-451a-8f63-7caebb9439dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bdcf157e-ff81-4e68-b52d-551aae8a1ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_657b613e-0977-451a-8f63-7caebb9439dc" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bdcf157e-ff81-4e68-b52d-551aae8a1ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e98d869b-ef8f-4925-aa52-68f560057719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_657b613e-0977-451a-8f63-7caebb9439dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e98d869b-ef8f-4925-aa52-68f560057719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c2c54539-d57a-4365-ad63-c493b6be5d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_33fab41c-3985-4bd2-9fb2-cbabed0c7554" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c2c54539-d57a-4365-ad63-c493b6be5d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_1ec94799-6538-4b23-9027-9c0ee8e38451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c2c54539-d57a-4365-ad63-c493b6be5d48" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_1ec94799-6538-4b23-9027-9c0ee8e38451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_96f9126f-b2b1-455f-a90a-99f154637487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c2c54539-d57a-4365-ad63-c493b6be5d48" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_96f9126f-b2b1-455f-a90a-99f154637487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_f4f0b145-160c-496c-b54d-35b3e0018a34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c2c54539-d57a-4365-ad63-c493b6be5d48" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_f4f0b145-160c-496c-b54d-35b3e0018a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_d0406be6-48a8-43b4-92f3-145680a97eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c2c54539-d57a-4365-ad63-c493b6be5d48" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_d0406be6-48a8-43b4-92f3-145680a97eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4f30158c-4e7a-4b01-bf4f-6cf5b23a7b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c2c54539-d57a-4365-ad63-c493b6be5d48" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4f30158c-4e7a-4b01-bf4f-6cf5b23a7b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_e196a4eb-f828-447c-af60-cf32fe542b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c2c54539-d57a-4365-ad63-c493b6be5d48" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_e196a4eb-f828-447c-af60-cf32fe542b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_112a19a2-0d4d-4573-9c01-633cdffb5e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c2c54539-d57a-4365-ad63-c493b6be5d48" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_112a19a2-0d4d-4573-9c01-633cdffb5e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb9def0d-11e9-4828-891b-61c9422f419b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c2c54539-d57a-4365-ad63-c493b6be5d48" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb9def0d-11e9-4828-891b-61c9422f419b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_48947ba7-5896-4228-ba01-f4d79db0af01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_33fab41c-3985-4bd2-9fb2-cbabed0c7554" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_48947ba7-5896-4228-ba01-f4d79db0af01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f05351b2-419a-47cc-852c-bb86c78f446d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_33fab41c-3985-4bd2-9fb2-cbabed0c7554" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f05351b2-419a-47cc-852c-bb86c78f446d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_343d4341-3ea2-42f5-9c88-aedacb4bff6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_33fab41c-3985-4bd2-9fb2-cbabed0c7554" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_343d4341-3ea2-42f5-9c88-aedacb4bff6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_47ab7c8e-868c-4c8c-844b-99373e58665e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_33fab41c-3985-4bd2-9fb2-cbabed0c7554" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_47ab7c8e-868c-4c8c-844b-99373e58665e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATION" xlink:type="simple" xlink:href="ccrn-20220331.xsd#ORGANIZATIONANDBASISOFPRESENTATION"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8ff32675-317e-4982-b33d-89a2b2732f47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_48c9f75b-a513-453f-b75a-66521f99a921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8ff32675-317e-4982-b33d-89a2b2732f47" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_48c9f75b-a513-453f-b75a-66521f99a921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="ccrn-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_18cca8c6-4852-4dc2-a41f-e0738d019cde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_05bd3bff-f570-4993-b9c9-302d475db6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18cca8c6-4852-4dc2-a41f-e0738d019cde" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_05bd3bff-f570-4993-b9c9-302d475db6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="ccrn-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_498a2b27-0b16-41d1-b442-2d5acdbc1e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_14456bb1-6cc2-427c-9f13-ddd35aea08a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_498a2b27-0b16-41d1-b442-2d5acdbc1e8a" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_14456bb1-6cc2-427c-9f13-ddd35aea08a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_917a4381-e75b-4439-95bf-354663454185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_498a2b27-0b16-41d1-b442-2d5acdbc1e8a" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_917a4381-e75b-4439-95bf-354663454185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_1965d255-b3f2-4f3f-8444-e382dca76247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_498a2b27-0b16-41d1-b442-2d5acdbc1e8a" xlink:to="loc_us-gaap_UseOfEstimates_1965d255-b3f2-4f3f-8444-e382dca76247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_0645b652-c421-46c9-8d51-e1f15a2c8684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_498a2b27-0b16-41d1-b442-2d5acdbc1e8a" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_0645b652-c421-46c9-8d51-e1f15a2c8684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_7e3b75ee-3f47-4078-8aa6-e247e0809068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_498a2b27-0b16-41d1-b442-2d5acdbc1e8a" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_7e3b75ee-3f47-4078-8aa6-e247e0809068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d888a76d-8477-4272-bede-17a6fbc925c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_498a2b27-0b16-41d1-b442-2d5acdbc1e8a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d888a76d-8477-4272-bede-17a6fbc925c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="ccrn-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a5a9b11f-3354-4800-8560-c2e6171c5c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_95f2dd03-b11f-4a7d-9590-dc042e5dadd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a5a9b11f-3354-4800-8560-c2e6171c5c82" xlink:to="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_95f2dd03-b11f-4a7d-9590-dc042e5dadd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_43dc8238-1396-4bee-96cd-60c57cdc48b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a5a9b11f-3354-4800-8560-c2e6171c5c82" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_43dc8238-1396-4bee-96cd-60c57cdc48b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b126a5c3-acb8-49a4-a0a2-0cceb5befe4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0476c760-d54d-4c58-856e-8c9b8b6122fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b126a5c3-acb8-49a4-a0a2-0cceb5befe4f" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0476c760-d54d-4c58-856e-8c9b8b6122fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_272340ef-f12b-473f-a330-89bf6a61e5c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0476c760-d54d-4c58-856e-8c9b8b6122fc" xlink:to="loc_srt_RangeAxis_272340ef-f12b-473f-a330-89bf6a61e5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1c9910f6-d30c-479a-81c1-ec100b897cc8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_272340ef-f12b-473f-a330-89bf6a61e5c3" xlink:to="loc_srt_RangeMember_1c9910f6-d30c-479a-81c1-ec100b897cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6bef987c-6118-4390-92da-ab8bdb8d6194" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1c9910f6-d30c-479a-81c1-ec100b897cc8" xlink:to="loc_srt_MinimumMember_6bef987c-6118-4390-92da-ab8bdb8d6194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a0202dc7-58ab-4aef-949f-8b351a91365e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1c9910f6-d30c-479a-81c1-ec100b897cc8" xlink:to="loc_srt_MaximumMember_a0202dc7-58ab-4aef-949f-8b351a91365e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_98343c2e-7e88-44f6-9c5c-fae3d0ad5348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_0476c760-d54d-4c58-856e-8c9b8b6122fc" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_98343c2e-7e88-44f6-9c5c-fae3d0ad5348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_712a7b5b-eda5-431c-99f8-b180446bf905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_98343c2e-7e88-44f6-9c5c-fae3d0ad5348" xlink:to="loc_us-gaap_UnbilledContractsReceivable_712a7b5b-eda5-431c-99f8-b180446bf905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SalesAllowanceBillingRelatedAdjustments_177138f2-71b5-4c1d-a88c-9ce7229ea5d5" xlink:href="ccrn-20220331.xsd#ccrn_SalesAllowanceBillingRelatedAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_98343c2e-7e88-44f6-9c5c-fae3d0ad5348" xlink:to="loc_ccrn_SalesAllowanceBillingRelatedAdjustments_177138f2-71b5-4c1d-a88c-9ce7229ea5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided_dbba19ce-eac0-48c7-82e8-d08d7502b1fe" xlink:href="ccrn-20220331.xsd#ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_98343c2e-7e88-44f6-9c5c-fae3d0ad5348" xlink:to="loc_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided_dbba19ce-eac0-48c7-82e8-d08d7502b1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAllowanceforDoubtfulAccountsDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAllowanceforDoubtfulAccountsDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAllowanceforDoubtfulAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_535c675d-121e-44b1-8a07-c66b8fb5d9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_c58cbb5e-b081-481c-af8c-06030c76b109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_535c675d-121e-44b1-8a07-c66b8fb5d9b6" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_c58cbb5e-b081-481c-af8c-06030c76b109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_4bfccf56-698d-4d10-a7d9-540b5d3086e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_c58cbb5e-b081-481c-af8c-06030c76b109" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_4bfccf56-698d-4d10-a7d9-540b5d3086e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_9d1aed38-b0a2-410e-9bb6-9c5f48a5946e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_c58cbb5e-b081-481c-af8c-06030c76b109" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_9d1aed38-b0a2-410e-9bb6-9c5f48a5946e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_a038755c-181f-49ed-a54b-211eb18cb242" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_c58cbb5e-b081-481c-af8c-06030c76b109" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_a038755c-181f-49ed-a54b-211eb18cb242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_d37c6a65-bce3-49ef-bb56-993c612d1769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_c58cbb5e-b081-481c-af8c-06030c76b109" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_d37c6a65-bce3-49ef-bb56-993c612d1769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringCostsDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringCostsDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7e89066a-19d7-4d24-83b5-328d5fb18574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4989ed8f-edab-443d-b06c-30f8632281fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e89066a-19d7-4d24-83b5-328d5fb18574" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4989ed8f-edab-443d-b06c-30f8632281fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1307265f-db45-4791-92b0-5ef4fb7b8d54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4989ed8f-edab-443d-b06c-30f8632281fd" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1307265f-db45-4791-92b0-5ef4fb7b8d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_de0fd2c7-d804-410d-a95c-f5f3bd4089f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1307265f-db45-4791-92b0-5ef4fb7b8d54" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_de0fd2c7-d804-410d-a95c-f5f3bd4089f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_b07bc6b1-e0e0-45c7-9908-bd5ee91cf06d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_de0fd2c7-d804-410d-a95c-f5f3bd4089f5" xlink:to="loc_us-gaap_EmployeeSeveranceMember_b07bc6b1-e0e0-45c7-9908-bd5ee91cf06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ExitCostsMember_43b1d9b0-ba53-4e32-876f-95a92f7952db" xlink:href="ccrn-20220331.xsd#ccrn_ExitCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_de0fd2c7-d804-410d-a95c-f5f3bd4089f5" xlink:to="loc_ccrn_ExitCostsMember_43b1d9b0-ba53-4e32-876f-95a92f7952db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_db59cc9b-7e1d-463d-8cff-d3726a81bf51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4989ed8f-edab-443d-b06c-30f8632281fd" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_db59cc9b-7e1d-463d-8cff-d3726a81bf51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_c8d13a6e-98a6-4a49-be89-694b7a6a87c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_db59cc9b-7e1d-463d-8cff-d3726a81bf51" xlink:to="loc_us-gaap_RestructuringReserveRollForward_c8d13a6e-98a6-4a49-be89-694b7a6a87c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_4d46f57b-c37a-4133-ba49-926137a83a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c8d13a6e-98a6-4a49-be89-694b7a6a87c8" xlink:to="loc_us-gaap_RestructuringReserve_4d46f57b-c37a-4133-ba49-926137a83a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_af79bd77-1d8b-4a5c-bfbb-abea4f6e523d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c8d13a6e-98a6-4a49-be89-694b7a6a87c8" xlink:to="loc_us-gaap_RestructuringCharges_af79bd77-1d8b-4a5c-bfbb-abea4f6e523d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_PaymentsForRestructuringAndAdjustments_3923df69-2cb4-45c8-8f70-007e2105ec4c" xlink:href="ccrn-20220331.xsd#ccrn_PaymentsForRestructuringAndAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c8d13a6e-98a6-4a49-be89-694b7a6a87c8" xlink:to="loc_ccrn_PaymentsForRestructuringAndAdjustments_3923df69-2cb4-45c8-8f70-007e2105ec4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_6c57f751-32b2-44af-9cbc-c65971943eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c8d13a6e-98a6-4a49-be89-694b7a6a87c8" xlink:to="loc_us-gaap_RestructuringReserve_6c57f751-32b2-44af-9cbc-c65971943eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/REVENUERECOGNITION" xlink:type="simple" xlink:href="ccrn-20220331.xsd#REVENUERECOGNITION"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/REVENUERECOGNITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_85106c84-1680-4066-99fe-e74aa157492b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_631b75a1-8c17-447b-8ce3-e66211d94207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_85106c84-1680-4066-99fe-e74aa157492b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_631b75a1-8c17-447b-8ce3-e66211d94207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONTables" xlink:type="simple" xlink:href="ccrn-20220331.xsd#REVENUERECOGNITIONTables"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9c89a7a9-b2bd-4e82-8562-53dd4edd7020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_868bc831-fa2a-43ad-a9a6-e4459a35500e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9c89a7a9-b2bd-4e82-8562-53dd4edd7020" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_868bc831-fa2a-43ad-a9a6-e4459a35500e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#REVENUERECOGNITIONDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_52c3770b-4639-40df-98a6-cf3b64bc2aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_8ad51106-7808-45bb-8392-cc2596c8a36f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_52c3770b-4639-40df-98a6-cf3b64bc2aea" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_8ad51106-7808-45bb-8392-cc2596c8a36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3397fc6e-02fd-4646-8df9-b01362853989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8ad51106-7808-45bb-8392-cc2596c8a36f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3397fc6e-02fd-4646-8df9-b01362853989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d803d0c9-0ee1-4b3a-a551-ce3d90c28121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3397fc6e-02fd-4646-8df9-b01362853989" xlink:to="loc_us-gaap_SegmentDomain_d803d0c9-0ee1-4b3a-a551-ce3d90c28121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NurseAndAlliedStaffingMember_de820d37-e081-49cf-922d-a7ed901968de" xlink:href="ccrn-20220331.xsd#ccrn_NurseAndAlliedStaffingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d803d0c9-0ee1-4b3a-a551-ce3d90c28121" xlink:to="loc_ccrn_NurseAndAlliedStaffingMember_de820d37-e081-49cf-922d-a7ed901968de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_PhysicianStaffingMember_943cc010-3e30-44d3-b9ef-e06997da0031" xlink:href="ccrn-20220331.xsd#ccrn_PhysicianStaffingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d803d0c9-0ee1-4b3a-a551-ce3d90c28121" xlink:to="loc_ccrn_PhysicianStaffingMember_943cc010-3e30-44d3-b9ef-e06997da0031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5151b80e-c395-462b-aa18-76fef703a8c2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8ad51106-7808-45bb-8392-cc2596c8a36f" xlink:to="loc_srt_ProductOrServiceAxis_5151b80e-c395-462b-aa18-76fef703a8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_87b7461c-2fd8-438e-aa62-6697cbf880f3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5151b80e-c395-462b-aa18-76fef703a8c2" xlink:to="loc_srt_ProductsAndServicesDomain_87b7461c-2fd8-438e-aa62-6697cbf880f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_TemporaryStaffingServicesMember_274b90c4-4de2-44e5-87b6-c7e2e4c5fb6e" xlink:href="ccrn-20220331.xsd#ccrn_TemporaryStaffingServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_87b7461c-2fd8-438e-aa62-6697cbf880f3" xlink:to="loc_ccrn_TemporaryStaffingServicesMember_274b90c4-4de2-44e5-87b6-c7e2e4c5fb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OtherServicesMember_3eff6412-d3ea-4eda-98c5-416022b0bb3e" xlink:href="ccrn-20220331.xsd#ccrn_OtherServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_87b7461c-2fd8-438e-aa62-6697cbf880f3" xlink:to="loc_ccrn_OtherServicesMember_3eff6412-d3ea-4eda-98c5-416022b0bb3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_515c9487-81f8-4095-876d-dc2058b9e309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8ad51106-7808-45bb-8392-cc2596c8a36f" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_515c9487-81f8-4095-876d-dc2058b9e309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e8cd2861-938b-4a15-9b19-6d7baa450821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_515c9487-81f8-4095-876d-dc2058b9e309" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e8cd2861-938b-4a15-9b19-6d7baa450821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/ACQUISITIONS" xlink:type="simple" xlink:href="ccrn-20220331.xsd#ACQUISITIONS"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/ACQUISITIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_05b6d9d1-b3fd-4c5d-9b91-57b445875975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_5cfc10ad-3a5a-41b0-b46f-295419daf873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_05b6d9d1-b3fd-4c5d-9b91-57b445875975" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_5cfc10ad-3a5a-41b0-b46f-295419daf873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/ACQUISITIONSTables" xlink:type="simple" xlink:href="ccrn-20220331.xsd#ACQUISITIONSTables"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/ACQUISITIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_bae94ea4-00ae-43b5-9467-41de9aa498b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_87d30888-97f9-4be9-a092-3b1592ca4423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_bae94ea4-00ae-43b5-9467-41de9aa498b7" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_87d30888-97f9-4be9-a092-3b1592ca4423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#ACQUISITIONSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_36135017-6a97-4c59-a8c0-7ff77bb3bed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2311a09a-9dcd-4907-bc9d-7a2350b23d27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_36135017-6a97-4c59-a8c0-7ff77bb3bed8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2311a09a-9dcd-4907-bc9d-7a2350b23d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a910a12c-adb1-4dfa-bbda-9cff9df00ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2311a09a-9dcd-4907-bc9d-7a2350b23d27" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a910a12c-adb1-4dfa-bbda-9cff9df00ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_386a0db8-e86c-4fec-a52c-24fcbc08c7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a910a12c-adb1-4dfa-bbda-9cff9df00ca1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_386a0db8-e86c-4fec-a52c-24fcbc08c7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SelectedIncMember_b9b7ff5c-291b-4791-9a04-a52a40514aa3" xlink:href="ccrn-20220331.xsd#ccrn_SelectedIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_386a0db8-e86c-4fec-a52c-24fcbc08c7ae" xlink:to="loc_ccrn_SelectedIncMember_b9b7ff5c-291b-4791-9a04-a52a40514aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_WorkforceSolutionsGroupIncMember_42f8451f-7c07-4bfa-aaf8-c47745c5a63e" xlink:href="ccrn-20220331.xsd#ccrn_WorkforceSolutionsGroupIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_386a0db8-e86c-4fec-a52c-24fcbc08c7ae" xlink:to="loc_ccrn_WorkforceSolutionsGroupIncMember_42f8451f-7c07-4bfa-aaf8-c47745c5a63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_MediscanMember_3b5d57c4-2bed-45f5-b924-566fc88da6d3" xlink:href="ccrn-20220331.xsd#ccrn_MediscanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_386a0db8-e86c-4fec-a52c-24fcbc08c7ae" xlink:to="loc_ccrn_MediscanMember_3b5d57c4-2bed-45f5-b924-566fc88da6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_35bf8445-7b7a-482e-a3e6-6b25b0279853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2311a09a-9dcd-4907-bc9d-7a2350b23d27" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_35bf8445-7b7a-482e-a3e6-6b25b0279853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a139f510-6dfc-4b23-8a03-e4049b098b78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_35bf8445-7b7a-482e-a3e6-6b25b0279853" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a139f510-6dfc-4b23-8a03-e4049b098b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_82091444-d5d8-43e0-a271-b56f87eaa53a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a139f510-6dfc-4b23-8a03-e4049b098b78" xlink:to="loc_us-gaap_CustomerRelationshipsMember_82091444-d5d8-43e0-a271-b56f87eaa53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b1d352d4-035a-4a0d-becf-321f07470912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2311a09a-9dcd-4907-bc9d-7a2350b23d27" xlink:to="loc_us-gaap_DebtInstrumentAxis_b1d352d4-035a-4a0d-becf-321f07470912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_97bb2fef-e116-4dc1-95fb-e12d357af202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1d352d4-035a-4a0d-becf-321f07470912" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_97bb2fef-e116-4dc1-95fb-e12d357af202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_EarnoutNotesPayableMember_879057c3-ed0c-4a93-bbb9-1358df207c7a" xlink:href="ccrn-20220331.xsd#ccrn_EarnoutNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_97bb2fef-e116-4dc1-95fb-e12d357af202" xlink:to="loc_ccrn_EarnoutNotesPayableMember_879057c3-ed0c-4a93-bbb9-1358df207c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2311a09a-9dcd-4907-bc9d-7a2350b23d27" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_962e10c6-3116-40d3-980c-4f2782d58774" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_962e10c6-3116-40d3-980c-4f2782d58774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_acc50c1f-c6b6-48dd-8c4a-6d08a1e3c397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_acc50c1f-c6b6-48dd-8c4a-6d08a1e3c397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0f96d9ff-0c91-41dc-a971-fb8bcf25196d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0f96d9ff-0c91-41dc-a971-fb8bcf25196d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_268a6a7a-9767-4dc6-8c79-d95db05afd60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_268a6a7a-9767-4dc6-8c79-d95db05afd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_36e5a841-f531-4ca1-9d96-b38cdb0918dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_us-gaap_Goodwill_36e5a841-f531-4ca1-9d96-b38cdb0918dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment_e57775a9-159f-4a1d-b562-3190d4a28c40" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_ccrn_BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment_e57775a9-159f-4a1d-b562-3190d4a28c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationContingentConsiderationTerm_c54004bd-5ee7-4856-921d-4011bf832f9b" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationContingentConsiderationTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_ccrn_BusinessCombinationContingentConsiderationTerm_c54004bd-5ee7-4856-921d-4011bf832f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0049cd21-bf90-45c5-9006-f517b048c3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0049cd21-bf90-45c5-9006-f517b048c3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_ddf8e812-ce34-4c27-8945-226f9f92981b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_ddf8e812-ce34-4c27-8945-226f9f92981b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_57bf0c6b-0316-414e-bcd2-e790f44bf4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_57bf0c6b-0316-414e-bcd2-e790f44bf4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8eff5799-7a77-42e4-8c05-737cf996e726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8eff5799-7a77-42e4-8c05-737cf996e726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_ad0b6d84-70a9-4210-ad01-323e3351ca25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_us-gaap_NotesPayable_ad0b6d84-70a9-4210-ad01-323e3351ca25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NotePayableNumberOfPaymentInstallments_f1fd6189-f54d-456d-b12a-370119071e4e" xlink:href="ccrn-20220331.xsd#ccrn_NotePayableNumberOfPaymentInstallments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_ccrn_NotePayableNumberOfPaymentInstallments_f1fd6189-f54d-456d-b12a-370119071e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NotePayableNumberOfInstallmentsPaid_069b24b6-8edf-4479-b4bf-85e9a2f76f1f" xlink:href="ccrn-20220331.xsd#ccrn_NotePayableNumberOfInstallmentsPaid"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_ccrn_NotePayableNumberOfInstallmentsPaid_069b24b6-8edf-4479-b4bf-85e9a2f76f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_b5d004ad-648d-486a-92de-d756f05ec4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1ed8130e-88f3-463e-aae8-518481cdaa1e" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_b5d004ad-648d-486a-92de-d756f05ec4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_5e9cb672-1647-4c60-83af-2d20dbea6735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ffa84dd5-c110-4a15-94ce-888c90e82da8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_5e9cb672-1647-4c60-83af-2d20dbea6735" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ffa84dd5-c110-4a15-94ce-888c90e82da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ec487327-e2cf-4a9d-a8fd-d918691942d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ffa84dd5-c110-4a15-94ce-888c90e82da8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ec487327-e2cf-4a9d-a8fd-d918691942d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96d1792d-3cbd-4a94-b9f7-61210e813610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ec487327-e2cf-4a9d-a8fd-d918691942d4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96d1792d-3cbd-4a94-b9f7-61210e813610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_WorkforceSolutionsGroupIncMember_db34c296-c69f-4456-af4b-f5fac1e525dc" xlink:href="ccrn-20220331.xsd#ccrn_WorkforceSolutionsGroupIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96d1792d-3cbd-4a94-b9f7-61210e813610" xlink:to="loc_ccrn_WorkforceSolutionsGroupIncMember_db34c296-c69f-4456-af4b-f5fac1e525dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ffa84dd5-c110-4a15-94ce-888c90e82da8" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_9846b4d7-285d-4b3b-a6d8-c861d7bbff9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_9846b4d7-285d-4b3b-a6d8-c861d7bbff9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_cb1d21e2-8137-451d-aec7-9495f1f01367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_cb1d21e2-8137-451d-aec7-9495f1f01367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_62d5028d-19dd-4a10-88d3-7cb69a52246a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_62d5028d-19dd-4a10-88d3-7cb69a52246a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a7bb3e97-9af4-4f46-8213-10cba508573c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a7bb3e97-9af4-4f46-8213-10cba508573c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_6c20f634-2308-456c-86b8-6b230a59bcef" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_6c20f634-2308-456c-86b8-6b230a59bcef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dff18bcf-1e19-4f63-be2d-50b0a7e637ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_us-gaap_Goodwill_dff18bcf-1e19-4f63-be2d-50b0a7e637ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_a804666a-dfdf-415c-8633-3958c811b7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_a804666a-dfdf-415c-8633-3958c811b7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_b8ad88b8-82a2-4b8e-ab02-e01fbec90522" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill_b8ad88b8-82a2-4b8e-ab02-e01fbec90522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_437654e7-33af-40ab-97e6-c2a3ea765d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_437654e7-33af-40ab-97e6-c2a3ea765d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits_5517014c-baa5-41ff-8f86-a026de3808df" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits_5517014c-baa5-41ff-8f86-a026de3808df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent_07d03d61-e64f-4264-9cd7-dc9e6c99df43" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent_07d03d61-e64f-4264-9cd7-dc9e6c99df43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent_9cfafcd3-e666-4673-bfce-839ddcc9542d" xlink:href="ccrn-20220331.xsd#ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent_9cfafcd3-e666-4673-bfce-839ddcc9542d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_a854a71f-b457-4721-9da1-f5af334510d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_a854a71f-b457-4721-9da1-f5af334510d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_d7e45078-84a6-4c6a-86a4-32145682ff88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_d7e45078-84a6-4c6a-86a4-32145682ff88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_619368ea-cae8-4bd8-8e4b-61ef1ba70ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bc69b13f-1e0a-4993-9b26-c2284473b4b9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_619368ea-cae8-4bd8-8e4b-61ef1ba70ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/COMPREHENSIVEINCOME" xlink:type="simple" xlink:href="ccrn-20220331.xsd#COMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/COMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b5295b11-3ce7-4e67-9700-9032c315e137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_6bfb6be8-156c-45d0-9eda-4c5b86803b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b5295b11-3ce7-4e67-9700-9032c315e137" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_6bfb6be8-156c-45d0-9eda-4c5b86803b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/COMPREHENSIVEINCOMEDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#COMPREHENSIVEINCOMEDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/COMPREHENSIVEINCOMEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7f9f96a3-10f2-456b-8566-5fe697607311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax_8225d649-62b7-429a-9413-4560e67d6f2f" xlink:href="ccrn-20220331.xsd#ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7f9f96a3-10f2-456b-8566-5fe697607311" xlink:to="loc_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax_8225d649-62b7-429a-9413-4560e67d6f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARE" xlink:type="simple" xlink:href="ccrn-20220331.xsd#EARNINGSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fa21c737-3cce-48e2-8f77-7f83fb977958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_30c86705-efbb-48ad-96c9-4da4e4705796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fa21c737-3cce-48e2-8f77-7f83fb977958" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_30c86705-efbb-48ad-96c9-4da4e4705796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARETables" xlink:type="simple" xlink:href="ccrn-20220331.xsd#EARNINGSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3ab7d88c-90da-4739-9cc7-0e56d77b4360" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_53cf7c66-e516-4fa1-b4ba-71e1282e2547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3ab7d88c-90da-4739-9cc7-0e56d77b4360" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_53cf7c66-e516-4fa1-b4ba-71e1282e2547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f0511ed5-e85f-457e-97d3-16fe05941c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_f3ea78d8-eb54-41b6-bbad-618e603fd7be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f0511ed5-e85f-457e-97d3-16fe05941c23" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_f3ea78d8-eb54-41b6-bbad-618e603fd7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b6f08691-eba3-4837-a648-2c02a6749a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_f3ea78d8-eb54-41b6-bbad-618e603fd7be" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b6f08691-eba3-4837-a648-2c02a6749a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_a1c0c478-a77e-4a9d-b29e-7c349c6bfc84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_f3ea78d8-eb54-41b6-bbad-618e603fd7be" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_a1c0c478-a77e-4a9d-b29e-7c349c6bfc84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1fbd998d-dbba-4e0e-87cb-680ed8266a55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f0511ed5-e85f-457e-97d3-16fe05941c23" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1fbd998d-dbba-4e0e-87cb-680ed8266a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8f96216d-6c5a-47bb-9148-3764e7e6d7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1fbd998d-dbba-4e0e-87cb-680ed8266a55" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8f96216d-6c5a-47bb-9148-3764e7e6d7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_3af39132-85eb-4ecf-a166-69d3a61e3d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1fbd998d-dbba-4e0e-87cb-680ed8266a55" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_3af39132-85eb-4ecf-a166-69d3a61e3d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9bf310dd-5f00-42fa-89bb-653929e9d0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_3af39132-85eb-4ecf-a166-69d3a61e3d7e" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9bf310dd-5f00-42fa-89bb-653929e9d0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_79d4ac27-9d1c-4f84-8cdb-07914ae74024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1fbd998d-dbba-4e0e-87cb-680ed8266a55" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_79d4ac27-9d1c-4f84-8cdb-07914ae74024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e909d63c-080b-47f0-9e12-03bc00872854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f0511ed5-e85f-457e-97d3-16fe05941c23" xlink:to="loc_us-gaap_EarningsPerShareBasic_e909d63c-080b-47f0-9e12-03bc00872854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_691f8ceb-7d9b-4153-bc1a-feb220b2727d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f0511ed5-e85f-457e-97d3-16fe05941c23" xlink:to="loc_us-gaap_EarningsPerShareDiluted_691f8ceb-7d9b-4153-bc1a-feb220b2727d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAdditionalInformationDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#EARNINGSPERSHAREAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2bb2d312-2652-4329-8b29-066113284634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_32dfa663-3a2f-44b5-b8b2-70fde141adb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2bb2d312-2652-4329-8b29-066113284634" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_32dfa663-3a2f-44b5-b8b2-70fde141adb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7be2cf7e-590b-4370-a045-e4e913c0ec26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_32dfa663-3a2f-44b5-b8b2-70fde141adb8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7be2cf7e-590b-4370-a045-e4e913c0ec26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_61b35b3e-9203-4c48-849a-bf8f2b6b3e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7be2cf7e-590b-4370-a045-e4e913c0ec26" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_61b35b3e-9203-4c48-849a-bf8f2b6b3e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ShareBasedPaymentAwardsMember_91fa179f-9a94-49c9-bb52-8c5da6791eae" xlink:href="ccrn-20220331.xsd#ccrn_ShareBasedPaymentAwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_61b35b3e-9203-4c48-849a-bf8f2b6b3e69" xlink:to="loc_ccrn_ShareBasedPaymentAwardsMember_91fa179f-9a94-49c9-bb52-8c5da6791eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4c6abd8a-9ca8-4212-a6ad-150e7a8596aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_32dfa663-3a2f-44b5-b8b2-70fde141adb8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4c6abd8a-9ca8-4212-a6ad-150e7a8596aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bb230fbc-4537-445b-a7f5-96181b84d14e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4c6abd8a-9ca8-4212-a6ad-150e7a8596aa" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bb230fbc-4537-445b-a7f5-96181b84d14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETS" xlink:type="simple" xlink:href="ccrn-20220331.xsd#GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETS"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f70dfabb-8059-41fb-b3e9-eecc697e3b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4e473412-5137-4dde-b0f5-1fcf15c94e24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f70dfabb-8059-41fb-b3e9-eecc697e3b20" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4e473412-5137-4dde-b0f5-1fcf15c94e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSTables" xlink:type="simple" xlink:href="ccrn-20220331.xsd#GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSTables"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ee38053d-35c9-438c-b60d-c9ecb5d91ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_0c8b2ea7-7958-416c-a1f9-b4d5b5cd1d39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ee38053d-35c9-438c-b60d-c9ecb5d91ad2" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_0c8b2ea7-7958-416c-a1f9-b4d5b5cd1d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_cd73b43c-4ad8-4767-85ee-c5929b8d7c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ee38053d-35c9-438c-b60d-c9ecb5d91ad2" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_cd73b43c-4ad8-4767-85ee-c5929b8d7c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3b1e03bd-d10c-494d-9733-0762c133ac09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable_ea741ae6-2fa5-49f8-8b00-9c9b7eef5618" xlink:href="ccrn-20220331.xsd#ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3b1e03bd-d10c-494d-9733-0762c133ac09" xlink:to="loc_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable_ea741ae6-2fa5-49f8-8b00-9c9b7eef5618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1ab3d22-98a4-4cde-9ecb-6b4cd5ed757f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable_ea741ae6-2fa5-49f8-8b00-9c9b7eef5618" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1ab3d22-98a4-4cde-9ecb-6b4cd5ed757f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c59943a6-ce03-422e-a2d6-44571cfaa61b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1ab3d22-98a4-4cde-9ecb-6b4cd5ed757f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c59943a6-ce03-422e-a2d6-44571cfaa61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DatabasesMember_0f0aec8c-568c-4b8c-ae13-40ccd4637a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DatabasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c59943a6-ce03-422e-a2d6-44571cfaa61b" xlink:to="loc_us-gaap_DatabasesMember_0f0aec8c-568c-4b8c-ae13-40ccd4637a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_e7239ab5-28ed-4e41-b352-85188ef2b550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c59943a6-ce03-422e-a2d6-44571cfaa61b" xlink:to="loc_us-gaap_CustomerRelationshipsMember_e7239ab5-28ed-4e41-b352-85188ef2b550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_12ec3daf-d976-460a-a5fa-775bb4c708da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c59943a6-ce03-422e-a2d6-44571cfaa61b" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_12ec3daf-d976-460a-a5fa-775bb4c708da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e5b37eb3-e426-418d-8286-e016a6c91a78" xlink:href="ccrn-20220331.xsd#ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable_ea741ae6-2fa5-49f8-8b00-9c9b7eef5618" xlink:to="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e5b37eb3-e426-418d-8286-e016a6c91a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d4334c3d-5685-4d54-87dc-34b266f56f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e5b37eb3-e426-418d-8286-e016a6c91a78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d4334c3d-5685-4d54-87dc-34b266f56f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a7490920-b031-45a6-a74e-062a8b620306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e5b37eb3-e426-418d-8286-e016a6c91a78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a7490920-b031-45a6-a74e-062a8b620306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_009cad77-a92e-42d3-98d9-4709c9b25c36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e5b37eb3-e426-418d-8286-e016a6c91a78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_009cad77-a92e-42d3-98d9-4709c9b25c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedTradeNames_a2f81bc4-8c95-46b5-8c7a-246f827ddf05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedTradeNames"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e5b37eb3-e426-418d-8286-e016a6c91a78" xlink:to="loc_us-gaap_IndefiniteLivedTradeNames_a2f81bc4-8c95-46b5-8c7a-246f827ddf05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d17917b8-7e7b-45ae-b24e-1f39d3dceb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_8991999c-204b-41c9-8d47-00f7846dab1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d17917b8-7e7b-45ae-b24e-1f39d3dceb7f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_8991999c-204b-41c9-8d47-00f7846dab1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9daed45f-49f8-451c-82e4-6b2179a33ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d17917b8-7e7b-45ae-b24e-1f39d3dceb7f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9daed45f-49f8-451c-82e4-6b2179a33ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_994eb307-ced1-4374-bf74-2ed0da142af2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d17917b8-7e7b-45ae-b24e-1f39d3dceb7f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_994eb307-ced1-4374-bf74-2ed0da142af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3d35dfcf-aaf3-4911-8925-ef3ae663919a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d17917b8-7e7b-45ae-b24e-1f39d3dceb7f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3d35dfcf-aaf3-4911-8925-ef3ae663919a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_05780bbc-5173-42f1-ba6d-294bcc4e882f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d17917b8-7e7b-45ae-b24e-1f39d3dceb7f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_05780bbc-5173-42f1-ba6d-294bcc4e882f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_5d0e538a-48cb-49fc-8a12-dc0cc104c0f8" xlink:href="ccrn-20220331.xsd#ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d17917b8-7e7b-45ae-b24e-1f39d3dceb7f" xlink:to="loc_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_5d0e538a-48cb-49fc-8a12-dc0cc104c0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_32e609a6-3623-4fa5-b1b8-f7a6616041ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d17917b8-7e7b-45ae-b24e-1f39d3dceb7f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_32e609a6-3623-4fa5-b1b8-f7a6616041ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d2c219d0-2034-40ea-bc24-c371fac8b0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_3f798ee1-9bdd-4eab-94e5-458a28f7335c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d2c219d0-2034-40ea-bc24-c371fac8b0ac" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_3f798ee1-9bdd-4eab-94e5-458a28f7335c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e7a3febf-2f09-4126-aaa2-36b7b144a233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3f798ee1-9bdd-4eab-94e5-458a28f7335c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e7a3febf-2f09-4126-aaa2-36b7b144a233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5775d41a-3cf3-49a5-8d3b-fd084419b229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e7a3febf-2f09-4126-aaa2-36b7b144a233" xlink:to="loc_us-gaap_SegmentDomain_5775d41a-3cf3-49a5-8d3b-fd084419b229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NurseAndAlliedStaffingMember_2a32ec75-5f28-4f12-a729-9fb13a93ee45" xlink:href="ccrn-20220331.xsd#ccrn_NurseAndAlliedStaffingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5775d41a-3cf3-49a5-8d3b-fd084419b229" xlink:to="loc_ccrn_NurseAndAlliedStaffingMember_2a32ec75-5f28-4f12-a729-9fb13a93ee45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_PhysicianStaffingMember_fc19bb1b-cfd8-44e0-8699-7b31ad748aff" xlink:href="ccrn-20220331.xsd#ccrn_PhysicianStaffingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5775d41a-3cf3-49a5-8d3b-fd084419b229" xlink:to="loc_ccrn_PhysicianStaffingMember_fc19bb1b-cfd8-44e0-8699-7b31ad748aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_7de9579a-ec7b-4852-a402-89e2887a3b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3f798ee1-9bdd-4eab-94e5-458a28f7335c" xlink:to="loc_us-gaap_GoodwillLineItems_7de9579a-ec7b-4852-a402-89e2887a3b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e18d8583-15ed-4b87-bf86-6f978bd887e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_7de9579a-ec7b-4852-a402-89e2887a3b5a" xlink:to="loc_us-gaap_Goodwill_e18d8583-15ed-4b87-bf86-6f978bd887e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/DEBT" xlink:type="simple" xlink:href="ccrn-20220331.xsd#DEBT"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/DEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ddf92300-5716-4285-9ab8-9b12eb913012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_16b1c7d2-ce51-4011-9d71-89558f6cc740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ddf92300-5716-4285-9ab8-9b12eb913012" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_16b1c7d2-ce51-4011-9d71-89558f6cc740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/DEBTTables" xlink:type="simple" xlink:href="ccrn-20220331.xsd#DEBTTables"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/DEBTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1e76a6d7-3059-4264-b881-5fff5da3c8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_e178840f-a20c-4a75-8b67-2a4afa272626" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1e76a6d7-3059-4264-b881-5fff5da3c8ed" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_e178840f-a20c-4a75-8b67-2a4afa272626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_3af84b6a-df12-4852-863f-2ad5a69f4539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1e76a6d7-3059-4264-b881-5fff5da3c8ed" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_3af84b6a-df12-4852-863f-2ad5a69f4539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#DEBTLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1cdf2075-ebc8-4313-8bbf-9e10c6d4499f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c9c8e4be-1de3-466c-82a6-cfcde635c86f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1cdf2075-ebc8-4313-8bbf-9e10c6d4499f" xlink:to="loc_us-gaap_DebtInstrumentTable_c9c8e4be-1de3-466c-82a6-cfcde635c86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2387fdae-ecf5-41b3-a531-b899539e70cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c9c8e4be-1de3-466c-82a6-cfcde635c86f" xlink:to="loc_us-gaap_DebtInstrumentAxis_2387fdae-ecf5-41b3-a531-b899539e70cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b8b1bcda-b0b8-48a5-966d-d32b1065ddeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2387fdae-ecf5-41b3-a531-b899539e70cf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b8b1bcda-b0b8-48a5-966d-d32b1065ddeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_A2021TermLoanCreditAgreementMember_39d466e2-9f05-4777-ba6d-6a36cc4e0c42" xlink:href="ccrn-20220331.xsd#ccrn_A2021TermLoanCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b8b1bcda-b0b8-48a5-966d-d32b1065ddeb" xlink:to="loc_ccrn_A2021TermLoanCreditAgreementMember_39d466e2-9f05-4777-ba6d-6a36cc4e0c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_EarnoutNotesPayableMember_378e990e-e99b-47e7-831f-6dc027fbdc3c" xlink:href="ccrn-20220331.xsd#ccrn_EarnoutNotesPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b8b1bcda-b0b8-48a5-966d-d32b1065ddeb" xlink:to="loc_ccrn_EarnoutNotesPayableMember_378e990e-e99b-47e7-831f-6dc027fbdc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f22300e7-ff2d-40fa-87a8-22498a01e3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c9c8e4be-1de3-466c-82a6-cfcde635c86f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f22300e7-ff2d-40fa-87a8-22498a01e3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dfacb9a2-eb53-4fcc-a8dd-a63e11acf66b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f22300e7-ff2d-40fa-87a8-22498a01e3fe" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dfacb9a2-eb53-4fcc-a8dd-a63e11acf66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_b7f568b7-d1a5-4a47-b501-ee8e345bffc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dfacb9a2-eb53-4fcc-a8dd-a63e11acf66b" xlink:to="loc_us-gaap_SecuredDebtMember_b7f568b7-d1a5-4a47-b501-ee8e345bffc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_3203e8eb-7468-4a22-b904-d5beac12e0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dfacb9a2-eb53-4fcc-a8dd-a63e11acf66b" xlink:to="loc_us-gaap_LineOfCreditMember_3203e8eb-7468-4a22-b904-d5beac12e0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_0d96fe72-9fee-4d35-8960-88f28e5eb3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dfacb9a2-eb53-4fcc-a8dd-a63e11acf66b" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_0d96fe72-9fee-4d35-8960-88f28e5eb3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_99cbe146-6265-4f55-b569-473e8f9c2f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c9c8e4be-1de3-466c-82a6-cfcde635c86f" xlink:to="loc_us-gaap_CreditFacilityAxis_99cbe146-6265-4f55-b569-473e8f9c2f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9c5f3219-48d7-42a9-93e5-015d9e0e0076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_99cbe146-6265-4f55-b569-473e8f9c2f2d" xlink:to="loc_us-gaap_CreditFacilityDomain_9c5f3219-48d7-42a9-93e5-015d9e0e0076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SeniorSecuredAssetBasedLoanMember_861c06bc-2d5c-4f31-a313-dc01007c76c2" xlink:href="ccrn-20220331.xsd#ccrn_SeniorSecuredAssetBasedLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_9c5f3219-48d7-42a9-93e5-015d9e0e0076" xlink:to="loc_ccrn_SeniorSecuredAssetBasedLoanMember_861c06bc-2d5c-4f31-a313-dc01007c76c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4e6e3cda-47d6-4500-a4df-eafd4f6c93f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c9c8e4be-1de3-466c-82a6-cfcde635c86f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4e6e3cda-47d6-4500-a4df-eafd4f6c93f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_45f348ca-578e-4fb5-9a34-6781459e7a42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e6e3cda-47d6-4500-a4df-eafd4f6c93f8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_45f348ca-578e-4fb5-9a34-6781459e7a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cb5fb57d-c9b3-4be2-bae6-54259892e11d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e6e3cda-47d6-4500-a4df-eafd4f6c93f8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cb5fb57d-c9b3-4be2-bae6-54259892e11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_8f1de0a8-caef-46ee-9d47-65710b9b4d33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e6e3cda-47d6-4500-a4df-eafd4f6c93f8" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_8f1de0a8-caef-46ee-9d47-65710b9b4d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_05a5cbdc-4143-444d-905f-78d4462f115c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e6e3cda-47d6-4500-a4df-eafd4f6c93f8" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_05a5cbdc-4143-444d-905f-78d4462f115c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7b5a58cc-b774-4641-abf9-222159de43a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e6e3cda-47d6-4500-a4df-eafd4f6c93f8" xlink:to="loc_us-gaap_LongTermDebtCurrent_7b5a58cc-b774-4641-abf9-222159de43a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3769b13e-4229-45a1-a001-5b952b5ad5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e6e3cda-47d6-4500-a4df-eafd4f6c93f8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3769b13e-4229-45a1-a001-5b952b5ad5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#DEBTMaturitiesofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d4cb3dae-f57c-4076-ac11-7578d748cd01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1d15df77-7199-483b-8073-d22f95b6f872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d4cb3dae-f57c-4076-ac11-7578d748cd01" xlink:to="loc_us-gaap_DebtInstrumentTable_1d15df77-7199-483b-8073-d22f95b6f872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e66ec56b-f7e3-4b52-aea4-0ad2f2a8a5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1d15df77-7199-483b-8073-d22f95b6f872" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e66ec56b-f7e3-4b52-aea4-0ad2f2a8a5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b8db39ea-99a3-4477-80c4-aae04bfbdd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e66ec56b-f7e3-4b52-aea4-0ad2f2a8a5e9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b8db39ea-99a3-4477-80c4-aae04bfbdd5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_c28c0bc9-e88c-4724-a213-807a17baf48b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b8db39ea-99a3-4477-80c4-aae04bfbdd5e" xlink:to="loc_us-gaap_SecuredDebtMember_c28c0bc9-e88c-4724-a213-807a17baf48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_91cc6a20-15f2-49e7-b88d-f01be2a62e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b8db39ea-99a3-4477-80c4-aae04bfbdd5e" xlink:to="loc_us-gaap_LineOfCreditMember_91cc6a20-15f2-49e7-b88d-f01be2a62e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_30cee963-e1cf-46cb-bb43-b0235542afcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b8db39ea-99a3-4477-80c4-aae04bfbdd5e" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_30cee963-e1cf-46cb-bb43-b0235542afcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d4b3fb6b-d1e4-4f7f-ba50-c253969ccb57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1d15df77-7199-483b-8073-d22f95b6f872" xlink:to="loc_us-gaap_DebtInstrumentAxis_d4b3fb6b-d1e4-4f7f-ba50-c253969ccb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9ca953b7-1fce-4221-9fb1-b6d1002a409e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d4b3fb6b-d1e4-4f7f-ba50-c253969ccb57" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9ca953b7-1fce-4221-9fb1-b6d1002a409e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_A2021TermLoanCreditAgreementMember_ceeb9bde-2d60-475a-97c8-a14bd69a3d95" xlink:href="ccrn-20220331.xsd#ccrn_A2021TermLoanCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9ca953b7-1fce-4221-9fb1-b6d1002a409e" xlink:to="loc_ccrn_A2021TermLoanCreditAgreementMember_ceeb9bde-2d60-475a-97c8-a14bd69a3d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_EarnoutNotesPayableMember_2c4f039e-5926-473e-9dd0-4a217141a8ee" xlink:href="ccrn-20220331.xsd#ccrn_EarnoutNotesPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9ca953b7-1fce-4221-9fb1-b6d1002a409e" xlink:to="loc_ccrn_EarnoutNotesPayableMember_2c4f039e-5926-473e-9dd0-4a217141a8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_67fe94f0-1845-4598-949b-af02cfccf5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1d15df77-7199-483b-8073-d22f95b6f872" xlink:to="loc_us-gaap_CreditFacilityAxis_67fe94f0-1845-4598-949b-af02cfccf5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2f516a64-7bbc-401e-999e-d92fa50f59f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_67fe94f0-1845-4598-949b-af02cfccf5ab" xlink:to="loc_us-gaap_CreditFacilityDomain_2f516a64-7bbc-401e-999e-d92fa50f59f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SeniorSecuredAssetBasedLoanMember_3c227fa2-373b-45e9-b59d-21a70f2c0e83" xlink:href="ccrn-20220331.xsd#ccrn_SeniorSecuredAssetBasedLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2f516a64-7bbc-401e-999e-d92fa50f59f9" xlink:to="loc_ccrn_SeniorSecuredAssetBasedLoanMember_3c227fa2-373b-45e9-b59d-21a70f2c0e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fc638272-a376-4c9e-bd08-cde61b2293c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1d15df77-7199-483b-8073-d22f95b6f872" xlink:to="loc_us-gaap_DebtInstrumentLineItems_fc638272-a376-4c9e-bd08-cde61b2293c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_44d09d5a-c186-47e9-8dc3-896b52280c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fc638272-a376-4c9e-bd08-cde61b2293c7" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_44d09d5a-c186-47e9-8dc3-896b52280c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_d28f2f98-63b3-4e16-9b7e-813bba31a756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_44d09d5a-c186-47e9-8dc3-896b52280c49" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_d28f2f98-63b3-4e16-9b7e-813bba31a756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e2c5482a-eb08-4ea8-9628-db79abb82694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_44d09d5a-c186-47e9-8dc3-896b52280c49" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e2c5482a-eb08-4ea8-9628-db79abb82694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_82868e8f-a57b-42e2-966b-9efa555cd577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_44d09d5a-c186-47e9-8dc3-896b52280c49" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_82868e8f-a57b-42e2-966b-9efa555cd577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f957c7a1-32ff-45ce-bbc8-b564f552346a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_44d09d5a-c186-47e9-8dc3-896b52280c49" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f957c7a1-32ff-45ce-bbc8-b564f552346a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_5e9d6350-816b-4349-961a-f7e1da74c168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_44d09d5a-c186-47e9-8dc3-896b52280c49" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_5e9d6350-816b-4349-961a-f7e1da74c168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LongTermDebtMaturityAfterYearFour_7437ce38-d3e6-4dce-9054-0b7d7b49c7db" xlink:href="ccrn-20220331.xsd#ccrn_LongTermDebtMaturityAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_44d09d5a-c186-47e9-8dc3-896b52280c49" xlink:to="loc_ccrn_LongTermDebtMaturityAfterYearFour_7437ce38-d3e6-4dce-9054-0b7d7b49c7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_40ba8b2f-9d39-42f8-8810-e91ca4d8ff47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_44d09d5a-c186-47e9-8dc3-896b52280c49" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_40ba8b2f-9d39-42f8-8810-e91ca4d8ff47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#DEBT2021TermLoanCreditAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_14bc4b4b-eb14-4a63-906a-00334574dfd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_22eccbf3-c958-467d-a38c-c64036fe9e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_14bc4b4b-eb14-4a63-906a-00334574dfd8" xlink:to="loc_us-gaap_DebtInstrumentTable_22eccbf3-c958-467d-a38c-c64036fe9e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e4a73b83-f939-4295-b259-abf59e4f64e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_22eccbf3-c958-467d-a38c-c64036fe9e6d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e4a73b83-f939-4295-b259-abf59e4f64e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ff0f1289-a52c-452d-915d-c386d04e0c18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e4a73b83-f939-4295-b259-abf59e4f64e2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ff0f1289-a52c-452d-915d-c386d04e0c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_289055e8-a207-49b2-962a-36429a98d93f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ff0f1289-a52c-452d-915d-c386d04e0c18" xlink:to="loc_us-gaap_SecuredDebtMember_289055e8-a207-49b2-962a-36429a98d93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f9230d1d-86a8-43e9-bf79-5dd0f3958394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_22eccbf3-c958-467d-a38c-c64036fe9e6d" xlink:to="loc_us-gaap_DebtInstrumentAxis_f9230d1d-86a8-43e9-bf79-5dd0f3958394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0091ce56-8bc3-46cd-951c-7346c940c8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f9230d1d-86a8-43e9-bf79-5dd0f3958394" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0091ce56-8bc3-46cd-951c-7346c940c8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_A2021TermLoanCreditAgreementMember_09f972d3-e8f4-43a3-b0f5-9f2d001f4006" xlink:href="ccrn-20220331.xsd#ccrn_A2021TermLoanCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0091ce56-8bc3-46cd-951c-7346c940c8a3" xlink:to="loc_ccrn_A2021TermLoanCreditAgreementMember_09f972d3-e8f4-43a3-b0f5-9f2d001f4006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember_ee600720-4505-4b34-b4a6-c5d7694b7e03" xlink:href="ccrn-20220331.xsd#ccrn_A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ccrn_A2021TermLoanCreditAgreementMember_09f972d3-e8f4-43a3-b0f5-9f2d001f4006" xlink:to="loc_ccrn_A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember_ee600720-4505-4b34-b4a6-c5d7694b7e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_A2021TermLoanCreditAgreementIncrementalTermLoanMember_23e32039-fcbb-4092-8afb-8b73cab5c6ce" xlink:href="ccrn-20220331.xsd#ccrn_A2021TermLoanCreditAgreementIncrementalTermLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ccrn_A2021TermLoanCreditAgreementMember_09f972d3-e8f4-43a3-b0f5-9f2d001f4006" xlink:to="loc_ccrn_A2021TermLoanCreditAgreementIncrementalTermLoanMember_23e32039-fcbb-4092-8afb-8b73cab5c6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_c2a92939-7bea-402f-8047-da9d7da5ee47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_22eccbf3-c958-467d-a38c-c64036fe9e6d" xlink:to="loc_us-gaap_VariableRateAxis_c2a92939-7bea-402f-8047-da9d7da5ee47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4c7237d4-a4e2-4407-aa6a-de6ac18d5a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_c2a92939-7bea-402f-8047-da9d7da5ee47" xlink:to="loc_us-gaap_VariableRateDomain_4c7237d4-a4e2-4407-aa6a-de6ac18d5a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_9fa15d14-3068-49b7-8dd2-e7275931d688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_4c7237d4-a4e2-4407-aa6a-de6ac18d5a9e" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_9fa15d14-3068-49b7-8dd2-e7275931d688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_30908520-14b1-4d78-82b6-d38f83caaa78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_22eccbf3-c958-467d-a38c-c64036fe9e6d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_30908520-14b1-4d78-82b6-d38f83caaa78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_8f5d9e3a-fdcd-4fe1-a12d-f3d77227aef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_30908520-14b1-4d78-82b6-d38f83caaa78" xlink:to="loc_us-gaap_DebtInstrumentTerm_8f5d9e3a-fdcd-4fe1-a12d-f3d77227aef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_3603dd42-5a08-472d-bd12-f251d42b5481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_30908520-14b1-4d78-82b6-d38f83caaa78" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_3603dd42-5a08-472d-bd12-f251d42b5481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6d2a3405-0cc0-46a1-bf5e-d48be7d92588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_30908520-14b1-4d78-82b6-d38f83caaa78" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6d2a3405-0cc0-46a1-bf5e-d48be7d92588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_DebtInstrumentVariableInterestRateFloor_0251d538-f9ab-4680-a1c7-72eca47d6e2a" xlink:href="ccrn-20220331.xsd#ccrn_DebtInstrumentVariableInterestRateFloor"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_30908520-14b1-4d78-82b6-d38f83caaa78" xlink:to="loc_ccrn_DebtInstrumentVariableInterestRateFloor_0251d538-f9ab-4680-a1c7-72eca47d6e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_e94ea8b7-8389-42f3-8fec-ff1f45fba6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_30908520-14b1-4d78-82b6-d38f83caaa78" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_e94ea8b7-8389-42f3-8fec-ff1f45fba6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#DEBT2019LoanAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2386f4ed-b9b8-44f3-a218-80029e729c61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_0e3ad474-dc18-4dae-85b0-ae9762f3a9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2386f4ed-b9b8-44f3-a218-80029e729c61" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_0e3ad474-dc18-4dae-85b0-ae9762f3a9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_0df09974-4156-4566-a4a4-425055e8a353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_0e3ad474-dc18-4dae-85b0-ae9762f3a9ad" xlink:to="loc_us-gaap_CreditFacilityAxis_0df09974-4156-4566-a4a4-425055e8a353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_cfd933df-557a-4293-8771-0c0debe22b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_0df09974-4156-4566-a4a4-425055e8a353" xlink:to="loc_us-gaap_CreditFacilityDomain_cfd933df-557a-4293-8771-0c0debe22b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SeniorSecuredAssetBasedLoanMember_6beba02c-26d9-4927-ae63-106839f84fb5" xlink:href="ccrn-20220331.xsd#ccrn_SeniorSecuredAssetBasedLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_cfd933df-557a-4293-8771-0c0debe22b49" xlink:to="loc_ccrn_SeniorSecuredAssetBasedLoanMember_6beba02c-26d9-4927-ae63-106839f84fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditSublimitAxis_d3b78ba4-4b9f-44c2-a615-496c11c3a0a8" xlink:href="ccrn-20220331.xsd#ccrn_LineOfCreditSublimitAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_0e3ad474-dc18-4dae-85b0-ae9762f3a9ad" xlink:to="loc_ccrn_LineOfCreditSublimitAxis_d3b78ba4-4b9f-44c2-a615-496c11c3a0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditSublimitDomain_d905a5d3-cf74-4574-a72c-7d1f8c3634d7" xlink:href="ccrn-20220331.xsd#ccrn_LineOfCreditSublimitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ccrn_LineOfCreditSublimitAxis_d3b78ba4-4b9f-44c2-a615-496c11c3a0a8" xlink:to="loc_ccrn_LineOfCreditSublimitDomain_d905a5d3-cf74-4574-a72c-7d1f8c3634d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SwingLoansSublimitMember_7849089b-d1e3-4233-b0dc-d1134da0b919" xlink:href="ccrn-20220331.xsd#ccrn_SwingLoansSublimitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ccrn_LineOfCreditSublimitDomain_d905a5d3-cf74-4574-a72c-7d1f8c3634d7" xlink:to="loc_ccrn_SwingLoansSublimitMember_7849089b-d1e3-4233-b0dc-d1134da0b919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_StandbyLettersOfCreditSublimitMember_3a59cd5d-dcc3-4d47-8695-5cd163cec105" xlink:href="ccrn-20220331.xsd#ccrn_StandbyLettersOfCreditSublimitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ccrn_LineOfCreditSublimitDomain_d905a5d3-cf74-4574-a72c-7d1f8c3634d7" xlink:to="loc_ccrn_StandbyLettersOfCreditSublimitMember_3a59cd5d-dcc3-4d47-8695-5cd163cec105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_125c65a0-a6a4-4c61-bd38-6dfb9bb898be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_0e3ad474-dc18-4dae-85b0-ae9762f3a9ad" xlink:to="loc_us-gaap_VariableRateAxis_125c65a0-a6a4-4c61-bd38-6dfb9bb898be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ebe7c7c1-984c-4343-9dbb-a7b56ae9e878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_125c65a0-a6a4-4c61-bd38-6dfb9bb898be" xlink:to="loc_us-gaap_VariableRateDomain_ebe7c7c1-984c-4343-9dbb-a7b56ae9e878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_9e3d1b49-da58-4e8b-afca-f65deca5723c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_ebe7c7c1-984c-4343-9dbb-a7b56ae9e878" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_9e3d1b49-da58-4e8b-afca-f65deca5723c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_63838c10-b916-4be3-a826-9762ba98c85b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_ebe7c7c1-984c-4343-9dbb-a7b56ae9e878" xlink:to="loc_us-gaap_BaseRateMember_63838c10-b916-4be3-a826-9762ba98c85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_0e3ad474-dc18-4dae-85b0-ae9762f3a9ad" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_02cb6cf5-9987-456d-8c53-982c9f2e3ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_02cb6cf5-9987-456d-8c53-982c9f2e3ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dfd7d960-efbf-4f75-9b3c-9e91c609c1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dfd7d960-efbf-4f75-9b3c-9e91c609c1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources_59ec3d63-d8a6-458f-91f9-37da95f8e837" xlink:href="ccrn-20220331.xsd#ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:to="loc_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources_59ec3d63-d8a6-458f-91f9-37da95f8e837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR_19b27aa0-0798-46bc-ad21-cc0667bd7781" xlink:href="ccrn-20220331.xsd#ccrn_LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:to="loc_ccrn_LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR_19b27aa0-0798-46bc-ad21-cc0667bd7781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditBorrowingBasePercentageOfAssets_8549f715-8f0d-436d-ab7f-b55a6c24a116" xlink:href="ccrn-20220331.xsd#ccrn_LineOfCreditBorrowingBasePercentageOfAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:to="loc_ccrn_LineOfCreditBorrowingBasePercentageOfAssets_8549f715-8f0d-436d-ab7f-b55a6c24a116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_LineOfCreditFacilityBorrowingBaseAvailability_d475321c-ecda-45d6-be71-538b5bfc6fd8" xlink:href="ccrn-20220331.xsd#ccrn_LineOfCreditFacilityBorrowingBaseAvailability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:to="loc_ccrn_LineOfCreditFacilityBorrowingBaseAvailability_d475321c-ecda-45d6-be71-538b5bfc6fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_f5c23b58-2a54-40ed-abe5-9a2d04158892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:to="loc_us-gaap_LineOfCredit_f5c23b58-2a54-40ed-abe5-9a2d04158892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_5f5cf4cd-d2bb-4dbd-b05e-be53f2bb7817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_5f5cf4cd-d2bb-4dbd-b05e-be53f2bb7817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_7ca3e677-f0a3-40ed-a41a-8f8498bd48ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_7ca3e677-f0a3-40ed-a41a-8f8498bd48ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_28dc64b1-fb86-4fcc-9c35-5e43bff486ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_28dc64b1-fb86-4fcc-9c35-5e43bff486ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_be707969-9535-40c8-9931-de935c6435e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_08dc4a26-fa4a-4caf-85b8-e7b7095fc549" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_be707969-9535-40c8-9931-de935c6435e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/DEBTNotePayableDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#DEBTNotePayableDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/DEBTNotePayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1ca00657-c0d7-48b6-8d4e-28e4139e3a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1edb6063-b9db-48ac-b9f9-7b4da5b73e50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1ca00657-c0d7-48b6-8d4e-28e4139e3a3c" xlink:to="loc_us-gaap_DebtInstrumentTable_1edb6063-b9db-48ac-b9f9-7b4da5b73e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_60b5ebef-87f4-43ed-8c3d-174a0a49c7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1edb6063-b9db-48ac-b9f9-7b4da5b73e50" xlink:to="loc_us-gaap_DebtInstrumentAxis_60b5ebef-87f4-43ed-8c3d-174a0a49c7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_72df4157-c839-440e-a6f4-95e612c297fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_60b5ebef-87f4-43ed-8c3d-174a0a49c7d9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_72df4157-c839-440e-a6f4-95e612c297fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_EarnoutNotesPayableMember_a545fd2a-ab72-427d-b5a5-dcf764bef53f" xlink:href="ccrn-20220331.xsd#ccrn_EarnoutNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_72df4157-c839-440e-a6f4-95e612c297fe" xlink:to="loc_ccrn_EarnoutNotesPayableMember_a545fd2a-ab72-427d-b5a5-dcf764bef53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b8e05722-ac1f-437d-8f38-a15072fe892b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1edb6063-b9db-48ac-b9f9-7b4da5b73e50" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b8e05722-ac1f-437d-8f38-a15072fe892b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ea48c03-2905-45e1-ac1a-84fabdac8223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b8e05722-ac1f-437d-8f38-a15072fe892b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ea48c03-2905-45e1-ac1a-84fabdac8223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_MediscanMember_c2c1d7cd-4ebb-4bf1-a83e-31d83277805c" xlink:href="ccrn-20220331.xsd#ccrn_MediscanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ea48c03-2905-45e1-ac1a-84fabdac8223" xlink:to="loc_ccrn_MediscanMember_c2c1d7cd-4ebb-4bf1-a83e-31d83277805c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f4d0a278-6e2f-413d-8619-c34bdf8d97f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1edb6063-b9db-48ac-b9f9-7b4da5b73e50" xlink:to="loc_us-gaap_DebtInstrumentLineItems_f4d0a278-6e2f-413d-8619-c34bdf8d97f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_ee82d034-f8d9-4198-ba3d-9f96759c771b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d0a278-6e2f-413d-8619-c34bdf8d97f9" xlink:to="loc_us-gaap_NotesPayable_ee82d034-f8d9-4198-ba3d-9f96759c771b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NotePayableNumberOfPaymentInstallments_e27c5655-73b9-4d9a-b4fd-aebbe956c5b5" xlink:href="ccrn-20220331.xsd#ccrn_NotePayableNumberOfPaymentInstallments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d0a278-6e2f-413d-8619-c34bdf8d97f9" xlink:to="loc_ccrn_NotePayableNumberOfPaymentInstallments_e27c5655-73b9-4d9a-b4fd-aebbe956c5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NotePayableNumberOfInstallmentsPaid_76941ca0-27ee-4990-adac-aa93c1484ebb" xlink:href="ccrn-20220331.xsd#ccrn_NotePayableNumberOfInstallmentsPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d0a278-6e2f-413d-8619-c34bdf8d97f9" xlink:to="loc_ccrn_NotePayableNumberOfInstallmentsPaid_76941ca0-27ee-4990-adac-aa93c1484ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_31c334b1-fca3-4642-8ba3-83eafe1c4b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4d0a278-6e2f-413d-8619-c34bdf8d97f9" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_31c334b1-fca3-4642-8ba3-83eafe1c4b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/LEASES" xlink:type="simple" xlink:href="ccrn-20220331.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1a9ffb67-d92b-46b4-b565-5674ad643d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_2b545b5a-9c23-4495-9d41-dcb24d3762b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1a9ffb67-d92b-46b4-b565-5674ad643d2b" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_2b545b5a-9c23-4495-9d41-dcb24d3762b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/LEASESTables" xlink:type="simple" xlink:href="ccrn-20220331.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_845b95ff-a476-440d-b8b2-263854e32721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock_1b2cdadc-06be-415c-8f43-e8dcb3983412" xlink:href="ccrn-20220331.xsd#ccrn_AssetsAndLiabilitiesLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_845b95ff-a476-440d-b8b2-263854e32721" xlink:to="loc_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock_1b2cdadc-06be-415c-8f43-e8dcb3983412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0b7add5e-a695-4e3c-be24-85f649502ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_845b95ff-a476-440d-b8b2-263854e32721" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0b7add5e-a695-4e3c-be24-85f649502ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_b306d99a-001c-411d-800d-3027891ec37b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_845b95ff-a476-440d-b8b2-263854e32721" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_b306d99a-001c-411d-800d-3027891ec37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/LEASESAdditionalInformationDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#LEASESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/LEASESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a81e0495-387a-469d-b459-ac1f417940a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_2f26a4bb-64e0-4439-9189-af5e0e64cb70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a81e0495-387a-469d-b459-ac1f417940a7" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_2f26a4bb-64e0-4439-9189-af5e0e64cb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/LEASESSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#LEASESSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/LEASESSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_828dcf15-16c8-4429-ab2c-18001fd56470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bf6e0ce7-0b70-4fc2-8948-5ceaa40597e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_828dcf15-16c8-4429-ab2c-18001fd56470" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bf6e0ce7-0b70-4fc2-8948-5ceaa40597e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bfd30d0c-9b8b-4744-b126-6a17524f42a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_828dcf15-16c8-4429-ab2c-18001fd56470" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bfd30d0c-9b8b-4744-b126-6a17524f42a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8ee2a427-6732-43e8-b415-f43d64cdb7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_828dcf15-16c8-4429-ab2c-18001fd56470" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8ee2a427-6732-43e8-b415-f43d64cdb7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_331c24b3-a9e1-44b4-959c-b5641cedc2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_828dcf15-16c8-4429-ab2c-18001fd56470" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_331c24b3-a9e1-44b4-959c-b5641cedc2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_122bd02e-eab6-4a8d-bdee-aea5dad51ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_828dcf15-16c8-4429-ab2c-18001fd56470" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_122bd02e-eab6-4a8d-bdee-aea5dad51ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#LEASESOperatingLeaseMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_79d3f62e-d27e-45e2-9873-74f5ae99bcbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_161af743-76a6-4da1-a9c4-44c984290134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79d3f62e-d27e-45e2-9873-74f5ae99bcbe" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_161af743-76a6-4da1-a9c4-44c984290134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9a0bae5a-53d7-48ac-9a4b-210992590057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79d3f62e-d27e-45e2-9873-74f5ae99bcbe" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9a0bae5a-53d7-48ac-9a4b-210992590057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fa1850ff-e94f-4655-9899-f3b4437db114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79d3f62e-d27e-45e2-9873-74f5ae99bcbe" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fa1850ff-e94f-4655-9899-f3b4437db114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_841cdda4-42db-40e6-b01b-c99d81b0daa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79d3f62e-d27e-45e2-9873-74f5ae99bcbe" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_841cdda4-42db-40e6-b01b-c99d81b0daa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_554df9b9-d38c-47e5-b41d-84a97e51a71f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79d3f62e-d27e-45e2-9873-74f5ae99bcbe" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_554df9b9-d38c-47e5-b41d-84a97e51a71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_196890d2-7d39-485b-8719-7f44a04d9a53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79d3f62e-d27e-45e2-9873-74f5ae99bcbe" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_196890d2-7d39-485b-8719-7f44a04d9a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d0cc6b14-c978-4231-bc59-5905fb743d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79d3f62e-d27e-45e2-9873-74f5ae99bcbe" xlink:to="loc_us-gaap_OperatingLeaseLiability_d0cc6b14-c978-4231-bc59-5905fb743d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_35346141-6c4e-4886-8eac-a186e99b9e11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79d3f62e-d27e-45e2-9873-74f5ae99bcbe" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_35346141-6c4e-4886-8eac-a186e99b9e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7dd5b389-9dc7-4aa2-a4dd-95c37fd5dd05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_79d3f62e-d27e-45e2-9873-74f5ae99bcbe" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7dd5b389-9dc7-4aa2-a4dd-95c37fd5dd05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails_1" xlink:type="simple" xlink:href="ccrn-20220331.xsd#LEASESOperatingLeaseMaturityDetails_1"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/LEASESLeaseCostsDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#LEASESLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/LEASESLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2a763c37-23ae-49e8-b9cb-1a558f10be23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_ce0a5f43-ef7a-485c-94b9-21943575d427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2a763c37-23ae-49e8-b9cb-1a558f10be23" xlink:to="loc_us-gaap_OperatingLeasePayments_ce0a5f43-ef7a-485c-94b9-21943575d427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6062c645-3c03-4c78-a8a6-2e1a7fbf165d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2a763c37-23ae-49e8-b9cb-1a558f10be23" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6062c645-3c03-4c78-a8a6-2e1a7fbf165d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_ba662ce7-3f40-4d1a-814b-f7acca4e7d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2a763c37-23ae-49e8-b9cb-1a558f10be23" xlink:to="loc_us-gaap_OperatingLeaseCost_ba662ce7-3f40-4d1a-814b-f7acca4e7d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_0f5201ff-507f-4fcb-a004-81e94aae0c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2a763c37-23ae-49e8-b9cb-1a558f10be23" xlink:to="loc_us-gaap_ShortTermLeaseCost_0f5201ff-507f-4fcb-a004-81e94aae0c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_bada62eb-8a5e-4118-9ac4-38bf4bea2f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2a763c37-23ae-49e8-b9cb-1a558f10be23" xlink:to="loc_us-gaap_VariableLeaseCost_bada62eb-8a5e-4118-9ac4-38bf4bea2f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="ccrn-20220331.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c44d26cc-a235-40a3-a5a3-9bc58bf74bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_3ab835cf-38a7-44a1-9d58-9065c1635b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c44d26cc-a235-40a3-a5a3-9bc58bf74bdf" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_3ab835cf-38a7-44a1-9d58-9065c1635b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="ccrn-20220331.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_27e466af-6125-46d4-bece-00fbf763cf8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_105127a9-8a99-4aed-af73-01121141a889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_27e466af-6125-46d4-bece-00fbf763cf8c" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_105127a9-8a99-4aed-af73-01121141a889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_e380a1ca-0f9c-49dc-8312-dd1cef4f5a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_27e466af-6125-46d4-bece-00fbf763cf8c" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_e380a1ca-0f9c-49dc-8312-dd1cef4f5a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3f562f1b-1266-469d-87d5-4bd58561af86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c473ff2e-c76e-4dc6-822b-9d05aa835304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3f562f1b-1266-469d-87d5-4bd58561af86" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c473ff2e-c76e-4dc6-822b-9d05aa835304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_666c2f81-0905-4342-9502-b16e94ed6bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c473ff2e-c76e-4dc6-822b-9d05aa835304" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_666c2f81-0905-4342-9502-b16e94ed6bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e3a57112-32d7-4fd5-8212-95892a306758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_666c2f81-0905-4342-9502-b16e94ed6bf0" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e3a57112-32d7-4fd5-8212-95892a306758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_DeferredCompensationMember_3e9e8a8b-e65b-4af7-829b-59951d9c47d1" xlink:href="ccrn-20220331.xsd#ccrn_DeferredCompensationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e3a57112-32d7-4fd5-8212-95892a306758" xlink:to="loc_ccrn_DeferredCompensationMember_3e9e8a8b-e65b-4af7-829b-59951d9c47d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_ee1bbb72-19ba-44fe-af07-1bb0b0539029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c473ff2e-c76e-4dc6-822b-9d05aa835304" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_ee1bbb72-19ba-44fe-af07-1bb0b0539029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d5a476cd-7ce2-4fc5-a1e8-84319c2f6fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_ee1bbb72-19ba-44fe-af07-1bb0b0539029" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d5a476cd-7ce2-4fc5-a1e8-84319c2f6fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_DeferredCompensationMember_b96439e5-6c28-450d-8b49-2abe342e0fd4" xlink:href="ccrn-20220331.xsd#ccrn_DeferredCompensationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d5a476cd-7ce2-4fc5-a1e8-84319c2f6fb3" xlink:to="loc_ccrn_DeferredCompensationMember_b96439e5-6c28-450d-8b49-2abe342e0fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2f9b924d-1352-4172-a35a-2bfa08a39a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c473ff2e-c76e-4dc6-822b-9d05aa835304" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2f9b924d-1352-4172-a35a-2bfa08a39a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4956cdb1-2ad1-4208-aa7d-77de90b6f2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2f9b924d-1352-4172-a35a-2bfa08a39a9a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4956cdb1-2ad1-4208-aa7d-77de90b6f2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_255ca8a2-c7d6-464c-bf9e-308ec479d282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4956cdb1-2ad1-4208-aa7d-77de90b6f2b0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_255ca8a2-c7d6-464c-bf9e-308ec479d282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_35b4000a-d40c-46a0-8a68-20b9adaec7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c473ff2e-c76e-4dc6-822b-9d05aa835304" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_35b4000a-d40c-46a0-8a68-20b9adaec7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_885c0e57-0e1a-4289-a0e5-3743b36f123d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_35b4000a-d40c-46a0-8a68-20b9adaec7dc" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_885c0e57-0e1a-4289-a0e5-3743b36f123d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_e8b57afb-4198-4348-b7d0-aa17c6adef4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_35b4000a-d40c-46a0-8a68-20b9adaec7dc" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_e8b57afb-4198-4348-b7d0-aa17c6adef4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b0e2a243-c58a-4d7c-b9aa-76f4d324474f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_c365f61d-8655-4e01-9f8f-75678181cdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b0e2a243-c58a-4d7c-b9aa-76f4d324474f" xlink:to="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_c365f61d-8655-4e01-9f8f-75678181cdfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7948d4c0-d981-4222-b8eb-1ba06bb58cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_c365f61d-8655-4e01-9f8f-75678181cdfa" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7948d4c0-d981-4222-b8eb-1ba06bb58cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_65a284d0-b4c0-47c5-9a7e-07ed392901be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7948d4c0-d981-4222-b8eb-1ba06bb58cdd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_65a284d0-b4c0-47c5-9a7e-07ed392901be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_99f63125-71c9-4806-a93b-fc6c2ad6fa33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_65a284d0-b4c0-47c5-9a7e-07ed392901be" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_99f63125-71c9-4806-a93b-fc6c2ad6fa33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_416a7085-b686-4c08-bfdd-bee2bd380f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_c365f61d-8655-4e01-9f8f-75678181cdfa" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_416a7085-b686-4c08-bfdd-bee2bd380f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9c46c91f-a215-45a0-88ef-b97bd82e6c80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_416a7085-b686-4c08-bfdd-bee2bd380f0b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9c46c91f-a215-45a0-88ef-b97bd82e6c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_EarnoutNotesPayableMember_65b374e5-1635-49b6-a449-1ab897284bb9" xlink:href="ccrn-20220331.xsd#ccrn_EarnoutNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9c46c91f-a215-45a0-88ef-b97bd82e6c80" xlink:to="loc_ccrn_EarnoutNotesPayableMember_65b374e5-1635-49b6-a449-1ab897284bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_6e666595-9ff7-4e06-bbc7-6a18ed59c0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9c46c91f-a215-45a0-88ef-b97bd82e6c80" xlink:to="loc_us-gaap_SecuredDebtMember_6e666595-9ff7-4e06-bbc7-6a18ed59c0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_95dba209-14b7-46aa-8f88-68f7e2f8d750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_c365f61d-8655-4e01-9f8f-75678181cdfa" xlink:to="loc_us-gaap_CreditFacilityAxis_95dba209-14b7-46aa-8f88-68f7e2f8d750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_97dc675b-9ce7-488f-9750-c563dae61472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_95dba209-14b7-46aa-8f88-68f7e2f8d750" xlink:to="loc_us-gaap_CreditFacilityDomain_97dc675b-9ce7-488f-9750-c563dae61472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SeniorSecuredAssetBasedLoanMember_e3e28afe-2500-427a-8ddd-8d27f129f423" xlink:href="ccrn-20220331.xsd#ccrn_SeniorSecuredAssetBasedLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_97dc675b-9ce7-488f-9750-c563dae61472" xlink:to="loc_ccrn_SeniorSecuredAssetBasedLoanMember_e3e28afe-2500-427a-8ddd-8d27f129f423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_878624b3-675f-4e02-b4bc-fb90cd9e4ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_c365f61d-8655-4e01-9f8f-75678181cdfa" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_878624b3-675f-4e02-b4bc-fb90cd9e4ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_519df301-8247-4f23-ae52-c58d392f6c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_878624b3-675f-4e02-b4bc-fb90cd9e4ec5" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_519df301-8247-4f23-ae52-c58d392f6c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_8370d536-33aa-4dc1-b1ea-2350955c2a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_519df301-8247-4f23-ae52-c58d392f6c59" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_8370d536-33aa-4dc1-b1ea-2350955c2a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_2685a4ae-09fe-47f9-a8fd-c42e61284021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_519df301-8247-4f23-ae52-c58d392f6c59" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_2685a4ae-09fe-47f9-a8fd-c42e61284021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c48f4b46-1058-40cf-9bc5-720cb0d95576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_519df301-8247-4f23-ae52-c58d392f6c59" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c48f4b46-1058-40cf-9bc5-720cb0d95576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_93aea921-bd9f-446f-9d76-dc44021715b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_c365f61d-8655-4e01-9f8f-75678181cdfa" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_93aea921-bd9f-446f-9d76-dc44021715b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_450e4cb1-39d5-425c-bdb6-f961b12addde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_93aea921-bd9f-446f-9d76-dc44021715b9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_450e4cb1-39d5-425c-bdb6-f961b12addde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_WorkforceSolutionsGroupIncMember_7c69677a-a803-4da7-9dd7-641638b3ebba" xlink:href="ccrn-20220331.xsd#ccrn_WorkforceSolutionsGroupIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_450e4cb1-39d5-425c-bdb6-f961b12addde" xlink:to="loc_ccrn_WorkforceSolutionsGroupIncMember_7c69677a-a803-4da7-9dd7-641638b3ebba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SelectedIncMember_5b9105d6-2b4a-4904-bd40-ae9962acb088" xlink:href="ccrn-20220331.xsd#ccrn_SelectedIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_450e4cb1-39d5-425c-bdb6-f961b12addde" xlink:to="loc_ccrn_SelectedIncMember_5b9105d6-2b4a-4904-bd40-ae9962acb088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_addce8dd-fff0-476b-b265-37fb0e6d09cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_c365f61d-8655-4e01-9f8f-75678181cdfa" xlink:to="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_addce8dd-fff0-476b-b265-37fb0e6d09cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_d52d9341-6abd-43cc-a95b-0fe8a117cae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_addce8dd-fff0-476b-b265-37fb0e6d09cc" xlink:to="loc_us-gaap_DebtInstrumentFairValue_d52d9341-6abd-43cc-a95b-0fe8a117cae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditFairValueDisclosure_bbdd34c0-3e42-466c-a3fd-0b4b398ed401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LinesOfCreditFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_addce8dd-fff0-476b-b265-37fb0e6d09cc" xlink:to="loc_us-gaap_LinesOfCreditFairValueDisclosure_bbdd34c0-3e42-466c-a3fd-0b4b398ed401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_43a3b0be-e309-415d-b5a1-2e1100e21c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_addce8dd-fff0-476b-b265-37fb0e6d09cc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_43a3b0be-e309-415d-b5a1-2e1100e21c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ccrn-20220331.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4d4718ce-62b1-4cc9-8af8-601f9c2b7422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_fdd68faa-8ab5-4632-947c-29f7ce2450d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4d4718ce-62b1-4cc9-8af8-601f9c2b7422" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_fdd68faa-8ab5-4632-947c-29f7ce2450d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="ccrn-20220331.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f6a15d9a-7c48-446e-b016-b505b95d771f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_44a58467-6f76-4fbc-b0dd-d55134f6c99d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f6a15d9a-7c48-446e-b016-b505b95d771f" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_44a58467-6f76-4fbc-b0dd-d55134f6c99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#STOCKHOLDERSEQUITYAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_823ad00e-3cb3-498a-bf51-1bc9fe0c50b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_029191d5-9fab-4f18-b5be-ba27a2d3fe73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_823ad00e-3cb3-498a-bf51-1bc9fe0c50b7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_029191d5-9fab-4f18-b5be-ba27a2d3fe73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1ef1dcaa-93bd-4ad6-a0c8-46615ac938ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_029191d5-9fab-4f18-b5be-ba27a2d3fe73" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1ef1dcaa-93bd-4ad6-a0c8-46615ac938ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4b9093c8-0d4b-476f-a21e-f069a2f4c4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1ef1dcaa-93bd-4ad6-a0c8-46615ac938ee" xlink:to="loc_us-gaap_EquityComponentDomain_4b9093c8-0d4b-476f-a21e-f069a2f4c4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f43f463b-ddcc-41c0-980d-b33e4ecbca10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4b9093c8-0d4b-476f-a21e-f069a2f4c4a3" xlink:to="loc_us-gaap_CommonStockMember_f43f463b-ddcc-41c0-980d-b33e4ecbca10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_28f763ca-2dbb-4fc4-80c9-258c76109ced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_029191d5-9fab-4f18-b5be-ba27a2d3fe73" xlink:to="loc_us-gaap_PlanNameAxis_28f763ca-2dbb-4fc4-80c9-258c76109ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_021d37f3-faea-44ad-a483-6c0dd43fa4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_28f763ca-2dbb-4fc4-80c9-258c76109ced" xlink:to="loc_us-gaap_PlanNameDomain_021d37f3-faea-44ad-a483-6c0dd43fa4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OmnibusPlanMember_665296c2-4f40-4768-8237-c9761cdcb06f" xlink:href="ccrn-20220331.xsd#ccrn_OmnibusPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_021d37f3-faea-44ad-a483-6c0dd43fa4ee" xlink:to="loc_ccrn_OmnibusPlanMember_665296c2-4f40-4768-8237-c9761cdcb06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eb9023b1-7ace-475a-9ba5-34242706b407" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_029191d5-9fab-4f18-b5be-ba27a2d3fe73" xlink:to="loc_srt_RangeAxis_eb9023b1-7ace-475a-9ba5-34242706b407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b244b55b-a2e7-43ed-8dc0-fca6447c5cf5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_eb9023b1-7ace-475a-9ba5-34242706b407" xlink:to="loc_srt_RangeMember_b244b55b-a2e7-43ed-8dc0-fca6447c5cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7a947f61-c935-4542-8b39-6ef2f01f4a46" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b244b55b-a2e7-43ed-8dc0-fca6447c5cf5" xlink:to="loc_srt_MinimumMember_7a947f61-c935-4542-8b39-6ef2f01f4a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_a0cc932c-0fbe-4528-a9a1-298a0a9c686b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_029191d5-9fab-4f18-b5be-ba27a2d3fe73" xlink:to="loc_srt_TitleOfIndividualAxis_a0cc932c-0fbe-4528-a9a1-298a0a9c686b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3297a411-7ac5-4417-8b7f-268968eaef72" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_a0cc932c-0fbe-4528-a9a1-298a0a9c686b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3297a411-7ac5-4417-8b7f-268968eaef72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_b643bdb6-edc4-4ee4-8c0d-4907545a8e53" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3297a411-7ac5-4417-8b7f-268968eaef72" xlink:to="loc_srt_DirectorMember_b643bdb6-edc4-4ee4-8c0d-4907545a8e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_edfa468f-0e02-4d67-a5e7-aa3214536175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_029191d5-9fab-4f18-b5be-ba27a2d3fe73" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_edfa468f-0e02-4d67-a5e7-aa3214536175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_74cc10dd-6f6d-4789-8ff9-8126ec8fd577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_edfa468f-0e02-4d67-a5e7-aa3214536175" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_74cc10dd-6f6d-4789-8ff9-8126ec8fd577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f717a33a-ef6d-4e5a-b3da-5d77f79efcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_74cc10dd-6f6d-4789-8ff9-8126ec8fd577" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f717a33a-ef6d-4e5a-b3da-5d77f79efcbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_24e1bc0a-c056-4989-9c6f-70bcf47078b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_029191d5-9fab-4f18-b5be-ba27a2d3fe73" xlink:to="loc_us-gaap_AwardTypeAxis_24e1bc0a-c056-4989-9c6f-70bcf47078b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab0ef765-6ec8-4b79-8a03-0ca6e97b474f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_24e1bc0a-c056-4989-9c6f-70bcf47078b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab0ef765-6ec8-4b79-8a03-0ca6e97b474f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b041426a-99f2-4bbb-9b32-68534456ef75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab0ef765-6ec8-4b79-8a03-0ca6e97b474f" xlink:to="loc_us-gaap_RestrictedStockMember_b041426a-99f2-4bbb-9b32-68534456ef75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_5ee45d6c-54ff-40e7-852f-ecd131a707fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab0ef765-6ec8-4b79-8a03-0ca6e97b474f" xlink:to="loc_us-gaap_PerformanceSharesMember_5ee45d6c-54ff-40e7-852f-ecd131a707fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba8f9a7e-6b1f-4550-8040-5c463e34fad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_029191d5-9fab-4f18-b5be-ba27a2d3fe73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba8f9a7e-6b1f-4550-8040-5c463e34fad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_71ab1c59-c551-4331-9f0b-8513ff542e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba8f9a7e-6b1f-4550-8040-5c463e34fad3" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_71ab1c59-c551-4331-9f0b-8513ff542e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_474d9f61-edf4-4827-a7ca-a3947b6fd1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba8f9a7e-6b1f-4550-8040-5c463e34fad3" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_474d9f61-edf4-4827-a7ca-a3947b6fd1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c2392c52-e0cf-45c9-b55b-c14c67385cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba8f9a7e-6b1f-4550-8040-5c463e34fad3" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c2392c52-e0cf-45c9-b55b-c14c67385cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f08b8bd8-4d8b-455b-bf01-ec7a8330b0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba8f9a7e-6b1f-4550-8040-5c463e34fad3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f08b8bd8-4d8b-455b-bf01-ec7a8330b0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a5e9a903-f2dd-4f7c-ac75-91cb460c90ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba8f9a7e-6b1f-4550-8040-5c463e34fad3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a5e9a903-f2dd-4f7c-ac75-91cb460c90ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage_df9dadc4-330f-4f4f-96ec-373851e11304" xlink:href="ccrn-20220331.xsd#ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba8f9a7e-6b1f-4550-8040-5c463e34fad3" xlink:to="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage_df9dadc4-330f-4f4f-96ec-373851e11304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_13d58c18-48ae-4afc-a936-31f38016c96e" xlink:href="ccrn-20220331.xsd#ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba8f9a7e-6b1f-4550-8040-5c463e34fad3" xlink:to="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_13d58c18-48ae-4afc-a936-31f38016c96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c56264f3-c502-4c2e-9e9d-970b90dc4cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba8f9a7e-6b1f-4550-8040-5c463e34fad3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c56264f3-c502-4c2e-9e9d-970b90dc4cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet_f516b2cd-bd11-430f-a246-bbe3b99fdfad" xlink:href="ccrn-20220331.xsd#ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba8f9a7e-6b1f-4550-8040-5c463e34fad3" xlink:to="loc_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet_f516b2cd-bd11-430f-a246-bbe3b99fdfad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#STOCKHOLDERSEQUITYRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4c85e9e1-414c-4657-852f-92e06eb25e39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2acd185-7624-4eb7-b05b-a24a4a16f4af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4c85e9e1-414c-4657-852f-92e06eb25e39" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2acd185-7624-4eb7-b05b-a24a4a16f4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_417e27b7-32b6-482d-a0aa-f16284125fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2acd185-7624-4eb7-b05b-a24a4a16f4af" xlink:to="loc_us-gaap_AwardTypeAxis_417e27b7-32b6-482d-a0aa-f16284125fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90efd7a4-0381-4eb2-ad77-efb4422c3d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_417e27b7-32b6-482d-a0aa-f16284125fb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90efd7a4-0381-4eb2-ad77-efb4422c3d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_3cbac5c8-b776-4047-8857-c5a55d577e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90efd7a4-0381-4eb2-ad77-efb4422c3d6a" xlink:to="loc_us-gaap_RestrictedStockMember_3cbac5c8-b776-4047-8857-c5a55d577e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_b295b4bd-708f-4124-8604-61164b0c15a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90efd7a4-0381-4eb2-ad77-efb4422c3d6a" xlink:to="loc_us-gaap_PerformanceSharesMember_b295b4bd-708f-4124-8604-61164b0c15a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84d0d2ca-4549-4e99-b3d1-0e6875da9c05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2acd185-7624-4eb7-b05b-a24a4a16f4af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84d0d2ca-4549-4e99-b3d1-0e6875da9c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06871a7c-1b17-4f30-b7f5-207eaf452dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84d0d2ca-4549-4e99-b3d1-0e6875da9c05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06871a7c-1b17-4f30-b7f5-207eaf452dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_df94ace6-234a-48cc-8e21-47c922bd62e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06871a7c-1b17-4f30-b7f5-207eaf452dd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_df94ace6-234a-48cc-8e21-47c922bd62e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0d7b4a19-44ab-41b7-aa9c-8bd293895e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06871a7c-1b17-4f30-b7f5-207eaf452dd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0d7b4a19-44ab-41b7-aa9c-8bd293895e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_84d1ac43-2812-4b0f-99b4-c61cc9a05dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06871a7c-1b17-4f30-b7f5-207eaf452dd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_84d1ac43-2812-4b0f-99b4-c61cc9a05dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d720712b-3f3b-42a3-8847-9821eb1e842a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06871a7c-1b17-4f30-b7f5-207eaf452dd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d720712b-3f3b-42a3-8847-9821eb1e842a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_55c22213-c0ea-49b9-aa1f-8c48a2301e86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06871a7c-1b17-4f30-b7f5-207eaf452dd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_55c22213-c0ea-49b9-aa1f-8c48a2301e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6f363edf-f3f3-4ca2-97f8-88815193288d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84d0d2ca-4549-4e99-b3d1-0e6875da9c05" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6f363edf-f3f3-4ca2-97f8-88815193288d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_39d47990-7d4c-44a4-84fc-6177c2c677b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6f363edf-f3f3-4ca2-97f8-88815193288d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_39d47990-7d4c-44a4-84fc-6177c2c677b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ea3dcc32-5ab3-4e4a-afbc-b0f42da17511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6f363edf-f3f3-4ca2-97f8-88815193288d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ea3dcc32-5ab3-4e4a-afbc-b0f42da17511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_39857cb1-ca1c-4ff5-9667-a7bded2dc505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6f363edf-f3f3-4ca2-97f8-88815193288d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_39857cb1-ca1c-4ff5-9667-a7bded2dc505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_cd6a49c8-5540-4ab5-b650-455849a07e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6f363edf-f3f3-4ca2-97f8-88815193288d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_cd6a49c8-5540-4ab5-b650-455849a07e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_216b7711-07f5-43a7-9f9e-0a2819db1c20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_6f363edf-f3f3-4ca2-97f8-88815193288d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_216b7711-07f5-43a7-9f9e-0a2819db1c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SEGMENTDATA" xlink:type="simple" xlink:href="ccrn-20220331.xsd#SEGMENTDATA"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/SEGMENTDATA" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7ae663d3-794d-493b-9473-3180dc07c4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_3121b29a-a121-4d76-8daa-c91bafbd5d53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7ae663d3-794d-493b-9473-3180dc07c4b3" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_3121b29a-a121-4d76-8daa-c91bafbd5d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SEGMENTDATATables" xlink:type="simple" xlink:href="ccrn-20220331.xsd#SEGMENTDATATables"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/SEGMENTDATATables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_96f9e934-3e26-4db1-8368-53762733e64b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_561f7456-01d7-4489-b39d-8330d01c91eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_96f9e934-3e26-4db1-8368-53762733e64b" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_561f7456-01d7-4489-b39d-8330d01c91eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/SEGMENTDATADetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#SEGMENTDATADetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/SEGMENTDATADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_574af8f0-a2cb-4122-adc8-918dad11325e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_3105eb6e-9510-48eb-ad5f-1bc65017b032" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_574af8f0-a2cb-4122-adc8-918dad11325e" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_3105eb6e-9510-48eb-ad5f-1bc65017b032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3777df38-17ea-48d5-82c5-5cdc176f0891" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_3105eb6e-9510-48eb-ad5f-1bc65017b032" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3777df38-17ea-48d5-82c5-5cdc176f0891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_47fbf36d-09b6-4edf-8c1e-7400848b6ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3777df38-17ea-48d5-82c5-5cdc176f0891" xlink:to="loc_us-gaap_SegmentDomain_47fbf36d-09b6-4edf-8c1e-7400848b6ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NurseAndAlliedStaffingMember_63e688fc-fba4-4b58-9c68-d5ad6a2893bf" xlink:href="ccrn-20220331.xsd#ccrn_NurseAndAlliedStaffingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_47fbf36d-09b6-4edf-8c1e-7400848b6ed6" xlink:to="loc_ccrn_NurseAndAlliedStaffingMember_63e688fc-fba4-4b58-9c68-d5ad6a2893bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_PhysicianStaffingMember_2bf420a5-5167-4a30-bca7-14a2965ad0ba" xlink:href="ccrn-20220331.xsd#ccrn_PhysicianStaffingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_47fbf36d-09b6-4edf-8c1e-7400848b6ed6" xlink:to="loc_ccrn_PhysicianStaffingMember_2bf420a5-5167-4a30-bca7-14a2965ad0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_012f56a5-ff19-42f1-b2e2-001fc58bf132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_3105eb6e-9510-48eb-ad5f-1bc65017b032" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_012f56a5-ff19-42f1-b2e2-001fc58bf132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7a854113-11a0-42dc-93e1-aeb183798ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_012f56a5-ff19-42f1-b2e2-001fc58bf132" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7a854113-11a0-42dc-93e1-aeb183798ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard_77970edd-251c-42af-8ac8-2439c26dd53a" xlink:href="ccrn-20220331.xsd#ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_012f56a5-ff19-42f1-b2e2-001fc58bf132" xlink:to="loc_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard_77970edd-251c-42af-8ac8-2439c26dd53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_SegmentReportingUnallocatedCorporateExpenses_1c3150d8-d9e6-478e-a795-dfbe5b1d0cb0" xlink:href="ccrn-20220331.xsd#ccrn_SegmentReportingUnallocatedCorporateExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_012f56a5-ff19-42f1-b2e2-001fc58bf132" xlink:to="loc_ccrn_SegmentReportingUnallocatedCorporateExpenses_1c3150d8-d9e6-478e-a795-dfbe5b1d0cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ad218491-4bc4-49dc-a015-63cc4e8cf136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_012f56a5-ff19-42f1-b2e2-001fc58bf132" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ad218491-4bc4-49dc-a015-63cc4e8cf136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_AcquisitionAndIntegrationRelatedCosts_2cfc6cf0-c0e8-4e8c-9775-134b41483eb6" xlink:href="ccrn-20220331.xsd#ccrn_AcquisitionAndIntegrationRelatedCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_012f56a5-ff19-42f1-b2e2-001fc58bf132" xlink:to="loc_ccrn_AcquisitionAndIntegrationRelatedCosts_2cfc6cf0-c0e8-4e8c-9775-134b41483eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_a0232d6e-5398-4be7-b4d0-869cb800c2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_012f56a5-ff19-42f1-b2e2-001fc58bf132" xlink:to="loc_us-gaap_RestructuringCharges_a0232d6e-5398-4be7-b4d0-869cb800c2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_fe7e61a2-8ece-42fd-b168-e38135c7aa1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_012f56a5-ff19-42f1-b2e2-001fc58bf132" xlink:to="loc_us-gaap_AssetImpairmentCharges_fe7e61a2-8ece-42fd-b168-e38135c7aa1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_08b1e063-0706-4900-95e3-b9acf78d9cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_012f56a5-ff19-42f1-b2e2-001fc58bf132" xlink:to="loc_us-gaap_OperatingIncomeLoss_08b1e063-0706-4900-95e3-b9acf78d9cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/CONTINGENCIES" xlink:type="simple" xlink:href="ccrn-20220331.xsd#CONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/CONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d430ebfe-cdaa-4ecb-a6a4-cbfc8010a827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5cf1911a-4617-4bd0-8c8a-88795ce75a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d430ebfe-cdaa-4ecb-a6a4-cbfc8010a827" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5cf1911a-4617-4bd0-8c8a-88795ce75a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/INCOMETAXES" xlink:type="simple" xlink:href="ccrn-20220331.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bc20847e-f4f6-46f6-9350-1ab33b2e8c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_591b0e3b-7edd-49b1-81a8-3cf554d2547f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bc20847e-f4f6-46f6-9350-1ab33b2e8c35" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_591b0e3b-7edd-49b1-81a8-3cf554d2547f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/INCOMETAXESDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#INCOMETAXESDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/INCOMETAXESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d9e7282a-94a8-411d-a00a-86443c0fd534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0f5d3c47-82fe-4e7c-950b-4bec540a28d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9e7282a-94a8-411d-a00a-86443c0fd534" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0f5d3c47-82fe-4e7c-950b-4bec540a28d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems_acb8a714-48b1-4917-b7b7-a1591b6b35f6" xlink:href="ccrn-20220331.xsd#ccrn_EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9e7282a-94a8-411d-a00a-86443c0fd534" xlink:to="loc_ccrn_EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems_acb8a714-48b1-4917-b7b7-a1591b6b35f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3eefdd60-96cf-4b1a-9c82-e708201d6843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9e7282a-94a8-411d-a00a-86443c0fd534" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_3eefdd60-96cf-4b1a-9c82-e708201d6843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_b5611b4d-d3bc-4eaf-af9e-793c01d677b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9e7282a-94a8-411d-a00a-86443c0fd534" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_b5611b4d-d3bc-4eaf-af9e-793c01d677b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_bad348b6-b9d1-4973-afae-9f02f988a01a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9e7282a-94a8-411d-a00a-86443c0fd534" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_bad348b6-b9d1-4973-afae-9f02f988a01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="ccrn-20220331.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6b15dff0-8bab-403e-b128-4e626628a90c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_47a4807f-897c-413c-a230-beeaba2bdf3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6b15dff0-8bab-403e-b128-4e626628a90c" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_47a4807f-897c-413c-a230-beeaba2bdf3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="ccrn-20220331.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_4eb787fb-dc4a-44bb-9a27-bb97ed148b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b7bde243-71a8-40d4-af1c-d0acf10f2ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_4eb787fb-dc4a-44bb-9a27-bb97ed148b14" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b7bde243-71a8-40d4-af1c-d0acf10f2ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7d755cd3-b40c-4613-88a8-482bb7e2d58b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b7bde243-71a8-40d4-af1c-d0acf10f2ad1" xlink:to="loc_us-gaap_DebtInstrumentAxis_7d755cd3-b40c-4613-88a8-482bb7e2d58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_80e4fbc7-4c9c-4e39-a819-4d8c29843e60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7d755cd3-b40c-4613-88a8-482bb7e2d58b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_80e4fbc7-4c9c-4e39-a819-4d8c29843e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_EarnoutNotesPayableMember_c693976e-6fc3-4327-a307-9e503c801e71" xlink:href="ccrn-20220331.xsd#ccrn_EarnoutNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80e4fbc7-4c9c-4e39-a819-4d8c29843e60" xlink:to="loc_ccrn_EarnoutNotesPayableMember_c693976e-6fc3-4327-a307-9e503c801e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f7459cea-3a64-4d3d-a4ae-0b09d740f527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b7bde243-71a8-40d4-af1c-d0acf10f2ad1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f7459cea-3a64-4d3d-a4ae-0b09d740f527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4888a43e-5c4a-44dd-bcb5-16c47bd13d97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f7459cea-3a64-4d3d-a4ae-0b09d740f527" xlink:to="loc_us-gaap_RelatedPartyDomain_4888a43e-5c4a-44dd-bcb5-16c47bd13d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_MediscanMember_23b305e4-2e54-4bba-b647-8492c8331ecf" xlink:href="ccrn-20220331.xsd#ccrn_MediscanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4888a43e-5c4a-44dd-bcb5-16c47bd13d97" xlink:to="loc_ccrn_MediscanMember_23b305e4-2e54-4bba-b647-8492c8331ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_988428c1-0a0a-4a40-8cd3-be9375b578e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b7bde243-71a8-40d4-af1c-d0acf10f2ad1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_988428c1-0a0a-4a40-8cd3-be9375b578e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_41bd95f2-5e9f-4137-9e06-ff49272127c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_988428c1-0a0a-4a40-8cd3-be9375b578e0" xlink:to="loc_us-gaap_NotesPayable_41bd95f2-5e9f-4137-9e06-ff49272127c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ccrn_NotePayableNumberOfPaymentInstallments_4576e1bf-2d4b-4014-95b4-6943632859d3" xlink:href="ccrn-20220331.xsd#ccrn_NotePayableNumberOfPaymentInstallments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_988428c1-0a0a-4a40-8cd3-be9375b578e0" xlink:to="loc_ccrn_NotePayableNumberOfPaymentInstallments_4576e1bf-2d4b-4014-95b4-6943632859d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_fe65964b-ca91-41a2-9799-cfbd72e7443d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_988428c1-0a0a-4a40-8cd3-be9375b578e0" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_fe65964b-ca91-41a2-9799-cfbd72e7443d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.crosscountryhealthcare.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="simple" xlink:href="ccrn-20220331.xsd#RECENTACCOUNTINGPRONOUNCEMENTS"/>
  <link:presentationLink xlink:role="http://www.crosscountryhealthcare.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_b34df95d-6ce1-44d5-b05f-c72d3714d2e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_e1d67bdd-3da1-4316-a6c8-06103b6b4c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_b34df95d-6ce1-44d5-b05f-c72d3714d2e6" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_e1d67bdd-3da1-4316-a6c8-06103b6b4c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ccrn-20220331_g1.jpg
<TEXT>
begin 644 ccrn-20220331_g1.jpg
M_]C_X1#?17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    D    <@$R  (    4
M    EH=I  0    !    K    -@ +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P($-#(#(P,3D@*$UA8VEN=&]S:"D ,C Q.3HP-CHQ-R Q-#HT-CHR
M,@     #H $  P    $  0  H ( !     $   Z<H , !     $   7=
M      8! P #     0 &   !&@ %     0   28!&P %     0   2X!*  #
M     0 "   " 0 $     0   38" @ $     0  #Z$         2     $
M  !(     ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4 9(     !_]L A  ,
M" @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,
M# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,
M#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !
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M4')I;G0 .$))300E       0UPI0%;\,*P7ZOCQ>"-2! 3A"24T$.@
MY0   !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0
M  !);G1E96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET
M8F]O;      +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93
M971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F
M4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O
M9D--64L .$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P
M=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O
M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 2P    !  $!+     $  3A"24T$)@      #@             _@
M.$))300-       $    'CA"24T$&0      !    !XX0DE- _,       D
M          $ .$))32<0       *  $          3A"24T#]0      2  O
M9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M!@       0 U     0 M    !@       3A"24T#^       <   ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H   X0DE-!         (  #A"24T$ @       @  .$))
M300P       ! 0 X0DE-!"T       8  0    (X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #60    8
M            !=T   Z<    $@!# $, 2 !? $8 :0!N &$ ; !? $P ;P!G
M &\ 7P!2 $( 1P    $                          0             .
MG   !=T                      0                         0
M 0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P  !=T     4F=H=&QO;F<   Z<    !G-L:6-E<U9L3',    !3V)J8P
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M;VYG   .G     -U<FQ415A4     0       &YU;&Q415A4     0
M $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E
M>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L
M:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T
M06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G
M0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M"71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG          QB
M;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"
M24T$*       #     (_\        #A"24T$%       !     (X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MDTFLUL%=I-=;+6V_V_\ 1KJ$DDB;32DDDD%/_]D .$))300A      !=
M 0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    %P!! &0
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M(
M    $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0
M  ($    %')865H   (8    %&=865H   (L    %&)865H   )     %&1M
M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4
M)&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P    #')44D,   0\
M   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT
M("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C
M !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y-C8M
M,BXQ
M          !865H@        \U$  0    $6S%A96B
M    6%E:(        &^B   X]0   Y!865H@        8ID  +>%   8VEA9
M6B         DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N
M:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                                     &1E<V,
M        +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E
M("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@
M8V]L;W5R('-P86-E("T@<U)'0@                            !D97-C
M         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y
M-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N
M(&EN($E%0S8Q.38V+3(N,0                                  =FEE
M=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6
M %    !7'^=M96%S          $                        "CP    )S
M:6<@     $-25"!C=7)V        !      %  H #P 4 !D '@ C "@ +0 R
M #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0": )\
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M>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$?^6
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M 1$  A$! Q$!_\0!00 !  (" P$! 0$           0* PD'" L&!0(! 0$
M  <! 0$              0(#! 4&!P@)"A    ,' 00%"0D! 0$  P$! 0($
M #$#!08'"" P0!$)$#05-0I0(4$3%!8V.!E@<!(R,Q<W&#F &D+0(B0E(Q$
M 00! @(% @\*" P$ @$5 @$#! 4&$0< $B A@1,(,100,$#P05%Q(A75EK9W
MMSA0D;'!M7;6-Y=X8:'A,B,6-IA@<-'Q0M(STR34%X> E"4U4C2G8D-3E;AR
M@I,F9B<8T&-S@T1T158)$@ "  ($!@P)!0T%" (" @,! A$# "$Q!"!!47$2
M!3! 88&1H;'1(C)R$Q#!0E*2LM(S!E!B(W,48/#A@J+"D[,T=)0U!W" 0R05
M\5-CH\/3U-7B@T2T%M E5,3_V@ , P$! A$#$0   +_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                             !^;/#\:K+)EC]%1F
M                     'SM:6--#]6G-^M3B                 (TT/G:
MTH^DH3YX                 !\Q7EQQA^K3F_6IQ
M
M
M            '1/;,?J,Z-A=:N\8OH[M6/ZNY^TXKR%'^0?9VL_:+ WG>S4\
MALYT3*[C>:9SNYJU^                              !^/5EU:[[B=3?
M0\-KJW3&=,-GL>N&;M?E;B0#DVPJ]G\%=]X]4R&RK1\IMZYQF^^&I9
M       =(=JL-1_1<+K7W?%]'MKQ_5S/6G$&2HQ9H"9+'F7&5^U6OW?>+5,A
MLFTC*;:N=YGNMJ]^           !PKE*&H?HV%UB[WB>@VWX[J/L=EP-E[?\
M*K*!R38U>R>$NNZ6KW^Q#3,EM2T#,;.]$RO[%*8
M
M
M     #C:^I5X^RZU7?[-K/2':K      #8/IV2L?\3VC?WQ_8_HJ,P     %
M';U5H/7[,6P       _L^HMYON[2KSOB;CM9KUYWSU+([+M&RG,&-K@
M    =7,_:5J>X:MH"Z_K?"65H      =X-5O[%_%MGL-\:V7[FTJ
M #CV\I5Z>RZW7<[-K/1?;,>      .\.JW]@+CVR6&^-;+S+C*X        '
M\1:<^E8.MSVW5]0O1\+^74@     !S!C:^]3D^P6.N*;/WUU'(@
M
M
M               ?GSPK@=LU>JGZ U#A?*4        .U6OWEN[SEN>\OE.P
M     #S2?<?+.J6P68          GR1V>:)EK!/'=DWU\CV'Z2A.       .
M.KVE5)]!:?6Y[=J_SM:4       #GW#W-M+SQN-@_CFRY8       !BBKS]E
MUJI=Z'TW@K+6X        Y"LJMEWAVTVAN#;;]]9U       !KJW3&4V_2^C
MZU=XQ8        S0;K>79ZV_YUW/NCK%\
M
M                                                        .K&?
MLZ/7JG0=9&]XH         #=_P KS]TOS#O7+..K    #S2?<?+.J6P68
M        ':K7[RXUYJW;<_S'.@     #7-NN,HV>K- ZD;%9          ;B
M.:YN[EY:WWFG%UP     !Q5D*-(3U/H6FSIF#          ':O7[RZ_Y=WO:
MSS[,      ?X5A.[ZG4O]$:=^14E          ^FH3VM//NWV?N#[9+EB
M
M
M                  !K8W?%T-O6W/.#,M;@          =Q]9OK[/D?HG</
M6KT   #S2?<?+.J6P68            _N"TSP/;K8WGG<?\ 0    #2QT_!4
M=O56@_&75,          #N'K5[?L\A]&[::[>     #A;*4//^]@<XZ#;?C@
M          !^E)&WAYQW2S#PW:@    /\*=GI32:V';]6            W+\
MSSEXGRKOW(=E5
M
M                                  UO;MBZ _K_ )SQK?4@
M   .QV$NO0(\?='[FZQ?   #S2?<?+.J6P68             MK>=]RM&\$V
MT    :>^DX2A[ZUY[^%5E            [5:_>>A5XWZ3V/PET    /P:TOG
M[^P><:PM\Q(            %J#@.W6P_/6X@   "KSWG4JD7HK30
M    -F^B96_%Y%Z+R58U0
M
M                                        .L>=M/.P]G\SX'R]N
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M8\=WM/J9L-EKBW7&:>>E83K)G;0    ;<^<YJ^UY&Z)^M3B
M
M
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M&K$]VU33WTG"    6D.";;;3\[[D
M
M                                              !70[3K%,OTUHX
M '8##W-Y#RIO^U/G^7     &**N%VO5Z@'I'2OG:TH  %S[S'O-B7C&S  #S
M2?<?+.J6P68  ]6/Y^=?      $.:%?SL.N4X?2VD?$W5,  3)8^FIX7ZKV#
MPUR  *YG:M8IG^F='   YBQE>\CY4W_;ASK,@    "--"KUWG4ZF7H;3H\T
M !^]1F]'?Q3T_N=K%\  !4_]":=5<[_J(  ^]LZEZ;RAT'<!S?-      ?@5
MI:S7<]5JF^@M/^2N)  !RC85KW/DSH.UGGV8  &O[<,;YSOM/F0  %G#A6UV
MY/.FYSY(@     :CNBX:F1Z;T;J)L=D  /Z+2_ MNME>>=Q
M
M
M     'PUW3\U'W#RW@/+VP  ['82Z]!WQUTCMQKEZ      !J:Z'AJ'WK3GO
MP5Y3  '.>)N/2N\/=2Y"LZH 'FD^X^6=4M@LP !ZL?S\Z^       -+/3\%1
M$]:<]_D  %WWROON^;DFQ  ?-UY/-.]P\MZXYNU  '*N/K>@=X\Z/L T_)
M     5S^TZQ3.]-:/_(  -]G(]BN[^6-]   \WWVSR_H]M5@  +N7EG?=^/(
MMB       '0G;L=11]8\^Z@;)9 #LY@KN^KY'Z'WRU'(@  5/_0FG57._P"H
M@ #=IRW/7KO)W0?]       ..KVE2L]0:+HTZMKX _4IQN1^:-XL6<7V8
M
M
M               "N!VS5Z;?I?2  !^Q2F]"'QSTC95H^5        TY]*PE
M#CUMSS\^>   N%^;=VLL<.VD #S2?<?+.J6P68  ]6/Y^=?        \^[V)
MS?5;O^(  %IC@6W6R_/.X@ :$NN:[2)]3Z$  !>T\F]!W7\NSP       %,S
MTUH]<_M.L  #]NE-Z8GAKJG83#7( '%60H^7K[RY-CB  [;:[>>E1X?ZGE@
M       X1RMO0C]<\[US;KC!L T_)7TO(_0^R.$N@  !0(]?\YU)]$PP  ]%
M3Q?TS8?IF3        Q15"O1VEUENZ:H.0K*K>4\J;_N-YIFP
M
M           !^/2ONB&F^A>%,7O6W'I?C/\ U    =.>*>ANM?,.R?S&'^31
M_F9_,8_S%_,S^9H_S%_,T?XB_F=_,8_Q%_,T?YG?Q&/\S1_B9_,T?XF?S&/\
M3OYF?Q&/\3OYFC_$8_Q._4N;*55HR:U#Z*^Q7VF1P').7U/FO8-!YCSFBYYJ
M8                              \Z#VES+7WN.-  %F;AFU6_?-^Z@
M      54/0.H52_06G@#]"2.[GEF>M,\"V[8#I^2  \TGW'RSJEL%F  /5C^
M?G7P       *M7?-1J8^A].  %B;C&S7/?,>\@ 4'?7?.]/W2,(  -T?,,[?
M \E]"        '&-_2\U?V_RSA+*T  !<%\W;K9>X;M0 &O;<L;YTOM'F0
MWB<JS]Y_RCT         #B;(T?/N]A\W["8:YO.^4N@<DV-4   #S4O</+.I
M.Q68 'Z]./J@^ NNRY8@       #_"GSZ2TK15UC7KYODCH>P_3,F
M
M               !PEAM^K:^>_J7HLX]] ^)[;;H]Q"QQWCYA6L?0_R$_P!0
M   XYUG;ZJOR2^YO4_DW<OXJ38JK%/-AGFQ5&*M'#4CAGCAJ38J[!4FPSL%6
M?#78*DV&>."O'%5FC5(X:LV&O&/4CAJ38*Z/6FP5)L%:."M-@J31ZS!7FP5)
MHU6.&XC^_D,7VGW/C?>+H?GS8WTWRWM1ZOX^YFS6B@
M         =.=EL?-B]O<N  'U5O/Z8GAKJG.N)N         /Q:LOG3^T>9]
M#MMQWUUM/8"X_LEG#A6U]P]:O0  /-)]Q\LZI;!9@ #U8_GYU\       "O9
MV36J5_I_10 !8%X]LEU[R[O8 ^(NJ?E[>\N3?.5Y0 !Z&/C7I6S+1LJ
M   !5+]!:?50] Z@  -MO.LS?V\@]&  U8[_ (CSZO8G-P !N+YKF[['D;H@
M         X(RUOR_CJW[%*8    >8[[KY3U^S%L !(ECZCW@GK7WMI4
M    C30X%RUOV#P]R
M                                       !IBXY[LJ/^5?M#Q3:;;@N
M(1[F,>XA@N%CONGS"M:^@_D)_J   ''.M;A51^2GW+ZH<G[KBJL4\V&>;%48
MJT<-2.&>.&I-BKL%2;#.P59\-=@J389XX*\<56:-4CAJS8:\8]2.&I-@KH]:
M;!4FP5HX*TV"I-'K,%>;!4FC58X;B,>K/'J,%Q&/5GDW-MM)ZSY"L&>@?FML
M[Z7Y-                           KB]KUBFMZ8T<  ;PN59^]#Y1Z
M       !J/Z+AM4G0</9.XCM'/N'N0   /-)]Q\LZI;!9@ #U8_GYU\
M  "OUV'6Z4/J+1  !8)X[LEUKR]O8 U1]!P_G\>PN<  #M[KE[Z4OA_J7^@
M       '3K9;'S8?;W+@ !]U:5/47\%=:_2DB -=^YXSSK/:',P !]G:S^E1
MX@ZGV(PMR              !YHWN/EG578+,  72_,.]6&.-;*
M
M                      /\1K0>9_JY6=\X?5R+7C@N&"XA'N8Q[B&"X1[E
M8_[A\PK7/?OD)_J   ''&M;A50^2_P!S.IO*>Z8IYL,\V*HQ5HX:D<,\<-2;
M%78*DV&=@JSX:[!4FPSQP5XXJLT:I'#5FPUXQZD<-2;!71ZTV"I-@K1P5IL%
M2:/68*\V"I-&JQPW$8]6>/48+B,>K/'JQP5XQZT^SSI_DJV-ZF^.':[9^.@
M                        4G?4>AU_NP:X  +J?E_>["''-D
M      \TGW'RSJEL%F  /5C^?G7P       *]?9-:I8>G]%  %DGB.T7&O-6
M[@"MAV_5J=?I320 !8FXQLUSWS'O(         'F@>Y.5]6\_:  #TF/$74>
MY>LWP X9R=#S!/>')_Y  !M)T'+WU/(_0^1K*J              //Z]@\XU
M0]"PX  Y6Q];T /'_1MANF9,
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MO[G?F3>=J?/\N             !4[]"Z=5@[]J(  'V]I4MJ^>-RL><3V?\
M;I3
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M(            Z/[58><%[8Y?AB   ';'7KRROP[:=_7(-CYAQM<
M
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M.7,=6
M                               &"6I4Z\;_ &BT1\ ^BN&X1[AAN81K
MB."XA@N&"XA'N8Q[B&"X1[E'N6"XA@N'^16=.S_*ZTYVWY,   #BO5=XJ<_)
M_P"Z?5SFW:L-2.&>.&I-BKL%2;#.P59\-=@J389XX*\<56:-4CAJS8:\8]2.
M&I-@KH]:;!4FP5HX*TV"I-'K,%>;!4FC58X;B,>K/'J,%Q&/5GCU8X*\8]:>
M/4C'N8QZLV"I-&N8V%^X?-:UWZ,^/V:,@                       \L?W
MWR/Y2XD  ^KMY_4X\"=<                'FD^X^6=4M@LP !ZL?S\Z^
M    !U)V*RH(^O>==0-DL@ !;I\Y[G9ZX1M@ %';U5H.B7K.O  "^_Y%Z+N$
MYMF@         *>_I+2JTG<=5  %U[R[O=@7CVR  #3!T[!41_6?/H<T
M !RYCJVX7FV;W,\RSFXCFN;YAQM<         #@[*V_G6>T.9]8,]:     #
M]FE-M#T/+;FN99S<US+.=T]7OP
M                                                 !$DKU)/%7VQ
MTB\'^@<>NPW"/<,-S"-<1P7$,%PP7$(]S&/<0P7"/<H]RP7$,%P_R(6BNU?*
M*T-VKY2   #BK5=XJ;?*7[J=6N:=JPSQPU)L5=@J389V"K/AKL%2;#/'!7CB
MJS1JD<-6;#7C'J1PU)L%='K38*DV"M'!6FP5)H]9@KS8*DT:K'#<1CU9X]1@
MN(QZL\>K'!7C'K3QZD8]S&/5FP5)HUS&/5CO=[%\^+>_I3XOS)J
M              'EC^^^1_*7$@ 'U=O/ZG'@3K@                \TGW'
MRSJEL%F  /5C^?G7P    !$FATAVJPT2=9UZM3W#5N-KZD  -KW/<Q?N\A=%
M_7IS  4=O56@Z)>LZ\  +[_D7HNX3FV:          I[^DM*K2=QU4  77O+
MN]V!>/;(  !7C[+K5,CTWHWY\\      !^M3CM'T'+[MN6Y[>#RO/]C\)=
M       ='MJQ] _U]SKK;F[4      #NCK%]NSY;GMX_*M@V*Z7D_P"X
M
M                  /SJ5U4@\1_;?2MPCWU@N$>NPW"/<,-S"-<1P7$,%PP
M7$(]S&/<0P7"/<H]RP7$,%P_R("TYVWY,6=.S_*X   <5:MO%3'Y3?=7JSS7
MM6&I-BKL%2;#.P59\-=@J389XX*\<56:-4CAJS8:\8]2.&I-@KH]:;!4FP5H
MX*TV"I-'K,%>;!4FC58X;B,>K/'J,%Q&/5GCU8X*\8]:>/4C'N8QZLV"I-&N
M8QZL8]2?=9UGPE<B]+?$G]JK8@                     #RQ_??(_E+B0
M#ZNWG]3CP)UP                >:3[CY9U2V"S  ':W7[P    #\6I+PME
M*'RMQ(   -T_+\[=Y\L[[R'950 !1V]5:#HEZSKP  OO^1>B[A.;9H
M   "GOZ2TJM)W'50 !=>\N[W8%X]L@   U"]'PM)?U)H?7[,6P       F2Q
MVO<]S%A;C>R[O^5Y[Z2A.       !ULSEK2(]3:%JFZ#AP       .Y.LWU@
M7CVQV$>.;+V$PUR
M                                   /S:-W43\,_<'37PSW?@KL%PCU
MV&X1[AAN81KB."XA@N&"XA'N8Q[B&"X1[E'N6"XA@N'^1 "TYVWY,6=.S_*X
M   <4ZMO%2WY4_=;JQS;M>*NP5)L,[!5GPUV"I-AGC@KQQ59HU2.&K-AKQCU
M(X:DV"NCUIL%2;!6C@K38*DT>LP5YL%2:-5CAN(QZL\>HP7$8]6>/5C@KQCU
MIX]2,>YC'JS8*DT:YC'JQCU)\%Q';STOQ==1]-?#+Z6OBP
M       /+']]\C^4N)  /J[>?U./ G7                !YI/N/EG5+8+,
M           #O9J>0M-<"V[>UR;8?[@   H[>JM!T2]9UX  7W_(O1=PG-LT
M         !3W]):56D[CJH  NO>7=[L"\>V0   #B/(T:J/H'3ZY_:=9^6N)
M        .P6'N;+_  W:K(_$=H^[M*@       CS0K[]AURJ%Z$T[K3G+4
M     #Z&C-OKY'L5IC@6W=O];O0
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MNL"                     /+']]\C^4N)  /J[>?U./ G7
M    !YI/N/EG5+8+,          ?KTYMOO-\U: X/MFT[0,O_H   !1V]5:#
MHEZSKP  OO\ D7HNX3FV:          I[^DM*K2=QU4  77O+N]V!>/;(
M !URS=K6^[9J]?'L>M]>,S;        =CL)=7 /-^Z[U>3[        !\S7D
MT+]<UZN3VK6-<&[8L       #]ZC-96X?M-KGSYN'VUK4
M
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M+NCK%\
M                      /F[/+4^OG]]V=57%?9N"X8+AAN(8*[!<(]=AN$
M>X8;F$:XC@N(8+A@N(1[F,>XA@N$>Y1[E@N(8+A_D0  _P!0MA=T^0EDWL'S
M#   '%&K[Q4@^6GW9ZJ<X[5@JSX:[!4FPSQP5XXJLT:I'#5FPUXQZD<-2;!7
M1ZTV"I-@K1P5IL%2:/68*\V"I-&JQPW$8]6>/48+B,>K/'JQP5XQZT\>I&/<
MQCU9L%2:-<QCU8QZD^"XC'JQC59\%S'OKMWGB];Z;^ O,N0TD
M         >6/[[Y'\I<2  ?5V\_J<>!.N                #S2?<?+.J6P
M68            &ZKE^=NY>6=]Y'LJH  H[>JM!T2]9UX  7W_(O1=PG-LT
M        !3W]):56D[CJH  NO>7=[L"\>V0       1IH:[=SQNH#I&$U$]&
MPNLO>L5^!6E      VM<^S%]GR-T3["VG         '6/.VFGSI.%U$=&PNI
M?HF&X:R=      #FG%U_0!\?]'[\ZAD0
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MR<,O:>F_@#V%RW.                    /+']]\C^4N)  /J[>?U./ G7
M               !YI/N/EG5+8+,  7!_-NZ@    ?/5Y> <O;=#]MQ^K;?L
M1\A<R   ;8>>YB_AY!Z-^E)$ "CMZJT'1+UG7@ !??\ (O1=PG-LT
M  !3W]):56D[CJH  NO>7=[L"\>V0         <?7E/5/T'#Z>^DX33-TW!]
M4M@LP    -^'(MBNY^6=]           @SPUX;GC-/O2,+IMZ9@]:^[XN+-
M    =F\%=^B_XMZ;S3BZX
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MS\_W:/-\G                   'EC^^^1_*7$@ 'U=O/ZG'@3K@
M         \TGW'RSJEL%F  /5C^?G7P     !Q'D:-5KO^H5H.Y:K_$0  N/
M^:=WLB<2V@ "CMZJT'1+UG7@ !?7\C=$W&<US8         %/#TGI-:ON&K
M "Z]Y=WNP+Q[9           /XBUU;IC-"77-=T ]@USA_)4    +Z'DCH>Y
M/F><            '7C,VVBGK&O5XNS:UT6VS'@   6%^-[+=,\P;T
M
M       !\/B]CIT?./[VZY.1^K<%>&"O'#7A@N&"X8;B&"NP7"/78;A'N&&Y
MA&N(X+B&"X8+B$>YC'N(8+A'N4>Y8+B&"X?Y$   !_J%L;NGR"LD]@^8H
MXFUG>*B7R_\ NWU0YWVW#/'!7CBJS1JD<-6;#7C'J1PU)L%='K38*DV"M'!6
MFP5)H]9@KS8*DT:K'#<1CU9X]1@N(QZL\>K'!7C'K3QZD8]S&/5FP5)HUS&/
M5C'J3X+B,>K&-5GP7,8]2/\ D0[)9CF-[KTY^?[N)L'%@
M   /,)]W<HX2RMN  /5 \!]=^CH3                >:3[CY9U2V"S  'J
MQ_/SKX       J0^BM,J]=YU,  =O=<O?2C\0=2_N  4J?4&B5\NQZV  +SG
ME'H&\?E6?          I:>GM%KS]EUH  7D?*>_[TN4;             /@;
MRG6L[?JU6;ONH_#7=,  #9[HF6]";QOTD             8XM,?3<%4']'Z7
MTTV:Q   _6IQ]+;PYU3LO@[H
M                                    #X/$[-39^:_WYU^\I]/8;A@K
MPP5XX:\,%PP7##<0P5V"X1Z[#<(]PPW,(UQ'!<0P7#!<0CW,8]Q#!<(]RCW+
M!<0P7#_(@   !D2VYN]?'&Q-UKYK@  #B36=YI^?+O[T=8M"[!@KQQ59HU2.
M&K-AKQCU(X:DV"NCUIL%2;!6C@K38*DT>LP5YL%2:-5CAN(QZL\>HP7$8]6>
M/5C@KQCUIX]2,>YC'JS8*DT:YC'JQCU)\%Q&/5C&JSX+F,>I'_(@.<\GH-['
MTU\!.]FS\                   'G&^UN8]#MMQP  ])#Q)U#NGJ]^
M          !YI/N/EG5+8+,  >K'\_.O@      #X"\I^8Y[KY1Q]>4P !Z1
M/B7J'=K5K\ 5$/1NEUB^[:H  +AOFS=K*W#]I          H2^N>=Z=NE80
M 7]_('1MMG.\R             .C^U6%![UUSKJ[G[0  ?W!Z9OAGJO9/!W0
M             'Q-U3I$^IM"TD=3P(  %Q3S7NUD_B&T@
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MG@  !=W\L;[OLY'L0               'FD^X^6=4M@LP !ZL?S\Z^
M !06]><ZU"]'PH  O*^4]_WG<HV  5Q.UZQ37],:.  +"?&]DNH>8-[
M     \ROW1RKKAF[4  >E3X?ZEVZUR]              U_;AC?.S]G\S_)J
M0  %[#R=T'=GRW/              #YRO+YVWL[F?0C;L<  -^'(MBNY^6=]
M
M            XOP&YTX/F=]^^BW+O2&&M+AKQPW#!7A@KQPUX8+A@N&&XA@K
ML%PCUV&X1[AAN81KB."XA@N&"XA'N8Q[B&"X1[E'N6"XA@N'^1     #(EMS
M=Z^.-B;K7S7   '"VJ="I_\ S)^\'6'1>Q1JD<-6;#7C'J1PU)L%='K38*DV
M"M'!6FP5)H]9@KS8*DT:K'#<1CU9X]1@N(QZL\>K'!7C'K3QZD8]S&/5FP5)
MHUS&/5C'J3X+B,>K&-5GP7,8]2/^1  <C7>M7A_2GP9VA[KY2
M      %6KOFHU,?0^G  #?-R38;OOE??@         -;.[XNJSW_ %"T9P7;
M=H&AY8   #S2?<?+.J6P68  ]6/Y^=?        ID>FM&KI]IUD  7'?-.[V
M1N);0 -8&^8GSV_8_-@ !VEP%WZ77ASJF2         #HWM>/\X#VQS   <G
M6%7U#/!O69,L0             !0\]:\]TO].P0  N/>:=WLB\2V@
M       "OUV'6Z4/J+1  !MEYYF;_P!X_P"C
M                                               #BS7MUII?,']
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MFQV7\1=OM;O0         -=NYXSSKO:',P !M9Y]F/0*\>]'
M                                                           X
M>UC?J;'R]_0+T[YSWO%7A@KQPUI<->.&X8*\,%>.&O#!<,%PPW$,%=@N$>NP
MW"/<,-S"-<1P7$,%PP7$(]S&/<0P7"/<H]RP7$,%P_R(     ?MU+&[-Z/\
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M\3YZ_LCFP  W7<NSU[7R;T$
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MMEN+SIN8
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M=M?/Z]@\XZ<[+8@ #NSJU_Z.GBGI_P"M3B !YI/N/EG5+8+,  >K'\_.O@
M     56._P"H50_0FG@ "V[YUW*T-P;;0 /RZD/-E]N\MZE;%9@ #D2RJ^@%
MX_Z-L=TG*       5H^Y:K3X](Z4  !8DXQLUS_S'O(  X1RMOYXGLOFO478
M[( 2Y8V7.&[3;#\][C]S:5       !KRW/&>=A[/YG@B  Y.L*OI\^$.L?N4
MI@ /\*57J#1*^78];  VCZ#E[I_F#>NYNLWP       _#JR^<;[6YCTJVBP
M %]3R/T3<?S3-@
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MXFCEZJT#K9G+4  ?T7X/(G1-P/-\V  /-)]Q\LZI;!9@ #U8_GYU\
M"KSWG4JD7HK30 !:T\^[A:O\_;>  -!?7M=I(>I="   Y1L*UWGRQONYGF6<
M     'Y\\*J'H'4*K_?M0QQ  #[*VG](_P 1]1[18&[  ^5N)* OK_G.L#?,
M2  !VCP%W;3\\;EOAY)L,R6(     '!V5M_/J]B<WZ1;58  "P;QS9+JWE_>
MP !5R[WJ52GT1IH  'T]">RWPW:;0'!]LYAQM<     "/-"FGZ8T>NAVG60
M!SABKCTT?"_5?HJ,P
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M^;0               '%M_1\X3VQS#K3G+4  #^C=QRS/6CN";=L;TK)@
M=2=BLJN7>]2KV]CUN#/   "P[QG9;HWF+>@  /-)]Q\LZI;!9@ #U8_GYU\
M      "LWW/5:@'I#2@ !:@X#MUL/SUN(  Q1>?U[!YQJFZ#AP  ,D&^CDFQ
M6HN ;=W5U>_   &*+41T;"U,/0^FZY]UQ@   MK^=MRM&<%VT  5$/1NEUB^
M[:H    .Y6LWUC_B>T;WN2[!SYB+D   #'%I@Z=@J<WI72.K&?M  !.DCZ-'
MBSIW>W4L@ !K&WO$^>[[&YO'F@   !R38U;!G'=DL%<=V38'IV2_T    Z;;
M-8T\O26DZ<NEX0  "V7YYW&TQP+;@
M                                     .N6@==IO?*']"'7W3^HX:K'
M68:[#58:[%7A@KQPUI<->.&X8*\,%>.&O#!<,%PPW$,%=@N$>NPW"/<,-S"-
M<1P7$,%PP7$(]S&/<0P7"/<H]RP7$,%P_P B   _;J6-UKT;\,MS?0_$0
M      X1UCH=-SYR?>?JOI?8\%2;!6C@K38*DT>LP5YL%2:-5CAN(QZL\>HP
M7$8]6>/5C@KQCUIX]2,>YC'JS8*DT:YC'JQCU)\%Q&/5C&JSX+F,>I'_ "(
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MZ=]M:U
M              !PGI_2*8GR/_1%U[TOJN*O##58ZS#78:K#78J\,%>.&M+A
MKQPW#!7A@KQPUX8+A@N&&XA@KL%PCUV&X1[AAN81KB."XA@N&"XA'N8Q[B&"
MX1[E'N6"XA@N'^1  #].>UNF^BOASNPZ/X7          '".L=#II?.?[U=6
MM,[%@K1P5IL%2:/68*\V"I-&JQPW$8]6>/48+B,>K/'JQP5XQZT\>I&/<QCU
M9L%2:-<QCU8QZD^"XC'JQC59\%S&/4C_ )$     +_?J?\[FQ7;?-0
M          KW]CUNEAZ?T3'$           !W.UB^]!CQWTCGW#W(   \TGW
M'RSJEL%F  /5C^?G7P       -1_1<-0,]?<Y  ',^,K^EOX<ZGR+950  -7
M6^XF@EZ]YS\=<R            =V-6O_ $(O'/2>:<77   'YL\*I?H+3ZMW
M?-2AS0             V':9D_0C\<=)^RMIP  !I^Z1A:27J70N"LM;@
M        ?:VM3T%O'?2-C&E9,
M                                 1Z=6G-\F?T(:^^(>J<-6.*O##58
MZS#78:K#78J\,%>.&M+AKQPW#!7A@KQPUX8+A@N&&XA@KL%PCUV&X1[AAN81
MKB."XA@N&"XA'N8Q[B&"X1[E'N6"XA@N'^1  ?ISVMT'T1\0-WG2?"
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M3L9A;H    #5;O\ B*4OJ+1.I&Q60           '>S4\A?]\?\ 1^>L1<
M  #K_F+:E_Z<T;2YT_!            ?96T]ZCR?T'<3S7-@
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M        HK^L.?:1.IX$  "PQQK9;I?F'>@  !T9VO'T9O5N@=&]KQX
M    &\GE.?NH>8-[Y*L:H     'PUW3JQ=]U&LYW/5?E;B0          ;E^
M9YR[GY9WWEG'5@     -&W5M?J$^CM+ZMY^T          ':; 7=YGRET#9)
MI&4
M            P25:/'QB_2UULT'K^.JPU8XJ\,-5CK,-=AJL-=BKPP5XX:TN
M&O'#<,%>&"O'#7A@N&"X8;B&"NP7"/78;A'N&&YA&N(X+B&"X8+B$>YC'N(8
M+A'N4>Y8+B&"X?Y$!^G/:W0?1'Q W>=)\(             #K]JO3:8GSS^]
MO6;4^M1ZS!7FP5)HU6.&XC'JSQZC!<1CU9X]6."O&/6GCU(Q[F,>K-@J31KF
M,>K&/4GP7$8]6,:K/@N8QZD?\B     &WS?O&=Y3TM\$P
M  .(LC1J9^A]-KN]FUK\>K*       !W4U>^N">;MVW%\US8     \TGW'RS
MJEL%F  /5C^?G7P       !U-V&S\\GV7S3@3+VX  W7\NSU[3R;T$   #Y.
MXDJT=]U&LCW75/C;F0       #L]@;NW=YRW3>OR?8        .JNP6=6/ON
MHZ!>OZY\Y7E        '8/#7-M3SON5@CCVR9(       /D;F2N'VO6*R/==
M3ZZ9JV        '[=*:QGQ79[8GGK<.4;"L
M                                            .@G"O5%-SY(_H7_B
MK#'58:L<5>&&JQUF&NPU6&NQ5X8*\<-:7#7CAN&"O#!7CAKPP7#!<,-Q#!78
M+A'KL-PCW##<PC7$<%Q#!<,%Q"/<QCW$,%PCW*/<L%Q#!</\B'Z<]K=!]$?$
M#=YTGP@              .ONJ]-I??/;[X=9=6ZO@KS8*DT:K'#<1CU9X]1@
MN(QZL\>K'!7C'K3QZD8]S&/5FP5)HUS&/5C'J3X+B,>K&-5GP7,8]2/^1
M  #;_OWC&\CZ6^"H                  '4C8K*MEV_5]!_7==X0RMN
M /[@V7Z-E;(G$]HWK\FV']:G$     "DYZCT/@/+VP  OO\ D7HH
M'6'/6E5[OVHZA^CX7@/+VV*(#=#S'.WE_*6_@    =>,S;5MNW:M7S['K?7C
M,VP     &P;3LE8TXKL]@'C^Q_46\X         Z_9BVKW=DUO0=UW7.C^U6
M       V":=DK$?&=FL#<=V/[:UJ         ?.UI='W5<!7W[#K>I[H>'_(
MJ2@     <\8BXWY<BV.R7Q':.UVO7@
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MO'5[2']P<IV%;M-@+OO=J61V>Z'E=Q/-LYVSUV\
M          _/GAK,WK%:E^AX;7'NV+Z8;-8];<Y:_"7=,9H.5\?6[08"[[T:
MID-E^C97<!S?-]S]8O@           !TVV:QU.="P^M?>,5T;VNPZL9^SX1R
MMO\ DU(#]"2/-.+K]I\!>=Y-4R&RC1\IMUYSFNX6MWH           '$61HZ
MF>B8;61O6)Z#;?CNHFQV77O,VWQUS(/[@Y.L:W9'!W7=/6+[8EI>3VL\_P Q
MLST7*_H21
M                    %47Y=_=/4WY@]V?Q5ACJL-6.*O##58ZS#78:K#78
MJ\,%>.&M+AKQPW#!7A@KQPUX8+A@N&&XA@KL%PCUV&X1[AAN81KB."XA@N&"
MXA'N8Q[B&"X1[E'N6"XA@N$R>A<R]#?$C>CTSP*                .OFK=
M-I9> ?OCUDU7K4:K'#<1CU9X]1@N(QZL\>K'!7C'K3QZD8]S&/5FP5)HUS&/
M5C'J3X+B,>K&-5GP7,8]2/\ D0     MH]V^/EC_ *]\R@
M        /S9X?C59?W*4T^2(
M_(J0_+J2_049I<L0                 /F:\N.,/JK><
M  #\>K+^9/#]^C-,EB
M                                *>OR6_03KKX+ZV_BK#'58:L<5>&&
MJQUF&NPU6&NQ5X8*\<-:7#7CAN&"O#!7CAKPP7#!<,-Q#!78+A'KL-PCW##<
MPC7$<%Q#!<,%Q"/<QCW$,%PCW*/<L%Q#+=4+DGH3XG[W^G_/X
M      =>]7Z=2N\!_?+K!J_6<-Q&/5GCU&"XC'JSQZL<%>,>M/'J1CW,8]6;
M!4FC7,8]6,>I/@N(QZL8U6?!<QCU(_Y$     /09]6?G,[[[1YZ
M
M
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M/\VG]H
M
M
M   "K=\SOMQIR\F_0?\ BK#'58:L<5>&&JQUF&NPU6&NQ5X8*\<-:7#7CAN&
M"O#!7CAKPP7#!<,-Q#!78+A'KL-PCW##<PC7$<%Q#!<,%Q"/<QCW$,%PCW++
M=T+C/I'XG;V^I?/X                   =>=8Z=2C\&_?3J_K/6X]1@N(Q
MZL\>K'!7C'K3QZD8]S&/5FP5)HUS&/5C'J3X+B,>K&-5GP7,8]2/^1     7
M!._?&&P9U;YR@
M
M
M          :.?%GTPK3_ #O^Q_\ %6&.JPU8XJ\,-5CK,-=AJL-=BKPP5XX:
MTN&O'#<,%>&"O'#7A@N&"X8;B&"NP7"/78;A'N&&YA&N(X+B&"X8+B$>YC'N
M(8+AENZ%Q3TO\3M['5?G\                    .O&L].I.^$/OMU>UGK.
M"XC'JSQZL<%>,>M/'J1CW,8]6;!4FC7,8]6,>I/@N(QZL8U6?!<QCU(_Y$
M  .X^P<5]"SU?^<']VKCP
M
M
M                  .M?.^QT=_C#^EO%48ZK#5CBKPPU6.LPUV&JPUV*O#!
M7CAK2X:\<-PP5X8*\<->&"X8+AAN(8*[!<(]=AN$>X8;F$:XC@N(8+A@N(1[
MF,>XAENZ%Q#TW\3MZO6?G\                     .NFL]0I$>#_O_ -<,
M%T^/5GCU8X*\8]:>/4C'N8QZLV"I-&N8QZL8]2?!<1CU8QJL^"YC'J1_R(
M #]>I9WT?4'Y\ME&X>8                      !Q;?T>D6U6'5_/6G#63
MH?+UY/T9)N6L=6[/X&[[U:GD.:,97              AS0Z@[)9=/-ELNO\
MF+;CJ]I18P^RMJG-6+K]K=?O.[FJW_V]K4
M
M                                              IY?)O]!&NO@OK;
M'58:L<5>&&JQUF&NPU6&NQ5X8*\<-:7#7CAN&"O#!7CAKPP7#!<,-Q#!78+A
M'KL-PCW##<PC7$<%Q#!<,%Q"/<Q7-*WYZ>^*V^;L'SS
M     '635>LTDO#7WWZW8#J,>K'!7C'K3QZD8]S&/5FP5)HUS&/5C'J3X+B,
M>K&-5GP7,8]2/^1   #_ %"X-W_XP6">J_.<                    #'%J
MZWW$:.NJX#41T;"])]IL,,0  ']P=T]8O]QG-,WOBY+L.Q_2<H
M!Q'D:.C/J^OZ5^GX+5MOV(XUOJ0   _3IQV"Z=DMQ'-LWO>Y+L/>75,@
M  ./KRGPIE+<  <EV-7F'&UP        ..;VEPSDZ   Y+L:O,.-K@")-#J]
MGK0  =I<!>9X         !UXS-M\U7D  E2Q[18&[ XNOZ/$F1H@
M       <MXZMRC85@/F:\G7G,VP        _4DCRGCZW(ME5     ' >7MOC
M[F0  #L5A;KZ*C,         !QU>TN&,G0   [#8:Y^FH3@
M                =$.)>GZ:7R0_0Y&GGPU8XJ\,-5CK,-=AJL-=BKPP5XX:
MTN&O'#<,%>&"O'#7A@N&"X8;B&"NP7"/78;A'N&&YA&N(X+B&"X8+B'^74EN
MGU!\7=^79OG6                       .N&M=2I<>*/O!TTU+N&"O&/6G
MCU(Q[F,>K-@J31KF,>K&/4GP7$8]6,:K/@N8QZD?\B   _0GMK<O>?CE8;ZQ
M\W0                   !^?/#07U[7*OW>-3Z0[58       ;(-)REJ/@&
MW;G^8YW_ $        '6S.6M6;OFHU^NQ:W\;<R      #^C:YSW,6J_/^W[
M6N?9@     5^NPZW2A]1:(  ++?#MJN$>;=U         KG]IUFF9Z:T8  6
M6^';5<(\V[J .*,A1\O/WGR8  6^/.&Z6:^%[6         //*]E<UUH[SB@
M .5L?6]0WP9UD"KSWG4JD7HK30               +;OG7<K0W!MM UH[SBO
M/*]E<U         '(5E5[C:U>["=.R6UWGN9W,<RSG+N.K   :$.NZ[2+]3:
M$  !:"X-MEN'SKN8         %!SUWSK3_TC"@ #NUJU_P"C/XKZ=]%1F
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MJ,WHR^+.G=X-5OP        -,73L'0Y]:\\  &:#T"O'O2-J?/\ +@
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MG60*O/>=2J1>BM-                MN^==RM#<&VT#6CO.*\\KV5S4
M        ?34)[9?GG<;-W"MKR0 #J7L5GYQ/M;F'PUW3  &VCG>9O]>0.C?Z
M        ?/UI?.(]K\PZ9[-8@ "P;QS9+JWE_>P
M          /G;#+U ?E?]^-=_$?5^&JQUF&NPU6&NQ5X8*\<-:7#7CAN&"O#
M!7CAKPP7#!<,-Q#!78+A'KL-PCW##<PC7$?]NJ5MOU=\7=]/</G6
M                   /@['8M;//O4G1C3^_]>\+TGX6EGL4\<4\V*JQ3QQ3
MQQ58XIXSIZ'*5[J7;7/<>V4;AY@[U;/P'^T                    !CBI^
M^D-*K1=RU4           2)8V^?.&Z68N&[4    !P[DJ% CU_SG7KN6-
M        'WMG4OB>2NA[8N>Y@   5^NPZW2A]1:(  ++?#MJN$>;=U
M   KG]IUFF9Z:T8  66^';5<(\V[J .*,A1\O/WGR8   ;_>/['=F\N;X
M     //*]E<UUH[SB@ .5L?6]0WP9UD"KSWG4JD7HK30               +
M;OG7<K0W!MM UH[SBO/*]E<U             %C+BNSW+O,^\?W  *QG=M4J
M'^C=+   O&^5-_WK<GV        "L=W75*AOH[2P !S?BKCTB_$O4.:<77
M                              'P>$VBFW\I_P!!O2GE7HG'68:[#58:
M[%7A@KQPUI<->.&X8*\,%>.&O#!<,%PPW$,%=@N$>NPW"/<,-S#^;J2VQZS^
M+N^;N?SJ
M     %33T-IU6?ONH@    ??V=3L;A;K[:TJ?*W$G6C.VG'UY3    ']%P_S
M7NUE+B&T@   ?,5Y//\ ?8/.=8N]XD    ?W!SQB;CG/$W$^2/%^0I=;,W:_
MBU90   !R)95?0>\<](V Z?D@  *_78=;I0^HM$  %EOAVU7"/-NZ@
M  5S^TZS3,]-:,  ++?#MJN$>;=U '%&0H^7G[SY,   !=U\L[[ONY%L0
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M]^]?-\
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MI^94@  +./"MKMY><=T       I<>G=%KQ]FUH  ;7>>YCT O'_1\D
M                            '7;1>LTN_E+^A[@S6.CX:K#78J\,%>.&
MM+AKQPW#!7A@KQPUX8+A@N&&XA@KL%PCUV&X8[F6U?ZV^-U@/T%\UP
M                                                  !UWS-MYOOM
MGE_$V1H@  ; =/R5RKS/N^SC1,L    (\T-!O7==J#>C]+X/RMN  !S;BJ_H
M]>*.G\^8BY  &J7H.'\_KV#SC'$  !N YOFKD_F?>.WFN7H    ^-N9*OO>=
M2JT]\U+\:K*  !8[XIL]RCS/O   K]=AUNE#ZBT0  66^';5<(\V[J
M  !7/[3K-,STUHP  LM\.VJX1YMW4 <49"CY>?O/DP    V0:3E/0E\<=)_>
MHS       >>5[*YKK1WG%  <K8^MZAO@SK('%U_1XDR-$     #SD_:O,>-+
MZD !R78U?1L\5=.      Y;QU;E&PK :T=YQ7GE>RN:@ #>UR;8;Q/E7?@
M  !QK?4M;^[8O0?UW7=!/7M<_,J0   M!<&VRW#YUW, "H-Z/TNLKW35  !^
MW2F]&+Q9TWO-JF0      UY[EC/.T]G\TAS0  ^GH3^C3XKZ;W3U>_
M                             Z@\Q[W3'^6'Z$^+\-N&&NQ5X8*\<-:7
M#7CAN&"O#!7CAKPP7#!<,-Q#!78+A'KOXN9;5?KKXWV /0WS6
M                                               I+>I-#T"]?UP
M #?QR#8[HOF+>?IJ$X     '7+-VM$SUCS[6YN^+   W\\@V.[5Y;WP #!%Y
MU'M'F6OK<<:  !:%X-MEM;SON4B6(     &J7H.'H@>M.>\:WU(  ?H21]''
MQ3T[O%JN0  K]=AUNE#ZBT0  66^';5<(\V[J        !7/[3K-,STUHP
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MV6?Q5X8*\<-:7#7CAN&"O#!7CAKPP7#!<,-Q#!78+ACN);5'K_XW[_/1/S6
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M*YKK1WG%  <K8^MZAO@SK(       'EY>\^3<4Y"B !RMCZWJ&^#.L@
M  :T=YQ7GE>RN:@ #>UR;8;Q/E7?@      !7N['K=*WU!H@  'IS^$^K<^8
MBY  T\])PE"3UUSO^0  7?/+&^[Y^1[$    !HLZQK]&_P!5Z   .Z&L7WHU
M^*^G?46\X                                    U]<8]3U#?FQ]X.)
M<+NV"O'#6EPUXX;A@KPP5XX:\,%PP7##<0P5WZ=_C[6OLCXR[T?0/SN
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M7-=:.\XH #E;'UO4-\&=9        \O+WGR;BG(40 .5L?6]0WP9UD
M #6CO.*\\KV5S4  ;VN3;#>)\J[\       /Q*LOF&>[N4<59"B  /0Q\:]*
MV9:-E0 !2!]4:#H:ZWKP  [%X6Z]([Q)U#DJQJ@   ?&75/S=?;7+^K.?M
M/[@O]>0.C;9N>9D                                     <#:ATVKW
MX)^S&J7@?MC!6AAKQPW#!7A@KQPUX8+A@N&&XAWDZ7YTM@>T/BYWNZ)YR
M                                                       'X-:7
MS&O=?*>'\E0  %XSRKO^]?DVP         :P=\Q/GR^Q>;Q)H#^C;?SK,V@.
M#[;MOYUF?[@ XOOZ/F%>[N4?@UI0 !?$\E="W/\ ,<Z        /@KNGYI/N
M/EG!^5MP !=B\N;Y8!X_L8 K]=AUNE#ZBT0  66^';5<(\V[J        !7/
M[3K-,STUHP  LM\.VJX1YMW4 <49"CY>?O/DP     &X?FV;OJ^1NB9X
M !YY7LKFNM'><4 !RMCZWJ&^#.L@       >7E[SY-Q3D*( '*V/K>H;X,ZR
M       !K1WG%>>5[*YJ  -[7)MAO$^5=^        \^+V-S;5SON)  %^;R
M'T7;[SC-  #@C+6_F[^VN7\-Y.@  +,'#=JN!^;MU    JK>@-0JB^@]/  &
M_KD&QW:?+>^                                       =&.4>DM(?E
M[Z*ZN.'^R>O^M]-P5X8*\<->'(^P:?LM[/Y'W7^A_GWM4[/XSSS4P
M                                                   -3O0L/Y_W
ML'G   [38"[]*[P]U.?)$         4L_3^BU^NPZWO%Y3G[/_"-LV&Z9DP
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M==GYQEC(
M        *H_H/3ZJGH#4  !9TX3M=N_SEN@         ' F7M_@KREVXUR]
M  %3/T-IU6CONH@ "S+PS:K?WF_=0        !K4WC%>>/[+YJ  .X^M7WI.
M>(>H@"OUV'6Z4/J+1  !9;X=M5PCS;NH        %<_M.LTS/36C  "RWP[:
MKA'FW=0!Q1D*/EY^\^3  #:MS_,=%=LQW">4H  #Z&C-Z%?C;I6Q?2\F
M!YY7LKFNM'><4 !RMCZWJ&^#.L@       >7E[SY-Q3D*( '*V/K>H;X,ZR
M      !K1WG%>>5[*YJ  -[7)MAO$^5=^        H0>NN=:>^DX4  7[O(7
M1=NO.<T  !CBH">O^<:F^AX<  ;4- R_H'>/.D98  !2!]4:#H:ZWKP  NG>
M8-ZL*\;V4
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M/R%S(  +M?EO?-_'(-C  UB;WB?/=]C\VPQ  ;3= R_H(^/.D98
M
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MP$::'G@>S.::Y-UQ@ 'T-&;T8/%G3>\6JY
M
M                   #R^?>/)N(LE1  D2Q]4OP#UW]"2(
M 'G!>V.8=&=KQX  ],CPSU3LW@KL         #SSO9/-=9N]8H  >CQXHZ?W
MKU/( 5^NPZW2A]1:(  ++?#MJN$>;=U         KG]IUFF9Z:T8  66^';5
M<(\V[J .*,A1\O/WGR8  ;VN3;#>)\J[]Q=?T?.4]J\QZL9^T   NY>6=]WX
M\BV(   #SRO97-=:.\XH #E;'UO4-\&=9        \O+WGR;BG(40 .5L?6]
M0WP9UD       #6CO.*\\KV5S4  ;VN3;#>)\J[\       -;^[8OSO/9O-
M !L%T[)>B]XMZ:    /Q*LOG6>T.9]"MNQP  LJ\/VFX=YLW8"OGV+6Z5'J'
M1  !:;X%MULCSSN(                                         'Y\
M\.),C1_2DCRICZV6
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MGVYR[KWF;8 #N#K=[Z.?BGI_U]M.
M        .@^WXZOYV#6]171L-TCVK'_D5(#[6UJ;!M.R6Y+F>;L#\>V3L?A+
MH
M>6/[[Y'\I<2  ?5V\_J<>!.N               #S=/;?+^D^T6   ].+PIU
M;L#A[D         #S]?87.-4W0<.  /1@\6]-V!Z=D@*_78=;I0^HM$  %EO
MAVU7"/-NZ@        5S^TZS3,]-:,  ++?#MJN$>;=U '%&0H^7G[SY,  -
M[7)MAO$^5=^ JG>@=/JF^@M0   V.:5E/0I\;])_>HS   >>5[*YKK1WG%
M<K8^MZAO@SK(       'EY>\^3<4Y"B !RMCZWJ&^#.L@       :T=YQ7GE
M>RN:@ #>UR;8;Q/E7?@     !UPS=K2K]0:)I_Z1A0 !W8U:_P#1A\6]-^JM
MYP    !3J]*:36Q[?JP  V@Z'EO0=\<])J2^B=,J]]YU, #^B_9Y"Z+MUYSF
M@                                       .LN=M*=OI/2=)?4L#_$0
M   ^BHS63.(;3:[\^;A]U:5
M                     !Y8_OOD?REQ( !]7;S^IQX$ZX
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M&I_,UY  -\W)-AN^^5]^
MU+]#PU&3U=H'#^2H     #O)JF0OD>2>A=M]=O0
M                                    /+']]\C^4N)  /J[>?U./ G7
M               !YNGMOE_2?:+   >G%X4ZMV!P]R         !Y^OL+G&J
M;H.'  'HP>+>F[ ].R0%?KL.MTH?46B  "RWP[:KA'FW=0        *Y_:=9
MIF>FM&  %EOAVU7"/-NZ@#BC(4?+S]Y\F  &]KDVPWB?*N_ #@/+VWG/^T^9
M=>,S;  "1+&^_P"1>B;?.<9H  >>5[*YKK1WG%  <K8^MZAO@SK(       '
MEY>\^3<4Y"B !RMCZWJ&^#.L@       :T=YQ7GE>RN:@            ;8.
M>YBZYY=WOM/@+P      #2YT_!4/_6G/0    !RYCJWI%^).H<^8BY
M                                 &FOIF#HK>L.?_,UY      !V.PE
MUZ _C[H_<[6+X
M          >6/[[Y'\I<2  ?5V\_J<>!.N               #S=/;?+^D^T
M6   ].+PIU;L#A[D         #S]?87.-4W0<.  /1@\6]-V!Z=D@*_78=;I
M0^HM$  %EOAVU7"/-NZ@        5S^TZS3,]-:,  ++?#MJN$>;=U '%&0H
M^7G[SY,  -[7)MAO$^5=^  U3=!P] ?U_P Y_-G@  .?\/<^C3XKZ=SWB+@
M#SRO97-=:.\XH #E;'UO4-\&=9        \O+WGR;BG(40 .5L?6]0WP9UD
M      #6CO.*\\KV5S4           ?76T^X'F^;L7<6V;<+S;-_Z
M 49?5O/]&W5L     !<[\R;S8HXOLP
M         U%]&PM#[UISWY&YD       '8["77H#^/NC]SM8O@
M                                              /+']]\C^4N)  /
MJ[>?U./ G7               !YNGMOE_2?:+   >G%X4ZMV!P]R
M !Y^OL+G&J;H.'  'HP>+>F[ ].R0%?KL.MTH?46B  "RWP[:KA'FW=0
M    *Y_:=9IF>FM&  %EOAVU7"/-NZ@#BC(4?+S]Y\F  &]KDVPWB?*N_  "
MK'WW4:G'H;3@  -P?-LW?9\C=$SP #SRO97-=:.\XH #E;'UO4-\&=9
M   \O+WGR;BG(40 .5L?6]0WP9UD       #6CO.*\\KV5S4          #F
M+&5]YO*<_MMYUFMPO-LUR%9U0       !UZS-MYN_MKE_%.0H@   ;/=#RWH
M.^.ND298@                                      :B^C86B#ZTY[\
M=<R        #L=A+KT!_'W1^YVL7P
M                         \L?WWR/Y2XD  ^KMY_4X\"=<
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M       !78[/K-,/TYHP   _;I3>BQXNZ9WPU+(@
M                  :B^C86B#ZTY[\=<R         #L=A+KT!_'W1^YVL7
MP                                                       'EC^
M^^1_*7$@ 'U=O/ZG'@3K@               \W3VWR_I/M%@  /3B\*=6[ X
M>Y          \_7V%SC5-T'#@ #T8/%O3=@>G9("OUV'6Z4/J+1  !9;X=M5
MPCS;NH        %<_M.LTS/36C  "RWP[:KA'FW=0!Q1D*/EY^\^3  #>UR;
M8;Q/E7?@  .#LK;^=#[2YEUKSEJ  /H:,WH5^-NE;%]+R8'GE>RN:ZT=YQ0
M'*V/K>H;X,ZR       !Y>7O/DW%.0H@ <K8^MZAO@SK(       &M'><5YY
M7LKFH             V-Z5D[]'D/HO,&-K@      #!%Y]OL3F^K7?L0  !:
M'X-MMMSSKN0                                      &HOHV%H@^M.
M>_'7,@          ['82Z] ?Q]T?N=K%\
M                            /+']]\C^4N)  /J[>?U./ G7
M       !YNGMOE_2?:+   >G%X4ZMV!P]R         !Y^OL+G&J;H.'  'H
MP>+>F[ ].R0%?KL.MTH?46B  "RWP[:KA'FW=0        *Y_:=9IF>FM&
M%EOAVU7"/-NZ@#BC(4?+S]Y\F  &]KDVPWB?*N_   #5UON)\_CV%SC\BI*
M .XVM7WHM^+>F<A6=4>>5[*YKK1WG%  <K8^MZAO@SK(       'EY>\^3<4
MY"B !RMCZWJ&^#.L@       :T=YQ7GE>RN:@ #>7RG8+MOEK?    !@BXXO
MJ76#/6FMG=\5H,Z[KNLW>L4  !N+YKF[Z_D;HG^@       Z#[?CO.4]J<Q
M '8'#W/I6^'NI?:VM0                                      :JN@
M8>A%ZZYW\=<R           #L'AKF_UY Z-WFU3(
M        <4Y"CUBSUIQ%DJ/RU>3^X1RP?Z#\FI*!+EC]-0GY.L*O/>(N.P6'
MN94L0                 !Y:WOCDGPMW3  _:I3>J3X!ZZ
M  /-]]L\OZ/;58  #TSO#'5>RN#N@         //5]D<VUC;WB0 !Z.?BGI_
M?#4L@!7Z[#K=*'U%H@  LM\.VJX1YMW4        "N?VG6:9GIK1@ !9;X=M
M5PCS;NH XHR%'R\_>?)@ !O:Y-L-XGRKOP   %7[O&IU'?1>F   6).,;-<_
M\Q[R//*]E<UUH[SB@ .5L?6]0WP9UD       #R\O>?)N*<A1  Y6Q];U#?!
MG60       -:.\XKSRO97-0 !O:Y-L-XGRKOP      _PK<]MU>G/Z5TC'$
M +[WD7HFX7FV;       '%&0H^7G[SY,  -@6G9+T8?%O30
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M$NZ?G(>U>8]1MCL@            !SWB+CT O'W1^\VJ9
M          8(M4?0L/IHZ9@_EKB2=)-.EA,DC.DC.A&;)&;)-,E9)0    ER
MQV=:+EMLG/,Q,EB                //5]D<UUC;WB@ !Z%GC;I6S?1<J
M            !1(]9\]TI]0P0  O?^2^A;I.89T         0YH>7%[VY+\+
M=TP ,\'J7>!NN?76TX%?KL.MTH?46B  "ROP[:;AGFW=@        *Y_:=9I
MF>FM&  %GSA&V6Y_.>Y@#BC(4?+S]Y\F  &]KDVPWB?*N_    #AK)T/.D]H
M\RZN9^T  '83#7/HZ^*>GT-/6W/-:.\XH #E;'UO4-\&=9        \O+WGR
M;BG(40 .5L?6]0WP9UD       #6CO.*\\KV5S4  ;VN3;#>)\J[\
M-<.[8OSNO9O-  !V'PUSZ;GA7JP       XHR%'R\_>?)@ !L"T[)>C#XMZ:
M                                     !5+]!:?50] Z@
M    .>\1<>@%X^Z/WFU3(                       #CN]I5S>TZQTMVBP
MG233)(S81GR33983:<9TL9LL9LD9TDTJ5_<     '<'6[[>YR?8/V*4P
M           %+ST[HM=_LVM  "W-YTW.S[P?;          /E;B3K_F+;M5K
M]X   *BWHS3*PO=]3  %I7@>W6SO/&X@        #H+M^.\Y;VIS$  =J=?O
M/2Z\.=3 &BSK&OT;_5>@  "P#Q_8[L7ES?         *Q?=M4J(>C=+  %K#
MS]M]K/S[N  XHR%'R\_>?)@ !O:Y-L-XGRKOP    &LS>L5Y]GL3F_X564
M;QN59_K/G+76CO.*  Y6Q];U#?!G60       /+R]Y\FXIR%$ #E;'UO4-\&
M=9        UH[SBO/*]E<U  &]KDVPWB?*N_       #\FI#RR???(OR*D
M!ZEO@;K?VUK4       XHR%'R\_>?)@ !L"T[)>C#XMZ:
M                      /D[B3S*O='*N'<G0               Y[Q%QZ
M7C[H_>;5,@                      .),C1JY=ZU+@?+VTZ6,V6,VG&;+-
M-E3I9ITD)LD9TL9LLTV1.DFD2OZ@     [R:KD-Y_*-@_H
M %>KLFM4L?3^B@ #8_I.4]$3QETL         "N?VG6*<_I72=\/)=AM!\&V
MSO)JF0  &C3JVOT9_5N@  #OIJ.1]&_Q5TX         57^_:C4\]"Z<  -X
MO*L_>>\H]  &JKH&'\_'V'S@  ;/]#RWH2>..D@        4W_2VD5O.VZN
M +FOF7>;%W%MF '%&0H^7G[SY,  -[7)MAO$^5=^     %9GN>JU O2&E
M?4V\_P M<2  <K8^MZAO@SK(       'EY>\^3<4Y"B !RMCZWJ&^#.L@
M    :T=YQ7GE>RN:@ #>UR;8;Q/E7?@       /,3]V\HX(RUN  /3B\*=6[
M X>Y       XHR%'R\_>?)@ !L"T[)>C#XMZ:
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MX7ZKV-PET      !Q1D*/EY^\^3  #8%IV2]&'Q;TT
M                   5$?1NEUBN[:H                .=\3<7[/(71=@
M&GY(                    </Y*A5+]!:AP%E[:;",V2,^G&=*FRQFRS3:<
M9TL9LL9LL9TD)U.:;",V6,VG&;+'-*     ^TMJEEOAVT_34)P
M    !YZOLCFNL;>\4  -E>CY7T*/&_2?T)(@       "F%Z<T:NSV?60 !;;
M\[;E:(X+MH H!>P.<ZF>AX8  ;2M!R_H)>.^D9X        *VG;M7IS^E=(
M 'ZE./IF>&.J]@\/<@ >99[HY5UOS=J  +LWES?-_O']C        ZJ;!9^:
MC[AY;%F@ !^I3CZ@O@[K/)5C5 '%&0H^7G[SY,  -[7)MAO$^5=^      XE
MR-'SI_:/,NIVPV8    '*V/K>H;X,ZR       !Y>7O/DW%.0H@ <K8^MZAO
M@SK(       &M'><5YY7LKFH  WM<FV&\3Y5WX       #S5?<'+>HVQV0
M]+?PYU/M9K]X      !Q1D*/EY^\^3  #8%IV2]&'Q;TT
M                      43/67/M)_4<"                !S3BZ]_KR!
MT;8!I^2                   '%.0HU+?1&F]?LQ;S9$V6,Z6,V2,^G&;+&
M=!-DFF21G2QG233I83)(SY(S81FR1FR33)624    !MUYUFMH&AY8
M        : NP:Y29]1Z&  !:0X)MMM/SON0       %=CL^LTP_3FC  "1+'
MT:O%?3>^.I9$ :(.M:]1[]4Z"  !;Q\X[I9RX5M8       Z/[58>=][,YIQ
M[>T@ !NVY;GKUOD[H(  I2>H=$K[]BUL  =Q=:O?1O\ %73_ *^VG
M%,OTUH]=#M.L  #:5H.7]!GQUT@ #BC(4?+S]Y\F  &]KDVPWB?*N_
M#7!NV+\][V-S;YRO*    .5L?6]0WP9UD       #R\O>?)N*<A1  Y6Q];U
M#?!G60       -:.\XKSRO97-0 !O:Y-L-XGRKOP       'FZ>V^7])]HL
M !Z6_ASJ?:S7[P      #BC(4?+S]Y\F  &P+3LEZ,/BWIH
M                        \_SV#SC4_P!"PX                 YIQ=>
M_P!>0.C; -/R0                  XGR-&I7Z'T[K7G+.;+--DC-E398SI
M9IM-.DC.EC-E3I)IDD9T(SI)ILL)M.,Z6,V6,V2,Z2:5*_N     <P8ZO94X
M?M/^@              'XE67S;/;G+^I6Q60  _HMD>>=QM+<#V[^X
M!74[1K--7TQH\&>   W[<AV.[;Y:WP #\FI#S=?;7+NGFRV0  G21NL>7][W
M^\?V,      =/]DLO/\ O8'..KN?M  !_<'H:>->E;+-'RH  U!=(PM!GUWS
MH  #?UR#8[L/EW>Y$L0     !IFZ;@Z'_K3GL6:   N;^9-YL6<7V8 #BC(4
M?+S]Y\F  &]KDVPWB?*N_       5K^WZM3L]*:2    .5L?6]0WP9UD
M   #R\O>?)N*<A1  Y6Q];U#?!G60       -:.\XKSRO97-0 !O:Y-L-XGR
MKOP       'G,>U.8] ]OQP  ])CQ%U'N7K-\      !Q1D*/EY^\^3  #8%
MIV2]&'Q;TT                                     4.O6O/-,/3L&
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M^).H=V-7OP      .*,A1\O/WGR8  ; M.R7HP^+>F@
M                   "G5Z4TFMCV_5@                 !S3BZ]_KR!T
M;8!I^2                '$>1HU!_1^E=8<]:3I)ILB;+-/D38)M.:;+&;+
M&;)&?33I8S98SI9IDB=)-.EC-EC.DA-DFFRITLTR2,Z2.>#_ &    #<7S;-
M[*M'RH               %%OU?S_ $@=4P    ^QMI]]_(MCW[<@V+9KHV5_
M8I3  #I-M-AH%Z_KE<SM.L<19*B  !F@O7>3N@[K^79X   48?5W/]'75<
M  .QV$NK)?$=HWP<EV'M5K]X  ./;REIKZ9A*V?;]6U?;YB0  !SGB;CT;_%
M73NP.'N0  !I+ZE@:*'K'GP   Y?QM:QSQ3:-\?)-A[RZKD/[@  ''5[2T[]
M)PE;+M^KZMM^Q    N0>:=WLA\2V@  <49"CY>?O/DP  WM<FV&\3Y5WX
M    <77]'SKO:',^GVR60   Y6Q];U#?!G60       /+R]Y\FXIR%$ #E;'
MUO4-\&=9        UH[SBO/*]E<U  &]KDVPWB?*N_        >>W['YMK W
MS$@ #T2/&/2]C>E90      #BC(4?+S]Y\F  &P+3LEZ,/BWIH
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M]I1ZC@0 !<Z\R;S8IXOLP      '%&0H^7G[SY,  -@6G9+T8?%O30
M                              !\!>4_,I]T<IXQOZ0
M     '-.+KWXO(G1=C&EY,              <67]&G3Z5TGJ+LEG/IPFR1FR
MS381FTXSY)ILL)TLTZ2,R1.EC-EC-DC/IQFRQG039)ILD9LL9TDTZ6$R2,^2
M,V$9LD9LDTR5DE   #NIK%_OAY+L(                ZI[!9^?=[$YOU9S
M]H           !9[X1MEN?SGN?\ H    .INPV?GX>P^;]7<_:
M "=)&[!Y=WS?KR'8@    .,KZEY[GL?FW0S;L<           !VZUR]]"SQO
MTGGW#W(  '%&0H^7G[SY,  -[7)MAO$^5=^        %<OM6L4T/3.C@  <K
M8^MZAO@SK(       'EY>\^3<4Y"B !RMCZWJ&^#.L@       :T=YQ7GE>R
MN:@ #>UR;8;Q/E7?@       *D/HK3*O7>=3  '>C4\AZ*/C#IGU5O.
M .*,A1\O/WGR8  ; M.R7HP^+>F@
M     5.?0NG58N_:B                   .6<=6OW^0NB[&]*R@
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MFXIR%$ #E;'UO4-\&=9        UH[SBO/*]E<U  &]KDVPWB?*N_
M :F.AX:@'[ YR  !N%YMF[OWE??>8,;7      XHR%'R\_>?)@ !L"T[)>C#
MXMZ:                                     !\-=T_.B]H\RZ9;/8@
M                 #EG'5K]_D+HNQO2LH            .*<A1IB^F]&Z>;
M+939(SI)IL$V5/IQFR1G2QFRS39$V2;]"1,@G4YILL9D$Z2:=33I8SI8S98S
M:<9TLTV5-EFG20FTXSI8S8339$Z2:1*_J   =Z]4R.\KE.?
M    'R%S)4=]%:96Y[=J\.:         '<G6;ZZWY>WO9_H>6       ^"NZ
M=/[TCI5>#LVLX8@        -@^G9*[AY9WWO9J>0       X^O*=-/TSH^@G
MKVN          ;R^4[!= \Q;SRQCZP   '%&0H^7G[SY,  -[7)MAO$^5=^
M        XYO:7G9^S^9]+MGL0 .5L?6]0WP9UD       #R\O>?)N*<A1  Y
M6Q];U#?!G60       -:.\XKSRO97-0 !O:Y-L-XGRKOP       $>:'G;>S
MN::[=SQ@  %U[R[O=@7CVR      <49"CY>?O/DP  V!:=DO1A\6]-
M                                '1+;<?Y\7L7FW$V1H@
M        #EG'5K]_D+HNQO2LH           .)\C1I:>G=%Z;[-83I9ILD9L
MD9TLTV5.EA-ISSI8S94Z2:;(FRS?H2)D$VG-.EC,EC-DC/IITL9LL9TLTR1.
MDFG2QFPC.IPFR3394Z6:9)&=)'/!_L  &T70\OMPYUF0
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MK.A)ZYYWTKVBP  %U[R[O=@7CVR      <49"CY>?O/DP  V!:=DO1A\6]-
M                                      UR;KBZ"'KWG7$V1H@
M             #EG'5K]_D+HNQO2LH          .,[ZE2E]1:)TAVC'SY(S
M81G21FR33)4Z6:;+&?)";)&=+-,E3J<TZ2,V"?)--E3:<9LL9L(S9(SZ<9TJ
M;+&;+--IQG2QFRQFRQGTX39)IL$V6:;3C-ECFE  ;T^4;!WBU7(
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M/&=.=ELNO^8MN.;VECB^JMYN;<5<=K]?O.^.HY'8/IV2^@HS
M ?Q%T\V2QU_[ACNH>R677O,6W&U]2@3PGR1Y*L:O83#7/;S7+WO_ *?D>X6M
MWV2
M                                                         :_]
MPQM CU_SGA/*4                   !RSCJU]WR-T39;HV5        '&%
M_2I#^I] Z);78381G2QFR1GTTV6,Z6:;*FTYITL9DL9L'Z%*,R5.EFFRQFTX
MSI9I\D)LLTV2,V5-EC.EFFTTZ2,Z6,V5.DFFR338)TDTZ2$V2,V6,V6,Z2,V
M2:5*_N =Y=5R&]#E&P
M
M
M                   =&=KQ_G^^P><<"9>W                   ')5C5
MOQ>1>B[-]$RH       XNOZ-'7U5H/0_;L=-D39)ILL9LL9TDT^FFP39)ITL
M9DD9TDTV";*GTXS9(SI8S99ILB;+-^A33()U.:;+&9!.DFG4TZ6,Z6,V6,VG
M&=+--E399ITD)U.,V6,V$TV2,Z2,B5DA&Q+QC9>QV%N@
M
M
M                                            !TCVFPH#>O\ G/7'
M-VH                   Y*L:M^+R+T79OHF5      ''5[2HP^KM U^[AC
MI\B;!-DC-DC.DC-A&;3F_0D394V6:;)&;)&=+--E3I83:<\Z6,V5.DFFR)LL
MWZ$B9!.I3381F2QFR1GTTZ6,V6,Z6:9(G233I8S81G4X3I)IDJ=+--DC-DCL
M%T[);N.6YX
M
M
M            =,=GL: GK_G/67.V@                   Y*L:M^+R+T79
MOHF5     ''-[2HO>K^?ZZ=TQDZ2:;+&?)"9+&=)--D3I9ILL9M-/DC.A&;)
M&;)-,E3I9ILL9\D)LD9TLTR5.IS3I(S8)\DTV5-IQFRQFPC-DC/IQG2ILL9L
MLTVG&=+&;+&;+&?3A-DFFP399N9,77L@<3VC[&VG
M
M
M                                           ZD;%9>?K["YQU=S]H
M                   .2K&K?B\B]%V;Z)E0   !QQ>TJ)WK'GVN/=L7.EFF
MR)LDTV6,^2$V$9M.:;+&=+&=)&;33I8SI9ILJ=3FFRQF0C-EC^A3A,DC.EFF
MRQFR1G233I83I9ILD9LB;+&=+&9)&?3C.EC-E399ILD9TL9LLT^2$R2,Z2/W
MEK4L6<6V?L)AKD
M
M
M                 #JSG[3S^?87..I&Q60                   Y*L:M^
M+R+T79OHF5    I$^I]"TE=2P$ZG--E399ILD9LL9TD9\L)DL9M.:=+&;",Z
MG-.IPG0C-EFFR1FR1G2S394V5/IQFRILLTZ2,R2,Z6:?)";+&;)--EC-E399
MIU-.DC.EC-EC-DC.DFF2ITLT^2')5A5L/\:V;LU@KL
M
M
M                                              #J[GK2@7Z^YSTR
MV>Q                   ')5C5OJ>1^B;1="RP   ZF[#9T&/7O.NN&:M)L
MDTZ6,V6,VG--E3I8SI$V6,V2,Z6,V6,VG-/D394Z6:;+&;3C.EFFP394ZE&;
M+&=+&=+-,IITLT^1,@G4YIDL9L$Z2:=3398SI8SI8S:<9LLTV5S;B[BQSQ39
M^=\1<
M
M
M           =<<U:^?\ >P><]*]HL                   !][9U+Z/DCH>
MU7G^8   '4W8K.@UZ\YWUQS-I-EC-DC-A&=3FFRQG2)LJ=)&;+&=)&;+&;)&
M?)&;+&=+&;)-,D3I9ILJ=+"=3FFRS394Z2:;)&;+&?(FRIM.:;",V6,V2/Z%
M-,EC.EC-EFFR.RF#N[)7$=HY7Q]8
M
M
M                                  #@7+V_G^^P><=&-KQX
M           ^]LZE]'R1T/:KS_,   #J=L5G0<]=\ZZX9FUFRQG2QFRQFR33
M9(SY8398S:<TV5.EFG2QFTTZ2,Z6,V6,Z2:9+&;+&=+&=)";3C.EFFP3:<TZ
M2,V"?)--E3:<9LL9L(S*<?T)(S94V6/<;6;^R;Q':/NK2H
M   !JSS%@ !^K+'9OB;X  #X&I)KQREF !RG1J=^<;=@ :TLK8_@3P
M YRMZO=K'W0    '2+(6O"%Q2  ^EDCLGQ5\    !QO5DU]Y.S  Y>H5.]V.
MNP     -;N5LOE9Y0       !LCQ5[]3),!K2RMC^!/  #:%B+^5   /P)I=
M:66L@ /M*<VQC%WH   '$]:GIISN,U>9:PZ8W]KPO7I0XPY'I5.TEG<;$L9>
M[EL'DN\&/NP      -8^6L?RYH  <_VU;N;87(    'RT\NMS*V0    'TLD
M>P-M6[/6EQ(@    _ FEUI9:R       ';&RN.S=I7
M                                     '!66MZ"/KWG6O\ W#&@
M              #[VSJ7T?)'0]JO/\P   .IVPV=!_UWSKKAFK6;+&=+--DC
M,DC.EC/DA-A&;3FFRQFRQG21G4TZ6,Z6:;*FTYILL9LL9L$^G&;(G2S398S)
M(SI)ITL)TLTV2,V1-EC.EC,DC^A3CL U#)60.)[1])0F
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M;%&L9H
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M-]O5    '6RZH>?OTG3P      /NZ<]Q+1]DVG8C(  #A&XI>>ETO30
M !9SU/.V*-8S0
M         XFR-&@AZ]YUKDW7%@                  #[VSJ7T?)'0]JO/\
MP   .I^PV=!3UYSGK_F+>=+&;+&;3FFRITL9TB;+&;)&=+&;+&;3FGR)LJ=+
M--EC-IQG2S38)LJ=2C-EC.EC-EFF2)TLWZ%-,@G4YYLK<GS3.;_>/['E@
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MGG;%&L9H
M    #C*^I4(/77.M9&]XH                   ?>V=2^5Y)Z'M<Y]F   !
MTYV6QH4>N>=\"9>WFR1FPC.IS398SI(398SI(S98SI(S98S9(SY(S98SI8S9
M)IDB=+--E3I83J<TV6:;*G2339(S98SY$Z5OKY%L>\'E>?
M      'FR=3T@ #DJE/Z*/,=T   Z17]I1!Z)J8 &R?%7UW30=I  \]/I>F\
M(7%(      #<K@\G<&TC9    !2VWO6-5N8QX  '*=&IZ'/,]RGPB   !K]R
M5G1FZ#J@ &TS#W]T_1-H      \_CI&G]:[N@        /0(YMN'9.UK@>>G
MTO3>$+BD !Z.W+]V^EDB  .$;BEYZ72]-  [<V5Q?BYSMX %>39L-5_VW @
M "?",",   +&&KYJS7JF=    ^:GE\[SIFF?&5)0  -Q.#R5Q+2-E    '6R
MZH>?OTG3P       -[&O9:V'INP@ <(W%+STNEZ:       +.>IYVQ1K&:
M                                                       '&M]2
MH:>MN>:L=_Q                    ^QMI[WWDOH6W3G.:   '3K9;&A3ZX
MYYP)E[:=+&;+&;3FG2QG2PFRQFTYILJ=+-.EC-IITD9TL9LL9TDTR6,Z6,V6
M,^2$RG&=+--@FTYITD?UY(V0.);1M\YQF@                    /-DZGI
M  ')5*?T4>8[H  !TBO[2B#T34P -D^*OKNF@[2 !YZ?2]-X0N*0 &TS#WX
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M#*[C<'DP
M     /@KNG0U];\\U1]!PX                   ^QMI[WWDOH6W3G.:
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MV^EDB  .$;BEYZ72]-  [<V5Q?BYSMX U"YO&TWMXUH #G.WJWR^=[=R[0J
M 4_-VUO3/G<8 !?;YUMW<"QN0  !5GV_ 5_-DPX   %WK0-JV0XN]    ZV7
M5#S]^DZ> !W=Q]U>^YYMH '"E>EY_?2=/^3GE  ]&SE^Z_7R3 #A&XI>>ETO
M30 .[N/NKWW/-M
M                  ^/N9*('K3GNHOHV%                   'V-M/>^
M\E]"VZ<YS0   Z=[+94+?6_.^!<O;399ILD9TL9LD9\L)DL9M.:=+&;",ZG-
M.IPG0C-EFFR1G21FRS394V5/IQFRN1+*M:[\^;AL$T[)
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M2J #A&XI>>ETO30 .[N/NKWW/-M
M                               'Q]S)1@]7<_TU],P8
M       ^QMI[WWDOH6W3G.:   '3O9;*A?ZWYWP-E[>;+&;3FFRITL9TJ;)&
M;)&=)&;",VG-/D394Z6:;+&;3C.EFFP397,V*N+=?G/<^Y>LWP
M            \V3J>D  <E4I_11YCN@  '2*_M*(/1-3  V3XJ^NZ:#M( 'G
MI]+TWA"XI  >DWRS=P        !0"Z1I_6&[H #=E@,II-S^+ &0]!_FFX\\
M6]8   :_<E9T9N@ZH !M,P]_=/T3:         --6<QE/G=];  L":UF+2^H
MY\    >>GTO3>$+BD !Z.W+]V^EDB  .$;BEYZ72]-  [<V5Q?BYSMX IG[S
MK.I3-8X "YUHNS;8<-D0 !TBO[2B#T34P +E6C;-MQPN1   ZN7=O0'Z1J
M^RIS;4<1D-/F;QH [HV%U?*YWMH   '6RZH>?OTG3P .[N/NKWW/-M  %&;H
M.J:_<E9@ >BCS'<^2J50 <(W%+STNEZ: !W=Q]U>^YYMH
M                                                 'S->2C-ZMT#
M2WT_!                   #[&VGO?>2^A;=.<YH   =/-ELJ&/K;G? N7M
MYTL9LDTV6,Z2$V6,Z2,V6,Z2:;*FR1GR1FRQG2QFR339$V6;LEA+FX1YMW7L
MU@KL                      #S9.IZ0 !R52G]%'F.Z   =(K^TH@]$U,
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MO?<\VT
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M^ZO?<\VT
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M4@ ._6.O)$   _'FAT5R%H !VYLKB_%SG;P!2PWO5]6>8L  +NF@[3LGQ5\
M       !\E/+YW?3=,^5GE %Z?GNV=\\==^>]TK3N!KFB -MF%R-R_1MF
M'6RZH>?OTG3P .[N/NKWW/-M '\FBC8<34]W+7@ + 6MYBTSJ&?  X1N*7GI
M=+TT #]66/+5&H  !<AT?9MA>,O
M                             !^74A2C]0Z'H,Z]KH
M     ^FH3WJ?)_0-RG,\X   .GNR6-#?UMSW@;+V\Z2,V6,V2,^5,E3J<9LL
MTV$9U.:=3AM4T#,6]_..Z_8VTX                        \V3J>D
M     ;)\5?7=-!VD #ST^EZ;PA<4@    !:7U#/V!-;S     ^+J2^=WTS3/
MG)Y0!>3Y]M>PC&WFD7/XJH]NFN@ 7;]!VG99BKX  #7[DK.C-T'5  -IF'O[
MI^B;0        !IJSF,I\[OK8 %@36LQ:7U'/@   #ST^EZ;PA<4@
M!VYLKB_%SG;P!2PWO5]6>8L  +NF@[3LGQ5\        !JIS&/I=;WK  Y+H
MS^B%S/<YT(U ]VUO3!G<8 /N:<_HA<RW/Z"6(  '6RZH>?OTG3P /L:<W=&Q
MN@/Y. KBCU\NJ( '>3'W=W/0=IY$I3@ <(W%+STNEZ:     !=TT':=D^*O@
M
M  (4\*6'I[1:_'8M;                   'TU">]3Y/Z!N4YGG   !T]V2
MRH<^MN><#Y>WFTYILJ=+&=*FR1FR1G21_5EFL0<7V:R[P[:?T)(@
M                >;)U/2         -D^*OKNF@[2 !YZ?2]-X0N*0
MM+ZAG[ FMY@    :F<SCJ96]:R /O:<_HD\QW/\ 5A'KK=4?/NZ3IP %AK6<
MS:!U+/   :_<E9T9N@ZH !M,P]_=/T3:         --6<QE/G=];  L":UF+
M2^HY\    >>GTO3>$+BD        .W-E<7XN<[> *6&]ZOJSS%@ !=TT':=D
M^*O@        *J^X:_H,V/$ #;;A<C<NT;9AHIV'$U.MRUX "Z]H6T;/<3?@
M  =;+JAY^_2=/      '8VUK[W]=RU@36\Q]7),  .$;BEYZ72]-      NZ
M:#M.R?%7P
M            CS0J?^A-/JW=[U*+-                   #Z:A/>I\G] W
M*<SS@   Z>[)94//6O/>!\O;39)ILL9TD)LL9TD>[>K7]K_SWN.R#2<H
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M!VG9/BKX
M            :P=\Q-2[T/INJ[?\1_$0                  ^FH3WJ?)_0
M-RG,\X   .GVR65#WUKSW@?+VTVG-^I)-LITC)6"..[)N;YEG9TD0
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MFZ/HFS@  <W4*OTLDP
M                       ZF[#9ZK>@8?IQLME\%>4P
M /IJ$UIC@6W<E6-4   =/MDLM%76=>[NZKD-G&B97L#A[D
M             #S9.IZ0 !]]2GO2\^VP  #J)>VU-?>=9  V3XJ^NZ:#M( '
MGI]+TWA"XI  >DWRS=P       .GE];4)^BZB !=UT#:>[EA= :8<[C*IFXZ
M^ !:VT[8-\NNY<  :_<E9T9N@ZH !M,P]_=/T3:         --6<QE/G=];
M L":UF+2^HY\    >>GTO3>$+BD !?#YYMOT$DP  XBKTJ/._P"J@ =N;*XO
MQ<YV\ 4L-[U?5GF+  "[IH.T[)\5?        "OMLN'JV[=@ !RU0J7\N<;?
ME *E6YZ]J#S>-  O]\WV_M!:7   ZV75#S]^DZ> !W/L+F\%H&U #B2M3KX;
M-A]#&Q8@ #8OB[V\)H&U  <(W%+STNEZ: !W=Q]U>^YYMH
M
M                                                  'FR=3T@ #D
MJE/Z*/,=T   Z17]I1!Z)J8 &R?%7UW30=I  \]/I>F\(7%( #TF^6;N
M   !7IV;#5>MMP(      &V+#9"YSHNS@ #7[DK.C-T'5  -IF'O[I^B;0
M      !IJSF,I\[OK8 %@36LQ:7U'/@   #ST^EZ;PA<4@ /1VY?NWTLD0 !
MPC<4O/2Z7IH ';FRN+\7.=O %+#>]7U9YBP  NZ:#M.R?%7P  UUY.RIA;WK
M  %U_0MH[Y8Z\  I2[YJ^K[+V       %J;3]@WZZYEP !ULNJ'G[])T\ #N
M[C[J]]SS;0 ,10DZ-J/42]M@!G@]%+F6Z<A4IP!PC<4O/2Z7IH '=W'W5[[G
MFV@
M
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MA&XI>>ETO30 .[N/NKWW/-M
M
M                            \V3J>D  <E4I_11YCN@  '2*_M*(/1-3
M  V3XJ^NZ:#M( 'GI]+TWA"XI  >DWRS=P      !\'4D\[SINF?AS0
M  %U30]HVCXB_  U^Y*SHS=!U0 #:9A[^Z?HFT         ::LYC*?.[ZV !
M8$UK,6E]1SX    \]/I>F\(7%( #T=N7[M]+)$  <(W%+STNEZ: !VYLKB_%
MSG;P!5,W'7]"^Q8@ "SSJ6=L1:SF@ !I]S>-IS;QK0 %Z'GNU]^L=> #4SF<
M=3*WK60      !]1)-Z(W,MS^MDF  ZV75#S]^DZ> !W=Q]U>^YYMH  J/;I
MKND7/XH "_'SG;^W%E< #A&XI>>ETO30 .[N/NKWW/-M
M
M                                                 \V3J>D  <E4
MI_11YCN@  '2*_M*(/1-3  V3XJ^NZ:#M( 'GI]+TWA"XI  >DWRS=P
M !J)S6.IM;SK(       &_[6\Q:=U#/@ :_<E9T9N@ZH !M,P]_=/T3:
M     --6<QE/G=];  L":UF+2^HY\    >>GTO3>$+BD !Z.W+]V^EDB  .$
M;BEYZ72]-  [<V5Q?BYSMX TG9[%U%=UUP #L=:U[Y/.]MY$I3@ 4^-VUO37
MG<8 !Z"?-MQ[$6M8 52-QU[0WL6)        NAZ)L^UC#Y  #K9=4//WZ3IX
M '=W'W5[[GFV@ "H]NFNZ1<_B@ +\?.=O[<65P .$;BEYZ72]-  [NX^ZO?<
M\VT
M
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MN+*X '"-Q2\]+I>F@ ?523=L[*X    &_P!UO,;P<!E0
M
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MW<"QN0!PC<4O/2Z7IH       LYZGG;%&L9H
M
M                                   >;)U/2  .2J4_HH\QW0  #I%?
MVE$'HFI@ ;)\5?7=-!VD #ST^EZ;PA<4@      -RN#R=P;2-D '2R_M:&_1
M-2  N/:/LNWW"9(  "J%N.O:(=BQ( %IS4,_O_UO, #7[DK.C-T'5
M!<&TC9-RN#R8   TU9S&4^=WUL "P)K68M+ZCGP   !YZ?2]-X0N*0 'H[<O
MW;Z62(  X1N*7GI=+TT #MS97%^+G.W@ ? 5)*)?0]3ZKWEN      .QMK7O
MG<ZVWD"G. *\^S8:KYMN! 'Z,(^A_P RW/DNE.  !Y_G2-/ZSW=  "^]SG;N
MWME<@#K9=4//WZ3IX '=W'W5[[GFV@ "K-M^ K^[)AP +F>B[-MHPV1 '"-Q
M2\]+I>F@      "SGJ>=L4:QF@
M
M                        !YLG4](  Y*I3^BCS'=   .D5_:40>B:F !L
MGQ5]=TT':0 //3Z7IO"%Q2       W*X/)W!M(V0 5VMGPM8G;,$ /TY8^B#
MS/<^1Z4X  &H#-XVG'O&M  ;1L1?W5=#V@ :_<E9T9N@ZH       +@VD;)N
M5P>3   &FK.8RGSN^M@ 6!-:S%I?4<^    //3Z7IO"%Q2  ]';E^[?2R1
M'"-Q2\]+I>F@ =N;*XOQ<YV\  =5[RWI.;[J_6^ZH     #EBC4NRZ%M/=['
MW0 %)7?=6UG9:Q &Q#&7MXOG^U   "IYN6O:)]AQ( %HO4<]80UK,@#K9=4/
M/WZ3IX '=W'W5[[GFV@ #2WGL74(W77  -G^(O[J^A[1E .$;BEYZ72]-
M    %G/4\[8HUC-
M
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M.G@ =W<?=7ON>;:  /F)Y:)W0M3Z>7UL !=GT+:=FF)O@.$;BEYZ72]-
M   %G/4\[8HUC-
M
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MS.8SBVM3 &XW!Y/LW:5P/EIY=-V<Q@       [UXZ[[GV-T
M
M
M                                                           (
M<7&-6G#C#DBE4_>EB
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MZ0G 3^S<\EX*4RE'&W"7RY=-55*6<2I@3IDZ2#N,YD$HJ!-5MHIE*@$!*.X
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M!$ ";7#I"3BOOC+R,JO54\5HMUZYB#^Y5;L6YE<$,FN[6L 4%\5Y1E=W:1F
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M?[NG-<Z[X\0$1$C$<1Q'E>5BOM[<$4NQJZD9#7,ANW:*?6GGP= ,5@8' X'
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MBL1B.(XCRO*Q7E>&B'#B1HE#T/#D4/?JPH^35M)JTHJ<T+.2L5@># X'@Q7
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M5RM9-UDBD*.0HQ#CT.86$&<P@P@Q@XL(<>AS"#"#<&%A!A 6'S[2M9?^"+Y
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M\JSJ)ZR::I3"]5+?(,P[PW>JHG FJE8?"'HJH_&/JI:'P3;K44/\$SU4^?\
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M;'7PI6]]*BP.Z >Q6%@<#"P/;T WI!P.%X/!PL#RL+F*P]!>DK>GT@X'^GT
M\&R@Q8D-^I35%+S^BY_Y,B?J:8?ZGD*8=X;L4 ,*1!*H@HI;*88;*IN\=5/=
MU[K5/6-5+]W[-2B2K"JZ8,#*$:I(;<4JQ2B/+9^G5[D>&2*59326,RN3KTFY
M$.>&:7U(<C0HL.,3[G)+)9M44VQ3Q(D]DD0/!["PL+V]'_RP,# X'@P.!@8'
M [5F=B##E9-A;NXE56MJJQ]\*5OA2H.Z >Q6%@<#"P/;T WI!P.%X/!PL#RL
M+F*P]!>DK>GT@X'^GT \&%^2F,M,7\IVMZ(JBW53>2XGZFF'^IY"F'>&\%.<
MADL_F*<4,_1JQV%3=XZJ>[KW6J>L:J7[OVIBE."F02Y0RFF5<-HZ-4F'<)5/
MHJ5H<2'%)N2J5H5;*:6%E$IF"7<4$R4R^(@F">80ON:D4BG-3S?%'%&4V-E+
M \'L+"PO;T?_ "P,# X'@P.!@8' [4( (9BX=#(!V%N[B55:ZJK'7PI6^%*]
M /8K"P.!A8'MZ ;T@X'"\'@X6!Y6%S%8>@O25O3Z0<#_ $^@'@PO!V0N.=(7
M^INX5NZMM;57DJ)^IIA_J>0IAWAO<KGD=$,&-"40M53=XZJ>[KW6J>L:J7[O
MW 0 042:7*6CTL46CR*90&.0\,VUE4VBRZ)#B0XT/=(Z%&J:/3"0[1Z;F$)H
MR90G':IE,9)&ELQA3&!]S%/4].ZKG>+.+$DL/(^@'@]A86%[>C_Y8&!@<#P8
M' P,#@=K$ $,Q<.AD ["W=Q*JM;55C[XTK?"E6![%86!P,+ ]O0#>D' X7@\
M'"P/*PN8K#T%Z2MZ?2#@?Z?0#P87@X'7ZL)2%^Z2NK:JL+.UAY)B?J:8?ZGD
M*8=X:O=9.WNLG;W63M[K)V]UD[>ZR=O=9.WNLG;W63M[K)V]UD[&I6$+'I6.
M#1I!,X+1(42$;7)YH:7QBF*8NFIN\=5/=U[K5/6-5+]W[I%@P8Q5%/2Z,RBE
MU!&42]:EVDAF@I8N[B &!1)I:H912Q64269)F$! =DB614*A,HAJX'W+4O2]
M05K4&,6*]-V%DXNZ >#V%A87MZ/_ )8&!@<#P8' P,#@=L! !#,7#H9 .PMW
M<2JK6U58Z^-*WQI4'L5A8' PL#V] -Z0<#A>#P<+ \K"YBL/07I*WI](.!_I
M] /!A>#@<UZ+)T7?&DKQ69K6R-6>2(GZFF'^IY"F'>&Z1T\!229TZ:$7732\
M8L+34W>.JGA 97NM4B'M&JE^[]X4R>7JF54Q&(T=-'3'V,B7BM2;TH1I50*J
M8@G97*UJ+94XO&"H^Y6DJ1J2NJ@Q@Q@I^P5/BX7= /!["PL+V]'_ ,L# P.!
MX,#@8&!P.V(@ AF1AZ6G V%NKB55:VJK&WQI6^%+,5A8' PL#V] -Z0<#A>#
MP<+ \K"YBL/07I*WI](.!_I] /!A>#@=T7:M%1=Z*2OC8NL;$U=Y'5E_ JU$
M-^,GD&8=X;M44K*37+E(HUNFJ __ +]5-FXRW=:H, KM5- (2[>HL&%'(OIH
MHM%A1(!]<E5^R3#?'LND"-6RV7*D!]93&(9"I!8D^Y.CJ.J2OJDQGQHINP%-
ML+A=T \'L+"PO;T?_+ P,#@># X&!@<#MD<A(A,P\/#T<?86YN+5-K*KLO>F
MD[VTF5A8' PL#V] -Z0<#A>#P<+ \K"YBL/07I*WI](.!_I] /!A>#@=TW+M
MI2-VJ1R!QZJ^P-4>1IL3U<RU2N)ZV7^09AWANT:$2/"C0C0(VJ5QO7R_151.
M$;52T3BGW6H8GXYIJD!/PRK?%\N3S"&M11T,?6AC^TH]]BPH<:'.),9 .NEX
M_P")/]R5#4-5%QZHQPQII*P%/ YA<+N@'@]A86%[>C_Y8&!@<#P8' P,#@=L
MSD)$)F'AX>CC["V-SJLM+5EE;T4G>VDQ8' PL#V] -Z0<#A>#P<+ \K"YBL/
M07I*WI](.!_I] /!A>#@=HKN@Z4N53.1N-566!J#R+4D+\$RU4U']8@\@S#O
M#=Z@A>KF>JFC_BENBJ8?%+JIB-^!;NJV-[0LU2Z'ZI!OLTEY)@F,4Q#:J<B?
MCEN_'(2(2:(32]7JIF)^!?\ <C0-OZMN=5&.&.-+X_TL# YA<+N@'@]A86%[
M>C_Y8&!@<#P8' P,#@=M#D)$)F'AX>CC["V-SJLM)5EE[TTG>ZDP<#"P/;T
MWI!P.%X/!PL#RL+F*P]!>DK>GT@X'^GT \&%X.!VFL*/INO:;R=Q?J&PL_\
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MO!P.VG,MJHBNL?)XE S>KAL  7[%B4IF]7#8   \B_@(+>KA^1A*4S>KAL
M ?<M@RGA0<8!<#S/%P.%O0#>EO0# YA<+N@'@]A86%[>C_Y8&!@<#P8' P,#
ME*E,B39>Y>J;HJ?(EI;M5=9JKK-WCI&]E)%87,5AZ"])6]/I!P/]/H!X,+P<
M#MIE371;A7[_ .9,$5H*L91<#S/%P.%O0#>EO0# YA<+N@'@]A86%[>C_P"6
M!@8' \&!P,#*%*9$FR\R]4W04>1K2W:JZS57V:O'2-[*1%S%8>@O25O3Z0<#
M_3Z >#"\' [9Y$W+AVFLZ8QCF_YDY<$]"865%P/,\7 X6] -Z6] ,#F%PNZ
M>#V%A87MZ/\ Y8&!@<#P8' RA2F1)\O,O5-T%'DBTMVJNLU5UG+R4A>RD&*P
M]!>DK>GT@X'^GT \&%X.!VSYAMX2U/6__,O+3K B"N1<#S/%P.%O0#>EO0#
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M8L># +VA+V[0E[=H2]NT)>W:$O;M"7MVA+V)$)%)Y=Q,OB-D+J08L*/#,\7
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M,Q@^68BB!"8\T2E89L1NUC"/:IF[5,W:IF[5,W:L1NU8C=JQ&":G8)J#%FD
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M;%A$CPY@AB2]3Y(3J(J6++)G"F,+>E"B$FA+UT5?$ >@!8!X,(<&>P"SNE[
M/!A\PO /. >;0'G8!X,[I?TCYV >+!YMC+ XJ?(D2'#C$F5.Q(3" E'<T4N5
M+SRZ3II>&WBP84>',J>BP&=NB"5*I@9!+$TO)MXT&$HAS.01DH[K+)#'5M 3
MP4L+8J.KZJ9[QW.-!AJ(4Q0Q)>ITI^L;BHZQI3]8W&=]UZJ9[QW$0 0FR R!
M7KI?N_:J.KZI1WG]CIE+X4Q3J$\5+%\D)U$5+%EDSA3&%O"A1"30ER^*OBAY
MA%@'H>P#T/8!9W3P8!9PO9X!H>P"SND>@!X,YGL ["5%_P#V\C+I2C7@MD*U
M)N*=*H5'0TT0K0X9(1-R7R9&O9;)%J+<4J)4L.@IN#"8I2D+N4PD:1:RV4K4
M.Y(Y4M7"@D*1&.S4=7U4SWCNDSEY)BFBPCP8FA/UC<5'6-*?K&XSONO53/>.
MY+D,%? 72Y3+XFJE^[]JHZOJE'>?V/F<LA3&$H3Q4L7R0G414L663.%,86[1
MX\)/"F$QB+XHAP9[ +.Z7L_H$& >+ /0 \&$.#/8!X,[H = L'G /-T /!AZ
M 9PO8!XZY:3\*?R0KEB%:RFEX@,HEB]-LR$/$,FD$R4,EII)":'"AP2;LKDZ
M!8RFF%!&CH5B79PX46,9-3LPCLEIQ# 8A"0R[LKD<O5LIIE7#:.C5IMI 1JE
M(IJ95Q&22.7I=L<H'+[N2QO=R6-[N2QO=R6-[N2QO=R6,CE"-#%W59*$2V+[
MN2QO=R6-[N2QO=R6,2GI:0VXGIZ6G-[N2QO=R6-[N2QO=R6-[N2QB4]+2&W%
M0GAJH/NY+&]W)8WNY+&]W)8WNY+&]W)8R.4(T,7<SD)$*HIR7QA/2IP;W64-
M[K*&]UE#>ZRAI3+SRY-M3E Y?=R6-[N2QO=R6-[N2QO=R6-[N2QH$B0)HWV0
MF<L@S&$I31DD;R0G414L663.%,86Z1X\)/"F$RB3"(P,YA\[ /%G=(@SV >#
M.9[ /'H >A[%%G,/FT /!G,\ Z %G= >=@'@P^;44!,,,@0X?DN,B2*&BT[+
M(C'I6"+&I6.##2ZYO=>8,%+KF)2L46ATLE!H4BED)H<&%!#?(TM0*&BTU+CL
M>E2"QJ64@WNNO;W7F#%I98Q*5,T.ET16A26606(0D,N^1I:@CM$IN6G8]*PQ
M8U+* 8:77-[KS!@I=<Q:64"Q*5A@T.FY:1H,M00&=]\LREL&8P5*:,DC>2$Z
MB*EBRN:P9C#W*/'A)X4QF45?&'IX\6 >AX /0 \&<P@P"P#P80Z7] L \0!G
M: %G"P#T!Y^E[%%G:9=!]9'_ .:YC+H,Q@JDL9'&\D0(\5/%E<TA3&%N$>/"
M30IE,8J^(]BBSNE[ SA'S@ \>@& >#"'!GL L[I>P#P8?,+P#S@'FT!YV >#
M.Z7](^=@'BP>;0C@>H@_\V3"70)C!6(XR*-Y(@1XJ>+*YI"F,+;1HT-/"F4R
MB3"*46$.##YV >+!YN@!808/.P>818!Z'L ]#V 6=TB# +.%[/ !T/8!9W2/
M0 \&<SV#HEZ?UD3_ )N7H(,P@K$4=#&\D0(\5/%E<TA3&%M(T:$GA3.9Q9A$
M<P^=@\[.%G@ ] ,(<&>P"SNE[/Z!!@'BP#T /!A#@SV >#.U"P>< \W0 \&'
MH!G"]D\$ZB)#AEA$_P";UR& O@+44=#'\D0(\5/%E<TA3&%LHT:$GA3.:1)C
M$#S= #P$?,+P!G"+ /'H!G,/G8!XL'FZ 'SB##YV >#><&'SL \>@!Z!\[%%
M@\S.'I >#.%X!T +.Z \[0B'BG2IB)H?_.*U% 7P5R&.@C^2($>*GBRN:0IC
M"V,_4+#JW,]@'H#@P>9A\[/8!X"[I>P"SF> #T +><&$& >+ /!G=+V >#"#
M!YP!N/#0 LX6#H?T0H42,=*D(F+_ ,YK44!= 7R^/+XWDB!'BIXLKFT&8P]@
MN0P5\%8CC(HP>9A8!X] >=@%A!GL L[H >@&<(L ] >=@%G,]@%G=+V 6\X"
M\ \X .A[ /!G=,!/$4G3)H:8G_.JQ'!6P5\OCR^-Y(A18D")*9M#F,/8+D,%
M?!6HHR*, L[I>P#Q;AP86 >+!QZ %A!GL \&'S=+V >+.9[ /%@'AT /!A!@
M%@'AT/8!T/8!9S)DL14>! AIR?\ .ZI+!609C+HTNC>2(46) B2F;0YC#V"U
M%!7P5J*.BC /%G= #P86#S@X7,\ 'H!G,]@%G= "SV>P#P;AP;S"P#T +.9[
M +.80T +"R-&=6:%"AP2>1>TT;=IHV[31MVFC;M-&P3)((ZXD0L(G::-NTT;
M=IHV[31MVFC:$N31HFDTQ2$-VFC;M-&W::-NTT;=IHV[31MVFC;M-&W::-NT
MT;=IHV[31MVFC;M-&W::-H*Q/'/LXRU/ /VFC;M-&W::-NTT;=IHV+,4AS;.
M)$)!)VFC;M-&W::-NTT;=IHVA+DT8^U/,$I#=IHV[31MVFC;M-&W::-NTT;=
MIHV[31MVFC;M-&W::-NTT;=IHV[31MVFC;M-&W::-NTT;$,!R])IBD(;M-&W
M::-NTT;=IHV[31L \0U&,!"]IHV[31MVFC;M-&W::-B3!+$/L8D6%!"+-X16
M/-%9V,J4F83G%OQ&8L>.5B3!61H<X,#05J:/N S)( ]IHV[31MVFC;M-&W::
M-H*Q.H-LSF A>TT;=IHV[31MVFC;M-&W::-NTT;=IHV[31MVFC;M-&P3)&+%
M5)CL @.R,8"%[31MVFC;M-&W::-NTT;=IHV[31MVFC;M-&W::-NTT;=IHV[3
M1MVFC;M-&W::-H"F"H^V*I+ 609E+8TNC>2(46) B2F;0YC#V"U%!7P5J*,A
MCAYV#H >#.9[ SA8!X] #Q9W0 \6#H >#<.#/8!;S@W#BP#QZ 'H>P"SF=H0
M(3J1(0D,GDN'^IK7=4TRWKNE1^OMY3UK9JXGK5.D!$!@Q/6P=E,.IZ99US:J
MNL[DEZMTJ/U])?RZE'Z&E)UK68Q2@JFK'.>(;8IIC&@- 40E!-HIB^I@:D,7
MU2K9JNK;6'&BPA@S:*5H"B$H+K4?H;A)OR_;%2F@JX,RED>71?)$*+$@1)3-
MH<QA[!<A@KX*Q''01WL ] <&#S,/G9[ / 7=+V 6<SP >@!;S@P@P#Q8!X,[
MI>P"P@P>< %N/#H02XRABE H>3(?ZFM=U33+>NZ5'Z^WE/6MDJB>I3ZY3%_&
MGV4PZGIEG7-JJZSN27JW2H_7TE_+J4?H:4G6M42(2"16MB*C;2#&B0#I51%4
M/9S>+^&%K@1/6P=DJZMMR1#PS(EQ5(:E'Z&X2;\OVR4)X2J%,Y9%ET7R1"BQ
M($24S:',8>P7(8"^ K21D,<6 >/0'G8!8?,SV 6=T /0#.%@'H#SL LYGL L
M[I>P"WG 7MYA"72T8C.\G0_U-:[JFF6]=TJ/U]O*>M;*;Q>$+7*HGX%.RF'4
M],LZYM576=R2]6Z5'Z^DOY=2C]#2DZUI$0*"U6*J)MD\<Z>+#B%BP]E,XOK%
M6N4Q?Q0-DJZMN!#FAG31RJ(.E1^AN$F_+]LX\"$IA325Q9=%\D0HL2!$E4VA
M3&'L%Z"#,(*I)&0QW=+V >+.$6 >(!QZ %A!GL \&=TO8!XLYGL \6#S= "P
M@P"P#P:7RO@/D^'^IK7=4TRWKNE1^OMY3UK93.+ZQ5KA1!A10$!#8S#J>F6=
M<VJKK.Y)>K=*C]?27\NI1^AI2=:TS53^$-@("&PE,?@.Q,8"%.<8A]<JB_@4
M[)5U;<93&_#%TJ/T-PDWY?MI'@0E$*:RF++HGDB'$B08DHF\.80]@O009A!5
M)(R*,[H >#"P>=G"YG@ ] ,YGL L[H 6>SV >#<.#>86 >@!8 $1ETL"#Y1A
M_J:UW5-,MZ[I4?KZ>S%C=F+&[,6-V8L;LQ8W9BQNS%C=F+&[,6-V8L:7HU">
M/L3F A#F$Y]A+XOK4NQF'4],LZYM8Z%4>/V>L;L]8W9ZQNSUC=GK&BI5$$NF
M% BQQ[/6-V>L;L]8W9ZQNSUC=GK&@%$D#I4?KZ2_EU*/T-*3K6@YBD)%B&C1
M-*9+%4F@RQ-" I"$Z(B5/%95*S0PTP(@P8P#Q#83*)ZM+L(1QAQ $#!L575M
M*>&$:-V1 ;LB W9$!NR(#'DX<(Z:,F-I3G]7'TJ/T-,,AHI^S%C=F+&[,6-V
M8L;LQ8W9BQNS%C=F+&[,6-V8L:6IHR</MK%A0X\.:RF++HGDB'$B08DHF\.8
M0]@O009A!5I(R.,'0 \&<SV!@\W0 \>@!XL[H >+!T /!N'!GL MYP;AQ8!X
ML0ICFE\M*F#RC#_4UKNJ:9;UW2H_7WF9Q?5I=C)XOGV,PZGIEG7-SFW5=,G_
M %=DH_7TE_+J4?H:4G6M$TB^K3:8$$T>+!A$@0],S3!!BZ49_P :783>+QB;
M&7Q?6I=BJZMI1=;TQH)(\,Y1(?20?Q$T*/T-*+K?W Q(<.-#F\HB2^)Y(AQ(
MD&)*)O#F$/8+T$%?!6)(R., ] <&#S,/G9[ /!G=+V 6<SP >@!;S@P@P#Q8
M!X-#A1(T1!+H:,OE*'^IK7=4TRWKNE1^OO,WB\8NC@/#0BB^J5;&8=3TRSKF
MYS;JNF3_ *NR4?KZ2_EU*/T-*3K6B<'XQ-,GA!KF9 .DTRP>*/8*XGK5.@0$
M-,GB\#;%5U;2BZWJ7@ *],+]+0H_0THNM_<%$APXT.<2<Z _DB'$B08DHF\.
M80]@N0P5\%8DC(HP#QZ \[ +#YF>P"SN@!Z 9PL ] >=@%G- @1541"AA(H?
ME.'^IK7=4TRWKNE1^OO*J)ZY1HBI_P ,MTIXGKH.PF'4],LZYN<VZKID_P"K
MLE'Z^DOY=2C]#2DZUHF@\5>F5@ )-2[JFF5=4UJHGJ4^@A1.>:00A1]".+ZI
M3L575M*+K>J8=<TPOTM"C]#2BZW]P9R$BDF\F.@-Y(AQ(D&)*)O#F$/8+D,%
M?!5I(R&-T/8!XLYA8!X@''H 6$&>P#P9W2]DB6*LB(T<%'#\J0_U-:[JFF6]
M=TJ/U]X5Q/5)M!2B<T>"!DNF4Q?Q0-A,.IZ99US<YMU73)_U=DH_7TE_+J4?
MH:4G6M$SZYIEO4M2WSI/PF;\)F_"9OPF;\)FE8""77-XO"%HEL/UBN;P_P 4
M#2FB>N@;!5U;2BZWJF'7-,,.$/0H_0THNM_<(<A8A9Q)S(3>2(<2)!B2B;PY
MA#V"]!!7P522,AC, \&%@\[.9S/ !Z 9S/8!9W0A11EL5,F@I87E6'^IK7=4
MTRWKNE1^OO$WB\(>B6P_6*V4P_5*-$KB_@4["8=3TRSKFYS;JNF3_J[)1^OI
M+^74H_0TI.M:)GUS3+>I;I,XOK%6B3P^!5</UJ;3*(GXH.P5=6THNMZE1PB*
M-$"&,6-I4?H:476_N%,4IRSF3&1&\D$.>$>3S@B\FP7H(,P@JDD9%&8!9S/8
M&#S= #QZ 'BSN@!XM+I=%6G@P82>'Y6 1 >T%C=H+&[06-V@L;M!8W:"QNT%
MC'6JHA=,MZ[I4?KZ?:([>T1V]HCM[1';VB.WM$=O:([2DYSP]G,HGK%6B3P_
M,TVA_A4:(9QAQ"F Q=<PZGIEG7-SFW5=,G_5V2C]?2"]8 =H+&[06-V@L;M!
M8W:"QNT%C&7*S%TI.M:)GUS3+>I;F<P$(<PG/H0P_5I640_51]$KB?@5;!5U
M;2BZWI73 A":92G$Q]*C]#2 B4?:([>T1V]HCM[1';VB.WM$=O:([2\QC)/M
M\8I3EG,E%&/D@ASPCR><$7DV"]!!F$%4EC(XS P>9A\[/8!X,X>A[ +2V51%
MAH<,D$GV%EO7=*C]?:2?]/9'.$,AC"<VB7P_5I&FT/\ $GTRZ+ZQ+KF'4],L
MZYN<VZKID_ZNR4?K[DDZUHF?7-,MZEN<SB^K2Z(1!B1   !IK#_"IT0SC#.4
MP&+K5=6TD.:&;M!8W:"QNT%C=H+&.HCQ TI4D14>'#)")I4?H;66]2^WX@!@
MG,D,E'R00YX1Y/."+R;!>@@KX*M)&1QF#SL L/F9[ +.%@XB,ND8F8  H?8:
M6]=TJ/U]I)_T]E,XGJTNB&08D0  H,HA^M@:9/%X'US#J>F6=<W.;=5TR?\
M5V2C]?<DG6M$SZYIEO4MSF\7\471*X?XU71-X?XH&F6Q?6)=:KJVV@IXT<8$
MI !(0L,NI1^AM9;U+[@! !";4^("(" ^1R'/"/)YP1>38+D,%?!5I(R*,SV
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M=_K5Y,6Q\E5Y\<::#^./(6=_SP[WRXN<G>/#]?:.[MM[[V\U>(?^?G5R(_\
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MM7AIOYQT7X_@[5RAL;+>Y;9#9%6!N'C!>752=5U)0E3\LW/.FL\L?MGSA_\
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MS&'8W.#$C)&'JN-=NUEGY+D?X@##2T4/,#FZ9B9@0]AC=CU<;*:\^+>-]O\
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M\<KG\N?F,6PS[MAOEZ;TVZQ_MUF=FG</,:XI#\6(=B'X,4S$/Q8AVAQ&(?\
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M#,;#FT>:]HLL,3KNX:W=AG:$?@Q#\&AGXM#B-"B,0[0SM#/Q:'$XM#/P$A^
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M-&?!^K)GY;]. _SJZ/$ UY'6W9T\@2RR,R75SD[=(JZP2T\FF;#,L MAG)>
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M :Q.(^BBJ3FU>5EDE8&55CA7IY$-XAJ_&W8<T[Y ]/)H^?S<^>A\E6GP_O\
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MA1E'V^IW[A+Z8*8@Y*#<SPY^&U4Q:J\,U44$_P#YIKXM_P"::^+?^::^+?\
MFFOBW_FFOBW_ )IKXM_YIKXM_P"::^+?^::^+?\ FFOBW_FFOBW_ )IKXM_Y
MIKXM_P"::^+?^::^+?\ FFOBW_FFOBW_ )IKXM_YIKXM_P"::^+?^::^+?\
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M_-I^PZS_ $-T_P#-I^PZS_0W7_S:?L.L_P!#=?\ S:?L.L_T-U_\VG[#K/\
M0W7_ ,RG[#K/]#=?_,I^Q:R_0W7_ ,RD/L6LOT-U_P#,I^Q:R_0W7_S*?L6L
MOT-U_P#,I^Q:R_0W7_S*1%RUC^ANW_F4_8M8_H;M_P"73]CUC^ANW_ETA]CU
MC^BNW_ET_8]8?HKM_P"73]CUA^BNW_ET_8]8?HKM_P"73]CUA^BNW_ET_9-8
M?HKO_P"53]DO_P"BN_\ Y5/V2_\ Z*[_ /E4BTF^(<ADRH_DSV''3J7O]"G_
M 'J:+"](,IDK#\F8QXJ0:?.3=,AX9NCI'BANT _U'0)Q-(O(X3W14<-/H];2
M!'SB4L[:K^'%2%SUE=9O8O$IN1SEH'0@@V$5@[_R_=+FPA,=>]F9=.9TB#NJ
M"$S*,-/ABY-!YX#SR,4N/03\=A%A;HJ 8A]J#X4UD^4W=B=]I,>%D_&7S1@F
M;-8*JB))(  %I)-0&Z:-(U9&_3A5T#"4#NS""&_$# Y13NM8S L@'265+&B@
M-<";68@&UF,,0&%JS]TN_P"I3;&L-7DU,LN8!V2RL=_26.88=UFXA>0.&5,/
MYN%)G.(3+V3.;,U4O>T%5LD6.6)POL=U:%YOL9:PM67#Z1QNP(0;K1'5VG)U
MG<FT9LA@RG%5:#E5A$,,8)%)&MKIU)Z!H>:;&4[JL"IW1AW77DH53T,I^W+K
M4G=96@-Q,+5R'%-TO05G_-YZL,HMCSY2G-!FY5%NU)>LM6S#+FRS$$8\JL+"
MI%1!J(H+U(@D^7 3I4:T:%HQE&KT6S@](&AN=UA/OS#HI'HRXV--A9E"5,WS
M5.E1]8:QF&;.F&+,>0 5 "P*  !4 !L6KI,($7:239:9:EK*K2?PX3S81T03
MP"-"[F)8DDY2;=J)\.:^>,\"$F:;9@'^&Y_W@'58]<5'IUNVL=:3-!!4 *V=
ML2(N-CP 5L0H)&G//=79#]')!Z*_.:S3<BUB*JPH )C_ &3F^ZYGK(3%&MF.
M1$$6<[B@P%9@(FC7?X8DB[RXD";, >81E"5HF9N\WK*?:-:WB9>'RNQ:&XH-
M2C<  W/#+^']?S/HJEDSF/4Q"7,)\C$K'J6'H0*;!/\ AOXDD"?=IXK%C(PZ
MLR6UJ3$-:L-T$%2RG[#?HS[C/+&ZWH+!9JCR6Q).0$::1^<L4(.S#8QL>G<I
MTR2V5'9#PJ10?9]:3F Q36$X?\X/^#%"@76=WD7I<9 :4YWU+)_RZ!-;29UR
M8VF'?2Q^,D)A_14T]3WN5>*HD(X+#M)UU_& ^6KGJUQ%'F N/F)TW&^JD9SA
MS+Y>3HRY2L['(J@L3O 4O&MKQUI[EH6Z*V*HW%4!1N#:B7B[L4="&5@8$,#$
M$'$0:Q25K"H3EZ$Y1BF*!$@8E80=<@,+0? UZOLU),M;6=@JC.20*-=_A^4;
MW,$1WC124#E J=\W0!M#&D=:WAF3%+7HRQD@@J)'G-%MW8-6?NEW_4IMB\R\
M1NKG?$V2!RG#N_[W+_4S\&3<)/7GNDM<[L%'&:2[I($$E*J*,BJ  . 8=XG(
MT9,@]S+R:,LD%AVGTF!R$#%M2\_#D]K/II4=Y9BC\A@!\\Y<.\,!%[L5G+^(
M8-_RV?"N&G9&=;E[B;#CA#=PY\Q*S(>7,AN!M \ <G,-J_;M4S3*F%64D0((
M80@5,086B(,& -HHT^\,7=R2S,268FTDFLDY3L=Q_=Y/ZM<(HPB"(',:3[A-
MJ:1,>6<Z,5/)M0.A((,0140180<1%$O&MY[3F10JQ@   !4!  M"+&$6-9Q?
MV4/JK4VC>K\(AJXRI)^>1UG'^[!$/+(/1+:PUO/:?.;RF-@C8H$%51B50%&(
M84O4&OG^BJ63.8]3$$<^9B5CU+#T(%-@G_#?Q)($^[3Q6+&1AU9DMK4F(:U8
M;H(*EE)N-^!GW&>6-UO06"S5'DMB2<@AII'YRQ0@[*-C&SB=(<HZUAE)# Y0
M1 C>HLJ^3!?Y(M6=UX?-FCIQW7[P;E%N[S/L=Y-7=SB &.1)G4;( =%R;$^6
M+UK1A$7>4$&XTUK?1EL-_#-QEF$R^N)>[H+TW.8P5#N/M;1OKZ-TO(T9MI"D
M1*3( $]$DJ8>2Q,"0*-=_AF1I&SOIH@,ZRQ6=PN5KM0BGVG6]X><V($]%>R@
M@JCL@;%JS]TN_P"I3;%X_=)GZZ1AW<8_M:?J9^#=-(163IS3N:"G1.\Y3#OF
MLU,'ERR$/_$>")P.P.]M6YZQC!5F!7^K?H/P*Q->,#/ASKC-ZLZ6\LYG4J>(
MT:5,$&4D$9"# CAP=7NV.;H[[JRCC.'-N%Z&E+G(R,,JL"#OP-1Q4G:IO@Z4
MIJFQ.AK5QN,('<,0:P?D#5T[+=I$<_=J#QQPQ\079?H+W /"Q9RB%>03% 89
M6#[G]G<329\/?",VJM9MY4[Q22>)IHW1+\^D3ABB:AUZ_P!%4LJ:QZF((Y\S
M$K'J6'HP*[!/^&_B20)]VGC,R,.K,EM:DQ#6K#=!!4LI^PWZ,^XSR3=;T!!9
MJCR6Q).00TTCD98H0=D&QC: \"W:<QO=T$!W4PF*K_PGK*0%BG208E!KI]HU
M5-Z8 +RF@)DN/G+$Q&1E)4V QB!\JSKZPZ5XGM Y5154<#:>'(U<IZ-VD@D9
M'FG2/Y"R_D+5G[I=_P!2FV+S,Q"ZL.&;)(Y#AW*3C:>6]&60?6'WG!OM^A[J
M2J1R=X^E_P!+/;NX=VU<I@;Q.TCNK*6)'I.AWMK7&_DQ:9)EENV%"O\ E X>
ML+L! "?,8#(KL77B80P;IK V2)TN8<R.K'B&P!I9$N^20>ZF&PBWNWQZ!-AM
M0G2$065GN&L9;2ITLP96MW",1!%8(B"*P8;?N@C%I/>2VW-%V*_D%<.;JS6"
M:<J:(,,>X0<3*8$'$10I/!F79R>ZG 5,+=%O-<"U3; E8C^SF)I,^%_A>9]!
M6L^>I]YB,N61_AXG<>\ZJ]")>@PQX)>H==O!>K)FL;,DMR?)Q(WDU*>C C8)
M_P .?$<@3[M/&9D8=69+:U)B&M6&Z""I92;C?HS[C/)-UO0$%FJ/):T).00T
MTC\Y8H0=C&QC: \,N_:OFM)G2ZU93 CG!L(,014011-5:[*R+[4%:R7..*'F
MS#YEC'J&)T!\J:OEPZR%_P!([/R,-[#UC/C&$YD&:5"4.)*OD+5G[I=_U*;8
MUA?R*E65+!RZ19F S:*QSC#U?< >HDV81VRBKZC??9@7^]0Z\V6D:O(0G/5I
MYJZL>'<KE&J7)9_TCE?^EE_#M63+/^!,FI^69GY^[XAA7IP("8LIL7^Z139E
M*F,:XQ.%<K]&+=V$?MR^@T<Y72S$'8.YUG+A,4=":M4Q,QQKE5@5QP!@0T_0
M^TW41/>RP3 99B5E-TUI\[;U]U(YK!6>@W#"7,X(2^'APWN5_EK-E3!!E81!
M_"+016#6#&C7[X7)GRJR9+'Z1<?08P$P#$#![ -,F-&N]Y1I<Q#!E8%6!R$&
M!!W#_9L68P M-)GPS\+32+J(K.GJ8&<;"DLC_"Q,P][8/H^OX!ACPIJ/7C]&
MI94UC9B".3BQ*QLL-4"-@G_#GQ'($^[3QF9&'5F2VM28AK5AN@@J64_8;]&?
M<9Y)NMZ @LU1Y+8DG((::1^<L4(.Q#8QM >$4B*B*2_A_P")'^DJ65/8]?$$
MFD^5B5R>E4&Z5;?*=PN_^[N\E>"6HQ8<Z]$Q[V8[QRZ3$XZ\>/Y"U9^Z7?\
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M-;]9JH*,$88PDU%KJ9D63-8[PEN?48]DGJ[#.^'/B.3WLB;6"(!Y3B.C-E-
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M)8^:H7D V%KCJXK>;]9H@Q25NS"#ULDL'2\[1!$7O^L9AFSIABS-:<@R  5
M"  @  ,-OWB9ZLO#O/8D_JEVM?OK4]3#N_[I+_73]A%SO$;Q<B:Y9/2EQM,H
MFS*4/1)\TDM07[5,X34QBQD/FNIK4YZC:"17M$RY@#*:B"(@C=!MH9B2/LDT
M^7(@@CNRX&7G@H)RT,[5;+?I8Q+T)H&ZC&!_$=B?-HUVO<MI4Q:BKJ589P0"
M-I"_ZJF:#6,IK1U\UUQCC!K4@UT6[L1=[Y"N4QZV[*:K3&.%3BN(@-([1)UG
M=$9S_B*-"9Z:08PR,2-RAG?#MYTQ_NYU1S"8H@3D#(HRM3N=;W9Y!)@"1%6[
M+B*-^*Q_LC>\WIUERY8+,S$*JJ!$EB8  "LDU"CZ@U S2]5RSTFK5KRP-3,*
MB)0(BB&LF#N(Z*IAC#&P)J/7C]*I94UC;B".3CQ*QML-<"=@G?#OQ%)[V1-K
M!$ \IP#HS930.A,2-1K!!*L&1F4G5>M!WMVFQ:[7E00DY =_0FI$"9+))4D$
M%D9'; &QC: \(PUN%^)F7%C6+6E$VLFY&MDQUE>E'22]75Q,EN(JRF((.,'Y
M.E=A>084WL-R'Y#U9^Z7?]2FVBNL;R#-'^%+Z<S,5'5CB+E1NT:Z:H!N5W,0
M2IC.8;KB&AF2!%8+L*1.P-^\3/5EX=Y[$G]4NUK]]:GJ8=W_ '27^NG[$M^U
M7.:3-7&IM&1@8AE.-6!!R46Z?$R?9YEG?("9;=I:V0[HTEM/0%5%O5SF+-EN
M(JR,&4C<()!VEW&M[NDX0@"1TE[+B#+^*11KS\,3N]%O<S2 ^9)D IW X6 M
M8FC7/6$II,U+5<%3GKM!Q$5&T$C:(="008@BH@BP@Y:+<]?J;Y(%0>/TRC=)
M,)GXQ#97-E._U1>%FP$66QU[2&##)&$#B)VDUWO4M9LMJF5U#*1D*D$'?%&O
M&HF^QSC7HF+22<W63.I*C$E-#6T@JA,%F+TI;9G%43;HM!H6K_9!,OE\F+*E
M2E+.[$*JJHB68FH "LDT;4NI6:5JJ4VZK7EE-4R8+1+!KERSN.XTM%4V 88V
M%-1Z\?I5+*FL;<01R<>)6-MAK@3L$[X=^(I/>R)M8(@'E. =&;*:!T)B1J-8
M()5@R,RDZKUF.]NTV+7:\J"$G(#OZ$U(@3)9)*D@@LC*S>$;&-H#PC8/L\^,
MVYS#TDQH?/2./*M0;<,"$OMR<3)4P15A81XB+"#6#$$ CY-E=A>084WL-R'Y
M#U9^Z7?]2FURZ(9A'DKHQ.;295X2*,-5ZB8PL=IJ38__ %26TOR_%$W?7$V=
M=08CNE1KN(8P1!78;C%MC;]XF>K+P[SV)/ZI=K7[ZU/4P[O^Z2_UT_9._P!4
M7AY,3$J#%&[2&*MOB(Q$461\27<J;.]DUC.TMC$9259MQ13O=4WF7/QD ],=
MI#!U_&4;2-UUO(6:*]%K'0G&CCI*<Q@;&!%5&OVJ"U[NHK,!]++'SE'748V4
M9254".TEO-TF-*F+8R,589B""*+(UW+%\EBK2$$FC? T7AD*AB;7H$NUY$J:
M?\.="6\<@B=!SN(S;2:[WE%F2W$&5@&5AD(,01GH]^^%CW4RTR&/0;<EN:T.
M16)6-0*"CW._RVDS4,&5@01O'$;01416"1_8[,UAK"8LF1)4N[N0%51622<5
M&U-J<M(U3+:H5A[P5-3S1B0&N7*Q5,\7"A-A&&-B346NGZ5DF:QZV26Y/E>8
MQZW5/2A'8)WP[\12>]D3:P1 /*< Z,V4T#H3$C4:P02K!D9E)U9K,=[=IL6N
MUY402<@._H34B!,EDDJ2""R,K-X!L8V@/"-AT3&9=7/TDN-GSTC4'&\&%1Q%
M4OUP<3)3BHCC!%H(L(-8^3)787D&%-[#<A^0]6?NEW_4IMDR;PBS$-JL P.<
M&(H6DR?L<P^5)Z(WY9BD.RJG=L@UYN8^VW=:]*6#WBC*TJLYRA<"TP&PM^\3
M/5EX=Y[$G]4NUK]]:GJ8=W_=)?ZZ?LPFR6*.M89200=PBL4$N;.%[ECR9PTC
M^D!69'M,PW+:!-<29ET?&R_2R]TQ4!QEAH-GRZ6JKU+GXX*P+#.G6&^!M%]9
MZB"W>^6LG5ES3CB+$<^<.BQZXB2X>YWR6TJ;+,&5A @[HXQE%8JVF$U?>W[L
M?X;_ $DN&0*\0OXFB=V@EZ_N>=Y!_P"FY_ZF]0+<[ZBN?(F'NGCD >&D>P6I
M$;0[G6":,U1T)JP$Q#G\I<J&HXH&##[)K!8HT3+FKU)@&3(PB-)36IRJ0Q_L
M:F:QUE-21(DKI/,=@JJ,I)JMJ&,D@")(H=5:J+2=4R6Z*V->&!JFS1DQRY9Z
MO6;IP"[$,,;&FI-=O]+4LJ:QZ^1'/GXE8]>P]*!;8)WP]\0R>]D3:P14\MQ'
M1FRF@=&8L:C6""58,C,I.K-9CO;M-B;M>0().0<.C,6($R622I((+(RLU!L8
MV@/"-BTY/3D.1WDHFIMU?-<"PX[&B+$O^KW#RWX5.-6&)AC&^(@@_)<KL+R#
M"F]AN0_(>K/W2[_J4VX]^U<%NU^K.D!!)IR3 /*/^\ TJ^D&JA,U?K&694Z6
M8,IQ;H(J((K!!((K!(PV_>)GJR\.\]B3^J7:U^^M3U,.[_NDO]=/VB'0D$5@
MBH@[AH%D7QYB#R9L)HAD!>+*-Q66@375R#97DM#_ );QC^D&:@7[5]G<^3/!
MEPSO7+_+H)UV=9B&QE8,IS$$@[,9TD"5?I8^CF0AI?\ #F0M4XC64-8B-)6F
M7*^RS*FRB596$""/OB"*B($$@[5 U7?)LE1Y(8E-]&BAWUH$UK(E7I1C$93G
M.1I)P2Q0)?>\NC'SUTTCN-+TCOLJ@8ZJZ:>K+S*GCYCJQ&< Q&8@;-,U9K.6
M)DJ8-]3B93Y++B.\8@D'[+>/I)$R)E30*G48CD=:M)<Q$00?[&9NM-:35D7>
M0I>9,<P55&,[N( 1+$@ $D"GV&X:4C5,AHRI9J::PJ$Z<!Y7F)6)8.-BS'8Q
MAC9$U)KM_I:EE36/7R(Y\_$K'KV'I0+;!.^'OB&3WLB;6"*GEN(Z,V4T#HS%
MC4:P02K!D9E)U9K(=[=IL3=KR!!)R#AT9BQ F2R25)!!9&5F&QC: \(V/[3=
MNE+: F2R8*X\3#R6A5N@D%;_ '!M)6J(/61L:L,1' 1 @D$'Y*E=A>084WL-
MR'Y#U9^Z7?\ 4IA_L,KTWI^PRO3>G[#*]-Z?L,KTWI^PRO3>G[#*]-Z?L,KT
MWI^PRO3>G[#*]-Z?L,KTWI^PRO3>GT^KD:OR9K+5OHU>[Q4'VRX398QZ$Q)G
MK"7'BH%:\-=V.*<A7A9=-!OM"@O%RFI.EFQD8,IWU)&P&;=P%OT@$RFJ&F+3
M*8^:WDD]1C&PL"TF<I5T)5E(@008$$&L$&H@V'";]XF>K+P[SV)/ZI=K7[ZU
M/4P[O^Z2_P!=/VKWVKY\R0^66[(>%2*!+Q,2]H,4U!&';308G=8MOT":XNLR
M[MYTLB:F<@Z##, ] -5WR7-8V)I:,S]&^B_Y.R'7FK4_SEW6+ "N=+%HAC=!
M6N,B*5G0AM<3)9*L+"# C,10+(OKS$'DSH31#)%XL!V6% FN[D&RO(:'_+>,
M?T@H%E7M9+GR)P[H[@TFZ!)R*YH'0@@U@BL$;AV.9JJ_"IJT:%<MP#HNNZ(U
MY5)4U$TG:JOZZ,R2T#D(M5ERJP@1N'+_ &+SM;ZWG+(NTA2SNQ@ !QDDP"J
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MM<:X;0E)%;O=U),N1+)ZHLTG: ,R80"Y J5%1%VH,,;,LB0I=W("J!$DFH
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MG .C,EM Z++'=# E6!4D%M5:U73E/%I$]00DY ;1;HNL0)DLDE"165*LU!M
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M(8T9[S=S-DC_ !949B0RF TD_'5=B"ZINS3%QS"-&6,L9C06(R EL@-%O?Q
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M)D6/1E2ECW4B5&*RY:FP"UF/2=HLQ).V!AC8UD2%+NY 50(DDU  "TF@O]_
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MK59&!J&U7U?JDK>;[88&,N4?GD'I,/,4U>45J!>_ZRFM.FS#$LQX@+ !B4
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ME!WLV9=R?]Y*;EE]X!G)A0=QK&[UXFFJAX'*GBH/L\^7,CYKJUMEA-OA+,8
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M]R#BR:9'6/DCH@UL3\A/JC7"1!KES!#3E/"IT.(C&+&$58$&C:JUJL08F5-
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M2F'3@=U00N]_=EUI-K^FEW1Z[*KI)E]'*/H^&(Q;<&&/ )<L%F8@  1))J
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M0 &8?W9M:_#:+I3ITAFDC'W\HB;) .+2F(JDCR6(K!()5A C;8PEERP69C
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M<918^4J]V_I2]%CODT,S4E[>2V))H$Q<P9=%E&Z0YH9EYNQFRE_Q)/TB0RF
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M4_EE[_AYWL4_EE[_ (>=[%/Y9>_X>=[%/Y9>_P"'G>Q3^67O^'G>Q3^67O\
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M5 4#,!5\EIK?XG4I),"DBM7<8C,QHAQ*(,UI*CK+=[LBRY: !54!54"P "H
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MF[38)/48T)J8#SI9Z0RC26(TC19TE@R. RD&(((B"#C!%8.&OQ3<4Z<H!)X
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MNG\SO?\ $3O;I_,[W_$3O;I_,[W_ !$[VZ?S.]_Q$[VZ7>9,)9FE2R23$DE
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MBH/]0OLF4/\ AJ\P_E"4([]!,OQF7QQB=M%/02!WF9A1;M<I2R9:V*BA5&8
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M)E@U&'G-UFW3"P#[D/M5ZC*N,H]-["Y'^'+W?.:Q1E) I+N5REB5*E *JJ(
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M1JBZV2EZ30@7<UNYW6:)W!!; /"4< @B!!K!!M!&2C3[@/L,\UQEB,LG=E1
M'XA3=C1IMYD]]=U_QI722&5AUDW2RA8U!C@W76B?X$U'.ZH8:0_&6(WZ+-E$
M,K $$6$$1!&X1ASI<M82+P>^E9(.3I*.P\0!;HZ)-NTTNUW4O,F,%51:68P
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M\Y6'19?G*2-_94UCK]6NUTM"'HS9HQ5&N6AQL>D1U0 0X2YW.6LJ5+$%51
M;@XSE-9KPY^MKV>A(0M"S2-BJ-UF@HW32;K"]G2F3G9V.ZQB8;@L Q"K"NOU
MLOUQAK^\2_5F;1_TK6+QOMV6TFN;+%0?=9:EF9:F\H@;#>OJIGJ':5U^JE^H
M,*]?53/4.TM7]M_U3X:_O$OU9FTM7L*OHR/1=E\6'K+]XF^L=H77ZV7ZXP]8
M_5'E'W&WW5Q-<J<LS>F(%X(RCP_(\S5FLY8F2I@WU.)E/DLN([QB"0>XGQF7
M>8294T"IQD/FNOE+OB((/R&MQN*Z3MCQ*,;,<2C\ B2!3[-=QI3&@9DPBMSX
ME'DKBMK))/@B*1V"/@A2!\$12/@C@0V.3>1Y:E=]3'D;B^0AJN_O&^W50"2:
MYLL5*^ZPJ5[8F#>5 ; UUOTI9TIK5=0RG>,1FR4:?J.:US<UZ!C,E9A$Z:Q[
M3 8EH6-U-X0>7(/>1_$$)G"@H94]&1A:&!!&<&!PP;A<YA1O+<=W+AE#OHJ?
MQ23N46?\1WGO(5]U)B%S-,8!B,H55.1J"YZJD+(EC$HM.5B8LQ^<Q)W=@+,8
M 6FG^G:O:-RNS'1(LFO89G9%83<BWE0&P?Z5?WC?+JH$3;-EBI7W66I7W8-Y
M1AL'V;6\A9P'5-CKV7$&7,# XP:-.^';R'%O=3JFS+,4:).(!E3=:A_U.YS9
M2K:^CI2_TBZ2?E8?<ZOD3)[Y):,YX%!A19FLBEREFW2.G,AE"*8;S.AW*+/E
M2OM%X%?>S8,0?F+#13<(&EE8[#-UKK!M&7*$88V;R47*S&H<)@ 32=K:_'IS
M34,2**E1=Q15NF)-9.P_Z?>VA=;[!238DP>[?<!CH-940Q,%V$W/6LA)\LXF
M%ARJ:F4_.4@[M#.^'+SH?\*=$C\68H) R!D8Y6H3?;E,T1Y:#O$AE+2](#\:
M!RBD#A]UJ^1,GMDEHSG\D&%%F:QT+E+/GG3F0W):&W<=D-%O$N6;Q>5_Q9L&
M(.5%AHIN$ N!5I'85^&KDT95V.E.(L:;"I<TL$Q^>2"(H,.Z_6R_7&&O[Q+]
M69M&5K/5[Z$Z2VDIY01C5A%6&,$C'1-9W3HMU9B1B9<P"M3E&-3C4@P!B!L%
MZ^JF>H=I77ZJ7Z@PKU]5,]0[2U?VW_5/AK^\2_5F;2N##S9@]&=,'BP]82R(
M1F!_317_ #MH77ZV7ZXP]8_5'E'W&FXS#!+Y+9!DTTZ:\0=1NM#Y(F:LUG+$
MR5,&^IQ,I\EEQ'>,02#W$^,R[S"3*F@5.,A\UU\I=\1!!^04U?<5TIC\"@6L
MQQ*,?  20#]GNW2F- S)A%;GQ*/)7%CB22:1&##P0\$?!'P0\$/!':,J=C69
M#>93[(^0I6L]7OH391B#B.4$8U81##&":+K"Z]&8L%FR\<MX6;JFU6QC(P(&
MQ=W?I,N<N28BN.!@10F;J^6I/^[+RN*6RCBA2*+.E[BS8^LK&G[1>_TDG_L4
MBTZ]-GF2_%)%(O=FFGY\V9R*R@[XII:ON4F4P\I9:Z7I0TN/8YGPOJ1ZJUO$
MP<!DJ<F*8<?4'E;%*UGJ]]";*,0<1R@C&K"(88P31=873HN.C-EQKEO"L;JF
MU6L(W0P&Q%K]<9$QC:W=J&])0&XZ$I=GE1\R;,Y'9@-X0JR4BLZ]+N"9*\<D
MGCI^T7O]))_[%(NDZ9VII'J!:!KOJ^42/]X#-_6E_P %!*NZ++46!0% WA ;
M$T^>P1$!9F)@  (DDX@!6:=Q=25N-W)[L6:;6&:PRD5(#6JX@S-L8U3?WC?+
MJMIMFRQ4'W66I7_%;RC#8HZQNDF><KRT8\)!(X:1-R"'*DR:O$'T?R:'0:\)
MV9BU;O2EMQT_:+W^DD_]BD6G7IMPS)7BD@\=!WDF9-[4UQ'T"EM ;OJZ22+"
MZ]Z:MV9IF.[02I"!%%@4  9@*MB*W<@WR\ K*6W1Q&:PR)Y(/6> @0&@TV82
MS,223623623C)-N'=?K9?KC#7]XE^K,VDMZ$6N\V"SD'E+&I@+--+5RUK$!C
M27?+HXF2IJAE86%2(@C[\^P7KZJ9ZAVE=?JI?J#"O7U4SU#M+5_;?]4^&O[Q
M+]69M*7*'^#-FIPD3/S\.1K=!T+S+T2?^)*,*SNHR0CYIWMGNOULOUQAZQ^J
M/*/N-DZQNQA,D.KKG4@B.X80(QBJDG6=T,9<]%==\6'=!J(Q$$?)$S5FLY8F
M2I@WU.)E/DLN([QB"0>[F1FW:83W4V%1^:WFN,8L8=):H@;>2X7!-.8_ !C9
MCB48SO")(%.YD].<\.\F0K8Y!D48AOF))\,12(\,#@Q\$:0-G@C2.# TA@1V
M%CYK(>.'C^0TUE<#&%3H2=&8F-6APJ?):!W"NL-6O&P.AAIRV\UQBW#8PK!A
MMI]0?#DR,TQ6=.4]3$4ED>7B9QU+%.G$IL:ZRU>8^2Z'JS$C$J<F4,*U-=8B
M"NLM6M$&IT/6EMC5AER&QA6*MLF;-(55!)),  *R234 !62;*-J74[$7)#TG
ML,]AR2P:U!ZQ@QL &QRM9:O<RYTEM)2.,$8U81# U$$@U&@O<B"3T@)TJ-:-
ME&5&A%6R5'I @;9;6%_:),1+E@]*8\*E7<\YK%%=L 9FM=8MI3)AJ ZJ*.JB
MC$JBS&:R2223AW7ZV7ZXPU_>)?JS-IK\-ZT?_+SF^A8GW<QCU8XDF'>5S'RF
M(P[U]5,]0[2NOU4OU!A7KZJ9ZAVEJ_MO^J?#7]XE^K,VE?\ 5C&M'ES0,NFI
M1CO:"1SC#FZM,!-'3E,;%F*#".XP)1K8!B0(@4F7.]H9<V4Q5E-H85$'[X&T
M5;/=?K9?KC#UC]4>4?<<_P *WMJUC,D1QBV9+&8_2*,AF&P?),S5NLI8F2I@
M@0<61E-H8&L$5@T[N9&9=9A/=386_,?$)@%HL8=):H@;<2X7!-.8_ !C9CB4
M8SO")(%.XE=.<\.\F0K8Y!D08AOF))\$1X8C A2(I&D1X(>&'@C2(I'P0PHT
MJV"9G3UA\B+K'5;Z+6,IK28L8E7&,'+40:U(-=-*['N[P@^DDL>DN4KYZ1L8
M61 8*3#:[3Y[!$0$LS$  "LDDU #&31]3_##E)-CSQ%6?*LO&J96J9K!!:VV
M4:PU8\#4'0QT)B^:XQ[AM4U@BG?7-M"<H^DDL>FARCSD.)Q5B.BT5&UGOM_F
M+*E2Q%F8P YR; !634 31M6ZKTI-Q4UXGG0QOD3&J;[Q, NRIK/5CZ$Q+1Y+
MKC1QC4XQ:# @A@".]NI[N>@'>221I(<H\Y";&&9@K5;8^UZP;2=H]W*4C3F'
M<R*/*8U 920"VL-9/&T(@ZDM?-0<IM8UD[#=?K9?KC#7]XE^K,VI_H^LGC?+
MNM1)KFRQ4&W76H/C-35Q:&%>OJIGJ':5U^JE^H,*]?53/4.TM7]M_P!4^&O[
MQ+]69M*0)AA+O0,AOQX%/^8J#<!.P?;;H1)OR" <]68!8DR&3R7 )6P@B #:
MOUK*:3-7$;"(D!E(J93 P9208&NH[-=?K9?KC#UC]4>4?<=*O]S8I-DL'4C$
M08C.,1!J(B#4:2]97>"OU9J1KES *QET3:IQJ1CB!\D3-6ZREB9*F"!!Q9&4
MVA@:P16#3NYD9EUF$]U-A;\Q\0F 6BQATEJB!MI+A<$TYC\ &-F.)1C.\(D@
M4[F3TYSP[R9"MCD&1!B&^8D^"!M\$1X8'#CX(4@:0INX<:1%([&%\Z8HXF/B
M^14OERF-*FRS%64D$'<(X"+"*C51=7_%$)$ZP3Q5+?M@>[.Z.AET!03)9#*P
MB"#$$&P@BHC:G?:SF],B*2E@9C]E8U#*S$*,L8"ADN>XN@/1DJ3 PL,QJM-M
MX*,2@UG9TOVKYC2ILLQ5E,".<&P@Q!%1!%$U?\1Z-VO%@FV27/SO]TQW>@?.
M6I:!E,0;#M0B^/WEX(BLE""YR%L2+\YL4=$,:J=[?WT)*GH25CH)N_.;*[5V
M@06H;.E_U=-:3.EF*LI@1XB"*BI!#"(((,*)J_7I6ZWNH!K)4T[A/48^:QT2
M>JT2%&U6N.J2M[OE8,#&5*-G38=9@?(4XCI,M0+ZPUG-,V:]I.(8@!8JC$H
M R;%=?K9?KC#7]XE^K,VI*UC<',N;)8,I&48CE!%3 U$$@U&B:RN\%F#HS9<
M:Y<P"L;JFU#C4Y00,&]?53/4.TKK]5+]085Z^JF>H=I:O[;_ *I\-?WB7ZLS
M:0="008@BH@BP@Y:2[TS#[1* 2>N,.!UH>;,'2&*,5B2IV"[_NDO]=/V:Z_6
MR_7&'K'ZH\H^X\7V1%Y+P6=+C4Z;F1UM0XC4>BS R]9:MF"9*F"((Q9586A@
M:B#6#\DS-6ZREB9*F"!!Q9&4VA@:P16#3NYD9EUF$]U-A;\Q\0F 6BQATEJB
M!MA-7ZO33F/P 8V8XE&,[PB2!3N)/3G/#O)D*V.09$&(;YB3X(TB*1\$#X8'
MPQ%(T@<./@A2!\$12/@C@0P[O=\I9N  #E/R.)=SF=Y=XUR9D63=T<:'=4@$
MUL&HLF\O]BO!@-":0$)^9-J4[@;08XE-(C:!O6MIZ2$Q:1K;<51%F.XH)HUT
M^&)9E*:N_F %\Z)6J[A8L?FJ:->[Y,:;-<Q9F)9B=TFO::R)3_:+L/\ !F$D
M ?\ #;K2\PBL:RIHLH3?LUX: [J:0I)R(_5>NR!#'&@LVCW^M[PLK(L8NW90
M18YX0&,BC73X<0W648CO6@9I&X*UE[Q9L8931IT]B[L8EF)))-I)-9)RG::W
M6<?M=U%7=N3I*,DMZRH&)2&48E%M%2YSQ+GG_!FP29'(HC!_Q"VZ!M)EO\\/
M.'^#+@\R.0@&"9W*C)&C72Z_Y.ZFHHA.FX^?,J)&55"J;#I6[)=?K9?KC#7]
MXE^K,VJM\2+2)D%G(/*2-HQ::1)0YUB QI+OUR<3)4U0RL+"#9FW0:P:B 1@
MWKZJ9ZAVE=?JI?J#"O7U4SU#M+5_;?\ 5/AK^\2_5F;376.KS$63$/5F)&M6
MR9585J:[(@]]JV9"8HZ<IH"8F<8UR,L5.4&(&%=_W27^NG[-=?K9?KC#UC]4
M>4?<AWDN,RZS".]E1M^>F(3 +#8PZ+50(EZRU;,$R5,$01BRJPM# U$&L'Y)
MF:MUE+$R5,$"#BR,IM# U@BL&G=S(S+K,)[J;"WYCXA, M%C#I+5$#:R:OU>
MAF39A@ ,64DV!0*R34!3ND^DO$R!FS,I%BKD18U8S:<0%(>&-(CP0/AB,&!P
M(^"/@AX(>".R]T#5*55WSTCR@;WR2$U;>6[H?X3].7F"M'1SH5.[02]?71I9
MQO).DL?JW(91F=SN4 N%]E,QL1F[M]Y)FBQW@1L9GWJ8LI!:SL%49R2 *%9<
M\WN8/)D#2'IG1EPW0Q.Y1I.IY:W)#Y7O)L,[ (L1D0D&QL=#>K_->=,:UG8L
MQWR289!8,6UUE72\&;)7_"F_2) 8A$Z2#<1E%!+UW=WNS5=.7](FZ2*G4;@#
MG=H/]+ODJ<3Y(8!]]&@XWUV/O[_.20GG3'5!PL0*%+H[WR8,4I8+'==]$0W4
M#T,K5H6XRSYG3F0W9C" SHB'=HUXO3M,F-669BS$[I)).^=K1%%E+/\ M,E?
M(GQ> R!XB8("P:6B/-Q4$O7$F9=&QL/I9>Z8J!,&8(V?*#JR]RIQ/DJXT]]"
M0PWP-D)UI>Y4@Y&<:1S)'2.\#1DU/)F7M\3$=U+SQ8&9O=V(Y11I7??99)\B
M3%*MUXF8=T:04^;2)V5+Q+ZTM@PSJ8CC%.O*_1#GIUY7Z(<].O*_1#GIUY7Z
M(<].O*_1#GIUY7Z(<]!J[6C2S*#A^B@4Z2@@5QW3M8ZOU;-7N=(L%=0^B3;H
MQK )K(LC$PB3'KROT0YZ=>5^B'/3KROT0YZ=>5^B'/1[O,>5HS%*GZ(6,(''
MD.TDN\MY6C+4*/HA8H@,>04Z\K]$.>G7E?HASTZ\K]$.>G7E?HASTZ\K]$.>
MCW>8\K1F*5/T0L80./(=I2M:W$@39))72$1$@J8C'433KROT0YZ=>5^B'/3K
MROT0YZ=>5^B'/3KROT0YZ=>5^B'/0:NUHTLR@X?HH%.DH(%<=T[46\W68TJ8
MABK*2K Y01 B@E7LR[XHQS%(>';0K'.P8Y33_-ZN93\R<&XC+6'"=^G[#-]-
M*?L,WTTI^PS?32G[#-]-*2]97:4TE4DK*T6())5YCQJQ=,#>V9+Q+ZTM@PSJ
M8CC%.O*_1#GIUY7Z(<].O*_1#GIUY7Z(<].O*_1#GIUY7Z(<])NK+Z\LRIRZ
M+0E@&&X8U?<CWDJ,V[3#]+*)@#\Y?-<8C81T6J@1+UGJR8)DJ8-]3C5AY++C
M&^(@@GY(F:MUE+$R5,$"#BR,IM# U@BL&G=S(S+K,)[J;"WYCXA, M%C#I+5
M$#:B:OU>AF39A@ ,64DV!0*R34!3NTA,O$P#O)L+?FKC" V"TGI'$! V^&/@
MAA1%(CPP.#'P1I V>"-(X,#2&!' :;,,%4$DY !$TF7I[9C%LT3&&]9\F :N
MODZ2H\E9C:/H1T>*@$V;+O '^\E+RR^[)SQCNT_SEPES.Q,:7ZRS*?YBX35[
M,Q&Y0E/I+M>@=Q91Y9RT_9[W^CD_]^@[J[7HYUE#DFM3_+:N=^U-5.1'Q<V[
M2%RN<F5VR\SD,L<5"IO?<J<4I$3@:!?\JG>W^=,GMEF.SGA8D[= N-_G*HL4
MN709D?24<% +QW-XW7EE3_RV01WB-R@%\U<K;J3BO$TMO6I]/<IRGYK(U>^5
MX>*E=WO<>Q)_[]/V>]_HY/\ WZ'N;I>&R:7=KPPF-#CI"ZZM)W7G <0E-RBD
M+I=Y$D92'=N'35?R:$3+\\L'%*"RH9FEA6X6)H9UZF-,<VLS%F.<DD[<B* 7
M*_SE46*7+J,R/I+Q4 GF3>,I>7 G]$TL1WH;E +WJY'RE)K)Q,C[N/?QG_,7
M&:O9=&Y="GTEVO0.XLH\9G#DI^SWO]')_P"_3Z.[7HG=64.,3CR4/<7&:V32
M=%Y _CWJ?Y35R(?GS6?B5)>YC_ 1(,F[Y-"7$C]*TP1WH;E"+[?YS*;5#E%.
M=$T5XJ1-9/\ ;+W\B,R[S"!-E$U.,H\UU\EMXQ!(HFLM63!,E.-]3C5AY+#&
M#G$003\D3-6ZREB9*F"!!Q9&4VA@:P16#0:49MTF$]W-AOZ#XE<#>85K8P7:
M2:OU>AF39A@ ,64DV!0*R34!3NTA,O,P#O9L+?FKC" V"TFLUP AX(^"/A@:
M0/@B/#$8$#2(I&D1X(>&'@C2(I'P0PHTJ\/V9#TYYT?Q16QY%W_[M@O=T.G*
M> FRB>C,7Q.*]%H1!J,5)!36>K'TY;VCRD;&CC$PQBPB!!*D$_)$S5VL98FR
M9H@RGB(-H(-8(@00"#&D1&;<YI/=38;^@\*@X&8.!I+Y2KM!-7ZO0S)LPP &
M+*2; H%9)J IW:0F7F8!WLV%N/17&$!L%K'I-B AX8TB,*!M\$1X8'884@:0
MINX<:1%(X,31YJF,M.BG9&/\8Q.8@8O[MOVNXG2EO 391/1F*#Q,*]%P(B.,
M$@IK/5CZ2-4RGK(V-'&)AP$0()!!^29FKM8RQ-DS1!E/$0;00:P1 @@$&-(B
M,VYS2>ZFPW]!X5!P,P<#27RE79I>K]7RS,FS#!5'&2;  *R3  1),*:!A,O4
MP#O9D+<>@L:PB[VD>D18!#P1\.YX8>"-(BD?! ^&!\,1X('#CX(4@?!$4CX(
MX$*?8))^EG"N%JIC]*P;D=S^[>+]<3I(T!-E$]&8N0Y&%>BT(J<H+*5UCJM]
M);&4U/+;&KC$1B-8(K4D5_),S5VL98FR9H@RGB(-H(-8(@00"#&D1&;<YI/=
M38;^@\*@X&8.!I+Y2KLDO5^KY9F39A@JCC)-@ %9)J !),*5PF7N8!WDV&_H
M)&L(#F+GI-Y*K2'@CX(^"'AAX8TB/! ^&(P8' CX(^"'@AX(X37J?BJ48V;$
M!XSB$31[U>#%W,3N9 -P"H;G]W!=8:O:(,!,ED]&8OFMN^:UJFL51!766K6B
M#4Z'K2VQJPRY#8PK%7R3,U=K&6)LF:(,IXB#:"#6"($$ @QI$1FW.:3W4V&_
MH/"H.!F#@:2^4J[%+U?J^69LZ:8*HXR38 !628  $DPI7"9>YH'>S8;^@D:P
M@.8N1I-Y*K#P1\$<'=\,?!#"B,"!PXT@?!&D?##P0-(4:]7IM%%M/(!E)Q#'
M3OGZ,M8A%R#*?G'&=ZP#^[DNL-6O"P.ACH3%\UQCW#:IK!C1=8:O:!$!,ED]
M*6WFMN>:UC"L5Q ^2)FKM8RQ-DS1!E/$0;00:P1 @@$&-(B,VYS2>ZFPW]!X
M5!P,P<#27RE781K'5CB=>9HA.<B#HUIE 5E5%L?\2IXPT0N#'P0\$*1I$>".
M! ^"(P*\"(\$1X(&D/!#P1I$4CX(>!KU>VT57A)Q #&3B'BC2+]"4O52-0W3
ME;=Q6#=_NYKK+5K0(J=#U9BXU89,AM4UBN@OUQ.BZP$R43%I;9#9%3Y+@089
M"&4?)$S5VL98FR9H@RGB(-H(-8(@00"#&G>+&;<YC$2YN,8]"9"H.!8;' )6
M%:KL"ZPU>T0:IDLGHS%\UMWS6M4UBJ(*ZRU:T18Z'K2VQJPRC$;&%8JI5X(C
M A@1PHBF[@P/@J\%6% X$, WF]M#S5\ICD4<IL K-#/O!@HCH(+%'C)QG'N"
M ']W5-9ZL?1=:F4]5UQHXQJ>$&!!! -!?+BVC,6 FRB1IRVW<JFO1>$&&1@R
MCY(F7"_RQ-DS1!E-A'*"#6"($$ @@BG>RHS;E-/T<S&IM[N9"H,!8:@X$1 A
ME78%UAJ]H@P$R63T9B^:V[YK6J:Q5$%=9:M:(-3H>M+;&K#+D-C"L58,#2'A
MCX(8O##PQ%(CP0/@KP(CP0/@@?!'P1I&D*0I T[V>=)SU4!Z3'Q 8VL&Z8 F
M]7MHG$!8HR*,G&;22?[O":SU8^A,2T>2ZXT<8U.,6@P((8 @7NZ'0FI 391/
M2EMXT->BT($5&# @?)$RX7^6)LF:(,IL(Y00:P1 @@$$$4[V5&;<II^CF8U-
MO=S(5!@+#4' B($,J[ NL-7F(,!,EGJS%\UMWS6M4UBJ(*ZQU<T0:F0]>6V-
M6&(Y#8PK%6''P1\$#L%>!$;!&D:1P(&#SV'12/Y39%XVL&,AKU?'+NV/(,0
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M7QS,FS#%F-I/B L %0$   /N&F_B^NN%+["\@V67V3R[&LI;6( WS"@EK8H
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M !634*77^J']59"S-<D+,N=Q< K<":UG3P:FO@$"B=6ZFLZ5X@9&S7K^K?\
M22Z_2]*;K'5TI?>6L][NB*/>6M/D*/I*YLH=YI+,V"[?%WPC>3=KY=C4;4F(
M8:<F<D0)DJ8!!T.XRE756'^JZLA=M8W4(M]N9,6D3&!@R&K3D3=%C*F0Q%'
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M@RF)E3I1(TY$](CO)4R TEB""%=&68J.HUWJ0B1?9 5;Y<V8&;=II&]WDF9
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M4Y0?&+#PX\-DQ,AX00>2/]B5W^#_ (*N;7R_7F,%$ J(O7FS7:"2I2 Q9W(
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M%2C(.<XSXH4$Z0VBPX]PC&*"6W0FXUR[JY<UHW;=JS3E '"P&&&\U6/B\?\
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MP[#]NG#HIU=ULN9>7-AP-#>+@-TI[/L\&2D#41LD)$UE&2,1P&(XJ0FJKC-
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MFT&L4,W5YC\PGU2>0\-#+FJ586@B!VEH7="V4XAG-GCR4$V\?23/R1F&/.>
M;2T;P@.0V$9C;O6;E"]T/>+D-3#Q'B.Y0I,!4BT$0.T^[NR%CQ#.;!03;W"8
MXQ>2/:WZMRD!M RYJAE-H(B*&9<6T#YK5C>-HWX[U-"\(5W<1S&P[3"("2;
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M+Q>5CO74PW*[10;,,$^$;1G:RUE.2[W>[HTR;-F,$ERY: L[N[$*J*H+,S$
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M=$1PB/&!33DL'&4$'DVFUWFV,+<AQ$9J-(FB#*8'GS&T;$%8?1I6WB&_R1I
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M'U:>J-H/V6Y#AR>U]QI'FJH\?C^1!/D&##CW#E!III4XZRY.<'$?'\DF;-,
M./<&[3O'J L&(#[[3CX*0\$<&K K\,*5TCLQD'%6/']^[\@B\H.E*M[)MX#
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MW<V"M3E4V<QW0<,,I@107:]&$T5 XG_^6YCQ9-G[V<:\2XV.YXSBH9\\YAB
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MHZ++6"*:+=&:MHR[HW.3@)V R9PS'&#E'C&.ADSA7B.(C*/OJI X-?@B*0I
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MJ;41U6Q@\V48\\#3Z2=P+XR1R4C,+/G,!Q0/'3Z"6J[H%?#;Q_+Z@Y13W:\
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MHD&*WH#$=IMEM$ !1/2(U?71),^?-?;C0X4)AV5+ER7C1MF/&C,(1N&9*@B
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MYNGC^T.R^(S\RSC(G#6/!B\C,*MKHZCY_?7]H^HL0:^*)"4B7(,0'4012<,
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MR226O6I6-7(DUXII[ U">[['$6'NKB6X>S5@[R>=3RA-[A8C$YB02_\ 5,9
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M.ZH4;;[*G$8B7B*J+W;  Q.444BA *<R^K?#GXDJ^)S1IM??[)97-1M11B5
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M5.;S.:YRZHA:+U>HFLWV&W(O,*G&_'.ZI&WO/\/RR-'542ORW$YO/!GM*!&
M&ZUWS/,IQW674%P:?;7?EJGV$WME]Q"@R)ED0;5Y[8$(@(8[D%F2%53'SYD;
MJ[1TD)>1N/-DO&C2>H;+$,]Q7',UQ2X:1BVQK+*2MR&ALV1)#%N?46S;T=U$
M)$(4-M=%1%3K3BQR;PX9/;^'K+Y"O24QF0$K-=JYT@E-Y6FJJ>^%I5*ZX2"K
MD6P>CL@B(U ZM%GV.8;0V.=81!5\BW'VB\ZW Q,8C"_TEA9LUS 6M6PB<O\
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M=OH+V\+PG;Z"\)Q][A>$X7L_!PO9^'A."[>$]WCL]$NWH=G"^[Z-=NML[>I
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MT\ID ++;9Z2=TKBJ@..NMF7>JY$AQW$->54$A;4=0U7U86+[H4P5.:5$20.
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M[>.:$A1KV^QF/D-]'7F55_HYLM\$7JUTUT'R)ZMO\"D0ZZ'NIB[$W)MF,RD
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MBFW$@0F$2?EV"B\O,A"J*[/J54G(R+WC9O1T,VON'OU50HA2K_;VFA[Q8[R
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M,)EP8K^[F,QF9"BJ-.R(F&B[)9 _(I-B\T1)["&/MIZ3<;P;DN+932<6GP+
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MISNIZ1CF[&S^7VV$9WBTM)-7=5+W*IM%[V766<1Q"9F0I0:LRX4ELV7FU4'
M(5TXI=M=RW*?:+Q)I'CQ#Q67.2/B.Y<T 1MZ?MG9V!\RR'2172H)+A2VD548
M<G-M.OAZ98WE[9U]+2T\*59VUQ;38U=5U=;!9*3-L+&PF$#3##+8DXZZZ8B
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MV2T<CR6E%UEQ!<:,'!$DM]Q/ [;.7]4BOSI6P^:W+87T%O4G"C;>YO:$+<T
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M]2H=LW_!KQ&G[W[V;E;KRF59=*GQ&LI]KL:?-.M^+/1P[NR>:\HH<:PB&O\
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M414YFWLB>;)0E2@51B"I1XY*2O/.?<RXVNW)K@('VWIF+9/'8;.]PC)ACDU
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MG#N+!62[OF+E 74YD0>;1>9/LS[K?*[$?]3@QN/#IO-!C(T2@]6W>$6KY/\
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M6_!=;"?71.9J0E@VB:HBDJH8R_Z_^)W=4Z^:KGG&/XCD#FW>,.LF7,,9_',
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M26;953QNY;/']U3A[J5TB(PNK< 9><MS;"*TG4*>838YB*( D@)R\0ZOQ/\
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MPI_WA]HOCCC[9?A3_O#[1?'''VR_"G_>'VB^../ME^%/^\/M%\<<?;+\*?\
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M=9B^FY)NON_F%1@^"8K#.7:75O(1L3<Y5\UJZR*.KTR=*-$9AP8P&^^ZHMM
M1JB<7&V^WKMMM9X9XTUUF)A\65W&2[DL1GO^#NMS)\0M";-11]FC8-8C!*/?
M%,?9:D#ZF@;I;'Y?)QZW;5B/?T<A79>)9M2M.JX[CV8T/.+<R*>I<BJHO,&O
M?1G67Q!T?_1CCX/O7CE?'>W VCL9XO3H?,2LED&(3'A;6TJ'#'K>;!'8I$#4
MH&U-DWO2=J_WK,'^J+.>GXE_HHQ+YWEZDV)_>!:^KF[Z?B7^BC$OG>71WF^B
MC<3YH3/2,8WCQ-95E0JHT&Y.&MR%9BYM@4^2!V]08D2-I*94 EUKY]34IILB
MU;5P#PO=O;.]CY)@N?4,/(<<MX^H]_"EBHG'E,%[YB3&=%R-+C.(CC#[;C+B
M"8$B>HO%/^=>)_5I2=+9KZ5MO/G=#Z'A&_.O>#\D8_\ <+Q<_G7L_P#DC(.A
MXI_S4Q/ZRZ3U739I@>37V&Y=CLYFRHLFQFUFTMY43V"YFI5?9UYMO-&GDU$D
MU35%U153C']D/&U/J\=RV6Y%J,5W]9CQJC&,BE.Z,18.Y\"*@1ZJ6XXJ"-O%
M;;@GS)YRU#0"D/-/L.MOL/M@\R\R8N-/-."AMNM. JH0DBHHDBZ*G6G1SK8W
M*TCPY]K$6XP+)W6N\=PS<.H9<<Q?(VE$2/NA=,HT]MM$)Z&](9$A5Q"3,]K=
MPJ:1C^;8#D=KBV35$E-2B6M/+*)([EY/>O,.<J.QY#:JV\T0.MD39B2]*!79
MC;+$V,WJ<JL)W.&2^85V-S?.B#$=QB;3J1:F0^XU,-472!)ED@FX#6@D)(0D
MB$)"J*)"J:H0JGE1?87U%DF;9?;1*#%,0H;;)\EO)Y$,*GH:* Y:6]G+)M"+
MNV([3CI\HJNB+HBKU<9_O9:+,B8U)DIC6V..S%1#Q?;2A?=:QFK<:$W!"2^A
MNV5B@.$"S9,A6U1M0$>D[XJ=R*3SC:K8FXC_ -1HEA'-868;R,MA.JY#*&*B
M['QH":LG50Q5)IUZ)W@!(!/\ ;[#,QIH.0XMD]7+IKVEL6U=AV-;.:5F1'=0
M50A5474' (3 D0P(3%"3X4I FW>R.8V#XX+DKSB29E1*5M93N&Y.X ARS& 0
MRC/<J!*8'O 7O0D-M>OVO0[/Q\)Z"=OH]G"]GX/0[>%]Q>%]Q>%X^_QV>@O;
MZ">[QV?CX7LX7B-"A1GYDR9(9BQ(D5ER1)E29#B-,1HS#2*9N&:H( **JJJ(
MB*J\4?B+\1=&Q,WJF1VK' \#L6FY$7::-(;YV+>W8/4#R,P74175*Y%T366I
M%'^["T6YVWN%;ATVAH-9FN+TN3PVE<TYG([%RR\+9ZH*H;:(2*B*BHJ(J2)=
M1A>8;4SY/.3TG;3-;"/')X_(ZW39D%S 81.I$:BQ6@T_T=55>'7=OO$]=U;:
M.*L>OS+;2!?&31.H@@]<TEO6H) ',JD,!4,D1.4$75-*;?39J?'[K5';.'F]
M0]WW.2=VK$2!-'EY>1>?O-=55.7WJ*6G_4OPR?++=3]"^/UF>&/Y9[J?H7PO
M_P"DSPQ=?_YY[J_H7Q^LWPP_+/=7]"N/UF^&#Y:;K?H5Q^L[PO\ RTW7_0KC
M]9WA>\G_ /NFZ_Z$\?K/\+ORUW8_0GA1M=VO#7"B]V2H]7Y)NA9OJZBIR L:
M3B<0>54UU+O=4ZO>KKU,IF/B:V]H0+E\X+&<#R3+":U=5#[D;2;2HYH&A)S*
M&I>]ZD3F5F1N;O;NYGQLHA%$QJ%BVWM9)=0NM)34EB[E=VH]7*S,;/71>\TU
M%8<["/#M@TV\@JVZQDF>1Y>Y%ZU,:)#"PA2\Z=GC#?1414."VQR]: @HJIP#
M30 VVV MMMMB@ V )R@  /4B(G4B)Y/N6Z^^ZVPPPV;SSSQBVTRTV*FXZZX:
MH@B*(JD2KHB=:\93X7_"1DJP=L6UD4>YF\M')?9L]PGFG%9L<6P&SC&/<X_U
M*U,L6_Z2RZVV#"OYBL/5$6? E2(4Z%(9EPYD1YR-+B2XSB/1Y460RHFVXV8H
M8&"HHJB*BHJ<8QX7/%OD3#.XQMPZ+:O>:YE*V.XLA%\W@XCN!.DERC?&G(W
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M+1YP>5U;B[PV'.N0=3R<X2C> ^551515%5315Z+V88%3>>;^;'Q+3)<%"#&
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M$1$5(B5!$115(B5=$$43RJOL)Q79#;8L&PNV,T&)29ONS$G5=I9P'M"1[%<
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MQYLES3ZC.QK)&(_,7(S:5KT2Q8%254;?#7KZ>9[+V<Y9-OL!N+(:K(ZKJL+
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M($E7:_*]X'6UA93:$H:"XW2 I4D75%Y7DL' ,FI Z=)_Q7[D4W<;H[Y4C+&
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MX=G D"B*3$V!(&5%>%%ZM1,!)-?:XQG+((\D+)\?I<AAAJX7+%NJUNRCCS/
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M"@ #=;7(0CK'8%P@%UUU5_QI[VY(CK#Z9!N[N3>(]&$AC/);9E-G]['$E54
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M9[JNR)+Y(B"*>06VFQ%ML$%ML ;$13U!0[R;-WRUEY6*D.ZI9BO/8UFN-//
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M,@%5>9V91-LDV(Z#7/D2F-%GVW654.;87DT$+&AR?&K*+;4UI$-5!7(LV(1
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ML:V?$?1#:>8> VW )$42147IXOO)B!2K*C14HMR,*"3YO#SK Y[PE;4KZEJ
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M9)N]-OPB[LWC<;:?=J\[[;.YLWR2/@^ZUF01F:-7C71JNR(D!C1?>-6",&B
M,J4ZGH>*?\Z\3^K2DZ6S7TK;>?.Z'ZBWE^E;</YW3.ELU]*VWGSNA^HO%/\
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M_P"SQK[?L_R<?B_EXU]KV?Y./Q?R\+K]_P#DXT^]^/TN+95<Z76V,)X)$.?
MDO0YL20VO,V_%E1R$VS%>L2 D5/87B#B.^;A3Z\E:C0=P8T95GPO] 4RB#&3
M_B&]-$67';[T=-7&WE(G!B6E5-B65;81VI<&P@2&I<*9%?!'&9,62PI X!BJ
M*)"JHJ>3[A^)B +/=Q+_ "#%LXA.(+8!)'-L"JLDL'@0$3^;-D2FB54U4@)5
M5=>9>EX<)ZOH[88ACUUMI:,^4H;FW^3S,<J6#7R:E6,P'TT_T7$1>O7[@9/=
ME'[A-QMK-KLR!WN4:\\"#4.[>K(YT .\T*A5KG4CTY.3F3EY Z6'X[W_ 'S^
MT^Y.YN 2$(D)QKSZ]3<N.V2^71&LA! YM=!1!1=!1$]23K6RD-PZZLARK"?+
M>54:BPH3!294AU4U7E !(BT3R)QN)N)+1Q)>?9UEN:2D>!IMU)&4W\B\>1T&
M-00N9]>9 7E1?)U=*/#B,N2)4M]J-&CLBINOR'W$:99: >M2(E011/*J\83A
M;1 ;>(8CC>+MFVJ$!A04S-2! 0MM(J*C6J*C0?\ W@^1/1VK_>LP?ZHLYZ?B
M485UM'W-I,7=;94Q1UQIG,4!YT&U751!7&T(D31%(47RIKZCV)_>!:^KF[Z?
MBQLC:UFQ,)VL@QWN=Q.[BV%[<R)C7=HO(O.<5A>8A54Y=!5$(D7H;S?11N)\
MT)G3N/W?MQ/G+C_I>:[)[L4J76%YO5G FBVH-653.:))%1D5%,,3\WL*^2+<
MJ(]R$B. B&!MJ8%ENQVX[*OOU#B6F)92S%<BU6=X/8ON#CV7U FIH@2!;-J2
MPCAK&E-2(I&1LDJ]+!=]=M97+>X?9@=A3OONLU>6XS*)&LAP^\[I%58EA&YF
M3)!4FCY'VM'FFR' ]\=L+%9^(Y[2M6<9E\F/A*EL6C6)=8W=LQS,6IU=+;>A
MRVQ,A1QM5 B!1(O%/^=>)_5I2=+9KZ5MO/G=#]1;R_2MN'\[IG2V:^E;;SYW
M0_47BG_-3$_K+I.G<?N_;B?.7'_4/B%Q_P T"1>81B+V[^+/=V+DF)<[6ZY9
M+2")?_79=8Q85J:=:C))!]\J=/P\;G-2CAM83O-MQ?6+H>1RCB97%_K!#=TT
M56Y$%9##J(J*H&2(J+UIZ@WF^BC<3YH3.GX3/I7KOR9*_P #L.\$F%63K;*M
M5&YV]CL.3RMR>9PWMO,&G VJ*2 H?#TIET5%26L=!>8"T]78[O-LSD3E#E5"
MXK,N(\CLBARFAD.@=IBF5U8&"3*Z8@"CK2D)@8@^P;4AIEYMC.L%?;H<XH6X
M4'=#:^=-:D7V"WTAI5$A)$!9E5,4'#K+,&Q!X!(#%J2T^PU]T++.MP[Z+0T%
M</()NDAS;.<8$<:HIH(KWDJ6]REW;#2*NB$9<K8&8RJ"L.5A>U3,A5@XC$D:
M3+L&G-8\_,)C"Z2'%T0QB OF[2Z:(XX/?$B>M>/+_)Q^+^7C5/9]G^3CW?8X
M77[_ /)QI]Y/Y>-4^_\ R<?A3^7C5/O_ ,G&G\7\O'N>F1Z"^=F7FU]C*5;*
MGU1Z7C[T@A1RZQ]7.M%'3F>B<R-NIS*B"ZJ'Q69'CEG$N*.XB-SJRS@N([&E
MQG4]Z8%U*BHJ*)@2(0$BB2(2*B?<':+=!B/W-=N7LLS2ONHT2)+R3;S*9K5F
M\K_D)1K[6H;4--104555"1$Z7B'\.T^4GG&+Y51;O8S&=-">>K\NK0Q++!C(
M2J0LQ7ZJJ,@1$%'):E_.,M?4N6[A9E9L4N)8/C=WEN36\DD%BMH<>K7+:UFN
M:Z:HVPT9:)UKIHG6O VFQ&[&.9;8M0FYUMAC[ZTNX&/-$7=N+>87:]U/:;!S
M5KSH&3C&2?T3S@JA+Z1X7MVFHZ$.1X1G>W4^6 +S-%A=]$R6ICON>31Q+Z:3
M*?\ U#G3\2?A\L)2=Y<5&*;OXM%4Q#0J*4>'9N:"2ZF3@SJ'E04]ZC1JNJ*G
M+ZD\2N:M3/,[>RV\L-O<<< E&4.0;G.A@,"1!Y>OO8J6!S47_11DB7J%>GX8
MMO?-DEQ,AWPVX&Y8)31"QJLR>/<Y2:=WUZA71Y1HFJ:JFBD*>^3H0)O<,/?U
M=W[VYN5<=Y>\BH_1WF/]_&U_TU\_[I=.OD,_8UZ>XN.2#; ,M\.F6,PT5![U
MVUI<\QNT9: B,?>^:#-,A$2)5$5ZA0E]2>%3$U<T.[S[<K(A:\Z4.<<7QZLK
M3<\RTT<Y5N!3O=4[OFY=%[WJZ7C)R9V.J(B;#T4"5WP\JJJY=86\=8XEKJFD
M(D,PTZU0%7WZ)T-YOHHW$^:$SIW'[OVXGSEQ_P!,DU-0Q7UN^NW;-A?[-Y3)
M[J.#MBXT)VF"7DPM.6LNA:;:)Q23S:2$>5[X&G67KW$,MIK+',HQBWL*#(:"
MXB.P;6FNJF44&RK+&&^B&T\P\!MN 2:HJ*G3_P"A^YUTK&P6^%U ANS)\Q6J
M[;7<F1R5U)F2*^O=,P9Z=U779+R(()%EFX@0C!WQ3_G7B?U:4G2V:^E;;SYW
M0_46\OTK;A_.Z9TMFOI6V\^=T/U%XI_S4Q/ZRZ3IW'[OVXGSEQ_U#<X[;-=_
M5W]38TMDQ[W^FK[6&<&8U[]"'WS;A)UBJ>VB\7>.V(*W84-O94LX";=9()E7
M,.#*!6GQ$Q5#;).4Q0D\BHB]73V_RF4AI*R7"<4R"2CA 3B/W-$Q8O(9-B J
MO,XNJB*)[2(G5Z@WF^BC<3YH3.GX3/I7KOR9*_P-S+<;+YJ5N*8%BN09GDU@
M2"J0:#&*EVZMY7*2BBJW'8<)$4DU5-->-TM[\N<<*]W-S2[RI^.XZKPU<*?+
M5*:AC.+UJQ70ACP(R+Y&F03V/N!CN\VS.1.4.54+BLRXCR.R*'*:&0Z!VF*9
M75@8),KIB *.M*0F!B#[!M2&F7FV,ZP5]NASBA;A0=T-KYTUJ1?8+?2&E42$
MD0%F54Q0<.LLP;$'@$@,6I+3[#7W.L]P=P;-(5;"18]=71U;<N,BN'&R.'1T
M<,R'OI#W*J]:H#8(3KI T!F,C*LOE'"IHCC[&)8;$E.N4F+U9'[UF.!(*.RG
M402F33!#>)$30&@::;3KZO87VN-?;]CA%U_BX3C1?)[?\G&GWD_EXU_C_DXT
M_B_EX77[_P#)Q^+^7C7V_9_DX_%_+QJGL>S_ ">FM8+E\XCVUR><V/?2'"4,
M/NI)(T%PPJ]0Q'E41G-^0=!?'10<%T7&R$VS$3 P)" P).82$AZE14ZT5/N#
MMGN_ B^<3MF-UFH5H]R#_P #A^YM6M+92>]ZR3FMX5"SR)HA=YS*NH"B]+9_
M,K:>E?A6:SW=H]PGG#[N.WBNX+S->Q8374_FL5ULW5VKZZ+[R*2(FJ^IL9\)
MV'6G<9EOEW>1[@^:O<LJJVFH++_A(#W(J&'P[;,(T)"JH<>#,9<'E>36KRC$
M,@N\5R:CEMSZ7(L;M9]'>U$YK5&IM7;UCC4B.Z.J\KC3@DGL+Q48EXBJB-XC
M,#BJU%/(9,AK']WJR$B(TC@Y(T!0K=6AU/DM(J27RZG+ ->9&&MG]SX#69&V
MIRMK<V2/B>Y4)1%7'4:QV8Z8V -BB$Y)J)$Q@-40G4+44Z19[#B([9;(;I89
MF;\D&U<DAC>2$]MW<1 1.ONCE6U;)>5$U1(Z$JH(ET]C=S[6>M?A\G)/ZB;@
M.D0C$#"L^8+&;2?/YE35FM<?8ME1%UYH@]1?S2]2;$>%>FGKYQ/DSM[L\B-.
MFVH088R<-V\8?Y$T<!]X[YXVC+02CL.<JJH$/2BYY*C$=9L=MCFV;C(-LCB?
M#^11V]MJ>"XJ(H]Z3%S/EL(?4BQB,50P'H^(D([*O3L;;VZRZ&B"9HV%#NC3
M/6[Q(TVX6@UQ3%U1!1%T4S%M#7I^'.;)=5NMR^ZR/;:>"/&RCYY[B,['Z)HE
M%="1+5VO<Y#%4)1T30N4A]1^'_;!I[O0P;9ZWS!]L75,(\W<7+WJQQDFM- <
M5C'8[A=>JB0*J(FBKTM\,[=:[H\MWV+'F"(4$Y$+"\$JI;;X+W:*K??7$AL5
M[XDY@-$ %15<Z&\WT4;B?-"9T[C]W[<3YRX_Z;9^-G9.@Y\WQ.L9_P"O>-5<
M;5[*L.J8B1XNY,5AA.8Y]-';;8M$T7O:\ ?506":/]-S*,SNIN19"_68]42;
MBR=5^?+A8MCT7%J5)DDO?.N-0849DGG%5QQ1YW"(R(EZ.S7TK;>?.Z'ZBWE^
ME;</YW3.ELU]*VWGSNA^HO%/^:F)_672=.X_=^W$^<N/^HO$76P6NXA5^^V[
ML&&SSN.]S%B;@6$>.UWCRD9<H"B<Q$JKY555Z^GX9_W?MFOJYK?4&\WT4;B?
M-"9T_"9]*]=^3)7^!N28I5S5B7N^N:8OM8P3+B#+"@YG<RRQT05%U9>AU2UL
MA=/YLQ$ZE)%^X6.[S;,Y$Y0Y50N*S+B/([(H<IH9#H':8IE=6!@DRNF( HZT
MI"8&(/L&U(:9>;8SK!7VZ'.*%N%!W0VOG36I%]@M](:51(21 6953%!PZRS!
ML0> 2 Q:DM/L-?<RSW"W"M$A5D-%CUM;'5MRXR.X<;(X=%10S(>^D/<JKUJ@
M-@A.ND#0&8OYCF$A853#61$Q#$(C[CE/B=.XXA)&C(2#WTE[E ILTP0WC1.H
M&@::;U]OV./+KV>3KXT]:\(NO;[7'XN$77C3R*G^?CK7R?Q<?B]OC5/8]G^3
MC3V?:XZ_O_R<:?>3^7C7^/\ DX_"GX.OC5/3'=I<JG*]E&%P@=QN7)<'O;?$
M&>6,W"U)=3>K246O;6.36B*K3A?<'?O9$6&Y%CGFW%]#QH'1 F@S2J93(,%D
MNHYU<K-S$@NEUHN@]1"NA(ZP^TXP^PX;+S+P$VZRZV2@XTZV:(HD*HJ$*IJB
M]2]/!KBZM_A#=?:V)!VPW9;DOJ]9R[R@@BQ2Y?,4UYS^'*\69SK_ "H"R_.V
M@U[E?4F<[O[DV[='@^WN.S\ER&P-6E=2)";_ **% 9=,$>ERWE;B0HR$A/2'
M&V@]\:)QN1OUFQNM3<TNW#I*0I!2(N)XA7BD#%,4@*N@HW!A TVX8 /?/=[(
M-.\>-5]"+/@2I$*="D,RX<R(\Y&EQ)<9Q'H\J+(943;<;,4,#!4451%145.*
M[&]T9K7B7VXB Q&2MW!LGH>X5=$9T%4J-SF6I$MXU3RK=Q[!>I$!6DZ^*JBP
M_< ,"W0L0;;7:;<\8^+Y4_.+0%B8W/-PZRY4RYU9:K)KLE6TYWHS.O*G0WGV
M4L$:1O<W;;+L0B2'EY0K[BVIG6:"W0M%1#A3O-Y;:D))S-IS"2:BMG1W,*16
MV]-83:FUKI;:M2H%E722ASH4EHNL7&G0)LQ7R*BIT]OK6WM G;F;4QX^TVYS
M;AIYZ_;8M!;9Q_)) D2F?PM4K#ENR.40.7YVV"?T1(GJ+(,ORBTB4>,XK26N
M29%=3W.Z@U%%1P'+.WM)KJ(O*U'CM..N%IU"*KQNYOU8A)BP,RR1UO$:F60J
M]1X)1LA1X74.@VJ@CS5='8*6K>@G()YQ$U->GNYOQ90U9L-YMPHF,T3[K1\S
M^';60WHP3(;KG4@/6]I:QW4;ZB*(/.I* H'0\1^VC4=)4W,]DMS*.H:4%<Y;
M^5B$M<>?$$\I-3DCNBGMBG3PG<7&GO-LCP'+L;S6@D:JG<76+7+-Y5/:I_\
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M1T<EPS?41(U@O30; G3;TCS(<AB7#EL-28LJ,ZV_&DQGVT=8D1WVE43 Q5"
MQ545%1473U%"\&6W5R"9ONI"BWF\,B"ZGG&-[:-21D5&+O.@FK<B_DM<[P":
M&D!@P=!69X*O2I\<HH+]G>7]I7TE-6QD$I-A:VLL(-=!CB2HBFZ\X#8(JHFJ
MIU\;,;$U:L.#MM@5)16DN,/=L6F3FRMEF%VVWJO*D^V?FS.75=.]TU737I>(
M#9\8B0H&![KYI3T+ @K0+BA73L[$) -+_-%ZK>AO".JZ(2(BKY5Z5UX><AL>
M]S3PZW!-4K4AYLI-AM;F<Q^VH'F>=4<<^#K'X1@.(@J++"P0YDYQ%/4.\F^T
MMZ,-IA^)RFL-ARE AML_OC&AP>L[@D)7 .SDQCDH($H1Q>=).1LE278V$E^;
M/GR7YLV9)<-Z3+ERG5?DR9#SBJ1FX9$1D2ZJJJJ]*GQVEBN3KB^M*^EJ8+6B
MNS+.TEA!@16D7_2<=< !_A7C:S::K5LJ[;+;K"\ A&US*#T?$,<C4#;Z$:"1
M*XD?G4B1")552ZU7H[S?11N)\T)G3N/W?MQ/G+C_ *=F^R^Z=*W>X3GE,_46
MD9>0)<)U='JZ[J))B7<3H,@6I<*0B*K;S8%HJ(J+E>RF?-.2V(+GPMA&7-QC
MCUN=8//>-*/):Y%54$B0"8F,(1+'E-O,J1<B&7I>S7TK;>?.Z'ZBWE^E;</Y
MW3.ELU]*VWGSNA^HO%/^:F)_672=.X_=^W$^<N/^HO&/'E@C;KGB@WWG@(F)
MHL:UW-L[.$?,"JFI,O-DJ>5%71=%14Z?@T_=3\/'U14_J#>;Z*-Q/FA,Z?A,
M^E>N_)DK_ W(JLW'#'#-J-K\:9$PY1:;E5K^8*VTO,O,//:F2KHGOE)-.K5?
MN'C.\NS632,8S3&)&K;B<S]7=U;Y#\)XUDM9S"$VNF@*-R8SBIKH+C9-O-MN
M &48N<?&-T,8CPHVZFU<F:+]IBMH^/(%I5F?*<VEFF)E GB">167D;D-F"?<
MBXW'W'N JJ*J#NX\=OD=M;VU= B@T-#!(A61,D*)(VVBH(BA.NDVRVXX$C-,
MRD+!J(2R(F&X=$D..TV(TSCB$D6*AH/?2GN4#FS3!#?-$Z@:!EEK7V_8XU3A
M.-%7^3C3UKPBHO7[G")Y/Q\=:_R<:>M>-?X_Y.-?;]C^7C77MX_ GW_9XU]O
MV?Y./=]CC7VO9_DX_%_+PNOW_P"3C3[WX_3,HV?M)',_1&65XL+CBJ2U4^0C
M&00&A)=!!B4;,@1%%U*0Z2Z:=?W H/$)C-:<K,O#C:OR;WS5I3DSMJ\R?CUV
M2*XVRG,[\&3VJZP$BU%B-Y^Y[U"-?2,?\$WB"R%6J>;,:K?#WG-L^1-54Z<^
MC;.TES+)%Y(S[I*="^Z2"TX105+NSA@UZAN_"IX=\F;/>_)ZUZOW-S:CFH3^
MT&-V4;D<I*R9'U[K)+!AQ>5P'!=K6%1\>24[&<9Z46! BR)LZ;(9B0X<1ER3
M+ERY+B,QXL6.RA&XXX9(  "*I*J(B*J\;:[2SH[#>>3XQYWNO*9[HUD[CY8R
MU*NH2OL^]="K9"+3,/#IWC4,'%1"->C WNQNN\[S;PU6LK(YG< I2IFU^3JQ
M6YTP( GO_,7F:ZV4G"Y6H\:6H^^-47IT?@DWSR%&LQQJ'YEX?LIM7] R?%J^
M-SCM;-EO+U3ZMH"*F4EY7X0^:#R.1&!D^H+;<[*SB7.:6X3*7:?;U92,6&=9
MBC"$VT0@O>-5D'O&Y-O-1-&65$ YI+\9IW--VMR[V3DF=9_?SLCR2XE$NK\Z
M:>HQXK.JBQ%C-(W&AQ6]&V&&VV6A%ML13I5^ZE]5N2MOO#3#B[AS9+K7-!D[
MCRWCA[85).>47FI+<J\94?(M:@EU&B%TL+WOKJ_N*/?O;R(%I-$4096?;8JU
MC-RA\J:)I2NX]R\W62H?E0>KI8'O?2)-G4,*0>/;D8S#>1I<NVXO'6V\DI>4
MR$"?;0&I]?WBH S(T<S]Z)(N*[C;?W\#*,*S6CK\CQF_K'%<AVE1:1TDQ)#?
M,B$!:+RN-."+C9H3;@B8D*>H*+PD;?VR2\)V,M'[G<N7"D=Y"N]X),,H#5*2
M!J!IC<)U^,9"6J3)DQAP$.**]/9>/(AK*QO::9)WPRESN2>;C1MNS:EXP3HI
MH/*[D+U-'+G73E<)="TY"Z.\WT4;B?-"9T[C]W[<3YRX_P"GS,:8"!3[SX*W
M/R#9K,I(BT$2\-A%FXE>R1%3^";@6P8DZ:]P\+$L1<6.K+N1X-FE'88UEV(7
M=GCF38_;,+&LJ:\IY9P+.MFL%_-<9> @+153JU1531?2]FOI6V\^=T/U%O+]
M*VX?SNF=+9KZ5MO/G=#]1>*?\U,3^LNDZ=Q^[]N)\Y<?]1>+_P#>!W,^<K_3
M\&G[J?AX^J*G]0;S?11N)\T)G3\)GTKUWY,E?X&^))IYYQUN$QLS&B 9*0QX
MY["8O,)EE%_FBKKKKBHG^D1+Y5^XN,[R[-9-(QC-,8D:MN)S/U=W5OD/PGC6
M2UG,(3:Z: HW)C.*FN@N-DV\VVX 91BYQ\8W0QB/"C;J;5R9HOVF*VCX\@6E
M69\IS:6:8F4">()Y%9>1N0V8)]QKG<G<JY"IH:D.[CL-\CUM?6SH$4&@H(!$
M*R)DA15&VT5!$4)UTFV6W' =RK*73JL7JCDQ<&P:+)-VJQ>J=--54E04D3Y"
M"!39I A.D@B(ML-M--^OJX]?7QZ^KCJ\GX>$5%[>$3R>73[_ !UKY/XN-?;]
MCA%UZ_<X1/6O'E_DX_%_+PG7U>POM<>[['"Z_?\ Y.-/O)_+QJGW_P"3C\*?
MR\:I]_\ DXT_B_EX]STO!LU5Y6H%==,1;S15Y3QZUUK+OF%/YRA'=<=!%_TQ
M%?*B+P)"2$)(A"0JBB0JFJ$*IY47V%^X&08AE%7$O,9RJDM<;R*EGM][!MZ*
M\@.5EO5S6D5.9J1'=<:<'7K$E3C<[8JY;FNU5!<':8#>36E%<HVXO#*=AU\#
MPBC;CA1E2-.5G4&YC,EC7F:)$Z0D)*)"J$)"JH0DBZH0JGD5/87C&?#1XSLI
M:@6<1J+1[;[_ .13^2';-"0QJ[%]U[.5[UB2 \K<;(7W$;>%$&P('A67(!UH
MP<:< 7&W&R0VW&S3F P,=45%1=45/+Z?D?AZ\)][691O6X$ZCS;<^ XQ9XWM
M&XHK%EUM \'.Q89&TJF)]91Z]P='D>DB;#-A<7%A-MK>VFR[.UM;.6_/LK.R
MGOE*G6%A.E$;KS[SIDXZZX2D9*I$JJJKTW?$MG%4XYM=X=[*',QM)3&L+*-Y
M'&DEX[%:)P=#"A:(;B0H$A-R5KD5";<-.E<XSD-=$N*#(JFQHKRHGM"_!M:>
MWAG7V==-8+J-I]APVG 7J425.-S=CY[4QS'ZNT6_VXN)@DI9#MKD+AS<2LT?
M)$1UUIKF@33#WJ3(TD$_F=.ON*>PFU-O4S8EG56M9+?@65990'QE0;"OG12!
MUE]ET!<:=;)" D0A5%1%XQWP\>(VXK\;\1%9!@U&+9=82F(51OD$=M(S1-D:
M-M1LF5$'SB B\DXE5Z&B$1Q6?3INXVZ]PV_<3&)D? =NJV4PF7;B7[#:*%72
MQ3YE:C-D;:S[)T.XBMDA%SNFRR[<;O;O7'?RW^\@8IBD!Q\,7P'%P?)V#C&,
M0727D:#7G??/5V2ZI//$3A*J=(&F@-QUPQ;;;;%3<<<->4  !U5555T1$\O&
M&XID56D#=C<-0W*W<[UL1G0LEOHC:5N)2"74A2DKQC0'&D,F_.AE.M]3ZZ]+
M-+NCKDFYQL)/9WEQ[NF.>9(HZ*(["W"JVW@$G$:*E?E6"M B]Z]"CBNFB$/3
MC>&_?Z\,/#QEULX[BF5SB=>'9S+;60A/.RG-54,=L724YXH*I$D%YX/(V<Q2
MBSX$J/-@S8[,N',B/-R8DN));1Z/*BR&5('&W )# P54)%14547T^7MAMC:P
MK'Q.[CTDAK&HS+D:8.U>/S16*[N)D,157EDJ*N#0Q'@47I K(=%R/'<:?EV-
MC+DS["?)?FSY\U]V5,FS)3JORI<N4^I&XZX9$;CADI$2JJJJKT]P/$KD$%6;
MW?;(F\>PXWV='&=N-O)+\%V=%<,1,$L;MV>#P)J)A BN(O7HG1WF^BC<3YH3
M.G<?N_;B?.7'_4%CXT-E*#O-Q<'IT7?#'*N-J_FN"4T5 8SR,PPFIV5#'#EG
MJJ*K]<"%S"L 0?\ 2MFOI6V\^=T/U%O+]*VX?SNF=+9KZ5MO/G=#]1>*?\U,
M3^LNDZ=Q^[]N)\Y<?]1>+5J,RVPV6[MU)(&A0!*1,BL3);RHG^DXZ9N&OLD2
MJO6O3\'LB6:..M^'+:. !" @B1JK"H=9"#E!$34666Q5?*JIJNJJJ^H-YOHH
MW$^:$SI^$SZ5Z[\F2O\  W/+!X21O*=NMJKZ(JLJTA1X^*MXP1"XJKWJ=[6N
MISIIHJ*'^AJOW%QG>79K)I&,9IC$C5MQ.9^KNZM\A^$\:R6LYA";730%&Y,9
MQ4UT%QLFWFVW #*,7./C&Z&,1X4;=3:N3-%^TQ6T?'D"TJS/E.;2S3$R@3Q!
M/(K+R-R&S!/N)<[E[EW(5-!4AW4>.WR/6U];/-D4#'\?@$0K(F2%$D;;0D$1
M0W73;9;<<!W*LJ=.IQ:J.3%P;!8LEQZIQ6I=--5(M!23/DH(%.G$"$X2"("V
MPVTTWHO^?CU]7")ZUXT7_-QIZUXZ_P#-Q^+V^$5%Z_<X3\'M^7A.OJ]A?:XU
M]OV.$77^+A.-%7^3C3UKQK_'_)QIY%3C1?8]GW?X./Q?R\:^W[/\G'XOY>-4
M]CV?Y/3-N+U]Y7["+1MX[:F9*3Y6&,.E1.OR"55U-\6 DJNO7WB+U:Z)]P W
MPV^IEF[T>'NNLK=(T&,;UGFFU:ZS\LQAMIA.=^37DBV]:&A+[R8PR"NS$])I
M-L-U6+3>_P /L!&(,"AEV#0Y[MW7"J-HF!Y!8ZI(B,-Z=U26#J1T01;BOP14
MR),QV%W(I<O:CL1W+[&B<2LS?$7I"J 1<KQ&:HS8:J8N-M/DVL=]0(HSSS:<
MZ^ESMQ]\-P\<VZQ"#S EA>RU&59RQ#O$K,?IH@NS;*80ZD$.!'>>)$4D#E15
M2^VC\+K5YLYLY.255WF:R'6X>ZFX=8ZVK$B*+\(S&@K7T54-B&\<QX$1'9+3
M3CT1>G@6R&V%85GF&?WC%3"4Q<\QJ8(BLJZR.X=:0E;@UL-M^=,<0546FBY1
M(^45V_V'VX87X PBH&/*MWV&F+/*LBF&LS(\MNNZ546582S=D&*$HM"H,-:,
MM-B/2'>#;^H\]WG\/D&UOH<6''[RQS+;5P?/,PQ5H6DYWI$1&_A6M;]\JDW(
MCM KDS7TAI]AUQA]AP'F7F3)MUEULD-MUIP%11(51%$D75%ZTXH]GO&V]=9K
MB,5N)5X]OS!8>M\XH(S6D=EC<FM;U>O(P!RZVL9"L1Y%5]JQ<=5UJGW VNS/
M&\_PJ_8[^HR;%+>'=5$P17E>9&7",T!YDM6Y$=SE=:<0FW0 Q(4]+N-O]BY%
M'O[ODVV_$)NGLDF;78+.1.[1S+<HJCY9\EDE7FJ:IY3Y@-J3)A'R\UQNOO;F
MUMG&9W&C/GE@X+<"GJVG3>B4&-U$=!C5]?')QQ68<1H&T(C<5%<<<,NF&_N=
M4_G&S?AXM8-NP,QD7(&7[N  6&(X\@.:(XU5HH74[3F02"$RZ"MRUTZ<J!/B
MQYL&;'>B3(<MEN3$EQ)+:LR(LJ.\A XVX!*!@:*A(JHJ*B\;D[/!'DCA3TQ,
MSVIL)'>'\)[:Y.^[)Q\4DN^^>=KS"142W51.>1$=)$Y5'7IU&T.\3%QNOX;0
M>!BO@-/-R,\VI:<<57'L%E3W&VY==UJ3E%+>!L51#AOQ5[YN37[E[';@T&X&
M)3T;!V54252QI9QM(\=/DU'*1N;63@%4(X<YAIU!43Y5 A)?2R(B01%%(B)4
M01%$U4B5?(B>RO%]M-X6;"@W>WQ)N166&:Q76;C:_:Z5J3$EUR9')6KVX8TT
M:@Q3*&PZNLQ\S9<@.Y#N!N'D]SF6:Y79/6V19-D,Y^RM[:P>1!)^5+D*JJ@B
M(MM F@-MB+;8B B*=+;/8K!63/(-QLH@48S.X<D1Z.I4EE9!DU@VWHOFU9 ;
MD3Y&BZJVT2#J2HBX+M7@\ *S$-O,4HL.QV$* AMU5!7-UL5R28(/>/N"WWLA
MY4YG'2-PE4B55Z.\WT4;B?-"9T[C]W[<3YRX_P"H"$A0A)%$A)$42%4T421?
M*B^RG'_6_:.B)GPY[NW4@FZ^OCJ,+:K<*8CD^?A9-M)R,U<X1=F42IRBV OP
MN01BLF_Z3LU]*VWGSNA^HMY?I6W#^=TSI;-?2MMY\[H?J+Q3_FIB?UETG3N/
MW?MQ/G+C_J+Q717'0>)W<2+9H8(HHC=UBE=<M-*A>R OH!+[*HJIU=/P@?N_
M;9_-ICU!O-]%&XGS0F=/PF?2O7?DR5_@;X>=V@8Y(>;;1W>!./-L\H.6.W&7
M.WKA/NCU$X3&3,BG,G-R-HFJH*(/W&QG>79K)I&,9IC$C5MQ.9^KNZM\A^$\
M:R6LYA";730%&Y,9Q4UT%QLFWFVW #*,7./C&Z&,1X4;=3:N3-%^TQ6T?'D"
MTJS/E.;2S3$R@3Q!/(K+R-R&S!/N%=;F[FW05&/U (U'CM\CUO?V[P$4#'\?
M@$0K)FR5$D;;0D$10W73;9;<<!W+,K=.IQ6I.5%P3 XLIQVIQ6H=--54E04D
M3Y""!SIQ A.D@@ ML-LLMZI_FX]?7QZ^KCU]?'EZTXZ_+^'CK7^3C3UKPG7V
M^UQK[?L<>77L\G7QIZUX1=>WVN/Q<(NO")Y/+I]_CK7R?Q<?B]OA%1>OW.-/
M9]KCK^__ "<:?>3^7C7^/^3C\*?@Z^-4]*W$PYQQ2+'LHK;Y@"YM0CY/6K#4
M&U7JY4<K#)43R$:JO\Y/N$]O7M?1FUX>MZ+N9-BQH$;E@;9[AS.>QN<)<%KW
MC,"8J/3Z1$$!!KOH8CI#$W?2*O-]MLQR; \PI7>^JLFQ&ZL*"[@FJISHQ8UC
MC;J :)RN-J7*8ZB:**JG%;C7B3PJDW]QN,#44LOJG(N";G,,"B-H_->@L'46
M:M@G4!P8CSI:D],(E4N(49G>>-M-DDM&>?%M[H7_ $^D17'M!!IS*9+C^.N%
MS*H\K%R9=6JBB*BK%O,7O:?)*2<'>0KBALX5Q5S _P#CBV%>;C+B?P@:].>U
MNGXA< BWU>KC3^%XK9_U\SD)0^]"))Q+#!G3(I&7O1<FM,M)UJ3@B)$EGC7A
M#VD7%VWFW(\?='>#S&ROF>=$!95+MU3.O0&'6U0B9>GV<P#14[R&*BHK+W"W
MOW&R?<G+I:$VEGD<Y7F:^*1]Y\'453'%N%71!)5((<".RP*JJBVBJOI#,6*R
M[)DR76V(\=ALWGWWWC1MEEEEM%(C(E01$4555=$Z^'-V=U:4&?$=NY3Q5NHD
MML"E[980\X%A7X"TJZ]W-?,6I=XJ+_M@9C=:1.=WTAS?#:^D-KP^[U7<V8U%
M@LN+"VUW&E\UC=8@Z@IR,P)Z]]/I$11$021$$!"(V3OI!9?L%N??X).E*VEQ
M4L%'L\4R1AM4TCY)B5N#]?-1!11;=>CJZUJJLN-G[Y*W'?%OM#/QR?I'C/[E
M[/*MQ0O.ERM',N-O[U\9L-H="==<@6,XR5>5N(*)UP1V8\0&VV96EB#1QL62
M^9H<X7ODU 7<$R9(=P"]2IH<%.M%3IED>Z^Y&"[:T(HXJ6^=971XK =5H><V
MX\F[?8%P]/(VVI$JZ(B*JHG$^JV?CY5XC\N8;<&.F+Q7\.V_;F!S#YO89OE$
M=)!#J@JCU743FB1>IS5-.+'&[K,@VKVKG Y'<VNVJ<GX]3VD)Q.[-C+KXG3L
M[A'!Y>^CRI20E).=N&TOI.#['[65:V&59K:!%\Z=!SX+QVF8_I[S*;Z0VB]S
M!KXR.2)!Z*1(*-M";SC;98#L1MO&TH<*J09FW#T=EBTRS)):^=9%E]YW.J%+
ML)1./F/,HM H,-:,M-B/I [L8%4'.WF\/,>VR6KBPF.]GY?MQ(;&1G.*-MM:
M&[(C@RW;5P^_+G8?C,M]Y-4D](C;@[';D91MKEL<!9<L\;L%89LH8NH_\&7]
M3(1R%90U,1,H5A'>8(A$B;5114@X[XN]H%OT:1MAS<O9GS2!:N@*<G?W.WF0
MR&XCKI+[]Y^#:Q@1$5&X?6B<16MN/$;M\-U*Y #%,UL'-N<L622"IQ(M#G85
M[TLP4D%3@(^VJHJ@9"FO .M&#C3@"XVXV2&VXV:<P&!CJBHJ+JBIY>F5]NON
M7@6VM,+;CJ66=9;0XK#=%I-32.]=OL(X7L(#?,2KHB(JJB<6%7M,N4>(S,(W
M?L,,XC!D8M@C<UE%1&[#.<I9;,VE73E?JJV>V2=:%IU\6F)6V41]J-I+$WVG
M=L-KW)]-!N*YT29&%FN2..E8W $VNDB,Z\W!<-$<2$"H/+Z1:>,?<2G./FV[
M]4[0;30Y[*A(HMJAFB]89.##O6#N0RH[2QG"!"\PCM.M&K,\T+I;S?11N)\T
M)G3N/W?MQ/G+C_J'-MFMTZ-K(<$S^D?I+VN-1!\ ,AD0K.LDD)+'FPI+;,R#
M*%.9F0TVZ/O@3C)=FLX%RRJ14KS;K-FXQQZ[/<#FR#"GOHP+JC4D.0HME$0B
M\WEMNMB;K7=/.^D;-?2MMY\[H?J+>7Z5MP_G=,Z6S7TK;>?.Z'ZB\4_YJ8G]
M9=)T[C]W[<3YRX_ZB\445YQMPW;K;NR0FN;E1JZV=QVX8;7G1%Y@!\1/V.9%
MT54T7I^%2U:?.0D' ;#%3)QTG3;=PC,++#7&%(T%41M8'( ::"*"B*0HA+Z?
MO-]%&XGS0F=/PF?2O7?DR5_@:QN550/.KO8+<.AR^4^VG/);PO*4+"<F89:3
MK4$E3*F8^J)[QN*1KH DJ?<?&=Y=FLFD8QFF,2-6W$YGZN[JWR'X3QK):SF$
M)M=- 4;DQG%3707&R;>;;< ,HQ<X^,;H8Q'A1MU-JY,T7[3%;1\>0+2K,^4Y
MM+-,3*!/$$\BLO(W(;,$^X&0[I[EVWP7C6/L@B-,"#]K=6DE>[K:"A@D0K(F
M2G/>--\R"*(3KIMLMNN [EF6.G48I4'*B8'@424X]48E4/&FJD6@))L)* !3
MIQ A.D@@ ML-LLM^OKX]?5QZ^OC5.I4X]?7QZ^KC7V^-4_S<=?'E_DXT_B]O
MA.OJ]A?:X3V/+^'C15_DXT]:\)U]7M^UQ^+V^$5%Z_<X3V/Q\:_Q^UV<:^W[
M'\O&NO;QI]Y/Y>%U^_\ R<:?Q?R\?P+[/N>E9O0$?*U;X$=B@J:H+DJDOHC+
M0(&NA$C<QXDZE5$0NM.O7[@YGLSNO1-Y#@V=5#M5;PE(6I<8^9'X%Q43%$EC
M3H4@&Y4*2(JK;S8%HJ(J+;;69J#MMB]EYS=[7Y^W'1FMSS#5D=W'G (*2,3X
MJJ,:T@DO,R\G,//'=CO.^E)<;:[A9SM[;":.#:8-EE_B=BC@IRB:3:"1'=U1
M.I%YM>&&*7Q39S;QV-!5K.ZW$-R''V^\1PVGYV?5ME)7F_FJ8OHXB+H)CU<=
MU86>SN4N=VV'G-]MDW'?Y@55)[EQB=7-\Q:HA)W?+U)RBBZZ_JK\*?R'W=_3
MGAMN+@?ADI3!SG)^MP+<9UUT>51[EQ+C+Y8(.J\VH@A:HGOM-44V(.\>.X2P
MXB"Z&'[7;>-.&/OE5 FY'7V4AM5U3WS+P%[U-%34N9V)NOXB-XLZK'D,3H;S
M/\D=QE$<'D=[O&&9 5X*8^]-0C(I)HA:HB>EXKXU?$=CR!)5N%D'A[V\M6FS
M*.+H><U^[.30'17E=T4'<>C.*A!_\^8(7F9CZ3F>S.Z]$WD.#9U4.U5O"4A:
MEQCYD?@7%1,426-.A2 ;E0I(BJMO-@6BHBHMMM5G#;]KC=@DB[VQW ;B>;U6
M?8:LI6(]BR+9. Q.C%HQ9UY.*<=W0O?QWH[SWI4:+MMXF=Z<9K(>GFU"UG^0
M66,L\K?=#RXO<O2:[J'1.N+Y$3_X4T99L=V\5SAIAL&FQR[:S .\)MONT!'I
M>+0:MYPD$%%7''",N<R,B/E(39E8%X8[EPG2<2598%N0T^V"@(HP T^81&N1
M%1212;4M274E3E1"1-K?"H"JBHA#@^[BD*JFB$/-G*IJGE35%3^#A K;S:3$
M20 'O<>VQAR7%(7>\)Q4RN59CJ2>\+WNG+Y$0O?<2(^4^*[=.(Q* 6Y#.#3Z
MO:QIUH>I6B#;"+3IR&GO7 3J-%5#0D54XD7F5Y!=Y/=RM/.KC(;6?=6DGEUY
M?.+"R<=>/35=.8U]*IL8QJJGWN19%:0*2BI:N,[,LK:WM)0PJZM@1&$4W7GW
MC!ML!15(E1$X/)<XB0+#Q([HU<)_<:W:-B:&%TQ*$^#M=03F5)M68KJ ]:R&
M"4)<T45#=CQH9#Z4]OKM?1*UX>MY[R0^$: PJ0MM-R)H.6-OA[P-IR,P;#D?
ML*7301!)$1!$8K9.^E-L[3;\;P;;Q&TY$K\*W&R['*MQOG[Q67ZJJEM1G0YM
M"4'&B'5$735$X;8:\14C)8+?_P#1YE@&VF1FXNH^^<MI=.E@O4/+IYYIUJNG
M-HJ,>?5^P>2]TZ3CGPWMS?,><@7DCO\ ]7+VOT!/85OD+VR7C]5?A3^0^[OZ
M<\(S&P#PQ4[B."?G==@>Y3LA1%%165&VS&4URKJBJJ-<W4FA(FNKR56?;>82
MKO?<BXQM5B<M8_>@@AW/]<V[=%[M44@[Q"U55Y^9-$1]O*?%CO$PS)1\)$7#
MLD7;:&^U)31]AZ%MRW5-$T2>]5H@4.55'ET5461=9+=V^0W$M4*7;7EE,MK.
M42)HBR)\\W'35/8YC7TIF7E<&9$\/>U<RMO-UKI._C-Y&]WOG-1MC3RV5$_.
MK7NR6:ZR8E%@BZ[W@/N1!>KZ>H@Q*RIJ842MK*V!':B0:^O@L#%A0845A!!M
MIIL!;;;!$$11$1$1.GO-]%&XGS0F=.X_=^W$^<N/^HK#"'4KZ?=?#O/LDV:S
M64WR_ N4+&0)%#:R6A)WX(N ;"+8 *$@$+$M&W'8C0+DV 9U0V&+YEAUW8XY
MDV/6K7<6%/=5,DH<^#)!%454'!5$,"("30@(A5%7I[-?2MMY\[H?J+>7Z5MP
M_G=,Z6S7TK;>?.Z'ZB\4_P":F)_672=.X_=^W$^<N/\ J+);@VU <^VJVORU
MDE#E1UN'5/8*K@ER#S)STICKS'UHJ<R:<H]+=#82?,;6_P!G-Q2R6IB&_P K
MA8-N9$\[CI&C.*JDC%Q!MCD.->]'SEA"$2-"<]/WF^BC<3YH3.GX3/I7KOR9
M*_P-W!VGS.,LO%-R,-R/"<@:! []*O):EVIEOQ#<14!]H75=CNHFK;@@8Z$*
M+QN)LWG4,X66;;9==8E<MJV3;4AZHF%'9LX?,J\\:8RC<N(Z*J+C+C9BJB2*
MOW'QG>79K)I&,9IC$C5MQ.9^KNZM\A^$\:R6LYA";730%&Y,9Q4UT%QLFWFV
MW .TJ!B8=O)B42,.Y^U3\Y'Y=2XX2,-Y/C+KW*Y-I);FB-/\O/'<7S>2B'W3
MC_JZ^W/W/OF*#%J!G4S7E=L+6P=$O,**B@:B4J=*(5!A@%Z_?&:@T#C@E?WY
M/4. T+TIC;[;YB43M?C]>Z7*5A8$*",FTE"(E+EJ/M--(#("/'KZN/7U\>OJ
MX]?7QZ^KC5.M%X]?5QZ^OCU]7'5Y/P\:IQU?Y^-%7^3C3UKPBHO7[G")Y/Q\
M=:_R<:>M>$Z^WVN-?;]C^7C77MX_ GW_ &>-?;]G^3CW?8XU]KV?Y./Q?R\+
MK]_^3C3[WX_2:=CG<'X2QC*86@?S7.[@)8\CW7_-_P"'YD\OOD'W?N'>[.;H
MP_-_.-;+#<T@PXDC)-O\LCAI R.@=DI__)FQN<!E1C<8(@YT,+7:C>"B<CN
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M$-\T0VZ^ !H[+>3D#E;%YYK$MD-I*E:[&,7C<TJPE(RY>95D,H!6ZR[)IC
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M +(<A)_']O<??EQ]NMN8\LG:['*YXN0K&Q,$$9=K+$1*9,4?:::0&0$..O\
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M4U3O$70D>/ _%EE]"WJ91X^7;54V6GR\[A T],IKJD3515H5<%CJ43+D5"0
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M\7\?K1R7]F.X'Q?Q^M')?V8[@?%_'ZT<E_9CN!\7\/;;;.9K<9!EK%!89,Y
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M4T8:<ZHD;E9$1=.2X]Z=BV\.!/FX_4O>89-CIRG(U;FF'S7@6]Q6V44-.[D
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MKQEMJ[%*;#D11DM(B*KD=7Q'G'WP]8ZIUI[?I&<>%#)[#6!>,3MR=K_.7?\
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M_:=M_P#&''ZKL:_:=M_\8<?JNQK]IVW_ ,8<?JNQK]IVW_QAQ^J[&OVG;?\
MQAQ^J[&OVG;?_&''ZKL:_:=M_P#&'$_<G>/"J?'\2?VPRK&6Y\#,\5OWUN+2
MWJY<..L&FE//()!&>57%#E31$5454]*S+<'(WO-\?P;%L@R^\?U%%:J,;J7;
MBQ,5/1-499/37V>,QS[(7>_O\XRG(<OO'^8S[ZXR6V>NK)WF<527F>?-=255
M]OK])V=G2Y2RKW ($S:?(>9P7C9D8$\E=0BZ[_.4W*0JI\U-$+F<77F30R])
M\1_YM8U]8%1TMKOS:W.^K^P].\0^;XGL%D%SBV8[Y[M95C5NSD.#LLVN/Y#G
MUA;TUDTS+M&W0%^,\VZ(NMB:(6A"*ZHGV<,E^4NW_P ;\?9PR7Y2[?\ QOQ]
MG#)?E+M_\;\?9PR7Y2[?_&_'V<,E^4NW_P ;\-YYO'M#<8/B3UQ"H&[J?<8K
M/8*XL&'I,.$C%-/DO<S@1WB0E;Y4Y5U5%5->C>4FR. V&?6N-5\>UO(=?84=
M>=?7RY/FD>2X=Y*B@2$XG*B-D2^VB)U\?9PR7Y2[?_&_'V<,E^4NW_QOQ]G#
M)?E+M_\ &_'V<,E^4NW_ ,;\?9PR7Y2[?_&_'V<,E^4NW_QOQX>,(RRM=ILI
MP[8S:7%<EJ'G8[SU5D&/8#7U%S6NO1#<:,F)++C1$TX0*HZB1)HJ^CX@OINW
M7^?D_I8G^;5%^2VNGX@OH1W7^8<_I>%SZ;MO_P OL]'+<_RJ7YAC.$8U>99D
M$Q$$BC4V/5KEK9/ !D*$2,M'RCS)S+HFO7QN)O%ESIG>[@Y199 ^P;ROA60G
MG.YIJ*,Z2"JL5T((\&-JB*C3((ODZ3^/;95<>!CE(]$_KGN%?]_'Q3$XTI5)
MMM]YD2<E370$UC0(PDX:IS&K3*&\$";FV.2-]\U:9:6==;BZ'BZ2Q)#>^"<
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M^$JVI:05ZM7-=>K1>@#C9DVXV0FVX!*!@8+S"8$/6BHO6BIQLINYYP$F=F6
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MDQ#0X,94T)*EHTDGKI**-R''=KJ2CK:^FI:B%%K*FHJH<>NJZNM@LC&A5]=
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MJ/DEE_\ K<?:7VH^267_ .MQ]I?:CY)9?_K<?:7VH^267_ZW'VE]J/DEE_\
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MS7?\J<W(EZVO)SKR\VN@\^I='&\4.0CMUL[EN68'8@9?\24"=9EFM!)(-?\
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MMIKN8[8*Y+L[:8<^?*<5<.55)QUPS7^%>/UD>)/Y8;7_ *'<?K(\2?RPVO\
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1:*9$:II_.55\J_\ [5E__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@   1,   !2" (   #XN*>2   [W4E$051X7NU]
MAU]42;;__"EO1B4XN[.[;W;?[KS][=O=SP8%%"6;&,:$B@3)B B2,S0TL<E!
M<@Z2!011!"5)DIQSSB+V[U35[=NW+PTT+8[KX/G4AP]];U7=NG7/MTZH4U5?
M\;\0GS\Q.9_SJ-'&,5-#.^BDBL^)LS[:NF%>_D7/ZWHW-S?9N3&MK[\=')X9
MVB$-#LT,C\S.S:VPB^U,8^/SF;FOK.W2U"]!&WQ/G/76OA[NXI5?7M6QO+S.
MSBV.MK:V&AH' GF/;QA$*ZIQ2"77;D?Y!I;4/.]>7=U@%Q!'J"L*&NV<L[5^
M"H%^@-Y0OQAD:9N6G%[?VS_%SGV(Z2OVA4-&P)1^(65*&MS36CPE]4#";9 4
M5#FG-(-/:X5>O1WSY&DGNQB?W]0\=$HC\*2:WTE5SDY)28-S^5:4EW]Q4\L@
MNSR#EI?7_()+E=3]X7%*Z@$B;= (@HOG+X=FY;UB%Q.E9R^ZKQO&GM8,.:49
MHJ#F3VK E?B1%[EP.2PUJYY=C$%K:QL!H:0K0I4TA%T!_RBJ!\!%177N/?O,
MSJXQ=LE#28<:.<,C,\!MRN?"3JIP!%SBHX"9'H9;<@58&3@O(O8)JVQ3\Z"2
M.O>DJB\4V3GY*JH1/ 0&A9>Q:B $HN;&G7C<!II3V6V 2I3/\3PXC]B%!926
M5:>D$03L+@ ,>C2J1%"GH)*P>_89RRMB)-C\_(J^60*K*Z@A  EAZ@H@4UDK
ML*"DF5W^\-'A1<[,[)+VC7!@A1-GO1!CJ7-AM 96.Z,)(ST'_PS&G.<%?X&E
MPJ(KF,5!C  OGD!<A3( U[*3>B ]]J-JST>$1I8S:P ")KY^.^JT9BAN@Q=4
MB-O .:/I=TH=4$<U"=_U43X?[AM8Q*H!Z.GS+FBJ D(::@G\#VA74/4Y<]X/
M'@U2"Q+-_? B1A:)(%Z8-8":9V&3 K<HC)&N0%*7HZSE!U(+>@F]++KKI8 :
M&?RHJ(E9PR&DPXL<:_M492T>@0VP M@#Z3DO.[O'IF<6QR?FZU_U>?D7 M,
M^Q*.!.ZI8JAM-'+@ELK% #/K9%.K!&&R3C*V3#A_.42@]G@!(P+/]?1.,)K
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MB^F\A33>0BJD\*7\Y-6G96_[WKS?P05\L-0_.$U;\,H:7+#1V3E$">SOLQ?
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M:.1 )3HWPA)3G[%27%*-HWON:0T_111.AB(^S:R3M[8HCI,".8;F#_=$#DT
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M,+EV=I;2Q @-#LVX>N7CW0C0I UK*P+)D8-S<@ER3*T3Z.N;FYN7]2*PV$$
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MN/TS$(6<EM9!)74N'9DG-D&/PS>N?O:)8U0_G#[\_)R"8@9RN+LQ%DT_@X>
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M^M$_7HW\\4K(5=VPFWH11&<S-8^WO(MT-ML'J?9.&=A)G>/N@PP>'VZ1(+
M#)Z*F-2&A*R&F5V#([_0%_H92 QR^-A[J&_V$,]&?0!X5#E*&D&E%2(S6=T]
M8S]="__Q:H3.U=!K-\)N(9TM&G0V,]#9K!-M[B.=S<$Y$PP>-\\<#U]D\*#
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E>RWN>X%0 LS$)&5/XI'N_P-LVN&E\7_6+     !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
MB5!.1PT*&@H    -24A$4@   -P   !+" (   "46WXM   )HDE$051X7NV=
M =*<( R%O9-W\D[>R3M9Y:WYXTM@4=A=M7S3V<&7B! B(G;:;FXT+D;'0J/Q
M:UI2-B['EY*RV\/F MR:=;D6MDZK-*KPI9A^*&.HJHHU6VSE5FE4X4LQ360/
MRJZ#%MVR%C5I9UO0GJYHG5T3^>"0Q,9;W@=K6OY,\SA-RY]AG,8Q_&:748D[
M6J2?%K7)==">;ED77!$%<=!NY(!#<M!BXRW18"&QNG[H^G'Y[8?U%^5#OTMJ
MSOLAUX=:=T7!]92R0 Z?$ 77:@N-HSA16Y)H2<&0A6,7"@-FOFW^&V5&W,^+
MKHXZ:83<D7-%P?4DJ^BVD"EJ8IZ":[6%QE$X:DL^;?/<.LE-89XKAT;('3E7
M%%Q/PM;@GO56%%S/M-46&D?91>WUO Y3H];+<<<O5DZ+*)"8=DZ<E2FB( [:
M33M8G4R-'/Z"]9HCAW&LG9&S&B<[0JZ>$'6!/$F,G>5:I:R5V%EI$PY%(6OC
M+:]@+6F(MYE:S^N+8'-%&3_%UR[T5%ZQPVM-]:?V%4"*?"=1OG:A9[.&;WUP
M#^N+-AL;C5^P)N6RC.S"DYN-C;NQO!#T?;],U;=>AH5U>I@F[]R+QLJ2B,C(
MA:7 YONPWE+8(6=+XVX,P["DXQ! @3UNPI*4ZWOW(U]Q_C=T(O:!FS[$NW&<
MU@^);:8L8!G[)1M^FP34@/4!>-O)L@M[YB<WS+&(64YFP_^$O%N 7^7EDG\T
M$$A3K=R%]0M.^*YX)K&6*/QV)*X ,A(9\,-HV(MB96GUZ[,^OD_O!^$9T=W\
M7:\$W)8R12$/+A(-C,X=GV-AIER_Y9QI^F/V($YC.XZ U$J%PGK"V\[]QF5;
M4YZ:*>?0;7ER%4;P^Q0VF*9) 3$A\02XYTN>OW=-RO6OJYU=4\YJZP'SI1VA
M+[!<]&@2R!Q?TF#4P.KV$"^I&2"JA4EYM"4VF/85ZM,4K2EG-2M@F OO[',@
M](>NB[P!;,M&^DX@%*[I*'W9Y@8BTQ^9+"F8N#&J]"6?HC7EO(TNRNC ]_-R
M#)LRK"9!.T]DLX".QT8+E9^K6=.9>>Y0G2>2DF9*&5/E\G&*]BEGDQ 5)XG/
M(6M!1/S<5(1*8BE24K,&R2V'"&]^M3B],*7*:SA*T3[EO(V-5GYR;QVBW]:"
M)<\F5!)+RKG26%(DC\86;>C+YNPN4%+#44K7E @3M;CB?/F)6.A$/-U.)"6K
MBBI)295@"DA?5X,,M@-T""Q42FHX2NF:TDU*T=.CHM>C!)ZM&!);N68(L+HQ
M!4B4D99+D$,.;T^L,I9T%=39Y2T,, 0X1?SMDTTS>%\F^Y#6M-#$TK,_>TNG
M*=VGE)ZS(6F:U9C98<.)B$6BAOE=5DD--(3]MBS#A7(&V.*.GR:]Z,R$>H?#
MS#:/8;E/?42K8B&UP9S"WS7!<*QWO_J:*N J^JQ"2O<I9^\-48B% /W4TZ&V
M(HX:;=5(O-BP9:1$D$QHDC1#6S.1FXH-&R49+W0J>H@5TL+M,H%ST0RI!"/B
MIA%Z)+&2H8&(L_ [A)U+$O>5%5&ZIIR]VTMC!T]GJINU"(?TWSH(L:34N6Z;
MAVI1Z.(9GP8M3^0<9<,YI*GS5N&<,4G/^_M-5R*99QLF^:H5Y)^-H0Q<E6X2
MI6O*V;PA6O38HP_B'\LY! YNB?JI-M+'@'5 B NCJ?/>I=9,*9?0ETO73+WN
M5?PE*441T&"KS][=BTM,V\,]T9@3E.Y3SADWKDX=1%8F3MM;K2-CI/_L%-!#
M)4C"N5:(KND0&(]8P]"&F#43W<A^/^$E&D]=PR%:@G(?69C2B5JGOF!0,(F>
MOK%CE.Y3SO&>:.1^DE2;X_.<W,UBBEUB"-BQQX4 F3##P42C@K.TDD8F)%R"
M:JN;E%0;>N%F WJG&Z-#A K=R"/1;9N1>52G1-B."_Q)/$2=-66W+2_8ID '
M=)]Q:$.#_FL3@FA'7>)+ET;HK8Y3W.NB'G>8$Z"UJ-.M,!V3M\B,* 5ML@V6
MZ&E1SP7]_B5/9SE\[.F2K+H!-$"D'PTC46=-*?3QCV#4,1QJ1>Y("9_N,T(C
ME>LTM9Y4,Y#Z[3QAE7P2E\.UM#B':UDQ!GJ->\F.-+J#L$CJV/CKWDD]J%/'
ML M/B364)OD0.JW/WEH?H2#Q!*7[E'-H]Q! Q]"L?MO6&@-H+GQT\E&AWR\W
M:1BDS_ 7J]SED]I4DV@B"41'_;!*\]#@_%PA4#^=CD9:$=?58@+)ISXRTCIT
MB6JE!MTD5([V(%8BZF"B6NBZ.])!(,T0A]-4V*?43&&O'R% AX4A@'*OMJ]S
M8BK(#8#3M6[KD<NY]6OK8%*J'+2'1+EH_N403%85R E6]Z 21$D[ZPE"BSHR
MHE-+9.Q ;R)\F@IKR@3;7?17^=OPG<9>2^LD"@E3(;%D2K?'<L@YACP9.G.?
MQ+#7G;9)%(\7K2NO"E184S9<8DGY$Y!/-/.=0!Z#;*A*A7W*ADOGO7/\$#QJ
MJ\]JGZ#"/F7#@L?EI9)R"LM]5B_)9]>43Z(WK]()\)ACM9%'6U-F,9B]ZS1X
M&V6UD4>%?<K_@4.K>WG594,CC\K[E$\E/\FF;?>.#8ULVIHRB_R9$GN!=WFE
MN"9M39D%)K^WJ8:,S$S?1HRV3YD%-I_3+^"2D0F?1@YMGS(7R3E\9T/FA4^&
MKW_&%^O.EI'EO-:4[=\\SP&[C^O7.@.2E4]HG&)]R5D>W^U_A\@'GT8P7V)J
M;+-C75YKRI:4C>O0+3=YMTZ6[='3N KA;\"'_W&L;54V+L*:E'C7:4_PQD5X
M?0T+KSM#FRL;5V#[AQ/6R;*M+!N7X._O#6!E^86'>*?^L@+M]BFOG1L.74^K
M%(JBD$Y6JY!.5M)ATF6-U47Y']B/4#]@OOS<<]P&71G_@.Y:8Z=+N:)(AV[Y
MJ+\<DB+ZV_+CX:YBOERWU%\?TBI#@Q&+-737&CM=RF]%(=/3-;DB*=8D= %6
M(Y>@\N-QNHJOX>NL&1)T66X.^!W73[Y+(?SFEG5J([(YL;:>6G</W50@<4T$
MSZK+B8N>\Z>+:EV+5G$O]S_@=W625Y_P$?(O1W>_6;J>;NU@8,  N=ER^E#*
M,3'FH$UD)<5U2_N[;B@G3K2'UOG!O.GJN'[G#?\A^-\L>.Q79LK$\! 82X%,
ML4,I5Q1)J>N?.-$>6N<'\[VN=GM$W'NQ&"M;Q:VS4"2EEK_&.KB*M3Z8'W0U
M'>N$DC#I<D61#MWR4?^8DG:PU@?S@ZZF8YU0K DBJ"6*0CI9K4(Z64F'*7$H
M(ITN95MX#$_K3^,!M*1L7(Z6E(W+T9*R<3G^ 1(.X 8-<+7O     $E%3D2N
#0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_2.jpg
<TEXT>
begin 644 image_2.jpg
MB5!.1PT*&@H    -24A$4@  !E\    +" (   !^A P     =4E$051X7NW8
ML0' 0 @#,?9?^E/C)CV62O $-P\     6DT>     *"&.@8   ! +W4,
M@%X#     (=E#]MR#0    "79 _;<@T     EV0/VW(-     )=D#]M^W@
G  !PF#H&    0"]U#    (!>'P<"Q(E;=C*9     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414471757752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CROSS COUNTRY HEALTHCARE, INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-33169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-4066229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6551 Park of Commerce Boulevard, N.W.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boca Raton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">998-2232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CCRN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,213,868,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001141103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414472349432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,208<span></span>
</td>
<td class="nump">$ 1,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $9,141 in 2022 and $6,881 in 2021</a></td>
<td class="nump">677,432<span></span>
</td>
<td class="nump">493,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">7,689<span></span>
</td>
<td class="nump">7,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceSettlementsReceivableCurrent', window );">Insurance recovery receivable</a></td>
<td class="nump">5,336<span></span>
</td>
<td class="nump">5,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">641<span></span>
</td>
<td class="nump">638<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">692,306<span></span>
</td>
<td class="nump">508,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $18,092 in 2022 and $17,729 in 2021</a></td>
<td class="nump">16,706<span></span>
</td>
<td class="nump">15,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">5,447<span></span>
</td>
<td class="nump">7,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">119,490<span></span>
</td>
<td class="nump">119,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedTradeNames', window );">Trade names, indefinite-lived</a></td>
<td class="nump">5,900<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">40,543<span></span>
</td>
<td class="nump">42,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Non-current deferred tax assets</a></td>
<td class="nump">9,117<span></span>
</td>
<td class="nump">11,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">26,925<span></span>
</td>
<td class="nump">21,956<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">916,434<span></span>
</td>
<td class="nump">732,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">164,224<span></span>
</td>
<td class="nump">109,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">74,733<span></span>
</td>
<td class="nump">65,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of debt</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="nump">4,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current</a></td>
<td class="nump">4,026<span></span>
</td>
<td class="nump">4,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income tax payable</a></td>
<td class="nump">29,140<span></span>
</td>
<td class="nump">7,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of earnout liability</a></td>
<td class="nump">8,250<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">1,122<span></span>
</td>
<td class="nump">1,364<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">283,245<span></span>
</td>
<td class="nump">199,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtNoncurrent', window );">Long-term debt, less current portion</a></td>
<td class="nump">218,475<span></span>
</td>
<td class="nump">176,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - non-current</a></td>
<td class="nump">9,704<span></span>
</td>
<td class="nump">10,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Non-current deferred tax liabilities</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Long-term accrued claims</a></td>
<td class="nump">26,443<span></span>
</td>
<td class="nump">25,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current earnout liability</a></td>
<td class="nump">8,250<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">14,037<span></span>
</td>
<td class="nump">13,788<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">560,361<span></span>
</td>
<td class="nump">435,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">318,125<span></span>
</td>
<td class="nump">321,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,304)<span></span>
</td>
<td class="num">(1,293)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="nump">39,248<span></span>
</td>
<td class="num">(22,735)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">356,073<span></span>
</td>
<td class="nump">297,528<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 916,434<span></span>
</td>
<td class="nump">$ 732,809<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedTradeNames">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trade name to gain or protect exclusive use thereof for a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedTradeNames</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceSettlementsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy.   For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceSettlementsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414477447944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowance for credit losses</a></td>
<td class="nump">$ 9,141<span></span>
</td>
<td class="nump">$ 6,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, accumulated depreciation</a></td>
<td class="nump">$ 18,092<span></span>
</td>
<td class="nump">$ 17,729<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414472450664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible List]</a></td>
<td class="text">Service [Member]<span></span>
</td>
<td class="text">Service [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">$ 788,732<span></span>
</td>
<td class="nump">$ 329,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DirectOperatingCosts', window );">Direct operating expenses</a></td>
<td class="nump">613,938<span></span>
</td>
<td class="nump">257,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">76,813<span></span>
</td>
<td class="nump">46,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td>
<td class="nump">2,369<span></span>
</td>
<td class="nump">504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,719<span></span>
</td>
<td class="nump">2,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_AcquisitionAndIntegrationRelatedCosts', window );">Acquisition and integration-related costs</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">480<span></span>
</td>
<td class="nump">1,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="nump">1,741<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">698,100<span></span>
</td>
<td class="nump">308,247<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">90,632<span></span>
</td>
<td class="nump">20,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expenses (income):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">3,521<span></span>
</td>
<td class="nump">671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">87,119<span></span>
</td>
<td class="nump">20,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">25,136<span></span>
</td>
<td class="nump">912<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to common stockholders</a></td>
<td class="nump">61,983<span></span>
</td>
<td class="nump">19,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Unrealized foreign currency translation loss</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 61,972<span></span>
</td>
<td class="nump">$ 19,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share attributable to common stockholders - Basic (in dollars per share)</a></td>
<td class="nump">$ 1.67<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share attributable to common stockholders - Diluted (in dollars per share)</a></td>
<td class="nump">$ 1.63<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (shares)</a></td>
<td class="nump">37,028<span></span>
</td>
<td class="nump">36,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (shares)</a></td>
<td class="nump">37,973<span></span>
</td>
<td class="nump">37,034<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_AcquisitionAndIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition and integration-related costs include costs for prior acquisitions, costs incurred for potential transactions, and accretion and valuation adjustments on contingent consideration liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_AcquisitionAndIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectOperatingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate direct operating costs incurred during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DirectOperatingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123410239&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414472716088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss, net</div></th>
<th class="th"><div>(Accumulated Deficit) Retained Earnings</div></th>
<th class="th"><div>Noncontrolling Interest in Subsidiary</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 154,909<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 310,388<span></span>
</td>
<td class="num">$ (1,280)<span></span>
</td>
<td class="num">$ (154,737)<span></span>
</td>
<td class="nump">$ 534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Vesting of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Vesting of restricted stock</a></td>
<td class="num">(2,026)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,026)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity compensation</a></td>
<td class="nump">1,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment, net of taxes</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net income</a></td>
<td class="nump">19,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">173,674<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">309,711<span></span>
</td>
<td class="num">(1,286)<span></span>
</td>
<td class="num">(135,289)<span></span>
</td>
<td class="nump">534<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">297,528<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">321,552<span></span>
</td>
<td class="num">(1,293)<span></span>
</td>
<td class="num">(22,735)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Vesting of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Vesting of restricted stock</a></td>
<td class="num">(5,028)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,028)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity compensation</a></td>
<td class="nump">1,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment, net of taxes</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net income</a></td>
<td class="nump">61,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 356,073<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 318,125<span></span>
</td>
<td class="num">$ (1,304)<span></span>
</td>
<td class="nump">$ 39,248<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414472642360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net income</a></td>
<td class="nump">$ 61,983<span></span>
</td>
<td class="nump">$ 19,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,719<span></span>
</td>
<td class="nump">2,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances', window );">Provision for allowances</a></td>
<td class="nump">3,179<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense</a></td>
<td class="nump">2,428<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_OperatingLeaseExpenseNonCash', window );">Non-cash lease expense</a></td>
<td class="nump">567<span></span>
</td>
<td class="nump">622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="nump">1,741<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity compensation</a></td>
<td class="nump">1,601<span></span>
</td>
<td class="nump">1,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Other non-cash costs</a></td>
<td class="nump">446<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(186,701)<span></span>
</td>
<td class="num">(76,581)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(557)<span></span>
</td>
<td class="nump">568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes</a></td>
<td class="nump">22,050<span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">62,979<span></span>
</td>
<td class="nump">26,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(1,273)<span></span>
</td>
<td class="num">(1,115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other</a></td>
<td class="num">(200)<span></span>
</td>
<td class="num">(319)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(29,038)<span></span>
</td>
<td class="num">(24,927)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,096)<span></span>
</td>
<td class="num">(1,186)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(2,096)<span></span>
</td>
<td class="num">(1,186)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Principal payments on term loan</a></td>
<td class="num">(437)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="num">(3,092)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Borrowings under Senior Secured Asset-Based revolving credit facility</a></td>
<td class="nump">415,176<span></span>
</td>
<td class="nump">148,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayments on Senior Secured Asset-Based revolving credit facility</a></td>
<td class="num">(372,874)<span></span>
</td>
<td class="num">(105,400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Cash paid for shares withheld for taxes</a></td>
<td class="num">(5,028)<span></span>
</td>
<td class="num">(2,026)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payments on note payable</a></td>
<td class="num">(2,426)<span></span>
</td>
<td class="num">(2,425)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">31,308<span></span>
</td>
<td class="nump">38,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash and cash equivalents</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">11,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 1,208<span></span>
</td>
<td class="nump">$ 13,488<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_OperatingLeaseExpenseNonCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Expense, Non-Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_OperatingLeaseExpenseNonCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision For Doubtful Accounts And Other Allowances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414475301800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BASIS OF PRESENTATION</a></td>
<td class="text">ORGANIZATION AND BASIS OF PRESENTATION<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nature of Business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of Cross Country Healthcare, Inc. and its direct and indirect wholly-owned subsidiaries (collectively, the Company). In the opinion of management, all adjustments necessary for a fair presentation of such unaudited condensed consolidated financial statements have been included. All such adjustments consisted of all normal recurring items, including the elimination of all intercompany transactions and balances.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form&#160;10-Q and Article 10 of Regulation&#160;S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These operating results are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2021 included in the Company&#8217;s Annual Report on Form&#160;10-K as filed with the SEC on February 28, 2022 (2021 Form 10-K). The December&#160;31, 2021 condensed consolidated balance sheet included herein was derived from the December&#160;31, 2021 audited consolidated balance sheet included in the 2021 Form&#160;10-K.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to the current year presentation. See the condensed consolidated statements of cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414475146888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Management has assessed various accounting estimates and other matters, including those that require consideration of forecasted financial information, in context of the unknown future impacts of the global </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 (COVID)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pandemic using information that is reasonably available to the Company at the time. Significant estimates and assumptions are used for, but not limited to: (i) the valuation of accounts receivable; (ii) goodwill, trade names, and other intangible assets; (iii) other long-lived assets; (iv) revenue recognition; (v) accruals for health, workers&#8217; compensation, and professional liability claims; (vi) valuation of deferred tax assets; (vii) legal contingencies; and (viii) income taxes. Accrued insurance claims and reserves include estimated settlements from known claims and actuarial estimates for claims incurred but not reported. As additional information becomes available to the Company, its future assessment of these estimates, including management's expectations at the time regarding the duration, scope and severity of the pandemic, as well as other factors, could materially and adversely impact the Company's consolidated financial statements in future reporting periods. Actual results could differ from those estimates.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prioritizes the mental health and well-being of its employees, especially in response to the COVID pandemic. While operating primarily through a remote workforce, the Company's offices remain open with stringent safety guidelines and procedures in place. Business travel, including visits to healthcare clients, continues to be somewhat limited at the request of the Company's clients who are continuing to cope with the pandemic twenty-four hours a day/seven days a week.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022, average bill rates rose slightly as the Company continued to experience higher demand across a wide range of specialties. Investments in people and technology, along with other improvements the Company has made during the pandemic, have allowed it to quickly respond to high demand levels that it is continuing to see across a wide range of specialties, including operating room, emergency room, pediatrics, labor and delivery, and medical and surgical services, not all of which are directly related to COVID needs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, the Company worked collaboratively with clients on adjusting bill rates in order to adapt to the rapidly changing market conditions. One of the Company's core values is to act ethically and responsibly, and it has been especially important during this pandemic to be transparent and build trust with its clients to re-enforce long-lasting relationships as both demand and bill rates increased to unprecedented levels.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable, net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The timing of revenue recognition, billings, and collections results in billed and unbilled accounts receivable from customers, which are classified as accounts receivable on the condensed consolidated balance sheets and are presented net of allowances for doubtful accounts and sales allowances. Estimated revenue for the Company employees', subcontracted employees', and independent contractors&#8217; time worked but not yet billed at March 31, 2022 and December 31, 2021 totaled $249.7&#160;million and $140.0&#160;million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally does not require collateral and mitigates its credit risk by performing credit evaluations and monitoring at-risk accounts. The allowance for doubtful accounts is established for losses expected to be incurred on accounts receivable balances. Accounts receivable are written off against the allowance for doubtful accounts when the Company determines amounts are no longer collectible. Judgment is required in the estimation of the allowance and the Company evaluates the collectability of its accounts receivable and contract assets based on a combination of factors. The Company bases its allowance for doubtful account estimates on its historical write-off experience, current conditions, an analysis of the aging of outstanding receivable and customer payment patterns, and specific reserves for customers in adverse condition adjusted for current expectations for the customers or industry. Based on the information currently available, the Company also considered current expectations of future economic conditions, including the impact of COVID, when estimating its allowance for doubtful accounts.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad Debt Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-Offs, net of Recoveries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,091&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the allowance for doubtful accounts, the Company maintains a sales allowance for billing-related adjustments which may arise in the ordinary course of business and adjustments to the reserve are recorded as contra-revenue. The balance of this allowance as of March 31, 2022 and December 31, 2021 was $1.1&#160;million and $0.8&#160;million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contract terms typically require payment between 30 to 60 days from the date of invoice and are considered past due based on the particular negotiated contract terms. The majority of the Company's customers are U.S. based healthcare systems with a significant percentage in acute-care facilities. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No single customer accounted for more than 10% of the Company&#8217;s revenue for the three months ended March 31, 2022 and 2021, or the accounts receivable balance as of March 31, 2022 and December 31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers restructuring activities to be programs whereby it fundamentally changes its operations, such as closing and consolidating facilities, reducing headcount, and realigning operations in response to changing market conditions. As a result, restructuring costs on the condensed consolidated statements of operations primarily include employee termination costs and lease-related exit costs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliation of the employee termination costs and lease-related exit costs beginning and ending liability balance is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:50.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee Termination Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease-Related Exit Costs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to restructuring costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,620&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Restructuring costs in the condensed consolidated statements of operations for the three months ended March 31, 2022 include an immaterial amount of ongoing lease costs related to the Company's strategic reduction in its real estate footprint, which are included as operating lease liabilities - current and non-current in our condensed consolidated balance sheets. Other costs were immaterial for the three months ended March 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414475329800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text">REVENUE RECOGNITION<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenues from customer contracts are generated from temporary staffing services and other services. Revenue is disaggregated by segment in the following table. Sales and usage-based taxes are excluded from revenue.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nurse<br/>And Allied<br/>Staffing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Physician<br/>Staffing</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Segments</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary Staffing Services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,133&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,181&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765,580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nurse<br/>And Allied<br/>Staffing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Physician<br/>Staffing</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Segments</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary Staffing Services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,033&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,860&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,008&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,233&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,241&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span></div>See Note 12 - Segment Data.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414476247704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITIONS</a></td>
<td class="text">ACQUISITIONS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selected</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2021, the Company purchased and acquired substantially all of the assets and assumed certain liabilities of Selected, Inc. (Selected) for a purchase price of $3.5&#160;million in cash, subject to adjustment, and $1.5&#160;million in shares (or 59,429 shares) of the Company's common stock. The transaction was treated as a purchase of assets for income tax purposes. As of March 31, 2022, the acquisition has not been fully integrated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sellers are also eligible to receive up to an additional $1.5&#160;million in earnout cash consideration, based on Selected's revenues for each of the twelve-month periods ending on the first and second anniversaries of the first day after the closing date. See Note 10 - Fair Value Measurements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was not significant and has been accounted for using the acquisition method of accounting. The Company has not completed its valuation of assets acquired and liabilities assumed. Any necessary adjustments will be finalized within one </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year from the date of acquisition. As a result, $6.5&#160;million has been recorded as goodwill on the Company's condensed consolidated balance sheets. See Note 7 - Goodwill, Trade Names, and Other Intangible Assets. Associated acquisition-related costs incurred have been included in acquisition and integration-related costs on the Company's condensed consolidated statements of operations for the three months ended March 31, 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cross Country Workforce Solutions Group (CCWSG)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, the Company purchased and acquired substantially all of the assets and assumed certain liabilities of Workforce Solutions Group, Inc. (WSG) for a purchase price of $25.0&#160;million in cash and $5.0&#160;million in shares (or 307,730 shares) of the Company's common stock. The parties agreed to a final net working capital reduction of $1.1&#160;million which was received in the fourth quarter of 2021.The transaction was treated as a purchase of assets for income tax purposes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sellers are also eligible to receive an earnout based on the business' performance through three years after the acquisition date that could provide up to an additional $15.0&#160;million in cash. The current portion of the liability of $7.5&#160;million is included in current portion of earnout liability and the non-current portion of $7.5&#160;million is included in non-current earnout liability on the condensed consolidated balance sheets. See Note 10 - Fair Value Measurements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of the assets acquired and liabilities assumed on June 8, 2021:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability - non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnout liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,027&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assigned a value to other identifiable intangible assets of $14.2&#160;million in customer relationships with a weighted average estimated useful life of 11.5 years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining excess purchase price over the fair value of net assets acquired of $22.1&#160;million was recorded as goodwill on the Company's condensed consolidated balance sheets. See Note 7 - Goodwill, Trade Names, and Other Intangible Assets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was not significant and has been accounted for using the acquisition method of accounting. The pro-forma impact on the Company's consolidated revenue from services and net income, including the pro forma effect of events that are directly attributable to the acquisition, was not significant. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mediscan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, the Company entered into a note payable of $7.3&#160;million related to contingent consideration assumed as part of the Mediscan acquisition, payable in three installments. The first two installments of $2.4&#160;million each were paid in the second quarter of 2020 and in the first quarter of 2021, respectively. The third and final installment of $2.6&#160;million, including interest, was paid in the first quarter of 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414475334360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMPREHENSIVE INCOME<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">COMPREHENSIVE INCOME</a></td>
<td class="text">COMPREHENSIVE INCOME<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total comprehensive income includes net income or loss and foreign currency translation adjustments, net of any related deferred taxes, and is included within the accompanying condensed consolidated statements of operations. Certain of the Company&#8217;s foreign subsidiaries use their respective local currency as their functional currency. Assets and liabilities of these operations are translated at the exchange rates in effect on the balance sheet date. Income statement items are translated at the average exchange rates for the period. The cumulative impact of currency fluctuations related to the balance sheet translation is included in accumulated other comprehensive loss in the accompanying condensed consolidated balance sheets and was an unrealized loss of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1.4&#160;million at March 31, 2022 and $1.3 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414475139368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS PER SHARE</a></td>
<td class="text">EARNINGS PER SHARE<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the numerator and denominator for the computation of the basic and diluted earnings per share:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(amounts in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to common stockholders - Basic and Diluted</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,983&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,448&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares - Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of diluted shares:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Share-based awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares - Diluted</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,973&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,034&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to common stockholders - Basic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to common stockholders - Diluted</span></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.53&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, there were 4,276 share-based awards that could potentially dilute net income per share attributable to common stockholders in the future that were not included in the computation of diluted net income per share attributable to common stockholders because to do so would have been anti-dilutive for that period. There were no such share-based awards for the three months ended March 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414476240424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS</a></td>
<td class="text">GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had the following acquired intangible assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.239%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets subject to amortization:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Databases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,572&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,572&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets not subject to amortization:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names, indefinite-lived</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,900&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,900&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, estimated annual amortization expense is as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:80.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.989%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December&#160;31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,543&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Goodwill, Trade Names, and Other Intangible Assets Impairment </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests reporting units&#8217; goodwill and intangible assets with indefinite lives for impairment annually during the fourth quarter and more frequently if impairment indicators exist. The Company performs quarterly qualitative assessments of significant events and circumstances such as reporting units&#8217; historical and current results, assumptions regarding future performance, strategic initiatives and overall economic factors, including COVID, and macro-economic developments, to determine the existence of potential indicators of impairment and assess if it is more likely than not that the fair value of reporting units or intangible assets is less than their carrying value. If indicators of impairments are identified a quantitative impairment test is performed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the Company performed a qualitative assessment of each of its reporting units and determined it was not more likely than not that the fair value of its reporting units dropped below their carrying value. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lthough management believes that the Company's current estimates and assumptions utilized in its qualitative testing are reasonable and supportable, including its assumptions on the impact and timing related to COVID, there can be no assurance that the estimates and assumptions management used for purposes of its qualitative assessment as of March 31, 2022 will prove to be accurate predictions of future performance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, goodwill by reporting segment was: $116.7&#160;million for Nurse and Allied Staffing and $2.8&#160;million for Physician Staffing, for a total of $119.5&#160;million. Goodwill includes amounts acquired from the acquisitions of WSG and Selected, calculated as the excess of the fair value of consideration exchanged as compared to the fair value of identifiable net assets acquired. See Note 4 - Acquisitions. During the measurement period, which is not to exceed one year from the acquisition date, the Company may record adjustments to the assets acquired or liabilities assumed, with a corresponding offset to goodwill. Upon conclusion of the measurement period, any subsequent adjustments would be recorded to earnings.</span></div>For its long-lived assets and definite-lived intangible assets, the Company reviews for impairment whenever events or changes in circumstances indicate the carrying amount may not be recoverable. As of March 31, 2022, the Company performed a qualitative assessment of its trade names and other intangible assets and determined it was not more likely than not that their carrying value may not be recoverable. During the three months ended March 31, 2021, the Company wrote off a discontinued software development project, resulting in an immaterial impairment charge.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414475298216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text">DEBT<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's long-term debt consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan, interest of 6.50% at March 31, 2022 and December 31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,396)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Secured Asset-Based Loan, interest of 1.88% and 1.60% at March 31, 2022 and December 31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,990)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(991)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note Payable, interest of 2.00% per annum at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,376&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,141)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,938&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,387)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion - note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion - term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,626&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,141)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,762&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,387)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, the current portion of the term loan is included in current portion of debt on the condensed consolidated balance sheets. In addition, the current portion of the note payable as of December 31, 2021 is included in current portion of debt on the condensed consolidated balance sheets. The Company has elected to present the debt issuance costs associated with its revolving line-of-credit as an asset, which is included in other non-current assets on the condensed consolidated balance sheets. As a result, the long-term debt in the above table will not agree to long-term debt, net of current portion on the condensed consolidated balance sheets herein.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the aggregate schedule for maturities of debt are as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term Loan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Secured Asset-Based Loan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Through Years Ending December&#160;31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,875&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,501&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Term Loan Credit Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 8, 2021, the Company entered into a Term Loan Credit Agreement (Term Loan Agreement) with</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> certain lenders identified therein (collectively, the Lenders) and Wilmington Trust</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, National Association as administrative agent and collateral agent, pursuant to which the Lenders extended to the Company a six-year second lien subordinated term loan in the amount of $100.0&#160;million (term loan). The term loan has an interest rate of one-month London Inter-Bank Offered Rate (LIBOR) plus 5.75% per annum, subject to a 0.75% LIBOR floor. The term loan was used to pay the cash consideration, as well as any costs, fees, and expenses in connection with the WSG acquisition (see Note 4 - Acquisitions), with the remainder used to pay down a </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">portion of the asset based credit facility. Fees paid in connection with the Term Loan Agreement have been included as debt issuance costs and as a reduction to the carrying amount of the term loan and are expected to be amortized to interest expense over the term of the Term Loan Agreement.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The borrowings under the Term Loan Agreement generally bear interest at a variable rate based on either LIBOR or Base Rate (as defined in the Term Loan Agreement) and are subject to mandatory prepayments of principal payable in quarterly installments, commencing on September 30, 2021, with each installment being in the aggregate principal amount of $0.3 million (subject to adjustment as a result of prepayments) provided that, to the extent not previously paid, the aggregate unpaid principal balance would be due and payable on the maturity date. The Term Loan Agreement contains various restrictions and covenants applicable to the Company and its subsidiaries, including a covenant to maintain a minimum net leverage ratio. The Company was in compliance with this covenant as of March 31, 2022. Obligations under the Term Loan Agreement are secured by substantially all the assets of the borrowers and guarantors under the Term Loan Agreement, subject to customary exceptions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2021, the Company amended its Term Loan Agreement (Term Loan First Amendment), which provided the Company an incremental term loan in an aggregate amount equal to $75.0&#160;million. Additionally, the Term Loan First Amendment increased the aggregate amount of all increases (as defined in the Term Loan Agreement) to be no greater than $115.0&#160;million. The borrowings will be used primarily to fund organic growth. Commencing on December 31, 2021, installments of the mandatory prepayments will be in the aggregate principal amount of $0.4&#160;million. All other terms, conditions, covenants, and pricing of the Term Loan Agreement remain the same. In conjunction with the Term Loan First Amendment, the Company entered into the Term Loan First Amendment to the Intercreditor Agreement, effective as of November 18, 2021, which sets forth the lien priority, relative rights, and other creditors&#8217; rights issues in respect of the collateral lenders.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term loan is secured by a second-priority security interest in the collateral as defined in the ABL Credit Agreement (Loan Agreement) (as described below), and Wells Fargo Bank, National Association as agent, as amended by the First Amendment, Second Amendment, Third Amendment, Fourth Amendment, and Fifth Amendment to the Loan Agreement (as described below). The lien priority, relative rights, and other creditors&#8217; rights issues in respect of the collateral lenders are set forth in the Intercreditor Agreement, by and among Wells Fargo Bank, National Association, as first lien agent, and Wilmington Trust, National Association, as second lien agent, as amended, restated, amended and restated, supplemented or otherwise modified from time to time in accordance with the terms thereof dated June 8, 2021 (Intercreditor Agreement).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Loan Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective October 25, 2019, the Company terminated its commitments under its prior senior credit facility entered into in August 2017 and entered into a Loan Agreement, by and among the Company and certain of its domestic subsidiaries, as borrowers or guarantors, Wells Fargo, PNC Bank N.A., as well as other Lenders (as defined) from time to time parties thereto. The Loan Agreement provides for a five-year revolving senior secured asset-based credit facility (ABL) in the aggregate principal amount of up to $120.0&#160;million (as described below), including a sublimit for swing loans up to $15.0&#160;million and a $35.0&#160;million sublimit for standby letters of credit.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2020, the Company amended its Loan Agreement (First Amendment), which increased the current aggregate committed size of the ABL from $120.0&#160;million to $130.0&#160;million. All other terms, conditions, covenants, and pricing of the Loan Agreement remained the same. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2021, the Company amended its Loan Agreement (Second Amendment), which increased the current aggregate committed size of the ABL from $130.0&#160;million to $150.0&#160;million, increased certain borrowing base sub-limits, and decreased both the cash dominion event and financial reporting triggers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, the Company amended its Loan Agreement (Third Amendment), which permits the incurrence of indebtedness and grant of security as set forth in the Loan Agreement and in accordance with the Intercreditor Agreement, and provides mechanics relating to a transition away from LIBOR as a benchmark interest rate to a replacement alternative benchmark rate or mechanism for loans made in U.S. dollars.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2021, the Company amended its Loan Agreement (Fourth Amendment), whereby the permitted indebtedness (as defined in the Loan Agreement), was increased to $175.0 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 21, 2022, the Company amended its Loan Agreement (Fifth Amendment), which increased the current aggregate committed size of the ABL from $150.0 million to $300.0 million, extended the credit facility for an additional five years, and increased certain borrowing base sub-limits. In addition, the agreement provides the option for all or a portion of the borrowings to bear interest at a rate based on the Secured Overnight Financing Rate (SOFR) or Base Rate, at the election of the borrowers, plus an applicable margin. The applicable margin will increase 10 basis points due to the credit spread associated with the transition to SOFR.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These amendments were treated as modifications of debt and, as a result, the associated fees and costs were included in debt issuance costs and will be amortized ratably over the remaining term of the Loan Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Availability of the ABL commitments is subject to a borrowing base of up to 85% of secured eligible accounts receivable, subject to adjustment at certain quality levels, minus customary reserves and subject to customary adjustments. Revolving loans and letters of credit issued under the Loan Agreement reduce availability under the ABL on a dollar-for-dollar basis. Availability under the ABL will be used for general corporate purposes. At March 31, 2022, borrowing base availability under the ABL was $300.0&#160;million and the Company had $51.5&#160;million of borrowings drawn, as well as $17.5&#160;million of letters of credit outstanding related to workers' compensation and professional liability policies, leaving $231.0&#160;million of excess availability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the interest rate spreads and fees under the Loan Agreement were based on SOFR plus 1.85% for the revolving portion of the borrowing base. The Base Rate (as defined by the Loan Agreement) margin would have been 0.75%  for the revolving portion</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The SOFR and Base Rate margins are subject to monthly pricing adjustments, pursuant to a pricing matrix based on the Company&#8217;s excess availability under the revolving credit facility. In addition, the facility is subject to an unused line fee, letter of credit fees, and an administrative fee. The unused line fee is 0.375% of the average daily unused portion of the revolving credit facility.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement contains various restrictions and covenants applicable to the Company and its subsidiaries, including a covenant to maintain a minimum fixed charge coverage ratio. The Company was in compliance with this covenant as of March 31, 2022. Obligations under the ABL are secured by substantially all the assets of the borrowers and guarantors, subject to customary exceptions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note Payable</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, the Company entered into a note payable of $7.3&#160;million related to contingent consideration assumed as part of a prior period acquisition, payable in three installments. The first two installments of $2.4&#160;million each were paid in the second quarter of 2020 and in the first quarter of 2021, respectively. The third and final installment of $2.6&#160;million, including interest, was paid in the first quarter of 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414475298216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease population of its right-of-use asset and lease liabilities is substantially related to the rental of office space. The Company enters into lease agreements as a lessee that may include options to extend or terminate early. Some of these real estate leases require variable payments of property taxes, insurance, and common area maintenance, in addition to base rent. Certain of the leases have provisions for free rent months during the lease term and/or escalating rent payments and, particularly for the Company&#8217;s longer-term leases for its corporate offices, it has received incentives to enter into the leases, such as receiving up to a specified dollar amount to construct tenant improvements. These leases do not include residual value guarantees, covenants, or other restrictions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the second quarter of 2020, in connection with the continuing developments from COVID, the Company expedited restructuring plans and either reduced or fully vacated leased office space. The Company is in the process of seeking to sublet some of the space where possible. The decision and change in the use of space resulted in a right-of-use asset impairment charge of $1.5&#160;million for the three months ended March 31, 2022. This loss was determined by comparing the fair value of the impacted right-of-use assets to the carrying value of the assets as of the impairment measurement date. The fair value of the right-of-use assets was based on the estimated sublease income for the space taking into consideration the time period it will take to obtain a subtenant, the applicable discount rate, and the sublease rate. For the three months ended March 31, 2022, the Company wrote off an immaterial amount of leasehold improvements and other property and equipment related to these locations. The Company did not record any lease-related impairment charges for the three months ended March 31, 2021. The measurement of the right-of-use asset impairments, using the assumptions described, is a Level 3 fair value measurement. See Note 10 - Fair Value Measurements for a description of Level 3 inputs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the lease-related assets and liabilities included on the condensed consolidated balance sheets:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.854%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification on Condensed Consolidated Balance Sheets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - non-current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.854%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reconciles the undiscounted cash flows for each of, and total of, the remaining years to the operating lease liabilities (which do not include short-term leases) recorded on the condensed consolidated balance sheets as of March 31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:75.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.989%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December&#160;31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,212&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,482)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: operating lease liabilities - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,026)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - non-current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding supplemental cash flows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,637&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets acquired under operating lease</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Included in Condensed Consolidated Statements of Operations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable and other lease costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense, short-term lease expense, and variable and other lease costs are included in selling, general and administrative expenses, direct operating expenses, and restructuring costs in the condensed consolidated statements of operations, depending on the nature of the leased asset. Operating lease expense is reported net of sublease income, which is not material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the Company does not have any material operating leases which have not yet commenced. The Company has an immaterial</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amount of finance lease contracts related to other equipment rentals which are not included in the above disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414475215832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy was established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Items Measured at Fair Value on a Recurring Basis:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial assets/liabilities required to be measured on a recurring basis were its: (i) deferred compensation asset included in other non-current assets; and (ii) deferred compensation liability included in other long-term liabilities on its condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company utilizes Level 1 inputs to value its deferred compensation assets and liabilities. The Company&#8217;s deferred compensation assets and liabilities are measured using publicly available indices, as per the plan documents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company&#8217;s financial assets and liabilities measured on a recurring basis is as follows:&#160;</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:58.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.401%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation asset</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities:</span></td><td colspan="9" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,450&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Items Measured at Fair Value on a Non-Recurring Basis:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's non-financial assets, such as goodwill, trade names, other intangible assets, right-of-use assets, and property and equipment, are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three months ended March 31, 2022 included impairment charges to right-of-use assets along with related property and equipment in connection with leases that were vacated. Accordingly, as of March 31, 2022, these assets were recorded at fair value using Level 3 inputs. See Note 9 - Leases for more information about these fair value measurements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments not measured or recorded at fair value in the condensed consolidated balance sheets consist of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses. The estimated fair value of accounts receivable and accounts payable and&#160;accrued expenses approximate their carrying amount due to the short-term nature of these instruments. Other financial instruments not measured or recorded at fair value include: (i) note payable, (ii) ABL, (iii) term loan, and (iv) and (v) earnout liabilities, as discussed below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(i) The Company paid the third and final installment on its note payable in the first quarter of 2022. Due to its relatively short-term nature, the carrying value of the note payable approximated its fair value. (ii) The carrying amount of the Company's ABL approximates fair value because the interest rates are variable and reflective of market rates. (iii) The estimated fair value of the Company's term loan was calculated applying an interest rate lattice model using Level 2 inputs from available market information. (iv) Potential earnout payments related to the WSG acquisition are contingent upon meeting certain performance requirements based on 2021 through 2023 performance. The Company performed an analysis using multiple forecasted scenarios to determine the fair value of the earnout liability. The earnout liability's carrying amount approximates fair value and is included in current portion of earnout liability and non-current earnout liability on the condensed consolidated balance sheets. (v) Potential earnout payments related to the Selected acquisition are contingent upon meeting certain performance requirements based on 2022 and 2023 revenues. The earnout liability's carrying amount approximates fair value and is included in current portion of earnout liability and non-current earnout liability on the condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and estimated fair value of the Company&#8217;s significant financial instruments that were not measured at fair value are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note Payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Secured Asset-Based Loan</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,501&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,501&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,200&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,200&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan, net</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,875&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,387&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,312&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,845&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnout Liability (WSG)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnout Liability (Selected)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk:</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See discussion of credit losses and allowance for doubtful accounts in Note 2 - Summary of Significant Accounting Policies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, based on the large number of customers in differing geographic areas, primarily throughout the United States and its territories, the Company believes the concentration of credit risk is limited.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414475230664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Repurchase Program</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022 and 2021, the Company did not repurchase any shares of its common stock. As of March&#160;31, 2022, the Company has 510,004 shares of common stock under the current share repurchase program available to repurchase, subject to certain conditions in the Company's Loan Agreement and Term Loan Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Payments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 19, 2020, the Company's stockholders approved the Cross Country Healthcare, Inc. 2020 Omnibus Incentive Plan (2020 Plan), which replaced the 2017 Omnibus Incentive Plan (2017 Plan), and applies to awards granted after May 19, 2020. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining shares available for grant under the 2017 Plan were cancelled and no further awards will be granted under that plan. The 2020 Plan generally mirrors the terms of the 2017 Plan and includes the following provisions: (i) an aggregate share reserve of 3,000,000 shares; (2) annual dollar and share limits of awards granted to employees and consultants, as well as non-employee directors, based on type of award; (3) awards granted generally will be subject to a minimum one-year vesting schedule; and (4) awards may be granted under the 2020 Plan until March 24, 2030.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock awards and performance stock awards activity issued under the 2017 Plan and the 2020 Plan (Plans) for the three months ended March&#160;31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.741%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Stock Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance Stock Awards</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Target <br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock awards, January&#160;1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(481,231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170,278)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock awards, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773,230&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,840&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards granted under the Company&#8217;s Plans entitle the holder to receive, at the end of a vesting period, a specified number of shares of the Company&#8217;s common stock. Share-based compensation expense is measured by the market value of the Company&#8217;s stock on the date of grant. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards granted to non-employee directors under the 2017 Plan, prior to the adoption of the 2020 Plan, vest in three equal installments on the first, second and third anniversaries of the grant date, while restricted shares granted under the 2020 Plan on and subsequent to June 2020 will vest on the first anniversary of such grant date, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or earlier subject to retirement eligibility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, effective in the three months ended June 30, 2020, the Company implemented modified guidelines that provide for accelerated vesting of restricted stock grants on the last date of service when a retirement-eligible director retires.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Plans, the number of target shares that are issued for performance-based stock awards are determined based on the level of attainment of the targets. During the first quarter of 2022, the Company's Compensation Committee of the Board of Directors approved a 120% level of attainment for the 2019 performance-based share awards, resulting in the issuance of 170,278 performance shares that vested on March 31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March 31, 2022, $1.6 million was included in selling, general and administrative expenses related to share-based payments, and a net of 419,500 shares of common stock were issued upon the vesting of restricted and performance stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, $1.3 million was included in selling, general and administrative expenses related to share-based payments, and a net of 317,605 shares of common stock were issued upon the vesting of restricted stock.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414475215832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT DATA<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT DATA</a></td>
<td class="text">SEGMENT DATA<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s segments offer services to its customers as described below:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9679;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nurse and Allied Staffing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Nurse and Allied Staffing provides traditional staffing, recruiting, and value-added total talent solutions including: temporary and permanent placement of travel and local nurse and allied professionals, managed services programs (MSP) services, education healthcare services, in-home care services, and outsourcing services. In addition, Nurse and Allied Staffing provides retained search services for healthcare professionals, as well as contingent search and recruitment process outsourcing services. Its clients include: public and private acute-care and non-acute care hospitals, government facilities, local and national healthcare plans, managed care providers, public schools and charter schools, outpatient clinics, ambulatory care facilities, physician practice groups, and many other healthcare providers throughout the United States.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9679;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Physician Staffing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Physician Staffing provides physicians in many specialties, as well as certified registered nurse anesthetists, nurse practitioners, and physician assistants as independent contractors on temporary assignments </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">throughout the United States at various healthcare facilities, such as acute and non-acute care facilities, medical group practices, government facilities, and managed care organizations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates performance of each segment primarily based on revenue and contribution income. The Company defines contribution income as income (loss) from operations before depreciation and amortization, acquisition and integration-related costs, restructuring costs, legal settlement charges, impairment charges, and corporate overhead. The Company does not evaluate, manage, or measure performance of segments using asset information; accordingly, total asset information by segment is not prepared or disclosed. The information in the following table is derived from the segments&#8217; internal financial information as used for corporate management purposes. Certain corporate expenses are not allocated to and/or among the operating segments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on operating segments and a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reconciliation to income from operations for the periods indicated are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from services:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nurse and Allied Staffing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physician Staffing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,732&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nurse and Allied Staffing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physician Staffing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,845&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate overhead </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration-related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,632&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,994&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414475218632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">CONTINGENCIES</a></td>
<td class="text">CONTINGENCIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various litigation, claims, investigations, and other proceedings that arise in the ordinary course of its business. These matters primarily relate to employee-related matters that include individual and collective claims, professional liability, tax, and payroll practices. The Company establishes reserves when available information indicates that a loss is probable and an amount or range of loss can be reasonably estimated. These assessments are performed at least quarterly and are based on the information available to management at the time and involve significant management judgment to determine the probability and estimated amount of potential losses, if any. Based on the available information considered in its reviews, the Company adjusts its loss contingency accruals and its disclosures as may be required. Actual outcomes or losses may differ materially from those estimated by the Company's current assessments, including available insurance recoveries, which would impact the Company's profitability. Adverse developments in existing litigation claims or legal proceedings involving the Company or new claims could require management to establish or increase litigation reserves or enter into unfavorable settlements or satisfy judgments for monetary damages for amounts in excess of current reserves, which could adversely affect the Company's financial results. The Company believes the outcome of any outstanding loss contingencies as of March 31, 2022 will not have a material adverse effect on its business, financial condition, results of operations, or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales and Other State Non-Income Tax Liabilities </span></div>The Company's sales and other state non-income tax filings are subject to routine audits by authorities in the jurisdictions where it conducts business in the United States which may result in assessments of additional taxes. The Company accrues sales and other non-income tax liabilities based on the Company's best estimate of its probable liability utilizing currently available information and interpretation of relevant tax regulations. Given the nature of the Company's business, significant subjectivity exists as to both whether sales and other state non-income taxes can be assessed on its activity and how the sales tax will ultimately be measured by the relevant jurisdictions. The Company makes a determination for each reporting period whether the estimates for sales and other non-income taxes in certain states should be revised. The expense is included in selling, general and administrative expenses in the Company's condensed consolidated statements of operations and the liability is reflected in sales tax payable within other current liabilities in its condensed consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414475339528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three-month period ended March 31, 2022, the Company calculated its effective tax rate estimating its annual effective tax rate as opposed to the quarter ended March 31, 2021, whereby the Company calculated its effective tax rate based on year-to-date results. The Company&#8217;s effective tax rate for the three months ended March 31, 2022 and 2021 was 28.9% and 4.5%, respectively, including the impact of discrete items. Excluding discrete items, the Company's effective tax rate for the three months ended March 31, 2022 and 2021 was 30.0% and 4.5%, respectively. The effective tax rate for the first quarter of 2022 was primarily impacted by federal and state taxes. Income tax expense for the three months ended March 31, 2021 was primarily impacted by international and state taxes as a result of the Company's valuation allowance on substantially all of its domestic deferred tax assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2021, the Company concluded that it was more likely than not that a benefit from a substantial portion of its United States federal and state deferred tax assets would be realized and released the majority of its valuation allowance. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, the Company had an immaterial amount of valuation allowance on its deferred tax assets related to state net operating losses not expected to be realized before expiration.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company had approximately $9.2 million of unrecognized tax benefits included in other long-term liabilities, $9.4 million, net of deferred taxes, which would impact the effective tax rate if recognized. During the three months ended March&#160;31, 2022, the Company had net increases of $0.3&#160;million to its current year unrecognized tax benefits related to federal and state tax provisions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax years 2012 through 2021 remain open to examination by certain taxing jurisdictions to which the Company is subject to tax, other than certain states in which the statute of limitations has been extended.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414475300408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONS<div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into an arrangement for digital marketing services provided by a firm that is related to Mr. Clark, the Company's Co-Founder &amp; Chief Executive Officer through March 31, 2022. Mr. Clark is a minority shareholder in the firm's parent company and is a member of the parent company's Board of Directors. Management believes the terms of the arrangement are equivalent to those prevailing in an arm's-length transaction and have been approved by the Company through its related party process. The digital marketing firm manages a limited number of digital publishers covering various Company brands for a monthly management fee. During the three months ended March 31, 2022 and 2021, the Company incurred an immaterial amount in expenses. The Company had an immaterial payable balance at March 31, 2022 and December 31, 2021.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides services to entities which are affiliated with certain members of the Company&#8217;s Board of Directors. Management believes the services were conducted on terms equivalent to those prevailing in an arm's-length transaction. Revenue related to these transactions was immaterial for the three months ended March 31, 2022. The Company had no revenue related to these transactions for the three months ended March 31, 2021. Accounts receivable due from these entities was an immaterial amount at March 31, 2022 and December 31, 2021.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the WSG acquisition on June 8, 2021, the Company continues to rent WSG's headquarters. The Chief Executive Officer and Founder of WSG, and currently a business unit president with the Company, is an agent of the lessor. The lease term is from January 1, 2020 through December 31, 2024. The Company paid an immaterial amount in rent expense for these premises for the three months ended March 31, 2022, and had an immaterial payable balance at March 31, 2022 and no payable balance at December 31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, the Company entered into a note payable of $7.3&#160;million related to contingent consideration assumed as part of a prior period acquisition, payable in three equal installments. The payees of the note are controlled by an employee of the sellers who remained with the Company. The third and final installment of $2.6&#160;million, including interest, was paid in the first quarter of 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414475123432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECENT ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">RECENT ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text">RECENT ACCOUNTING PRONOUNCEMENTS<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2021, the FASB issued ASU No. 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires contract assets and contract liabilities such as deferred revenue acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. Generally, this amendment will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. Historically such amounts were recognized by the acquirer at fair value in acquisition accounting. This guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The amendments should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The Company is currently in the process of evaluating this standard and expects to adopt this standard in its first quarter of 2023.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (c)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414472724152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Nature of Business</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nature of Business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of Cross Country Healthcare, Inc. and its direct and indirect wholly-owned subsidiaries (collectively, the Company). In the opinion of management, all adjustments necessary for a fair presentation of such unaudited condensed consolidated financial statements have been included. All such adjustments consisted of all normal recurring items, including the elimination of all intercompany transactions and balances.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form&#160;10-Q and Article 10 of Regulation&#160;S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These operating results are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2021 included in the Company&#8217;s Annual Report on Form&#160;10-K as filed with the SEC on February 28, 2022 (2021 Form 10-K). The December&#160;31, 2021 condensed consolidated balance sheet included herein was derived from the December&#160;31, 2021 audited consolidated balance sheet included in the 2021 Form&#160;10-K.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of Estimates<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Management has assessed various accounting estimates and other matters, including those that require consideration of forecasted financial information, in context of the unknown future impacts of the global </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 (COVID)</span> pandemic using information that is reasonably available to the Company at the time. Significant estimates and assumptions are used for, but not limited to: (i) the valuation of accounts receivable; (ii) goodwill, trade names, and other intangible assets; (iii) other long-lived assets; (iv) revenue recognition; (v) accruals for health, workers&#8217; compensation, and professional liability claims; (vi) valuation of deferred tax assets; (vii) legal contingencies; and (viii) income taxes. Accrued insurance claims and reserves include estimated settlements from known claims and actuarial estimates for claims incurred but not reported. As additional information becomes available to the Company, its future assessment of these estimates, including management's expectations at the time regarding the duration, scope and severity of the pandemic, as well as other factors, could materially and adversely impact the Company's consolidated financial statements in future reporting periods. Actual results could differ from those estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable, net</a></td>
<td class="text"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable, net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The timing of revenue recognition, billings, and collections results in billed and unbilled accounts receivable from customers, which are classified as accounts receivable on the condensed consolidated balance sheets and are presented net of allowances for doubtful accounts and sales allowances. Estimated revenue for the Company employees', subcontracted employees', and independent contractors&#8217; time worked but not yet billed at March 31, 2022 and December 31, 2021 totaled $249.7&#160;million and $140.0&#160;million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally does not require collateral and mitigates its credit risk by performing credit evaluations and monitoring at-risk accounts. The allowance for doubtful accounts is established for losses expected to be incurred on accounts receivable balances. Accounts receivable are written off against the allowance for doubtful accounts when the Company determines amounts are no longer collectible. Judgment is required in the estimation of the allowance and the Company evaluates the collectability of its accounts receivable and contract assets based on a combination of factors. The Company bases its allowance for doubtful account estimates on its historical write-off experience, current conditions, an analysis of the aging of outstanding receivable and customer payment patterns, and specific reserves for customers in adverse condition adjusted for current expectations for the customers or industry. Based on the information currently available, the Company also considered current expectations of future economic conditions, including the impact of COVID, when estimating its allowance for doubtful accounts.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad Debt Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-Offs, net of Recoveries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,091&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the allowance for doubtful accounts, the Company maintains a sales allowance for billing-related adjustments which may arise in the ordinary course of business and adjustments to the reserve are recorded as contra-revenue. The balance of this allowance as of March 31, 2022 and December 31, 2021 was $1.1&#160;million and $0.8&#160;million, respectively.</span></div>The Company&#8217;s contract terms typically require payment between 30 to 60 days from the date of invoice and are considered past due based on the particular negotiated contract terms. The majority of the Company's customers are U.S. based healthcare systems with a significant percentage in acute-care facilities.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock', window );">Restructuring Costs</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers restructuring activities to be programs whereby it fundamentally changes its operations, such as closing and consolidating facilities, reducing headcount, and realigning operations in response to changing market conditions. As a result, restructuring costs on the condensed consolidated statements of operations primarily include employee termination costs and lease-related exit costs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Accounting Pronouncement</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2021, the FASB issued ASU No. 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires contract assets and contract liabilities such as deferred revenue acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. Generally, this amendment will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. Historically such amounts were recognized by the acquirer at fair value in acquisition accounting. This guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The amendments should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The Company is currently in the process of evaluating this standard and expects to adopt this standard in its first quarter of 2023.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414475315608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Schedule of Allowance for Doubtful Accounts</a></td>
<td class="text"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad Debt Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-Offs, net of Recoveries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,091&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Restructuring and Related Costs</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliation of the employee termination costs and lease-related exit costs beginning and ending liability balance is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:50.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee Termination Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease-Related Exit Costs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to restructuring costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,620&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Restructuring costs in the condensed consolidated statements of operations for the three months ended March 31, 2022 include an immaterial amount of ongoing lease costs related to the Company's strategic reduction in its real estate footprint, which are included as operating lease liabilities - current and non-current in our condensed consolidated balance sheets. Other costs were immaterial for the three months ended March 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414475298216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenues from customer contracts are generated from temporary staffing services and other services. Revenue is disaggregated by segment in the following table. Sales and usage-based taxes are excluded from revenue.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nurse<br/>And Allied<br/>Staffing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Physician<br/>Staffing</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Segments</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary Staffing Services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,133&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,181&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765,580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nurse<br/>And Allied<br/>Staffing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Physician<br/>Staffing</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Segments</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary Staffing Services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,033&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,860&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,008&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,233&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,241&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414475362888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of the assets acquired and liabilities assumed on June 8, 2021:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability - non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnout liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,027&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414475318360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the numerator and denominator for the computation of the basic and diluted earnings per share:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(amounts in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to common stockholders - Basic and Diluted</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,983&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,448&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares - Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of diluted shares:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Share-based awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares - Diluted</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,973&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,034&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to common stockholders - Basic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to common stockholders - Diluted</span></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.53&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414475154968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Acquired Intangible Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had the following acquired intangible assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.239%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets subject to amortization:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Databases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,572&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,572&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets not subject to amortization:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names, indefinite-lived</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,900&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,900&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Annual Amortization Expense</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, estimated annual amortization expense is as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:80.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.989%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December&#160;31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,543&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414475218632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's long-term debt consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan, interest of 6.50% at March 31, 2022 and December 31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,396)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Secured Asset-Based Loan, interest of 1.88% and 1.60% at March 31, 2022 and December 31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,990)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(991)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note Payable, interest of 2.00% per annum at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,376&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,141)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,938&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,387)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion - note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion - term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,626&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,141)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,762&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,387)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Aggregate Scheduled Maturities of Debt</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the aggregate schedule for maturities of debt are as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term Loan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Secured Asset-Based Loan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Through Years Ending December&#160;31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,875&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,501&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414472712648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock', window );">Schedule of Supplemental Balance Sheet Information</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the lease-related assets and liabilities included on the condensed consolidated balance sheets:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.854%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification on Condensed Consolidated Balance Sheets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - non-current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.854%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease Maturity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reconciles the undiscounted cash flows for each of, and total of, the remaining years to the operating lease liabilities (which do not include short-term leases) recorded on the condensed consolidated balance sheets as of March 31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:75.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.989%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December&#160;31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,212&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,482)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: operating lease liabilities - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,026)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - non-current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding supplemental cash flows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,637&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets acquired under operating lease</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Included in Condensed Consolidated Statements of Operations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable and other lease costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_AssetsAndLiabilitiesLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Leases [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_AssetsAndLiabilitiesLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414476241272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis</a></td>
<td class="text">The estimated fair value of the Company&#8217;s financial assets and liabilities measured on a recurring basis is as follows:&#160;<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:58.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.401%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation asset</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities:</span></td><td colspan="9" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,450&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Schedule of Carrying Amounts and Estimated Fair Values of Significant Financial Instrument that were not Measured at Fair Value</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and estimated fair value of the Company&#8217;s significant financial instruments that were not measured at fair value are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note Payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Secured Asset-Based Loan</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,501&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,501&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,200&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,200&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan, net</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,875&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,387&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,312&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,845&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnout Liability (WSG)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnout Liability (Selected)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414476245752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock awards and performance stock awards activity issued under the 2017 Plan and the 2020 Plan (Plans) for the three months ended March&#160;31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.741%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Stock Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance Stock Awards</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Target <br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock awards, January&#160;1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(481,231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170,278)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock awards, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773,230&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,840&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414475193816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT DATA (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of Information on Operating Segments and Reconciliation to Loss From Operations</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on operating segments and a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reconciliation to income from operations for the periods indicated are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from services:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nurse and Allied Staffing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physician Staffing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,732&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nurse and Allied Staffing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physician Staffing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,845&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate overhead </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration-related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,632&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,994&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414472390968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled contracts receivable</a></td>
<td class="nump">$ 249.7<span></span>
</td>
<td class="nump">$ 140.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_SalesAllowanceBillingRelatedAdjustments', window );">Sales allowance, billing-related adjustments</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided', window );">Threshold period, past due for payment of services provided</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided', window );">Threshold period, past due for payment of services provided</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_SalesAllowanceBillingRelatedAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Allowance, Billing-Related Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_SalesAllowanceBillingRelatedAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold Period, Past Due For Payment Of Services Provided</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(c)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55302-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414471686024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Allowance for Doubtful Accounts (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="nump">$ 6,087<span></span>
</td>
<td class="nump">$ 3,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad Debt Expense</a></td>
<td class="nump">2,369<span></span>
</td>
<td class="nump">504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-Offs, net of Recoveries</a></td>
<td class="num">(365)<span></span>
</td>
<td class="num">(699)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">$ 8,091<span></span>
</td>
<td class="nump">$ 3,221<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414476153576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restructuring Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charged to restructuring costs</a></td>
<td class="nump">$ 480<span></span>
</td>
<td class="nump">$ 1,238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Termination Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at beginning of period</a></td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charged to restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_PaymentsForRestructuringAndAdjustments', window );">Payments and adjustments</a></td>
<td class="num">(160)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ccrn_ExitCostsMember', window );">Lease-Related Exit Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at beginning of period</a></td>
<td class="nump">2,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charged to restructuring costs</a></td>
<td class="nump">389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_PaymentsForRestructuringAndAdjustments', window );">Payments and adjustments</a></td>
<td class="num">(192)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at end of period</a></td>
<td class="nump">$ 2,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_PaymentsForRestructuringAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Restructuring And Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_PaymentsForRestructuringAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ccrn_ExitCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ccrn_ExitCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414469002120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">$ 788,732<span></span>
</td>
<td class="nump">$ 329,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ccrn_TemporaryStaffingServicesMember', window );">Temporary Staffing Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">771,551<span></span>
</td>
<td class="nump">321,381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ccrn_OtherServicesMember', window );">Other Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">17,181<span></span>
</td>
<td class="nump">7,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_NurseAndAlliedStaffingMember', window );">Nurse And Allied Staffing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">765,580<span></span>
</td>
<td class="nump">313,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_NurseAndAlliedStaffingMember', window );">Nurse And Allied Staffing | Temporary Staffing Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">749,447<span></span>
</td>
<td class="nump">305,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_NurseAndAlliedStaffingMember', window );">Nurse And Allied Staffing | Other Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">16,133<span></span>
</td>
<td class="nump">7,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_PhysicianStaffingMember', window );">Physician Staffing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">23,152<span></span>
</td>
<td class="nump">16,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_PhysicianStaffingMember', window );">Physician Staffing | Temporary Staffing Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">22,104<span></span>
</td>
<td class="nump">15,406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_PhysicianStaffingMember', window );">Physician Staffing | Other Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">$ 1,048<span></span>
</td>
<td class="nump">$ 827<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ccrn_TemporaryStaffingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ccrn_TemporaryStaffingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ccrn_OtherServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ccrn_OtherServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_NurseAndAlliedStaffingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ccrn_NurseAndAlliedStaffingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_PhysicianStaffingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ccrn_PhysicianStaffingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414469292840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 16, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 08, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,490<span></span>
</td>
<td class="nump">$ 119,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of earnout liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,250<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current earnout liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,250<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ccrn_SelectedIncMember', window );">Selected, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration, gross</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Equity consideration for acquisition, value</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity consideration for acquisition (in shares) | shares</a></td>
<td class="nump">59,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Earnout liabilities</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ccrn_WorkforceSolutionsGroupIncMember', window );">Workforce Solutions Group, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Equity consideration for acquisition, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity consideration for acquisition (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Earnout liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment', window );">Net working capital adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_BusinessCombinationContingentConsiderationTerm', window );">Contingent consideration liability, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of earnout liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current earnout liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ccrn_WorkforceSolutionsGroupIncMember', window );">Workforce Solutions Group, Inc. | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ccrn_MediscanMember', window );">Mediscan | Earnout Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_NotePayableNumberOfPaymentInstallments', window );">Number of installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_NotePayableNumberOfInstallmentsPaid', window );">Number of installments paid | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Net Working Capital Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_BusinessCombinationContingentConsiderationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_BusinessCombinationContingentConsiderationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_NotePayableNumberOfInstallmentsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Note Payable, Number Of Installments Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_NotePayableNumberOfInstallmentsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_NotePayableNumberOfPaymentInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Note Payable, Number Of Payment Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_NotePayableNumberOfPaymentInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ccrn_SelectedIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ccrn_SelectedIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ccrn_WorkforceSolutionsGroupIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ccrn_WorkforceSolutionsGroupIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ccrn_MediscanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ccrn_MediscanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ccrn_EarnoutNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ccrn_EarnoutNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414469248312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACQUISITIONS - Recognized Identified Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 119,490<span></span>
</td>
<td class="nump">$ 119,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ccrn_WorkforceSolutionsGroupIncMember', window );">Workforce Solutions Group, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,200<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits', window );">Accrued compensation and benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent', window );">Lease liability - current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent', window );">Lease liability - non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability', window );">Earnout liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,027<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,334<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Compensation And Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ccrn_WorkforceSolutionsGroupIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ccrn_WorkforceSolutionsGroupIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414475187432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMPREHENSIVE INCOME (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax', window );">Loss on currency fluctuations</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414472381720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE - Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income attributable to common stockholders - Basic and Diluted - Basic</a></td>
<td class="nump">$ 61,983<span></span>
</td>
<td class="nump">$ 19,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income attributable to common stockholders - Basic and Diluted - Diluted</a></td>
<td class="nump">$ 61,983<span></span>
</td>
<td class="nump">$ 19,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares - Basic (shares)</a></td>
<td class="nump">37,028<span></span>
</td>
<td class="nump">36,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of diluted shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Share-based awards (shares)</a></td>
<td class="nump">945<span></span>
</td>
<td class="nump">853<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares - Diluted (shares)</a></td>
<td class="nump">37,973<span></span>
</td>
<td class="nump">37,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share attributable to common stockholders - Basic (in dollars per share)</a></td>
<td class="nump">$ 1.67<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share attributable to common stockholders - Diluted (in dollars per share)</a></td>
<td class="nump">$ 1.63<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414478175704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ccrn_ShareBasedPaymentAwardsMember', window );">Share-based Payment Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares excluded from diluted weighted average shares (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,276,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ccrn_ShareBasedPaymentAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ccrn_ShareBasedPaymentAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414469175224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Acquired Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 78,572<span></span>
</td>
<td class="nump">$ 78,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">38,029<span></span>
</td>
<td class="nump">36,228<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">40,543<span></span>
</td>
<td class="nump">42,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedTradeNames', window );">Trade names, indefinite-lived</a></td>
<td class="nump">5,900<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DatabasesMember', window );">Databases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">30,530<span></span>
</td>
<td class="nump">30,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">19,138<span></span>
</td>
<td class="nump">18,375<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">11,392<span></span>
</td>
<td class="nump">12,155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">47,738<span></span>
</td>
<td class="nump">47,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">18,603<span></span>
</td>
<td class="nump">17,581<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">29,135<span></span>
</td>
<td class="nump">30,157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Non-compete agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedTradeNames">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trade name to gain or protect exclusive use thereof for a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedTradeNames</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DatabasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DatabasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414472374520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Estimated Annual Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 5,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">7,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">6,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">5,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">4,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">10,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 40,543<span></span>
</td>
<td class="nump">$ 42,344<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414476071192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 119,490<span></span>
</td>
<td class="nump">$ 119,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_NurseAndAlliedStaffingMember', window );">Nurse And Allied Staffing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">116,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_PhysicianStaffingMember', window );">Physician Staffing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_NurseAndAlliedStaffingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ccrn_NurseAndAlliedStaffingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_PhysicianStaffingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ccrn_PhysicianStaffingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414469134408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Long-term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 225,376<span></span>
</td>
<td class="nump">$ 185,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs</a></td>
<td class="num">(9,141)<span></span>
</td>
<td class="num">(6,387)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current portion</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="nump">4,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 223,626<span></span>
</td>
<td class="nump">$ 181,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Senior Secured Asset-Based Loan | Senior Secured Asset-Based Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate at period end (percent)</a></td>
<td class="nump">1.88%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 51,501<span></span>
</td>
<td class="nump">$ 9,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs</a></td>
<td class="num">$ (3,990)<span></span>
</td>
<td class="num">$ (991)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ccrn_A2021TermLoanCreditAgreementMember', window );">2021 Term Loan Credit Agreement | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate at period end (percent)</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 173,875<span></span>
</td>
<td class="nump">$ 174,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs</a></td>
<td class="num">(5,151)<span></span>
</td>
<td class="num">(5,396)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current portion</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="nump">$ 1,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ccrn_EarnoutNotesPayableMember', window );">Earnout Notes Payable | Note Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current portion</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ccrn_SeniorSecuredAssetBasedLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ccrn_SeniorSecuredAssetBasedLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ccrn_A2021TermLoanCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ccrn_A2021TermLoanCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ccrn_EarnoutNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ccrn_EarnoutNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414469724472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Maturities of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 225,376<span></span>
</td>
<td class="nump">$ 185,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | 2021 Term Loan Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">1,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_LongTermDebtMaturityAfterYearFour', window );">Thereafter</a></td>
<td class="nump">165,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">173,875<span></span>
</td>
<td class="nump">174,312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Senior Secured Asset-Based Loan | Senior Secured Asset-Based Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_LongTermDebtMaturityAfterYearFour', window );">Thereafter</a></td>
<td class="nump">51,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">51,501<span></span>
</td>
<td class="nump">9,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Note Payable | Earnout Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_LongTermDebtMaturityAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Maturity, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_LongTermDebtMaturityAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ccrn_A2021TermLoanCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ccrn_A2021TermLoanCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ccrn_SeniorSecuredAssetBasedLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ccrn_SeniorSecuredAssetBasedLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ccrn_EarnoutNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ccrn_EarnoutNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414469175096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - 2021 Term Loan Credit Agreement (Details) - Term Loan - USD ($)<br></strong></div></th>
<th class="th"><div>Nov. 18, 2021</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">2021 Term Loan Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Quarterly installment amount</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">2021 Term Loan Credit Agreement | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest margin (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_DebtInstrumentVariableInterestRateFloor', window );">Interest margin floor (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">2021 Term Loan Credit Agreement, Aggregate Amount of All Possible Increases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">2021 Term Loan Credit Agreement, Incremental Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_DebtInstrumentVariableInterestRateFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Variable Interest Rate Floor</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_DebtInstrumentVariableInterestRateFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ccrn_A2021TermLoanCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ccrn_A2021TermLoanCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ccrn_A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ccrn_A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ccrn_A2021TermLoanCreditAgreementIncrementalTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ccrn_A2021TermLoanCreditAgreementIncrementalTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414469445704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - 2019 Loan Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 21, 2022</div></th>
<th class="th"><div>Oct. 25, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Nov. 18, 2021</div></th>
<th class="th"><div>Mar. 08, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources', window );">Amount of indebtedness permitted from other sources</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ccrn_SeniorSecuredAssetBasedLoanMember', window );">Senior Secured Asset-Based Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Line of credit term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="nump">$ 130,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR', window );">Basis spread on variable rate, additional credit spread associated with SOFR</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_LineOfCreditBorrowingBasePercentageOfAssets', window );">Borrowing base, percentage of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_LineOfCreditFacilityBorrowingBaseAvailability', window );">Borrowing base availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit, carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Borrowing availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 231,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Quarterly commitment fee on the average daily unused portion (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ccrn_SeniorSecuredAssetBasedLoanMember', window );">Senior Secured Asset-Based Loan | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest margin (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ccrn_SeniorSecuredAssetBasedLoanMember', window );">Senior Secured Asset-Based Loan | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest margin (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ccrn_SeniorSecuredAssetBasedLoanMember', window );">Senior Secured Asset-Based Loan | Swingline Sublimit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ccrn_SeniorSecuredAssetBasedLoanMember', window );">Senior Secured Asset-Based Loan | Standby Letters Of Credit Sublimit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit, Amount Of Indebtedness Permitted By Senior Secured Asset Based Loan To Be Borrowed From Other Sources</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_LineOfCreditBorrowingBasePercentageOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit, Borrowing Base, Percentage Of Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_LineOfCreditBorrowingBasePercentageOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Basis Spread On Variable Rate, Additional Credit Spread Associated With SOFR</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_LineOfCreditFacilityBorrowingBaseAvailability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Borrowing Base Availability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_LineOfCreditFacilityBorrowingBaseAvailability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ccrn_SeniorSecuredAssetBasedLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ccrn_SeniorSecuredAssetBasedLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_LineOfCreditSublimitAxis=ccrn_SwingLoansSublimitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_LineOfCreditSublimitAxis=ccrn_SwingLoansSublimitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_LineOfCreditSublimitAxis=ccrn_StandbyLettersOfCreditSublimitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_LineOfCreditSublimitAxis=ccrn_StandbyLettersOfCreditSublimitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414469406808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Note Payable (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment of notes payable</a></td>
<td class="nump">$ 2,426<span></span>
</td>
<td class="nump">$ 2,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ccrn_EarnoutNotesPayableMember', window );">Earnout Notes Payable | Mediscan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_NotePayableNumberOfPaymentInstallments', window );">Number of installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_NotePayableNumberOfInstallmentsPaid', window );">Number of installments paid | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment of notes payable</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_NotePayableNumberOfInstallmentsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Note Payable, Number Of Installments Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_NotePayableNumberOfInstallmentsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_NotePayableNumberOfPaymentInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Note Payable, Number Of Payment Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_NotePayableNumberOfPaymentInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ccrn_EarnoutNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ccrn_EarnoutNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ccrn_MediscanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ccrn_MediscanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414475135384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating lease, impairment loss</a></td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414469396776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 5,447<span></span>
</td>
<td class="nump">$ 7,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current</a></td>
<td class="nump">4,026<span></span>
</td>
<td class="nump">4,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - non-current</a></td>
<td class="nump">$ 9,704<span></span>
</td>
<td class="nump">$ 10,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.41%<span></span>
</td>
<td class="nump">6.39%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414472398744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Operating Lease Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 3,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">4,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">3,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">2,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">15,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount of lease payments representing interest</a></td>
<td class="num">(1,482)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">13,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: operating lease liabilities - current</a></td>
<td class="num">(4,026)<span></span>
</td>
<td class="num">$ (4,090)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - non-current</a></td>
<td class="nump">$ 9,704<span></span>
</td>
<td class="nump">$ 10,853<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414477366456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 1,383<span></span>
</td>
<td class="nump">$ 1,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets acquired under operating lease</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">802<span></span>
</td>
<td class="nump">914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease expense</a></td>
<td class="nump">1,144<span></span>
</td>
<td class="nump">849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable and other lease costs</a></td>
<td class="nump">$ 757<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414476469048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis (Details) - Level 1 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=ccrn_DeferredCompensationMember', window );">Deferred compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations', window );">Deferred compensation liability</a></td>
<td class="nump">$ 2,450<span></span>
</td>
<td class="nump">$ 2,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=ccrn_DeferredCompensationMember', window );">Deferred compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Deferred compensation asset</a></td>
<td class="nump">$ 1,305<span></span>
</td>
<td class="nump">$ 1,398<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of obligations measured on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=ccrn_DeferredCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=ccrn_DeferredCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=ccrn_DeferredCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=ccrn_DeferredCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414473460216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Carrying Amounts and Estimated Fair Values of Significant Financial Instrument that were not Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 16, 2021</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ccrn_WorkforceSolutionsGroupIncMember', window );">Workforce Solutions Group, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Earnout liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ccrn_SelectedIncMember', window );">Selected, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Earnout liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Carrying Amount | Workforce Solutions Group, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Earnout liabilities</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Carrying Amount | Selected, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Earnout liabilities</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value | Workforce Solutions Group, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Earnout liabilities</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value | Selected, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Earnout liabilities</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Senior Secured Asset-Based Loan | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LinesOfCreditFairValueDisclosure', window );">Senior Secured Asset-Based Loan</a></td>
<td class="nump">51,501<span></span>
</td>
<td class="nump">9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Senior Secured Asset-Based Loan | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LinesOfCreditFairValueDisclosure', window );">Senior Secured Asset-Based Loan</a></td>
<td class="nump">51,501<span></span>
</td>
<td class="nump">9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Earnout Notes Payable | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Note payable, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Earnout Notes Payable | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Note payable, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Term Loan | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Note payable, fair value</a></td>
<td class="nump">173,875<span></span>
</td>
<td class="nump">174,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Term Loan | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Note payable, fair value</a></td>
<td class="nump">$ 174,387<span></span>
</td>
<td class="nump">$ 174,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionQuantitativeDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ccrn_WorkforceSolutionsGroupIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ccrn_WorkforceSolutionsGroupIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ccrn_SelectedIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ccrn_SelectedIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ccrn_SeniorSecuredAssetBasedLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ccrn_SeniorSecuredAssetBasedLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ccrn_EarnoutNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ccrn_EarnoutNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414473477320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>installment </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 19, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased', window );">Common shares left remaining to repurchase under the plan (up to) (in shares)</a></td>
<td class="nump">510,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage', window );">Performance attainment percentage</a></td>
<td class="nump">120.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="nump">481,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet', window );">Vested in period, net (in shares)</a></td>
<td class="nump">419,500<span></span>
</td>
<td class="nump">317,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="nump">170,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation | $</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ccrn_OmnibusPlanMember', window );">Omnibus Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for share-based payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ccrn_OmnibusPlanMember', window );">Omnibus Plan | Member of the Board of Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments', window );">Number of vesting installments | installment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ccrn_OmnibusPlanMember', window );">Omnibus Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Shares repurchased and retired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Target Attainment Level, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other than Options, Vested In Period, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number Of Vesting Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ccrn_OmnibusPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ccrn_OmnibusPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414473435784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock awards, beginning balance (in shares) | shares</a></td>
<td class="nump">1,039,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">215,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(481,231)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock awards, ending balance (in shares) | shares</a></td>
<td class="nump">773,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested restricted stock awards, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">21.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">8.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested restricted stock awards, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 13.97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock awards, beginning balance (in shares) | shares</a></td>
<td class="nump">522,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">154,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(170,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock awards, ending balance (in shares) | shares</a></td>
<td class="nump">506,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested restricted stock awards, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">18.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">7.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested restricted stock awards, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414476153016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT DATA (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">$ 788,732<span></span>
</td>
<td class="nump">$ 329,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard', window );">Contribution income</a></td>
<td class="nump">111,866<span></span>
</td>
<td class="nump">38,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_SegmentReportingUnallocatedCorporateExpenses', window );">Corporate overhead</a></td>
<td class="nump">16,254<span></span>
</td>
<td class="nump">14,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,719<span></span>
</td>
<td class="nump">2,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_AcquisitionAndIntegrationRelatedCosts', window );">Acquisition and integration-related costs</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">480<span></span>
</td>
<td class="nump">1,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="nump">1,741<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">90,632<span></span>
</td>
<td class="nump">20,994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_NurseAndAlliedStaffingMember', window );">Nurse And Allied Staffing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">765,580<span></span>
</td>
<td class="nump">313,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard', window );">Contribution income</a></td>
<td class="nump">110,101<span></span>
</td>
<td class="nump">37,417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_PhysicianStaffingMember', window );">Physician Staffing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from services</a></td>
<td class="nump">23,152<span></span>
</td>
<td class="nump">16,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard', window );">Contribution income</a></td>
<td class="nump">$ 1,765<span></span>
</td>
<td class="nump">$ 1,428<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_AcquisitionAndIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition and integration-related costs include costs for prior acquisitions, costs incurred for potential transactions, and accretion and valuation adjustments on contingent consideration liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_AcquisitionAndIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Income Loss Before D And A Acquisition And Integration Contingent Consideration Restructuring Legal Impairment And Corporate Overheard</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_SegmentReportingUnallocatedCorporateExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Segment Reporting Unallocated Corporate Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_SegmentReportingUnallocatedCorporateExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_NurseAndAlliedStaffingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ccrn_NurseAndAlliedStaffingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ccrn_PhysicianStaffingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ccrn_PhysicianStaffingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414472238696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">28.90%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems', window );">Effective tax rate, excluding discrete items</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">9.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross increase to current year unrecognized tax benefits related to federal and state tax issues</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate, Continuing Operations, Excluding Discrete Items</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140414476069112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment of notes payable</a></td>
<td class="nump">$ 2,426<span></span>
</td>
<td class="nump">$ 2,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ccrn_EarnoutNotesPayableMember', window );">Earnout Notes Payable | Mediscan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ccrn_NotePayableNumberOfPaymentInstallments', window );">Number of installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment of notes payable</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ccrn_NotePayableNumberOfPaymentInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Note Payable, Number Of Payment Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ccrn_NotePayableNumberOfPaymentInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ccrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ccrn_EarnoutNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ccrn_EarnoutNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ccrn_MediscanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ccrn_MediscanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>ccrn-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ccrn="http://www.crosscountryhealthcare.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ccrn-20220331.xsd" xlink:type="simple"/>
    <context id="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if611e8a760f3465bbf65e189ed94ebea_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i023808945518453896c9849a64047565_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i798e22e9e3a7404081e3a29a885acc05_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6fff72e2c7d84067bc8bb587ed543e9d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied70dd28a73c4c189e455c91623e1d44_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa76515236cd482480f6edceb7a94048_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief163b9f5ac240299549314b12d15ebf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d3c21c3ae5d48b38f7e5a3af77e2ef9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i865e8e69b5b142859c5383ff31f2359e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i93c333a1a88c41d393ef6f6edbc2458a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iad9600f7c5114b968f1ff06bfc50d97e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie4839b02de7646be8e2c4ba6e1e37b8d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifa8d7b4e22284c6b95ba3cb021a55a3a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9d524f09611145fd86df59fb4e37a8e0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7268129d5164471885e991a61169c5cc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i865ee0b793804235a633da41b19d67ff_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i88d0c2f866014453b998a2cb5527a438_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0666e2b0300d466098ae349ea4af461e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i424193d374524b0cb3b883919afb98b6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1b2ed9790cf643579bf3f5081650b685_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8f999eb4ac1c4a3b8709a282faf39953_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i17355322df2d4d97a85fd60c4263a2fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i06767ccc204342efa16a4ea58b5982f0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia9576d1354b14e038a13830965d5d0a2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2985b0df2b8a4b409d8fe07243d00383_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic731257373c0453aa86943e4ce2a621e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2f82736797ee4a15bdf1e4bfe3b7c9e0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iace66efe42844004a2c58ff78aba6bfe_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0ffb9692d7734ac0865c2244a805f4d7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ide49c6639275478fb68a6d4fecf08904_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if2e65fe2c72345ff9fa9e61c8de78784_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i123bae647d194e0aa87a3eeb155cbbc1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i123a8da54abc487d9a3a822dee374164_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6f916c87f5844845bdfa58e6b0815916_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7bc99217a5124b478bddc5a0566fedaf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie8cefece24e942d5a8357106949400d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ccrn:ExitCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8c1b8bcd9e5449e8becb131e830d5a44_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iff6a7e25073a4b0aabe092d1fa279920_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ccrn:ExitCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6122e323ba5148c68be7d2705dc85e93_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifa36abaca6d64d6fb19eca4e3d5f6e6c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ccrn:ExitCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i31aa1178ab274d94b1a27d7f903f71ad_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8c6b46f3057c41ae9eb9f22f1e50b97d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibda3d097b5e34888bd4ce3a4a893ea70_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5c44d67d24f445078de88bbafab90724_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i389a47646ea1490cb51a4d0322234613_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i634a7f36c8c948219ef2af135e76fa0f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1f67d3164490454dbd2421830ac30a99_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie35cd3b9be00467fbc0b9f82f0c6c7da_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic536f98865ef4aab8fc1a7e5f5e582c9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i99d6ce4715d142a8bc5ce8abc5584a20_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i500ea7c7700c49718811026ceaaeafcd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:TemporaryStaffingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if1921e703c434f25a791d61baf58dc3c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i370fcef443ef4801a10e7a73c103bdf9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia5392157ee224225b8abb8f26dbf4fd9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ccrn:OtherServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ide86e9d4790e48b881466a5c8b847256_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iad432390898d40dabc7fcb10fd9dd0ae_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iddc9cc886ecc4548a8c7f9a14a4fa974_D20211216-20211216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:SelectedIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-16</startDate>
            <endDate>2021-12-16</endDate>
        </period>
    </context>
    <context id="i7d964a81b82746d29b5d9b48e092bd36_I20211216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:SelectedIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-16</instant>
        </period>
    </context>
    <context id="i99afbe71598e40ef97034d2edf4c411e_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:WorkforceSolutionsGroupIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="i93a5acd42c2647e59b5add3dd10a6587_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:WorkforceSolutionsGroupIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:WorkforceSolutionsGroupIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-08</instant>
        </period>
    </context>
    <context id="i6d3157fac8554807a3ac2c4583f90eca_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:WorkforceSolutionsGroupIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7c6769ab62314e58bd5be4d34d3bb062_I20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:WorkforceSolutionsGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-08</instant>
        </period>
    </context>
    <context id="id5ac2467fe50486d918b7f212f790165_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:WorkforceSolutionsGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="ib4c754f48f6947ce94f0c29faed347d7_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:MediscanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="idb38d75eba334b9c9661cc92d3d27b1e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:MediscanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i693a80db9468442f89e54f2d5e8f012c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:MediscanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifc034a2451eb4ad2a115858bbcbb76a3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:MediscanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i70a127889d9c4f5facf6c1e12bc5ef60_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:MediscanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic58e2e7af6004065bc3df5d18eda6a7f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ccrn:ShareBasedPaymentAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1a13d2d2a7ff4121984d558f70731480_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ccrn:ShareBasedPaymentAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i57ab4d2044634d1997af982de4e6ecf0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DatabasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibe98f92bed0843dbbed8160370da0659_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DatabasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idfe0db93f1004e008d12e054ef21e25c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i55a5b324377c46699174b4a56c307cf9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i47c182809d2b46f9a875cd3fd058837d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if89026b691fb4fb7b264f411d8d9b428_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i24a8be762a2a4907a7c8cca553b30556_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:NurseAndAlliedStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i94654808d0da4588b241ae072d795aa4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ccrn:PhysicianStaffingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i010ea7a8f38b4cb2ad448e4252b0d49d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:A2021TermLoanCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:A2021TermLoanCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id40b9c2a2b954b16991ea116d1d59043_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5621975f70784aa29783102660abc224_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b7ceee3e87f40c494783ab3badd4980_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18d296e84536494a9f07c3e749a9af7c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i82cd05f641874a9cbbe754810cef2c8a_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:A2021TermLoanCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="i96ec9493e07f4d46bfd5d30d2e5c107c_I20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:A2021TermLoanCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-08</instant>
        </period>
    </context>
    <context id="ib708536e37a243168ff725de39ebb968_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:A2021TermLoanCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="i5020fde8638840f299ef873613611b4e_I20211118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:A2021TermLoanCreditAgreementIncrementalTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-18</instant>
        </period>
    </context>
    <context id="idcf113a7dd6d430ab8a1df6502e3ce9b_I20211118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-18</instant>
        </period>
    </context>
    <context id="i57d3f89fcaaa4996af9b46ce7ea8742a_D20211118-20211118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:A2021TermLoanCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-18</startDate>
            <endDate>2021-11-18</endDate>
        </period>
    </context>
    <context id="if5ea6576089f4784ba8f14453a2b1f66_D20191025-20191025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-25</startDate>
            <endDate>2019-10-25</endDate>
        </period>
    </context>
    <context id="i60d48a75f49947d18289dbf4a324b770_I20191025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-25</instant>
        </period>
    </context>
    <context id="i8b3c8d82e07543fc99205a3c46af08b6_I20191025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ccrn:LineOfCreditSublimitAxis">ccrn:SwingLoansSublimitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-25</instant>
        </period>
    </context>
    <context id="i74307f2549e54ddd9cd8d5738288941a_I20191025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ccrn:LineOfCreditSublimitAxis">ccrn:StandbyLettersOfCreditSublimitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-25</instant>
        </period>
    </context>
    <context id="i4338d967d578487f9eb052fd67dd54b1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib19eb57fb973471fb2c67e92a4731b51_I20210308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-08</instant>
        </period>
    </context>
    <context id="i8b42bcc4941c443dae883bd802178090_I20211118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
        </entity>
        <period>
            <instant>2021-11-18</instant>
        </period>
    </context>
    <context id="i993410e5ec1b472995349d7ec0413a8c_I20220321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-21</instant>
        </period>
    </context>
    <context id="ia214024d55344795bd46a7a0c209b921_D20220321-20220321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-21</startDate>
            <endDate>2022-03-21</endDate>
        </period>
    </context>
    <context id="i95b50a07ae9e4b7695f586f6672f3956_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id0b6e77d084e4d879d689a6bca85f0e4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9559a9dd705841ba838ccd6ba16e3d37_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifa90684f57ec460f92896a283e5a90d3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i495fb315b409472492e63b658e2d1f69_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ccrn:DeferredCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie29a28d5bec04a9a89dd3aad07f2f287_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ccrn:DeferredCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i14c7086aa5ac419fb6760c4660fcbb9f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ccrn:DeferredCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic5ad89b3e2c34d8baa20d7aaa26a7b15_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ccrn:DeferredCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a52a3cb4a2040cb8b1b261cb0ee596b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i56ac23aba6aa4403a0bad0cba4ae5902_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0bf46906e48741ed893ff4a25259f391_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03cfea49b0a745c8963d38be107a4c1a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9bb29dbc47e244bdab628f989817d591_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia8bb48f02ecf42d9aeaca2be048ca7f8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i70a1b0b08d174a06886a168bcf0b7dbb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1748aed1a144618a97c5849fa459254_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ccrn:SeniorSecuredAssetBasedLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d432683d3b6435ba0c48c4efd028d04_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id9729fca27ba4b91a962fe9441fbd9cc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i77d0216a9f1b4205af250d1c80679b15_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id44bfe574f91423a9f3987ed1f01a93a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id106177b91204212b84484a1a875400b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:WorkforceSolutionsGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if502c32883544beda4be6398c9526e3e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:WorkforceSolutionsGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0553a10fc40144f8a768aabc88e29e1a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:WorkforceSolutionsGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i887ee4f6baf748d98a8def4c75aea2d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:WorkforceSolutionsGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i29edde64b2264b2aa2d76cb1e65aeb1b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:SelectedIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id8cf64a57b224d7c87d32895718dc0f5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:SelectedIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i39f100435cf24b988a31207c13a30eb4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:SelectedIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iae329d6e3c6a4d0d82b7abd882130b4f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ccrn:SelectedIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7193b285bbb7464db035176165d555b2_I20200519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ccrn:OmnibusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-19</instant>
        </period>
    </context>
    <context id="i9be85c5f345e42d68f473356014730e2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ccrn:OmnibusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i95016a76eb2d4e2bb36c7a7aceb60b64_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib59ced0f2c644556a8fe7a1d5d8f161a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia39ce4bfecff4fc1995df5920a618bf6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i34b2f55df92d4cbbb60faf19e1ead3be_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1517da25a84b468e8171eb1381c84236_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i00fee55829f24128b87768be086342b2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i95f14a36e510429b9814bb8e62be49e0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ccrn:OmnibusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0518a6d4c63940e7a94abc3ec794e0f8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2c0d11239d38482d878be193fb27e8f6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if94c5d761a504a69a0f377a89797162b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i50316e467cb343f5859c8c6826909b1c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ccrn:MediscanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id23201d22a6f4efdbb89f5ada9e5702d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001141103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ccrn:EarnoutNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ccrn:MediscanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="installment">
        <measure>ccrn:installment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80L2ZyYWc6MDNkNGY4YjEyMjFiNGM2NDkyYmNiMDJmNzcyYmRmMDAvdGFibGU6YWFiY2NiMDI2N2U1NGM1YjgyYjA3MDkxMjZiYzg5NGYvdGFibGVyYW5nZTphYWJjY2IwMjY3ZTU0YzViODJiMDcwOTEyNmJjODk0Zl8zLTEtMS0xLTI5MTU4_53b31d86-2ae2-429f-8fc6-1c54d368439d">0001141103</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80L2ZyYWc6MDNkNGY4YjEyMjFiNGM2NDkyYmNiMDJmNzcyYmRmMDAvdGFibGU6YWFiY2NiMDI2N2U1NGM1YjgyYjA3MDkxMjZiYzg5NGYvdGFibGVyYW5nZTphYWJjY2IwMjY3ZTU0YzViODJiMDcwOTEyNmJjODk0Zl80LTEtMS0xLTI5MTU4_e7b182ff-9936-42ce-86bf-605ed527f7f5">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80L2ZyYWc6MDNkNGY4YjEyMjFiNGM2NDkyYmNiMDJmNzcyYmRmMDAvdGFibGU6YWFiY2NiMDI2N2U1NGM1YjgyYjA3MDkxMjZiYzg5NGYvdGFibGVyYW5nZTphYWJjY2IwMjY3ZTU0YzViODJiMDcwOTEyNmJjODk0Zl81LTEtMS0xLTI5MTU4_b2ccf1fb-0b97-4f98-ada9-a3442fa565de">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80L2ZyYWc6MDNkNGY4YjEyMjFiNGM2NDkyYmNiMDJmNzcyYmRmMDAvdGFibGU6YWFiY2NiMDI2N2U1NGM1YjgyYjA3MDkxMjZiYzg5NGYvdGFibGVyYW5nZTphYWJjY2IwMjY3ZTU0YzViODJiMDcwOTEyNmJjODk0Zl82LTEtMS0xLTI5MTU4_661e49fa-52a0-4058-85ba-06aa7830e52f">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80L2ZyYWc6MDNkNGY4YjEyMjFiNGM2NDkyYmNiMDJmNzcyYmRmMDAvdGFibGU6YWFiY2NiMDI2N2U1NGM1YjgyYjA3MDkxMjZiYzg5NGYvdGFibGVyYW5nZTphYWJjY2IwMjY3ZTU0YzViODJiMDcwOTEyNmJjODk0Zl83LTEtMS0xLTI5MTU4_fdfd3078-48ca-461d-a73a-debafab65a69">false</dei:AmendmentFlag>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfNC0wLTEtMS0yOTE1OA_6dda0d30-5890-4c9f-8681-d8b74b39df62">http://fasb.org/us-gaap/2021-01-31#ServiceMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfNC0wLTEtMS0yOTE1OA_ba26ef12-921a-472b-ab46-50883adf7edb">http://fasb.org/us-gaap/2021-01-31#ServiceMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <dei:DocumentType
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzg1_9357359c-c5ac-41d4-8b4d-bc45cc9e0bbe">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzc5_6cdd5c09-d6b0-4ad3-a52f-40b090fc4517">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl83Mjc1_43e3320b-600f-43ef-979b-5239fa97b960">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzgw_8eb87418-6921-4b8c-870c-d7fbf80e378f">false</dei:DocumentTransitionReport>
    <dei:EntityRegistrantName
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzgx_10aa0b81-beb3-4b98-8e67-85cd239ddaa0">CROSS COUNTRY HEALTHCARE, INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGFibGU6NGEzZDc2NGJkMTU5NDJkMWJjMWZhNTdhZTA2NjcyN2YvdGFibGVyYW5nZTo0YTNkNzY0YmQxNTk0MmQxYmMxZmE1N2FlMDY2NzI3Zl8wLTAtMS0xLTI5MTU4_346f4f84-8950-4c7f-9125-409ce6381ad4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGFibGU6NGEzZDc2NGJkMTU5NDJkMWJjMWZhNTdhZTA2NjcyN2YvdGFibGVyYW5nZTo0YTNkNzY0YmQxNTk0MmQxYmMxZmE1N2FlMDY2NzI3Zl8wLTEtMS0xLTI5MTU4_d691f72a-4dcb-427b-b848-fb02a3113d17">0-33169</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGFibGU6NGEzZDc2NGJkMTU5NDJkMWJjMWZhNTdhZTA2NjcyN2YvdGFibGVyYW5nZTo0YTNkNzY0YmQxNTk0MmQxYmMxZmE1N2FlMDY2NzI3Zl8wLTItMS0xLTI5MTU4_b75c6cb0-3eb3-4e54-b296-e5e83f22b204">13-4066229</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzcx_35cd143d-9883-43f4-a184-4e8ee6f725dd">6551 Park of Commerce Boulevard, N.W.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzc0_b8a83857-905f-499b-a250-fb82480e3af6">Boca Raton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzc1_4ca1e5c2-6686-4e3e-b8eb-4afae75717e9">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzg4_13f51a7a-a802-4813-830f-76d37e43f011">33487</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzkx_11467b27-b957-4de1-9da5-c00a600e1d96">561</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzgy_80cb1e8b-7747-493a-915d-a0b537dcb203">998-2232</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGFibGU6MjdlOTQ0ZDBjMDkyNGZmOWExYzY4ZGViMDRjMjlmZGEvdGFibGVyYW5nZToyN2U5NDRkMGMwOTI0ZmY5YTFjNjhkZWIwNGMyOWZkYV8xLTAtMS0xLTI5MTU4_57611d0d-7f31-4a80-9cd5-294cf5faa608">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGFibGU6MjdlOTQ0ZDBjMDkyNGZmOWExYzY4ZGViMDRjMjlmZGEvdGFibGVyYW5nZToyN2U5NDRkMGMwOTI0ZmY5YTFjNjhkZWIwNGMyOWZkYV8xLTEtMS0xLTI5MTU4_e721cb22-01f3-4d9c-803a-ff10322bf655">CCRN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGFibGU6MjdlOTQ0ZDBjMDkyNGZmOWExYzY4ZGViMDRjMjlmZGEvdGFibGVyYW5nZToyN2U5NDRkMGMwOTI0ZmY5YTFjNjhkZWIwNGMyOWZkYV8xLTItMS0xLTI5MTU4_0f40e6c1-b1a8-4e9d-af59-86519f62b32a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzky_2d2ca179-5551-4be2-992b-2e8364518bad">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzkz_d6f4bc17-2773-4ba3-923e-e403182c84cf">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzc2_186f7bec-ccb3-44c4-8f37-6a440b4b56aa">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzg5_d1e1b242-d90e-4930-ab28-76dfde1a7815">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85Mzgz_ad6e0743-3464-4b2e-83f3-f5a84bf4bdfe">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl80Mzk4MDQ2NTIwNTAz_d6e0707d-9db4-4390-bd98-78af24021eb1">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="if611e8a760f3465bbf65e189ed94ebea_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xL2ZyYWc6MjE4YzlhYzI2NWVhNGRkNmFhNzMzNmVkNWIyOTlkNWIvdGV4dHJlZ2lvbjoyMThjOWFjMjY1ZWE0ZGQ2YWE3MzM2ZWQ1YjI5OWQ1Yl85MzA2_5c9db77d-5767-4992-8ccf-713b6c41d8cc"
      unitRef="shares">38213868000</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNC0xLTEtMS0yOTE1OA_794969b6-9dc8-41cf-a607-7c9b01c0dbbd"
      unitRef="usd">1208000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNC0zLTEtMS0yOTE1OA_b2bcc68b-844c-4256-9f6c-557e78595a9f"
      unitRef="usd">1036000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNS0wLTEtMS0yOTE1OC90ZXh0cmVnaW9uOmU3MDQxOGVhYThlNDRkMzU5ZWE0ZTU0MTEzNjQ5NTg0XzQ3_76cebee4-8616-4c12-ae19-6564c242c6e3"
      unitRef="usd">9141000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNS0wLTEtMS0yOTE1OC90ZXh0cmVnaW9uOmU3MDQxOGVhYThlNDRkMzU5ZWE0ZTU0MTEzNjQ5NTg0XzYz_2c785537-2856-44f9-826d-ace102157932"
      unitRef="usd">6881000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNS0xLTEtMS0yOTE1OA_891dd19a-27b6-49a8-9bbf-8b4a243859bf"
      unitRef="usd">677432000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNS0zLTEtMS0yOTE1OA_4d775b85-4bf5-4255-a140-b0ea29e09e2b"
      unitRef="usd">493910000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNi0xLTEtMS0yOTE1OA_573bb87a-80a2-40f8-908a-e0829582a3de"
      unitRef="usd">7689000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNi0zLTEtMS0yOTE1OA_805a9d0c-4270-4a53-976b-16ea6bcba95c"
      unitRef="usd">7648000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:InsuranceSettlementsReceivableCurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNy0xLTEtMS0yOTE1OA_ac703da3-6b76-4f84-ad5e-e172e8a4af4d"
      unitRef="usd">5336000</us-gaap:InsuranceSettlementsReceivableCurrent>
    <us-gaap:InsuranceSettlementsReceivableCurrent
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNy0zLTEtMS0yOTE1OA_f4510074-a6cc-4fa9-9202-b6efee4f70a8"
      unitRef="usd">5041000</us-gaap:InsuranceSettlementsReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfOC0xLTEtMS0yOTE1OA_c95c2940-0c7a-4720-9ca8-f45bff5a3aba"
      unitRef="usd">641000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfOC0zLTEtMS0yOTE1OA_2fc15305-5c6a-443a-832d-36361aab95ae"
      unitRef="usd">638000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfOS0xLTEtMS0yOTE1OA_e1042c67-02d0-46ee-b975-53da9fe8d7c8"
      unitRef="usd">692306000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfOS0zLTEtMS0yOTE1OA_755fbfc3-407d-47bc-9ce1-30dc77715ade"
      unitRef="usd">508273000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTAtMC0xLTEtMjkxNTgvdGV4dHJlZ2lvbjpkZjhkZmI4NTMxZjA0YzZkYjk2ZjFhYTM2YTg4NGMwMV8xNjQ5MjY3NDQxNzU1_014f6a0e-042c-44ab-a147-61a8076b013c"
      unitRef="usd">18092000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTAtMC0xLTEtMjkxNTgvdGV4dHJlZ2lvbjpkZjhkZmI4NTMxZjA0YzZkYjk2ZjFhYTM2YTg4NGMwMV8xNjQ5MjY3NDQxNzUy_a023a5f3-2e87-4005-b8df-914f9701bcbb"
      unitRef="usd">17729000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTAtMS0xLTEtMjkxNTg_37fd1375-ea1b-4cca-8023-87a6a44f9e64"
      unitRef="usd">16706000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTAtMy0xLTEtMjkxNTg_626fb72a-8bde-4eeb-abdc-e1bb86e9d3f2"
      unitRef="usd">15833000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTEtMS0xLTEtMjkxNTg_e41d2eb2-c697-4bb6-b5e5-e70efd11003d"
      unitRef="usd">5447000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTEtMy0xLTEtMjkxNTg_9b2ccf8b-da3d-4721-9c4f-e6daaa263b2a"
      unitRef="usd">7488000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTItMS0xLTEtMjkxNTg_81a7b4fc-3379-43e5-88e1-e86881864443"
      unitRef="usd">119490000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTItMy0xLTEtMjkxNTg_854bba10-9f59-4959-8410-7e6d45ba2b39"
      unitRef="usd">119490000</us-gaap:Goodwill>
    <us-gaap:IndefiniteLivedTradeNames
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTMtMS0xLTEtMjkxNTg_24dab7ad-fe21-432b-9489-34f85154f627"
      unitRef="usd">5900000</us-gaap:IndefiniteLivedTradeNames>
    <us-gaap:IndefiniteLivedTradeNames
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTMtMy0xLTEtMjkxNTg_7d2d3c64-0d09-4d39-be9d-3c39b73c5854"
      unitRef="usd">5900000</us-gaap:IndefiniteLivedTradeNames>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTQtMS0xLTEtMjkxNTg_d1b04310-1273-4608-9ec2-d7a5cf4836a9"
      unitRef="usd">40543000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTQtMy0xLTEtMjkxNTg_4d635149-a268-4750-bcc5-11381dc3f126"
      unitRef="usd">42344000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTUtMS0xLTEtMzIxMzI_6c79acfb-3e67-4e88-95a9-87ccb2df8379"
      unitRef="usd">9117000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTUtMy0xLTEtMzIxMzI_3ad0a21b-ca0d-4164-af4d-a423006c1a58"
      unitRef="usd">11525000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTUtMS0xLTEtMjkxNTg_be89089c-e92e-49a5-87ca-ce97ec161ef6"
      unitRef="usd">26925000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTUtMy0xLTEtMjkxNTg_6dcb67f2-5aaf-4016-b4c5-6b91d4408d0d"
      unitRef="usd">21956000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTYtMS0xLTEtMjkxNTg_858070fc-a507-4f58-b867-708728214496"
      unitRef="usd">916434000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMTYtMy0xLTEtMjkxNTg_3be7d6be-a606-4705-9989-0151e8c339c4"
      unitRef="usd">732809000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjAtMS0xLTEtMjkxNTg_54cb512a-b6d5-473d-9455-5923ccb6c56a"
      unitRef="usd">164224000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjAtMy0xLTEtMjkxNTg_0d588d0b-8e65-41e7-af36-251eb40b2370"
      unitRef="usd">109753000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjEtMS0xLTEtMjkxNTg_de30d4c7-1efe-41f9-853f-4b66b75aa7aa"
      unitRef="usd">74733000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjEtMy0xLTEtMjkxNTg_0d5f85a2-8546-4bbf-8471-a0ca7cb030d6"
      unitRef="usd">65580000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjItMS0xLTEtMjkxNTg_cae04602-7c62-4ffa-8a6e-60cef5986955"
      unitRef="usd">1750000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjItMy0xLTEtMjkxNTg_9e2b648e-2387-438d-957b-b3b7d7dad65b"
      unitRef="usd">4176000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjMtMS0xLTEtMjkxNTg_4c10032b-3140-4954-98d4-2c51027dfb5e"
      unitRef="usd">4026000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjMtMy0xLTEtMjkxNTg_63b18203-e058-4194-9ae7-fb06020483f4"
      unitRef="usd">4090000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjUtMS0xLTEtMzIxNDM_5c188a2e-6147-4453-ace8-02d6e989b5f9"
      unitRef="usd">29140000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjUtMy0xLTEtMzIxNDM_5dae2c57-351d-4917-9217-f1c6e1f96afb"
      unitRef="usd">7307000</us-gaap:TaxesPayableCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjQtMS0xLTEtMjkxNTg_9138c97d-b808-44bd-a1fa-bf824e89dc22"
      unitRef="usd">8250000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjQtMy0xLTEtMjkxNTg_0fd728ff-6968-42ab-b1c2-a0df7a072c2e"
      unitRef="usd">7500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjUtMS0xLTEtMjkxNTg_dec2d693-5486-435e-9fd0-d19a956f36b8"
      unitRef="usd">1122000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjUtMy0xLTEtMjkxNTg_91f33308-7991-46db-bae7-bff7607a4dcf"
      unitRef="usd">1364000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjYtMS0xLTEtMjkxNTg_cad3dd81-fa34-4454-af27-9a28a4cf8e28"
      unitRef="usd">283245000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjYtMy0xLTEtMjkxNTg_d41e6b50-c35c-40c5-9144-8cbd7eee3400"
      unitRef="usd">199770000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLongTermDebtNoncurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjctMS0xLTEtMjkxNTg_e62af5e7-29dd-4b4f-af56-5ee5687136c1"
      unitRef="usd">218475000</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:OtherLongTermDebtNoncurrent
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjctMy0xLTEtMjkxNTg_f0ea74f4-3946-4b9e-be3a-de7acb8e49c9"
      unitRef="usd">176366000</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjgtMS0xLTEtMjkxNTg_a08a5177-14b4-4efb-900c-45fb5f721756"
      unitRef="usd">9704000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjgtMy0xLTEtMjkxNTg_5fe13b3d-6383-4c49-8565-f5671011e6e8"
      unitRef="usd">10853000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjktMS0xLTEtMjkxNTg_dbefa421-03f6-45c0-ab12-fc9e44542737"
      unitRef="usd">207000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMjktMy0xLTEtMjkxNTg_76d6ce81-ad34-40a6-b88e-63b7b44c769d"
      unitRef="usd">190000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzAtMS0xLTEtMjkxNTg_7075e72f-6417-4f35-9bac-327776a4197c"
      unitRef="usd">26443000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzAtMy0xLTEtMjkxNTg_f7013942-d793-4253-a5a8-d3e3c9fdbc34"
      unitRef="usd">25314000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzEtMS0xLTEtMjkxNTg_0cd4dda6-5649-409c-8792-405ceab27cd6"
      unitRef="usd">8250000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzEtMy0xLTEtMjkxNTg_f3035dba-2392-4db3-9321-3250883946d4"
      unitRef="usd">9000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzItMS0xLTEtMjkxNTg_b867e760-646b-4133-8cd1-e3e8f87d9e93"
      unitRef="usd">14037000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzItMy0xLTEtMjkxNTg_7d2872a7-7a5d-4cc5-a5a2-ecd58470c295"
      unitRef="usd">13788000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzMtMS0xLTEtMjkxNTg_97041cd6-c14d-46d4-aa3f-79e01eaae9d4"
      unitRef="usd">560361000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzMtMy0xLTEtMjkxNTg_a0f75c26-0af9-4948-be9c-31e55328e355"
      unitRef="usd">435281000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzUtMS0xLTEtMjkxNTg_c8354567-fbeb-4cc4-8021-ef05d0818ab8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i023808945518453896c9849a64047565_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzUtMy0xLTEtMjkxNTg_80ca81b3-04a4-4a1a-9e65-68b35c929c3e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzgtMS0xLTEtMjkxNTg_7d33a462-2cab-4db1-9e46-592d19ccca30"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzgtMy0xLTEtMjkxNTg_541ffa6e-b465-44a1-884f-0bae570f60da"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzktMS0xLTEtMjkxNTg_479a97b4-bd7e-4315-b573-c53e515d3c21"
      unitRef="usd">318125000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfMzktMy0xLTEtMjkxNTg_b19fb58d-99aa-49fc-8a8c-03ffc808f5dd"
      unitRef="usd">321552000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNDAtMS0xLTEtMjkxNTg_8301d9a7-b948-4087-b5ab-8d92da758be2"
      unitRef="usd">-1304000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNDAtMy0xLTEtMjkxNTg_f4ce58ae-9ba7-4f8b-8a25-ef817a0db42b"
      unitRef="usd">-1293000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNDEtMS0xLTEtMjkxNTg_0ff1e621-2b19-447a-a42b-222b657f6655"
      unitRef="usd">39248000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNDEtMy0xLTEtMjkxNTg_5e3aa7b4-6269-47a6-b145-19c71a9fa649"
      unitRef="usd">-22735000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNDQtMS0xLTEtMjkxNTg_13bf172a-0291-4c31-952d-d75d2be9bc08"
      unitRef="usd">356073000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNDQtMy0xLTEtMjkxNTg_d1130ba6-2820-4814-a6f8-716bb98e77da"
      unitRef="usd">297528000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNDUtMS0xLTEtMjkxNTg_9f71fbf7-9768-4d86-9e47-2995365fed4f"
      unitRef="usd">916434000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8xOS9mcmFnOmYyMjA5OWNmNDdkYjQ0YjliNGU0MGMwYTBlYTI5ODBhL3RhYmxlOjJkYWZlZjc2MzZmNDRjMTJhYjI3N2IyZWNmY2QxYzI1L3RhYmxlcmFuZ2U6MmRhZmVmNzYzNmY0NGMxMmFiMjc3YjJlY2ZjZDFjMjVfNDUtMy0xLTEtMjkxNTg_d3fba70e-808e-49b6-9be6-869e3f137745"
      unitRef="usd">732809000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfNC0xLTEtMS0yOTE1OA_b68a049e-eb64-42aa-a54d-7409a2cacf6c"
      unitRef="usd">788732000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfNC0zLTEtMS0yOTE1OA_e22305dd-2a61-473b-a09f-79af41673e1a"
      unitRef="usd">329241000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DirectOperatingCosts
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfNi0xLTEtMS0yOTE1OA_fe6c2b19-056e-4b50-a561-bc40302000d7"
      unitRef="usd">613938000</us-gaap:DirectOperatingCosts>
    <us-gaap:DirectOperatingCosts
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfNi0zLTEtMS0yOTE1OA_4d676f75-f698-4978-8f4e-281ea441a72a"
      unitRef="usd">257776000</us-gaap:DirectOperatingCosts>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfNy0xLTEtMS0yOTE1OA_b1fb26f6-ff5a-4b7d-983c-f109cd5dfca5"
      unitRef="usd">76813000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfNy0zLTEtMS0yOTE1OA_1cf05beb-1881-47ab-919d-f19e6d7c1edf"
      unitRef="usd">46327000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfOC0xLTEtMS0yOTE1OA_fbf859ff-c5c4-4972-baea-9b4d457cba31"
      unitRef="usd">2369000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfOC0zLTEtMS0yOTE1OA_af99e25d-7e23-4c3f-82ca-51b6ae8ed09c"
      unitRef="usd">504000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfOS0xLTEtMS0yOTE1OA_de4e9cbc-2759-413a-ac05-5cd2d0886411"
      unitRef="usd">2719000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfOS0zLTEtMS0yOTE1OA_11c0de07-f4d2-4cc4-9ef7-641fa492de3b"
      unitRef="usd">2253000</us-gaap:DepreciationDepletionAndAmortization>
    <ccrn:AcquisitionAndIntegrationRelatedCosts
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTAtMS0xLTEtMjkxNTg_36f4cbf9-ad6e-41fa-8c86-01676e0b0821"
      unitRef="usd">40000</ccrn:AcquisitionAndIntegrationRelatedCosts>
    <ccrn:AcquisitionAndIntegrationRelatedCosts
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTAtMy0xLTEtMjkxNTg_37941326-f7dc-496c-afab-eb38ef72afff"
      unitRef="usd">0</ccrn:AcquisitionAndIntegrationRelatedCosts>
    <us-gaap:RestructuringCharges
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTEtMS0xLTEtMjkxNTg_409d9fe3-66e5-4313-b4e0-6bfe42c5e99c"
      unitRef="usd">480000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTEtMy0xLTEtMjkxNTg_60254c99-2626-4d5e-bf04-e9c403ecd96d"
      unitRef="usd">1238000</us-gaap:RestructuringCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTItMS0xLTEtMjkxNTg_1d0fc2d2-8bc8-461d-8908-bc3dc505cbf2"
      unitRef="usd">1741000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTItMy0xLTEtMjkxNTg_b1411083-c016-4bf8-9668-597f1ecfea9a"
      unitRef="usd">149000</us-gaap:AssetImpairmentCharges>
    <us-gaap:CostsAndExpenses
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTMtMS0xLTEtMjkxNTg_0a00b429-5f94-49c8-80e8-99387d18a35a"
      unitRef="usd">698100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTMtMy0xLTEtMjkxNTg_3dcf3f7b-6fd4-47ff-bc83-12f459926a94"
      unitRef="usd">308247000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTQtMS0xLTEtMjkxNTg_302285c3-1e22-48d9-965f-21a99fa50edb"
      unitRef="usd">90632000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTQtMy0xLTEtMjkxNTg_9fc58c9a-7ba8-4374-bee3-8cc987368438"
      unitRef="usd">20994000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTYtMS0xLTEtMjkxNTg_147b74fb-c920-4205-a08a-8f685b750f7a"
      unitRef="usd">3521000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTYtMy0xLTEtMjkxNTg_0d852673-bbec-4577-9c4e-363be80b42ba"
      unitRef="usd">671000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTctMS0xLTEtMjkxNTg_a807185d-fb56-4e50-922f-3eab1a1c0c5c"
      unitRef="usd">8000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTctMy0xLTEtMjkxNTg_990a9cc7-4c3b-4d17-ac94-e48bbc7c57e9"
      unitRef="usd">37000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTgtMS0xLTEtMjkxNTg_7d63e522-9f69-4fd1-baf2-e8a87e5d5b96"
      unitRef="usd">87119000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTgtMy0xLTEtMjkxNTg_2d8be03c-51f7-48fa-8c22-8407a0232ccd"
      unitRef="usd">20360000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTktMS0xLTEtMjkxNTg_d204518c-0fc4-4ab7-859d-e7d62bdd8ded"
      unitRef="usd">25136000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMTktMy0xLTEtMjkxNTg_41ce910b-50eb-4637-b619-4647eb5cd384"
      unitRef="usd">912000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjItMS0xLTEtMjkxNTg_37d00c1d-ae6d-4299-9147-53f285ccbabc"
      unitRef="usd">61983000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjItMy0xLTEtMjkxNTg_fffa8766-b7fb-49b2-bf0d-6242e5236c1c"
      unitRef="usd">19448000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjUtMS0xLTEtMzI3Njg_f0609260-96f4-4496-90ff-5f99d2a252bd"
      unitRef="usd">-11000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjUtMy0xLTEtMzI3NjA_c0e9de15-9b35-435e-bb33-9e8012add9b8"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjYtMS0xLTEtMzI3ODA_e4f2d81c-6b93-4427-b468-ac31248b85f6"
      unitRef="usd">61972000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjYtMy0xLTEtMzI3NzQ_898d1ec4-0cc5-4b76-b4bc-c27d45d64239"
      unitRef="usd">19442000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjQtMS0xLTEtMjkxNTg_ac2aad56-e2b6-4f42-80a9-93b9f50687e1"
      unitRef="usdPerShare">1.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjQtMy0xLTEtMjkxNTg_6caa8afd-1883-4acf-a368-7929a8d6f596"
      unitRef="usdPerShare">0.54</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjYtMS0xLTEtMjkxNTg_fd85843b-1ed6-4437-a8a4-09f42884024d"
      unitRef="usdPerShare">1.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjYtMy0xLTEtMjkxNTg_ff72e80c-9a75-45dc-a52e-5c74b90065b2"
      unitRef="usdPerShare">0.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjktMS0xLTEtMjkxNTg_c78aab41-3bb6-4a73-be26-c74d9b4e0941"
      unitRef="shares">37028000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMjktMy0xLTEtMjkxNTg_10f88dc3-5903-4235-97a8-e6052488cb8d"
      unitRef="shares">36181000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMzAtMS0xLTEtMjkxNTg_c4ae6181-c02d-4f44-9b71-6dd1ef05fba7"
      unitRef="shares">37973000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yMi9mcmFnOjI3ZDE3YTFmMzdmYzQ1OWViYzBkNTE0MzRlYjIzODk0L3RhYmxlOmFmNDA5MWQ4MWQwMTQ1NGE4YmFlZDcwNmQ3YTFhMTk1L3RhYmxlcmFuZ2U6YWY0MDkxZDgxZDAxNDU0YThiYWVkNzA2ZDdhMWExOTVfMzAtMy0xLTEtMjkxNTg_4c247fc0-f27f-4836-84d1-f6e3a0ea3cb8"
      unitRef="shares">37034000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="i798e22e9e3a7404081e3a29a885acc05_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMi0xLTEtMS0yOTE1OA_5b376691-5009-4ca0-97b2-4dee5847b226"
      unitRef="shares">37024000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i798e22e9e3a7404081e3a29a885acc05_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMi0zLTEtMS0yOTE1OA_cec1d3d5-4400-459e-a655-bf314c4935f5"
      unitRef="usd">4000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6fff72e2c7d84067bc8bb587ed543e9d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMi01LTEtMS0yOTE1OA_7b87ed21-96fc-4a19-bb15-159e2676f937"
      unitRef="usd">321552000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ied70dd28a73c4c189e455c91623e1d44_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMi03LTEtMS0yOTE1OA_42dc6aa2-2f6a-4f8d-9134-f0a26ac89347"
      unitRef="usd">-1293000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaa76515236cd482480f6edceb7a94048_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMi05LTEtMS0yOTE1OA_34e82771-49b3-4e32-9da4-af4ce9fd0d12"
      unitRef="usd">-22735000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief163b9f5ac240299549314b12d15ebf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMi0xMS0xLTEtMjkxNTg_d7275fc1-f11c-48db-a7b0-84841b0f11b4"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMi0xMy0xLTEtMjkxNTg_19e90ca6-ff4d-46d0-aa5e-485ddab2052c"
      unitRef="usd">297528000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i2d3c21c3ae5d48b38f7e5a3af77e2ef9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMy0xLTEtMS0yOTE1OA_22774c73-474f-4843-8e55-37c46fe06124"
      unitRef="shares">419000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i865e8e69b5b142859c5383ff31f2359e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMy01LTEtMS0yOTE1OA_76057cd4-22e5-451c-ba5d-48654b82068b"
      unitRef="usd">-5028000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMy0xMy0xLTEtMjkxNTg_1d2aba6c-347b-4ea6-af3b-e81a65d20c97"
      unitRef="usd">-5028000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i865e8e69b5b142859c5383ff31f2359e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfNC01LTEtMS0yOTE1OA_f6e49a78-118a-447d-b343-4434202b6497"
      unitRef="usd">1601000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfNC0xMy0xLTEtMjkxNTg_9b6ea6a3-85ff-41d4-a9bf-7967a8126c31"
      unitRef="usd">1601000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i93c333a1a88c41d393ef6f6edbc2458a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfNS03LTEtMS0yOTE1OA_006edf2e-174a-4b4a-ac5d-06702de8c2d3"
      unitRef="usd">-11000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfNS0xMy0xLTEtMjkxNTg_39c358c0-aa99-4387-a3bd-7c1c50596843"
      unitRef="usd">-11000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="iad9600f7c5114b968f1ff06bfc50d97e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfOC05LTEtMS0yOTE1OA_38cbd0be-5612-425a-b042-ac4d7f055d51"
      unitRef="usd">61983000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfOC0xMy0xLTEtMjkxNTg_71e603d0-966f-4bb9-90cc-293bcc34792a"
      unitRef="usd">61983000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ie4839b02de7646be8e2c4ba6e1e37b8d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfOS0xLTEtMS0yOTE1OA_f4e3ca22-7f09-410e-90db-fdbafec5fbad"
      unitRef="shares">37443000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie4839b02de7646be8e2c4ba6e1e37b8d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfOS0zLTEtMS0yOTE1OA_c23739f2-3578-44d3-8b31-21d4cad07db7"
      unitRef="usd">4000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa8d7b4e22284c6b95ba3cb021a55a3a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfOS01LTEtMS0yOTE1OA_961e421d-9554-4cf6-9fb8-51247bfb6fd4"
      unitRef="usd">318125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9d524f09611145fd86df59fb4e37a8e0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfOS03LTEtMS0yOTE1OA_af5f23bf-133a-4584-9d30-3452a1675d84"
      unitRef="usd">-1304000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7268129d5164471885e991a61169c5cc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfOS05LTEtMS0yOTE1OA_77e737fe-97d1-4fd0-8c01-27168e7c8bd0"
      unitRef="usd">39248000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i865ee0b793804235a633da41b19d67ff_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfOS0xMS0xLTEtMjkxNTg_d2ad1d3f-3921-4ca1-901b-8fb66e1f729d"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfOS0xMy0xLTEtMjkxNTg_f7b60c06-73b3-4aa6-8c3c-08738ae8b8e2"
      unitRef="usd">356073000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i88d0c2f866014453b998a2cb5527a438_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTMtMS0xLTEtMjkxNTg_f2f8d2c8-8c7a-4dda-9717-ee06d69f443a"
      unitRef="shares">36177000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i88d0c2f866014453b998a2cb5527a438_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTMtMy0xLTEtMjkxNTg_77531302-1ea9-4ea1-8929-9055b0c300e2"
      unitRef="usd">4000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0666e2b0300d466098ae349ea4af461e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTMtNS0xLTEtMjkxNTg_052e5790-0a1b-46f8-81d4-bce8265a5735"
      unitRef="usd">310388000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i424193d374524b0cb3b883919afb98b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTMtNy0xLTEtMjkxNTg_a5abcd34-4627-426f-910c-6e00c6c07d56"
      unitRef="usd">-1280000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1b2ed9790cf643579bf3f5081650b685_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTMtOS0xLTEtMjkxNTg_157b08df-2cc7-44f3-b6ea-ac21b5c7061e"
      unitRef="usd">-154737000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f999eb4ac1c4a3b8709a282faf39953_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTMtMTEtMS0xLTI5MTU4_e3151e57-983e-451d-8f84-2e2761da70b4"
      unitRef="usd">534000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i17355322df2d4d97a85fd60c4263a2fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTMtMTMtMS0xLTI5MTU4_82c0b49c-cf3e-4bba-8149-47f402fbf61a"
      unitRef="usd">154909000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i06767ccc204342efa16a4ea58b5982f0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTQtMS0xLTEtMjkxNTg_7bd39d12-95b3-41c5-b53f-497d3076eb88"
      unitRef="shares">318000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia9576d1354b14e038a13830965d5d0a2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTQtNS0xLTEtMjkxNTg_f4ec7375-3056-4f4a-806a-25e87707078f"
      unitRef="usd">-2026000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTQtMTMtMS0xLTI5MTU4_693ba2cd-3465-4031-9645-d5491559a28e"
      unitRef="usd">-2026000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia9576d1354b14e038a13830965d5d0a2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTUtNS0xLTEtMjkxNTg_1029367a-5452-4261-901e-ccd0e31e6ac0"
      unitRef="usd">1349000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTUtMTMtMS0xLTI5MTU4_e3315471-7188-40fc-8216-22ca6e1f4bc1"
      unitRef="usd">1349000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i2985b0df2b8a4b409d8fe07243d00383_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTYtNy0xLTEtMjkxNTg_4fa24d48-1ce2-48f3-8327-a002bbd352f6"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTYtMTMtMS0xLTI5MTU4_d3ba781d-7918-40c8-89ce-4ee3d6164b37"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ic731257373c0453aa86943e4ce2a621e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTgtOS0xLTEtMjkxNTg_929bbea4-b2bc-4fee-afde-83bfa9f8a92c"
      unitRef="usd">19448000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTgtMTMtMS0xLTI5MTU4_c261e007-f0f4-4372-a489-6314de4bc910"
      unitRef="usd">19448000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i2f82736797ee4a15bdf1e4bfe3b7c9e0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTktMS0xLTEtMjkxNTg_2202c118-7d5c-4579-9fb8-1c0fe30c621a"
      unitRef="shares">36495000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f82736797ee4a15bdf1e4bfe3b7c9e0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTktMy0xLTEtMjkxNTg_e370cd26-4971-45c7-addb-b2b80e54a5a8"
      unitRef="usd">4000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iace66efe42844004a2c58ff78aba6bfe_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTktNS0xLTEtMjkxNTg_ec94bf02-e6f4-4fdb-b9ac-ed84eac54beb"
      unitRef="usd">309711000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ffb9692d7734ac0865c2244a805f4d7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTktNy0xLTEtMjkxNTg_9a2a91a2-02fd-4bd3-969c-c57493dc5f54"
      unitRef="usd">-1286000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ide49c6639275478fb68a6d4fecf08904_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTktOS0xLTEtMjkxNTg_eaa5a4d4-da57-41da-bb30-784227bcd40f"
      unitRef="usd">-135289000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2e65fe2c72345ff9fa9e61c8de78784_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTktMTEtMS0xLTI5MTU4_a264cff1-3cdb-4a89-a3a6-a1e653d4f557"
      unitRef="usd">534000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i123bae647d194e0aa87a3eeb155cbbc1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8yOC9mcmFnOjMxZGJmNzA3NTEzMDRhNWNiMWFiYzI5ZmY0ZTJjYmEzL3RhYmxlOjhhYWZmM2RhMmI5MDQyZmRiY2E3ZGY1ZDBhNzY3NWQ0L3RhYmxlcmFuZ2U6OGFhZmYzZGEyYjkwNDJmZGJjYTdkZjVkMGE3Njc1ZDRfMTktMTMtMS0xLTI5MTU4_02a23b69-730c-456f-a6fd-78642b40ab88"
      unitRef="usd">173674000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfNC0xLTEtMS0yOTE1OA_46f317cb-ee8f-4313-9c62-1d6b6b9c8e28"
      unitRef="usd">61983000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfNC0zLTEtMS0yOTE1OA_1e86f1a9-9ad9-400b-8615-0885e6a7fdee"
      unitRef="usd">19448000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfNi0xLTEtMS0yOTE1OA_79d739ec-57f0-4c63-8693-eb1e2d5a912d"
      unitRef="usd">2719000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfNi0zLTEtMS0yOTE1OA_cd17788c-bbea-4bb3-bb69-3898e0e833a9"
      unitRef="usd">2253000</us-gaap:DepreciationDepletionAndAmortization>
    <ccrn:ProvisionForDoubtfulAccountsAndOtherAllowances
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfNy0xLTEtMS0yOTE1OA_1832df05-fede-4f10-ab12-5b152f21d975"
      unitRef="usd">3179000</ccrn:ProvisionForDoubtfulAccountsAndOtherAllowances>
    <ccrn:ProvisionForDoubtfulAccountsAndOtherAllowances
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfNy0zLTEtMS0yOTE1OA_ea562490-bb76-4c43-812e-d2a5638da3ce"
      unitRef="usd">1095000</ccrn:ProvisionForDoubtfulAccountsAndOtherAllowances>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfOC0xLTEtMS0yOTE1OA_6892dd66-3a66-446f-95e7-95c1b1ceec0d"
      unitRef="usd">2428000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfOC0zLTEtMS0yOTE1OA_b630dfab-d626-4b58-bbb4-4ffa63c89d33"
      unitRef="usd">266000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <ccrn:OperatingLeaseExpenseNonCash
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfOS0xLTEtMS0yOTE1OA_775bd6a3-0057-4d80-a557-5f32d8e88634"
      unitRef="usd">567000</ccrn:OperatingLeaseExpenseNonCash>
    <ccrn:OperatingLeaseExpenseNonCash
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfOS0zLTEtMS0yOTE1OA_211d344e-f629-4c73-af99-fdd2be65cfaa"
      unitRef="usd">622000</ccrn:OperatingLeaseExpenseNonCash>
    <us-gaap:AssetImpairmentCharges
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTAtMS0xLTEtMjkxNTg_88b26b9f-a834-4acd-988c-742d77525c59"
      unitRef="usd">1741000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTAtMy0xLTEtMjkxNTg_5ffdfdd6-e96e-4881-8535-aeabdc0853d3"
      unitRef="usd">149000</us-gaap:AssetImpairmentCharges>
    <us-gaap:ShareBasedCompensation
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTEtMS0xLTEtMjkxNTg_c691d365-8dee-4512-9014-e86f405bcb7e"
      unitRef="usd">1601000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTEtMy0xLTEtMjkxNTg_33250f83-d2d4-4dd7-b6f8-6e0e3441d152"
      unitRef="usd">1349000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashExpense
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTItMS0xLTEtMjkxNTg_080a889c-bd47-4e3d-a1a5-dc907024f703"
      unitRef="usd">446000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTItMy0xLTEtMjkxNTg_93273c53-c556-475f-b884-46d986bf941b"
      unitRef="usd">214000</us-gaap:OtherNoncashExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTQtMS0xLTEtMjkxNTg_b3daf1fe-90cb-47d5-8588-3b349f3134fb"
      unitRef="usd">186701000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTQtMy0xLTEtMjkxNTg_c0bc1ed3-8f02-4507-8b8e-6706e8bf3a55"
      unitRef="usd">76581000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTUtMS0xLTEtMjkxNTg_10d3328c-7246-408a-a94c-cb7787fc151f"
      unitRef="usd">557000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTUtMy0xLTEtMjkxNTg_318f9801-6332-4f33-879e-359c45acb1de"
      unitRef="usd">-568000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTYtMS0xLTEtMzc1NjU_071fe692-6731-41db-a8fe-12d74233266b"
      unitRef="usd">22050000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTYtMy0xLTEtMzc1NzI_bbd42685-88ae-4d8a-9a33-287daf56b996"
      unitRef="usd">617000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTYtMS0xLTEtMjkxNTg_56dcd33e-ec27-4cc9-9318-8554fd224d9f"
      unitRef="usd">62979000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTYtMy0xLTEtMjkxNTg_9f148f0d-74f1-42c3-a043-cc264e0b7b0e"
      unitRef="usd">26507000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <ccrn:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTctMS0xLTEtMjkxNTg_6a825cd5-70df-4477-a5a1-251f077c8291"
      unitRef="usd">-1273000</ccrn:IncreaseDecreaseInOperatingLeaseLiabilities>
    <ccrn:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTctMy0xLTEtMjkxNTg_08c3e546-bf2a-4845-9d06-073e062f661e"
      unitRef="usd">-1115000</ccrn:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTgtMS0xLTEtMjkxNTg_b4a22d2a-2a72-4a73-ba2b-1210c9aefd8e"
      unitRef="usd">-200000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTgtMy0xLTEtMjkxNTg_39470ba5-ec55-4a9a-839a-08c1d72deb42"
      unitRef="usd">-319000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTktMS0xLTEtMjkxNTg_feb015ec-ef62-4a05-9248-8c07cdfefbaf"
      unitRef="usd">-29038000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMTktMy0xLTEtMjkxNTg_14c560d1-f385-4538-8f35-0a9a0811b471"
      unitRef="usd">-24927000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMjMtMS0xLTEtMjkxNTg_aeb7e0b5-89ac-4011-b54f-125aa793d041"
      unitRef="usd">2096000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMjMtMy0xLTEtMjkxNTg_bd4bdde6-2198-4fab-9cc9-7c2ae26cad72"
      unitRef="usd">1186000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMjQtMS0xLTEtMjkxNTg_94d29a12-1372-4c8c-96c4-ce80e26d9881"
      unitRef="usd">-2096000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMjQtMy0xLTEtMjkxNTg_e6883498-1693-4386-a647-a3242660a7c5"
      unitRef="usd">-1186000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMjgtMS0xLTEtMjkxNTg_48a33f9f-1686-45d9-9548-a74d1e923085"
      unitRef="usd">437000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMjgtMy0xLTEtMjkxNTg_9291068d-33bb-4551-b77a-0b10c80e2ee4"
      unitRef="usd">0</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMjktMS0xLTEtMjkxNTg_f3c924a2-756d-444e-b859-7066e803c0aa"
      unitRef="usd">3092000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMjktMy0xLTEtMjkxNTg_018ffaef-82c1-4c44-b24d-25a8c7eb5c9b"
      unitRef="usd">150000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzAtMS0xLTEtMjkxNTg_7b768368-9692-4fe0-b267-11e953ed5b0b"
      unitRef="usd">415176000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzAtMy0xLTEtMjkxNTg_03b0a398-1c38-42bd-992a-ed7757c06894"
      unitRef="usd">148016000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzEtMS0xLTEtMjkxNTg_f7ac4429-7090-4b95-bf91-e2f8095b3e49"
      unitRef="usd">372874000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzEtMy0xLTEtMjkxNTg_a9a143d8-c8e3-4e8f-a256-1af4220db07e"
      unitRef="usd">105400000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzItMS0xLTEtMjkxNTg_c6bb72fb-6c21-49a7-99f6-93d67e85e78a"
      unitRef="usd">5028000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzItMy0xLTEtMjkxNTg_5f227f91-e569-44bb-bf2c-fe5bc00224a0"
      unitRef="usd">2026000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzMtMS0xLTEtMjkxNTg_8f2ba99d-ef30-415e-9ed5-ab89f814b516"
      unitRef="usd">2426000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzMtMy0xLTEtMjkxNTg_ad75674e-f8eb-4c01-afc8-7f84b79c1ee1"
      unitRef="usd">2425000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzUtMS0xLTEtMjkxNTg_c119e578-d82c-4127-96b7-67bdeab7fbf1"
      unitRef="usd">-11000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzUtMy0xLTEtMjkxNTg_df6b44a7-509e-4627-8c0c-305c548d1c1f"
      unitRef="usd">-11000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzYtMS0xLTEtMjkxNTg_3d8dafc1-e661-41e5-8af8-9baefcb76e07"
      unitRef="usd">31308000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzYtMy0xLTEtMjkxNTg_64e2f414-3479-4ec3-a74d-2ed0703cef7f"
      unitRef="usd">38004000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzgtMS0xLTEtMjkxNTg_8532487e-1c8e-4aca-80e3-4f01458b021f"
      unitRef="usd">-2000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzgtMy0xLTEtMjkxNTg_a6c47789-5169-431e-b707-8cf7e21e980f"
      unitRef="usd">-3000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzktMS0xLTEtMjkxNTg_9f5fa508-80fe-4704-a087-fd5174c883d3"
      unitRef="usd">172000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfMzktMy0xLTEtMjkxNTg_7eff9486-2da0-438a-97be-9abaaf56cf20"
      unitRef="usd">11888000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfNDAtMS0xLTEtMjkxNTg_c8708602-3cf9-4ef0-bd43-e028ab09589a"
      unitRef="usd">1036000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i17355322df2d4d97a85fd60c4263a2fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfNDAtMy0xLTEtMjkxNTg_11c92ae3-eff6-450a-919a-5caab6bb6803"
      unitRef="usd">1600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfNDEtMS0xLTEtMjkxNTg_b75c2a03-e781-4c24-8e66-23561aef03f4"
      unitRef="usd">1208000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i123bae647d194e0aa87a3eeb155cbbc1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zMS9mcmFnOjkxOGVjMmIzMzcxZTQyNGM4YTRiNmNmYzY2NTIwNGQyL3RhYmxlOjY3NjAwN2VmNWQ2NTQ5OTY4MmI4ZmRlNTUwOTY5ODQ2L3RhYmxlcmFuZ2U6Njc2MDA3ZWY1ZDY1NDk5NjgyYjhmZGU1NTA5Njk4NDZfNDEtMy0xLTEtMjkxNTg_4be730ef-1867-4bd8-958a-0d680399cce3"
      unitRef="usd">13488000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zNy9mcmFnOmQwYzBmMmRlYjY0ZjRlMGE5ODkwZjdhZDFlOTNjNWRiL3RleHRyZWdpb246ZDBjMGYyZGViNjRmNGUwYTk4OTBmN2FkMWU5M2M1ZGJfMjE1Nw_ebfc4021-8043-411b-bc3a-09838906d39c">ORGANIZATION AND BASIS OF PRESENTATION&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nature of Business&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements include the accounts of Cross Country Healthcare, Inc. and its direct and indirect wholly-owned subsidiaries (collectively, the Company). In the opinion of management, all adjustments necessary for a fair presentation of such unaudited condensed consolidated financial statements have been included. All such adjustments consisted of all normal recurring items, including the elimination of all intercompany transactions and balances.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form&#160;10-Q and Article 10 of Regulation&#160;S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These operating results are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2021 included in the Company&#x2019;s Annual Report on Form&#160;10-K as filed with the SEC on February 28, 2022 (2021 Form 10-K). The December&#160;31, 2021 condensed consolidated balance sheet included herein was derived from the December&#160;31, 2021 audited consolidated balance sheet included in the 2021 Form&#160;10-K.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior year amounts have been reclassified to conform to the current year presentation. See the condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zNy9mcmFnOmQwYzBmMmRlYjY0ZjRlMGE5ODkwZjdhZDFlOTNjNWRiL3RleHRyZWdpb246ZDBjMGYyZGViNjRmNGUwYTk4OTBmN2FkMWU5M2M1ZGJfMjE0OQ_60e90b93-9c0a-41ca-ac77-1110243d550f">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nature of Business&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements include the accounts of Cross Country Healthcare, Inc. and its direct and indirect wholly-owned subsidiaries (collectively, the Company). In the opinion of management, all adjustments necessary for a fair presentation of such unaudited condensed consolidated financial statements have been included. All such adjustments consisted of all normal recurring items, including the elimination of all intercompany transactions and balances.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF8zNy9mcmFnOmQwYzBmMmRlYjY0ZjRlMGE5ODkwZjdhZDFlOTNjNWRiL3RleHRyZWdpb246ZDBjMGYyZGViNjRmNGUwYTk4OTBmN2FkMWU5M2M1ZGJfMjE0NQ_fc3b3b7b-84d0-48d6-acca-fd94736b2323">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form&#160;10-Q and Article 10 of Regulation&#160;S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These operating results are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2021 included in the Company&#x2019;s Annual Report on Form&#160;10-K as filed with the SEC on February 28, 2022 (2021 Form 10-K). The December&#160;31, 2021 condensed consolidated balance sheet included herein was derived from the December&#160;31, 2021 audited consolidated balance sheet included in the 2021 Form&#160;10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfODA3MA_c60afccc-caa7-4d34-ab63-6e7aa6438ecb">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Management has assessed various accounting estimates and other matters, including those that require consideration of forecasted financial information, in context of the unknown future impacts of the global &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;COVID-19 (COVID)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; pandemic using information that is reasonably available to the Company at the time. Significant estimates and assumptions are used for, but not limited to: (i) the valuation of accounts receivable; (ii) goodwill, trade names, and other intangible assets; (iii) other long-lived assets; (iv) revenue recognition; (v) accruals for health, workers&#x2019; compensation, and professional liability claims; (vi) valuation of deferred tax assets; (vii) legal contingencies; and (viii) income taxes. Accrued insurance claims and reserves include estimated settlements from known claims and actuarial estimates for claims incurred but not reported. As additional information becomes available to the Company, its future assessment of these estimates, including management's expectations at the time regarding the duration, scope and severity of the pandemic, as well as other factors, could materially and adversely impact the Company's consolidated financial statements in future reporting periods. Actual results could differ from those estimates.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;COVID&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company prioritizes the mental health and well-being of its employees, especially in response to the COVID pandemic. While operating primarily through a remote workforce, the Company's offices remain open with stringent safety guidelines and procedures in place. Business travel, including visits to healthcare clients, continues to be somewhat limited at the request of the Company's clients who are continuing to cope with the pandemic twenty-four hours a day/seven days a week.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2022, average bill rates rose slightly as the Company continued to experience higher demand across a wide range of specialties. Investments in people and technology, along with other improvements the Company has made during the pandemic, have allowed it to quickly respond to high demand levels that it is continuing to see across a wide range of specialties, including operating room, emergency room, pediatrics, labor and delivery, and medical and surgical services, not all of which are directly related to COVID needs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Throughout the pandemic, the Company worked collaboratively with clients on adjusting bill rates in order to adapt to the rapidly changing market conditions. One of the Company's core values is to act ethically and responsibly, and it has been especially important during this pandemic to be transparent and build trust with its clients to re-enforce long-lasting relationships as both demand and bill rates increased to unprecedented levels.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable, net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The timing of revenue recognition, billings, and collections results in billed and unbilled accounts receivable from customers, which are classified as accounts receivable on the condensed consolidated balance sheets and are presented net of allowances for doubtful accounts and sales allowances. Estimated revenue for the Company employees', subcontracted employees', and independent contractors&#x2019; time worked but not yet billed at March 31, 2022 and December 31, 2021 totaled $249.7&#160;million and $140.0&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally does not require collateral and mitigates its credit risk by performing credit evaluations and monitoring at-risk accounts. The allowance for doubtful accounts is established for losses expected to be incurred on accounts receivable balances. Accounts receivable are written off against the allowance for doubtful accounts when the Company determines amounts are no longer collectible. Judgment is required in the estimation of the allowance and the Company evaluates the collectability of its accounts receivable and contract assets based on a combination of factors. The Company bases its allowance for doubtful account estimates on its historical write-off experience, current conditions, an analysis of the aging of outstanding receivable and customer payment patterns, and specific reserves for customers in adverse condition adjusted for current expectations for the customers or industry. Based on the information currently available, the Company also considered current expectations of future economic conditions, including the impact of COVID, when estimating its allowance for doubtful accounts.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bad Debt Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-Offs, net of Recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(365)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the allowance for doubtful accounts, the Company maintains a sales allowance for billing-related adjustments which may arise in the ordinary course of business and adjustments to the reserve are recorded as contra-revenue. The balance of this allowance as of March 31, 2022 and December 31, 2021 was $1.1&#160;million and $0.8&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contract terms typically require payment between 30 to 60 days from the date of invoice and are considered past due based on the particular negotiated contract terms. The majority of the Company's customers are U.S. based healthcare systems with a significant percentage in acute-care facilities. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No single customer accounted for more than 10% of the Company&#x2019;s revenue for the three months ended March 31, 2022 and 2021, or the accounts receivable balance as of March 31, 2022 and December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restructuring Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers restructuring activities to be programs whereby it fundamentally changes its operations, such as closing and consolidating facilities, reducing headcount, and realigning operations in response to changing market conditions. As a result, restructuring costs on the condensed consolidated statements of operations primarily include employee termination costs and lease-related exit costs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reconciliation of the employee termination costs and lease-related exit costs beginning and ending liability balance is presented below:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Employee Termination Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease-Related Exit Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to restructuring costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;________________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Restructuring costs in the condensed consolidated statements of operations for the three months ended March 31, 2022 include an immaterial amount of ongoing lease costs related to the Company's strategic reduction in its real estate footprint, which are included as operating lease liabilities - current and non-current in our condensed consolidated balance sheets. Other costs were immaterial for the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfODA3OA_a2d72451-295b-4a1f-a562-52ecf5f3dd68">Use of Estimates&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Management has assessed various accounting estimates and other matters, including those that require consideration of forecasted financial information, in context of the unknown future impacts of the global &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;COVID-19 (COVID)&lt;/span&gt; pandemic using information that is reasonably available to the Company at the time. Significant estimates and assumptions are used for, but not limited to: (i) the valuation of accounts receivable; (ii) goodwill, trade names, and other intangible assets; (iii) other long-lived assets; (iv) revenue recognition; (v) accruals for health, workers&#x2019; compensation, and professional liability claims; (vi) valuation of deferred tax assets; (vii) legal contingencies; and (viii) income taxes. Accrued insurance claims and reserves include estimated settlements from known claims and actuarial estimates for claims incurred but not reported. As additional information becomes available to the Company, its future assessment of these estimates, including management's expectations at the time regarding the duration, scope and severity of the pandemic, as well as other factors, could materially and adversely impact the Company's consolidated financial statements in future reporting periods. Actual results could differ from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfODA2NA_982dab38-6f47-4fd6-adc9-94c85e842db0">&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable, net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The timing of revenue recognition, billings, and collections results in billed and unbilled accounts receivable from customers, which are classified as accounts receivable on the condensed consolidated balance sheets and are presented net of allowances for doubtful accounts and sales allowances. Estimated revenue for the Company employees', subcontracted employees', and independent contractors&#x2019; time worked but not yet billed at March 31, 2022 and December 31, 2021 totaled $249.7&#160;million and $140.0&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally does not require collateral and mitigates its credit risk by performing credit evaluations and monitoring at-risk accounts. The allowance for doubtful accounts is established for losses expected to be incurred on accounts receivable balances. Accounts receivable are written off against the allowance for doubtful accounts when the Company determines amounts are no longer collectible. Judgment is required in the estimation of the allowance and the Company evaluates the collectability of its accounts receivable and contract assets based on a combination of factors. The Company bases its allowance for doubtful account estimates on its historical write-off experience, current conditions, an analysis of the aging of outstanding receivable and customer payment patterns, and specific reserves for customers in adverse condition adjusted for current expectations for the customers or industry. Based on the information currently available, the Company also considered current expectations of future economic conditions, including the impact of COVID, when estimating its allowance for doubtful accounts.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bad Debt Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-Offs, net of Recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(365)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the allowance for doubtful accounts, the Company maintains a sales allowance for billing-related adjustments which may arise in the ordinary course of business and adjustments to the reserve are recorded as contra-revenue. The balance of this allowance as of March 31, 2022 and December 31, 2021 was $1.1&#160;million and $0.8&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;The Company&#x2019;s contract terms typically require payment between 30 to 60 days from the date of invoice and are considered past due based on the particular negotiated contract terms. The majority of the Company's customers are U.S. based healthcare systems with a significant percentage in acute-care facilities.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:UnbilledContractsReceivable
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfNDE2Mw_f1da3a81-e5fd-422b-9460-e0d1dc873d7a"
      unitRef="usd">249700000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:UnbilledContractsReceivable
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfNDE3MA_f24ea75e-2a99-4da4-8a71-2dc09b8040d0"
      unitRef="usd">140000000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfODA4Nw_24e6c580-ee7f-47c3-a545-87447b70f8d1">&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bad Debt Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-Offs, net of Recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(365)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjVkMWQyZGNiNWQ5YjRkYTBhMWYyZTFjYmE4NThiMTBhL3RhYmxlcmFuZ2U6NWQxZDJkY2I1ZDliNGRhMGExZjJlMWNiYTg1OGIxMGFfNC0xLTEtMS0yOTE1OA_eec503df-2df2-4721-9ca9-1544ba453f90"
      unitRef="usd">6087000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i17355322df2d4d97a85fd60c4263a2fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjVkMWQyZGNiNWQ5YjRkYTBhMWYyZTFjYmE4NThiMTBhL3RhYmxlcmFuZ2U6NWQxZDJkY2I1ZDliNGRhMGExZjJlMWNiYTg1OGIxMGFfNC0zLTEtMS0yOTE1OA_2d5625bf-3510-487c-8dd4-e7721eb2aa6a"
      unitRef="usd">3416000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjVkMWQyZGNiNWQ5YjRkYTBhMWYyZTFjYmE4NThiMTBhL3RhYmxlcmFuZ2U6NWQxZDJkY2I1ZDliNGRhMGExZjJlMWNiYTg1OGIxMGFfNS0xLTEtMS0yOTE1OA_91ac00d7-a5bf-4678-8d7b-75c99e217900"
      unitRef="usd">2369000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjVkMWQyZGNiNWQ5YjRkYTBhMWYyZTFjYmE4NThiMTBhL3RhYmxlcmFuZ2U6NWQxZDJkY2I1ZDliNGRhMGExZjJlMWNiYTg1OGIxMGFfNS0zLTEtMS0yOTE1OA_9dc1dde0-908f-4c7e-87b6-40e70861aba1"
      unitRef="usd">504000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjVkMWQyZGNiNWQ5YjRkYTBhMWYyZTFjYmE4NThiMTBhL3RhYmxlcmFuZ2U6NWQxZDJkY2I1ZDliNGRhMGExZjJlMWNiYTg1OGIxMGFfNi0xLTEtMS0yOTE1OA_8dfe0c4a-434d-4659-bf9c-24b07e50253a"
      unitRef="usd">365000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjVkMWQyZGNiNWQ5YjRkYTBhMWYyZTFjYmE4NThiMTBhL3RhYmxlcmFuZ2U6NWQxZDJkY2I1ZDliNGRhMGExZjJlMWNiYTg1OGIxMGFfNi0zLTEtMS0yOTE1OA_0019d961-08b0-4feb-86a8-8fafca6fc614"
      unitRef="usd">699000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjVkMWQyZGNiNWQ5YjRkYTBhMWYyZTFjYmE4NThiMTBhL3RhYmxlcmFuZ2U6NWQxZDJkY2I1ZDliNGRhMGExZjJlMWNiYTg1OGIxMGFfNy0xLTEtMS0yOTE1OA_34e058e4-d020-4b77-98c3-3169e582353c"
      unitRef="usd">8091000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i123bae647d194e0aa87a3eeb155cbbc1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjVkMWQyZGNiNWQ5YjRkYTBhMWYyZTFjYmE4NThiMTBhL3RhYmxlcmFuZ2U6NWQxZDJkY2I1ZDliNGRhMGExZjJlMWNiYTg1OGIxMGFfNy0zLTEtMS0yOTE1OA_e77fd4ef-b813-43bb-b5d8-54dced10d033"
      unitRef="usd">3221000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <ccrn:SalesAllowanceBillingRelatedAdjustments
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfNTc3Nw_8ff1d91f-81e1-4eff-8465-1cab99979427"
      unitRef="usd">1100000</ccrn:SalesAllowanceBillingRelatedAdjustments>
    <ccrn:SalesAllowanceBillingRelatedAdjustments
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfNTc4NA_bcca6826-d60d-4d63-8785-fdb65d6ee3b6"
      unitRef="usd">800000</ccrn:SalesAllowanceBillingRelatedAdjustments>
    <ccrn:ThresholdPeriodPastDueForPaymentOfServicesProvided
      contextRef="i123a8da54abc487d9a3a822dee374164_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfNTg2Ng_573c7350-adae-41a7-93c2-63df297e8b44">P30D</ccrn:ThresholdPeriodPastDueForPaymentOfServicesProvided>
    <ccrn:ThresholdPeriodPastDueForPaymentOfServicesProvided
      contextRef="i6f916c87f5844845bdfa58e6b0815916_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfNTg3Mg_42d88196-b99f-4dd9-9e83-fdd17f112ed6">P60D</ccrn:ThresholdPeriodPastDueForPaymentOfServicesProvided>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfODA5MA_7efbfb95-61bf-43f7-939f-63b0422d4a67">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restructuring Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers restructuring activities to be programs whereby it fundamentally changes its operations, such as closing and consolidating facilities, reducing headcount, and realigning operations in response to changing market conditions. As a result, restructuring costs on the condensed consolidated statements of operations primarily include employee termination costs and lease-related exit costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RleHRyZWdpb246ZmE3ZTllODc1OGUxNDhiYTk4ZjdhNTk0YTM4Y2JjMGJfODA5Nw_109b4ecc-c3a4-4e9e-a9b7-1a38e7cd97dc">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reconciliation of the employee termination costs and lease-related exit costs beginning and ending liability balance is presented below:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Employee Termination Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease-Related Exit Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to restructuring costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;________________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Restructuring costs in the condensed consolidated statements of operations for the three months ended March 31, 2022 include an immaterial amount of ongoing lease costs related to the Company's strategic reduction in its real estate footprint, which are included as operating lease liabilities - current and non-current in our condensed consolidated balance sheets. Other costs were immaterial for the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i7bc99217a5124b478bddc5a0566fedaf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjlmYWFiMmRhNzFhNzRjYzQ4ODViMTQ1NjM3ZjBmMWUwL3RhYmxlcmFuZ2U6OWZhYWIyZGE3MWE3NGNjNDg4NWIxNDU2MzdmMGYxZTBfMy0xLTEtMS0yOTE1OA_77fb7f8e-ab4a-4153-9d0b-b0a1841a2faf"
      unitRef="usd">160000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ie8cefece24e942d5a8357106949400d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjlmYWFiMmRhNzFhNzRjYzQ4ODViMTQ1NjM3ZjBmMWUwL3RhYmxlcmFuZ2U6OWZhYWIyZGE3MWE3NGNjNDg4NWIxNDU2MzdmMGYxZTBfMy0zLTEtMS0yOTE1OA_c0cf36e4-8913-45ea-ba55-06c6c25f7c14"
      unitRef="usd">2423000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i8c1b8bcd9e5449e8becb131e830d5a44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjlmYWFiMmRhNzFhNzRjYzQ4ODViMTQ1NjM3ZjBmMWUwL3RhYmxlcmFuZ2U6OWZhYWIyZGE3MWE3NGNjNDg4NWIxNDU2MzdmMGYxZTBfNC0xLTEtMS0yOTE1OA_c692e820-86e6-4d5a-af55-bbb990aba9eb"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="iff6a7e25073a4b0aabe092d1fa279920_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjlmYWFiMmRhNzFhNzRjYzQ4ODViMTQ1NjM3ZjBmMWUwL3RhYmxlcmFuZ2U6OWZhYWIyZGE3MWE3NGNjNDg4NWIxNDU2MzdmMGYxZTBfNC0zLTEtMS0yOTE1OA_9ad6cba2-7415-4fd7-a10f-c56cf3e4021f"
      unitRef="usd">389000</us-gaap:RestructuringCharges>
    <ccrn:PaymentsForRestructuringAndAdjustments
      contextRef="i8c1b8bcd9e5449e8becb131e830d5a44_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjlmYWFiMmRhNzFhNzRjYzQ4ODViMTQ1NjM3ZjBmMWUwL3RhYmxlcmFuZ2U6OWZhYWIyZGE3MWE3NGNjNDg4NWIxNDU2MzdmMGYxZTBfNS0xLTEtMS0yOTE1OA_651a82b8-b440-4376-996d-308ea609ad13"
      unitRef="usd">160000</ccrn:PaymentsForRestructuringAndAdjustments>
    <ccrn:PaymentsForRestructuringAndAdjustments
      contextRef="iff6a7e25073a4b0aabe092d1fa279920_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjlmYWFiMmRhNzFhNzRjYzQ4ODViMTQ1NjM3ZjBmMWUwL3RhYmxlcmFuZ2U6OWZhYWIyZGE3MWE3NGNjNDg4NWIxNDU2MzdmMGYxZTBfNS0zLTEtMS0yOTE1OA_eebfe1ff-ac54-4171-ab3b-4a3c50446943"
      unitRef="usd">192000</ccrn:PaymentsForRestructuringAndAdjustments>
    <us-gaap:RestructuringReserve
      contextRef="i6122e323ba5148c68be7d2705dc85e93_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjlmYWFiMmRhNzFhNzRjYzQ4ODViMTQ1NjM3ZjBmMWUwL3RhYmxlcmFuZ2U6OWZhYWIyZGE3MWE3NGNjNDg4NWIxNDU2MzdmMGYxZTBfNi0xLTEtMS0yOTE1OA_84be9e69-d5e1-40a8-b912-8cf85160cb97"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ifa36abaca6d64d6fb19eca4e3d5f6e6c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80MC9mcmFnOmZhN2U5ZTg3NThlMTQ4YmE5OGY3YTU5NGEzOGNiYzBiL3RhYmxlOjlmYWFiMmRhNzFhNzRjYzQ4ODViMTQ1NjM3ZjBmMWUwL3RhYmxlcmFuZ2U6OWZhYWIyZGE3MWE3NGNjNDg4NWIxNDU2MzdmMGYxZTBfNi0zLTEtMS0yOTE1OA_50b90b64-12b9-493c-bc80-67824eddf9a8"
      unitRef="usd">2620000</us-gaap:RestructuringReserve>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RleHRyZWdpb246MmI1MzY3MTgzNDRkNDUzMjlmZDZiOWZkNDgwMmUwODVfODIx_8924a251-2515-4671-bbcb-f6f2fc367f26">REVENUE RECOGNITION&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's revenues from customer contracts are generated from temporary staffing services and other services. Revenue is disaggregated by segment in the following table. Sales and usage-based taxes are excluded from revenue.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nurse&lt;br/&gt;And Allied&lt;br/&gt;Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Physician&lt;br/&gt;Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Segments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Temporary Staffing Services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nurse&lt;br/&gt;And Allied&lt;br/&gt;Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Physician&lt;br/&gt;Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Segments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Temporary Staffing Services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;     &lt;/span&gt;&lt;/div&gt;See Note 12 - Segment Data.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RleHRyZWdpb246MmI1MzY3MTgzNDRkNDUzMjlmZDZiOWZkNDgwMmUwODVfODI0_e6b4597a-8c0e-4214-820a-678f47e5964e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's revenues from customer contracts are generated from temporary staffing services and other services. Revenue is disaggregated by segment in the following table. Sales and usage-based taxes are excluded from revenue.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nurse&lt;br/&gt;And Allied&lt;br/&gt;Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Physician&lt;br/&gt;Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Segments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Temporary Staffing Services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nurse&lt;br/&gt;And Allied&lt;br/&gt;Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Physician&lt;br/&gt;Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Segments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Temporary Staffing Services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31aa1178ab274d94b1a27d7f903f71ad_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMy0xLTEtMS0yOTE1OA_e7d00163-1085-4e1f-999e-5582c2ed3644"
      unitRef="usd">749447000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c6b46f3057c41ae9eb9f22f1e50b97d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMy0zLTEtMS0yOTE1OA_b3b67d98-4314-4f25-9174-68189d09c3c3"
      unitRef="usd">22104000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibda3d097b5e34888bd4ce3a4a893ea70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMy03LTEtMS0yOTE1OA_35c02285-fc35-4ac6-925f-909aaec82ec3"
      unitRef="usd">771551000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c44d67d24f445078de88bbafab90724_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfNC0xLTEtMS0yOTE1OA_4717b3c5-1a80-435b-9dbf-082e7786e1d8"
      unitRef="usd">16133000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i389a47646ea1490cb51a4d0322234613_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfNC0zLTEtMS0yOTE1OA_9e804a99-1e6d-4f15-b454-853c9de47ffa"
      unitRef="usd">1048000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i634a7f36c8c948219ef2af135e76fa0f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfNC03LTEtMS0yOTE1OA_e4da5880-34a5-43f3-bf00-9582aefee591"
      unitRef="usd">17181000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f67d3164490454dbd2421830ac30a99_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfNS0xLTEtMS0yOTE1OA_e169ef26-f9ed-4b69-9296-0471bf735e99"
      unitRef="usd">765580000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie35cd3b9be00467fbc0b9f82f0c6c7da_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfNS0zLTEtMS0yOTE1OA_ca749508-a8e4-4059-aba7-ffbbb6bdbc1d"
      unitRef="usd">23152000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfNS03LTEtMS0yOTE1OA_e7a921e3-a247-430a-9076-535f5343c215"
      unitRef="usd">788732000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic536f98865ef4aab8fc1a7e5f5e582c9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMTAtMS0xLTEtMjkxNTg_e291db7d-fa7a-48b1-8df4-eef30e003e5d"
      unitRef="usd">305975000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99d6ce4715d142a8bc5ce8abc5584a20_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMTAtMy0xLTEtMjkxNTg_969d2553-66b0-4657-8742-2b39bd51f2dd"
      unitRef="usd">15406000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i500ea7c7700c49718811026ceaaeafcd_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMTAtNy0xLTEtMjkxNTg_a92f7903-70f6-43e4-89a9-43d25a11240e"
      unitRef="usd">321381000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1921e703c434f25a791d61baf58dc3c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMTEtMS0xLTEtMjkxNTg_cef51be9-a3df-4b33-b4b9-71ac5d6f77d2"
      unitRef="usd">7033000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i370fcef443ef4801a10e7a73c103bdf9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMTEtMy0xLTEtMjkxNTg_09e843e8-c949-40d3-9289-51e9579d5808"
      unitRef="usd">827000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5392157ee224225b8abb8f26dbf4fd9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMTEtNy0xLTEtMjkxNTg_c9e06875-8076-45dd-89db-f014f90cbb5d"
      unitRef="usd">7860000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide86e9d4790e48b881466a5c8b847256_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMTItMS0xLTEtMjkxNTg_e085f5e2-1847-412e-a557-f69da6bb2398"
      unitRef="usd">313008000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad432390898d40dabc7fcb10fd9dd0ae_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMTItMy0xLTEtMjkxNTg_20082648-8a66-4b20-8d91-2b71afbfda7b"
      unitRef="usd">16233000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80My9mcmFnOjJiNTM2NzE4MzQ0ZDQ1MzI5ZmQ2YjlmZDQ4MDJlMDg1L3RhYmxlOjM5NWFmOWY1YzViMjQ5NDVhMDVkNjM0NWJhN2UwYTgwL3RhYmxlcmFuZ2U6Mzk1YWY5ZjVjNWIyNDk0NWEwNWQ2MzQ1YmE3ZTBhODBfMTItNy0xLTEtMjkxNTg_c903ac52-eac8-43f1-94ba-c4cdf43b1a63"
      unitRef="usd">329241000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMjczOQ_3c8780fe-125a-47d6-84ac-2d314b9de267">ACQUISITIONS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selected&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2021, the Company purchased and acquired substantially all of the assets and assumed certain liabilities of Selected, Inc. (Selected) for a purchase price of $3.5&#160;million in cash, subject to adjustment, and $1.5&#160;million in shares (or 59,429 shares) of the Company's common stock. The transaction was treated as a purchase of assets for income tax purposes. As of March 31, 2022, the acquisition has not been fully integrated. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The sellers are also eligible to receive up to an additional $1.5&#160;million in earnout cash consideration, based on Selected's revenues for each of the twelve-month periods ending on the first and second anniversaries of the first day after the closing date. See Note 10 - Fair Value Measurements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition was not significant and has been accounted for using the acquisition method of accounting. The Company has not completed its valuation of assets acquired and liabilities assumed. Any necessary adjustments will be finalized within one &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year from the date of acquisition. As a result, $6.5&#160;million has been recorded as goodwill on the Company's condensed consolidated balance sheets. See Note 7 - Goodwill, Trade Names, and Other Intangible Assets. Associated acquisition-related costs incurred have been included in acquisition and integration-related costs on the Company's condensed consolidated statements of operations for the three months ended March 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cross Country Workforce Solutions Group (CCWSG)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 8, 2021, the Company purchased and acquired substantially all of the assets and assumed certain liabilities of Workforce Solutions Group, Inc. (WSG) for a purchase price of $25.0&#160;million in cash and $5.0&#160;million in shares (or 307,730 shares) of the Company's common stock. The parties agreed to a final net working capital reduction of $1.1&#160;million which was received in the fourth quarter of 2021.The transaction was treated as a purchase of assets for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The sellers are also eligible to receive an earnout based on the business' performance through three years after the acquisition date that could provide up to an additional $15.0&#160;million in cash. The current portion of the liability of $7.5&#160;million is included in current portion of earnout liability and the non-current portion of $7.5&#160;million is included in non-current earnout liability on the condensed consolidated balance sheets. See Note 10 - Fair Value Measurements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value of the assets acquired and liabilities assumed on June 8, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability - non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnout liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assigned a value to other identifiable intangible assets of $14.2&#160;million in customer relationships with a weighted average estimated useful life of 11.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The remaining excess purchase price over the fair value of net assets acquired of $22.1&#160;million was recorded as goodwill on the Company's condensed consolidated balance sheets. See Note 7 - Goodwill, Trade Names, and Other Intangible Assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition was not significant and has been accounted for using the acquisition method of accounting. The pro-forma impact on the Company's consolidated revenue from services and net income, including the pro forma effect of events that are directly attributable to the acquisition, was not significant. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mediscan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2020, the Company entered into a note payable of $7.3&#160;million related to contingent consideration assumed as part of the Mediscan acquisition, payable in three installments. The first two installments of $2.4&#160;million each were paid in the second quarter of 2020 and in the first quarter of 2021, respectively. The third and final installment of $2.6&#160;million, including interest, was paid in the first quarter of 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="iddc9cc886ecc4548a8c7f9a14a4fa974_D20211216-20211216"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMTA5OTUxMTYzNjEzMw_e7c8b84f-e4b2-4062-84ed-165fd255eaa3"
      unitRef="usd">3500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="iddc9cc886ecc4548a8c7f9a14a4fa974_D20211216-20211216"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMTA5OTUxMTYzNjE0Nw_92c1f151-1b2a-488f-8963-eb3ea708b222"
      unitRef="usd">1500000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="iddc9cc886ecc4548a8c7f9a14a4fa974_D20211216-20211216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMTA5OTUxMTYzNjE2MQ_d3119505-c5fb-4c05-b718-58c14a1aae1a"
      unitRef="shares">59429</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7d964a81b82746d29b5d9b48e092bd36_I20211216"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMTA5OTUxMTYzNjE4NA_dab8d622-19ca-426d-b261-6edf00a711f6"
      unitRef="usd">1500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:Goodwill
      contextRef="i7d964a81b82746d29b5d9b48e092bd36_I20211216"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMTA5OTUxMTYzNzk4Mg_a65a331a-6b7b-486d-be10-704e9cb75342"
      unitRef="usd">6500000</us-gaap:Goodwill>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i99afbe71598e40ef97034d2edf4c411e_D20210608-20210608"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMjM3_3668b6f3-c379-438b-9bf4-a2f516849dae"
      unitRef="usd">25000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i99afbe71598e40ef97034d2edf4c411e_D20210608-20210608"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMzE2_1afb64f8-d40e-4433-b232-eef26d35c69a"
      unitRef="usd">5000000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i99afbe71598e40ef97034d2edf4c411e_D20210608-20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMzMz_dea2d21e-d3dd-4763-9eb1-df14562c9f3c"
      unitRef="shares">307730</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <ccrn:BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment
      contextRef="i93a5acd42c2647e59b5add3dd10a6587_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMTA5OTUxMTY0MjkxNQ_b6b5b17b-f714-4808-b818-1d83a599ece9"
      unitRef="usd">1100000</ccrn:BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment>
    <ccrn:BusinessCombinationContingentConsiderationTerm
      contextRef="i99afbe71598e40ef97034d2edf4c411e_D20210608-20210608"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfNTQ4_5e9f0cb6-02fe-404c-aca7-c045bea8c696">P3Y</ccrn:BusinessCombinationContingentConsiderationTerm>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfNjE3_a81e2a3e-4bad-4db9-b9f4-392ca5456640"
      unitRef="usd">15000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i6d3157fac8554807a3ac2c4583f90eca_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfNjY5_8760bc7d-8c98-488d-a5a7-e577cd792467"
      unitRef="usd">7500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i6d3157fac8554807a3ac2c4583f90eca_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfNzU1_fae3f54c-8acd-4c3b-bfab-f88b010d0f6a"
      unitRef="usd">7500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMjc0MA_4e18ebb2-ea2e-4dfb-95c7-1cc27594e4d4">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value of the assets acquired and liabilities assumed on June 8, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability - non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnout liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfMS0xLTEtMS0yOTE1OA_f92e3889-9cd4-4177-b5c3-24d6e8b0b3d7"
      unitRef="usd">957000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfMi0xLTEtMS0yOTE1OA_a032eb42-f33c-463d-a9e9-a90e91bbc5d0"
      unitRef="usd">11991000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfMy0xLTEtMS0yOTE1OA_ae61efdb-ef8c-45d8-b60c-5ca1ccf6c579"
      unitRef="usd">59000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfNC0xLTEtMS0yOTE1OA_30dd469b-25ff-4b64-b3aa-7ca584aebfe6"
      unitRef="usd">10000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <ccrn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets
      contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfNS0xLTEtMS0zNjQ0NQ_ec828296-1677-4822-8861-5ad3e1d4b1ae"
      unitRef="usd">1078000</ccrn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets>
    <us-gaap:Goodwill
      contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfNS0xLTEtMS0yOTE1OA_340e4cbe-0f34-485f-bd7e-6e00ef00ca20"
      unitRef="usd">22066000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfNi0xLTEtMS0yOTE1OA_15ae9184-9c53-4e1f-af17-f18e087f74bc"
      unitRef="usd">14200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <ccrn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill
      contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfNy0xLTEtMS0yOTE1OA_a75380b5-47a8-4b1b-acb5-f4c9d70cc83c"
      unitRef="usd">50361000</ccrn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfOC0xLTEtMS0yOTE1OA_46787b87-0d05-432c-a4b9-0369c94f7d9c"
      unitRef="usd">3562000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <ccrn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits
      contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfOS0xLTEtMS0yOTE1OA_dee8a54b-8446-47d8-8ddf-6c35e06a9f08"
      unitRef="usd">1387000</ccrn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits>
    <ccrn:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent
      contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfMTEtMS0xLTEtMzY0NTI_bc347e2e-b67e-4502-a0c9-b632d8439afb"
      unitRef="usd">316000</ccrn:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent>
    <ccrn:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent
      contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfMTItMS0xLTEtMzY0NTI_4496bb23-a6a7-485a-ba63-b1bb8cb103fd"
      unitRef="usd">762000</ccrn:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability
      contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfMTAtMS0xLTEtMjkxNTg_5d52130c-7060-4b7c-a590-f5732b3a176b"
      unitRef="usd">15000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfMTEtMS0xLTEtMjkxNTg_59377d2f-68a0-426c-ac29-e1cb5ab5e200"
      unitRef="usd">21027000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RhYmxlOjgxMjA0MjhlZGRlMTRiYzQ5OTM0M2QxNmFlYmMxMDNhL3RhYmxlcmFuZ2U6ODEyMDQyOGVkZGUxNGJjNDk5MzQzZDE2YWViYzEwM2FfMTItMS0xLTEtMjkxNTg_cf3191e0-d283-4a32-9ed9-9679b9b5c3dd"
      unitRef="usd">29334000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i7c6769ab62314e58bd5be4d34d3bb062_I20210608"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMTUwOQ_45470e3c-3aa5-4a2b-bace-fa97c1add698"
      unitRef="usd">14200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="id5ac2467fe50486d918b7f212f790165_D20210608-20210608"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMTU4Nw_ade074e8-f907-49b3-a08b-249b448ec23c">P11Y6M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:Goodwill
      contextRef="i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMTc2MQ_ea2cda0d-e13f-42af-bd80-97d81bc6f394"
      unitRef="usd">22100000</us-gaap:Goodwill>
    <us-gaap:NotesPayable
      contextRef="ib4c754f48f6947ce94f0c29faed347d7_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMTA5OTUxMTY0MTgzNA_075fb178-d46c-4bad-8c39-a74b9244dedc"
      unitRef="usd">7300000</us-gaap:NotesPayable>
    <ccrn:NotePayableNumberOfPaymentInstallments
      contextRef="ib4c754f48f6947ce94f0c29faed347d7_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMzg0ODI5MDcxMjY2Mw_ac53bd64-a43d-43cc-a7cc-ef2c02fc6054"
      unitRef="installment">3</ccrn:NotePayableNumberOfPaymentInstallments>
    <ccrn:NotePayableNumberOfInstallmentsPaid
      contextRef="idb38d75eba334b9c9661cc92d3d27b1e_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMTA5OTUxMTY0MTkyNg_d6ece42f-2dcd-4575-a40c-eb9a112873e1"
      unitRef="installment">2</ccrn:NotePayableNumberOfInstallmentsPaid>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i693a80db9468442f89e54f2d5e8f012c_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMzg0ODI5MDcxMjY2Nw_b3026ad5-dc8f-4a3e-8678-88a38c001d73"
      unitRef="usd">2400000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="ifc034a2451eb4ad2a115858bbcbb76a3_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMzg0ODI5MDcxMjY2Nw_e2559305-7eb4-4fe0-b847-5bb3ed1985d1"
      unitRef="usd">2400000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i70a127889d9c4f5facf6c1e12bc5ef60_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80Ni9mcmFnOmNmMTY0NmUyZjNkMzQwZjliNGZmZjA5ODAxMmFlMzM5L3RleHRyZWdpb246Y2YxNjQ2ZTJmM2QzNDBmOWI0ZmZmMDk4MDEyYWUzMzlfMzg0ODI5MDcxMjY3MQ_0e1d8e8b-62bc-4bd7-a9a3-5fed86c4cbd8"
      unitRef="usd">2600000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80OS9mcmFnOmM0NGY3MzBkYzU0MzRmZmY4NGQxYjM5MWE2MjkxMGM2L3RleHRyZWdpb246YzQ0ZjczMGRjNTQzNGZmZjg0ZDFiMzkxYTYyOTEwYzZfOTg0_1cc429d6-b1d0-4d20-9dec-6313f87721da">COMPREHENSIVE INCOME&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total comprehensive income includes net income or loss and foreign currency translation adjustments, net of any related deferred taxes, and is included within the accompanying condensed consolidated statements of operations. Certain of the Company&#x2019;s foreign subsidiaries use their respective local currency as their functional currency. Assets and liabilities of these operations are translated at the exchange rates in effect on the balance sheet date. Income statement items are translated at the average exchange rates for the period. The cumulative impact of currency fluctuations related to the balance sheet translation is included in accumulated other comprehensive loss in the accompanying condensed consolidated balance sheets and was an unrealized loss of&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $1.4&#160;million at March 31, 2022 and $1.3 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; at December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <ccrn:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80OS9mcmFnOmM0NGY3MzBkYzU0MzRmZmY4NGQxYjM5MWE2MjkxMGM2L3RleHRyZWdpb246YzQ0ZjczMGRjNTQzNGZmZjg0ZDFiMzkxYTYyOTEwYzZfMTA5OTUxMTYyOTA3Mw_febb1d0d-80ce-4fb3-a709-eb05a1f227b9"
      unitRef="usd">-1400000</ccrn:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax>
    <ccrn:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF80OS9mcmFnOmM0NGY3MzBkYzU0MzRmZmY4NGQxYjM5MWE2MjkxMGM2L3RleHRyZWdpb246YzQ0ZjczMGRjNTQzNGZmZjg0ZDFiMzkxYTYyOTEwYzZfNzkz_8defc148-7545-4892-91a8-b5e73ee9cc70"
      unitRef="usd">-1300000</ccrn:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RleHRyZWdpb246NThkMTVkNzIyYWUzNDhlZTg2OWRmNzAyZTMyNDM1MmVfNDA1_5ef214f7-90d4-40cd-b247-ff4ddb66876c">EARNINGS PER SHARE&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of the numerator and denominator for the computation of the basic and diluted earnings per share:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(amounts in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to common stockholders - Basic and Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares - Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of diluted shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Share-based awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares - Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share attributable to common stockholders - Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share attributable to common stockholders - Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2021, there were 4,276 share-based awards that could potentially dilute net income per share attributable to common stockholders in the future that were not included in the computation of diluted net income per share attributable to common stockholders because to do so would have been anti-dilutive for that period. There were no such share-based awards for the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RleHRyZWdpb246NThkMTVkNzIyYWUzNDhlZTg2OWRmNzAyZTMyNDM1MmVfNDAy_94664a6d-b386-4e8e-a5c9-2d3920bdfdf7">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of the numerator and denominator for the computation of the basic and diluted earnings per share:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(amounts in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to common stockholders - Basic and Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares - Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of diluted shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Share-based awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares - Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share attributable to common stockholders - Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share attributable to common stockholders - Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfNS0xLTEtMS0yOTE1OA_b0162f79-bfdb-4c25-8b59-e7e1b1ab38ac"
      unitRef="usd">61983000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfNS0xLTEtMS0yOTE1OA_da6b6529-eb88-4411-a616-e6f1df28885e"
      unitRef="usd">61983000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfNS0zLTEtMS0yOTE1OA_8a202ec9-689f-4e58-bc35-2210125f8c50"
      unitRef="usd">19448000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfNS0zLTEtMS0yOTE1OA_8b5583e9-376d-47e2-8cde-d6dc33fd7cc4"
      unitRef="usd">19448000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfOC0xLTEtMS0yOTE1OA_f99de772-2fa0-42d3-a5f6-1ea0ed9e0e7a"
      unitRef="shares">37028000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfOC0zLTEtMS0yOTE1OA_a685c58d-041c-4a7e-ad60-74116a89abcc"
      unitRef="shares">36181000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfMTAtMS0xLTEtMjkxNTg_cc413781-f9ce-44dc-9cc7-d09ef4eed39c"
      unitRef="shares">945000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfMTAtMy0xLTEtMjkxNTg_95226b53-6c18-42a1-bec2-dded92a0b09c"
      unitRef="shares">853000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfMTEtMS0xLTEtMjkxNTg_eae4d3b6-289a-4410-9ba7-74ab6e2c4939"
      unitRef="shares">37973000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfMTEtMy0xLTEtMjkxNTg_40a1c77c-79d2-4bbe-9326-cb692b5ace2e"
      unitRef="shares">37034000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfMTMtMS0xLTEtMjkxNTg_5cb0ab01-673b-496b-9588-2d05d315a7ac"
      unitRef="usdPerShare">1.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfMTMtMy0xLTEtMjkxNTg_34cefbc8-50ea-471d-aa63-e308c9eb077d"
      unitRef="usdPerShare">0.54</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfMTUtMS0xLTEtMjkxNTg_181a39de-e6b0-4601-a0b9-0138a792c3ce"
      unitRef="usdPerShare">1.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RhYmxlOjA1ZDk0MzU2ODUyZTQxY2FiZjI1NGNiMWQzYTk2NzU5L3RhYmxlcmFuZ2U6MDVkOTQzNTY4NTJlNDFjYWJmMjU0Y2IxZDNhOTY3NTlfMTUtMy0xLTEtMjkxNTg_ec24cdc4-bfce-42dc-b6c3-a492111a522e"
      unitRef="usdPerShare">0.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic58e2e7af6004065bc3df5d18eda6a7f_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RleHRyZWdpb246NThkMTVkNzIyYWUzNDhlZTg2OWRmNzAyZTMyNDM1MmVfMTA5OTUxMTYyODkyMQ_670101ad-5d59-4aa0-ab61-9adf49506775"
      unitRef="shares">4276000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1a13d2d2a7ff4121984d558f70731480_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81Mi9mcmFnOjU4ZDE1ZDcyMmFlMzQ4ZWU4NjlkZjcwMmUzMjQzNTJlL3RleHRyZWdpb246NThkMTVkNzIyYWUzNDhlZTg2OWRmNzAyZTMyNDM1MmVfMTA5OTUxMTYyODkyNw_587d1a86-a934-40fd-bc27-c1e7d5013a08"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RleHRyZWdpb246ZGE4NDhmYTcxMjJkNGE5Nzg2NGI3MmNkNjdkNWIwM2NfNDMyMw_f960f133-e4c8-4220-9abf-9eb31bcd2477">GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had the following acquired intangible assets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Databases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-compete agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names, indefinite-lived&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, estimated annual amortization expense is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.989%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ending December&#160;31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Goodwill, Trade Names, and Other Intangible Assets Impairment &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company tests reporting units&#x2019; goodwill and intangible assets with indefinite lives for impairment annually during the fourth quarter and more frequently if impairment indicators exist. The Company performs quarterly qualitative assessments of significant events and circumstances such as reporting units&#x2019; historical and current results, assumptions regarding future performance, strategic initiatives and overall economic factors, including COVID, and macro-economic developments, to determine the existence of potential indicators of impairment and assess if it is more likely than not that the fair value of reporting units or intangible assets is less than their carrying value. If indicators of impairments are identified a quantitative impairment test is performed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2022, the Company performed a qualitative assessment of each of its reporting units and determined it was not more likely than not that the fair value of its reporting units dropped below their carrying value. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;lthough management believes that the Company's current estimates and assumptions utilized in its qualitative testing are reasonable and supportable, including its assumptions on the impact and timing related to COVID, there can be no assurance that the estimates and assumptions management used for purposes of its qualitative assessment as of March 31, 2022 will prove to be accurate predictions of future performance.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2022, goodwill by reporting segment was: $116.7&#160;million for Nurse and Allied Staffing and $2.8&#160;million for Physician Staffing, for a total of $119.5&#160;million. Goodwill includes amounts acquired from the acquisitions of WSG and Selected, calculated as the excess of the fair value of consideration exchanged as compared to the fair value of identifiable net assets acquired. See Note 4 - Acquisitions. During the measurement period, which is not to exceed one year from the acquisition date, the Company may record adjustments to the assets acquired or liabilities assumed, with a corresponding offset to goodwill. Upon conclusion of the measurement period, any subsequent adjustments would be recorded to earnings.&lt;/span&gt;&lt;/div&gt;For its long-lived assets and definite-lived intangible assets, the Company reviews for impairment whenever events or changes in circumstances indicate the carrying amount may not be recoverable. As of March 31, 2022, the Company performed a qualitative assessment of its trade names and other intangible assets and determined it was not more likely than not that their carrying value may not be recoverable. During the three months ended March 31, 2021, the Company wrote off a discontinued software development project, resulting in an immaterial impairment charge.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RleHRyZWdpb246ZGE4NDhmYTcxMjJkNGE5Nzg2NGI3MmNkNjdkNWIwM2NfNDMzMw_16b89e71-e5fe-487e-98b3-c6f417a40edb">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had the following acquired intangible assets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Databases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-compete agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names, indefinite-lived&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i57ab4d2044634d1997af982de4e6ecf0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNC0xLTEtMS0yOTE1OA_ab610927-427f-48b5-aefc-9e0da4f1ddb5"
      unitRef="usd">30530000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i57ab4d2044634d1997af982de4e6ecf0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNC0zLTEtMS0yOTE1OA_eb88b524-9fdb-4294-8b56-d37b7c3bd790"
      unitRef="usd">19138000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i57ab4d2044634d1997af982de4e6ecf0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNC01LTEtMS0yOTE1OA_cd7a6e0c-1873-4317-ba37-bc5f75603c3c"
      unitRef="usd">11392000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ibe98f92bed0843dbbed8160370da0659_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNC03LTEtMS0yOTE1OA_69ce716c-a7bd-42fa-bf84-5f502a784d32"
      unitRef="usd">30530000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibe98f92bed0843dbbed8160370da0659_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNC05LTEtMS0yOTE1OA_a05984ea-63eb-4e22-be07-e11038beacac"
      unitRef="usd">18375000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ibe98f92bed0843dbbed8160370da0659_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNC0xMS0xLTEtMjkxNTg_ddf277ae-5069-477f-b34b-61339eaf21f3"
      unitRef="usd">12155000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idfe0db93f1004e008d12e054ef21e25c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNS0xLTEtMS0yOTE1OA_c8ec48ba-c9a0-425b-bd83-58b5873e5d81"
      unitRef="usd">47738000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idfe0db93f1004e008d12e054ef21e25c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNS0zLTEtMS0yOTE1OA_a539d7ba-ca7c-4b78-be14-dd1d950ebbcd"
      unitRef="usd">18603000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idfe0db93f1004e008d12e054ef21e25c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNS01LTEtMS0yOTE1OA_fc78bf44-0e70-4d70-9f42-5930f390d1d6"
      unitRef="usd">29135000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i55a5b324377c46699174b4a56c307cf9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNS03LTEtMS0yOTE1OA_c2fb53e7-6715-405e-92b8-ec2400040d18"
      unitRef="usd">47738000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i55a5b324377c46699174b4a56c307cf9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNS05LTEtMS0yOTE1OA_a2bee017-a7ed-486f-af4b-22404c70957d"
      unitRef="usd">17581000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i55a5b324377c46699174b4a56c307cf9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNS0xMS0xLTEtMjkxNTg_574790aa-2ad6-46bd-9ee6-fb396ff567c4"
      unitRef="usd">30157000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i47c182809d2b46f9a875cd3fd058837d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNi0xLTEtMS0yOTE1OA_8bf2731f-9045-436e-b468-22a0b1d4e221"
      unitRef="usd">304000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i47c182809d2b46f9a875cd3fd058837d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNi0zLTEtMS0yOTE1OA_5e606afa-a932-4a74-93ea-9b1441d2b21b"
      unitRef="usd">288000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i47c182809d2b46f9a875cd3fd058837d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNi01LTEtMS0yOTE1OA_7a2daeb0-b6e5-47f5-bc04-66a8883aef35"
      unitRef="usd">16000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if89026b691fb4fb7b264f411d8d9b428_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNi03LTEtMS0yOTE1OA_2892ee68-d0d4-4bd0-bf9f-69cf68a51351"
      unitRef="usd">304000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if89026b691fb4fb7b264f411d8d9b428_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNi05LTEtMS0yOTE1OA_28acbd8d-6a4a-41a3-b012-c533ef9d9ba1"
      unitRef="usd">272000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if89026b691fb4fb7b264f411d8d9b428_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNi0xMS0xLTEtMjkxNTg_6174b63b-4ab8-4fa2-826e-1f6a9d1c86db"
      unitRef="usd">32000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNy0xLTEtMS0yOTE1OA_4336fcae-11f4-4aff-a888-c9a8f950a495"
      unitRef="usd">78572000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNy0zLTEtMS0yOTE1OA_5a20afe0-58c1-48fa-bb53-c70f7d283477"
      unitRef="usd">38029000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNy01LTEtMS0yOTE1OA_46af9022-7748-494b-8122-20c843aaac20"
      unitRef="usd">40543000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNy03LTEtMS0yOTE1OA_6c6bac8a-60bd-483c-9fb1-dfe97ee3825b"
      unitRef="usd">78572000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNy05LTEtMS0yOTE1OA_89809a19-3a52-49ac-aa94-0e888a2638ef"
      unitRef="usd">36228000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfNy0xMS0xLTEtMjkxNTg_59b16482-4408-4b69-b870-d4db6eb96b96"
      unitRef="usd">42344000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedTradeNames
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfMTAtNS0xLTEtMjkxNTg_98d7b65b-16f8-4fbd-944c-7585066082cd"
      unitRef="usd">5900000</us-gaap:IndefiniteLivedTradeNames>
    <us-gaap:IndefiniteLivedTradeNames
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOmE5NzJiZDYxODY2YTRhZGY4YTRmZTlhMTlmMzdhMDJmL3RhYmxlcmFuZ2U6YTk3MmJkNjE4NjZhNGFkZjhhNGZlOWExOWYzN2EwMmZfMTAtMTEtMS0xLTI5MTU4_86ad37e9-00bb-44de-9188-f03a73227b8f"
      unitRef="usd">5900000</us-gaap:IndefiniteLivedTradeNames>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RleHRyZWdpb246ZGE4NDhmYTcxMjJkNGE5Nzg2NGI3MmNkNjdkNWIwM2NfNDMzNQ_2c3719d3-c4ea-401a-b608-2f96edec5301">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, estimated annual amortization expense is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.989%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ending December&#160;31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOjU3ZGQ1Y2E5NTljYjRlNmNhYWQ5NGZiZDlkMzM2ZjVlL3RhYmxlcmFuZ2U6NTdkZDVjYTk1OWNiNGU2Y2FhZDk0ZmJkOWQzMzZmNWVfMS0xLTEtMS0yOTE1OA_c4c867db-1a86-4b3a-96bd-c12e6757eaa1"
      unitRef="usd">5374000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOjU3ZGQ1Y2E5NTljYjRlNmNhYWQ5NGZiZDlkMzM2ZjVlL3RhYmxlcmFuZ2U6NTdkZDVjYTk1OWNiNGU2Y2FhZDk0ZmJkOWQzMzZmNWVfMi0xLTEtMS0yOTE1OA_5383db97-a1a5-4105-a298-ee20d7a0c555"
      unitRef="usd">7117000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOjU3ZGQ1Y2E5NTljYjRlNmNhYWQ5NGZiZDlkMzM2ZjVlL3RhYmxlcmFuZ2U6NTdkZDVjYTk1OWNiNGU2Y2FhZDk0ZmJkOWQzMzZmNWVfMy0xLTEtMS0yOTE1OA_620d0b87-f293-4e71-b560-90c9f79b9072"
      unitRef="usd">6479000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOjU3ZGQ1Y2E5NTljYjRlNmNhYWQ5NGZiZDlkMzM2ZjVlL3RhYmxlcmFuZ2U6NTdkZDVjYTk1OWNiNGU2Y2FhZDk0ZmJkOWQzMzZmNWVfNC0xLTEtMS0yOTE1OA_8ac75a2c-e622-453e-b9f2-b657dd3166a1"
      unitRef="usd">5921000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOjU3ZGQ1Y2E5NTljYjRlNmNhYWQ5NGZiZDlkMzM2ZjVlL3RhYmxlcmFuZ2U6NTdkZDVjYTk1OWNiNGU2Y2FhZDk0ZmJkOWQzMzZmNWVfNS0xLTEtMS0yOTE1OA_90329f19-f102-4209-aa90-2adce5a18e5c"
      unitRef="usd">4751000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <ccrn:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOjU3ZGQ1Y2E5NTljYjRlNmNhYWQ5NGZiZDlkMzM2ZjVlL3RhYmxlcmFuZ2U6NTdkZDVjYTk1OWNiNGU2Y2FhZDk0ZmJkOWQzMzZmNWVfNi0xLTEtMS0yOTE1OA_a90cdb34-a27a-4435-9074-4b479f4f0697"
      unitRef="usd">10901000</ccrn:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RhYmxlOjU3ZGQ1Y2E5NTljYjRlNmNhYWQ5NGZiZDlkMzM2ZjVlL3RhYmxlcmFuZ2U6NTdkZDVjYTk1OWNiNGU2Y2FhZDk0ZmJkOWQzMzZmNWVfNy0xLTEtMS0yOTE1OA_7da4e9ee-b53b-4e63-b7a0-ceb656f8f621"
      unitRef="usd">40543000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="i24a8be762a2a4907a7c8cca553b30556_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RleHRyZWdpb246ZGE4NDhmYTcxMjJkNGE5Nzg2NGI3MmNkNjdkNWIwM2NfMTA5OTUxMTYzNDE5MQ_53f946a7-5b42-4937-a89b-ebc3df6c6712"
      unitRef="usd">116700000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i94654808d0da4588b241ae072d795aa4_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RleHRyZWdpb246ZGE4NDhmYTcxMjJkNGE5Nzg2NGI3MmNkNjdkNWIwM2NfMTA5OTUxMTYzNDIwNw_49142779-5bd3-4152-8878-de0bcef4325d"
      unitRef="usd">2800000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81NS9mcmFnOmRhODQ4ZmE3MTIyZDRhOTc4NjRiNzJjZDY3ZDViMDNjL3RleHRyZWdpb246ZGE4NDhmYTcxMjJkNGE5Nzg2NGI3MmNkNjdkNWIwM2NfMTA5OTUxMTYzNDIyMQ_c43f4b57-e133-4e0f-b1fd-e7a9fc8cb285"
      unitRef="usd">119500000</us-gaap:Goodwill>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfODQ3Nw_afdf7267-3b56-4a65-b04a-63fbec2ec20c">DEBT&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's long-term debt consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan, interest of 6.50% at March 31, 2022 and December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Secured Asset-Based Loan, interest of 1.88% and 1.60% at March 31, 2022 and December 31, 2021, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note Payable, interest of 2.00% per annum at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion - note payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion - term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2022 and December 31, 2021, the current portion of the term loan is included in current portion of debt on the condensed consolidated balance sheets. In addition, the current portion of the note payable as of December 31, 2021 is included in current portion of debt on the condensed consolidated balance sheets. The Company has elected to present the debt issuance costs associated with its revolving line-of-credit as an asset, which is included in other non-current assets on the condensed consolidated balance sheets. As a result, the long-term debt in the above table will not agree to long-term debt, net of current portion on the condensed consolidated balance sheets herein.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2022, the aggregate schedule for maturities of debt are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Senior Secured Asset-Based Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Through Years Ending December&#160;31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Term Loan Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On June 8, 2021, the Company entered into a Term Loan Credit Agreement (Term Loan Agreement) with&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; certain lenders identified therein (collectively, the Lenders) and Wilmington Trust&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, National Association as administrative agent and collateral agent, pursuant to which the Lenders extended to the Company a six-year second lien subordinated term loan in the amount of $100.0&#160;million (term loan). The term loan has an interest rate of one-month London Inter-Bank Offered Rate (LIBOR) plus 5.75% per annum, subject to a 0.75% LIBOR floor. The term loan was used to pay the cash consideration, as well as any costs, fees, and expenses in connection with the WSG acquisition (see Note 4 - Acquisitions), with the remainder used to pay down a &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;portion of the asset based credit facility. Fees paid in connection with the Term Loan Agreement have been included as debt issuance costs and as a reduction to the carrying amount of the term loan and are expected to be amortized to interest expense over the term of the Term Loan Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The borrowings under the Term Loan Agreement generally bear interest at a variable rate based on either LIBOR or Base Rate (as defined in the Term Loan Agreement) and are subject to mandatory prepayments of principal payable in quarterly installments, commencing on September 30, 2021, with each installment being in the aggregate principal amount of $0.3 million (subject to adjustment as a result of prepayments) provided that, to the extent not previously paid, the aggregate unpaid principal balance would be due and payable on the maturity date. The Term Loan Agreement contains various restrictions and covenants applicable to the Company and its subsidiaries, including a covenant to maintain a minimum net leverage ratio. The Company was in compliance with this covenant as of March 31, 2022. Obligations under the Term Loan Agreement are secured by substantially all the assets of the borrowers and guarantors under the Term Loan Agreement, subject to customary exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 18, 2021, the Company amended its Term Loan Agreement (Term Loan First Amendment), which provided the Company an incremental term loan in an aggregate amount equal to $75.0&#160;million. Additionally, the Term Loan First Amendment increased the aggregate amount of all increases (as defined in the Term Loan Agreement) to be no greater than $115.0&#160;million. The borrowings will be used primarily to fund organic growth. Commencing on December 31, 2021, installments of the mandatory prepayments will be in the aggregate principal amount of $0.4&#160;million. All other terms, conditions, covenants, and pricing of the Term Loan Agreement remain the same. In conjunction with the Term Loan First Amendment, the Company entered into the Term Loan First Amendment to the Intercreditor Agreement, effective as of November 18, 2021, which sets forth the lien priority, relative rights, and other creditors&#x2019; rights issues in respect of the collateral lenders.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The term loan is secured by a second-priority security interest in the collateral as defined in the ABL Credit Agreement (Loan Agreement) (as described below), and Wells Fargo Bank, National Association as agent, as amended by the First Amendment, Second Amendment, Third Amendment, Fourth Amendment, and Fifth Amendment to the Loan Agreement (as described below). The lien priority, relative rights, and other creditors&#x2019; rights issues in respect of the collateral lenders are set forth in the Intercreditor Agreement, by and among Wells Fargo Bank, National Association, as first lien agent, and Wilmington Trust, National Association, as second lien agent, as amended, restated, amended and restated, supplemented or otherwise modified from time to time in accordance with the terms thereof dated June 8, 2021 (Intercreditor Agreement).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2019 Loan Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective October 25, 2019, the Company terminated its commitments under its prior senior credit facility entered into in August 2017 and entered into a Loan Agreement, by and among the Company and certain of its domestic subsidiaries, as borrowers or guarantors, Wells Fargo, PNC Bank N.A., as well as other Lenders (as defined) from time to time parties thereto. The Loan Agreement provides for a five-year revolving senior secured asset-based credit facility (ABL) in the aggregate principal amount of up to $120.0&#160;million (as described below), including a sublimit for swing loans up to $15.0&#160;million and a $35.0&#160;million sublimit for standby letters of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 30, 2020, the Company amended its Loan Agreement (First Amendment), which increased the current aggregate committed size of the ABL from $120.0&#160;million to $130.0&#160;million. All other terms, conditions, covenants, and pricing of the Loan Agreement remained the same. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 8, 2021, the Company amended its Loan Agreement (Second Amendment), which increased the current aggregate committed size of the ABL from $130.0&#160;million to $150.0&#160;million, increased certain borrowing base sub-limits, and decreased both the cash dominion event and financial reporting triggers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 8, 2021, the Company amended its Loan Agreement (Third Amendment), which permits the incurrence of indebtedness and grant of security as set forth in the Loan Agreement and in accordance with the Intercreditor Agreement, and provides mechanics relating to a transition away from LIBOR as a benchmark interest rate to a replacement alternative benchmark rate or mechanism for loans made in U.S. dollars.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 18, 2021, the Company amended its Loan Agreement (Fourth Amendment), whereby the permitted indebtedness (as defined in the Loan Agreement), was increased to $175.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 21, 2022, the Company amended its Loan Agreement (Fifth Amendment), which increased the current aggregate committed size of the ABL from $150.0 million to $300.0 million, extended the credit facility for an additional five years, and increased certain borrowing base sub-limits. In addition, the agreement provides the option for all or a portion of the borrowings to bear interest at a rate based on the Secured Overnight Financing Rate (SOFR) or Base Rate, at the election of the borrowers, plus an applicable margin. The applicable margin will increase 10 basis points due to the credit spread associated with the transition to SOFR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These amendments were treated as modifications of debt and, as a result, the associated fees and costs were included in debt issuance costs and will be amortized ratably over the remaining term of the Loan Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Availability of the ABL commitments is subject to a borrowing base of up to 85% of secured eligible accounts receivable, subject to adjustment at certain quality levels, minus customary reserves and subject to customary adjustments. Revolving loans and letters of credit issued under the Loan Agreement reduce availability under the ABL on a dollar-for-dollar basis. Availability under the ABL will be used for general corporate purposes. At March 31, 2022, borrowing base availability under the ABL was $300.0&#160;million and the Company had $51.5&#160;million of borrowings drawn, as well as $17.5&#160;million of letters of credit outstanding related to workers' compensation and professional liability policies, leaving $231.0&#160;million of excess availability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2022, the interest rate spreads and fees under the Loan Agreement were based on SOFR plus 1.85% for the revolving portion of the borrowing base. The Base Rate (as defined by the Loan Agreement) margin would have been 0.75%  for the revolving portion&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The SOFR and Base Rate margins are subject to monthly pricing adjustments, pursuant to a pricing matrix based on the Company&#x2019;s excess availability under the revolving credit facility. In addition, the facility is subject to an unused line fee, letter of credit fees, and an administrative fee. The unused line fee is 0.375% of the average daily unused portion of the revolving credit facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Loan Agreement contains various restrictions and covenants applicable to the Company and its subsidiaries, including a covenant to maintain a minimum fixed charge coverage ratio. The Company was in compliance with this covenant as of March 31, 2022. Obligations under the ABL are secured by substantially all the assets of the borrowers and guarantors, subject to customary exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Note Payable&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2020, the Company entered into a note payable of $7.3&#160;million related to contingent consideration assumed as part of a prior period acquisition, payable in three installments. The first two installments of $2.4&#160;million each were paid in the second quarter of 2020 and in the first quarter of 2021, respectively. The third and final installment of $2.6&#160;million, including interest, was paid in the first quarter of 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfODQ4MQ_74d2996e-3a70-42b2-bc32-7f1461cac13a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's long-term debt consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan, interest of 6.50% at March 31, 2022 and December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Secured Asset-Based Loan, interest of 1.88% and 1.60% at March 31, 2022 and December 31, 2021, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note Payable, interest of 2.00% per annum at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion - note payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion - term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i010ea7a8f38b4cb2ad448e4252b0d49d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfMy0wLTEtMS0yOTE1OC90ZXh0cmVnaW9uOmE4MDgyYjJkMGFhYTRmNzNhZDlhMzkyZjkyMjIwZjZiXzI3_4fa15427-88fd-46ce-8b9e-589d37340d2b"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfMy0wLTEtMS0yOTE1OC90ZXh0cmVnaW9uOmE4MDgyYjJkMGFhYTRmNzNhZDlhMzkyZjkyMjIwZjZiXzI3_7ddc6aa0-6a63-4de4-ab7d-552063d3a2dd"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfMy0xLTEtMS0yOTE1OA_1209fb0d-119e-4a25-9e79-dce4abec1d4f"
      unitRef="usd">173875000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfMy0zLTEtMS0yOTE1OA_b7a92633-9ab3-4b42-8624-2219f719625b"
      unitRef="usd">5151000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i010ea7a8f38b4cb2ad448e4252b0d49d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfMy01LTEtMS0yOTE1OA_ea894b07-318e-46e4-aa34-32d736dee4ad"
      unitRef="usd">174312000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i010ea7a8f38b4cb2ad448e4252b0d49d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfMy03LTEtMS0yOTE1OA_2809196a-874f-4732-bdc7-c78d90e707ab"
      unitRef="usd">5396000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="id40b9c2a2b954b16991ea116d1d59043_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNC0wLTEtMS0yOTE1OC90ZXh0cmVnaW9uOmE5YzIyOWY4ZDk0ZTRiYjI4ZTQ3YmRlMmRkNTRkMzg1XzQ5_02c52fea-32d4-4f0b-accc-fe88c924c674"
      unitRef="number">0.0188</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i5621975f70784aa29783102660abc224_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNC0wLTEtMS0yOTE1OC90ZXh0cmVnaW9uOmE5YzIyOWY4ZDk0ZTRiYjI4ZTQ3YmRlMmRkNTRkMzg1XzU2_4f76a5db-c06c-4d96-852f-a5eb62f50759"
      unitRef="number">0.0160</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id40b9c2a2b954b16991ea116d1d59043_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNC0xLTEtMS0yOTE1OA_94d3b622-d99c-4740-b6d9-c1816e3494ec"
      unitRef="usd">51501000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="id40b9c2a2b954b16991ea116d1d59043_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNC0zLTEtMS0yOTE1OA_c2a4a120-7710-400e-99dc-3aa912e9adc8"
      unitRef="usd">3990000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5621975f70784aa29783102660abc224_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNC01LTEtMS0yOTE1OA_a733b3de-6f12-4547-9014-7885f9120bf8"
      unitRef="usd">9200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i5621975f70784aa29783102660abc224_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNC03LTEtMS0yOTE1OA_635268b5-b0e7-406c-8a99-0686359a7ec1"
      unitRef="usd">991000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5b7ceee3e87f40c494783ab3badd4980_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNS0wLTEtMS0yOTE1OC90ZXh0cmVnaW9uOjYwNWM3N2VkNzkzMjQ1YWM4YTk3NmFjMDU1NjU1OWIyXzMw_758c76bc-160d-4da1-a6ac-e6f8fc82f6a5"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i18d296e84536494a9f07c3e749a9af7c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNS0xLTEtMS0yOTE1OA_581ef7a7-400e-45ff-8652-56b12f49b4ed"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i18d296e84536494a9f07c3e749a9af7c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNS0zLTEtMS0yOTE1OA_72803e3d-ccba-4e72-8651-a4eb54db38b7"
      unitRef="usd">0</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5b7ceee3e87f40c494783ab3badd4980_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNS01LTEtMS0yOTE1OA_8328d648-4401-40c8-bce5-4cb9c8fb72fd"
      unitRef="usd">2426000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i5b7ceee3e87f40c494783ab3badd4980_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNS03LTEtMS0yOTE1OA_1c946d7b-450c-4735-868d-6f2ffd668a31"
      unitRef="usd">0</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNi0xLTEtMS0yOTE1OA_ef41249b-d7b0-42dc-bb52-76019259e2c2"
      unitRef="usd">225376000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNi0zLTEtMS0yOTE1OA_b8abcb1c-a9ad-4df1-ac43-1ba3fdc1f4e9"
      unitRef="usd">9141000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNi01LTEtMS0yOTE1OA_e74ba88d-5e91-4dd4-9a3a-1236bb48ee8d"
      unitRef="usd">185938000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNi03LTEtMS0yOTE1OA_6d72b390-23f7-4a2c-b4e4-4934271c71a4"
      unitRef="usd">6387000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebtCurrent
      contextRef="i18d296e84536494a9f07c3e749a9af7c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNy0xLTEtMS0yOTE1OA_e0efc99b-08a4-4d07-8f89-28bd810a5651"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i5b7ceee3e87f40c494783ab3badd4980_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfNy01LTEtMS0yOTE1OA_1654c957-022d-468f-a98e-f9a51204b93b"
      unitRef="usd">2426000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfOC0xLTEtMS0yOTE1OA_4713d71e-3ff4-40f5-b2b0-3b4820d3de8b"
      unitRef="usd">1750000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i010ea7a8f38b4cb2ad448e4252b0d49d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfOC01LTEtMS0yOTE1OA_dde97bf0-49c3-4418-9738-798704141810"
      unitRef="usd">1750000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfOS0xLTEtMS0yOTE1OA_2c458e3a-32ac-4d68-af91-51f8f8329ea3"
      unitRef="usd">223626000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfOS0zLTEtMS0yOTE1OA_f87566a6-9790-4a12-84b5-ec5ced2fe8d8"
      unitRef="usd">9141000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfOS01LTEtMS0yOTE1OA_5b3a2bd8-7bf4-4f25-9968-523e299edc0c"
      unitRef="usd">181762000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjIxY2I1NTRjOTAwZDQzMWE5Y2MwYWY0MGZhN2U2OWMxL3RhYmxlcmFuZ2U6MjFjYjU1NGM5MDBkNDMxYTljYzBhZjQwZmE3ZTY5YzFfOS03LTEtMS0yOTE1OA_521e9ca0-addd-48ff-a626-579b55c04511"
      unitRef="usd">6387000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfODQ4NA_878bf812-623b-4200-b378-e008212b4125">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2022, the aggregate schedule for maturities of debt are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Senior Secured Asset-Based Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Through Years Ending December&#160;31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfMy0xLTEtMS0yOTE1OA_552982b2-6a81-4483-8826-355094bca66a"
      unitRef="usd">1312000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="id40b9c2a2b954b16991ea116d1d59043_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfMy0zLTEtMS0yOTE1OA_86256b30-0c7d-4461-b837-3daa997b6d43"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfNC0xLTEtMS0yOTE1OA_20f8974c-3d1c-47bc-b21a-9a1c9c201f4b"
      unitRef="usd">1750000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="id40b9c2a2b954b16991ea116d1d59043_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfNC0zLTEtMS0yOTE1OA_3afb4f15-bd2f-4a22-8de7-40f72757e3e2"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfNS0xLTEtMS0yOTE1OA_9673b29d-efce-4ae1-a477-74ac9713841d"
      unitRef="usd">1750000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="id40b9c2a2b954b16991ea116d1d59043_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfNS0zLTEtMS0yOTE1OA_0dd840a6-d85b-49e7-be58-b9d5e6238029"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfNi0xLTEtMS0yOTE1OA_99a23e0c-3a28-48ab-8105-0e2d8e234081"
      unitRef="usd">1750000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="id40b9c2a2b954b16991ea116d1d59043_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfNi0zLTEtMS0yOTE1OA_bbe409c0-2798-458a-91c6-a2ee351c75da"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfNy0xLTEtMS0yOTE1OA_83671746-9f43-4896-9cdf-937f249e5688"
      unitRef="usd">1750000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="id40b9c2a2b954b16991ea116d1d59043_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfNy0zLTEtMS0yOTE1OA_cc04981c-0d8f-4e64-8e78-e49870b8e27e"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <ccrn:LongTermDebtMaturityAfterYearFour
      contextRef="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfOC0xLTEtMS0yOTE1OA_be902e87-d9ca-4c6e-8060-bb5b18f6cff9"
      unitRef="usd">165563000</ccrn:LongTermDebtMaturityAfterYearFour>
    <ccrn:LongTermDebtMaturityAfterYearFour
      contextRef="id40b9c2a2b954b16991ea116d1d59043_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfOC0zLTEtMS0yOTE1OA_7f72a51c-6de9-4f6e-92b9-7c6aa0f18068"
      unitRef="usd">51501000</ccrn:LongTermDebtMaturityAfterYearFour>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfOS0xLTEtMS0yOTE1OA_4fa94845-8c28-4b18-ab39-0d085d8a839d"
      unitRef="usd">173875000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id40b9c2a2b954b16991ea116d1d59043_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RhYmxlOjRhMzY0MzQxNTllMDQxMTk4MmJlZTcwODg0YzlhNjNkL3RhYmxlcmFuZ2U6NGEzNjQzNDE1OWUwNDExOTgyYmVlNzA4ODRjOWE2M2RfOS0zLTEtMS0yOTE1OA_e3526fa5-ffce-427b-852c-b9c87b2b4068"
      unitRef="usd">51501000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="i82cd05f641874a9cbbe754810cef2c8a_D20210608-20210608"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfODQ4Mg_9744a90a-543f-4438-85ed-46888a34ec5d">P6Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i96ec9493e07f4d46bfd5d30d2e5c107c_I20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMTI5NA_d1489a96-af28-46d9-84d1-9846c97d95f1"
      unitRef="usd">100000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ib708536e37a243168ff725de39ebb968_D20210608-20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMTQwMg_59762908-7ea6-4ae9-9353-3b2ddf759e2c"
      unitRef="number">0.0575</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ccrn:DebtInstrumentVariableInterestRateFloor
      contextRef="ib708536e37a243168ff725de39ebb968_D20210608-20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMTQyOQ_3ea58b83-58b1-4bc9-8a3d-0e545c866f4a"
      unitRef="number">0.0075</ccrn:DebtInstrumentVariableInterestRateFloor>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="i82cd05f641874a9cbbe754810cef2c8a_D20210608-20210608"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMjI5MA_6683629d-1fb5-401d-ad10-948d32dbe813"
      unitRef="usd">300000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5020fde8638840f299ef873613611b4e_I20211118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMTA5OTUxMTYzOTgxNA_5995b743-0331-4201-a33e-6087f7ee9859"
      unitRef="usd">75000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="idcf113a7dd6d430ab8a1df6502e3ce9b_I20211118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMTA5OTUxMTYzOTgyOQ_2c809929-2b1b-439b-9793-545027998579"
      unitRef="usd">115000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="i57d3f89fcaaa4996af9b46ce7ea8742a_D20211118-20211118"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMTA5OTUxMTYzOTg0NQ_34c294b9-bb9f-4e26-961f-3dc9bcc16488"
      unitRef="usd">400000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="if5ea6576089f4784ba8f14453a2b1f66_D20191025-20191025"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfODQ4NQ_53b599e2-0b0e-424b-92c5-7a021664ee8c">P5Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i60d48a75f49947d18289dbf4a324b770_I20191025"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNDYwMw_f78906a6-0ad0-4577-967f-342ed1d750e7"
      unitRef="usd">120000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i8b3c8d82e07543fc99205a3c46af08b6_I20191025"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNDY3MQ_c748fc35-0c98-4faf-a931-3cb46f077337"
      unitRef="usd">15000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i74307f2549e54ddd9cd8d5738288941a_I20191025"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNDY4MA_7dead3a9-8802-47ca-a5e4-500fdbe32171"
      unitRef="usd">35000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i60d48a75f49947d18289dbf4a324b770_I20191025"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNDg2OA_14e9fcbc-7f07-48ff-9a4d-07404b28e43c"
      unitRef="usd">120000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i4338d967d578487f9eb052fd67dd54b1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNDg3NA_418dd0b9-3d29-4eaf-a96e-544a3c891cf2"
      unitRef="usd">130000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i4338d967d578487f9eb052fd67dd54b1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNTExOA_3805706e-4b7b-46e5-8989-a0386b251f52"
      unitRef="usd">130000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ib19eb57fb973471fb2c67e92a4731b51_I20210308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNTEyNA_741cdc85-97ed-46e3-a582-631d467e09be"
      unitRef="usd">150000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <ccrn:LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources
      contextRef="i8b42bcc4941c443dae883bd802178090_I20211118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMTY0OTI2NzQ1MDc0NQ_711294f9-9c82-4e49-97fe-c1437f3db6e9"
      unitRef="usd">175000000</ccrn:LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ib19eb57fb973471fb2c67e92a4731b51_I20210308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMTY0OTI2NzQ1MTQ1NA_ced723da-6b8e-4ead-9b83-3878a1feea55"
      unitRef="usd">150000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i993410e5ec1b472995349d7ec0413a8c_I20220321"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMTY0OTI2NzQ1MTQ2Mg_58d359ea-1ffe-4808-b4fe-dac50a27e7ab"
      unitRef="usd">300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="ia214024d55344795bd46a7a0c209b921_D20220321-20220321"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMTA5OTUxMTY0MjA3OA_503b4fe8-8fb7-460f-9561-cb0e5d8bdd17">P5Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <ccrn:LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR
      contextRef="ia214024d55344795bd46a7a0c209b921_D20220321-20220321"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMTA5OTUxMTY0MjA3NA_0db30749-d76a-4eaf-aedd-8898aef85df5"
      unitRef="number">0.0010</ccrn:LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR>
    <ccrn:LineOfCreditBorrowingBasePercentageOfAssets
      contextRef="i60d48a75f49947d18289dbf4a324b770_I20191025"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNTk1NA_b2f7657f-e3fb-4ecf-9eaa-33ddb55844d4"
      unitRef="number">0.85</ccrn:LineOfCreditBorrowingBasePercentageOfAssets>
    <ccrn:LineOfCreditFacilityBorrowingBaseAvailability
      contextRef="i95b50a07ae9e4b7695f586f6672f3956_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNjUyMg_4fe52437-96e6-45c6-95dc-feb7271eb392"
      unitRef="usd">300000000</ccrn:LineOfCreditFacilityBorrowingBaseAvailability>
    <us-gaap:LineOfCredit
      contextRef="i95b50a07ae9e4b7695f586f6672f3956_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNjU0NQ_30c7ea49-17cc-415a-870a-db82a49de71d"
      unitRef="usd">51500000</us-gaap:LineOfCredit>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i95b50a07ae9e4b7695f586f6672f3956_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNjU4MA_23179574-09c8-40d8-9d40-79ebc2f7b9ca"
      unitRef="usd">17500000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i95b50a07ae9e4b7695f586f6672f3956_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNjY5NA_41300356-5e48-454c-905e-dde354fe7af1"
      unitRef="usd">231000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id0b6e77d084e4d879d689a6bca85f0e4_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNjgzMw_c901e690-63bb-4537-b65e-fceb2c6e139b"
      unitRef="number">0.0185</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i9559a9dd705841ba838ccd6ba16e3d37_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNzAwOQ_6360ebea-3fd3-4dfc-8d63-06ec66ebaf85"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="ifa90684f57ec460f92896a283e5a90d3_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNzQwOA_4a1797a2-57dc-48f8-94e0-43aebb673372"
      unitRef="number">0.00375</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:NotesPayable
      contextRef="ib4c754f48f6947ce94f0c29faed347d7_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfNzk2MQ_6bfa1db3-1663-45d4-81b0-1e80e3697f2a"
      unitRef="usd">7300000</us-gaap:NotesPayable>
    <ccrn:NotePayableNumberOfPaymentInstallments
      contextRef="ib4c754f48f6947ce94f0c29faed347d7_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMzg0ODI5MDcwODI2Ng_ac53bd64-a43d-43cc-a7cc-ef2c02fc6054"
      unitRef="installment">3</ccrn:NotePayableNumberOfPaymentInstallments>
    <ccrn:NotePayableNumberOfInstallmentsPaid
      contextRef="idb38d75eba334b9c9661cc92d3d27b1e_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMzg0ODI5MDcwODI2Mg_408550fb-1b56-4496-8864-c7f68ea61d92"
      unitRef="installment">2</ccrn:NotePayableNumberOfInstallmentsPaid>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i693a80db9468442f89e54f2d5e8f012c_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMzg0ODI5MDcwODI3MA_b3026ad5-dc8f-4a3e-8678-88a38c001d73"
      unitRef="usd">2400000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="ifc034a2451eb4ad2a115858bbcbb76a3_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMzg0ODI5MDcwODI3MA_e2559305-7eb4-4fe0-b847-5bb3ed1985d1"
      unitRef="usd">2400000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i70a127889d9c4f5facf6c1e12bc5ef60_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF81OC9mcmFnOjFiYmNiYWEwYWY0YzQxZWRiMjM4Y2U5MDc1YmZjMjg4L3RleHRyZWdpb246MWJiY2JhYTBhZjRjNDFlZGIyMzhjZTkwNzViZmMyODhfMzg0ODI5MDcwODI3Ng_0e1d8e8b-62bc-4bd7-a9a3-5fed86c4cbd8"
      unitRef="usd">2600000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RleHRyZWdpb246ZjM0ZjBiODJlZTNjNDdlYzg5Y2E4YWE2ZWJkYjVjNWZfMzY5NQ_0a8b8ee3-b9ef-42bd-a1ac-05e216bf3125">LEASES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's lease population of its right-of-use asset and lease liabilities is substantially related to the rental of office space. The Company enters into lease agreements as a lessee that may include options to extend or terminate early. Some of these real estate leases require variable payments of property taxes, insurance, and common area maintenance, in addition to base rent. Certain of the leases have provisions for free rent months during the lease term and/or escalating rent payments and, particularly for the Company&#x2019;s longer-term leases for its corporate offices, it has received incentives to enter into the leases, such as receiving up to a specified dollar amount to construct tenant improvements. These leases do not include residual value guarantees, covenants, or other restrictions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in the second quarter of 2020, in connection with the continuing developments from COVID, the Company expedited restructuring plans and either reduced or fully vacated leased office space. The Company is in the process of seeking to sublet some of the space where possible. The decision and change in the use of space resulted in a right-of-use asset impairment charge of $1.5&#160;million for the three months ended March 31, 2022. This loss was determined by comparing the fair value of the impacted right-of-use assets to the carrying value of the assets as of the impairment measurement date. The fair value of the right-of-use assets was based on the estimated sublease income for the space taking into consideration the time period it will take to obtain a subtenant, the applicable discount rate, and the sublease rate. For the three months ended March 31, 2022, the Company wrote off an immaterial amount of leasehold improvements and other property and equipment related to these locations. The Company did not record any lease-related impairment charges for the three months ended March 31, 2021. The measurement of the right-of-use asset impairments, using the assumptions described, is a Level 3 fair value measurement. See Note 10 - Fair Value Measurements for a description of Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the lease-related assets and liabilities included on the condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.854%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Classification on Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.854%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below reconciles the undiscounted cash flows for each of, and total of, the remaining years to the operating lease liabilities (which do not include short-term leases) recorded on the condensed consolidated balance sheets as of March 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.989%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ending December&#160;31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amount of lease payments representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: operating lease liabilities - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Information&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding supplemental cash flows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets acquired under operating lease&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Included in Condensed Consolidated Statements of Operations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable and other lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease expense, short-term lease expense, and variable and other lease costs are included in selling, general and administrative expenses, direct operating expenses, and restructuring costs in the condensed consolidated statements of operations, depending on the nature of the leased asset. Operating lease expense is reported net of sublease income, which is not material.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2022, the Company does not have any material operating leases which have not yet commenced. The Company has an immaterial&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amount of finance lease contracts related to other equipment rentals which are not included in the above disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RleHRyZWdpb246ZjM0ZjBiODJlZTNjNDdlYzg5Y2E4YWE2ZWJkYjVjNWZfMTI0OQ_e3fd6ed6-1ac1-4e2e-b406-af138b405e55"
      unitRef="usd">1500000</us-gaap:OperatingLeaseImpairmentLoss>
    <ccrn:AssetsAndLiabilitiesLeasesTableTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RleHRyZWdpb246ZjM0ZjBiODJlZTNjNDdlYzg5Y2E4YWE2ZWJkYjVjNWZfMzY5Ng_e18267ca-0505-46a2-aec2-158fa964f437">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the lease-related assets and liabilities included on the condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.854%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Classification on Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.854%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ccrn:AssetsAndLiabilitiesLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOmY1ZDM4N2I0MGRhNTQyZDdiOTA3YzIyZWZhODhmYjIxL3RhYmxlcmFuZ2U6ZjVkMzg3YjQwZGE1NDJkN2I5MDdjMjJlZmE4OGZiMjFfMi0xLTEtMS0yOTE1OA_e41d2eb2-c697-4bb6-b5e5-e70efd11003d"
      unitRef="usd">5447000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOmY1ZDM4N2I0MGRhNTQyZDdiOTA3YzIyZWZhODhmYjIxL3RhYmxlcmFuZ2U6ZjVkMzg3YjQwZGE1NDJkN2I5MDdjMjJlZmE4OGZiMjFfMi0zLTEtMS0yOTE1OA_ff2c2e25-8968-41a4-b78d-4e490befd885"
      unitRef="usd">7488000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOmY1ZDM4N2I0MGRhNTQyZDdiOTA3YzIyZWZhODhmYjIxL3RhYmxlcmFuZ2U6ZjVkMzg3YjQwZGE1NDJkN2I5MDdjMjJlZmE4OGZiMjFfMy0xLTEtMS0yOTE1OA_4c10032b-3140-4954-98d4-2c51027dfb5e"
      unitRef="usd">4026000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOmY1ZDM4N2I0MGRhNTQyZDdiOTA3YzIyZWZhODhmYjIxL3RhYmxlcmFuZ2U6ZjVkMzg3YjQwZGE1NDJkN2I5MDdjMjJlZmE4OGZiMjFfMy0zLTEtMS0yOTE1OA_6fc3ca3d-66ae-4d8e-aed7-007a6fe0b108"
      unitRef="usd">4090000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOmY1ZDM4N2I0MGRhNTQyZDdiOTA3YzIyZWZhODhmYjIxL3RhYmxlcmFuZ2U6ZjVkMzg3YjQwZGE1NDJkN2I5MDdjMjJlZmE4OGZiMjFfNC0xLTEtMS0yOTE1OA_a08a5177-14b4-4efb-900c-45fb5f721756"
      unitRef="usd">9704000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOmY1ZDM4N2I0MGRhNTQyZDdiOTA3YzIyZWZhODhmYjIxL3RhYmxlcmFuZ2U6ZjVkMzg3YjQwZGE1NDJkN2I5MDdjMjJlZmE4OGZiMjFfNC0zLTEtMS0yOTE1OA_cf6baad2-1abe-4616-bf22-75657f97051e"
      unitRef="usd">10853000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjdjZDYxMDU0MWViYjRiYTNhZTBmNjBjNWVmNWUxNjk5L3RhYmxlcmFuZ2U6N2NkNjEwNTQxZWJiNGJhM2FlMGY2MGM1ZWY1ZTE2OTlfMS0xLTEtMS0yOTE1OA_19068705-52e4-4238-88eb-b1e657b1f3ff">P3Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i023808945518453896c9849a64047565_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjdjZDYxMDU0MWViYjRiYTNhZTBmNjBjNWVmNWUxNjk5L3RhYmxlcmFuZ2U6N2NkNjEwNTQxZWJiNGJhM2FlMGY2MGM1ZWY1ZTE2OTlfMS0zLTEtMS0yOTE1OA_d3c6627f-559e-49d0-8835-1185c72c4835">P3Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjdjZDYxMDU0MWViYjRiYTNhZTBmNjBjNWVmNWUxNjk5L3RhYmxlcmFuZ2U6N2NkNjEwNTQxZWJiNGJhM2FlMGY2MGM1ZWY1ZTE2OTlfMi0xLTEtMS0yOTE1OA_5537702c-38b1-4fdc-9ed0-162c6f56062b"
      unitRef="number">0.0641</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i023808945518453896c9849a64047565_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjdjZDYxMDU0MWViYjRiYTNhZTBmNjBjNWVmNWUxNjk5L3RhYmxlcmFuZ2U6N2NkNjEwNTQxZWJiNGJhM2FlMGY2MGM1ZWY1ZTE2OTlfMi0zLTEtMS0yOTE1OA_dc3ea5b6-0667-4b67-9f52-3aa3dae768ca"
      unitRef="number">0.0639</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RleHRyZWdpb246ZjM0ZjBiODJlZTNjNDdlYzg5Y2E4YWE2ZWJkYjVjNWZfMzY5OA_434e5500-d3aa-45e3-93e5-6c078526e842">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below reconciles the undiscounted cash flows for each of, and total of, the remaining years to the operating lease liabilities (which do not include short-term leases) recorded on the condensed consolidated balance sheets as of March 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.989%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ending December&#160;31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amount of lease payments representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: operating lease liabilities - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjczODlhM2ZiMDUxOTQxOGRiYzYyNzM3NDEyNmUxNjk4L3RhYmxlcmFuZ2U6NzM4OWEzZmIwNTE5NDE4ZGJjNjI3Mzc0MTI2ZTE2OThfMS0xLTEtMS0yOTE1OA_0e8eed5a-46bc-42f8-8974-a51cefa09ace"
      unitRef="usd">3499000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjczODlhM2ZiMDUxOTQxOGRiYzYyNzM3NDEyNmUxNjk4L3RhYmxlcmFuZ2U6NzM4OWEzZmIwNTE5NDE4ZGJjNjI3Mzc0MTI2ZTE2OThfMi0xLTEtMS0yOTE1OA_0fe53a9b-0502-4a2a-9277-3de29eb0acc6"
      unitRef="usd">4998000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjczODlhM2ZiMDUxOTQxOGRiYzYyNzM3NDEyNmUxNjk4L3RhYmxlcmFuZ2U6NzM4OWEzZmIwNTE5NDE4ZGJjNjI3Mzc0MTI2ZTE2OThfMy0xLTEtMS0yOTE1OA_4298378b-fd62-453b-bc8e-6d6f227dd825"
      unitRef="usd">3956000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjczODlhM2ZiMDUxOTQxOGRiYzYyNzM3NDEyNmUxNjk4L3RhYmxlcmFuZ2U6NzM4OWEzZmIwNTE5NDE4ZGJjNjI3Mzc0MTI2ZTE2OThfNC0xLTEtMS0yOTE1OA_ce2693ef-7e74-496f-b4c8-87d4200490bd"
      unitRef="usd">2759000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjczODlhM2ZiMDUxOTQxOGRiYzYyNzM3NDEyNmUxNjk4L3RhYmxlcmFuZ2U6NzM4OWEzZmIwNTE5NDE4ZGJjNjI3Mzc0MTI2ZTE2OThfNi0xLTEtMS0yOTE1OA_0a3dda89-923c-40b9-aa86-c22e4adcb963"
      unitRef="usd">15212000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjczODlhM2ZiMDUxOTQxOGRiYzYyNzM3NDEyNmUxNjk4L3RhYmxlcmFuZ2U6NzM4OWEzZmIwNTE5NDE4ZGJjNjI3Mzc0MTI2ZTE2OThfNy0xLTEtMS0yOTE1OA_33ac78a6-7591-4c54-974f-195d8de9399b"
      unitRef="usd">1482000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjczODlhM2ZiMDUxOTQxOGRiYzYyNzM3NDEyNmUxNjk4L3RhYmxlcmFuZ2U6NzM4OWEzZmIwNTE5NDE4ZGJjNjI3Mzc0MTI2ZTE2OThfOC0xLTEtMS0yOTE1OA_abf57638-ef17-424a-8f77-390e9b6cfc0e"
      unitRef="usd">13730000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjczODlhM2ZiMDUxOTQxOGRiYzYyNzM3NDEyNmUxNjk4L3RhYmxlcmFuZ2U6NzM4OWEzZmIwNTE5NDE4ZGJjNjI3Mzc0MTI2ZTE2OThfOS0xLTEtMS0yOTE1OA_d058f248-921e-45db-8c18-cfb8efc2062a"
      unitRef="usd">4026000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjczODlhM2ZiMDUxOTQxOGRiYzYyNzM3NDEyNmUxNjk4L3RhYmxlcmFuZ2U6NzM4OWEzZmIwNTE5NDE4ZGJjNjI3Mzc0MTI2ZTE2OThfMTAtMS0xLTEtMjkxNTg_72c3f0de-b9fb-4bab-8e51-6081104e3b04"
      unitRef="usd">9704000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RleHRyZWdpb246ZjM0ZjBiODJlZTNjNDdlYzg5Y2E4YWE2ZWJkYjVjNWZfMzcwMA_a576f39f-70b9-4a24-9cb4-fa346232fff1">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding supplemental cash flows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets acquired under operating lease&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Included in Condensed Consolidated Statements of Operations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable and other lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOmIwOTI2YmNmZTJmMDQwMzc5OWZkZjliMzgzNWM0ZGRjL3RhYmxlcmFuZ2U6YjA5MjZiY2ZlMmYwNDAzNzk5ZmRmOWIzODM1YzRkZGNfNS0xLTEtMS0yOTE1OA_d866a96f-29d4-4d13-9f5a-ada02224c361"
      unitRef="usd">1383000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOmIwOTI2YmNmZTJmMDQwMzc5OWZkZjliMzgzNWM0ZGRjL3RhYmxlcmFuZ2U6YjA5MjZiY2ZlMmYwNDAzNzk5ZmRmOWIzODM1YzRkZGNfNS0zLTEtMS0yOTE1OA_de3d0326-4409-47a3-b248-9fd7ff232e2a"
      unitRef="usd">1637000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOmIwOTI2YmNmZTJmMDQwMzc5OWZkZjliMzgzNWM0ZGRjL3RhYmxlcmFuZ2U6YjA5MjZiY2ZlMmYwNDAzNzk5ZmRmOWIzODM1YzRkZGNfNi0xLTEtMS0yOTE1OA_a85709eb-a157-4e2e-b435-257581c08955"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOmIwOTI2YmNmZTJmMDQwMzc5OWZkZjliMzgzNWM0ZGRjL3RhYmxlcmFuZ2U6YjA5MjZiY2ZlMmYwNDAzNzk5ZmRmOWIzODM1YzRkZGNfNi0zLTEtMS0yOTE1OA_0b43ab92-2766-4602-aced-375d3e90fce6"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjk5Mzk1ZjY5NTE5YTQyMjY4MDFkNjQzM2MzNTQ5OTI4L3RhYmxlcmFuZ2U6OTkzOTVmNjk1MTlhNDIyNjgwMWQ2NDMzYzM1NDk5MjhfNS0xLTEtMS0yOTE1OA_02c637ac-96aa-41ec-b6fe-8db5975de28d"
      unitRef="usd">802000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjk5Mzk1ZjY5NTE5YTQyMjY4MDFkNjQzM2MzNTQ5OTI4L3RhYmxlcmFuZ2U6OTkzOTVmNjk1MTlhNDIyNjgwMWQ2NDMzYzM1NDk5MjhfNS0zLTEtMS0yOTE1OA_6462a25f-9fea-47e7-98eb-c390b96e99d7"
      unitRef="usd">914000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjk5Mzk1ZjY5NTE5YTQyMjY4MDFkNjQzM2MzNTQ5OTI4L3RhYmxlcmFuZ2U6OTkzOTVmNjk1MTlhNDIyNjgwMWQ2NDMzYzM1NDk5MjhfNi0xLTEtMS0yOTE1OA_5b4daa5d-3ad1-4bd0-98da-4a6d83819e81"
      unitRef="usd">1144000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjk5Mzk1ZjY5NTE5YTQyMjY4MDFkNjQzM2MzNTQ5OTI4L3RhYmxlcmFuZ2U6OTkzOTVmNjk1MTlhNDIyNjgwMWQ2NDMzYzM1NDk5MjhfNi0zLTEtMS0yOTE1OA_456dd94e-3036-43c9-859b-860f4b73a5b5"
      unitRef="usd">849000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjk5Mzk1ZjY5NTE5YTQyMjY4MDFkNjQzM2MzNTQ5OTI4L3RhYmxlcmFuZ2U6OTkzOTVmNjk1MTlhNDIyNjgwMWQ2NDMzYzM1NDk5MjhfNy0xLTEtMS0yOTE1OA_e92a8fff-6878-4f6e-ac96-b347ecd4a565"
      unitRef="usd">757000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82MS9mcmFnOmYzNGYwYjgyZWUzYzQ3ZWM4OWNhOGFhNmViZGI1YzVmL3RhYmxlOjk5Mzk1ZjY5NTE5YTQyMjY4MDFkNjQzM2MzNTQ5OTI4L3RhYmxlcmFuZ2U6OTkzOTVmNjk1MTlhNDIyNjgwMWQ2NDMzYzM1NDk5MjhfNy0zLTEtMS0yOTE1OA_43a5a3c0-302f-48d1-8c00-4e926eec00a2"
      unitRef="usd">468000</us-gaap:VariableLeaseCost>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RleHRyZWdpb246N2Q1MTdiOTdkZTYzNGM4ZTljZmRjYjE4MWI3ZjNiNTdfNTIwMQ_f418c3f5-9b8a-441f-801e-3b9f99137f9c">FAIR VALUE MEASUREMENTS&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy was established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Items Measured at Fair Value on a Recurring Basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial assets/liabilities required to be measured on a recurring basis were its: (i) deferred compensation asset included in other non-current assets; and (ii) deferred compensation liability included in other long-term liabilities on its condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company utilizes Level 1 inputs to value its deferred compensation assets and liabilities. The Company&#x2019;s deferred compensation assets and liabilities are measured using publicly available indices, as per the plan documents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the Company&#x2019;s financial assets and liabilities measured on a recurring basis is as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Items Measured at Fair Value on a Non-Recurring Basis:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's non-financial assets, such as goodwill, trade names, other intangible assets, right-of-use assets, and property and equipment, are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The three months ended March 31, 2022 included impairment charges to right-of-use assets along with related property and equipment in connection with leases that were vacated. Accordingly, as of March 31, 2022, these assets were recorded at fair value using Level 3 inputs. See Note 9 - Leases for more information about these fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Fair Value Disclosures:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial instruments not measured or recorded at fair value in the condensed consolidated balance sheets consist of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses. The estimated fair value of accounts receivable and accounts payable and&#160;accrued expenses approximate their carrying amount due to the short-term nature of these instruments. Other financial instruments not measured or recorded at fair value include: (i) note payable, (ii) ABL, (iii) term loan, and (iv) and (v) earnout liabilities, as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(i) The Company paid the third and final installment on its note payable in the first quarter of 2022. Due to its relatively short-term nature, the carrying value of the note payable approximated its fair value. (ii) The carrying amount of the Company's ABL approximates fair value because the interest rates are variable and reflective of market rates. (iii) The estimated fair value of the Company's term loan was calculated applying an interest rate lattice model using Level 2 inputs from available market information. (iv) Potential earnout payments related to the WSG acquisition are contingent upon meeting certain performance requirements based on 2021 through 2023 performance. The Company performed an analysis using multiple forecasted scenarios to determine the fair value of the earnout liability. The earnout liability's carrying amount approximates fair value and is included in current portion of earnout liability and non-current earnout liability on the condensed consolidated balance sheets. (v) Potential earnout payments related to the Selected acquisition are contingent upon meeting certain performance requirements based on 2022 and 2023 revenues. The earnout liability's carrying amount approximates fair value and is included in current portion of earnout liability and non-current earnout liability on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and estimated fair value of the Company&#x2019;s significant financial instruments that were not measured at fair value are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note Payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Secured Asset-Based Loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnout Liability (WSG)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnout Liability (Selected)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See discussion of credit losses and allowance for doubtful accounts in Note 2 - Summary of Significant Accounting Policies. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Overall, based on the large number of customers in differing geographic areas, primarily throughout the United States and its territories, the Company believes the concentration of credit risk is limited.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RleHRyZWdpb246N2Q1MTdiOTdkZTYzNGM4ZTljZmRjYjE4MWI3ZjNiNTdfNTE5NQ_3a294061-b8c0-4fc2-8bc9-e4d1aa8bf6ec">The estimated fair value of the Company&#x2019;s financial assets and liabilities measured on a recurring basis is as follows:&#160;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i495fb315b409472492e63b658e2d1f69_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOjhmOWU2YzBhY2UyYjQ4ZDk5YmJhMGE1M2Y5Mjk0ZGM0L3RhYmxlcmFuZ2U6OGY5ZTZjMGFjZTJiNDhkOTliYmEwYTUzZjkyOTRkYzRfNC0xLTEtMS0yOTE1OA_0e869822-0719-40c9-8f57-388df3f013bd"
      unitRef="usd">1305000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie29a28d5bec04a9a89dd3aad07f2f287_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOjhmOWU2YzBhY2UyYjQ4ZDk5YmJhMGE1M2Y5Mjk0ZGM0L3RhYmxlcmFuZ2U6OGY5ZTZjMGFjZTJiNDhkOTliYmEwYTUzZjkyOTRkYzRfNC0zLTEtMS0yOTE1OA_d7fd73f5-7bd4-4e84-a8ea-884a335038e3"
      unitRef="usd">1398000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations
      contextRef="i14c7086aa5ac419fb6760c4660fcbb9f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOjhmOWU2YzBhY2UyYjQ4ZDk5YmJhMGE1M2Y5Mjk0ZGM0L3RhYmxlcmFuZ2U6OGY5ZTZjMGFjZTJiNDhkOTliYmEwYTUzZjkyOTRkYzRfNy0xLTEtMS0yOTE1OA_96b7961e-58e1-4212-b9fd-e032e00b524a"
      unitRef="usd">2450000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations
      contextRef="ic5ad89b3e2c34d8baa20d7aaa26a7b15_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOjhmOWU2YzBhY2UyYjQ4ZDk5YmJhMGE1M2Y5Mjk0ZGM0L3RhYmxlcmFuZ2U6OGY5ZTZjMGFjZTJiNDhkOTliYmEwYTUzZjkyOTRkYzRfNy0zLTEtMS0yOTE1OA_90d0c418-9b80-4644-a1c2-7cbdc228df7e"
      unitRef="usd">2457000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RleHRyZWdpb246N2Q1MTdiOTdkZTYzNGM4ZTljZmRjYjE4MWI3ZjNiNTdfNTIxNg_77b8d5b2-16cc-45db-8671-5b3caa7f9742">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and estimated fair value of the Company&#x2019;s significant financial instruments that were not measured at fair value are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note Payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Secured Asset-Based Loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnout Liability (WSG)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnout Liability (Selected)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i7a52a3cb4a2040cb8b1b261cb0ee596b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNC0xLTEtMS0yOTE1OA_1f7f7429-4d7b-4896-8657-5b1d2f9334ad"
      unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i56ac23aba6aa4403a0bad0cba4ae5902_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNC0zLTEtMS0yOTE1OA_d983a2c6-dffe-42a1-93b6-bd9054525ce8"
      unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i0bf46906e48741ed893ff4a25259f391_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNC01LTEtMS0yOTE1OA_6f1f2ae2-06ee-41a1-973b-46f832d633b3"
      unitRef="usd">2426000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i03cfea49b0a745c8963d38be107a4c1a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNC03LTEtMS0yOTE1OA_d1276f5e-c111-42d3-bf75-46ee255c0a36"
      unitRef="usd">2426000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:LinesOfCreditFairValueDisclosure
      contextRef="i9bb29dbc47e244bdab628f989817d591_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNS0xLTEtMS0yOTE1OA_3f5623e8-0a04-4e6f-ba2e-42adf3f29715"
      unitRef="usd">51501000</us-gaap:LinesOfCreditFairValueDisclosure>
    <us-gaap:LinesOfCreditFairValueDisclosure
      contextRef="ia8bb48f02ecf42d9aeaca2be048ca7f8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNS0zLTEtMS0yOTE1OA_ac0e91da-6cb0-46fa-b82e-54d5c8deec75"
      unitRef="usd">51501000</us-gaap:LinesOfCreditFairValueDisclosure>
    <us-gaap:LinesOfCreditFairValueDisclosure
      contextRef="i70a1b0b08d174a06886a168bcf0b7dbb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNS01LTEtMS0yOTE1OA_71059074-3f4f-4033-9c4e-bb6436d4b649"
      unitRef="usd">9200000</us-gaap:LinesOfCreditFairValueDisclosure>
    <us-gaap:LinesOfCreditFairValueDisclosure
      contextRef="ia1748aed1a144618a97c5849fa459254_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNS03LTEtMS0yOTE1OA_85d2fa1e-4a66-4ffd-b8fe-4dcbe42157b1"
      unitRef="usd">9200000</us-gaap:LinesOfCreditFairValueDisclosure>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i6d432683d3b6435ba0c48c4efd028d04_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNi0xLTEtMS0yOTE1OA_b9e641e3-9748-4ddf-9ec2-d607c3f3a944"
      unitRef="usd">173875000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="id9729fca27ba4b91a962fe9441fbd9cc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNi0zLTEtMS0yOTE1OA_0a1a5210-1afe-4db6-b22a-dc2981479de3"
      unitRef="usd">174387000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i77d0216a9f1b4205af250d1c80679b15_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNi01LTEtMS0yOTE1OA_f90db467-15cd-410a-a7f8-637c57eadb97"
      unitRef="usd">174312000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="id44bfe574f91423a9f3987ed1f01a93a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNi03LTEtMS0yOTE1OA_e30ab461-27e9-4871-857b-3db38a7ae5fb"
      unitRef="usd">174845000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id106177b91204212b84484a1a875400b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNy0xLTEtMS0zMjQyNw_8d6d2591-60f1-4eb1-bb3c-5faf28f32a79"
      unitRef="usd">15000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if502c32883544beda4be6398c9526e3e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNy0zLTEtMS0zMjQyNw_f4110304-dc1b-45ec-bb69-242386e7269e"
      unitRef="usd">15000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0553a10fc40144f8a768aabc88e29e1a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNy01LTEtMS0zMjQyNw_9b05bc97-02dd-4bd0-8eda-7ca72d2f83dc"
      unitRef="usd">15000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i887ee4f6baf748d98a8def4c75aea2d2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNy03LTEtMS0zMjQyNw_55d6c938-f57f-4cb7-9a6f-09a419de0cbe"
      unitRef="usd">15000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i29edde64b2264b2aa2d76cb1e65aeb1b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNy0xLTEtMS0yOTE1OA_3041b0a6-826c-447e-bae5-71251eb2e811"
      unitRef="usd">1500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id8cf64a57b224d7c87d32895718dc0f5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNy0zLTEtMS0yOTE1OA_e12c1f4c-ba84-48c3-b800-fc900267f342"
      unitRef="usd">1500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i39f100435cf24b988a31207c13a30eb4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNy01LTEtMS0yOTE1OA_f9705464-b0eb-4e57-9471-dcc3581f1a6f"
      unitRef="usd">1500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iae329d6e3c6a4d0d82b7abd882130b4f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82NC9mcmFnOjdkNTE3Yjk3ZGU2MzRjOGU5Y2ZkY2IxODFiN2YzYjU3L3RhYmxlOmM2MjY4ZmFiNjlhMjQwNzJiY2E0ODdiYjQzZjhhMjE3L3RhYmxlcmFuZ2U6YzYyNjhmYWI2OWEyNDA3MmJjYTQ4N2JiNDNmOGEyMTdfNy03LTEtMS0yOTE1OA_550dbc14-0517-4f58-ad24-65794a7b596c"
      unitRef="usd">1500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMzIyMw_f28b7409-6555-4640-9e59-8dabd455513c">STOCKHOLDERS&#x2019; EQUITY&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022 and 2021, the Company did not repurchase any shares of its common stock. As of March&#160;31, 2022, the Company has 510,004 shares of common stock under the current share repurchase program available to repurchase, subject to certain conditions in the Company's Loan Agreement and Term Loan Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 19, 2020, the Company's stockholders approved the Cross Country Healthcare, Inc. 2020 Omnibus Incentive Plan (2020 Plan), which replaced the 2017 Omnibus Incentive Plan (2017 Plan), and applies to awards granted after May 19, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The remaining shares available for grant under the 2017 Plan were cancelled and no further awards will be granted under that plan. The 2020 Plan generally mirrors the terms of the 2017 Plan and includes the following provisions: (i) an aggregate share reserve of 3,000,000 shares; (2) annual dollar and share limits of awards granted to employees and consultants, as well as non-employee directors, based on type of award; (3) awards granted generally will be subject to a minimum one-year vesting schedule; and (4) awards may be granted under the 2020 Plan until March 24, 2030.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restricted stock awards and performance stock awards activity issued under the 2017 Plan and the 2020 Plan (Plans) for the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Performance Stock Awards&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Target &lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock awards, January&#160;1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,039,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(481,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170,278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock awards, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards granted under the Company&#x2019;s Plans entitle the holder to receive, at the end of a vesting period, a specified number of shares of the Company&#x2019;s common stock. Share-based compensation expense is measured by the market value of the Company&#x2019;s stock on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Awards granted to non-employee directors under the 2017 Plan, prior to the adoption of the 2020 Plan, vest in three equal installments on the first, second and third anniversaries of the grant date, while restricted shares granted under the 2020 Plan on and subsequent to June 2020 will vest on the first anniversary of such grant date, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or earlier subject to retirement eligibility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In addition, effective in the three months ended June 30, 2020, the Company implemented modified guidelines that provide for accelerated vesting of restricted stock grants on the last date of service when a retirement-eligible director retires.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Plans, the number of target shares that are issued for performance-based stock awards are determined based on the level of attainment of the targets. During the first quarter of 2022, the Company's Compensation Committee of the Board of Directors approved a 120% level of attainment for the 2019 performance-based share awards, resulting in the issuance of 170,278 performance shares that vested on March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the three months ended March 31, 2022, $1.6 million was included in selling, general and administrative expenses related to share-based payments, and a net of 419,500 shares of common stock were issued upon the vesting of restricted and performance stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2021, $1.3 million was included in selling, general and administrative expenses related to share-based payments, and a net of 317,605 shares of common stock were issued upon the vesting of restricted stock.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i06767ccc204342efa16a4ea58b5982f0_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMTMy_41c2d8e0-d5f7-4aa1-9d6b-c890d65c2b4f"
      unitRef="shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i2d3c21c3ae5d48b38f7e5a3af77e2ef9_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMTMy_8f5335b4-e6b6-4135-a54b-b63ec3713294"
      unitRef="shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMjA0_8a7e18b8-74bf-4a4e-8567-3308820b4c21"
      unitRef="shares">510004</us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i7193b285bbb7464db035176165d555b2_I20200519"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfOTE2_6f8be641-b23c-4138-b0d3-bec40ff30ae7"
      unitRef="shares">3000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9be85c5f345e42d68f473356014730e2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMzIyMQ_6eefd626-5347-420a-afbf-91a67883dc33">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMzIxNQ_19a08ff5-bf24-4f11-8f0b-4dda8936d0a1">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restricted stock awards and performance stock awards activity issued under the 2017 Plan and the 2020 Plan (Plans) for the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Performance Stock Awards&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Target &lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock awards, January&#160;1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,039,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(481,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170,278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock awards, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i95016a76eb2d4e2bb36c7a7aceb60b64_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfMi0xLTEtMS0yOTE1OA_febd175e-86c8-479e-9eb8-0e1f5a0000f3"
      unitRef="shares">1039455</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i95016a76eb2d4e2bb36c7a7aceb60b64_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfMi0zLTEtMS0yOTE1OA_f119b2ef-8f55-460c-96d4-54634d702f1b"
      unitRef="usdPerShare">9.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib59ced0f2c644556a8fe7a1d5d8f161a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfMi01LTEtMS0yOTE1OA_9b378c9f-4b7f-4062-af20-c934d682712d"
      unitRef="shares">522166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib59ced0f2c644556a8fe7a1d5d8f161a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfMi03LTEtMS0yOTE1OA_c662e000-8edf-4056-a6f0-ca074be537bf"
      unitRef="usdPerShare">8.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia39ce4bfecff4fc1995df5920a618bf6_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfMy0xLTEtMS0yOTE1OA_3a78637c-69ca-4b8c-8442-fb99e700f3a9"
      unitRef="shares">215006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia39ce4bfecff4fc1995df5920a618bf6_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfMy0zLTEtMS0yOTE1OA_c074fdb2-73cf-4757-a552-b132de1f59d1"
      unitRef="usdPerShare">21.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i34b2f55df92d4cbbb60faf19e1ead3be_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfMy01LTEtMS0yOTE1OA_d513ee55-4774-4158-b5af-f84027007189"
      unitRef="shares">154952</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i34b2f55df92d4cbbb60faf19e1ead3be_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfMy03LTEtMS0yOTE1OA_b8b8eda7-7371-4d16-b481-38d931e855bf"
      unitRef="usdPerShare">18.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ia39ce4bfecff4fc1995df5920a618bf6_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNC0xLTEtMS0yOTE1OA_3921600c-b8d7-4839-844a-fa058c19ff72"
      unitRef="shares">481231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia39ce4bfecff4fc1995df5920a618bf6_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNC0zLTEtMS0yOTE1OA_cfb0b987-2248-4587-8ebf-084d042f30f5"
      unitRef="usdPerShare">8.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i34b2f55df92d4cbbb60faf19e1ead3be_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNC01LTEtMS0yOTE1OA_84ca2268-51e0-4a68-96b9-314aac123834"
      unitRef="shares">170278</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i34b2f55df92d4cbbb60faf19e1ead3be_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNC03LTEtMS0yOTE1OA_7ceb9ad4-b38d-4e33-b36d-bcc937f63984"
      unitRef="usdPerShare">7.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ia39ce4bfecff4fc1995df5920a618bf6_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNS0xLTEtMS0yOTE1OA_1c3a9aea-7a5b-477c-8d3f-24815e467f1c"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ia39ce4bfecff4fc1995df5920a618bf6_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNS0zLTEtMS0yOTE1OA_83fb6751-714a-43d6-a011-fa5842f4cadc"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i34b2f55df92d4cbbb60faf19e1ead3be_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNS01LTEtMS0yOTE1OA_ef6bc877-06ce-422d-8d63-d09d98131c11"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i34b2f55df92d4cbbb60faf19e1ead3be_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNS03LTEtMS0yOTE1OA_75b8d55e-4d0d-496c-9e6d-b2db397d290c"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i1517da25a84b468e8171eb1381c84236_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNi0xLTEtMS0yOTE1OA_06b1f656-9e5d-4f7c-ade9-cfc03688c18e"
      unitRef="shares">773230</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i1517da25a84b468e8171eb1381c84236_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNi0zLTEtMS0yOTE1OA_569a7109-a2fd-4750-87bc-c368d9857f4f"
      unitRef="usdPerShare">13.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i00fee55829f24128b87768be086342b2_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNi01LTEtMS0yOTE1OA_e9c68be4-568d-4ac3-8d33-44f85b06b998"
      unitRef="shares">506840</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i00fee55829f24128b87768be086342b2_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RhYmxlOjAxMzRkYTQ0Mjg1ZDQ3Nzk5YTY1MTk3ZTY4MWZjYzliL3RhYmxlcmFuZ2U6MDEzNGRhNDQyODVkNDc3OTlhNjUxOTdlNjgxZmNjOWJfNi03LTEtMS0yOTE1OA_0c435937-a42b-4443-a0d2-46420f3fd1e7"
      unitRef="usdPerShare">12.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <ccrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments
      contextRef="i95f14a36e510429b9814bb8e62be49e0_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMTgwNQ_2ef77b09-8e36-4295-9bb5-f855b56ab1c3"
      unitRef="installment">3</ccrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments>
    <ccrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMTA5OTUxMTYzMjA2OA_d26d2ca2-0db8-4e28-8d9b-e540e80fe011"
      unitRef="number">1.20</ccrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i34b2f55df92d4cbbb60faf19e1ead3be_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMTA5OTUxMTYzMjA3NA_4363d75a-cb56-4365-ad73-a0472d22d5d5"
      unitRef="shares">170278</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0518a6d4c63940e7a94abc3ec794e0f8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMjcwNg_1132d110-d86c-48f7-927d-f461d2e5ad48"
      unitRef="usd">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <ccrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet
      contextRef="ia39ce4bfecff4fc1995df5920a618bf6_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMjgzOA_e7c8ea22-6352-4f24-8b62-0fbbe278e0bf"
      unitRef="shares">419500</ccrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2c0d11239d38482d878be193fb27e8f6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMjk4NA_96ea3832-b134-4d43-a63a-84016c988e3e"
      unitRef="usd">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <ccrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet
      contextRef="if94c5d761a504a69a0f377a89797162b_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF82Ny9mcmFnOjE2M2I5ZDI3MTUzMTRlNjZhMDJmYzIxYTExOWRmNTQ2L3RleHRyZWdpb246MTYzYjlkMjcxNTMxNGU2NmEwMmZjMjFhMTE5ZGY1NDZfMzExNg_22109e6b-40c5-434b-bd6f-8cf5844315e3"
      unitRef="shares">317605</ccrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RleHRyZWdpb246ODAyYWIwZWEwNjVkNDZkZWE0NDQzNTk1NTg2YjYwNDVfMzU2OA_8f146f2d-5cd9-41df-98ec-665ac5ca544b">SEGMENT DATA&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s segments offer services to its customers as described below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25cf;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nurse and Allied Staffing &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Nurse and Allied Staffing provides traditional staffing, recruiting, and value-added total talent solutions including: temporary and permanent placement of travel and local nurse and allied professionals, managed services programs (MSP) services, education healthcare services, in-home care services, and outsourcing services. In addition, Nurse and Allied Staffing provides retained search services for healthcare professionals, as well as contingent search and recruitment process outsourcing services. Its clients include: public and private acute-care and non-acute care hospitals, government facilities, local and national healthcare plans, managed care providers, public schools and charter schools, outpatient clinics, ambulatory care facilities, physician practice groups, and many other healthcare providers throughout the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25cf;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Physician Staffing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Physician Staffing provides physicians in many specialties, as well as certified registered nurse anesthetists, nurse practitioners, and physician assistants as independent contractors on temporary assignments &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;throughout the United States at various healthcare facilities, such as acute and non-acute care facilities, medical group practices, government facilities, and managed care organizations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates performance of each segment primarily based on revenue and contribution income. The Company defines contribution income as income (loss) from operations before depreciation and amortization, acquisition and integration-related costs, restructuring costs, legal settlement charges, impairment charges, and corporate overhead. The Company does not evaluate, manage, or measure performance of segments using asset information; accordingly, total asset information by segment is not prepared or disclosed. The information in the following table is derived from the segments&#x2019; internal financial information as used for corporate management purposes. Certain corporate expenses are not allocated to and/or among the operating segments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information on operating segments and a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reconciliation to income from operations for the periods indicated are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from services:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nurse and Allied Staffing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Physician Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contribution income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nurse and Allied Staffing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Physician Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate overhead &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition and integration-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives).&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RleHRyZWdpb246ODAyYWIwZWEwNjVkNDZkZWE0NDQzNTk1NTg2YjYwNDVfMzU2NA_17743470-6a96-4f22-84d0-8ba2eb7bfe08">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information on operating segments and a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reconciliation to income from operations for the periods indicated are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from services:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nurse and Allied Staffing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Physician Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contribution income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nurse and Allied Staffing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Physician Staffing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate overhead &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition and integration-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives).&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f67d3164490454dbd2421830ac30a99_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfNS0xLTEtMS0yOTE1OA_28f3d93e-1cf6-4164-a506-0640121fcdfd"
      unitRef="usd">765580000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide86e9d4790e48b881466a5c8b847256_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfNS0zLTEtMS0yOTE1OA_7c5ff0c1-2e50-4082-9774-09775eea6d69"
      unitRef="usd">313008000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie35cd3b9be00467fbc0b9f82f0c6c7da_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfNi0xLTEtMS0yOTE1OA_6c11becb-3b14-4e9c-b120-21cd7c38a24f"
      unitRef="usd">23152000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad432390898d40dabc7fcb10fd9dd0ae_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfNi0zLTEtMS0yOTE1OA_f5785474-3bde-4e02-b4b0-2230bf358eab"
      unitRef="usd">16233000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfNy0xLTEtMS0yOTE1OA_718ff009-c7e4-4509-9112-c8f0793e63f1"
      unitRef="usd">788732000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfNy0zLTEtMS0yOTE1OA_d16aa131-59cb-4956-ae9b-95a00402d63d"
      unitRef="usd">329241000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard
      contextRef="i1f67d3164490454dbd2421830ac30a99_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTAtMS0xLTEtMjkxNTg_930211ad-a9f2-490b-988d-70c146ceddaf"
      unitRef="usd">110101000</ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard>
    <ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard
      contextRef="ide86e9d4790e48b881466a5c8b847256_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTAtMy0xLTEtMjkxNTg_d9821eab-4322-478e-b7c3-2bc7e54d0c37"
      unitRef="usd">37417000</ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard>
    <ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard
      contextRef="ie35cd3b9be00467fbc0b9f82f0c6c7da_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTEtMS0xLTEtMjkxNTg_0c589c77-e102-4fe0-b0e8-ccc953ff90c9"
      unitRef="usd">1765000</ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard>
    <ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard
      contextRef="iad432390898d40dabc7fcb10fd9dd0ae_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTEtMy0xLTEtMjkxNTg_4466d9c2-9e71-440d-b9ca-26944330ff79"
      unitRef="usd">1428000</ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard>
    <ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTItMS0xLTEtMjkxNTg_fd170f26-9268-469d-bac9-169aed84d133"
      unitRef="usd">111866000</ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard>
    <ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTItMy0xLTEtMjkxNTg_96a5fbdc-86f0-48bd-a252-e06cf1cc764b"
      unitRef="usd">38845000</ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard>
    <ccrn:SegmentReportingUnallocatedCorporateExpenses
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTQtMS0xLTEtMjkxNTg_41ef2cf8-9685-4c20-a8d0-2bd5f96319c4"
      unitRef="usd">16254000</ccrn:SegmentReportingUnallocatedCorporateExpenses>
    <ccrn:SegmentReportingUnallocatedCorporateExpenses
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTQtMy0xLTEtMjkxNTg_be59c291-db8d-4206-8add-5bcc46b59e08"
      unitRef="usd">14211000</ccrn:SegmentReportingUnallocatedCorporateExpenses>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTUtMS0xLTEtMjkxNTg_f0819776-f115-439f-b8b2-8a739e8e5acc"
      unitRef="usd">2719000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTUtMy0xLTEtMjkxNTg_8c93bcd7-1c63-4b77-b74e-9697063418bf"
      unitRef="usd">2253000</us-gaap:DepreciationDepletionAndAmortization>
    <ccrn:AcquisitionAndIntegrationRelatedCosts
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTYtMS0xLTEtMjkxNTg_df8ce719-848e-48b0-abf9-4ca6c8b40e28"
      unitRef="usd">40000</ccrn:AcquisitionAndIntegrationRelatedCosts>
    <ccrn:AcquisitionAndIntegrationRelatedCosts
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTYtMy0xLTEtMjkxNTg_218b063f-3dba-4359-9fd1-8019100ca37c"
      unitRef="usd">0</ccrn:AcquisitionAndIntegrationRelatedCosts>
    <us-gaap:RestructuringCharges
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTctMS0xLTEtMjkxNTg_6885145f-03e8-4ba1-9355-512300efb6d3"
      unitRef="usd">480000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTctMy0xLTEtMjkxNTg_c20a6871-776c-4e69-a133-c68c83e1171b"
      unitRef="usd">1238000</us-gaap:RestructuringCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTgtMS0xLTEtMjkxNTg_e0169b01-cb5e-44b0-9100-1a8ea387136d"
      unitRef="usd">1741000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTgtMy0xLTEtMjkxNTg_308931de-2bbb-42fa-a4be-a2542ffe0c8f"
      unitRef="usd">149000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OperatingIncomeLoss
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTktMS0xLTEtMjkxNTg_cc883229-c33e-4549-a656-81f00b84a3da"
      unitRef="usd">90632000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83MC9mcmFnOjgwMmFiMGVhMDY1ZDQ2ZGVhNDQ0MzU5NTU4NmI2MDQ1L3RhYmxlOmVkYjdlYTE1NjkwZjRlODM5MGJjODhmNmE4NmI4OTVmL3RhYmxlcmFuZ2U6ZWRiN2VhMTU2OTBmNGU4MzkwYmM4OGY2YTg2Yjg5NWZfMTktMy0xLTEtMjkxNTg_ccac4972-3410-413b-b66b-81c03b554b2a"
      unitRef="usd">20994000</us-gaap:OperatingIncomeLoss>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83My9mcmFnOjBmMjIwY2RlMDUwNzRmZTZiMjhhZjRkNzg1NmMyNzQ0L3RleHRyZWdpb246MGYyMjBjZGUwNTA3NGZlNmIyOGFmNGQ3ODU2YzI3NDRfMzE2NQ_5e4a6d2a-feca-4dc1-b69a-e579434ffa34">CONTINGENCIES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is involved in various litigation, claims, investigations, and other proceedings that arise in the ordinary course of its business. These matters primarily relate to employee-related matters that include individual and collective claims, professional liability, tax, and payroll practices. The Company establishes reserves when available information indicates that a loss is probable and an amount or range of loss can be reasonably estimated. These assessments are performed at least quarterly and are based on the information available to management at the time and involve significant management judgment to determine the probability and estimated amount of potential losses, if any. Based on the available information considered in its reviews, the Company adjusts its loss contingency accruals and its disclosures as may be required. Actual outcomes or losses may differ materially from those estimated by the Company's current assessments, including available insurance recoveries, which would impact the Company's profitability. Adverse developments in existing litigation claims or legal proceedings involving the Company or new claims could require management to establish or increase litigation reserves or enter into unfavorable settlements or satisfy judgments for monetary damages for amounts in excess of current reserves, which could adversely affect the Company's financial results. The Company believes the outcome of any outstanding loss contingencies as of March 31, 2022 will not have a material adverse effect on its business, financial condition, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales and Other State Non-Income Tax Liabilities &lt;/span&gt;&lt;/div&gt;The Company's sales and other state non-income tax filings are subject to routine audits by authorities in the jurisdictions where it conducts business in the United States which may result in assessments of additional taxes. The Company accrues sales and other non-income tax liabilities based on the Company's best estimate of its probable liability utilizing currently available information and interpretation of relevant tax regulations. Given the nature of the Company's business, significant subjectivity exists as to both whether sales and other state non-income taxes can be assessed on its activity and how the sales tax will ultimately be measured by the relevant jurisdictions. The Company makes a determination for each reporting period whether the estimates for sales and other non-income taxes in certain states should be revised. The expense is included in selling, general and administrative expenses in the Company's condensed consolidated statements of operations and the liability is reflected in sales tax payable within other current liabilities in its condensed consolidated balance sheets.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83Ni9mcmFnOmQ2ZTQ0NDQ1MDdjNzRlNzk5MTFmMzM1OWU3ODFhODYzL3RleHRyZWdpb246ZDZlNDQ0NDUwN2M3NGU3OTkxMWYzMzU5ZTc4MWE4NjNfMjM1Ng_8e6a0dbc-3b3f-46e9-ac85-d1333b2b38bd">INCOME TAXES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three-month period ended March 31, 2022, the Company calculated its effective tax rate estimating its annual effective tax rate as opposed to the quarter ended March 31, 2021, whereby the Company calculated its effective tax rate based on year-to-date results. The Company&#x2019;s effective tax rate for the three months ended March 31, 2022 and 2021 was 28.9% and 4.5%, respectively, including the impact of discrete items. Excluding discrete items, the Company's effective tax rate for the three months ended March 31, 2022 and 2021 was 30.0% and 4.5%, respectively. The effective tax rate for the first quarter of 2022 was primarily impacted by federal and state taxes. Income tax expense for the three months ended March 31, 2021 was primarily impacted by international and state taxes as a result of the Company's valuation allowance on substantially all of its domestic deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2021, the Company concluded that it was more likely than not that a benefit from a substantial portion of its United States federal and state deferred tax assets would be realized and released the majority of its valuation allowance. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2022 and December 31, 2021, the Company had an immaterial amount of valuation allowance on its deferred tax assets related to state net operating losses not expected to be realized before expiration.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the Company had approximately $9.2 million of unrecognized tax benefits included in other long-term liabilities, $9.4 million, net of deferred taxes, which would impact the effective tax rate if recognized. During the three months ended March&#160;31, 2022, the Company had net increases of $0.3&#160;million to its current year unrecognized tax benefits related to federal and state tax provisions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax years 2012 through 2021 remain open to examination by certain taxing jurisdictions to which the Company is subject to tax, other than certain states in which the statute of limitations has been extended.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83Ni9mcmFnOmQ2ZTQ0NDQ1MDdjNzRlNzk5MTFmMzM1OWU3ODFhODYzL3RleHRyZWdpb246ZDZlNDQ0NDUwN2M3NGU3OTkxMWYzMzU5ZTc4MWE4NjNfMzEw_8648e57c-8f01-4e44-ab81-09c089f5b82a"
      unitRef="number">0.289</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83Ni9mcmFnOmQ2ZTQ0NDQ1MDdjNzRlNzk5MTFmMzM1OWU3ODFhODYzL3RleHRyZWdpb246ZDZlNDQ0NDUwN2M3NGU3OTkxMWYzMzU5ZTc4MWE4NjNfMzE3_ad05ec03-d8a5-494f-b315-4764edb00101"
      unitRef="number">0.045</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <ccrn:EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83Ni9mcmFnOmQ2ZTQ0NDQ1MDdjNzRlNzk5MTFmMzM1OWU3ODFhODYzL3RleHRyZWdpb246ZDZlNDQ0NDUwN2M3NGU3OTkxMWYzMzU5ZTc4MWE4NjNfMzc5_65c303e9-eeb1-48e3-84b2-84204c001bda"
      unitRef="number">0.300</ccrn:EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems>
    <ccrn:EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems
      contextRef="i028a79fda4fd4a2f98a4a8da11cf6952_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83Ni9mcmFnOmQ2ZTQ0NDQ1MDdjNzRlNzk5MTFmMzM1OWU3ODFhODYzL3RleHRyZWdpb246ZDZlNDQ0NDUwN2M3NGU3OTkxMWYzMzU5ZTc4MWE4NjNfMzg2_c8915b63-eaca-4cc9-ab7c-f6ac3f6d54a0"
      unitRef="number">0.045</ccrn:EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83Ni9mcmFnOmQ2ZTQ0NDQ1MDdjNzRlNzk5MTFmMzM1OWU3ODFhODYzL3RleHRyZWdpb246ZDZlNDQ0NDUwN2M3NGU3OTkxMWYzMzU5ZTc4MWE4NjNfMTg5OA_02941c86-8c93-4e68-ae56-0c10ee927f01"
      unitRef="usd">9200000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83Ni9mcmFnOmQ2ZTQ0NDQ1MDdjNzRlNzk5MTFmMzM1OWU3ODFhODYzL3RleHRyZWdpb246ZDZlNDQ0NDUwN2M3NGU3OTkxMWYzMzU5ZTc4MWE4NjNfMTk3MQ_681b950b-de65-40d3-b2e6-0e96a75ccbf5"
      unitRef="usd">9400000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83Ni9mcmFnOmQ2ZTQ0NDQ1MDdjNzRlNzk5MTFmMzM1OWU3ODFhODYzL3RleHRyZWdpb246ZDZlNDQ0NDUwN2M3NGU3OTkxMWYzMzU5ZTc4MWE4NjNfMjEyNA_38b14005-f0d1-478d-8a41-29ad471e9092"
      unitRef="usd">300000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83OS9mcmFnOmFiMmUwZGQ2NDhhODQwMmVhZWNjNzQxZGE0MTc1ZjNiL3RleHRyZWdpb246YWIyZTBkZDY0OGE4NDAyZWFlY2M3NDFkYTQxNzVmM2JfMzMxMg_90ae777b-acf0-4f0f-80e3-e93cb27f54be">RELATED PARTY TRANSACTIONS&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has entered into an arrangement for digital marketing services provided by a firm that is related to Mr. Clark, the Company's Co-Founder &amp;amp; Chief Executive Officer through March 31, 2022. Mr. Clark is a minority shareholder in the firm's parent company and is a member of the parent company's Board of Directors. Management believes the terms of the arrangement are equivalent to those prevailing in an arm's-length transaction and have been approved by the Company through its related party process. The digital marketing firm manages a limited number of digital publishers covering various Company brands for a monthly management fee. During the three months ended March 31, 2022 and 2021, the Company incurred an immaterial amount in expenses. The Company had an immaterial payable balance at March 31, 2022 and December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides services to entities which are affiliated with certain members of the Company&#x2019;s Board of Directors. Management believes the services were conducted on terms equivalent to those prevailing in an arm's-length transaction. Revenue related to these transactions was immaterial for the three months ended March 31, 2022. The Company had no revenue related to these transactions for the three months ended March 31, 2021. Accounts receivable due from these entities was an immaterial amount at March 31, 2022 and December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the WSG acquisition on June 8, 2021, the Company continues to rent WSG's headquarters. The Chief Executive Officer and Founder of WSG, and currently a business unit president with the Company, is an agent of the lessor. The lease term is from January 1, 2020 through December 31, 2024. The Company paid an immaterial amount in rent expense for these premises for the three months ended March 31, 2022, and had an immaterial payable balance at March 31, 2022 and no payable balance at December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2020, the Company entered into a note payable of $7.3&#160;million related to contingent consideration assumed as part of a prior period acquisition, payable in three equal installments. The payees of the note are controlled by an employee of the sellers who remained with the Company. The third and final installment of $2.6&#160;million, including interest, was paid in the first quarter of 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:NotesPayable
      contextRef="i50316e467cb343f5859c8c6826909b1c_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83OS9mcmFnOmFiMmUwZGQ2NDhhODQwMmVhZWNjNzQxZGE0MTc1ZjNiL3RleHRyZWdpb246YWIyZTBkZDY0OGE4NDAyZWFlY2M3NDFkYTQxNzVmM2JfMjk2MQ_4c77bbcd-abf2-43db-8dd6-34150a317775"
      unitRef="usd">7300000</us-gaap:NotesPayable>
    <ccrn:NotePayableNumberOfPaymentInstallments
      contextRef="i50316e467cb343f5859c8c6826909b1c_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83OS9mcmFnOmFiMmUwZGQ2NDhhODQwMmVhZWNjNzQxZGE0MTc1ZjNiL3RleHRyZWdpb246YWIyZTBkZDY0OGE4NDAyZWFlY2M3NDFkYTQxNzVmM2JfMzA1OA_89ac02e4-bcc4-42e6-9d1e-9f0a8c6b635e"
      unitRef="installment">3</ccrn:NotePayableNumberOfPaymentInstallments>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="id23201d22a6f4efdbb89f5ada9e5702d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF83OS9mcmFnOmFiMmUwZGQ2NDhhODQwMmVhZWNjNzQxZGE0MTc1ZjNiL3RleHRyZWdpb246YWIyZTBkZDY0OGE4NDAyZWFlY2M3NDFkYTQxNzVmM2JfMTA5OTUxMTYzMzMzMw_3b38867e-6f4b-46e2-843c-222abd7d1e6a"
      unitRef="usd">2600000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF84NS9mcmFnOjIzOWM5MzdmNDNlZDQyYzVhZGQxOGY3MWU3YmU5ZDhkL3RleHRyZWdpb246MjM5YzkzN2Y0M2VkNDJjNWFkZDE4ZjcxZTdiZTlkOGRfMTIxNQ_9916cc37-557e-459b-90ca-048038c04b3a">RECENT ACCOUNTING PRONOUNCEMENTS&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 28, 2021, the FASB issued ASU No. 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires contract assets and contract liabilities such as deferred revenue acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. Generally, this amendment will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. Historically such amounts were recognized by the acquirer at fair value in acquisition accounting. This guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The amendments should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The Company is currently in the process of evaluating this standard and expects to adopt this standard in its first quarter of 2023.&lt;/span&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiZjQ2MmRiYmMxMzRiMjM5YTc3NDZmZGE5ODAxZTA0L3NlYzoxYmY0NjJkYmJjMTM0YjIzOWE3NzQ2ZmRhOTgwMWUwNF84NS9mcmFnOjIzOWM5MzdmNDNlZDQyYzVhZGQxOGY3MWU3YmU5ZDhkL3RleHRyZWdpb246MjM5YzkzN2Y0M2VkNDJjNWFkZDE4ZjcxZTdiZTlkOGRfNzY5NjU4MTM5ODExNA_cc0a2308-16cd-4ef5-9acb-188d73ef2833">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 28, 2021, the FASB issued ASU No. 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires contract assets and contract liabilities such as deferred revenue acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. Generally, this amendment will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. Historically such amounts were recognized by the acquirer at fair value in acquisition accounting. This guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The amendments should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The Company is currently in the process of evaluating this standard and expects to adopt this standard in its first quarter of 2023.&lt;/span&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>78
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" !N2Z549#7W+DH%  !X%0  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;)6877/B-A2&K[>_0L/THIT)L24#(3N$&7#(;J99PD*V.]M.+X0MP!/;<F49
MDG_?(QOL;,8<NS?@K_/ZT;'T'DFC@U3/Z4X(35ZB,$YO.CNMDX^6E7H[$?'T
M4B8BACL;J2*NX51MK311@OMY4!1:S+8'5L2#N#,>Y=<6:CR2F0Z#6"P42;,H
MXNIU*D)YN.G0SNG",MCNM+E@C4<)WXJ5T-^2A8(SJU3Q@TC$:2!CHL3FIC.A
M'UV'F8#\B3\#<4C?'!/3E+64S^;DWK_IV(9(A,+31H+#WUZX(@R-$G#\>Q3M
ME.\T@6^/3^IW>>.A,6N>"E>&WP-?[VXZPP[QQ89GH5[*PV=Q;%#?Z'DR3/-?
M<BB>[?4ZQ,M2+:-C,!!$05S\\Y=C(MX&L#,![!C W@70<V]PC@%.WM""+&_6
M+==\/%+R0)1Y&M3,09Z;/!I:$\3F,ZZT@KL!Q.FQ*_="D2Y)=UR)=&1IT#1W
M+.\8/RWBV9EXAWR1L=ZE9!;[PO\YW@*6$HB=@*8,%?S"U25QZ 5A-F,U/"X>
M/DE,N%T7_A..4^;'R?4<-#]_3]:I5M#E_D$D>Z5D+Y?LG9&\E5X& T&3I]=$
MU&4<#Z=V]RM"T2\I^NTHOF9<::'"5[(4B52ZC@B7TBH3"-&@)!JT(UH(%4C?
M]"@"?;HV1;C2J0_]\N%#0S>X*MFN6GXSQ<'"<@<ZGRY<:\/#%,O7L&0:HCJS
M6 ?:?+5M8#HGP,UY5)LM7,==/JY6Q'W\-G]:_B"?9Y.'I\_N9#F[(/=S%^&\
M+CFOVW#>QYY4D#%NDG=!5AH^+9&*N#*+M7J%?[\6'A>_G2&$U*Y<T&[#>!>$
M@LRS:"U4K17B(G;7<>C@&@-Z8\NT#= 3?R'W/G2\8!-X>>8P/%R2.MV>/1@P
MAA*RBI"U(9SX/A2.].)T0![@.?(8UW[+!LE!OT_)@JMG(C?0'Z)(*$^0J<Q"
ML>?*OR#SR^^7&'SEZM3Y7_"N.8/.^"0/<2TX+C>5'B=+KF6,T54%@N(6_YZN
M'"L+)?=![-7G%M>\>\#0JJI!<:]_C[:0J>8A^2M(S@[@!D7'Z0VO,+:J?E#<
M]O./.(')['D47* _H!A(52PH[O /T!U"LMC)&'437.3Z>MAES,&J%ZU*!<4]
M_BG0X&PPJBC[;?T[60DO4Y"M6JR&:@'#$EP()J;>\P5)N")['F:"_&I?VK9-
M20+3I7PRB7%7I8/B]@[EU@_B+5F]1FL9UN+B JZ[G&.STJI",-S<3RDCLQ=O
MQ^.M.%MM&X3FD]7M!)O!L:I(L%9%PLV4,G.38D*2IPL,(ZN=S3<H_GB_!OB9
MK"H.K%5QN(]A9EFLU,Q4CI]0:\EPQ0:RROE9*^<WE1[F'N"K6ZEJQT&#SL3S
M8"T*LQGA%V(87>7\K)7SKR(>AF2:I7 [K?^.N$[3')-5AL]:&?X,:O'6=*U/
MH*!WICHG/*Y/'"[8B%;Y/</M^I2LG8!D84"X3"-0Y?L,M^S3>"PL<E58Y"I?
M69/'3$.EC(V;U:YJ"^5^KFSV7O9C9\BH,QP,P59'UKX.K+)_UFJIX,+04U"9
M[F&M_D+^$/79PJ6,R=,>I;:#I:PR>-;@ST?ON@M24S-_""@HV,*O0:[;I:SK
M8%7<J1S?P8VZ7/.]9;N#B[4#LD&L:3NB\GP'=^CW5,?%\GDN7.XKFJO*[QW<
MG2> Y!=8(:_KX-,&@;.#T'JSMV4\*-_R2XEG5HW%-E=YM=Q6G.2;:5;U>+$G
M^84;"TM)*#80:E]>P6A3Q39?<:)EDN^4K:76,LH/=X+[0ID'X/Y&2GTZ,2\H
M-UO'_P%02P,$%     @ ;DNE5*$5RX<#!P  @1T  !@   !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6RMF=MNVS@0AE]%, IL"\2U>- I2 RX278;H$V#.MV]
M9B0Z%BJ)7I+.X>V7E&U)%@_.Q=XDDCRD_AD.YR.IBQ?&?XLUI3)XK:M&7$[6
M4F[.9S.1KVE-Q&>VH8WZ9<5X3:2ZY4\SL>&4%&VCNIK!,(QG-2F;R?RB?7;/
MYQ=L*ZNRH?<\$-NZ)OSM"ZW8R^4$3 X/?I9/:ZD?S.87&_)$EU3^VMQS=3?K
M>BG*FC:B9$W Z>IRL@#G5SC4#5J+OTOZ(@;7@7;ED;'?^N:VN)R$6A&M:"YU
M%T3]>Z97M*IT3TK'O_M.)]T[=</A]:'W/UOGE3./1- K5OU3%G)].4DG04%7
M9%O)G^SE*]T[%.G^<E:)]F_PLK<-)T&^%9+5^\9*05TVN__D=1^(00. '0W@
MO@%\;P.T;X!:1W?*6K>NB23S"\Y> JZM56_ZHHU-VUIY4S9Z&)>2JU]+U4[.
MKW[<7=_<+6^N W6U_/'M]GKQH&Z^++XM[JYN@N77FYN'93 -?BVO@X\?/@4?
M@K()'M9L*TA3B(N95!IT3[-\_[XON_=!Q_N^$_XY0. L@"&$EN97_N;7-.^:
M@^/F,^5YYS[LW(=M?\CE_I9SVLB "$&E./?TB+H>4=LC=O5(Q#I0L0ER?4'_
MW9;/I%*OL,9JUU7<=J4GW/,<P#"]F#T/(V(Q"E'<&1VIQ)U*[%6YR'.V5:+4
M3,RI4OA8T;.@456#K0)2J;E-FIP*??<A.P,8Z%'7(]9Z]B$^2]/#(V#S:_?R
M:" Y3A*,X,@STPQG* .AW;>H\RWR^G;/Z8:414!?5:T3U!KXR'AS$J?92)[-
M"*=V<7$G+O:*NVW$ENO@ZLBS9\K?!D-@4QH;(B(T&/V=4HM1B(%=:=(I3;Q*
M?\@UY:H$#2>(36!BCO7@U3M]%AOD"&3:R4N]\AZ8)-4[Y*7FJS.(PG$$3;,H
M3&&"["*S3F1V(A45;[E\:Z>-K@4;14#9S[0\W];;BDA:*/0H#.<E:>&FYQU(
MS\(,'D\\D)PE,//-O,SP \2)X:W%*DJ1PUD0]BP)_2FCG%4.-$]!115: ZX9
M.F6KZ5;=N(=HW^M1\#%.1IHM5@E.'5D$!OP#7LU_,5:\E%5E%0;,.($,9^%8
MVDF[8W$]G0#T)SDG!0T:4E-QID9=+4_*II1T6JFE3V%5#,U09J&A]X35L=J>
M?,"/OEW%*!M)FJ=2E;/]D+?I;A6+S/H?1AB-U5K,(,+8(;='(/ S\(XUTT/]
M4)&EZJH()'GU9:I)K P (U--*P B&#D$]UP#?K#MXML,9'N4FO""JO!%8ZD6
M,Y!%CM4%Z"D'_)C;56>//)-8&8@QPF-]IEV"8!IF#H$]W$#RKH5?59+'LBIE
M2;VK/]!C"?BYU*VL-N2-M)- %6Y5Z/F6^I<DP$20B@B$1D@L=F&61*[JW;,*
M^&&UV(O,6:U5[DBDU3_21A4>QT":*$EP@HPY;)K%490Z2@[LB0/]Q#D,XX;Q
M S@+^FBM-M#D!TBB<6FT6&&0..8#["D#_909DW&0=FISM9_.5M4F6G (QSRW
M6KGP P>;(S]^;AN5"[2MB?MLMDHT:0(S@(W(FF8)"A.'QAXZ\,1^R\P 2GC#
MMOW<?K.J-JF20C,=3"N5,Z[ ]NB!?O0<KZT'R6!5:L,)'.^E;%8H=D 2]LR!
M?N8<+[-/*;70)$40CZECL0-9EB2NN/;8@7[L?&/-TU127K=5X$Q--B$Z\?L,
ML0HW,0-!BA-#N&FGB@.*7?6AQQ$\L=GRUH<!\JWJS>U5EH1C;EBL0)BZL %[
MX$$_\)S+J%/)8G(,AN.EE,4(..M:3SKH)UV?)@<PYQ4I:[M,DUPPQL8BU686
M(>"8?Z@''/(#;AC==]4U9 +,4M<L5FH#X @LZC&'3F"NK6M5%]X3*8 L^R8<
MHG$2V,Q0XMKZH1YOZ,3NJJUMIS1:]DIQB.+Q$8?%#J,(IHY3&#0X3SP!.%;7
MI=3G!F)WKL@:72AHD[L4>_O3WP7.Q8;D]'*RX510_DPG\\!V%/L_='3L<\]'
MA+VK\Z5D^>\UJPK*Q1_MP8E\\Q[.]CQ#?I[I:*I5@M OL ;/1-.XD'I-CF7U
MX$)^<"V*HM1P4OFHSRZG91/D9%.J_+2*-#&$0 J,W9W-#H(H@@ZY/:Z0'U>+
MP<$5VZUEU*:!T[7^OO.L\,6$/35-!DT!,E!E-8.9 U6H1Q7RH^HGE40]*MI*
MJN:0"#X>'\&MRKR4GZS*31"A#&+CK-XTFT*8(,?>'_7(0GYD[6J5L,P+JUJ3
M1DA5K61,+8L=5%M)Z"BMN,<6]F/+**UMZ7JO_'WGPT\>UM,!BYWU=& V^#ZF
M/TY^)_RI;(1::ZU4P_!SH@+ =]_[=C>2;=I/9H],2E:WEVM*E&QMH'Y?,28/
M-_HK7/?5=?X?4$L#!!0    ( &Y+I51>S- N>@(  &0%   8    >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&ULC51=3^,P$/PKJX@'D#C2IH6VJ(U4VB*0^*@(
MW#V<[L%-MHV%8P?;:>'?W]HMN0(MNI?$Z^SLS$Z\[J^4?C8YHH770D@S"')K
MR_,P-&F.!3,GJD1)7^9*%\Q2J!>A*36RS(,*$4:-QEE8,"Z#N._WICKNJ\H*
M+G&JP51%P?3;!0JU&@3-X'WC@2]RZS;"N%^R!29HG\JIIBBLJV2\0&FXDJ!Q
M/@B&S?-1V^7[A)\<5V9K#:Z3F5+/+KC.!D'#"4*!J745&+V6.$(A7"&2\;*I
M&=24#KB]?J]^Z7NG7F;,X$B)7SRS^2#H!I#AG%7"/JC5%6[Z.77U4B6,?\)J
MG=OI!9!6QJIB R8%!9?K-WO=^+ %:+;W *(-(/I?0&L#:/E&U\I\6V-F6=S7
M:@7:95,UM_#>>#1UPZ7[BXG5])43SL:C^[OQY"Z9C(%6R?W-]7CX2,'%\&9X
M-YI <C69/"9P.&4:I<W1\I2)(_@!3\D8#@^.X "XA,=<58;)S/1#2YI<Y3#=
M\%^L^:,]_+=,GT"K>0Q1(XIVP$??P\>8UO#F1WA(3M1V1+4=D:_7VE,OL<PB
M'5(+:@Z77#*9<B9@J@SWI^[W<&:LIK/WYQNR5DW6\F3M/63#-%65M(:F(46^
M9#.!Q\ $#1;1(M"(0JHQXQ:$,@9WNKMF./,,;F*7<:_9)B>6VQY^33KK=O\E
M?1#?KL6WOQ4_U723:/L&]-\!7RI>.MM(?YI6127(QHS&B6X6,M!9MTM\^XNN
M9K?1BSZIWY'5Z42]3_+#K1EP]P\=K 67!@3."=<XZ9P&H-<SO0ZL*OU8S)2E
M(?/+G*Y!U"Z!OL^5LN^!F[3Z8HW_ E!+ P04    " !N2Z54-45AH;T%  "-
M%0  &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;+58VV[;.!#]%<+8AQ9(
M8I&R=0D2 XF=8@TT%\3I]J'8!UEF;**2Z)*TD_;K=R@IDBU2;!:+?;$D>GAT
M9C@SA^+%"Q??Y892A5[SK)"7@XU2V_/A4*8;FB?RC&]I ?\\<Y$G"A[%>BBW
M@B:K<E*>#8GG!<,\8<5@<E&./8C)!=^IC!7T02"YR_-$_+RF&7^Y'.#!V\ C
M6V^4'AA.+K;)FBZH^K)]$/ T;%!6+*>%9+Q @CY?#J[P^93$>D)I\1>C+_+@
M'FE7EIQ_UP_SU>7 TXQH1E.E(1*X[.F49IE& AX_:M!!\TX]\?#^#?U3Z3PX
MLTPDG?+L*UNIS>4@&J 5?4YVF7KD+W_2VJ&QQDMY)LM?]%+;>@.4[J3B>3T9
M&.2LJ*[):QV(@PDX[)E Z@GDO1/\>H)?.EHQ*]V:)2J97 C^@H2V!C1]4\:F
MG W>L$(OXT()^)?!/#69WM_-;NX6-S,$=XO[S_/9U1,\+)[@<GMS][1 ]Y_0
M_</-X]73' S0*?JRF*$/?WQ$<I,(*A$KT-.&[V12K.0)^N/H^6*H@*)^T3"M
MZ5Q7=$@/'1_=\D)M)+HI5G1U/'\(KC7^D3?_KHD3\#819\C')XAXA%CX3-\_
M'3OH^$VX_1+/[\&;%RG/*5JH1%$H!H6^72VE$I#,?SO01PWZJ$0?]: _TCTM
M=A0]"YZC*012 T-"J0V:EJE$Q0EZ$'RU@V%8(+2@8L]2BK[=O"I=FLN,HL],
M=LE4@7:_NX&ZI?F2"AO"]+\@' 5DW 1D_/Z R K?FI453%#"Z,ZWGX11%/J0
M,?M#!TPSG\1DA!NS(Y9!PS)P)L7]EHI$L6*-Z"NT9TGEN</WL$$-G;[/F(!6
MB;@!;O._@AH?.!9@/_:CCO^F&1F'81C8_8\:IM%O%CZ#H?4)6M,"R&9E:B8K
MZ'9,UX;N\T[RD<$J#"+L=[B;5J/ )Z&=>MQ0CYW4KY,5B,92O?&ST8O-H/E!
MW&%G&HV]D9T;]MK>[KE3@(*TIRRI!%,'->="L5_E@+4Y>R;7$'>YVJS(V.]A
M>Z!$V,GV*OVQ8Y(U9%FAZ%J47$\%S:!CKE#*I;++"C:7U^OR-FV\'M*D)4U^
MTV$@1:&=[H0NL7YZQ*07&?Q,(TP.:O"88BLYV'=2G.?;A(E2;5+0[+6]B&J0
MHY>'!YVMIFBQ&L4]#%O9PN[._\055/W[.E4-==2JX@A[1C!-.]^+R*BGX'$K
M*=BM*;6$EY)24^:%G>K8H!![@2$J%C/BQ7%?];>J@G\C*VI#11-+](&5Q#^Z
MM 6WXH+=ZC*'XH3MG[/Q85,N_#$Q4LJB/6&/HN)64K!;4RKG*Y=/4$&5E:"I
M":==R;/9^'U)U,H&=NM&G41+"A]BM*:)5/+:D_.F.D0A-ONR16D\/^CI<:25
M$>*6D7E#S[7:Q*(*8^P''9(6LQB3'HJM=A"W=MS!!V\=Q40IP98[E>C-K.+0
MD_,<% 6VO^GW#<]65%AC3$QQ"' <=7<1%C,<CT8]39JT.D+(.XH5N()B;_16
M?/^6%JYZ):T($+<(?"G@(S]COT!#=<JQ=0%?ET+0(OV)8(]5R*S:)61<VL-C
M-OY3W"UEFU'/WI"TXD#<XC"UQ,3*<&1LSF$!PVZWM9CI!>S+P%86B%L6#C(0
M1*'Z.GY/+L(7]74B6:K[,UKQ+$M@K$'X:/6T8A(>NG 6A%U'32OO;-RC*J15
M%1+\7W[.6+;3F[A_X6E@\]2H2=,*/.W9CY)6XDCH+,FOY1$0\$WVH/)KVGA5
M'7SPG9(*]JFP87&6:"M9Q"U9=1I4\/9PF%KDAQ[I2I;-+,!1CZ:25K2(6[2:
M]7-1-#7(#^/06#*;F>=WLW-X<+"54]BZZO,^"0NQ*U1U!M2,-F>*5^5)6F?\
M&I]/JY/!%J8ZJ+R%'3$K),KH,T!Z9R%P$M797_6@^+8\/EMRI7A>WFYH BFM
M#>#_9\[5VX-^07,"._D'4$L#!!0    ( &Y+I50L\3M1$P4  +84   8
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M\-A!&/K-I4O9JD39N!0_7Z"O88L]0.$H;BF_<AXAQEZLT2[0WXBK&;QCB0,
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MM2]#+*Z%\6F1-8[[<@>7#07$'=K)M4J(.50><0M(?Y$&Q)%,=*5+;,C0RL$
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MF&-_!L,SM#&K*^%##16VJ1D^SW>3V5.THUW[)/!Q2]H,! [>Z(\X6$56=P7
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MF"U,HA])&#.YAH!->#->REBGNG@8B==@%&MULH^_ 3.'HF!H"Z7R!JUQ_,&
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M4T#)5"VQE,#VR/=AJQ^%V?!WMZBG867\N$9$498FX/W2P$3"#]J@_A#[^7\
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MUEM%M:GGL;C,FMDNI[CM#3;!/$A!/S.>Y1EO,YU&&,D,@4!.J/,BON\W:JW
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M&$+Y$PV\KSVL/UUA?X&Y>\P//Y_F,;_[HR#_+W(]9.\XSPZ -67#^O\'@=Y
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M+)C)RKGO_')=GA9[#(@,J<@1)/YZNB1C.!!@/ PQBRDE.\Z?Q^@?$W=P6<E
ME\[\K<M8GQ;O"U%2)3L3O[K-'S3P.>)XRIF0?L4FVQXM"Z&Z$%TS. -!HVW^
MEX^##C.']WNO."P'AV7"G1,EE!]DE&<GWFV$9VM$XX=$-7D#G+:\*7?1XZN&
M7SR[_')S?WWS^]7-Y?75W<DB(B1_6*C!_2*[+U]Q/Q"?G8UU$%>VI/*Y_P)0
M)CS+$<_%\LV GZ7?%0?[.V*YMUR^$>]@XG>0XAV\QL\UC8ZHHAB$M*6X!%QM
MUV25IB ^Z*","YTG\<_Y*D2/(OGWC:R'4];#E/7P_ZKZICLWXG%HI:+3 IT6
MR/=4/(\I/M%:&G'KG2(J02B(C]XU(J)A1'3I?T?$FD"X::7="AV$MKTS/95X
M$+WTVG5!&!WU6G*#[ AEI&["#MM1&)?QSKHYQ/*BG>6+M8P"40)Q/$[E/+Z@
MLX5RG<>RJX2&[*LN@%\(N^*^!AE4;XSD X)IS %MMFAN(V/"34UKW);H75XJ
M)^.435MENI+SE;K790<%&!MZ(#5Y3Q,% *V0$OAA8[1<:1#=0A'YF/FT<NOA
M!D.>"XHRNDDM\)<KH]%700P[$,2F)HR17FJ#;XPBST0>+HQ( ? HBT!5!=8<
M0%;)FI-*N#>NLQ%2"2]1AJQ1,E7XMB+DD@&85R9!@#[08-1-A@!*0RFC8EOR
M#  B(:.!8Q0/G?20"]XI'8QX8F'W\@;-$3_Q@.R-M)C ')ICL6DJ) XR%(T(
M>FUU!9*PF9E_Z\IU>D"4DI ;,XI2A,P\Z9X"37PF#2K1N@A?S7ODF!UJKX+Q
M=E=<S''_7'.%XM0E^5S07&F>>I[:SPM?EM\P1D,RR%)/(P ?E?(HHSP;V**<
M)@+6 IAN\[8\=-KS5IRKR&6'XTVY!C;8R P]F9:ZJM F3-.#%?:A2EU9.^S?
MDP"K[1SA+X#4>9_$?]KBG:':@?09?T"35C$DY7ID8=$VM58UCK_.@ 1BJO@B
M/K>#CL-N@$0)3R JJ<>IW.:2@H;TJ -+,YL*0T<EGFGDS$= K@UVF L.4XO3
M>'!4"=4@X+QRN-O'+F,?T.7JIWGRJ?7P'3[$5O#K;"5[YY,B@6(TE"G *L Q
M5-NI+H- P8C&68H\F4K9(']>S&4X$,<$"%R1XTZ,F4=Q,PV9A>/^PD;_1^8*
MXP\'"U2".ZX%+X;*BHRF/LT(&BN(<R;1N@@Q;-KN%U6J<RG"$(<CH(RG(VX*
M&&#615%+-*B<RFZ$*2B#=/;9'-Z9X4264N?I/T#F/+CR^7'X0R@EL4,5KF_@
M<R<-Y6[YDDZ$N\B3^\;9=]<V\;F7C^+3,' 9^<].T\7LOM*07Z=;62H5&_/5
M95J=+G[G^;[S9)YOC9!DC:9 <59PW=O][:@0/M_$\DMT;;K]K%S$72H]UKB\
MDF<#?*\<9M#PP@FFZ_#9#U!+ P04    " !N2Z54'@C5Q\H$   =#   &0
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MYK@G7+.,-B_!5G$!G-N =3(^%MC?R;$ [G-KP^:%'6S_(SC["U!+ P04
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MDA'2]](@SHU(D(RZ4?4U6(=?=954C_=W!*)I\K;VB<FE0ML_G7+]9K[^V&
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M:(S5[C.) S1ZYBE27>&-NI=%+5NYN#3 FV']*?T!STL[$B)J-N.1;8- !$T
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MA<H>H'WKZF9B =HGVNP_4$L#!!0    ( &Y+I522'.D%1 ,  !0'   9
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ME)51M,O)SXQGD^7\?OYY!8O9$E9WD^4,KA[9.D7]<>@;"F#-_&@/-BW!@G?
M0GB0PB0:9B+&^-S?)V(5N^# ;AI<!'Q@J@YALP9!(P@NX(65VM#AA>^I94IP
ML=6P0 6KA"F$;Y.U-HHNQ_<+^*T*O^7P6^_@KZAFXB)%D!NXD5DN!0JC[6Q>
M9*B8D0J8B.$6A:3#=',J+&=;&.;N*1E/F>91:<C3PF ,%?'\0/RMT[E(SI;W
M0.<LPI%']:M1O: W?DR0&*14FP0/QIX\:"3.1,LD8&@[.A-B5\29F/@W,0>?
M$T%V:5V)BO>B\%24MJ(&\)@HQ+-K!'0)HJ2Z!?;3A"N6R<(RXH+ 9:$)5]<
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MFOXOH.8#]'VIE-TN^(+Z'\CT7U!+ P04    " !N2Z54VC>=_;L#  !="0
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MUWV2M2H?\W)@Y-8]H"MIZ#EVW0U]_Z"R!K2>2JIA-; ;U%]4X[\!4$L#!!0
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M0TJH!ZH=BJU@Y,X-HK4T--;<MJ#_""IK0.<;*<U!L 'Z/]/\7U!+ P04
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MEESP7M J^%49 Y^T:O8J2IK7,O$^D^^LJ]&Z>6Z=44-];Y_+4C4(&\= C0R
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M6?RR]O%U O1]HY3=;YR!\<?!\C]02P,$%     @ ;DNE5+84+\XF P  ! D
M !D   !X;"]W;W)K<VAE971S+W-H965T,S0N>&ULQ59-;]LX$/TK Z&'%DBM
M#SN.4]@&'*=I!<1.$,>[6"QZH*6QQ98B59*VDW^_0TE1W<96;]N+1%+SWKR9
M$3D<[I7^9C)$"T^YD&;D9=86'WS?)!GFS'14@9*^K)7.F:6IWOBFT,C2$I0+
M/PJ"OI\S+KWQL%R[U^.AVEK!)=YK,-L\9_KY"H7:C[S0>UEXX)O,N@5_/"S8
M!A=HE\6]IIG?L*0\1VFXDJ!Q/?(FX8=I6 )*B[\X[LW!&%PH*Z6^N4F<CKS
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M0),8=K*+1=$'QAI;:BG22])Q\O<[I!19CBUM%DA?)-[FS)G#T6CZ6R%_J11
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MOPW3[4%#S\8T*)D&3J;WY"6/T'Q)4ZZH!$OR0IYBVD0RV/*/>BC8)'D9;$6
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MNV4W/. 7$"C[ C[?26F>+VS+7'Y3S?\%4$L#!!0    ( &Y+I52'UELL"P(
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M H!V ?8\5PJ/CANR_DU)WP%02P,$%     @ ;DNE5#23I>=[ P  .0L  !D
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M=#0S+GAM;,6746^;.A3'OXJ%]K!);<$& IF22#3)MDA96C79]G!U'USB)-8
M9[9IMOOIKTTH$""TDR+U)<%PSO'/AW/^V(,#XS_%CA )?L=1(H;&3LK]1],4
MX8[$6-RP/4G4DPWC,99JR+>FV'."UYE3')G(LGIFC&EBC ;9O7L^&K!41C0A
M]QR(-(XQ_W-+(G88&M!XOO% MSNI;YBCP1YOR9+(;_M[KD9F$65-8Y((RA+
MR69H!/#C&&4.F<5W2@ZB<@WT4AX9^ZD'L_70L#01B4@H=0BL_I[(F$21CJ0X
M?N5!C6).[5B]?H[^*5N\6LPC%F3,HA]T+7=#PS? FFQP&LD'=OA"\@6Y.E[(
M(I']@D-N:QD@3(5D<>ZL"&*:'/_Q[SP1%0?HG'% N0-ZK8.=.]C90H]DV;(F
M6.+1@+,#X-I:1=,766XR;[4:FNC7N)1</:7*3XX^W]U-?LSF\RNP>@@F4[ (
MODZ75R!83,#=ZLOT <P6JV#Q>78[GX)@N9RNEN :!.&OE'*R!K-$XF1+'R,"
M B&(%.#]A$A,(_%!F7U;3L#[=Q_ .T 3L-JQ5.!D+0:F5-QZ=C/,&6^/C.@,
MXU?,;X -KP"R$&IQ'W>[3TA8N,-3=U-EJT@9*E*&LGCVF7B?:$(EN9ZK\EL#
MM2*5!54WU9O-M/PS5T' 3))8_-N!8!<(=H;@G'MKG D!QICS/S39@B!F:2+;
M$GL,T\O"Z(Y^&GF^ZZDD/E7S]Y+5":-3,#J=C$$8IG$:8:D2H@"YI/]AW;EM
MF,=(;@7 ]BW4KV&V6/40\MLQW0+3[<1<**E\12+=QMR.Y3IVC;#%"MF.TT[8
M*PA[G80KCM<$)#@FXDIU4E%KD:ZU-M9>@\+M6U8-]06C$U*O(/4Z2;4":4T5
M'27N%['\M^JR?H'0OTR7]9N%:;EV/>,O69TP0JL4<.MB?9:'JC+ /K3]&FF;
MF6][[AG4RK<&7J+7\B@GTT.[7U>M-C,$W7.4I;Q#U$DYSKZZA*M=2I1E4NSH
MOJND82G;T'ZKHH:E+L-N87YU6<.FX#J>UZR6E\Q..4MAAMW*_%>%W51>Z/>L
MNCZWF7FN#\^@E@H-NR7ZM87=%%VDVL^M4S;-; NZWAG*4IUAMSPO6'(=LGA/
M) %XRPE1VW'96=BE6,,W4VM8RC6\D%[#-BEVZF^AV^ATZUBJ-;J<6J.F#"._
MWGUM1N>V;JA4:G01I<ZC5'>.L%<';-K8=3ZS<H#1IT>UX]_21("(;)23=>.I
MY?'C@>PXD&R?G6D>F51:G5WNU"&6<&V@GF\8D\\#?4PJCL6C_P%02P,$%
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MA1VD,<#O*X%=5 S,E;#\%\#D;U!+ P04    " !N2Z54+\ @H(\#   I#@
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M[;2CF0S+DAX!-#Z ]O=:NZ/A$_3/2OH'4$L#!!0    ( &Y+I518]PC9QP(
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M%K3BYDZN/\'&3V+Y4LFU^R7K36[@D;321A8;,"HHF*B?]&E3AQU F.P!A!M
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MGQ)$F@7P?".$?IV8PZKZ.)G\!5!+ P04    " !N2Z54F7\8'.X"  #A!P
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MT"G)8G7'E[_3HJ"6B1?Q6.:_L"QL_09$F50\*9SU"!*6KH[D9]&(-8<@K'%
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M6F8_/7K3 ]]*L?\.;3\OHM3/WT+6=IF]'>7: R/X94+[+H+ ZE6 CD_$:EF
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M& /]_Y3K:HH+\R&T_+3>_P]02P,$%     @ ;DNE5"P:GPZ,!    1(  !D
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MP.?C)_9WWCMYF3&#$R6^\,PN1L$@@ QS5@I[K58?<.VG[_A2)8S_A]7Z;!1
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ME[\LOW;.;L(%YP2_$SW^!5!+ P04    " !N2Z54UDS DN !  #C(P  $P
M %M#;VYT96YT7U1Y<&5S72YX;6S-VLM.PS 0!=!?B;)%C>M7>8BR ;;0!3]@
MD@F-FL26;:#\/4X*E4"EHBH2=].HM3UWXI'.JI</;XY"MN[:/LSS98SN@K%0
M+JDSH;".^K126]^9F+[Z)^9,N3)/Q,1T.F.E[2/U<1*'&OG5Y0W5YKF-V>TZ
M_1P:V\]S3VW(L^O-QB%KGAOGVJ8T,:VSE[[ZEC+Y2"C2R7%/6#8NG*0-.=N9
M,*S\'/!Q[OZ%O&\JRA;&QSO3I5ULW;(0WUH*Q?X2.WJT==V45-GRN4M'BN \
MF2HLB6+7%INB)_N38[IAVGSRH_/',OL"T\Z%MRZDB7DZ/.YS),/IB4N%R,=F
M_RMN$U/IH]^/AFE75/TR.UWOJ_6K<1Z!C8_C[_CKC+?U#^Q#@/0A0?I0('UH
MD#YF('V<@O1Q!M+'.4@??(K2"(JH'(54CF(J1T&5HZC*45CE**YR%%@YBJP"
M15:!(JM D56@R"I09!4HL@H4606*K )%5H$BJT215:+(*E%DE2BR2A19)8JL
M$D56B2*K1)%5HLBJ4&15*+(J%%D5BJP*15:%(JM"D56AR*I09%4HLFH4636*
MK!I%5HTBJT:15:/(JE%DU2BR:A19-8JL,Q199_\IZZ.UJS^.'Y]%9YK^,Y^-
M_^VY>@=02P$"% ,4    " !N2Z54!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( &Y+I50V]H"W[P
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( &Y+I5297)PC$ 8  )PG   3              "  <T!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ;DNE5&0U]RY*!0  >!4  !@
M             ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( &Y+I52A%<N' P<  ($=   8              " @8X-  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !N2Z547LS0+GH"  !D
M!0  &               @(''%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ ;DNE5#5%8:&]!0  C14  !@              ("!=Q<
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( &Y+I50L\3M1
M$P4  +84   8              " @6H=  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " !N2Z54XV&=RXX&   ^&@  &
M@(&S(@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ ;DNE
M5)(S%;BY!   9 L  !@              ("!=RD  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( &Y+I53+,@'^U0P  )4@   8
M      " @68N  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" !N2Z54NVE4GRP#   -!P  &               @(%Q.P  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ ;DNE5-5FIES!!P  M10  !D
M             ("!TSX  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " !N2Z54Z"9BMU0#  "8!P  &0              @('+1@  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( &Y+I53N2+(/>@,
M )H(   9              " @59*  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ ;DNE5+NG;:SX!@  =A   !D              ("!
M!TX  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !N2Z54
MBO?^(\4.  "4+0  &0              @($V50  >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( &Y+I5239L\9DP@  .\5   9
M      " @3)D  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ ;DNE5)W/GP1T"0  :AH  !D              ("!_&P  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " !N2Z545@"N_68'  "?$@
M&0              @(&G=@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( &Y+I50TO$)-X@8  %$0   9              " @41^  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ ;DNE5,?+XU8
M!0  &@L  !D              ("!784  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " !N2Z54'@C5Q\H$   =#   &0
M@(&4B@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( &Y+
MI53=O&_4604  )$-   9              " @96/  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ ;DNE5 <T(\ &!   )PD  !D
M         ("!)94  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    " !N2Z54$E^W>#<+  !D'@  &0              @(%BF0  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( &Y+I52N4<OD3P0  *X)
M   9              " @="D  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ ;DNE5)(<Z05$ P  % <  !D              ("!5JD
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !N2Z5497M7
MPTD#  #L!@  &0              @('1K   >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( &Y+I51CP!86) ,  $P'   9
M  " @5&P  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
M;DNE5*VX"L/+ P  70@  !D              ("!K+,  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " !N2Z54T35>W-(#   O"0  &0
M            @(&NMP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( &Y+I50O3 T&S00  (T,   9              " @;>[  !X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ ;DNE5-HWG?V[ P
M70D  !D              ("!N\   'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    " !N2Z54?/Y-]!X#  "E!@  &0              @(&M
MQ   >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( &Y+I53!
MSR.Y\ ,  "@(   9              " @0+(  !X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ ;DNE5+84+\XF P  ! D  !D
M     ("!*<P  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &Y+I51!2R4Y]P,  %\-   9              "
M@;K?  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ ;DNE
M5(?66RP+ @  7P0  !D              ("!Z.,  'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    " !N2Z54-).EYWL#   Y"P  &0
M        @($JY@  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( &Y+I53<+EUJA (  ,T%   9              " @=SI  !X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ ;DNE5'3Q*4O0 P  (@\
M !D              ("!E^P  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    " !N2Z54^5K@V,@"  !2!P  &0              @(&>\
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( &Y+I52;22\[
M? (  ,\&   9              " @9WS  !X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ ;DNE5$*;C#4)!   #A   !D
M ("!4/8  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " !N
M2Z54+\ @H(\#   I#@  &0              @(&0^@  >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( &Y+I51S*R@5!0,  *0*   9
M          " @5;^  !X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#
M%     @ ;DNE5$C!23.0!   S!(  !D              ("!D@$! 'AL+W=O
M<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " !N2Z54V$WS9^P"   Q
M"0  &0              @(%9!@$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM
M;%!+ 0(4 Q0    ( &Y+I50SKS9(' (  &($   9              " @7P)
M 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ ;DNE5%CW
M"-G' @  MP<  !D              ("!SPL! 'AL+W=O<FMS:&5E=',O<VAE
M970U,BYX;6Q02P$"% ,4    " !N2Z54<C%,VNT"  "H"   &0
M    @('-#@$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (
M &Y+I529?Q@<[@(  .$'   9              " @?$1 0!X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L! A0#%     @ ;DNE5':0EV:2 @  #0<  !D
M             ("!%A4! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"
M% ,4    " !N2Z54*PPQLI($  !F%P  &0              @('?%P$ >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( &Y+I50L&I\.C 0
M  $2   9              " @:@< 0!X;"]W;W)K<VAE971S+W-H965T-3<N
M>&UL4$L! A0#%     @ ;DNE5'VY#*<,!   61(  !D              ("!
M:R$! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " !N2Z54
MGBSWS@\$  "*#@  &0              @(&N)0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Y+GAM;%!+ 0(4 Q0    ( &Y+I50T>USNY (  /\'   9
M      " @?0I 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%
M  @ ;DNE5,#"Z=_) @  [ <  !D              ("!#RT! 'AL+W=O<FMS
M:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " !N2Z543.:<Q1P#   *$@
M#0              @ $/, $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( &Y+
MI527BKL<P    !,"   +              "  58S 0!?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( &Y+I50$,_-['P4  "0H   /              "  3\T 0!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !N2Z54]4F2S $"  !>)   &@
M            @ &+.0$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " !N2Z54UDS DN !  #C(P  $P              @ '$.P$ 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     10!% -H2  #5/0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>145</ContextCount>
  <ElementCount>270</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATION</Role>
      <ShortName>ORGANIZATION AND BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - REVENUE RECOGNITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/REVENUERECOGNITION</Role>
      <ShortName>REVENUE RECOGNITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/ACQUISITIONS</Role>
      <ShortName>ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/COMPREHENSIVEINCOME</Role>
      <ShortName>COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117106 - Disclosure - EARNINGS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARE</Role>
      <ShortName>EARNINGS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2121107 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETS</Role>
      <ShortName>GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2133109 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2139110 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2143111 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2147112 - Disclosure - SEGMENT DATA</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/SEGMENTDATA</Role>
      <ShortName>SEGMENT DATA</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2150113 - Disclosure - CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/CONTINGENCIES</Role>
      <ShortName>CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2151114 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2153115 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2155116 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/RECENTACCOUNTINGPRONOUNCEMENTS</Role>
      <ShortName>RECENT ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - REVENUE RECOGNITION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONTables</Role>
      <ShortName>REVENUE RECOGNITION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/REVENUERECOGNITION</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - ACQUISITIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/ACQUISITIONSTables</Role>
      <ShortName>ACQUISITIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/ACQUISITIONS</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2318304 - Disclosure - EARNINGS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARETables</Role>
      <ShortName>EARNINGS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARE</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSTables</Role>
      <ShortName>GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETS</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2327306 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/DEBTTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/DEBT</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2334307 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/LEASES</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2340308 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2344309 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2348310 - Disclosure - SEGMENT DATA (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/SEGMENTDATATables</Role>
      <ShortName>SEGMENT DATA (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/SEGMENTDATA</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Allowance for Doubtful Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAllowanceforDoubtfulAccountsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Allowance for Doubtful Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restructuring Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringCostsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restructuring Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - REVENUE RECOGNITION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails</Role>
      <ShortName>REVENUE RECOGNITION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - ACQUISITIONS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails</Role>
      <ShortName>ACQUISITIONS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - ACQUISITIONS - Recognized Identified Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>ACQUISITIONS - Recognized Identified Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - COMPREHENSIVE INCOME (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/COMPREHENSIVEINCOMEDetails</Role>
      <ShortName>COMPREHENSIVE INCOME (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/COMPREHENSIVEINCOME</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - EARNINGS PER SHARE - Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails</Role>
      <ShortName>EARNINGS PER SHARE - Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2420409 - Disclosure - EARNINGS PER SHARE - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAdditionalInformationDetails</Role>
      <ShortName>EARNINGS PER SHARE - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2423410 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Acquired Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails</Role>
      <ShortName>GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Acquired Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Estimated Annual Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails</Role>
      <ShortName>GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Estimated Annual Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails</Role>
      <ShortName>GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2428413 - Disclosure - DEBT - Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails</Role>
      <ShortName>DEBT - Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - DEBT - Maturities of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails</Role>
      <ShortName>DEBT - Maturities of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - DEBT - 2021 Term Loan Credit Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails</Role>
      <ShortName>DEBT - 2021 Term Loan Credit Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - DEBT - 2019 Loan Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails</Role>
      <ShortName>DEBT - 2019 Loan Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - DEBT - Note Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/DEBTNotePayableDetails</Role>
      <ShortName>DEBT - Note Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - LEASES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/LEASESAdditionalInformationDetails</Role>
      <ShortName>LEASES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - LEASES - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/LEASESSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>LEASES - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - LEASES - Operating Lease Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails</Role>
      <ShortName>LEASES - Operating Lease Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - LEASES - Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/LEASESLeaseCostsDetails</Role>
      <ShortName>LEASES - Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - FAIR VALUE MEASUREMENTS - Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - FAIR VALUE MEASUREMENTS - Carrying Amounts and Estimated Fair Values of Significant Financial Instrument that were not Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Carrying Amounts and Estimated Fair Values of Significant Financial Instrument that were not Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2445424 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2446425 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2449426 - Disclosure - SEGMENT DATA (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/SEGMENTDATADetails</Role>
      <ShortName>SEGMENT DATA (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/SEGMENTDATATables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2452427 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/INCOMETAXESDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/INCOMETAXES</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ccrn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2454428 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ccrn-20220331.htm">ccrn-20220331.htm</File>
    <File>ccrn-20220331.xsd</File>
    <File>ccrn-20220331_cal.xml</File>
    <File>ccrn-20220331_def.xml</File>
    <File>ccrn-20220331_lab.xml</File>
    <File>ccrn-20220331_pre.xml</File>
    <File>ccrn20220331-10qex10x2.htm</File>
    <File>ccrn20220331-10qex31x1.htm</File>
    <File>ccrn20220331-10qex31x2.htm</File>
    <File>ccrn20220331-10qex32x1.htm</File>
    <File>ccrn20220331-10qex32x2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ccrn-20220331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="538">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ccrn-20220331.htm": {
   "axisCustom": 1,
   "axisStandard": 21,
   "contextCount": 145,
   "dts": {
    "calculationLink": {
     "local": [
      "ccrn-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ccrn-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ccrn-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ccrn-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ccrn-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ccrn-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 431,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 2,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 7
   },
   "keyCustom": 31,
   "keyStandard": 239,
   "memberCustom": 18,
   "memberStandard": 25,
   "nsprefix": "ccrn",
   "nsuri": "http://www.crosscountryhealthcare.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.crosscountryhealthcare.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - ACQUISITIONS",
     "role": "http://www.crosscountryhealthcare.com/role/ACQUISITIONS",
     "shortName": "ACQUISITIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - COMPREHENSIVE INCOME",
     "role": "http://www.crosscountryhealthcare.com/role/COMPREHENSIVEINCOME",
     "shortName": "COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117106 - Disclosure - EARNINGS PER SHARE",
     "role": "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARE",
     "shortName": "EARNINGS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121107 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS",
     "role": "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETS",
     "shortName": "GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - DEBT",
     "role": "http://www.crosscountryhealthcare.com/role/DEBT",
     "shortName": "DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133109 - Disclosure - LEASES",
     "role": "http://www.crosscountryhealthcare.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139110 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143111 - Disclosure - STOCKHOLDERS' EQUITY",
     "role": "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147112 - Disclosure - SEGMENT DATA",
     "role": "http://www.crosscountryhealthcare.com/role/SEGMENTDATA",
     "shortName": "SEGMENT DATA",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150113 - Disclosure - CONTINGENCIES",
     "role": "http://www.crosscountryhealthcare.com/role/CONTINGENCIES",
     "shortName": "CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151114 - Disclosure - INCOME TAXES",
     "role": "http://www.crosscountryhealthcare.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153115 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155116 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS",
     "role": "http://www.crosscountryhealthcare.com/role/RECENTACCOUNTINGPRONOUNCEMENTS",
     "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - REVENUE RECOGNITION (Tables)",
     "role": "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONTables",
     "shortName": "REVENUE RECOGNITION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - ACQUISITIONS (Tables)",
     "role": "http://www.crosscountryhealthcare.com/role/ACQUISITIONSTables",
     "shortName": "ACQUISITIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318304 - Disclosure - EARNINGS PER SHARE (Tables)",
     "role": "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARETables",
     "shortName": "EARNINGS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS (Tables)",
     "role": "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSTables",
     "shortName": "GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327306 - Disclosure - DEBT (Tables)",
     "role": "http://www.crosscountryhealthcare.com/role/DEBTTables",
     "shortName": "DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ccrn:AssetsAndLiabilitiesLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334307 - Disclosure - LEASES (Tables)",
     "role": "http://www.crosscountryhealthcare.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ccrn:AssetsAndLiabilitiesLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340308 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344309 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "role": "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYTables",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348310 - Disclosure - SEGMENT DATA (Tables)",
     "role": "http://www.crosscountryhealthcare.com/role/SEGMENTDATATables",
     "shortName": "SEGMENT DATA (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnbilledContractsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnbilledContractsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i023808945518453896c9849a64047565_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Allowance for Doubtful Accounts (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAllowanceforDoubtfulAccountsDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Allowance for Doubtful Accounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i023808945518453896c9849a64047565_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restructuring Costs (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringCostsDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restructuring Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i7bc99217a5124b478bddc5a0566fedaf_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - REVENUE RECOGNITION (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails",
     "shortName": "REVENUE RECOGNITION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "ibda3d097b5e34888bd4ce3a4a893ea70_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - ACQUISITIONS - Additional Information (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails",
     "shortName": "ACQUISITIONS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iddc9cc886ecc4548a8c7f9a14a4fa974_D20211216-20211216",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - ACQUISITIONS - Recognized Identified Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "ACQUISITIONS - Recognized Identified Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DirectOperatingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ccrn:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - COMPREHENSIVE INCOME (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/COMPREHENSIVEINCOMEDetails",
     "shortName": "COMPREHENSIVE INCOME (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ccrn:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419408 - Disclosure - EARNINGS PER SHARE - Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails",
     "shortName": "EARNINGS PER SHARE - Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i1a13d2d2a7ff4121984d558f70731480_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420409 - Disclosure - EARNINGS PER SHARE - Additional Information (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAdditionalInformationDetails",
     "shortName": "EARNINGS PER SHARE - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i1a13d2d2a7ff4121984d558f70731480_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423410 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Acquired Intangible Assets (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails",
     "shortName": "GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Acquired Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Estimated Annual Amortization Expense (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails",
     "shortName": "GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Estimated Annual Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Additional Information (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails",
     "shortName": "GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i24a8be762a2a4907a7c8cca553b30556_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428413 - Disclosure - DEBT - Long-term Debt (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails",
     "shortName": "DEBT - Long-term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - DEBT - Maturities of Debt (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails",
     "shortName": "DEBT - Maturities of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i7cfc6b7fa94a4a8c982cafd55a1312f7_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i82cd05f641874a9cbbe754810cef2c8a_D20210608-20210608",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - DEBT - 2021 Term Loan Credit Agreement (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails",
     "shortName": "DEBT - 2021 Term Loan Credit Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i82cd05f641874a9cbbe754810cef2c8a_D20210608-20210608",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i8b42bcc4941c443dae883bd802178090_I20211118",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ccrn:LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - DEBT - 2019 Loan Agreement (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails",
     "shortName": "DEBT - 2019 Loan Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i8b42bcc4941c443dae883bd802178090_I20211118",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ccrn:LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i88d0c2f866014453b998a2cb5527a438_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i88d0c2f866014453b998a2cb5527a438_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfNotesPayable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - DEBT - Note Payable (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/DEBTNotePayableDetails",
     "shortName": "DEBT - Note Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - LEASES - Additional Information (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/LEASESAdditionalInformationDetails",
     "shortName": "LEASES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ccrn:AssetsAndLiabilitiesLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - LEASES - Supplemental Balance Sheet Information (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/LEASESSupplementalBalanceSheetInformationDetails",
     "shortName": "LEASES - Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ccrn:AssetsAndLiabilitiesLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - LEASES - Operating Lease Maturity (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails",
     "shortName": "LEASES - Operating Lease Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - LEASES - Lease Costs (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/LEASESLeaseCostsDetails",
     "shortName": "LEASES - Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i14c7086aa5ac419fb6760c4660fcbb9f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - FAIR VALUE MEASUREMENTS - Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i14c7086aa5ac419fb6760c4660fcbb9f_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i65a1d1e2b5f949c2984f6f55c6c41b60_I20210608",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - FAIR VALUE MEASUREMENTS - Carrying Amounts and Estimated Fair Values of Significant Financial Instrument that were not Measured at Fair Value (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Carrying Amounts and Estimated Fair Values of Significant Financial Instrument that were not Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "id106177b91204212b84484a1a875400b_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445424 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i71a85a5aa3644dc28a45d3f3e9a9acad_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i95016a76eb2d4e2bb36c7a7aceb60b64_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446425 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i95016a76eb2d4e2bb36c7a7aceb60b64_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449426 - Disclosure - SEGMENT DATA (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/SEGMENTDATADetails",
     "shortName": "SEGMENT DATA (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ccrn:OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ccrn:ProvisionForDoubtfulAccountsAndOtherAllowances",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452427 - Disclosure - INCOME TAXES (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/INCOMETAXESDetails",
     "shortName": "INCOME TAXES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfNotesPayable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454428 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "role": "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "i50316e467cb343f5859c8c6826909b1c_I20200331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION",
     "role": "http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATION",
     "shortName": "ORGANIZATION AND BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - REVENUE RECOGNITION",
     "role": "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITION",
     "shortName": "REVENUE RECOGNITION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ccrn-20220331.htm",
      "contextRef": "iac75bbfef3aa468dbbd5a581abe54fbd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 46,
   "tag": {
    "ccrn_A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Term Loan Credit Agreement, Aggregate Amount Of All Possible Increases",
        "label": "2021 Term Loan Credit Agreement, Aggregate Amount Of All Possible Increases [Member]",
        "terseLabel": "2021 Term Loan Credit Agreement, Aggregate Amount of All Possible Increases"
       }
      }
     },
     "localname": "A2021TermLoanCreditAgreementAggregateAmountOfAllPossibleIncreasesMember",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ccrn_A2021TermLoanCreditAgreementIncrementalTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Term Loan Credit Agreement, Incremental Term Loan",
        "label": "2021 Term Loan Credit Agreement, Incremental Term Loan [Member]",
        "terseLabel": "2021 Term Loan Credit Agreement, Incremental Term Loan"
       }
      }
     },
     "localname": "A2021TermLoanCreditAgreementIncrementalTermLoanMember",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ccrn_A2021TermLoanCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Term Loan Credit Agreement",
        "label": "2021 Term Loan Credit Agreement [Member]",
        "terseLabel": "2021 Term Loan Credit Agreement"
       }
      }
     },
     "localname": "A2021TermLoanCreditAgreementMember",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ccrn_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Before Tax",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Before Tax",
        "negatedTerseLabel": "Loss on currency fluctuations"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentBeforeTax",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/COMPREHENSIVEINCOMEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ccrn_AcquisitionAndIntegrationRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition and integration-related costs include costs for prior acquisitions, costs incurred for potential transactions, and accretion and valuation adjustments on contingent consideration liabilities",
        "label": "Acquisition And Integration-Related Costs",
        "terseLabel": "Acquisition and integration-related costs"
       }
      }
     },
     "localname": "AcquisitionAndIntegrationRelatedCosts",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ccrn_AssetsAndLiabilitiesLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Leases [Table Text Block]",
        "label": "Assets And Liabilities, Leases [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLeasesTableTextBlock",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ccrn_BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Net Working Capital Adjustment",
        "label": "Business Combination, Consideration Transferred, Net Working Capital Adjustment",
        "terseLabel": "Net working capital adjustment"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredNetWorkingCapitalAdjustment",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ccrn_BusinessCombinationContingentConsiderationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Term",
        "label": "Business Combination, Contingent Consideration, Term",
        "terseLabel": "Contingent consideration liability, term"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationTerm",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation, Current",
        "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation, Current",
        "terseLabel": "Lease liability - current"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationCurrent",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ccrn_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation, Noncurrent",
        "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation, Noncurrent",
        "terseLabel": "Lease liability - non-current"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedLeaseObligationNoncurrent",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Compensation And Benefits",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Compensation And Benefits",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensationAndBenefits",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill",
        "totalLabel": "Total assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-Of-Use Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-Of-Use Assets",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ccrn_DebtInstrumentVariableInterestRateFloor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Variable Interest Rate Floor",
        "label": "Debt Instrument, Variable Interest Rate Floor",
        "terseLabel": "Interest margin floor (percent)"
       }
      }
     },
     "localname": "DebtInstrumentVariableInterestRateFloor",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ccrn_DeferredCompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Compensation [Member]",
        "label": "Deferred Compensation [Member]",
        "terseLabel": "Deferred compensation"
       }
      }
     },
     "localname": "DeferredCompensationMember",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ccrn_EarnoutNotesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnout Notes Payable",
        "label": "Earnout Notes Payable [Member]",
        "terseLabel": "Earnout Notes Payable"
       }
      }
     },
     "localname": "EarnoutNotesPayableMember",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTNotePayableDetails",
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails",
      "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ccrn_EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate, Continuing Operations, Excluding Discrete Items",
        "label": "Effective Income Tax Rate, Continuing Operations, Excluding Discrete Items",
        "terseLabel": "Effective tax rate, excluding discrete items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsExcludingDiscreteItems",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ccrn_ExitCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exit Costs [Member]",
        "label": "Exit Costs [Member]",
        "terseLabel": "Lease-Related Exit Costs"
       }
      }
     },
     "localname": "ExitCostsMember",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ccrn_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]",
        "label": "Finite Lived And Indefinite Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ccrn_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ccrn_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Liabilities",
        "label": "Increase (Decrease) In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ccrn_LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit, Amount Of Indebtedness Permitted By Senior Secured Asset Based Loan To Be Borrowed From Other Sources",
        "label": "Line Of Credit, Amount Of Indebtedness Permitted By Senior Secured Asset Based Loan To Be Borrowed From Other Sources",
        "terseLabel": "Amount of indebtedness permitted from other sources"
       }
      }
     },
     "localname": "LineOfCreditAmountOfIndebtednessPermittedBySeniorSecuredAssetBasedLoanToBeBorrowedFromOtherSources",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ccrn_LineOfCreditBorrowingBasePercentageOfAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit, Borrowing Base, Percentage Of Assets",
        "label": "Line Of Credit, Borrowing Base, Percentage Of Assets",
        "terseLabel": "Borrowing base, percentage of assets"
       }
      }
     },
     "localname": "LineOfCreditBorrowingBasePercentageOfAssets",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ccrn_LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Basis Spread On Variable Rate, Additional Credit Spread Associated With SOFR",
        "label": "Line Of Credit Facility, Basis Spread On Variable Rate, Additional Credit Spread Associated With SOFR",
        "terseLabel": "Basis spread on variable rate, additional credit spread associated with SOFR"
       }
      }
     },
     "localname": "LineOfCreditFacilityBasisSpreadOnVariableRateAdditionalCreditSpreadAssociatedWithSOFR",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ccrn_LineOfCreditFacilityBorrowingBaseAvailability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Borrowing Base Availability",
        "label": "Line Of Credit Facility, Borrowing Base Availability",
        "terseLabel": "Borrowing base availability"
       }
      }
     },
     "localname": "LineOfCreditFacilityBorrowingBaseAvailability",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ccrn_LineOfCreditSublimitAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Sublimit [Axis]",
        "label": "Line Of Credit Sublimit [Axis]",
        "terseLabel": "Line Of Credit Sublimit [Axis]"
       }
      }
     },
     "localname": "LineOfCreditSublimitAxis",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ccrn_LineOfCreditSublimitDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Line Of Credit Sublimit [Axis]",
        "label": "Line Of Credit Sublimit [Domain]",
        "terseLabel": "Line Of Credit Sublimit [Domain]"
       }
      }
     },
     "localname": "LineOfCreditSublimitDomain",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ccrn_LongTermDebtMaturityAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Maturity, After Year Four",
        "label": "Long-Term Debt, Maturity, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturityAfterYearFour",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ccrn_MediscanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mediscan",
        "label": "Mediscan [Member]",
        "terseLabel": "Mediscan"
       }
      }
     },
     "localname": "MediscanMember",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTNotePayableDetails",
      "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ccrn_NotePayableNumberOfInstallmentsPaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Note Payable, Number Of Installments Paid",
        "label": "Note Payable, Number Of Installments Paid",
        "terseLabel": "Number of installments paid"
       }
      }
     },
     "localname": "NotePayableNumberOfInstallmentsPaid",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTNotePayableDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ccrn_NotePayableNumberOfPaymentInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Note Payable, Number Of Payment Installments",
        "label": "Note Payable, Number Of Payment Installments",
        "terseLabel": "Number of installments"
       }
      }
     },
     "localname": "NotePayableNumberOfPaymentInstallments",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTNotePayableDetails",
      "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ccrn_NurseAndAlliedStaffingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nurse and allied staffing [Member]",
        "label": "Nurse And Allied Staffing [Member]",
        "verboseLabel": "Nurse And Allied Staffing"
       }
      }
     },
     "localname": "NurseAndAlliedStaffingMember",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATADetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ccrn_OmnibusPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omnibus Plan",
        "label": "Omnibus Plan [Member]",
        "terseLabel": "Omnibus Plan"
       }
      }
     },
     "localname": "OmnibusPlanMember",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ccrn_OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Income Loss Before D And A Acquisition And Integration Contingent Consideration Restructuring Legal Impairment And Corporate Overheard",
        "label": "Operating Income Loss Before D And A Acquisition And Integration Contingent Consideration Restructuring Legal Impairment And Corporate Overheard",
        "terseLabel": "Contribution income"
       }
      }
     },
     "localname": "OperatingIncomeLossBeforeDAndAAcquisitionAndIntegrationContingentConsiderationRestructuringLegalImpairmentAndCorporateOverheard",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ccrn_OperatingLeaseExpenseNonCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Expense, Non-Cash",
        "label": "Operating Lease Expense, Non-Cash",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpenseNonCash",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ccrn_OtherServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Services [Member]",
        "label": "Other Services [Member]",
        "terseLabel": "Other Services"
       }
      }
     },
     "localname": "OtherServicesMember",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ccrn_PaymentsForRestructuringAndAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Restructuring And Adjustments",
        "label": "Payments For Restructuring And Adjustments",
        "negatedTerseLabel": "Payments and adjustments"
       }
      }
     },
     "localname": "PaymentsForRestructuringAndAdjustments",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ccrn_PhysicianStaffingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physician staffing [Member]",
        "label": "Physician Staffing [Member]",
        "terseLabel": "Physician Staffing"
       }
      }
     },
     "localname": "PhysicianStaffingMember",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATADetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ccrn_ProvisionForDoubtfulAccountsAndOtherAllowances": {
     "auth_ref": [],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision For Doubtful Accounts And Other Allowances",
        "label": "Provision For Doubtful Accounts And Other Allowances",
        "verboseLabel": "Provision for allowances"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccountsAndOtherAllowances",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ccrn_SalesAllowanceBillingRelatedAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Allowance, Billing-Related Adjustments",
        "label": "Sales Allowance, Billing-Related Adjustments",
        "terseLabel": "Sales allowance, billing-related adjustments"
       }
      }
     },
     "localname": "SalesAllowanceBillingRelatedAdjustments",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ccrn_ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Indefinite Lived And Finite Lived Intangible Assets [Table]",
        "label": "Schedule Of Indefinite Lived And Finite Lived Intangible Assets [Table]",
        "terseLabel": "Schedule Of Indefinite Lived And Finite Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedAndFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ccrn_SegmentReportingUnallocatedCorporateExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment Reporting Unallocated Corporate Expenses",
        "label": "Segment Reporting Unallocated Corporate Expenses",
        "terseLabel": "Corporate overhead"
       }
      }
     },
     "localname": "SegmentReportingUnallocatedCorporateExpenses",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ccrn_SelectedIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selected, Inc",
        "label": "Selected, Inc [Member]",
        "terseLabel": "Selected, Inc"
       }
      }
     },
     "localname": "SelectedIncMember",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ccrn_SeniorSecuredAssetBasedLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Asset-Based Loan [Member]",
        "label": "Senior Secured Asset-Based Loan [Member]",
        "terseLabel": "Senior Secured Asset-Based Loan"
       }
      }
     },
     "localname": "SeniorSecuredAssetBasedLoanMember",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails",
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Target Attainment Level, Percentage",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Attainment Percentage",
        "terseLabel": "Performance attainment percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAttainmentPercentage",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other than Options, Vested In Period, Net",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other than Options, Vested In Period, Net",
        "terseLabel": "Vested in period, net (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodNet",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ccrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number Of Vesting Installments",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number Of Vesting Installments",
        "terseLabel": "Number of vesting installments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ccrn_ShareBasedPaymentAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Payment Awards [Member]",
        "label": "Share-Based Payment Awards [Member]",
        "terseLabel": "Share-based Payment Awards"
       }
      }
     },
     "localname": "ShareBasedPaymentAwardsMember",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ccrn_StandbyLettersOfCreditSublimitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Standby Letters Of Credit Sublimit [Member]",
        "label": "Standby Letters Of Credit Sublimit [Member]",
        "terseLabel": "Standby Letters Of Credit Sublimit"
       }
      }
     },
     "localname": "StandbyLettersOfCreditSublimitMember",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ccrn_SwingLoansSublimitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swing Loans Sublimit [Member]",
        "label": "Swing Loans Sublimit [Member]",
        "terseLabel": "Swingline Sublimit"
       }
      }
     },
     "localname": "SwingLoansSublimitMember",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ccrn_TemporaryStaffingServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Staffing Services [Member]",
        "label": "Temporary Staffing Services [Member]",
        "terseLabel": "Temporary Staffing Services"
       }
      }
     },
     "localname": "TemporaryStaffingServicesMember",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ccrn_ThresholdPeriodPastDueForPaymentOfServicesProvided": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold Period, Past Due For Payment Of Services Provided",
        "label": "Threshold Period, Past Due For Payment Of Services Provided",
        "terseLabel": "Threshold period, past due for payment of services provided"
       }
      }
     },
     "localname": "ThresholdPeriodPastDueForPaymentOfServicesProvided",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ccrn_WorkforceSolutionsGroupIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Workforce Solutions Group, Inc.",
        "label": "Workforce Solutions Group, Inc. [Member]",
        "terseLabel": "Workforce Solutions Group, Inc."
       }
      }
     },
     "localname": "WorkforceSolutionsGroupIncMember",
     "nsuri": "http://www.crosscountryhealthcare.com/20220331",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Member of the Board of Directors"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r260",
      "r292",
      "r334",
      "r336",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r544",
      "r546",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r260",
      "r292",
      "r334",
      "r336",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r544",
      "r546",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r176",
      "r309",
      "r311",
      "r493",
      "r543",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r176",
      "r309",
      "r311",
      "r493",
      "r543",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r260",
      "r292",
      "r323",
      "r334",
      "r336",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r544",
      "r546",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r260",
      "r292",
      "r323",
      "r334",
      "r336",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r544",
      "r546",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r181",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Schedule of Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r7",
      "r21",
      "r182",
      "r183"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowances of $9,141 in 2022 and $6,881 in 2021"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r30",
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r24",
      "r50",
      "r51",
      "r52",
      "r530",
      "r551",
      "r554"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r49",
      "r52",
      "r58",
      "r59",
      "r60",
      "r98",
      "r99",
      "r100",
      "r410",
      "r547",
      "r548",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss, net"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r352",
      "r353",
      "r354",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r337",
      "r339",
      "r358",
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Equity compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r339",
      "r350",
      "r357"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r188",
      "r198",
      "r199",
      "r202"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r28",
      "r188",
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, allowance for credit losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "negatedTerseLabel": "Write-Offs, net of Recoveries"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Shares excluded from diluted weighted average shares (shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r84",
      "r219"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r92",
      "r160",
      "r166",
      "r172",
      "r194",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r407",
      "r411",
      "r431",
      "r479",
      "r481",
      "r513",
      "r528"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r11",
      "r46",
      "r92",
      "r194",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r407",
      "r411",
      "r431",
      "r479",
      "r481"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Deferred compensation asset"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r341",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Accounting"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r333",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTNotePayableDetails",
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r333",
      "r335",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTNotePayableDetails",
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Equity consideration for acquisition (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r397",
      "r398"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Equity consideration for acquisition, value"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r396",
      "r399",
      "r403"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Earnout liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r396",
      "r400"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current portion of earnout liability",
        "verboseLabel": "Current portion of earnout liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r396",
      "r400"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Non-current earnout liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ACQUISITIONS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability": {
     "auth_ref": [
      "r390",
      "r391"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability",
        "terseLabel": "Earnout liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r390",
      "r391"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Other intangible assets",
        "verboseLabel": "Other intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "totalLabel": "Total liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r390",
      "r391"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r6",
      "r29",
      "r86"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r81",
      "r86",
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r81",
      "r440"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r40",
      "r242",
      "r517",
      "r534"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r243",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for share-based payments (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r98",
      "r99",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20",
      "r481"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r54",
      "r56",
      "r57",
      "r65",
      "r521",
      "r537"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r64",
      "r72",
      "r520",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "COMPREHENSIVE INCOME"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/COMPREHENSIVEINCOME"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": {
     "auth_ref": [
      "r231",
      "r232",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.",
        "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]",
        "terseLabel": "Restructuring Costs"
       }
      }
     },
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails",
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails",
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DatabasesMember": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal rights granted to the owner or licensee of collections of information stored in electronic form (such as on computer disks or files).",
        "label": "Database Rights [Member]",
        "terseLabel": "Databases"
       }
      }
     },
     "localname": "DatabasesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r274",
      "r281",
      "r282",
      "r284",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "DEBT"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r91",
      "r96",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r287",
      "r288",
      "r289",
      "r290",
      "r452",
      "r514",
      "r515",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTNotePayableDetails",
      "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Interest margin (percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails",
      "http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r18",
      "r285",
      "r515",
      "r527"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "totalLabel": "Total debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r257",
      "r287",
      "r288",
      "r450",
      "r452",
      "r453"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r272",
      "r287",
      "r288",
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "verboseLabel": "Note payable, fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r37",
      "r286",
      "r450",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Interest rate at period end (percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r37",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTNotePayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r38",
      "r91",
      "r96",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r287",
      "r288",
      "r289",
      "r290",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTNotePayableDetails",
      "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to principal.",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "terseLabel": "Quarterly installment amount"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r38",
      "r91",
      "r96",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r283",
      "r287",
      "r288",
      "r289",
      "r290",
      "r294",
      "r295",
      "r296",
      "r297",
      "r449",
      "r450",
      "r452",
      "r453",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTNotePayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt term (in years)"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r31",
      "r270",
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Debt Issuance Costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r362",
      "r363"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Non-current deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r84",
      "r93",
      "r372",
      "r380",
      "r381",
      "r382"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r362",
      "r363"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Non-current deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r84",
      "r155"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DirectOperatingCosts": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate direct operating costs incurred during the reporting period.",
        "label": "Direct Operating Costs",
        "terseLabel": "Direct operating expenses"
       }
      }
     },
     "localname": "DirectOperatingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r309",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r66",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r118",
      "r121",
      "r131",
      "r132",
      "r133",
      "r137",
      "r138",
      "r418",
      "r419",
      "r522",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income per share attributable to common stockholders - Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r66",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r121",
      "r131",
      "r132",
      "r133",
      "r137",
      "r138",
      "r418",
      "r419",
      "r522",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income per share attributable to common stockholders - Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r440"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee Termination Costs"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r58",
      "r59",
      "r60",
      "r98",
      "r99",
      "r100",
      "r104",
      "r112",
      "r114",
      "r140",
      "r195",
      "r293",
      "r298",
      "r352",
      "r353",
      "r354",
      "r373",
      "r374",
      "r417",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r547",
      "r548",
      "r549",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r272",
      "r287",
      "r288",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r420",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r420",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Schedule of Carrying Amounts and Estimated Fair Values of Significant Financial Instrument that were not Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r272",
      "r287",
      "r288",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r421",
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails",
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r272",
      "r287",
      "r288",
      "r420",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r272",
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r272",
      "r324",
      "r325",
      "r330",
      "r332",
      "r421",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r272",
      "r287",
      "r288",
      "r324",
      "r325",
      "r330",
      "r332",
      "r421",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations": {
     "auth_ref": [
      "r420",
      "r421"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of obligations measured on a recurring basis.",
        "label": "Obligations, Fair Value Disclosure",
        "terseLabel": "Deferred compensation liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisObligations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r272",
      "r287",
      "r288",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails",
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSEstimatedFairValuesofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Option, Quantitative Disclosures [Line Items]",
        "terseLabel": "Fair Value, Option, Quantitative Disclosures [Line Items]"
       }
      }
     },
     "localname": "FairValueOptionQuantitativeDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresTable": {
     "auth_ref": [
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value under fair value option.",
        "label": "Fair Value Option, Disclosures [Table]",
        "terseLabel": "Fair Value Option, Disclosures [Table]"
       }
      }
     },
     "localname": "FairValueOptionQuantitativeDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r214"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "verboseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r210",
      "r212",
      "r214",
      "r217",
      "r494",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r214",
      "r498"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r210",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r214",
      "r494"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Other intangible assets, net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails",
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSEstimatedAnnualAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r206",
      "r207",
      "r481",
      "r512"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "ccrn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill",
       "weight": 1.0
      },
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r62",
      "r160",
      "r165",
      "r168",
      "r171",
      "r174",
      "r511",
      "r518",
      "r524",
      "r539"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r222",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r94",
      "r366",
      "r370",
      "r371",
      "r378",
      "r383",
      "r385",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r95",
      "r113",
      "r114",
      "r158",
      "r364",
      "r379",
      "r384",
      "r540"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r133"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Share-based awards (shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedTradeNames": {
     "auth_ref": [
      "r216"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trade name to gain or protect exclusive use thereof for a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Trade Names",
        "terseLabel": "Trade names, indefinite-lived",
        "verboseLabel": "Trade names, indefinite-lived"
       }
      }
     },
     "localname": "IndefiniteLivedTradeNames",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InsuranceSettlementsReceivableCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy.   For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Insurance Settlements Receivable, Current",
        "terseLabel": "Insurance recovery receivable"
       }
      }
     },
     "localname": "InsuranceSettlementsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r61",
      "r154",
      "r448",
      "r451",
      "r523"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: amount of lease payments representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letters of credit outstanding"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r34",
      "r92",
      "r167",
      "r194",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r408",
      "r411",
      "r412",
      "r431",
      "r479",
      "r480"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r27",
      "r92",
      "r194",
      "r431",
      "r481",
      "r516",
      "r532"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r36",
      "r92",
      "r194",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r408",
      "r411",
      "r412",
      "r431",
      "r479",
      "r480",
      "r481"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r541",
      "r542"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "terseLabel": "Long-term accrued claims"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r18",
      "r515",
      "r527"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "verboseLabel": "Line of credit, carrying amount"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Line of Credit Facility, Expiration Period",
        "terseLabel": "Line of credit term"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Borrowing availability"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r32",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Quarterly commitment fee on the average daily unused portion (percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Senior Secured Asset-Based Loan"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LinesOfCreditFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time.",
        "label": "Lines of Credit, Fair Value Disclosure",
        "terseLabel": "Senior Secured Asset-Based Loan"
       }
      }
     },
     "localname": "LinesOfCreditFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Long-term Debt, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of debt",
        "verboseLabel": "Less current portion"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r96",
      "r244",
      "r276"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r96",
      "r244",
      "r276"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r96",
      "r244",
      "r276"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r96",
      "r244",
      "r276"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails",
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r38",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails",
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r81",
      "r82",
      "r85"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r4",
      "r53",
      "r55",
      "r60",
      "r63",
      "r85",
      "r92",
      "r103",
      "r107",
      "r108",
      "r109",
      "r110",
      "r113",
      "r114",
      "r129",
      "r160",
      "r165",
      "r168",
      "r171",
      "r174",
      "r194",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r419",
      "r431",
      "r519",
      "r535"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Consolidated net income",
        "totalLabel": "Net income attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r118",
      "r119",
      "r130",
      "r133",
      "r160",
      "r165",
      "r168",
      "r171",
      "r174"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net income attributable to common stockholders - Basic and Diluted - Basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r120",
      "r125",
      "r126",
      "r127",
      "r128",
      "r130",
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net income attributable to common stockholders - Basic and Diluted - Diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]",
        "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r2",
      "r101",
      "r102",
      "r105",
      "r106",
      "r115",
      "r116",
      "r117",
      "r192",
      "r193",
      "r196",
      "r197",
      "r318",
      "r319",
      "r320",
      "r321",
      "r355",
      "r375",
      "r376",
      "r377",
      "r416",
      "r435",
      "r436",
      "r437",
      "r469",
      "r495",
      "r496",
      "r497",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/RECENTACCOUNTINGPRONOUNCEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Accounting Pronouncement"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.",
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Non-compete agreements"
       }
      }
     },
     "localname": "NoncompeteAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAcquiredIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r298",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest in Subsidiary"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other expenses (income):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r18",
      "r515",
      "r529"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Notes payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTNotePayableDetails",
      "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Note Payable"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r160",
      "r165",
      "r168",
      "r171",
      "r174"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Income from operations",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r458",
      "r467"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r454"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Operating lease, impairment loss"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: operating lease liabilities - current",
        "terseLabel": "Operating lease liabilities - current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails",
      "http://www.crosscountryhealthcare.com/role/LEASESSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities - non-current",
        "verboseLabel": "Operating lease liabilities - non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.crosscountryhealthcare.com/role/LEASESOperatingLeaseMaturityDetails",
      "http://www.crosscountryhealthcare.com/role/LEASESSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r457",
      "r461"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.crosscountryhealthcare.com/role/LEASESSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r464",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r463",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r5",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ORGANIZATIONANDBASISOFPRESENTATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r45",
      "r481"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r48",
      "r50",
      "r438",
      "r439",
      "r441"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Unrealized foreign currency translation loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment, net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r35",
      "r481"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermDebtNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.",
        "label": "Other Long-term Debt, Noncurrent",
        "terseLabel": "Long-term debt, less current portion"
       }
      }
     },
     "localname": "OtherLongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashExpense": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.",
        "label": "Other Noncash Expense",
        "terseLabel": "Other non-cash costs"
       }
      }
     },
     "localname": "OtherNoncashExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Cash paid for shares withheld for taxes"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r73",
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash consideration, gross"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Stock Awards"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r341",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r8",
      "r10",
      "r204",
      "r205"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-term Lines of Credit",
        "verboseLabel": "Borrowings under Senior Secured Asset-Based revolving credit facility"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r76",
      "r80"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r14",
      "r15",
      "r221",
      "r481",
      "r525",
      "r533"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation of $18,092 in 2022 and $17,729 in 2021"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r67",
      "r200"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Bad debt expense",
        "verboseLabel": "Bad Debt Expense"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r165",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATADetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r165",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of Information on Operating Segments and Reconciliation to Loss From Operations"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATATables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r331",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r331",
      "r472",
      "r476",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r470",
      "r471",
      "r473",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Repayments of Long-term Lines of Credit",
        "negatedLabel": "Repayments on Senior Secured Asset-Based revolving credit facility"
       }
      }
     },
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedTerseLabel": "Principal payments on note payable",
        "terseLabel": "Payment of notes payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.crosscountryhealthcare.com/role/DEBTNotePayableDetails",
      "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSecuredDebt": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.",
        "label": "Repayments of Secured Debt",
        "negatedLabel": "Principal payments on term loan"
       }
      }
     },
     "localname": "RepaymentsOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock Awards"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r84",
      "r224",
      "r231",
      "r235"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring costs",
        "verboseLabel": "Charged to restructuring costs"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATADetails",
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r225",
      "r226",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r226",
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r298",
      "r356",
      "r481",
      "r531",
      "r550",
      "r554"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings (accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r98",
      "r99",
      "r100",
      "r104",
      "r112",
      "r114",
      "r195",
      "r352",
      "r353",
      "r354",
      "r373",
      "r374",
      "r417",
      "r547",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "(Accumulated Deficit) Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r151",
      "r152",
      "r164",
      "r169",
      "r170",
      "r176",
      "r177",
      "r179",
      "r308",
      "r309",
      "r493"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue from services"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible List]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r310",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUE RECOGNITION"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r462",
      "r467"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets acquired under operating lease"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r38",
      "r96",
      "r287",
      "r289",
      "r294",
      "r295",
      "r296",
      "r297",
      "r449",
      "r450",
      "r453",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r208",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Acquired Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Aggregate Scheduled Maturities of Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r474",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r228",
      "r235",
      "r236",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r229",
      "r230",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Schedule of Restructuring and Related Costs"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r341",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Estimated Annual Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTLongtermDebtDetails",
      "http://www.crosscountryhealthcare.com/role/DEBTMaturitiesofDebtDetails",
      "http://www.crosscountryhealthcare.com/role/FAIRVALUEMEASUREMENTSCarryingAmountsandEstimatedFairValuesofSignificantFinancialInstrumentthatwerenotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "SOFR"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r148",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r174",
      "r179",
      "r228",
      "r237",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]",
        "verboseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATADetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r160",
      "r163",
      "r168",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r178",
      "r179",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT DATA"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATA"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATADetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Equity compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested restricted stock awards, ending balance (in shares)",
        "periodStartLabel": "Unvested restricted stock awards, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested restricted stock awards, ending balance (in dollars per share)",
        "periodStartLabel": "Unvested restricted stock awards, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)",
        "terseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r338",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r299",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders' Equity and Share-based Payments [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r459",
      "r467"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease expense"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r88",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r3",
      "r148",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r174",
      "r179",
      "r208",
      "r223",
      "r228",
      "r237",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Business Segments"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/GOODWILLTRADENAMESANDOTHERINTANGIBLEASSETSAdditionalInformationDetails",
      "http://www.crosscountryhealthcare.com/role/REVENUERECOGNITIONDetails",
      "http://www.crosscountryhealthcare.com/role/SEGMENTDATADetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r42",
      "r58",
      "r59",
      "r60",
      "r98",
      "r99",
      "r100",
      "r104",
      "r112",
      "r114",
      "r140",
      "r195",
      "r293",
      "r298",
      "r352",
      "r353",
      "r354",
      "r373",
      "r374",
      "r417",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r547",
      "r548",
      "r549",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r140",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r19",
      "r20",
      "r293",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Vesting of restricted stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r19",
      "r20",
      "r298",
      "r340",
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Vesting of restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased",
        "terseLabel": "Common shares left remaining to repurchase under the plan (up to) (in shares)"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r19",
      "r20",
      "r293",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "terseLabel": "Shares repurchased and retired (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r25",
      "r26",
      "r92",
      "r190",
      "r194",
      "r431",
      "r481"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r59",
      "r92",
      "r98",
      "r99",
      "r100",
      "r104",
      "r112",
      "r194",
      "r195",
      "r298",
      "r352",
      "r353",
      "r354",
      "r373",
      "r374",
      "r405",
      "r406",
      "r413",
      "r417",
      "r431",
      "r442",
      "r443",
      "r447",
      "r548",
      "r549",
      "r564"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income tax payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable, net"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r225",
      "r226",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRestructuringCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnbilledContractsReceivable": {
     "auth_ref": [
      "r43",
      "r492"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.",
        "label": "Unbilled Contracts Receivable",
        "terseLabel": "Unbilled contracts receivable"
       }
      }
     },
     "localname": "UnbilledContractsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r361",
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r368"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Gross increase to current year unrecognized tax benefits related to federal and state tax issues"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r460",
      "r467"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable and other lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/LEASESLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails",
      "http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/DEBT2019LoanAgreementDetails",
      "http://www.crosscountryhealthcare.com/role/DEBT2021TermLoanCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]",
        "terseLabel": "Effect of diluted shares:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r120",
      "r133"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (shares)",
        "totalLabel": "Weighted average common shares - Diluted (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r118",
      "r133"
     ],
     "calculation": {
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (shares)",
        "verboseLabel": "Weighted average common shares - Basic (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.crosscountryhealthcare.com/role/EARNINGSPERSHAREComponentsofNumeratorandDenominatorforComputationofBasicandDilutedEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(c)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14172-108612"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14210-108612"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14217-108612"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55302-109406"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r558": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r559": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r560": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r561": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r562": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r563": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0001628280-22-012463-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-012463-xbrl.zip
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MIB*@/"9DZ2UC7*L91.T?#7>/J)YUTW$71+<XMLU:/(M^D$MAPF&PCF+OUU^
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MV4P1CZ\'7X4['E5DS=]=AU=%/9ZCREJ5/O9,D8_+9%!/@S0,":XEXDQ$9%+
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MY%3D5.1T2Y:#J;;*I&!Y"MS29+3E5@=+B$_2B,)R'BW+F7.A2<.<I3X@QJ5
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M:WMS?1]^V=N'_^QLM?;W&KNO&AOK>W\V7OVU^WZO]O/YU[NNA7,=E+39L$>
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M#A!<B)4U)9L W_50ZZ62S;KSCK_[\=BVPR2Q=D0O>Y5_:L0WGUGPJV8LI#*
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MG4W 2DP3L_F,MH5-HYLITB/RBSQ;9+@[,E.0X8&088;H$.Z%Q(&@Q#00'<$
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M63G6QT R@KP* 4=8,IC"YFE@.\?P_QV,_3IVO!_/MS",[\#VSWS0X:0_EM_
M]XYC->,!;(I^EML8NB9ZU,R.A&\Q>^$'XWV58'5Z&5Y]Y2G)0\I+E=4I+UV
M!PUB]D558#@]Q?\=W.SL&B_":%4K3V"5OE^)?'A2.=E'3JW1"$(;CJ7^Q+'0
MFUZJU7D\6S3'Z(&R,S(HUVN@5_.3"6I6[@G8^S]&SJY&%BA(:P0E(Z\L["3D
MXO@":=[P\>BXTSN->5?' 6S?T4YJ9W?&X!@VR[F:Y!4YVY>KC?>'[<ZT6Q2^
M_&CD!!T>PL%Z %\(SSC*W8@RAH$B^MB<V8V]!+!>^6:/LGL%'C9V\>4,T(Q
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MR%K?/A%L'(^YO2&S'/%H(K(@,40LTU'Y8%3P]>E!_79<<*E]H<+=+^(8G!:
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M+YML3#!>P:5K=-IL8VY6#'U<6O!=CR5LQ8C'Y07?_4J%;W_IRPSV.73^.5@
M^; =>6KZ*A$+FA*]7:BM]=O5UIEF^4ZD2"]6EN_-2]C(]7,+%7T-$':MU6K&
M4/SY90CL#T@N?]!RS"#S_ TM^]\'9[VF;]KVM&O]'*Z,:O^F1YY.'\SG+Z7J
M,MMB E?0>"$7K*HF<,<R;%\HSB.>KXT*DE;E!'Z2]%Y&K"5$:>NHXL%P1RQ5
M026#65+$3M_#]QYOT$9A(.6 VEXOPK]AV_Y8D#B)Q]GRPSB)NFA\^W"\]6V'
M[)S_ ^/Z)!KK_QS4U_\Y:AS6<>/;GSGVXG0'WC<>)U$_/R([WW;$[N$_AXUO
MFV>-]2.X?N.T\0WF>OZ)[!1UPOXXV%J_L29!5 %C(ADB6 O$(TG(&!.1$)IZ
M&D,N\+^TJKA9YES-42)P59>@ JZ[<W6DXS(Q+)3GQ$83G4F4)A)S9)"J@&O1
M@&L\P,LQ)U4P&G%&..*)"F2(XDAJHDW QC//EE8I72:8SSUN/8NE5&%AA84%
M%KI@&7"$<B(RKK5V@?O(<B]WPZ)5CTF'KK#P-;&0C;<'%A[V+7=]\0R4..LE
M,E2 )H>-M=%K&C,6*D66A7AR7\LJ<>HF=BPC%VZSCW^Z"@S"<QY /E.>.!=8
MZ1 !=YQ-UAFLZ&.*GU20\VJ0<T.!%*Z(<LP+1*S.>=7"(1-<0AC 1BDM(PDZ
MYU4O$S9E_:BJ/LKS>W6TL5Q)+J,EW&#O!+$\8$8I95P25G'G@G'G1&V5J#&W
MQB 290#CB CDN.!("^9-B%RE9($[ES&_K2_<BS/G<YA %<./TG(9MRHQZ;4W
M7%-B8J(V$2:BDLGB5#'\@C'\N 40>;!"@R2&C1:Y1Q%#+F&,C-#4QA2C, 08
M7BT3/:4!4-53>N!I63YEG=:(>O"AZ1OUMSQ\_F\&BDD"LX@1R4'Q I$<'-A(
ME&B&K8?_C*F@>*&@>++B5"0RBU>)DHF@>SEID*%&(@PFDTL*9*XQ2ZM*BF6A
M9U7I>YK@BWD^;JOP\*?#P\B$#\P9%S'F4B7GL3-)TX2]]"K8"@\7# \G"HU;
MQ8W &ED=.>)8&&2=52@EYYQTP7D2EE8I6R9BLI[70L'A0ISB51#[TT'LH[*I
M*HB=7XB=L/Z5-91$ABSE"JQ_;)'!2B+!1!*,,T^) )53ZV7%%@9CATZ#T4 N
MLL(*M)ME6L18#9^KXY^B,=]+OO-5?*5/FD>5]G-+V@^ITGZJM)^Y7/8J[6>Q
M]Z]*^ZG2?JJTGRIB]#$6HQ=,)J.U%#%Q:YU.GE@5P9J(.2^D/*0@(XN15!;C
M7%N,]>VU;"V6!Q6'1S\:V_M[D1H2G I :LHBKAU!.B2.@*@9CABS*,+2*L-B
MV2@Q1R&C5:Q[A5QW(9<Q0?K(%1&!<&JU\\)';>%_0G,[;/=1(=<B(=?9=>0R
MT@0J!$-2.HRX% IIQ2FBCAD7!$DT '(1L<RQG'O@6H@C@PH,YVENTT3A8QRM
M\@H,1,^-(EH3@BG@H[71)A\J,%PT,&R,@:$U-"F#&5(X2<19T<_9&O@-,-(2
M0CD&M&"4++-I _^JS)\J\^<Q'3-(/HI2F'G.<E:N56!H2.)L$CIXYBO,62S,
MV9@P'7U,@KAHD&4A(>X80XX[@Q2Q7@29E IT:54MXRKS9^ZXDX&<@/WC("D2
MUYA8@J.RBGE@1!?2"SEV*@:<C@''A#XV4<,&:N0-!U&/ T.&:H,$B48H$X3&
M>FE5TRGKM2R6E5.Q]"BZ1S"0N$+%2"FGN3*S=4XG*H-+/(7*5[MP_#ZNY'L3
ML=1*()V#>K@( 93\X%#"A*><ONFRKU8MZQNZ&%>Y/:^<VW-SH["ISIK?J,]E
MA@OT9L \1"VC"1QL^LBUTYIP*:WP\"M75,@*S!<+S#<G#]ZPSL>H%!&=8S4)
MC<@*H5"2)ECI<F,14-X88<L83YF<_0*<-N?'=A7F5I@[O0(=. .NP]KH ,:4
M=5XE[P@&W3D$;&.%N0N'N6,*- 4HI9)KI*T$!=I1C'0PL)U.$9M<"E:YHE@-
MG=9EM7"0NQ 'CA6,5S ^-8QCJJTRP,L\!6YI,CI7. R6$ ^ZE: 5C"\:C$_Z
M03"S7E 4K<]U7Q-!ACN+//<A<>:(E2P?=IIERF=UV/GZ.+YPG447Y<IG7=AJ
MUZI=JZZL%K9:V 6]LEK815S8:M>J7:NNK!:V6M@%O;):V$5<V&K7JEVKKJP6
MMEK8!;VR6MA%7-AJUZI=JZZL%K9:V 6]LEC8W_K6M2+\/S2_KXZ.K1N#X]AM
M^M5_%Q_F9XV>XY\_](+FT(M:_N?BN/QB;#GFHMD>V.),_?5&]^^QH901%4Q(
MS76B(EC!L50Z62^QIP)K;D/B2ZM?8JPU.OU8([2&1M71:NNV;U<FIU=[YG^N
MK^[%6JX6%?<FOBRG2%SBD@;G/&$\1PM;I;A,P1J-2<1\C\NEB2<^W^Y,U)XK
M=H>OE-$6DS__?8V\:T^O4WP]9N>/00\&T^N][QR[9KO8Q?5FS[<ZO4$W;L.;
M_FAU_-$KQ]\TFL/XF^/&<7T;[CO^>K9[V#BJGW\ZW3UL-1L?X1V':\4[ZL<?
M6O7SNOB+?6[%_WP^V_T63ASE<H?N_&C &'>W_SRNTT_GC?4_CK>^;6*X\[B^
M?L3KZQMG.]^^GM?/6ZE^Z,^W/NTQKY7&*2)"A45<!8F *SRB@1'N3(A4JC*F
M"A@@AK4<Q>24--[AZ$.,/#IL32 D=Q2E6--B_6//VQ/8@7YW +"V]O[3U\TO
MF]N;6XTO$U#V<&J_D;GO'\OUL5,"8("#U"XJSH.U 0>++<?>)6TQ67I>!BF>
M^*[9MZVF?P#+?(FMZ/LQ3(<)KP.^6^W:>O3QV,5NC<BRCNURK7\0:\!W,)ZS
MVLF@ZP]L+X::;<-__K^#9A?^Z U<KV]ADVRK=5:#'[5.*NZSO5[L]\J+>ST@
M&!"AL=NWS7:MU;2NV6KVFS!^N'JT3LNUS;9?J?TR^OO7''I7LQ=OKIT S<5\
MQ_^=)O\F>..]UC)ZSP775GN5C"7<\F2-*ON6$@*DA4:_7 LB%.. ]+<]*^IO
M;G?6RD48(53L?>QV>KV'10S*GPVQMN%9VU]_P+O.&X<;Y_73O:B*)*B$(D@]
M!,*= GK%@(@4*=>#BM;FX+^5VXK5 1NT"BAIU[SM'2QG6CP$RJGU.S4;#@>]
M?MZGY8($7Y5B;A!A[SOM7C/$;O''=A<X-\4N\-,&4%3_;#-74HV]?F\3. >P
MKQWR+UFGK(CK <2%&Z=[AGJ2B""(.)JK(>J$M)$,15<T2->.4KJT2AY"7+T#
M"YM1^P7 Z%8J*J^9+2%M-C[<1DD%\O2:>0PW4LQ6=T0P(*H!T[?2EV* Y;</
M(R+\<Q,1K7_: S6*&($%\B(YQ#W\YA312&@/FTBLC<0NK0JSS*F9H*,AW?PZ
M$HA#0?H_/2"2X^-.%O&@N*[4MN&[?D: (4V=VA[\'6T_B]K>5?D'#QI*U2P8
MFVUX#MQJ?^0K3CH@?U9J:X5$O5:/GI9RW%Z23 V>5FMW^C478[N6!EER-X&
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M-(?F1;-$ %VP.L=5V6&+]%MU7;(,^DSO!&R5YO?8.BOE3?^@V2U[@)0]/Z]
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M/2*[ZJUE\-PTQ;>3@_,H8)G,P;F.*^^'QU5KA3ZQ&!DX"P(QXQDXA&*30)M
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MW\-*^?</XD0X!MR</[Z(R:@U<S=XWQJ$&');^!NNSS[C6J==/J[3#K&=VZ3
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M*2DJ0F0F.F>DOA%DIJ"S/VROV?MRTHTV;+7_L=UF5E?RH,D%:2'ZT]'6IU,
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M%-RQ'(/>T^M^+9)]Y53'JC,ESB6KRR 5EH&KOQ;=81]$.B+N; F.82?A\+5
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M+?N1+JX3>K#[A7"O@C46Y0"K"% W(*6Y0SCGF!LJ/6=VM2U[S4V7,R8=L /
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MS!F!.N%EP(3:I'M@S$O=8RYX='[;^3#.BGH0ZBUH34%@^[M?#,,TTTX@9V5
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MX)QX^2C#2O<&AX??+D\+>-Y,ZJG^:;<WF$RF]7N5NV/-*.:%51@6A3;?[\F
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M6)]M(G;]0+VHASNWMMWV1;>3XJK&D5;^VT5,:MG0O4@90;I;]?GT,SB??H#
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MG=7DF>0/X$H$PX@P'"N>4ZZHSYC)A/34D9"I+^]6BTHM 7Z!O\[CR&GR@X:
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M>ZEA!"*RIP4^",-60UL[KO^9ZCW1!FI\'+;;NG<5'_015G(18%5W!HW=\EI
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M:^7^,+LQC-S.RK",Q(N+$A.2HMRO4*P_-KV56#8FK"F,$'K5TA=]_V+TX0]
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M;A6!'!F(K%X%M[V/6.SBMP<^8*<TBA-X>5'T6RF!1=\RR9Y4)B96%6+!\!4
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MY<69G_Q0/HC5>/%:W%_0N=2N)&M0@A:/:(O/PW 9,<"BVRJ]B/'V\OO(KHO
M&6Z<]^?LW=@6>5Y2LUO:YD,H.2H_O<)L-+]>G>AU22YI.LSG*\\D!Q@QI2Y2
ME#\OU61D:?<R_* >/H#"'.4ZBG\ 0,-..%A&*1JIE3(/P,V>1YV $,>P$#\;
M!TPXVJT,H*) BZ9 >9(?4=^0LR =.A12SF RR%",3>-0'B2,F(RHG1U<UD(
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MV*Z]$I%IW<(9.4=@&W(*IR:<"LH71:(6KV$Y["6>(1H>W0ZFL_?0@F9KB3#
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M[<#D!GS>DO'PXD-XHWQA1YY7NWBLQ8"H-2MYK9@Y0%5/NVEHEXZ3*<-\U+:
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M=SY"CW.M8VJ#M1Y[^RO[VM+-R%<9;%_3MV6P:J<WV*K!]I9Z[,ZU"I_N%_N
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MBE'*/(YIL(2B\@GRUF0LX^#L\A)>2TZ6IW1;0 G\#]@;;',B?+/1B(83.3_
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MX[_P=RR5FH2^DS<'8"&[E%5Q18Z&DLJWT+CX?@X_XP5YE _E)>L% /*;]S%
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MX6<6/,)$1\M>$R@.?!*SRE[@^03"&,SH*'\H(!RJY#S+ZYP"ZP:VB;]<G7H
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M(7<963=6_]F#Z]Y!/&X5WS(4:68.HQQ'V)%&YOPVW'C:C]\^9<P]@JV^$Q\
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MHW*3T7X?VY""!%ORY.IJZ%DPO2T'\BE.9]-NL/\9)BL<6<DS<R4"K7T#2IH
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M(2@O 87(H)((X*WF8(W./":+I5&JU0V [A@>@T?%I^VFOW^K^L+@?!(FL9#
M14Z#*T3/&(4'$1/'R&+)OHWE= V8[7-/%UURX_E<+T9&9,>U-F"%%E5R'+R)
M9* DEX*65B=L$_>[BN2.RK(MN[>EP;>9I5M,>V_D?HL?<+K"M=J>A[3\<[Q\
M]V*U6-(@Y_N?TF15NU%78YC^R[610&)2J8P)4BF!@ 95*\X),KW&7<HBYC;A
M@WN '=+Y0=\,:BV['OO*7*%Z2!I95 I*CJX6MA@(16;0Y C)7,NH8QL&W:YA
M[AE7.SA]'\;S&K1_\2[,3VA\I79?0/+NN:W]TK4G^2+M6+YZ0D(%KG2;@LOK
M\0S)Z-R*"]?&W+:;_A[/5=_/,8V[.:#O)]A-\#3OG<[FR_'_=:^/3)"%EK4$
M:^N)CA/5K"V,@%H>LY2)F39I1IN@&Y*N[)4FO8NFQ^UWL9ROTG(U)SV]IJ\2
M(J"4!:*K;5VX1PA:<4C<$"!F<LAM,HVN0S.D\]9>2;'UU&]-@AH?&^VE_UV-
M%^-S1E:O]^3,93YOE=B->63(:])"TF8=:R6H4*3,! TYD,UHHU2&L2N4^#;X
MMOGCAG2\VHO,&\UT?T5=V,4\?B4W=QXF53/ET_%T3 0E@!]PW7B&D3B%)G_7
MV53(>)/D_J;L0;L8BF>H>:-X_6;XAG1BVZNJ:"">/C-X/HSK]4&O9O.7LU5<
MEM5DG8D_8CSQI$B)^> (4>3$8ZT=V$"3X)A1):E6&3PWHAK2N6^O-.E-%/W9
MI&.R>Y9?_,YS#<=5':*%)#B"2BR2A@L><O TA8'YPMITN+T.S9".?_NU.;>=
M^CZ[NE[M"_FE)Z3-11EK:LURUV:6)0(D$6(VT09,+#3*^+P%U+;CO1R&YBEX
MRXP#IQS),!9/MEU(9-:[+!7)P88VATBW'+,]M ?>#Q^N,O[^\]YO[N(UXR.%
M3#,[/4O.29^/YV&Z".G<$NQ^.I/&KV$\K>CWYJ3'IR<O.]_@=YR/9_G+%-'F
MSH0)"H)79"!F%<!EH6E@6AG/LLXM,R';#FY8$8 V-!T:1WH^LVQS",N4E4)8
M"QXU37A,"$YF1RR-J5@>N&-MRD5V=A3?S[E@Q""Y2*3U#*]I?XRTGF6V-G#2
MA@DM;+(/<R[XL'O.4+AY8[K>/678X^(]&\W:ER3%1N@#@O4N@/+>0S I@C')
M"%5",HV:8E\!,J@$@Z&R:!OA]6O[T.!FERF]QI2C1".*J34$EC#)FG 8#.CL
M7&+:^UC:5+W?CFM(X>6ATJM'R0XIE?3%WM'?7QV^^;--)NG73W^ 1-(;AM9?
M'FGMP]*%F^C3GG_^8U$K"@^F'XAI];R?K-8/9YV)#.<81 X@HT)0R,ED3K27
M)<DM5Q:+:K2-;(YQZP!H^-QU#CB>=0'^.=Y84C<J20?+/ (*S&26DU[V2-\9
MS"'1,L&@VM0T;8YQ4"E/C8CV3=RTC03["Z#1'%QI?-0='HY3/34Z:XQT^84+
M[SSS#$ECSVM!R$L\^Y=^/LO-V?^4WH7I";X-2]PO!=.2K(?L2Q$!+%.U$%@R
M\+Z$>HS G1298R.6[G:</83YKB/G%XO^ CFC2")JZ<"6S&KS"$GV&/GDM;0C
M<"5BJWJWS3$.R5D;,-^OB3FV($%OJN,.&I2L&\T3F80BA)K^Z<D!S45 T>0S
M^*RQR&;U(/?:JA\X//CH2;HM"5J3]!4Y-=-T&5^V++'"$6@I<=I_,X=0=^+(
MI/#DPL28VYP7;8YQ2![EXR?IMB3H[V+?;HAORL5AOYEN-<$C:QEGV@HP-M72
MSIQK.:X"7;*0,@GI2ILTW0:#&53.UN.A_4/3JK42O\X2$@EE-EZ#CV0.*5=3
MW%A)4$P1*=6P%.[4TOBN.7S'E,K;\G!(<&?=5B:3V<?:>Y!<5W0YF9J/X[J[
M>9PC3:9)NQDO44919+@2&;TAM_)NSQV2Q=^(/)?2+QM*I<]%=.$@2"3/:AT!
M*.-JSUJD?2X4!39Q%<EUD ';'.;=.75D5T9W8YYL+X;>3U-2U>WK0+N2Q7IZ
MO/:\MNOSANP>7GN]^^224CEAP\R/RV"&9.7NB!7;BF2WE3Y.*F4,1C!(>%2J
ME[V%$""JQ+436;'0ABQ]5?KLREC<$7MZ%UJ?>3M73%W:%N>K"TTB<?%[^%Q[
M(H]R<#H:;L$XJ8%TGX%8OV-.H!>J",9=JSR<34$.J0Q@1^1J)<*V'.M,KW-8
M=26<0;YXL0E'\J%DL%!"EJ \3^!=J==6(AJ>HM*-;HB\']XA518\)//Z%6Q_
M54[OPAR?$\A<TR]I_SY3NB620:^B@.BM 84T!UYG!L)RHWD2SH8V9O;U>(94
MD; C$O4@F'Z*(;]E\_77;-<!)Q-*1NUK9FTMU$L&G-$%N.0N>?0YEBO'I#>X
M[7=XZ)#:T^W"9V\ECQWL:U\ODAAI+M!%%0&M)F4GZ LY"1ET2,76@\"46MWM
M\7UTFU#*/W#"Q^XVK7M*K2&?.J_SZP2<]81T5B6%R4&1-<&39@)\* $"N0G6
M.F>P4=G49O@V"BVR'YY46XMN9[2ZJ$<ULUXREX%V6$$^*)EF(?H$*+Q1J28/
MIS;='^X <B."_2#!Z]8R;'>QQY7F>5I&[77@X$(6-4\X0\A&@TVUQM6A-*%-
M6[?O -N(3#]8A+M/6?5C>E\V[,[AO)YU1Z$C);-*OMIVQ190DLPZEYP@VT[P
MF(7/FON-;.W;GK(1#WZ0F':_4][O-0'?]M.RQ=@04@:'@=5^6A6+8N YE]+(
MX+1OHSFV:&?V@X6O>Y#,0^2+J2*\TRJ!$,BK4\AKOG:@(4>-(K%LL4V\^K[Y
M8O>O/WA37F)<'BP6JWJ ?=;O(1CF/.,*>*C&IJ#O8HP>9$*GC%$RR497C=X,
MZC%4&&Q+I9LJ#+:547]=>\X!G;>>.IZ1"5![=];[R6G8KV;S&V)R3&K:^Z6$
ME!7ID((.HM&$.PH6N)*B54["?1$/JH!TQW1K*MT>>Q"^_[(\#F?3DV.<GQZ.
MIT@_OB 3E:Q1GSD32EN0QDBR16BKB9DI2*XPK9T1V"A"_UUH=TR#^"'8U:^\
M^FQ$EA!S5SN[7@#$],Y)OFX*:FLT*9RN/=+(=#$B0M V@\A)!>4U-[I-@L0=
M@3Z"7(G>]5=#43916T>85D3]NKF/#"<?V2=-O*\#MS0%D3$-VA6C5:VB<*VZ
MDU\+Z([I$#^<BKJO;)HHINOU98A*=!=K%B\-\9<<[J"3!(96A'H7;ZNKO;\+
M[1%D-+14/MN+JXFZ>3U;?LWG*1J]M:6 21T:)2 J&\&45"3#$IQJ4V)_$Z([
M)C#\< KGWM+987.,O1?_\<?!T4%WU]A;3+.3Z?C_:%XRC6!<QIC/#JO.R^%S
MF%Y,WJ'?K4ZK0EV&\61Q&?QFS3-Z?'K_S35:3<V6S3>ZB.WSU:)JH@4Y;9$8
M?-8\^BK$\.6.]S7(O>M 7G[+E_JF+_?$>N95X:IVML-ZAB0C1*\56%D*+0>%
M^FJ5S@TQ]QV"[NWV8<E$C!89F'IOE'*<=$$V&;(,/-;D7*G;!,[N<OMPZP/.
M05/NQON-[R*ZWG;G/F?I_ K?LW=^34A9C%*,(0A7P*'WM;^W@,"$A:P*>=8V
M68%M&B?O8G1#*#-Z5(0?'.7Z.0?N<UA7KC]>C'C.V;M03?6N0[XN]:1*T:1[
M;]&@$T'N?$^[BG((I56/8B4,BR^#W$MN[F15;ZB*/ O0V6?:)LD["2PA9$SD
MV](NZ1O%''8RO"$$31_%&AHNZ0:YGBYME%T\>L03*0AG=$V48:!H8R0=D1GD
M:!S/3COIVMQQTG9<0ZBB^Z==05O2;)!+YV"Z#-.3<6=6TN:9#><";"ZTKWJK
M($ARV9)%IXO.UO(V![J-!C2$,/D_[6*Y+[$&N4K.F_M<;.=3N'-")UKY6090
MH5[6FX("J=%QI81DV*;8H^VXAE#G^$^[9K:DV2"7SL4"")F]Y1A)#YAB:GVQ
MA:!$ 9V,]0:]87;X1MF-!2\/K**ZQO0G]#?KWWT>%7*&=>UYEFOW$\710*P5
M<[Z6<K.8M9?#]R:O&=@0PO!#6BM-==*6O'J(^.,U _J\GN):5/$F3L8GW8?4
MQD%G5OW(FJ0U0PXEZ0C*I&JD& 8VYJ22S2'%*^4,O40A[X-U"%'Y(?)_B%09
M7OS]O/''Q11C>M]YC=EBQ%FM.RD9,)5Z34VU/1S-?HG*B"0]>F4;K(-M, \A
M-O^#K(>=46>0QNIYA.?B+R[WS1E9IGW*G$$IQ5<Q9(C620B,!8\BD!S:Y)'N
M=)A#"-0/<4$-GW/#-K=>K#=0C,X6C> \5^35^@#1<0/&*L.-*4SG]*"VUHO-
M#:U=-:T;TCH8'$D>>C=9AY*NG>W7N!QI[W06VD.PD093[WCW7A:PR7MOO$)C
MVQ1+-QK0<*S9[\3VB"W<Q.B@L,Q!29; \60@9,1";FSF5PL_AI8P^2CC&[TN
MB';V;(_D>6@5]%U%KWWA0G('-" )*NL H5KG!@5W6950=)NJ^YU$7Q^XAGA(
MRV1(1-IA]<3^WMO7!Z]_/?I]_^W1W_?>[E<O=3:MIRBS\IK&,*_K+DSS2YS.
M3NM\S.9EUMWYOEIV4&;E>5B,4WW+>+):8MX/\RFI@\5[/"O-WJ*X8G?@^J^]
M>*")[>E>U#^[]4^T_D! 3Y  1YR_*>=(NL<OWJR6BR7!(TPC9B7G*250MC:/
M]YZ!4TI#UCX+5HR35SN(]J0F[PATVVWFAL=]\YQ.=*,4HBZ.=D+,->1I!8(/
MR8'0.J@<6,ZJS5'2G6 .R7!JR;NKFKZ=+/MM=EC3#<.$-,/I;'H&;F^YG(\C
MZ0G:AHYG7QM@G!>8[\WG]?ZEKH9O9#P*98L$81EYJDDK\E2- I$0?3UVLJ)A
MQ]:ML _IQ&:7Q-RQU'=H;?SZYLW+/P\.#X_?[KW<?[WWV_[1WNN7;X[_OO_V
MX/7QWNM?#YX?[N\='>T?'WUU+]8946?VUA;61'\/[]]::#0Q/5D#K\936AV'
MXP_?/K::VUYJYIP2($N-.1GA(1;R^H+(/DH9=;1MRK9OQ[6M\KWETW^MXAQQ
M*Y5*G#Q;)VMOF&S HT\@DZMG_462^['K<7?(AK2C]\B=JWJR5P'UMF??@FHO
MI=7IJFMD=>FN');(.Y4$S'C+SWI5!4T&!DU,CI&+D$R;6P3OCG50\8.'X58?
M4ASDGKN_6(Y/NV%-IZLPN3BX\XZJ.]E]-X?QD/OP/2=K-SNRSD5'ESU(WS7\
M#[76 @LY*\&@Y2ZI1C>F/=B.?,W\O\73,*:Y)C/]U7A!!/EO#/,1CTH*9T)M
M[DI*@6<-7AD.*=O(N#2V:+9S7;LA^$>TK]^%@7?1O2W$O).M_UO@%>?QQQE!
M%=XPG4#[VF(PTZ1Y[R3(&"T+V<6@VT2)[@5W2$[Y8#AX'U$^(.M>S5;S$9G&
M5CME"2;Z:AUQB$P8R)%6"\_"^C@4VE6\0TI7'!3O[BS,!R+>:S)]CC_BY /^
M-ILNWRU&2B@6R"@&CD: LE: 3Z6 Y=EJ97*4C2*3V^$>4IK?8(BXE7#[2;^[
M&7#%F*YX:WMEB?,ORT>CE[9X#J'DVK@\,G"DKR$A3U$FP45AWW-PM@4QI+2Y
M!KS:J8P>TJ(C?N H:YN\UAQT8MT,J7HI: )NO1-2HPVFS6VO]P0\A*KOP2FU
M^XESAZ&=E_O/CVM?5UHFI[4I\!;AF9L^JO\0RT:@>PJ3=%=43!?+^:J[Z27,
MYY]KH]33BFXD<G+%2P8A61(J%QJB(<DR([1$(421;:*NMZ':5F&MV_S69ZQS
M@HNP+)I"SF]!TIRJAD"CQ=I5,#J9-+I&(8]KP PIA-$;.ZZJF6V%T-OV=1'(
MA5(\HWDH-BG R&M[8.<A(*DSH1&32#);WYX0PZS,W DG[BF*'>\LOX7E:MXE
M+\Y*#[O+31_79H?9"/PN=AF6G.#.%8A9B>J9&PC2TX\\%>;(L%"BS>'XKG:9
MKS-]L7/X[_/Q-(W?A\G!=!T<(\,L"&0.LJ\7,79'8SI;L$PEHGM$;=H$G.Z#
M]M'L4W?AUVTZJ8D8FVQD&R'M7$;F.*;LR&Q7M0],(K_1&4D:U@>&3@;&&_7F
MNA?<1[,-[I1R=Q;D0W#NAC.H++4+B@A2O"+4QD%0D59*J%F S$C5J)WBMLB'
M%&L? A.W%V\_(<YK('^^'"0KCI&C80HPVUUVS"SX^B6RY%5,(;J@OV>L;?:H
M(87!>^=(@]E^F*WPF[@\9A4$+Q(\IGIQ+GDO,3,/N7!F%"M9NS:!R:U@#RDV
M/@2%M*5@'\XL.P^G"L/1Z@@2@P:%6"^Y2P628)HGGA0O R#A((/CPV#?_42Y
MP_A%S=+;/[I\*_Q:AV\1Q]CD8_N/9]QY,#W%-0YQL4"\_-PO;2C6EUF^7.%(
MTJZ71(D@9,VSQB"@WA0&P5K'LF*QY#9%TILBW%K/W?:</Z9Y?"8^S/N?$KWU
M?#ER94RV]49YF0RH>FSI5&; 3#;!2:[SU:9@NYB6F^ .*>+1A'G?:+SF0NUM
MG[T!Y,@&'ZW2'(SV""H[ 4[3SF\D$Q:S"^%JWD)/#+L!T)!"&#OA4!^":<Z2
M*%D*2!!XSA$45_+,+ A91%Y\1,O:!%XW8DEOXUR?M'G+.(IL04G%R!(N-/>,
M9T"A7,Y%L)#:7'AW.ZXAZ=<^F++A4KB/5%JOB OG;T)ZY#D@Q%*[+_)2.V=Y
M 63#\I2,5*AVJD&'>2JZ0[[<4S;#\BU&O)%W01_\(/[%U0'MVL,PS/OLT8-6
M@=?+,!"\,!9JPCUS5FJES(_K8:R?<WT<.GCKHZH-!KP@]4KN-P2'##2M3*=T
MB<RT.6&^/^8A[85-.'@G7Z,_\?87V-MP4M:'PLRS*#FG&=&F$$@AZ[4@M<-]
MD=IBS$:UR>6_(] A;:K#(=X]!;ESMGT3]&99D@<>.90H":V4 0B]AL@"1B5$
M$NP!(BRW(![2R>J@^+>5:!]&[77Q;^523LD2S$S3HC1I9^=(60O,P:,N/NN'
M9>"=3C%V=6 [*.K=3Y@;.ASGK]<OD9[_M[_\/U!+ P04    " !N2Z54;(>%
M?KU+  !G3P, %0   &-C<FXM,C R,C S,S%?9&5F+GAM;.V]:7-;1Y(N_'U^
MA5_/US?'M2\=TW.#UN)67%G4D'3WG4^(K$W";1+0 *!MS:^_65@D;B !XM0!
M2"FBP\U-.$]E/J<J,RN7?_]??UZ<__![GDR'X]%??^3_QG[\(8_B. U''_[Z
MXV]GK\']^+_^XU_^Y=__/X#_\_/)VQ]>CN/E11[-?G@QR3C+Z8<_AK.//_PC
MY>D_?RB3\<4/_QA/_CG\'0'^8_Z/7HP_?9X,/WR<_2"8$#=_._E+*":P+!08
MB0J4<Q8">@=HE<HA)LZ<^O\__,5GIE.P"*8("RH6"<'8#$DDP;AQ2@DY_]#S
MX>B??ZG_"3C-/]#B1M/YMW_]\>-L]NDO/_WTQQ]__-N?87+^;^/)AY\$8_*G
MU5__N/SS/V_]_1]R_M?<>__3_+=?_G0ZO.L/Z6/Y3__GU[>G\6.^0!B.IC,<
MQ:\/H,>GV9=_>!6-_FGQ2_K3Z? OT_F_?SN..)NKY\$E_+#V+^IWL/HSJ#\"
M+D#R?_MSFG[\CW_YX8>%Y' 2)^/S?)++#\LO?SMY<QOI<#3[*0TO?EK^S4]X
M?DZ(YY\P^_PI__7'Z?#BTWE>_>SC))>UZ%=+KJ!TA?.O]=-^VAG31P(RB9>!
M2#(DQE:"=XCQKD_?'?.7SX*4"UZ>SSI$?/NS.\4[OL!AEP*^]=$=H)U_$%SD
MBY G74*]]KE7<*Y WD18/Y(@3:=Q?#F:33Y_S'@^^QAQDO\MCB]^FH-]<?SN
MY:MWIZ]>TA>GQV_?O#PZ>_7R](S^^^NK=V>GQZ]/SXY?_.^_';]]^>KD]-5_
M_O;F[+\>7E*,DQ'4C9C)Q:O_KX]YS)45$I6&HV'=G=[2M\MG5?S]KC7_.<NC
ME-.//PS37W\<,E6R01>ESUH99EURRDMFM2A)J5(&CWE@7?1JV>?C>.WYYW6+
M'G_AU#F&?#[_Z>!R"A\0/PU.9W1:UH.3Y)3?T)?3@161*\TS9,,"'7U< ^:@
M@6M+AZ*33""_S<CIBN$%IV'.R>4CB)N"_Y3/9]/53ZJF.3"^W.;_=3V6A4H?
MO[HWHTCFP#2_S(O_?S,ZG8WC/S^.SQ.9%J_^^W(X^WPR/C]_/9[\@9,T$-8&
M%)Y#CHZ!$D: 4P*!.Z=<"MZ&[)HL?4N@U^7RE>Q'DY6$EGO+(S>?:C%URI/9
MN#_%+,A!Z_OQA_&$/NZO/[)=>73ZD?:%Z?'EK!I,U08=N)12-MZ"39X ^5C
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M0'\4>, 'Z(4!6TBY\\[@>30<3Y86ZKR2?=[6ND8EET>3,SPR$R*(I",M5W)
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M^6WDVR;PG,:C^;5[P-$_CTO)=$!5?&_?_'Q\LBH>+\AUX@HDJU.3?+U<34E
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M52W^YR5!&<[(*?K]2D+<E?013"EFEQ*44AB0!Q8@"%-3XTI@V23F8^,<L\V
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M<3$L UDD*"("*W0P*"T<H*]3Q;Q#ACX:9S:Z@]](E7="^':/V=TUTF$RWIV
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M .CH !$ P!K  %L/X% *!OT#L,V CIH&P [&LY(^!MNY1$,#?2 HGV ;]$>
M25'3G-!?>+ SH%VB3X3^:H'8ZV< "*];_MYCC[?#".H[X4EXHA/>35!#0U!*
M$J$@N%/'%NV,HR!W 0I"45)6$2$GB)!1E)%5E)*"6 'X+=A7&6_1+-?#>O,6
M?#E-UP06@1X&7Z*E7]T>V(ZO[8&)KVX/#6R9!TR69H4WV^TE?ON7VD3]7JA=
M& #,U)98:^A SX. E?H$[$]0\QO :<"\9LV:M6N8UZYE9F=B9&+G8F-F9N/:
MR,'!Q<&QD9V9"DM?WP<8"Q,3"RO+.E;6=9RLK*R<E ]6SL4B['^&P<(SP+X&
MJ($8.$P(T+##X.RPA2:H88P++V&JD)1T,"HL-1 .8#2T=/0,:]8R,L%^G0GU
M$'PY<QV T<+@-+0T= ST:^C@S-)0)CN<=LMZ!-V>P[8<0NX_2=%S7KR=JKYU
M&Y=!H9VT#.'D1PV&[9<,A]M&T$3DACN/3^W8>]G(?M_S6)(L=[GQ)\QHVND7
M%1[M8YK"5^Z>2;_ZLO+S^+TGKZHZR"8.GD'A]S->5W=.R&F9.GH%1\1E%M5T
M3;(#&AI(6EJJ3 ST=$BJ"%L0ZVDA"=R%..BD?KK(29&@T.#CL/0VNS;"R4L:
MAEQHHLS(=GJ*  P[D,_+(2%BN>WW&<N2,)]61/A]"82_BK!0#YCAU#K9@2H@
M&UW2WKYKNYYH(JGDT#O)QX1-5KIZ8\CKEY.K!V?K)W/KK.-G!V)BD^"B?=S:
M+_*^3,GFY)J-WSCVJ-N;>-!%C&@Y\UXG?+]6YR]A.CI26O1FIJP*[XK6/7@S
MHM7Q2:"*5'ZD8.Q%[V K7T2&7T[N4=7T2=,G";9AF NN5[-08; 2OT,G69.(
M%NLOM$N$JULWR29>([2G$-:?&2CB8)L^=$F;&(5^Z'$\.MNZ:O LQCOC7$#%
M]4@T2D_W\9!NAN'!VV'9"Z#80'.'9D:OMMV.Z)#M9:UI?3@&HP0>V4Z/T*A?
M:O#%S ZH=(4[YKU&18R##UMN3ZN6+X"&P'LEW=D"%K[-J"F2QU%$G<F^2L:6
M<_R!FMWXO SI^7M*#8TCFF=<4HRM?_*3B> M2^;3)PEG?=3)L_> EXLP"W_P
M;S]/]IRH2IL*U)OC7P ?RQXL@#*5,Z=]\_(.),=;26[ M.;R73E9-ES@^"9A
M/#)AML5T >C?&^"YHR:GO@"T+?0L+G7XQEB5E?;6HK;>[:BJV'3]7&-+1F,A
MNKDF*KT=?=B6RS>_::AI =R!R/WN?22G<,3[\FGLB(ZKL#9S*Z[=F1W&XUG5
M;9R38.XP-%LVRW6K7=!,<',^_\-,]^VO24^'$F/,\BLBSE3U]GA4N?0FT*5+
M]6VN7E^M*E83U>\?,^P2VQW:I_N\H;KNH+2HWS6!/=O#$3FF 16S%4D+0&L!
M1"^ ZTD'>)4NHKW)^K+=VRYIGS70WG8I9N$#V3B$?+Z/Q5(H1O>66.F3-&/'
M[G3W/DN!U@5P>9YGOO%QWM4B?_=N'_S;N;AS159%3Q)S,FBZTC,U:ZOE&GMO
MML3-ART U(N2XFWNER]8%'07348&LA4%"R,V=B+Y3]DJS%]8ZUW2X/HVHWC4
M"I?3GM,@4!PV/4<?8->?LX,^L)KUI*IS2(9AG&ZI9P;JXORF@K9=LRV&LZIC
M,7KC$Q73F63-DCY-1Z/X*CO)8D0_77)ZV/@%DD+6 IA: /.B4\WCD$M0VPPX
ME?,Y=G)<=@XX.R<AI_7)8E8(?9[%O5UPYM3LU8#3JH,+8,]HP.V0B\&_S&+#
M-P^F],BE"]R94!KK"^Q$64VGDA^6GG=[^6[[G%31,049;C[7A'GX'%*5W!OX
MW-0+7Y-#+W&TB/G1M!G7 I#^A3:\3(SHGW]/=[:W1BYL7EQ,@44A^T* O&!^
M3A_1HI5MS*_)L7MR"[^5=U=W)4EULKA]A-7P6D>)3XQVBI&(5M7,E[N33!?+
MBF-O^WNA#L9SZ#(<?H%#^>P-"(DPF9N_6KH &+)CHA9 O*Q'<73?G#5B3KT@
M84YTP\VGQ;WD45:+F[[QK+4U%J_]!H@M\RQ.=HWG'NU97Q-<T3DVJJ-771IY
MO:JGQU]R_J.$2\SEBZ$:#V_?"@BI,1_GZ\VMR\A,]NL-WO.R-T])?$:*T+M5
M;D=>5IUL^7N^\3P1J_K)F?Q+-3V;^(CW/1AS3 _WU+;S[%2H["2]:ZP_,L%2
MZH#1%;C=,A41V*MW()_;=+JL>E^VM6GJL+NO.9;HE+;;+'^T_.C,C1+__"B<
MV^R0[Z6?:;7V])!' GWX4OK=7/R?C.\(E[0J>SB'PR>'(S/F;EP*U',U=FW"
MYXZ'8R<7@)+CAXQ7V>28/FOU]],% 0(Z[QP\'0\G?CP?LJ?))<HQK4E_LBK3
MZXOESU[^[F]C8S$=%T12<TKYC8]D?QF*D(GXY75C@VCMC*B?ZG7(T$X&*C@,
MF> D-'NN-YDR</!=-S+$W&Z^AOOT,7^WA]_NAKF[]OZ'I4*?6MU ^>_DV8SB
MM8ISK#KFW-,$[]NG9*TK9I=8?+33,"_)U:1"UT4V+V5.(-[QBT3GG)XO0]5,
M_*OITM)(<N #L\H<A=M#)>B6OIK0MCF!_BG5R%ZEAN[!N040-T^;K6JQL;'Y
M^MFJD6XOW5YY^:E-&^37BV:,#O.VX7KGW]68IK7,-B\ T\JCV5-=L63=B^7#
MB.X$@7@S/U<67-/]G+D#[UT37%!E\T2B027K>K8'^X>Z1RZEMV36M[;@O^3U
M<3==O31)LHHW;^K-'I(W$W,3'C\3F2=<"U4^CLV<$ZJ;#KD>=;U<+,"XK/C>
M=5G34Q$N!ZT]E3S/I00,$3.5*B<3H^.ODZ.?-C('W*OP1=69E2'1"L^+ 9'A
MP<!0:F2"(QFUST\UR=^Y)^N:\6=TZX79_H]G#V[LTQ'*-$5F#T[4UDP/3/JI
MWCB@=NWG$'S'IPANEH#>H,D9_OCMQ74U^6FDQ)N(&@2"E=^U_Q6W;9VMAZ?9
M;$-B\H2<GVK\ KAF1KSMT7_SYM/YB*HZ*U6#GL'&(=U]GNC<HX1>,F^7ZP(X
M.']VK_L;I@]A<)=$I;.[K1.B'*63Y$25J]_EF*775-R$YYD?>8NY+HN;\/6L
MFRWV%+M;M_?EQ\9MJ@L?R<;/_7VG/\9HVG;7LGGN3$I*$]X2[!HJ,2EU(V:>
M,2]_9K=CS^YY_'C@7;+?D[(YE^EX/8N[UGLXR2+F&9%Z'_T"(NI&M\[RMT\K
MJ42Q+8#D*NRU0WL+P]]<K0Y3(A_LR\N:R(PCYX9<F]@8*_M"/*EHEM\XN,=@
MJ.1-X)AJ6\&^H;@/$<$M^VHGS4(NF\?G7WY<'U.L]]-L#0[_(?!#:O2$>$JO
M5PW'3SWCR0F.O4>EN7=U346_OS,I,'-P_ES+C-YL4TS" D"H8+E[@RM9\Q%F
MFT@2[E6*&1*'[IJY-V&"=MTKT/Y,%'CC^.6@ZAA=E%9U..H]V7W"Y)!"VTQ&
M69=K[:O7'GZ*>98.G>3+"KBJ4.RY**/YL/[+XT[XP4"%WD#4M%ZYJF/OI&Y!
M?*X/7186@8D;^WG:V'BFI3CPBVK??;_#%["1(_-K/VW+>_ZYQ1^E-&MKAG-Y
MQ>7!2U]SWF4NT>-J08ONV !9=@&TJ)8C/,YS/_Q,PG9UD9IC@PC7*[IQEC_U
MN]S0.!/I3V.9EQEP=@%T%R3?^>D.WFYG^:>8K2FD:K*(HA*63)2J']VDW[RQ
M.M-S-BJF)!6:I;+1<VIE+^)Z._Q59LQTK77]JS 5Z%,614S8P.SDV?<IT\[3
MGHY[>NAOY$AH9C5$GK5RQTF+R/J:^-,W83)39ZX-E31/5\ZGHOT-/:U8\M#W
MSS].:ZQ&=H2PXL>P3>$C:-15WR>F\YL4VS61(C+X\:S8.>OAB\G3R@7&7@UN
M 6GDX_JNA0&>_,61#]R*Q# 3TI-]N(F9&G-R6L)XD;]A67:VL>+3FUZ/3];
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M H/%N&)P)"+470B)95JH92O$W^W7580Z.G],ZNJZ0DTD&6 <_IB:2-FHDC#
M$/$>!#0&(M_ZM? ^3])_4WB?)]2NE>+.6*P'D42P)>$)WV>RBN#73332=_SC
MBDD2;HZK6KG7V?7/" J187!$RB'3UE65:?UQT:_UN-G_3E]"&1"I]%?"Y8/"
MWR%?SEYJMCU:T0%/<+6%.MO9U=81(W',#>-(X>6FJ ,-?7M;DNU>6Q(&)42Y
MQ2PF*2N&D#-:OL4L)BFC*"FY1(RW=W;P^5.D&@0,1+::%"DF"9$B( I%:>1O
M2/$$(SP>NVQZVE\U1[UM+2TNN?JV-;6<CHZB-HY(LL51-K110A!&W-G97M'!
M%F.'D;25$I.R1\J+R<BB;<44[&S18I+R4@H(A#124E8.O5Q^+Q[M03$52OE%
M9V"/1T,\5OI/45I!#F%GYP#QD$4CQ3!(&4DQ.X2]E)BM M)>#H&PM\?((I>Y
M+>Z0VV)7<_7P@-@A]TI)RBM(R2A(JVON54<@%! R>^21"I)[I1%(27D-^64&
M!AB<O3/%V#6PMD0B2HAZO$D9%)![^]HABH8D6P+)PTV?@'=PQD+=2STQH_*
M1K7B?ENBB3/1V0Z+T?/$$*BGGR@A35LL$?,=$B."+8[H9DO X- ^*"$C@L=7
M(EU]:*! 0B"$!"$)%*':[#W0&,*RAO0AYX9UMB/8$GP$$9+BDA2RE5ZC[D]#
M@P423GHU7EM#8T5JHH&6NJ#V/@U9A(*LK)B4.(+B]*"!2G(F83%+_F\/EK24
MPCI31KXBUA8'V:VWV-(VN9 *M>W*$HLD$*W$UV(2JY@MJ1M#</;$V&L2\*Z"
M5,>EZ/R= 821E)*1E</(B2DXV,J*R<A3!I 4VEY,SD%:VMX6@T#:V2L(+96W
M7Z5J2GG[_[(\_J\/F44&A-\=,A(KS=[O3(2&C<]23QIBW+_V*=4#*]JB*1P@
ME=A"O2.TA/Q>UR Q\O((6RFT&$)>6EI,1E)>4DS> 8D1LT5*2\E#;91&V,LO
ME_=RPN"635\:LCXCA)RB%.0EH#22:OJ+9$2\ \D+&H!['#&4@?HGS7^Q+-H)
M&@X8:.*7H+;VK[7)3EY2!BDMCQ:3MG5 BLF@I:7$Y&4@"Y=!(#%R<O8.]M)H
MA^^UZ;ON['_3)C0>1SE+^MHNR()MH1@&0X!&@ -E=-NZN6&=T;84<@DW/)&T
M&$8(DO#?Y'CB[)<FC57NY?^J:A=G.XP;T>%OC) _:]"_'B'?G1O_8(3\X0M&
M_ZOQL2H^^%W^]HM^]'O<5ZH6I-;SM?__+.__J(T_-[__?Z,-B:\.5N+7OG=I
M6M6Q]:9,K(;.OAA!:EBIZ(42DE>0$T=*2LI(R@DM(9V@F5-64APA+2DC([.,
M], Y0^+IXR$AB,O^G<)3'PN%693K5\3O^'@5#1];W*H9<BFA8TMIK.UO,\PP
M6"S>Z[=X=2RTZ/KU3/NUK;^18PEGZ&5+0CMI4>X8?%>ZWRYT* &S(O52 H45
M2FCOXEPON,A)D,I*:!45)?!&"4D*+=:IM1A\V$)=]+T)CTI!I'):Y&[JY$S"
M++%SI48L4%RR]$RB<M8WT-/89VBXA"-0M"V%1*Y(@*$.L16$'=8#L_@L\0>U
M4COSOZU5\MLZ);^I4?(/Z]/?HVNDI[M/4(] &:^"DE((06/!/ZZ21 T<$9)0
M;$>%WY'V^_V!D%3X1CJ9/^Z.9?$0<@I(08U_4C"$S+>"R7S;:S*R?THN*3D9
M^7^TPV1EOQ5+_ENQ$#)_3IU2TG*R_ZA<"O*_UJ/\MX))(;_GZ+XU.HE?6?0R
MZO?<QJ]<Q.\5-]BK22VTO(^C(O@#?L /^ $_X ?\@/_WX.M)$ 8'!2]>0JHJ
M"Y^8CVAK:%A#(9"F]J%]U,,KYOV'G'%XFG4 N.)(!,JVXQ&SHX(,I8 &K 7T
M  & +9KHIF.H:42]LKQ/0Y"R-PF^ L1CHGKQTF^%V'Y]04'PWP$[VHU @MCH
M0VEI>RBR@=*GH336B^1&P5-NU'+:N5#2-)2[M)P$2$ HO9&2=EQ,[Z;2+*;5
M*&E[5YP]E*;([&;O:D])OX32/WMZ4"YEPP]!Z2!/9XP7E*Z$TMNP'J[.4)KR
M3@"G*\:6" #UMNXV$@;M!*4I=_*9"48&&E!:&8 US(ZKTG:KTB2,-_5]#@V\
MFP_UOK#@3O0N082"@KS@?HP7%D,BB>E#2K$EV MJX%W=;'$^ "RVF0KK?[/O
MNZJC_C#S3P)%MXNIL<-4G<$VE'S%?8\.?P< >3+4-[]\Q=E=!R#S#  ;Z[_B
MMMT"@ W26T;9JO9LH(R754=[SABT.*5#5^ _$OP)6%6?.(7=2O<(+B^.*?V&
MAF)P#X(@$;()C*#8KP?Q7R[X?3EV&V <,)1S XR@"33*G'&.D+J7]J(%G7&_
MI\2_6.Q7L#BN(>"X.P\XK<7!NC). !\H ;0<3 !N$0WEP%;T=FBM":!8GJE
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M$I L;8&_]5_\'P: >\B<!#(0/UJZ_MT' '.SEL-E6+7EZ@.7!L+KJ?(9K>L
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M_/R*+Q_O\%$#OAN_U-S#%FN^6ZP%9E0 K33UQUEO ;CKTS[I0+S@N VH"ET
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MS7T1^5?R!7JMEU@SZ&:8"\@*X FM0,##V;#2NM#29?SNSW#+F6CITK1ZWA)
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M8QL?43"SE(4W;,9C-^Y]]P(XXQ?6K;(+PO"*/AP7\9TMFWE5U220VO:/3[L
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M6/K@?5[VZ3E0LYI#^0NR#X",3F@@Q>G U&B=7%OW/[Z"6\M%_IG6&5<U<G6
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M_+TE5P8E8@'B"5M&=(509?U/  $7HM-R+<E8F-8_857CV*=,V[P*(#,TD^9
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MX?</<;:< @CJS_+E^6^E)3,UHV4!_UBM3?H)JML?BTPGXRW6EPY(% M+BX8
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M_OI/N9KS;5\X,GW8+*$\Y%4,OZ%UD$W=5)[ZEQ6KWN5)DD:_",)" T>#\->
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ML98WT.NK9]$^>!Z;E%>MHI(#+ZL]/8<%+)(6@=%-V5>:OE&LDG1<'B6J,37
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M?6<#:[MC)+SERIGIS,LV/!2=1XOJ^'R+ 5D\,B %]2I%.D4M7";4&IZ[SYZ
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MJAUM8=]::XIZF5PR>ODQ!*Y$>NMI&VE:T#V'PD+NTQ-&YJ\XXY)S652*(A@
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M%EK25FZ&#+]^HZG!;$&F_"7(1< N?@%$I-1;+'".BJO+WC8)>?F<7L;Y.PT
M=[A<N+-EBAX"OQOOV:I,/Q49@.^=,.:#)U=01^(W9/YJ>02@?8[TX];#01L4
M5]4#78SD[Z"K=[UDDT<&? 6K69=)MNK\-A+,[T;4<E2VY!HK\.M/KH6<MANW
M<B CQ9[KIVUT,0J+'-A9''=7FP2';*O#PP(&A=4>&[,]:JD?SK(_T<$F'ZJ2
MZ&/']7.>SJ 6RFN(&<U80%F-ULP?[<8"*UJ267?M6>C3$*.$(OQ[/.PC\REL
M<4"::B54^_Z\"?HYLS*TVD>3$:+CB8M/[6\*_?=29*&JV?PG.HNH.0<:]P0O
M[9MND/ M'Y4_5!\C WDLR(@&UD 4S:XDO<TOB1Y0J]N\%V98YU^U<J;[&2#N
M?J"B!#P%$A]&8"0YOD0'&+RC!^0@NW(T7 %R/\3H[@=TX1;(W'CDBJ[VOK<O
MJ)SR<-N2AR.Z"RHI6-#Y0H6Z@PQOLMZSGA;ZD_VV,,"U_:VN-N% O2RR5#FT
MA\XNN#5&LV^W,-T,*_L5?VKSG>AU[TH%"M?+4OS,SN8?A)%GS>"QDKM-J-.
M->S<T"#NJ2G].<21"I'9I*;Y0 GO->X&B_Y O(44A:KC_XIC'199WN [V**P
M1198N+\5DA;T#<.BS$RBA=Z6V X#Y'#WC2NV=[=BQDW$\Y5W0 X.P?B1R0V\
M",TU3C4)'I$\)NE/B$,5UL. IS]?NSDG:  ^:A/?ZXK+.4K(A<>?SX[*Q@UK
MM^KSZ(K6L6BV M2/C:?(%3WS<U>[B1%$DY-1!DN&]V?;/JV=!__4R21JCC:.
M++MJ.4NG60/A,@GI'7[)L#V#/1#(HJ/5C_L(PQ$<NA:#4.-?L):&02C,V4*<
MDC =@^9=W%=*]UP8PER[K4BL/'%UTNW4O&+JJ66[)9 O]-K+@BMG=M+683P@
M8;"^,UMQ2WJM"F!]T!X3W1,\L E!#*^@-/^4RHC1FZFA'J2*W8<#+&S1V@UE
M?,\@T,R40<%[VCSB#O[O,)/;4#50:"++4&<C/5L4M:<LTE::Y=(@_@9\/\X-
MM7'K%1MMAL'&8,JV[@Q?\8:J)?R%63G84VHIP'>AWG;S)H#\RVPGIL=Z/D5U
M@U4E.7E'M;#LOV8C\G:\R*5?^YIMHA5K-BSM8L]*B'#BVV(M_8(\DPN!'5QL
M79E*30 Q9LH-0U>ND%F!W,R*;70<1T\V]G.\'0\C?\;D<^VVPL!CPO24$=@]
M@!P'1<@Z$_WYKS@2]L/%'KN6#1Q>DT#E(Q!T"I5YZKFG"6+*?=WZDZBGE_40
M\8YGQII$>)Z!OXD,G\]:V#IJQUPA!GTN(MC=<\V9K->Z (B+_EG0B#I:!YW
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M4:YI:"V%2@XP 4)I]0O< -CSU'KF$2+/N_6_99A?Y5^<$A?WCK3R4.XL8'_
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M%WT/F(8_10(X<IQ\RVG.$_Y1J?^0L% 4K#7Z,23<"[#??; F+]O)-^+[(16
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MV+(,.DI'.T"Y@,"!1I1)[$F35:+G!PX0+],042K*F;]S@J<3B-VO04Q)4@Q
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MA9NC!R$/E[YI*-E=4IF'J#'EE%3U?L-Y XEN\C/;<WUF 0;?A+_Q/A-7GH%
M<'  F9WE[95M*K#"88I@O((9G/&Y@O:ZJ:>KGXD<ZLT7&U.C5<$Q=T39=DF^
MI3S:3T+_HB0HSE$E>\"9:R&\KJXMS1DQS,VVJ!E,9OPR_# R\=X@NQ7S+H;(
MUL5=^U\S]&PXJ0BQ(Z)Y6SO\K/FO,S.#>2/G6Y]='1=1:UA$I YA'DT1CAF^
M[ =1<(I"<1?-9(:&D_,MIS#$J 29+>]#8<HS\WJ)V8K[8-I$K S928<3!.X'
MZHRL-!02]I;3*DIPI?XQRX^WW=L:.+$)Q^RRU,03*'8V&P]7R /=#V,"9T]8
M&Y?.*M6Q*<Z1*N-7I9N'3=2R8:MB>M>*CO3DO;]LF C+.'M=O/G2(BVK\\P6
MWS)>;@C]LF:TG&8B==QPI4WENEC/)J6Q+K^W@D008/(7;JR)NXPJ63B[Q QF
MH*UQWI_AZH?(A0MR0GN8P?<2YYWJRMCU&1AX$ULWSIY3XR_?U9HDH(8\OT$=
MML*MDV6A>S$OTFO'!][:?^CJ17F/35%C<,\QO"LQ>KEFS_>]WQ8T>FP_U_T)
M3MR*#R,7C0LSO2TG-OC(@U#;N,/* @>-"*%:1[7Y!.;;AWS%^)A0!+3*/L9
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M  V??>W0+Q!.>9C55O/<=NM5M$-7 T/XX^,_Q]8%?=$]#YR:2L@?Y*7[<2H
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M>>LQ _QE-CLP:-E'<F<7NRPYIA/S Z,WE*N]<CTIF3K 98;+3I>**&?R-WB
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M!%B164U!EP1%O(:(<[/,[5TK,B7A'.";3/LVXHA7GW",C5W<19R_Z/X#-M%
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M>S(*L';?!]EMM](B(LK:X7=_#@\)SKS9O[L$\Q!1$Z/4<DBB)!5/!D0#" 7
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M;T!S>WE5 _")T-NT";X!>@#P]$H:P"G N 8(!* U4!%DOU>[[[;GU0V\.:X
M'B 25I$S,_4-Q =#UV!>UB9Q7.#J\)3($RL2KQ2J"LR4IB5(3:!] N7+/06
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MC&8(0<Z>Y\OJRCDK55E[*L)!\B\ ,4*VL%J[  #!EUIS/57:8V&QU& [*B9
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M'6RZ]\89<E*.:8LQY7:8_L84#B1LS,6E2L%WPDYJ3B^&?CF_ G'>=']'E+=
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MC*SF+CPW#''"?BUS!'U&F"P(CYT U@=L9U&*/F3OIR%\32LOUBNHC?6&\%^
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M<,[S>UO.$=S:KC)5]_I"7T'"HBM5/)ZDV%([;=;W_,2_FE\"\&[?PS.I^/1
M1-,=HGK93DZ,4_T)^R?"U@5<HC4ICHET;TR +K;PX--ONR",-(V6710+6MK8
M@1<'+?$*C_2=@>,4?M0.T*,K\@BC(*#DG,AJ1#;YE6FK&S#[7%\2OHM/3_B5
MVZ,ED1\0+TN']N%?L^E[P]09A0#2^5<3"\DYQZ_KZ+&]T7N9-[1/%3CC=Q;,
M 01W3H.:LFH8&;7I'$,&*-8+0$&])X7:*N^+R.V,8D2(KEV+S\CA-VY3[^O
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M(&A?+XF M0I\NB_ _"P:\PT1X]PW<[%Y-X)RABO%/*2X!>/;DBG9_6'"E4S
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M@J?WH#*%L]VNO#)B6]RL#.^5\[V$2=W=>]B[5.B33"]@1V,G@V,9S&N(.M/
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M1.RG%=;N?8Z&?KT!>]7]O@*BQCN*ITN0G.H]=9(_F?PUCU<F3#W6?BT@]Y2
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M<JK&#%8C? _IJR\@3\Z4HSOU20P7 6>P6]]G(I>VAA_;,(\)6EFO,ZNY0;Q
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M-N[0)[(JU%!B8 [FX]"@)J;*(.5T!<.E53<]O!M1F*PD&15HHI_.IVQ*Q"W
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ML/Z=GMB\ZIF)ODUS_1*RYV0?7#Y(6K0;RAAH7(TP(,PTU0W8>_>$I2C'$<_
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MH(""\U43RCCX_8I? [@DE1>'O9QRV3)EY[H?G*P'F/=;KD=M5@$"]\>;.4S
MX[<R/-G9V5']X/C ;]FGX\:^=GA-@R0N"5H53J>BF_\''*@C&&AHM%=O)XT2
M1XRF^@[XK-O%5"2Q9FCLM)>\5W_3+[ NNY41L<(_93%"VC 4%2&^>R>%+]%.
M?-<E6)M#"ZH3I4"?\O#%GB$L:$MMY7K7^>4!Y*&<$WUXG*@BLWW/[& - Z79
M*L;Q\_NM!8$\)77.]-46+>EOZHE<1C>)3C[=8T!N3ZC8?S;?,TLC!?NLM%LI
MY3$33S?W.<?<VG9LM]UR%;C3GM? ;FI&U4'O2Q/5#:CHG=.GN2]O?5SJKT)3
M/$38;,^K_D&]"G@59O B'P_5)*)FH3'H)WRKU-BDMN\#1J7^GL.H?VCIB *_
M[.N4%^;8/-'4F]NW:XP#(ULR/^9/W#8/3S65E+(Y^62)K,-2N7RUY +_,FQ.
MY F-"]_P-8\("[G]Y0<1.J];2IUR7#N5=C_F9-)5+<KB$1:O 4^7QN%;%_7X
M5"Y7PW^>^+QHP9JQ\9H#^<3F9&MS2Y:3[.)<<T=9T2BR%,(8%E5?PN_N(M&Z
M@*>RJ:&L+5A?WU(4ZE[MUWQ\<+*G8AEK]+WE@\_[<EZ=]+/1X9B,I+%.,YK5
MO@=)P\%I-!ECH<+[8T\J7DB>O9T=0$]XI72.]36J8_&NG5/AB@6^D9[/F\9=
M\,(QY\CY_Y#CL;3" ^2^[&WSH:&L[B5?:]_7:(V# DX)C25.ISR;_[287Y&8
M#IP4QO@57<0DDN(_1+=*>3:#F1TA8D+I4^=CFH)=UJVG56E1MA;<55T/R'PK
MZOH&O=M*H_%I(I-Z1_FA(\7G-//]G)$Z3XMVA.GQ(L)<0T&.^4&2Y&KYY%K=
M5X+E)H,<HEL'V<5AB3N:A.<6UD<>5<TUP[QE]4A:A^]]'"2E5IY'F Z5KH=H
M/DBJX G'28]=&4\/O)+Q!?\_UMX#K*ET^Q[&BHJ @O0F7830>U41%&DJ'0)(
M!^D@)505I1>E=P0$E!)Z"56EDQ $I/>21*J0*!")^)W@S-RY]X[.W-_W?WR$
M0 XG+^M=>^VU]CG1A_=1U$[YQE!3X^+(O,P\A];[F;VK&I\:9Z@@';/9&1XS
M&&2DI9$3TD0F9=.,RW$G7<6NUM<!E&CC]9UDVN7J,DMME[]C,L3"HVH1!5B_
M?\+0I-\8"D]*4@JK.9C\3C).YAJ?/ >$L65+F^Z_3Z'1.&![Q@=I:@V<5P_
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M_5G,5<WA4Z<+[R1XK+^[4+GB9-!E?''KWEM-THVQ"(_5ZS2RS9+>E\\N+KO
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M? @7$<MK%[1%*-^&NXH#NN4J_J,FD>^1)T_=.0'HE[+T,6*Q[@'*E0TR.-E
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M8@8%\@^1,<;,JF'42.4?9'27!H"E8GO8'M&9FP,@Z@NP4_BP8$*#9;1^=#.
M"^$B6AT1G>&_SQ+ZSTY?NZ %?/&'2[V4>12@+F <@MB=G&OMO(L13EV7I5CY
M!O #@MM4 ^BDG'X":S,]GT_ 'TOL%LNPR/ZLVBXJ/#MHVY\'9]9H&K?Q(6ZH
M$NW3\\0*WOC!SCTB.P$* *N5WQIX8P$< >1L6F"!Y(#F'N:_$Y' TBJU.J3)
M?BMP %LD\<$X@&0>A,C' _O?1!:PT8Z<-OQ-VT:&S &YE9O/OI-D>>30@B@L
MC)D7WCK"'Z>8]_[^CH 8!/K1@#&I11J]JWVU[:!-+,_,NE@3,<__5BH_+@H
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M7N7QH&]ORISU'/OFTE5HLA+UVR6V\H8P)PIZ$99-AE'>N3]N%R"FY%\V'*!
MB&,VP/X3A^AUH]B:)KU"RGM>3)'BNXFE [B3K=;!'%\AU[Z3Y#$2*QZ"F?,]
M^J+Y*\<M]&T;/QG76;8)YL%QG!;^V'!O/@;GB<G%ZA6U[Q/:JX@HBMN]_5H%
M")[6,<+JQVV2L>>C,UGRCP2JQ+A'D%HS'- *=6V>M I$!9E%9LI#H59C^[0^
MV[LVLC)'9]DL2NMDTK"!1<F8 56HW=V7=YUPP[;!837$7I5MDJ/ YF9P=&[0
M0#\27=976/+N3'DO[<&\?EUQ+<JUGR,2V<=OD3ZNX^#Y>&@9+6):JMIT.P\(
M?U0L0 ,A_LT*_ZL()$\\@CA^O%@;7Y7">=&1(/MNS3.\QBYQ_2^0Z"=[([5V
M^8%9M+Z$6._ ]4N5]U0Z]^M/[B]UM?]_U+IE7%S;MCU8N+L$"83@[AH(4+B[
MN[L$AX3@[DY1N$OA$H)K<'<($MPE2 C!_G#LOG?O.:]?_[K[0W^!77/;6G/.
M,<>8:^V_U$GV6XR$"L%7:SLD*7)W ];Y@ABSSP!Y]VI74_+-S;)TI=O^5A6E
M/'WGO=[ @_CEN>S-BWGPM1\C-]U>HZO<TO8RNNLG:G5+9U-)%OX^?!9V[G_Y
MQ'I-"&PW?O8CZKG^#KOLYI^@U^73R8;+N"AMLV@;BUW_K4/J?/YR2.P3GSPO
MCOWVF<W3W'_#S1.G*CQU-5!/<DWQV4//?/+4%Z)%$TRZUF:M;\S1Z:(J-#ZH
M_2=B-M]4094K4.SEE?(U>&F;)?LG:_!J%L>C;1!U$+N__+,(+M_L>2=;GST\
M2;VCVO]@$+[ANP?KIR=Z'.QP)LLLDUZS5SNZ,,#_ZY^#+/O5^0CI_'CW=R*@
MI:NS9_U.T\W@>-[L[7!,,Z)+CR"U_D^/4Z)/A/_-3?;>-7(I2U9_86F=WL8B
MLX)NU4ZOV(:1K:0UWO$$SM8&8J#Y<JHDZC#O!R$D6".=IX);P91DJ=>VX8_^
M[TF_7?2$/;>KNR%.4*^?E E^\%/K?T9@>1'WA*6-!;>0:U%6V^6/_>G&43].
MASY9W@0:L@O%?Q3(]9U$XWNJ%JTNEZU ZH9F/K&E0'V!7;LO#;ZU7M+Y"6Z;
M]Y]'HD,Y3^/>"H %?7D$W[^BTO$6ZACA9_QW 1+C_ @0 C]G8>9M,>]MIVUA
M.I@/L.0D*;'[%G*_U_M6(,01JBS#>\'"<O#',TZ(ZD2V<UL)]?-?VB>TC/K^
MQK:_XZ=N$36A).'"?IN*K]=Z/(%V: S2Z&9(GV4S4^0XE8XZVPV13Y]+I_X>
M<VS"M?2\N?&4#4\U!)6CGO=YE1!7 0;U[JDS5^:-XGCVP;<BF&6]?H@]25YC
M"GO >7V1+6N\O$_IXL\UM:,[QS)W'YY9?B'B@\SLZ"N%I])?;+FIAVY\D^Y:
M,OJ7?XIO.1+0[M,&X1]&M@)]+9R!'75\9&N+&7&.1V-2/.1?0PV7^97K=F$\
MH0]W'F(Q[HLY"8E=OC;X[)M31\J^V_F4L#==MZ^NKGBXDWF.4)PH.;ZS.RZZ
M!5$,O;X)-7\6NRHN8N-B2(+_-*@2K]1=)DW%WXOY]H,OYWGP(X#_^LVONL2O
M8/PFR.X+Y$^3P]33#^/K4!&J+VB/K<NSQ/>V&CU][3DDC9_4WI+7$S]8\0VB
M9HS>%'X]] 7N;VE&0@YT$XN?XS=(4]=L8?^/\_MA24F<+"^OHL&+]>.7%T6B
MVI2#_<L<:E!1_B"NN:7ZU^:J9$4N&U6>??D0&V/]HM%#^42M0?<:HN._"GWT
M'ZL5N,+X(;_K'=Y&EAA=KCF=,:;[CGQ[?<(?+_YJK;)>K:W?)_=7FOWH7IW#
MDUO]#'%UKJ_?J??D7OYQ;-CVN;$X*?H;TW+7BO<_8=?YW_PDZ.SAQ^2 O5?'
MO6V_UI(P:(/$V="TO=3APGXA7EM%/?=I<TI=(.M3H=O.4VZF^QK._JBM>\Z#
MCZIUW]N?8M*_DYKMA.1<VT_MB"S/"PS05.2$',K;E'R@<'!]3MOY)):;M1\/
MEHPI8X6M7[T$Q[[7FF]%L->5':]H#A6#&^C2+XMZN%@KIRV.BP8SS%IX8]V-
MG]J#WWN)/SXVM7[OY@+GB3#8;"LH4*;*$#?TT./\-'BQ)UR,A$P_$9=0[2[0
M$W[16"-24WCDI&(T7MJ\?CF^=F?VX8<I:9;P=9AYPX_V?U #34;_AM!LP<->
M/+2]R4&#Z92-G0Y)P4C-4^8W^]MPG@''QO"M3^+JJY:<[( >&+3Q"" G%"A4
MQQ)5GIM+>2:)6P.ECEW?9>CZ<&HDODQG1A"Y1@/VH,TXQ61RIJ;#0;NZP&RI
MW%HA-V%IL'LZCSVWW";58F]DW?,WMK]]R?6[$-J(@3?S,91G;4F1#^[9>V7"
M]Q=_6:_?/[Q:=#EHA2]U;(^1Q\^89^#YY2(R^S!D[A!C>!W[@X:UX9]X?1CJ
MP<W5)?7F[JEYN#M=OA Y0_LUE/DRH(+/;"XPG^_8\%3B]?X6GB>\LBO7<["7
M=#G2I%,WQ[DS>JH/SL9!XM$C-Q+/97_IM\QY^%:7F'3":G'$6+NU#]:J+'K>
M /4BBBH_:/%0/R_=J9"QN*>K'A5@K+]ILCZW)60>HUP)DWQ>3XL74:J0>.M<
M,.H=(,A\+M;7PNEE5JE+E?HQ_%\Z?EI T'$_ZQ7/Y3A&^B_+T-%[CIZ=A[3U
M"U^YLYN*^Z(&]S32WCXZV=2GMN>4QM49KGX[1=<@RQN_:D4O8T*5H*@7I5/W
M.DJGZ<\6J.EBXH9^^LE[QHMF3TFS_=^9ZT1[UA/-Q.F5(HNLDBY'R%MX.CF]
M_(:B6J\7^7 L&$<2>K;/@J\[K.+@J[W&^=FHM*#5(@D?Q_E:,< :[% [TO%/
M0^TH\O2>"2:4_'K@<8+]RZB(;"MG>1S=AUB=S:8*=58<]A%P4]3.] @ VVZL
M_?_K2,+3W=EY9=;='V\^13<ZQ'K=O'AT6%'BI].N9;1=$Z*Q/C'V^$8*]P*V
MU_N9''&N9J$);WK'/4$\GLM7R.F_,(+E[Q&ZBQX"UU5]@6>E=5_1:F0">MK^
M(I46R^-O*(2AS5[.)?7NLB@=7N47/A?:._<[=:-CO^ :FPGZB^,JOC')FG"Y
M_).*+4)8CVC6_?<W=>3\5%M[&HJ=?]>18/$1\_,*RN28X>Z%(JWA18?S[J$G
MM++MI98.'MQ86YPC'$@>X1H\SG/*E>6X:BNP?%#:+(.NM]\]W*=[$[%4Q[%U
MJ\B\;_;))=VPCMNKP\+NPF=D<><^K6[TW5DLED.>@M%R%H4VLJ8B@URD9BSA
MQ]\(Y?RI(C\"_!C_4YRZ[YYZMC"OV=^P&[S^1 B!_*\$*9]O]C,7C]WK+11S
M1'P "'E5P?A<&,#?[[2BW8YZ$E^#SW@8K>OG/@3H>'6N IIO.AJW7GL&^%JX
M_24V3($!1>B>6@6>FRDZV*5*X?(%Y=V;.IF$S_G]),<D[Z#^<]FAD8>_D\>%
M]]./G<\9N@S^$NK.[\]CI_]:KAK/"AW4R,8XO4 ?_O>F-S^3LTR@0Z#^W#(3
M=AJ*R^7]4RVY/*^Y@9ETMDT3KVY,#E;EJ:1?Z:!!Z;3530?_YF2F\:QHO1]F
MU>9>V<5PJ?V@]9B_!/0#X#]5[=R^YGFDJCV]382CEEIZ*$UZSVU%D([7/]0"
M,,>W>^WGN?Y6'Z]SQQD'T 3\J^C5ZQ4J/6:'= R17,^;97))8?;^()EUT=GI
M2%^=":Z,K$VE9I>_!GCK\\[UF]"@QO\XMOE,\V\H3B&ZL61?.['YFXK_5T%^
M*RN-7__%GC<]/IF9WA"BZ&8EN^+(>9$]=&-^U;'D1!0::5_C(BF8WG/*]7/9
MBVN5?46 9OI/:6.S^_4B\&ER,O]JP\[@TAZ,YD=BMPR?TOY25.'YA;_B=T4_
M2EWDMA=X3:RI".PYEI*Z\LS$OB$^D,Q$NZ(8"_GS@B91\P<Y0X&*Z?&$,SC-
MN%]LI./8#UL=4_V K_NF?O:7-9W<O[2^$7]D?(?6GL(+OX@S5(R9M!#-*^H9
MTKT=DO5,P_9<JY]_L#?^5QWQCX+S^8(F&4/^JCA07?7_T*FVI=1*?CC&<Y%0
MX]ZIFP[VNO)Z5U;4;V!#X!]GI5PAR28S_^9JB9B%?ES!58D!"2K*E%B"4KN0
M$"8AF$[&()&@D-E0_W0M(W-R\"MF19_BBF%A#%3CW\VIJ<V(*;3&'4?Q-4,O
M[O;Q/[@93-X(86K3_J]^^Q\=ZZP^$/DUCK-_K>(_(F-_\^)I>D_Z-$W78V.M
M-6YRP&82OVP@VBO3&K[/7".#K-6WPS,S_SF1U@<ZMB#&_UT^_]>UXNEQ8BQR
M%;>Q9H/U^4M@LIF[*(M"C<U@1*9>:$T$;\ED=J,?HP7I_E:R%?2J<7OY6KVH
M]W<.!:)5J.I%Z6(.0<7ZY^(U.]ZXBZ#(LBT]9\S]G.K+ H*^"/>_%K-WT+Q_
MZX?_DF9K\;Y/TLKXVL_.A\AZ*]U*9&6]J/TC=YQU^B.@.,Y^_7A8^G\W;#>F
M:$*OXSGCC> /H8W9]A&@:?WMZ/T&[KZX.OQ-2:'T;O8E&+$L5=;LT:/1QM3%
M0\DJ]@J:(PU5Z\XGZ!^'O>'X$Z,&9$0:]++]Q0DK"_+OSE(E_MH=N+?[SWKL
M.-#QA#TA2"^MU3VVML!0;H;V5Q>F>OQL0WY9L1<H:)SG7JUP#7P=_ZLYS*8N
M)-K7X4^;PS/HC\@T\<O2F3E8B"P+X';K$"-72&0Y>/@Y[#A9;>M:^7JZ1!J/
MYTU_J(E;\H)=905__?BOSM@+7]N\^XN^0)D+%3Z-&2K!A%K7_E]+]_^8/#O]
MGB@>%Y&2])' VYX,791I^S@#!E&NY!'*1'E<-W7>7/I;%SWI$_N._><F[+,S
MRPW]@LL_%DFW-6(4&_8W_B/M"JG=/71\&*BW+]]NA\?SF57ALR$/;:"A%1W,
MGT.4[6Q^*\!/K:X.A:AX]:Z]U2/@'>N\(FUZ+WXL+^=?_ /1X4[_G.1CLS[;
MV6/;49R$)_JVY(SFF2RO,3"RNQX!/J^ C(*..2FO>"9D,=+WJ$)'+[%[=HJ\
M"$S4Z51LVSY%I'=HY/]I_H5D?/$1MOJF/4#+>V%SB(?X>\B%=:47F4ET9\6S
M;>WOGO5?;_K'"TQB&5I@0AM%Q6[C'>C4IM?^_9I>=#W\5\@'H]&36_GAUP9;
M?_= <,]B$[S@DF#ZK=F^7E3]WT[L?S68OZ:8'_'I&L/>IX>A1F-U!Z_J[V[F
M?N6\7^NIK&('R9(BR'_'\+</E*4Z,V=?41^E8/J,J_AW;ZMX076G7WLM:IKP
MLHU-D7;I\AR]:<ISGCC5PEYGH:[9/:<H^9)&(5?OPX>0-'TW- LO7+-MZQ?$
M-S(;U()BKY%0P;7( ]--)%:"?S>M*())1S;FJ2/FPL:B4[R&OYL%%\O /)[5
M0;KX:([9M<[7^[_S[J"S0Q\_BMO5"HJ\?97Z:V<OY,U,<=9'P'@FZ=K-1?[7
M1X"@ZP??W;%8.^&^7MYDD_>V8 G==[39_X]"\'R!'7]7I&Q0PMHO)-<VV#'8
MH2ZMTF&J_I=>(GF2,M.XO:\> 0Q,CTL 1"AH:'@AP"/@5G!!5J7_'<Z@HNM#
M^$Y1XK 1/'L!NN+G-LJ4WI?&TB^3KA7WLFS0KV3Z!@+X?,0GA:5Y@RVR]N]Q
M1G^[(5<#DP+K!I]<%]/'>J>XV5?L0LFC3(-;#&OX?D14KU*5$R-ELT7*'(U#
MC/6HS[^AXH=>=CJ3CO$H_DDG7WW(>YCW'%4TI(G!^NM,:K%2NSG8;JZ)&&\_
MK,V]B+E_[=X\E+J8$CD CW"31L<NZ,Q@$L+JI [.5H04B&UJVX0&<RJ^HD)J
M06HTO:#&?XDCFL4F\BOO9V*[W2S[F-'P*K1+\,MZEG('!TPO*]C>$)4!+99-
MX9./G4@\KI;N-6KX-*Q8U/[17X\&O$N/<[LSZ;+CA9>6'A34$_Q\=%-B][X@
M>+T^A35-X_K9C:NZUYT-A%1^VV:/CRWHS'KCFYH4CL$E<@[ECS*ZJM9U49CO
ML(E @I@)*4"\":/Z/CS)27VXIA_#A 06]99#E[HS\K R5%M3<1 '%VF/%A09
MT7A)V."W+Q?ADNK5K%*R)X!U*!KR/_7H,:LB$Y/TNP<]^XMGHW>"NZ%=)HY=
M5@.\&/6A 8'-.,MO=4>Q]:63F_@W<;0;B6QQ2"'I:M+:',?$QY1=<CV!196Y
MD2&Z/#\ &W)HJ(01*CL65K_H#TA&>/Q%P;"M;5]1MBQDNVHV-?77)^7K$S".
M2[K@R4*SS&'G<.&-*Q.$Q;G8/[Q'QA1,LM'/3[N5:WL_9)*W=,#_Y+SSRR3'
M^$\M;9KN:0(+KIAQ_/)H>&OD_J>C]'M%$Z-%#U&?JU B8,JK$BU?AN$K;9ZB
M<F!:(38AA3+V@^[$ZWUIOBB>SZ,TBQ(D,@N\8=LLH,S+J<L#E&C1#_JC?/G-
M@Q#G0,6BV2E8[T%;QK/A2;;*KU8?@M+=A<YV$G^MG@<WJ-^]C.36X]5'NM='
M2:]:PO12(9"+,<-,N\%E=T0<.+2III=X9R1Y3?M"7I=J=T10ALX4M0@?*@H$
M%35I>2<I(&5XK9(S_3JN*8)NA!IM"7YV7@T'X6?LDVB2SM-DWXL>!;6='Y5R
M/@+"&?96^:25$=XVV'!M*LN]&#1I@X$%PW^+">PTA9.N?IVO7Z6RI-;+:FZD
M[C\ ]"?FZKM_WV0]FNF1<+)R^1W?RV;$B-J/7)H5 !4&I;@@M&L@=*KZ ^-F
M/O9VYC[PP6WSX4K(Z!&0Z?D(:/O_]+34QY!7]T\GZN_3'@'R/$O%8@IRTQ\+
M;7R3VU8Q[QZ.;[ -=M>,>=",8N/DD@;[*CA"B&>8Z&4,A/OI3;XC97Y]V26]
M7!12UR(?9[>?3\L7CLG?>^RPJZ:_9 2/>J]MN^0"1VA,0A%&Q/@(""M.&[5.
MIJ=/B\Q*1Q](\;!>/H#4-Z'$B@O3U*]8C/5F@C[5-.>"?'L5@@:VI[3P1Y9$
MG:,]?[J_:R6K:DZ#30-Q2>T*>71(-!MN"Z1!;)J3^;XYO93HB;2IF-:4]IK6
M^2+.Z +2@F<W@N<0S_Z.^]U=]0'WL\#(E\.48AY/6J)U5X4SW[#-UK27N> W
M0N%Y/-SN]L:N"M\[>H$K(S$J@] 3 \\O%%K_V@D66E$(^&0.@H\DG<JYF>'1
MMWV])2B!1V"J<5"]HB)Q,N.7M\I"SZR"D<Q)PLY>7@8ZL<:%U4#*&VF5Y1G,
M'\K4Z7?6"A!U"LQ<0E)1(V<"J@$ R]"Y=1Y$4Z?,[S>FE7HE1ZD;^,N *[GI
M)<5<LW?]48->_C2M>MO97"B'*$W6HG?:'_D^',%J\-9W)R;>)C"6RFB#_ "P
M"?+"  ;*#>CPCS_3HE>5RZ4-W_?L@GNKG1';<O:(4+)*XVJIHF08:!C8(ME6
M3!2F3MSJ@T&2ZOT2)C_T-.#?XN#Q=N4;<JDYIBIK^_U2>\6'H(5JEUY0%IVJ
MX;/O<2]C[\)L$Z)1$@ %ZQ"HG$M]Q#R-D4JQ-YX'E>(QD3DID5UJP72N5259
MRHG:NU?/0X 3;C5ON_PIF8W>W(V^AY<,JUYC&U+(N5]E4A(^Y@1@2P2PQ8NW
MWRFM7 Z%Q06%VWX^(=.+,C:J*6-&PS]V2ZDMS DH\RN#%X8%+!F:SYWC.V]0
MNJ:ZO00FG91B5?<J5W5@I+0-X*69?61'ZZ0'\9/QC)#AB)23B>=;!2MCV^'J
M7O=25=:BF6A=C_&8(*9@C,&U6Y5,Z%W)!2> UN=,DT%?0"<U_/*5X#X9A:0Y
M2(EQAD0W&Q8T&Q'7Z;KF)/<U#E%^$[-Q'9EV/,%()WV^7D-042(7DR8L5DLS
M6DY8  -L=![I7MOL @'G-8*PR$3>O/V7$M(Z1E/Q=')#7R_\,1"4U5V76<WB
MODA>OW6R,:8]KFU?Y2OC5J*-P#W0W;X;5";R]NORHI#ZY$NS+HMR'5T+*S4?
M6\#".O(CH FQR:;TO9*_!Q=EM5.+R3(TX\0;LNX NYJUU8%]!2-R^G)9O&M;
M4(J@*A: &[)VI:5;<=F; $LU*O16/,K["HMM'[X, W*5\3QB!(+>(3MS7A V
MNG[L'W&LW-25TF0-^+PWHC <\<6M\XL"J]7U892C)IM!' F?Z0-YE.BX00PW
MDM+B(V XYN H!(>&=2\6'%#!$_):"2(5%G:?JC[LSSH-FAT!27#;I>$")5YK
MQ\S:;D^]L#UN^T9"&$HYP318! _J+P#H<%?.)4250L(6>G#H:I(VR"'B.?YU
MU)6S"5&+TXS*?=+5M/4)PKBZQ]<2%SZ-<F$%=0E*O%\RUXDD,96DEAX!YG.U
M@2)OT.E!09L2]0Z!3RF:VUKN^(+=!IS7$!U@,Y_C!%^A4X*I$+:8J'NG4FB^
ME.J".1HWV@>)IS?=%G:5&8C+Q0(@EP$ * #H''A@ _CP0TJ=^>= !L"0A B:
M1&QY.R[<7.V\LTFG;[>I+@:H7W;4@I()M<D/0D<60 ;$PP161YG>QKI2T.\S
MQORPQC>=4.0;6%4"V@J;S2Y5:J4R?:3F71PM[R?D"P( ['UK;7$#RS\TY;AN
MU_2A<W%9O]ZKA[4%!#K/,>!9I;D@J)@$6@V(Z\C8:D6)X50?C*\P/P)*Y1MA
MI,$7Z^'OC/'3/)25AZ;\JC?9OT@.^.]EQMF2&!-JPMJ,1O-&JK/3<G%L5&@P
M89<Z?Q[65BD,HR_Q@\DFI*ZUI4S\A#:L54YH8CY"XF7G%!CE-61CWPV%H'F(
M5S*7".M*S9)1[-RGJI-NX\]/V:8-H4I+M"#9)EB,38!$G2(F0)TP=T@+FJ$N
M%KAF;)':8%!Y#%+3V-6G#9$08 YU8@)+ M#$L)3A\R7G#='HK,F9V(4K"C>9
M6(C)^E)RL+!T4LWD?;_#5CO"H]&K(H:+XGP6VC!5?P2@3T\?V*=TZ+F:&7:6
M'DE7UU@ F'I?0G?GB ( 'T)J4LP54HR&YJ)"7\-J((:1PV(+?=YUIV ^I U\
M8]3+1MZ7=XQ<@?Q&C !@?G"LSRB32 M4<TJPIP0/LE$F2,<L?=0NGY8F:C">
MD^C=<V+]1DX6@(3+0WPV)1&>S(H>]86@3P(+:FZ6#ZC!#U]^/W7Z*^EKU7>%
M8JG7;*UD^-@?SZ.";CL9W_*C8-5\K/R)K&?&.LU-&$7VH9 _O[*GC)Z$'%&V
M81%:5AA/70S:7PF [ =C+U@QAV)O]<VUL)W:D* F"%@PJEFN@9H,08?DTHC/
MW%2@?OLBATAA^G2?[ BH2UTXW((: )4$AF)%:%< C'F#>NL%31Y4Q:-@H8^;
MLK'N!./(F01E(IWJ!TV9>8".VK9A_-AWZA53M,5WS5AS9+<;['1E6MSU!B5T
M_ [DV%4)_B=%/;[ =6T1ER0::>]":W"+UC![L0RKN8 8,2)YM1@0%M/XOJ_P
M !)6<6C!38Y>]^E;+UL-,@-YPI5&I3ZA\Y=V5;9#_I=V?74).60Y4-5B,W#(
M!BR1[$;GE'W6(S)?<$\XD/%F-1&\H[FZW^4AQ!;1B@6U#!+4*X/.6JKOXD4$
MO^:A4R53.ET[;19?(%Q2?< MN],RLU91)$PEA::%VZ94)-B(JFA5[B0-'Q4&
M+VV=M[L6X\!_Q,<>((Q\^4.)NJ(M7TYHO5[%XKP]W.X0JZ5&L*(#4:+^'7Q2
M8^_P0,^05O0DC[HMWF0:X]?PI"M]!2YCK6^L9/ZA$"'7EH="[D/IC-SX+@U8
M,4PQ1 H"\CPZ]AV_^RS+*6GJ=O^W*LZY$1EF@%6E!56-E8W:?AF[ 75F+:[,
M.6ZROGXR2IG9YC;8)G9-<>'-)^H+-[6F3-1>D&T"( ]R 7CDD=_N*3IM#9"L
M7P91!4; =>7JJ[^#X,BG#84)"88VG5!BI#%FSW&<F_+'11H.C-++G,MBK44+
M@81R&19RX&^+X*F3*;^'&W_>1YE)PPDUG_RL?NE+[>]6,6:6G<F48C4&?')
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M9^86 &CTTE):C[^=7<28'$3(Z^ KGW9F,J$OIP6 '@%F.[>5EN5!7X@68\2
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M($RUI&G.@)-CFG3DZFR0KZ8R$:H#@>5^&JY[90-UQK.*5TW8M^,?2&F<3M]
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M<UCY_H&1)3&R+,4=HUS/ZH)@;-4W M-N<*R!D$1A,E<T*("/MX:!F)%+.#K
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M("JKB&3M6MJW,CN81D=OA%KJW>;KX)P3UHCJ/B3<Q(I*"3H^4U2;.7:26:O
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MKS;,:TO+@ 3)Z29GG[5.JI*+5_[WD.[6T%S)-E2MZ?P5R] ?Q+>^\:W54X^
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M/WO&/OY@W<;@P8$0$W__S)X+E3=^=VHYWYX2D(I=#; ]GC8IR=^P2D)D@(?
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M+:LVN/X#-%./#"5B1$TBJUGQ=<0((Y>_NK<YK#UJ=<"93/.88 6][&!D116
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M>,J/W>@H\-!?(3%_/I4]3.?P7H]K9JS>;%I>OJX+]6-"%ESZ7OQ)N(K:PA6
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M3Q&0DLCV>KF2&*'TKZ+HB;5 B!/4Z%%V,AOI]0YO^;7#IW:'%[J_!@,J%%W
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M;;I6FQHL<; H+Z\=9+V+#9JGFTSE_0F0)+VDOAAO-YN2R7* E7"[IT"4%L?
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M2-V 4;/K;QD[-]VE]B9RG:L,GO;[H+=D\Q?1YB].(]SA#,96:WK8LPEQ9-H
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MDXVPNN$GP##)MX-V&./(F_1"D9HB84J9#K?LA</, :VQE$'#;5]Z'U,?994
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M[.3'J^:/.-3"P,G_,MF9%Z*5MR_:-L^HV9=&;*>?@I'^J2-!12PD?W69YB?
M0*#REMD8=+M427(!GWZ-Q+T20J&LJ4M';1.)MP=AI9W# >.%P](E%VB\[04,
M=!VMM7'WP^OUZY;^P"WZGP""Y86&^$&R/MX,'@=IE0(FI.MM\,ATRY!1!I=5
M."ZUDJZCE0NV ;%D<U*&+_*>KPCU13^:#<.Q)AKF#*?SY+N)/8F\ %S)SQ1;
MR6YPN.:JH:9W3UL&P=PZ#="&;O.*)"I'L6!2PE%.9.^CHV[A33 G?9$G$"JW
MRLB1LCY@WF4P...UY:QDX['1[X-X3<E6J@A/JGYZU-I-BD+THYI53[?I0,9
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M<J[\RCS!)GN?\0 A$F_B1*[UT2BL#[$_RT[!JJ$UU-U-G/%*MH(6CFVU_!<
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M/A":QYI2SM7F55FGL(%)0<Z?E,K\BY?WLJV.PM^DS[[WYJMLZ\S!B4"!5D!
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M@/\E8.N_S*":>0E@CP.&-0,(V(.F>P(K3Y50=LM?@+%R"]][T#C][%H9]I@
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M2%5!KQJ59IY4[Q&*Y/G5>);%ZRN.E=(M$6PPQ'#103A[G],&*)@I)N=3FJR
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M1\$0MI4_;000]9$8"C9J2B&D!P;:7AU<A5QO*'R#\6T)P$_^B'%E4!F/8,$
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M_07 V+J">8DG<(/XNU6Q1+\ 9FDJP:TX3<)7OP!OG1,+*<HS]-*C\6GS B^
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MHU;+86QM+(I-Q%"E4GN-Y!=$5:>;71;=_5YB2(FOYE-6UWX! BO?^+6]-D?
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M*;,-EX%H0U",L0?.IE\?:C;3QAZV$Y*<I+93S(C%(AZ1"&1?Z9*CFC/A4V2
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MVJ%4_UHH% M?$U8."%"]ISN-&H;>L[JZ:A+E'Z"4VC6/R4<.JE-[QL]\:H'
M3Y;0F26<O>_$O2LY;^*DK5/,Z$X4\\8=QRYB7F,/E4;C,'A96O4;LH[_ ;+
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MXM/W\X]R;H3 [V/D=<4Y1YL%&K@#-PVA96G<^9[+95S; .<J(M/F&?.-LU\
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M'A92SBY48 R7!X("V'RU(<J$$+I7.B,1]V>GXL]P5E.OHR?,+9<<\CTG>B2
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M;PY7YP?YPJG@+1%#51+M-9+=HIYA"G&Z0'Q8]8]YV-NB0")("[39F4,@PE^
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M B2Q5;5C5S.\.<4"IS$[#Q[+_6Q]<IX$IG^N*3'@V*0<063VN)H15.7BK):
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M^UA1:N=B7Y$)PCZRBHV#QEJ.\?1\/K;T'!509C\VA]#[]U*>X:684I%W@E,
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MPMUI0P+FM4$^+.:)^ZPZ\>D$2',67.1(PF-!3+5*0]H'^@ ,[_X9FB^Q;=R
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M&_[[P_8V$N0M'EQ@P18&67#@52?4?SKYUE@??VF3=\#T0(I-@GH^W><_7:J
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M]9*J4JR)4N%"?E?_=I01_&5Y7$45"P3^\9&>G1Q;F1M3*\,Q+U/#-FIDY./
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M/2@4/[<C&?Z).]7&4*@,=7BA1KA &KLZ2E T<BRBOJ@S"-&Z&!D86,B#!H&
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M4(!3&P<''R/21 ^W')\-WH'^1"1,>ZVR.RX41&;Z_/)4*HG;;IT-B8R.H^E
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MLV-0#*\MY0$N0W[.BK&?&22V;(7?6+7U75*E,^091,D)SNB#]D-B1J\A< J
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M+].2U)+D5/""4H#5)$*TUI_:/?ZY5.K49*ZH'S+@!G>#. T .Q%V^(O>%9?
M;MN9O'9UE].3VY39,X%6I]X5(F-?W7P=*$CL&HU  *'A#6EA1JKFMIVDV8.,
M0I1:7#4Q<T^EW:D!/4?"C_T68@E= -4][ITX^9H*<5IWT=]X*K60KZHY+%7/
MP18V,O*+JG55RH+3#L<_5Q]S-1NS%B\^JID99%GNW&;[Y%Y4-T^L!9;EOZT;
M;.7- 4B&-J^^M'R3<E H'FATE-86Y/)B7XB6O^!BI"FJFWMX^Y+FY$Z4HA:L
M7SI34_"T\"VRL/S]J LB@G=%6\UO?:9Y?[9DL&1HZ'Z'C\O21=?*L[W'0E;J
MK\\W/@:?M=P,-8HBC4W-('08=GU$>P,@KV/J/ZAK*-AJZ-T".*C#369].%U\
M$?ECS4U=LR'$X*2#9,P/J?;<KA9@?%?+IZ/'+S*)39"<09$QA=^HR#".CM?V
MH+2R/_X2$XQW$Z5H68Q$8DJ+J'.8L++&'136;]N_>B"RYJ0VO:7+.:2SXB#3
M[72D%GDJ;\EM&X@R*J^ =SLZ_P$.?1&,^]^4YM?]")N+X!\VO^8V8_1??YIU
MU?V-E_++0?1E)?47IG.1Q$/I(KTO43'-2_;.]>CZ^R<1N$W[V=B9/)80?P6)
MT%29IKWGY4U(M'S!%'J#7V)!.FJ+A+%0T-Z5W8P6J]<[\U(+,H$FOQ;73.[N
MS+15R.E,=G* 2QH=8LRTOO/'7TW1TL[+J&MLD?92EY8PH6Z,:^MSNI8YE?-K
MOOX/.CI/YK$>/XAQG<?9[<''6?Z'U*%KOD_O7*.1ESIQ8^B%U^<O@KDD[8]J
MV),:+)>D2.J753V3MP[VD?XC :+I\S(8]0EN4D%RMZ@1HV"2EM(["J'=37&U
MW+R%!@ET+SSEOIVRMM_=%Z@Z>XY^95XL_V?" !55M,PP=E8)O*JX4+UWM=\7
MR%/[]V@S>7''Z]2:)I=#9+JSBF[.("'CD*#;VCNSI,^^?OO9)TU"X=7-*%I"
MPD]*;_ KQ#U=LK\)-5=Q^W>\-WL1 +V]:L[;/$:>6I<C=U0@97I"I1-9+2ET
M-RZA$)Q*NVO))"9.E6Z!VZ[B6#-\2.[+C__&*_CYX1G##FN[%-%"^Q!B9@SU
M]GNK,$#RS1M\8[K Y4OX+]=-1MF\J_WEL;+6ISI>MC\>#05XQFD@GOH,;^Q%
MW=ZM;VXUU6?P4SE@E*GOI;L!2UH:%DQCJ*G"Z2="P>1Z+?"AM]XS+SM56FDN
M&[:;62)GQ,:MH8LSPTG&-OH6M-]> F9)<Q]-,8]&L(%[3:P^<"S;??BSZ7O=
MOK],MBS$+"[)5E:YS*XD;S](7=XHTTOR<0VKHYL+BHRYG):WUU&_ ;25+YGI
MIOLY6X8K_X4VN]$L)$0D]Z'61M\68GAW@8.<]QGY%$C<2EM%> *@FJZ,8B#!
MO5LR#L)Z&Q*2\W,_>-J9X=)-]LP"V(ES[4X@4;F[BGY%JD6H6JX90+, 6\*-
MC(62=4*2.T\''1;J1VB9'W0!G+.Y-./2-:'-C@VV&"0:U5XXTO 48=].WGWV
MO!.EK:<8/O>P*;;M)X=6W*"["FVN*<M-D"<E! HV=#>R7'(\]4]9IN&HP2QS
MS5?H,/&4:7V:=R\:MG/]<4M(Y+  [U%[GY<2W;-6VIDC P&UL'CSN4::F:\.
MQ3\1RP19B[X^%Q,B2F_U=>F=1'P""Q;0)[>)#K_!SZ6)FT%]C0T%PBG^#7+T
MFX'\=X"6X&(T<-]MZV+1'E-*5=L-[]QZ(U.C:;549%_^T?H+G#;1334MQI)=
M5XR>&87M[&X^1-@_PF!+B,2FOR%Q./K=G46EKAIIH0]NGFST_AO5YNOZQ<^R
M'V7L4]^G%Q#'V/.3%B?^QD.5-#34FK^$SH*2S*RLS-C?./-\5+ L&,X4LTRD
M6K0J[,YRZ2/$!U-&:I'I1L$BYWV]ZPTI#!^M6RZ(R >0A!^.HK9145=S='TX
MP5D9;1"7)?(J2$XQ ^;KCW]=>U=^ C;$.Y7$^^=>ZBNR 7/$N+_4;NO.1CN%
MGZ:592R+?/X"WU2_%3#H)AI<B3,:7'R^AXKJ7V:[&$#,L$C9%9@X*3?ALGN+
MB UX-(]8VU=97]:]++]QCWZ/MINM>EM)&PKKOJ8,'-G4M"Z] TNFCVP/7*)T
MDGCNC*SWBF%J4(4QI DZVLIG^6_Q1D(5"Q8>Q9=&-TU5".2U!U]B!5JP DT=
M(6$;C:$;M6%KOEZ72QXG"YT_?L92-XY?7@DP1O4YY;5A!0AQ.P*$?2MK7NK4
MM<?.;;D1H1];O30\8\<4H[I6D:5<C?0/@1: >;@;2U^AP<%-%5''5^I."JXF
MTJ/RQO,"OGC>*0F(&!HX2?V+'8^4E_'K\[/Z<\_-8?XQ?K.W7W"-6_<"KWFO
M8UAOMF/R"^A=J)96P(YU8+8W]99GBY[-)Q/I[\:Y30%_-UZ6'^"?-9\R;G''
MF\-QE[<[DD$RWGLUB05T0Q2BIIQ4[O6F^2@RN\9GD+2)?^,-N//01#U1#G*3
M^(NT'Y4V:XM-7E%VR#.I,XE7=PM3]1I#LBL2E#?:KK268U;-\4MO$]S-.,,Z
MP3$Y 8\S=F+[$NQDUR:TF"K!,^2KKHT14OT7%))8$<-[41Q5KG[M'^_%ROI1
MI2F:*UB\"1>AB6ED?'T178>'E!6K=$6ZV6'%#]JZ[UP\Y?R5P9HN4_WP:4Q#
M4W(HZ,AZA.Q!Z$/;"6:06[N0TDKX-,K1@@X3!([=J'?F>E1BOR%ZOZ$07?&H
MLZ(\B"STF5TJ+1ZLBA)$!@+MZOPZPGF>I3'O'MSY9'+H;[7P([-+:4+1\ SK
MXUMR.6OS$*(G7F#LE7C<I72S-2 =-K#P:[5'KSZEM;=+KC1-U'*]H=LOF4#V
MN\2S9631EU"AB?O@&,8#JS"^&9D%:.KT^7C!G %T0<XK7ZVRNO(-\_Z#FH])
M\+H=PAO 2" WMX^?]#!\&\?46N%N6MF47YVN8T=P\LMA_#/S=3W;?2:E$R!E
M83KD.+'03*DS<O,M#:SD9*EB E.[4;KR*Y8.%68L/4*C!;B_HKM*3FAK:<-G
M1A_;I=4,W^Q\LKX>P0HZ*E(O3%Y&E%%1K[K6T_!FJ9%)1D&U5 S)VIKN;SP1
MG#7\ A6_\>!Q$( 4:KGX\4*!:ITUX#M%#H1JREC'6$M+5O'7\B>#\:TO/&(X
MAPO@/;,$I^#-&M9\T)J2]@.9\O1^W$M$K[F &/ 53,4N8K%Q46VW-[NX,1S>
MG]</Q"\ZD=D+:7NYOD4#&SJH$UIKG0X[ L\R;)NKONB']49,K8$7G4C3?[Y\
M>D-?\?%P< ]V]0Y<&I1U8F$N^48CA-*(<E,X?(C?=7?P8SRJ@*Z2PI=0)4E!
M7?'=MJ&X]2]I5YQ:813+,"N?CY&*4V[R92F2#[V'OHD*CG^U3K\?MTX+.5RK
M_G!A\1MOHD$YB2VPIB+\$"1G:,:B6]J*J4J9FXYZ+_7G*Q W-^!BRK"FA:+'
M-#1[?^P);N_ 'M&4@X-D(OOGMN0'? <'[-4W:RIJ;A%P(\)"=T%\-4-\D1+[
M%>1W4=P8-"<5CJ7Z]-.XHPQA'],%\ZT 0.]1&\GTRYP4AK!&H%9(R(KBZ\!)
ME?&'R:^Q"6_6_C&*C??*\'B5#/S&^ZKQ38HQ=X5X-_>R*%'4^E:N_H#I+X?O
M93,&6-.IR_E)U8[#[,!)?K$-E]W.6=2T=/\I_35+0OV-)?7_1Y;4&K7%QUAQ
MS9*L7GWO_C>6Q/V')?G]&TN2)__#DD:OU9IGV(5NV 7UL3/6XSC+PQDKX/30
M-W9%6L+4M+KS_,?#P+"-:J]KE=88MB;M3[ F<;DD0-AY'G#_&LJ.LZB=" ]/
M%G;2G "7@NVSC9("$=+B$ZA,3IG3[7WK;:SIU0&#V1%30$RGB=W,"W026RDW
MC2?FRMM]X26/FWZ"A3[ 4CJ#?L\N6@]J.*/W6"AO7G<4!<*5M2P0!@5Q<PLL
M7?W?>5+1^=")_L^U"\^-V"<+ 3Q/L4\.KUSZ< (]-A<1RZNQ$I=6W\I^'5^V
MGO0]=.P Y*X\] R0V#A(6Z^][#H\ZF/PK[EZ&>CEO_QM(Z[!%#5V]*"U@\'E
MO[DE[#(.D,-VD&O7OE54UCCF]DGJNN'X3\&?UXG*S4"]M=QGH%YW:AGZN(<8
M89J9GNS]L".CFTQP[5MUWC-@=;<)K<!)4Y@_1YJ;I[GHRJ27HY)A<MII/AO#
ME)M%1(>>+T+WU8*KPI,\CW,=$\<,#)@V]A9Z5+(>IX&<^CC/Q$G(K+51YW*)
M3,C4T;54\>_2]@"EWT_HX#8*$<]UCYG+$K\7Z0/YC==ZOGRUU2_E*_=]KC57
MWR.@\'CBBU;JU1%3SE[ U_2^&2J276&W*ZW%Y<(3>BHZ?-GWD3=>AD@JES/+
MERSM-;&.L>"#::U7),KZUP9#$^>MFDHX81>K-QHZ*Y-&'Q9G?(O&NO&6FAUN
M"0@RH 1$#.^&8F1ZNU P\@N-$ U"L2=Y4390*2NK9&I<TNW.=IWC(H7$"3=1
M(&]3-[^8>9OY*^7B=O Z@=%!CX6?\[SMU-,9_\_F+W5Y6?%*+1_7(H\4VV_)
M012QZSWG<J# /!9Y\LJ^BYI:X#'NC8JBOF3ZS52S!E=K*?_Q>FK1_%?L8##D
MDS@?MWF?+93,,A6%?;DUSZ$3N_VF?(B0(Y^M!UY:0T0OL=?B.<Z',4)$*)F\
MTW1Q-ZD4*"Z$>7PS=S2%)+;Q/&R+7%88<BXMHCL,_HU'VJ8I',E.1L# 2)CV
M0;J$1&:RF"]'GXJM;>'X5PUEJ:<%0YD+8]\&=D^LFV3@;:P&H^H.B._>J$7H
MCV)/IZC>ZLRO]S@:;/QJN8U<R8/O$W@_%B;!BI'6>X<?8_.LWD=7H(LSC_7-
MOJA1,I*308+BOC4L%.WDLIM%-#ZT9G =+'HSU\HEUNJ;J'S6=' ;N5'1V9!J
MA<EWH4C!CV*>EUWNNF#B(5M,L3#4DD%O44:W#<90@2,,\7T-#JW8R,[F8?9M
M*IAK0B;-LW_Y_,=S*5LAQX-#OD*ERK*RBM#!_C0IOUT0B=#0,S:XQ!HS"HC!
M<%+1B]:^I-C%/M71V*RIQ@\@2#W4?^]/DBDM%I?2:Z?OK#7XXX*,<%(NY9'6
MM!FR+2?X_,>?<O_V[;_N9EW#A6=^M-?+$YVDWWA[N<?N?S6R+S3^W<B>^ZN1
M7?3'R Y<EOJ-5V $Z]V8"BL'%'M&/_F'O&QDV)3KWWC9*/ _\+*-_\++CH@/
M*XD/!3ZN>1VL27Q>\S)9>7+!B/5P;N^P"#OX\N0W'G&?^<DU(7,B[KS6?9TN
M%TTF%&&?KQ@$;-;6)/A7*)8W:B?X5^4;'1K%U&+UU]"'$YV9!L#-RY&*;.O?
M>")EN?<9(:-T39BO,<\NYP#J($M:T,>!MR/'CN%%/-VN/O/GWWZ!P:*9=)GV
MNPK#P\6N&YA(SF05&;0R6CF4._)"7/AJO[^#IVVRZZG4R>K@YY]=)VF7LUX1
M/Y:;OD)H,]7J4D^J2F*%(EIH)Z7#84-DRVSD:52_)MI]66"$A+,E^<->6EJ^
M%77K^3*KD2Y72O LBA@I7OJ,#L'%%^8?RHW %5V6]._@&Y;/N3AVEBR_RXT'
MT4[/O;;+N[WH2-" <]2DAU6I:^+=F" CHP"!3GW 3P]_-@9*NM[/&0] ''Z:
M-<XMP8KX4UIU2/<5M>2V6;M\!8?X0%,7CN WX@XYJ&V.EC!M*-!G6N2"R$PY
M8YDYW-A]MGN +I/@/!<?^,R%-,W0<?]#ZK/#G?6LHQ=NMFZT7^LSHY[W"?AM
MT,R^^-%;T6(K\N0@_8D-K]R-ZK-/*6HPYY'WW:<RK/SH^&I^E^B:U+Z'[:6)
MD2-+8R7UL*)%*%B>R?F/GP>!F&IQ:%2U5J?!IC^Q"7-TMA<&9EE0=_<BYRV;
M8N([="WO(I$A8JS8DJMEZDK4DD*O!_X*K62/]:/#\[EG-;4]D3Z99V6E-_P'
MQ 3)R"A7$B!7W<)\-XE)BJ#J'V$FL.C#^]0>XZWZB>:IQX?VJR:?C5R%X[J
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M3+M! ('(&U-/56=O+91E* IF6)"+PKJW RH.RT\?AIZ4I=:^D8>YCU/"7]@
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M]8H,O.K79KY3@<S@_E(XX"$A1$U_UC0KF 6P>FG(IZT-H8P@JX>"E8!-L[%
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M%5B_*_9*[>>QTF0 9\M 9[E;BONNCBFV2;LSB8[R!G%Y)S#V-UKT,>_$FOI
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MV#D>K=F)]B6YHE+HY(KUX-V-@4"2,.YRK %A20H_J.6MYF\TPRF:(N[D@QQ
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M:W?3^U*:C;!FW.DHPC-&V0+2)T7=<CI)XC]7  V['<,:3AWM%%IJ&N,'5AZ
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M"T^T2P1;T$4:=-P(@%7/ P#COH+&1C6/ +0:-IE;98D+K@6$#I$V BG6\D:
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M$H+*.?)/W_AB4D&A CR!@G6RV;/V6W>1A/T>+*4Q&\->>EEQ],U]0[)T/R-
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M>S$8P@S3(!R\36N!4HA@K_2GH XX4]N[C(T[Z 5K)]T B+&!LC]=FDNG5VX
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M"Y3,D5-%GW TG7" 4IZ-B:2LI 5&HZ>E+AI?48S?&WH DCTB?%6UR [RV]0
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M FJNG]X O ,0WS<2T:;ASX\>U9G2N'P;/B[YN?8M=B.!<_>;ES_:SY.SU$)
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MW16*%54<(*RE,F*)A)0OTR:,H=S\-0,Y^)4HW_KY/A"$T;R.92M\&\S>[J"
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MNP%D9;R;,V8MRSB&MHD,\PAV?\G+K*9D+BH2:Y*C4*4TJ<64.DFU'JF^3WC
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MERMEE'L5< 3@&6K!PZQ7(_WJ<P$U*4F77)ET@D:91LF&U6#;F+DY:8I8]A&
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M L/!F\?E>H)CE"SH(R[Y>)_U$^E9W-H5.W!M\P0IG/M@< ?-99<>HX\(B+-
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MM@0)1T!=/9.88A_C>C30G[8'<2\JN9BC@'?O(UP&5V&T&8'Q5WB1VAT%?"1
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M"&3VL(56199!JLM\#29E7RY%MSVV"+HL6K?*F@\,7\I=%IO58,$6 OAXU6I
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M&11F("QXC\[6R$S4DIRBC(C/ST,8\)EP3CA9SZ^$##BCG<_1WV]@0W1.]T[
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M2_C>VPG(!+987 I 6UFORC<#?I:51KHYCQLWM$6$GFIQ709@G[Y*G+&8K90
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M+RZ<SJZ%]'@9TL H32@W5U7>:+"%ASUFLR2/7'#G2F##KK'*=&1/7R9^XBK
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MB^@2FXTD@B0N! +1R>;OF<Z>4LM=P[YG_[H9_IYOXK.^=#"@Q.Q[+O3#HU^
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M+4UMHHA*&!C@?YV6#V.(0> C? "2X5MDIU-;XJSVJ+D*\*FCKH=_1N>6;DF
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M9FK?G8^9(S,UO+;GDCD[W[Q1/6'B&6)_1_393J@7JM^T^AOE63T!C(?%>EY
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M#K84&=9+:PV)FGOJ:=F'MF2CFTX[-="??)M-N>&W_05UF8A)R0NE4R6;DOA
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M_-/.X]PN.9GK9:6$U)O:%9%8E4=.LB("/SJK[68C*PUIES":]H;L3HR?[@N
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MI"3LZY\X]#L)GY<5AR1)=A=FYVXX%"4]HCSVX+">&I!_5Z&[EZ=E=T,:UZJ
MWBF+*;9AUD@C_C/;2NK3SZN;ZGE%D2C!5F>H&>HQ:;?1PYF+".N@L4]AGRNN
MZ/QWK!2)A=JS6"J6^ !R[O6^V#,-"YA%#H/,MC6MKW?<+3"B!@:5U&0B0W68
MZ9!B\OBM C8!#L-H-$5"^X@9QXX5>[I3",ZB[;1/\#2WW;JA68<X'JX4+JZD
MIN:(YXT<R4 S0@M_!GY\/4F[X-W,E9]DH,VVP;P9;\D09:#M#X"VEJZ+.8G1
M"N-4[$<7G+;%V!_/)MFQI]FORW=8'-N6MU*!N^V$T#_K:;.@%Q*HUNDJJ_+V
M2@:\1/MQ03AEWT4AE_%61Q_PWBL"U'F<I#ZS+D,<W?<N:P?"S.=_+1>39B_I
M'D!IU#6/PM4X[_#4R>$LT>2]V?2T\0Y;C5YVC2J9%)*6BY1"&=S!MI$PSJ6J
M"A([ C.$] R_O>?'1!?>>:03F>(EI C0+'NG6LOJ7+@@&3NUC.\F]@LE;[)Y
M]#/MQ ?]'+IIB2AF]#GK,&L>BZ?YK8ZVD I9(($2D5"R/32GSRMDOZ [54 >
M&I]<D>:T08"7-(&#(TS_7R%3W5Q/KN[\6C'ST> /6M55 MQ.T2\1-&!K?=X1
M_NR^\,U:.O+<!'*CTUE(!=X]S>[38":Y-_#^0+=?*#;'<5%S'8-L_,X1]7VL
M'NFS+MGY10JR62W#/?=7-]Y.@0<C_[/T8L)];^V[VIR?<M%K%7_4YNC$$&JZ
M1]_5YJBR<6G2 *6DI%88VTRT%)6^#)@.#?"H7WP%=\<Y]ASCSW4I6[VD&OP,
M&?I@CA$K\)I]+?J!"XG4C[V\?9TT'[6W"^G_-2#K$S1OFF$ED3D,F5@8W6/L
MTC+_GJS#X5\LO^>7XYG;\9I:MWU;PB%FO9-6)GP%HCRTC_J*%V>PG*00M[=&
MUP610'YS318*:;W![\8C7?.EJ4%/!5>($QQE^71WUGZP.$J&1X*A W+@&C6B
M#*'\C7UZC3DQT<W<UTF3G+C+(C2SQ;$A]#$:WP6&.#K<LW$"L7E5;+! 0J%U
M:#FNO4YFT4T[O?R1OU#*O1;Y2=ID1[4RZY'8I&E*5E!?]X#XE#Z*O3"2E>D;
MSRDKAO=S,3%0/RV+=Q8!^F&KYT]J#M3W")0*\H!,Q.G9<U]]G_K9I*.>F1WG
MNN55)C*\ASB)-LR2\J:=SZURHTGN80G\0KG#P,CJ6T,<D;,#)YA?YM^PTLL3
MR=](\R[^49#^E>&\>_PN</5'?8M0_2E$X/RNWGI[=M?I'"XU&:!"GZC2@M"]
M$ W["U"=\BJ1K]V4_.[*9'/M=]<7H76RJV!T7K&H7?JSY@K\&(NE993?@D,J
MONRA<JE'#(GZ))*ON$X"Q_:X^H2N<!0EP(]Y7?0:/<C4K(ZE!W(;X!&K$MWE
M]BMH#&@NIGV1#RP_DVQNR>OKF!*#[YV'S&PV.[W@F"\M3*5G*'K7'0?; ]9T
MJTQUJ=DJ(0Q*7X[H/9SH>5'8UUJU269?8SH; 6?$XEEB??G^O65^?D%6UH7P
MZT&\<CVCA#VIBU0K!DN;R:44\W26U\DQJQH$L,ON2QA]FDI\GR>,G@<&K;I8
MC"!OYK$S[BWGX]%S6%<)":G8A G@5))_%UJP_2EIJ)7UAIN@BGTKF?:+IJ[^
M<X=RZZ=,6 BJ0!]"]G"@^)=L6-#CG/"VDE(42QPYV0%5,$ = *0%@M2T5VL]
M+G?MC^0EP,6+LU..G^9T^E3%[@_F)]RGV/0:%G=3?SA^3WHZI9LQ:VY!.$BP
M44_%8(,C99ZB.(1CBUD^5T4S,='X;:"5LEW-)^>(;P8!,P5/7#)>:YP\-M%[
M4JU#9Z_8/,9S\<2IJ_1)5V?G9%/W,9.9>3WID0LQQVKDS3BN-*GK6()U9101
M/[GP3C\ULU71;B[W08+AN$:_9<RX_7+K+Q3>\FYL12D(A36^NK)Y9AAM]82-
MT[5]1NGSS[E!G6 I6EIO>5@H[/Q3A/0'/3T4,K,@/7PQN]QWDAH%.'CC[B3%
M#]FFFO;*CD.4[;%P-/ +./1X@08Z_+?8CRBY/T22X @+<):;)S/B55"*O5X>
M['-T6S;4J3D0G QV=YLNF#9\B/WZ0MK@YT<2#-=F-0(%:'E !$275V.1-=\F
M=S=H1C%G]D<)O4^#5T!LN7"=,0?_? -=_:@$/=WTZZ8?W JX>OXM0]CXZO)%
M*[Q60F(.7(^,-6TKN0LBNYZ'37%E;;8$O7VX"MT5FO6G&;\B,NNYC\^W09;T
MWH?UGX#IS"[2\;/ES?4;T)NF\J;V6$'*&]L'5.4KVB3$E:_Q[%_58HU\QAM6
M*P!,MQ $*);:U3Y[GAEF?BZU%L0?MW+ZFHJE8J;\)(HVEF[\_5>@) _(LJ=6
MCPJ<S=,OY_F?);,BD1KJ#08"4NDVB3JPK6-9H=3<.\K/3GB;@,!7Z^HA:DA_
MU";]A3.?B"I;N4I[;W^Y1#1TJM\GG->U?'UUZ"LGWRXLB>:)V3WM2E6\Y*V>
MK/&/OU#2NVWS!7Q>C=]L<T;!F,G&:O]+] [[G&.HOYQBL\-(0;AHGBUD"% B
MMDWE9/N%.L^+(]*D93?Y;%#:\:.BZ<:^KM_+Z9NESMQE_F_4W,8Z;_J4/8ZR
M,UL^.*GPB68EWS?1+^WXV(IG7R,KWJRI4D=<<V![J_$;?0M8:GH!QW?HN[KE
M!:7_C;[KQOHR'4CT5:,Y8O2FUUG7COQIS):%^F/7J&\C1NO%S\AD9>8*HJ9D
M&?;%4U:O#6H^.5+YXS/EEBW;*-=:!>K@<"-X!W><B'?"AJ_$QC[5!%#BV0]:
MI?CU\,[0WI=P:VC(FN:3,,+,+K<6?%]ONZJO.$M.C-_EJ3"(:O<Y]TWUE%!G
M=5!#BRL8F-GW)>? >-_2 %FGAQ-KU^36F1LK*KI.V]LKDQ.(TM)_Y*!_SY5-
M(B'PUOX//CJ&)))XI853()N 4Z&6X#\K!N^DM>_D7Y4BWX6C$%TMB%VW.QF.
MI)O;LUV9$-%G?T3U;EG75LZ)IL\$E R;1P.*-NCJFG'9U=R7-A\2[Q".:ZE
M!C#/4H'*5>[)!%(R>XH_9ILJ7;',.?76?J$4:+\K(8-'U(=DJ].LQEM.:S-9
MP7@F*IVG*;0N7WED.GSW\K$Z@C/8"SY#7Y#%,JD=D'X()-[9X"ODH%**-I 5
M/I'RTOV%PM<I,&K2D/>]W;GPY5)66EHA99[B_E.S=+]L3V60?WJ$"[K5-RJ
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M,"G29827?(@?K)?..)%JE=R6^KGS@0!.I)Q'EU.-V+T7# P>K%]_D# FE8@
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M(SMI;1/0E7J970V4Y7A0G\ N]"(9(X6OUU/=*M&^6E&KF4R\-AAW@Z3%L&A
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M4<96]]G@"9)91K ]?LIE"I4.E4^A@^5GI"?M[NG +QZ2YSWH=2;GI T8G+?
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M _XL&M(@V[3(RWOX[NDX0!7%18HI:ZUD'>-4/_"-0<*"N\$WD.>#B.\9-_A
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M3*^<*E/"^0,\$1/R%0.@9$%:H^JB?3PW!A^3B,[7WT)UR1E.$67[0/:%@04
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M!/2QJCDI>;4P@_&*@PWKM9VTMK+<ROR4)M%D+2.M5](Y$RZE))"<>Z /8
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MT8%:J&'P<7I.-*XVN?*.\>5.BHXT3::QC(!)_"P:&PDZ3^-Z26YH)4*T8FZ
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M5PSDZK]Q2VA$C+! 4)]^V5# F<.@YXO2SOS/W1\/8+=5I2]&<3<D_J+NJSC
M>"BT0X,R8W8Q9FOM"K_@$R;BUG/:P$ACO\%$(ZMXRR"<VN_EO5A#K8%5IC<K
M"Y]!$@OFIP0^-'M!;P)M"S;@G1(8FHYTNC)/*Q$2(:4DD#( (B+2,@D30[F2
M=I;($6QZ*2>\8EIHOWRKOK<GW_#S:!29C!'="V(7M?"WA@EIO),<_Z>9*XV'
M@D'CTR%%43)NQ8PSQID1(UX9)K=A!N-,F''&.'(D*I5[QDR.#*\D]S4,,Y%0
M(L;-N >57"&%5**\NY_VP^YO]UV__>WNM^?3_[F?__/E>4X @3Q6% D^MT9S
M(MBF^*Y-=W!2R%4LCM*?>"[%I)D!X%W*MM9(.7)!4Y@0;#MI@&?I$MY="YTD
MOH3=O.>QG?,9;+3S_?NT^N@BD(XV-Y]9>>9G4Q&?:H-&6:@=9_Q"6C1W*4-H
M"@W%5)WN&PUKF F3BZ$K^$6S,>K$TJ>97?/D9\8D@[KZX69#^) <CRM%O<]X
M-+%JH$PBT^[<)FA9.Q*>/"L5O3&&5:\(4+$3/>/-07RC4V\X9R4.1,&ZC]J(
ML\R/:*I1Y<J4$?Y7N]-(7M]<(,V#4_+U>4IZ:=#3JD9W]2A&\W/:KQ&NH L.
MH5O*!G__YV'N^QEWV_89^8<#D^\Q0+/<$.Q?S[%>/!(VIQMPR/0T.!TT.#AP
MSXH$5%)Q(DOM*,JTHDIW<(\JK$UZ.H0TM69+._V01:NS![@%4I\E%)/,3KZ'
MB2]&P@QD)9[6/'O@K =['"LSY+A98%A8T(NS8Z'5OMP#&8$0 *)P982CUX%J
M^(%3EO]H80O_1=,QWJV>W ,,K.EASDC]LO>/60H[6T'DBU&$MGR!$4<1"7H9
MHJX_Q#M6P&V/ND]0?_*\/]NE\)2WS694:'K>?%< .]_H-:>)M>F_]EH]B.U^
MRH^9#VT7^RW0&(&Z!%RQR VNG;C+[IK"!<I-YS7\GL*\S?/UO&8N)[.+"245
M(3A#_4\!QZMX*#LS?UK_%FG6<O[^V*\X_/U/&8>R VXV8V+W /;1QZJZ-\QX
MHF'@']V)?6VR46"^3!$J.8I4<09ZH\%_:>FVH(KD@9!@L8W%P"@#H_I>6DZ<
M$CT%D_ZQ4:-FE6:*J\*INO14F"_JWPJ=%;C7D2/%#P=+#V?^3=V/SG79C5>^
M>P"#^I\>X0^VW>A[@,=3T?L(X7\,LRUE@JW3$AZ@IG6!S@ %UI;O*O61%*[)
M&&9+?T[1)X[JO4EH\Q>5)N?'%Y;PE<E]4:*95@ZM*VLO2C!J&AF4-7<&UUPC
MS#M.-ZH8&#B/EA4/[(VY%_[G+4FNU9A<Z>WNW#C><H:8U)->;V=/+[-ET3T$
MAL##/)JFUGFTLU@M7:K"LV^0C3POIYD'OZ^%-KLWUVF*QF:X+-@!+S0CGWY>
M7[+=%D_*&+V-Y&,)/MPQ.[U6?X5%=IH?2Q=,/W5Z7\$2,NJ].I9E@2!<T:#)
M?_"OQ="O:X'I51@]-P'%[;2!E?="[8)D10\?<%0%=#Q355(X4HO1M?!5F,,%
MDJL?ZQJ@!TQWYI1([KW9YLLP8:"?&P_>2A^O3%"H<3+DD((;HJ3^7RK@7V&2
MZMBXX*P9=W)0ME_]PJ(M?T:8MR>>1U%>\3"%:_DU[/;1E/*K-6DD%%W-$'[V
M,K&.G16<-?B>1*/DU,N\9?"G9_IZ6O*@Y'K$LG^L0&%WCEU3N$-*3;<*486C
ME/?C&5;+:&1>M#C&+1OY,H^."U1:5[#'OQOK=Q1PH@:(/2E3"34/ >$[.!"E
M'(+4H<W_2KL"M_!,%M'QB/2-(^L'=/Q>$50G92\?-C2&(XVMD!H;H CM" )G
MT.[2\#8#DCH+I?F*N67+;35(FPZS'E$C;2S/\\9:GCIOH?;V,4C^@$Q^RS[R
M].(I3K _;",:\33"7-?9F&L/(,=FHL@5I3+'QY,=C*K:\YO]3B6"[_1D)-AT
M7FV*3H=VX*]/BMOBU'.Z\9_5<7Q]MOI;BJ5?544NC!HEE/&VKDO'[P'RY4H2
M'_A=/QVV'C5:(]B4E+*FJ!5^WXCMX%4C_+SDV( ,K.HN07OX) IM"$<::AK(
M?'[38&/O^QQ4W>IS*$C!,&,+35[]V!+4R[B-U*+?U$?JY<0W.47<1R#P^C"+
M +7&BFRT<B;<.6HR$!KI5;IZ0WZ)+J+ :TS>3C)#$ :?[_11ED[4L;P*X.7#
M\0EEZ^*!EKRPIV%\#ALU@0O 4$M"5G#>.27SR&&?=11ZY1*9(E/6=+F\S3C[
M9<:51HC%XKF>.U,U4TY,HJ<C5P]^=-F4F4]Q44I\EI=YDBI[->"3$EZ0](+Y
M#2TY/=::&ONI+YO;D[&,@4L9>#)5"YC>2'ZI8I<\]A4(8SP>.LX% !P,B@<0
MK4&RUJ"034A&-Y76$R#<YVYWJ;&V%3MLY^%]A*/M!CF.QW-.5.@M'Y=*#9@B
M*:^&!>47W'VTCYQ63/322*G]';Z556O3C&[/$4LFI.(33K%!K1)KW4I-]A@/
M0V+69H\DU_UE!(&R(HTBZ)CP;B?WP'78E.[J2@ZA/<=+<*3/K@E:N>VORPIZ
MN(C(KW^O=%0;8'(XH6L_5=81M'QB8%V!YYM 4TGG!T^"&T-GT+]D5;2VBISS
M,+PJ;_,W9WC2R'#IX)1X5:?'A$'>5 Y8X46 C'63P,4VDZC6^T87<3)%\ 4/
ME:F,<;+'RR;Q@=/Z-G[M_';[F]+0S[/"H[L8#W9,^,C/\V(/9-D?TJRQ:LQJ
MR,3K\O9WG= Z?*A (=3APZ<FT*N#TWY*<; VOVT3-&17-:U3=Z:I;5PY,6G0
M@UY6KO;D KN7:B]$Y>UG.P],]=)]# H67S @K,6TZGOF0*'*S<%8'7U.E*5V
M=6KD5FF9K/)9[]7,KXYVZXO_1!#JZQCSI-6&UT\33*\(\T_>]YHS521L[["\
M5NQ)4OHB=B-UJ(@(DL:@QN!%L8Y##=$A/E%L@4Z\*$:#H-*;%CE%+ESV[A]K
MDB^F<+XLCJ?("@=:D?AO/4"Z_D])X=\@^#6J3Q"DO1.\QK_,S?UD2M3/9V2)
MZEXSC[BKX4E H>*/'>\ #H<XH5%GT.) [CW 25.!KN.PHV67?$5"L)[51=PE
M(K3OJ<NYK1]&7L5PKU8-37Z#8\=:'?%Q%FN]T[!7 7V/,Q(=9-6*,RV:13,Y
MW;YBQ8K0QEFJUUN.$B4+):VD_1>N/.8J.Y>_U&S((FJ^KND2BR!8\RP0<IL+
M<R^%NDJLO85.>A7!?2@Q6NBH\CW 1TS,WL0?4$L#!!0    ( &Y+I51U#%KT
MH\@  !=V"  5    8V-R;BTR,#(R,#,S,5]L86(N>&ULY+U9<^0XEB;Z/K\"
M-_MA,LV$2BX@"99U]Y@B0I$MLT@I6E)63M^T:VY8)4ZYW%4D%4O_^@&X^.YT
M@ Y2S+H/&1DAD<0Y'\@/!P=G^=?_]>UY#KZ(O,B6BW_[P?^+]P,0"[;DV>+Q
MWW[X[>$CQ#_\KW__'__C7_\?"/_WN[M/X,.2O3Z+10G>YX*4@H.O6?D$?N>B
M^#N0^?(9_+[,_YY](1#^>W73^^7+]SQ[?"I!X 7![F_SOU(94T\$",8A01!A
MG$!*4@Q)@I"@C/L>1A>/?TV%%W&:$!C+((&(R1#2.!&0!SSP_!@C%(350^?9
MXN]_U7]04@B@E%L4U3__[8>GLGSYZ\\_?_WZ]2_?:#[_RS)__#GPO/#G]NH?
MFLN_[5W_-:RN]M,T_;GZ[>K2(CMTH7JL__/__O73/7L2SP1FBZ(D"Z8'*+*_
M%M4//RT9*2O,3\H%CEZA_P7;RZ#^$?0#&/I_^5;P'_[]?P!0PY$OY^).2*#_
M_]O=]=$ATY_U%3\OQ*.>V<\BSY;\OB1Y^8E0,5?25T\KO[^(?_NAR)Y?YJ+]
MV5,NY.''SO-\ZZE:RE1+Z<=:RG\Y-MC/9XCO2-YR7U8'PE7JWKB2L0O3&V?B
M/BA^$,,+O#',V2+7+]35@H_U[JZ&.EOTX25V]5HL2S(?X;58#[,A\ES_X)/Z
M6S.,?E 'F5;C--2](:KX5HH%%S5;;CT:9/S??E!_FS&6+V8WRU)\)M\)G8N;
MUV<J\ENI_JD7PFM-[O.Y_FLQ\U%,I4 ("AQ@B @2D%#*(4:>%T2I1P,OFI6K
MUWPF%O"W^U:B:ECK,7^PT+\\\AWGHEB^YFR] C[/#RUK:D73:R#^>4&>1?%"
MFAN4X-I8J'7Y]UI4L)0@VY#R7W]>J^@&ZOE; #@?&#LE,&@DO@ -DK<2-%*#
MZT$1Y8UI5]DE8R.[-?C$$5ZR+?GFVI1;YKM8+5D?K&JVU#=";3![86W-_8O-
MHW[>>Q\N\U9DDK,3T]%<\3-;*I/UI81;[[PV\7OK5BY[OT(UTDJT'\ RYR)7
M6Y4#:FZ_]I<*0%_9%,^?EF2AMBL\*R\?<R'T@R\?U=_TZG+YO'Q=E+?R<C[_
MO"R*3(ESO6!J;U.(XE>AY9K))$[]5&U19!K%$ 6$0,S3  8\3B1"TD<4&9.Z
M(Z&FQOI:*Z#5 EHO4"L&5II=@)5NH%9.+Q!*/=#J!U8*6A";JQDV6$O>8-X&
M7FSLI^SVV)2!/VKM_K\WF#N+5>L-YG"D9<WA7#I:]1QCW;DLNAIKO'73,3I;
M"ZOK9]NMO*\%?"3D97:M=E4R6V2E^)1]47NXG'!QH]_@&4DB=8<70AIB[<J+
M"20D":&,?(9"'"*:TMD7D=/EJ07UY%@V7^KFB,-]J)5LH+KB0FV06KGA7 MN
MQIZG$0Y(P .,U'[:CZ7:A5*%<!P09;_$29P$L2"^T2[4*;YC6"&CH-MM+#C%
M;& +8"TCK(0$-7Z5F.<O \9(K!U$A5*B@D&2@E9Z- _Y67/:SV)>%NU/]#+@
M0\]OO-W_<GJT4=C=6.F6LLUOZ,?#]T\D%^\4K?/WR^<7L2@J2^0RS]6+4"T)
M[[ZO+VDV8)=?2<ZO_O&:E=_U7BRO+)CBMGP2^<,36=R^Z$<4?Q-%*?CUHG9_
MSB3W>:2X!H;$]R'R4@Q3[ L8(.)[-.4L$-B&=,82?&H<5DL'?LP6H-#Z%3_9
M$==H$YX0'B4^2Z ?X! B$7&84B1@1' 0)"FCU).S/<_^GVO>S8Y!_G\Y_6;+
MX*1F<YQ5M=('ZA-9#C:5!AM: _H=;%[7NA\KU2] K3S8T!Y4ZH-2Z0\: "Y
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MNG,\, 5K52Z _A-L:'0!ULK6O]3SOONSK1MJ$$"+ OBQQ>&G"[""8IWDJL$
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M9Z'>ED4YBZ*4<!]%,&6Z!A^./8@)\J'O\Q GR(^HL"I68BO U,AASUCBC<Q
MJ65I+EE/AN'^=4"(A]ZJGJPPVLI?9?95Z8!:A9%JC': -UZ-T4-"3*?&: =$
M5C5&NY[3<_^X*#.>S5]+94XU;3LS45Q]TSEURM2JVE0\O[RV&]DKDNL2ISH5
MKPKZN7S6XLQ\J<PA002D(0D@4G]7=E&,8$+2B$CBRS"V:H#C1*JID60E6@%$
MHT7=RJ724OWCZRZ#%O75/];_M^Q'YV96#?>>8\_5T)O0#7W 6B%PM35O&SII
M[V"KE:;>.FKS M2:.=R.N@3:[;[4B63C;E!=@KFW4W7Z\!Y!1FT=$34,S19-
M-&85=_G?:M/,U;*1R<J"KK?-[<[Z<L$_J1]G\TI>];O79_7#K4M6V=:_+)?\
M:S97_!#**&$R@)A) E$H/$@X)I!('G'L82%CSZ3BQ]B"6RT/(]3Z>-!C-&6M
M 6FDM@CS&7/.NU>&*<_DP(O'JO[4AMH78*TXV-2\K:FZ<GMJU\J&]J!1_V+O
MPG5-CQ:#B;XH%B%F$WUA1HI:F]Z+8Q<1]P:SUQED-Z8\X\7MO0'*6Z& ;S%^
MOWWMJ@7LN^_MT-_?S]7J6E7RXRS%J3)5H$R#!**J5ZN?,NC[)(PDPR@05HV"
M.D>;VCYT)2&H1.Q5AK(;7K.-HS/0!E[3+?&RWM<9X>!TO]8]XJC[,"/E=_=7
M9C?U(XX#%*?HJR*KBJN**G7-,GC*[J$3>O</F265M5')#C:$'R06JA]N3K\5
M2Q%&_7CZP;/[-?5\2L^ZT(/UA:^ZOQ?7BSK-]&1K^%D:$B2C0$!"4ETK600P
M]40(?>Y[7AKQ6+T/5C6HIZ+9U.R-2D*U]_@Q6P"^G,])7H 7D=<>;DO']F1
M-BT&/15Y)[2FF#0[Z.QU< &:@A8;\("Z_UFI  (-0A>@QDBGY=8H'3@YK2X!
M&BJ@L0(56 YK84]M_MW6W9Z,=N/6^)Z,VD=6].D)>)XMOFF&Z/VE3U" .0\A
M36@,491@F,:)A RK'[#8E\RW.FX^,L[4%M*5,;YM=MOOWH_A:K>9.0.ML78M
M%D#UWIL<@6&03<CN6&^RVSBB\+%MQ;'+>^X?]'&JX+>*<1::?)K,BL6C#HFY
M7\I\]1O= >W;_5?RHG_39KS[)!*ACV :,&7SIP)#*A(/,L9X$(DXQ$EL9?.?
M(\W4Z.7^]N.=I35^UF086M!C03RTU5OK 5;B@I4F=3W^'S7^/VW\OM(':(7J
M"]S5,'"*K5N+\BR)QK4"78"W9[DY>:@=M19Y.7O(2MTS3#TT^Y+Q5S+_/2N?
M[L2\,AR+I^SE85G7Q_VPU.G*,^IA&21I "EB!"*?)I#X D$6!3X/99@8Y@;W
M&'MJM%F)KV/ U@J /VI1#<VR/A/039X#PSHP5?9"U)C\SL"FB^K48S=H3OUK
ME^+ZC#L*H9T!2$M?YSQB(#_RT>Z&=8M#-:K.TE7OW8UZ$YN/*O9BG\B 0DZ%
M#Q'%%*:1/A8.4L(\/PQD8%0_?T@AIT9_=?=1+:HEZPTZDXZ\LP//S\ \:C,U
M[CV;9V WKI.RCZ#3\C>> ;6UZ_"<L7I$,M\L2]%47:S;,N@5IBC)?%X)H\O0
MSCR$E<%)!$Q\C!5M4P^FB> 0Q1Z*&!8))D:%P$P'G!H%UW)J@RG;D!2\*%$M
MPD)-D.ZFU2'P&Y@BM;1MF=:+IGL*N)5@4V3PV3V0%G&QC@$=*9[U?&#MXD\M
M4.J,&S5YSGCQGA9:;<5IVMS7S_[689\+ELVS)H=EE;;X.5_*K/RT+ J=Y](V
MLGU8K@ODB+K!^"PFL1<(QG77;PD1BF.(TR2 'F*!AY OD\2JJ\/Y(DV-V+<U
MT@2_3@6NE0(_:K5^JG/25AV=RR78U W\46EG:9<[F&$S*WS<>1MX01EKRJSM
M=7<H.[7.'8@UJBWN#L9=R]OAD^U;"7Y2[\_\\]-RT7;$DT(9S5'(823U29G'
M!<1!XL$$14BD@>^+R(B<#SU\:C1;R0<J :U;">X!U\UYY\(Q,'M9(&'52O"8
MRKU;">X]<+16@L=4V6PE>/2:?K;6^USPK/Q(6!7HWGBX(B)BZ=$$QES$$*4R
MA-CW8N@G*>*1YP41MO)5'AID:A]J+2-HA>SI<#P(IYFI<BY( W^^UOC8-WGO
M ,!M*_9# XW;,+U#U;VVYEW7]BS,4J?'M7DF), R(ERJW5&((/+5HIR&"CD_
M43\/4"Q2;E=A9>OQ4_O0:^DL:YYL V;V0?>'86C??9VX.T12S6&=W18$V1YB
MW,H>!]7;*]%Q^*J^SI"Y-L(_D[S\_I"31:$>J0\]UZ74PQA',HRA#%(?HCA6
MB[6'N(Z>H"&B4>JEJ9VKHWO J7W/C;R@$AAL2MR[]OE)S$V=#^Z0'-RU< Z(
M/1P&9L@X=@><&'3DS;X9!/M;></[^M'-ARP7K%SY!W0!S&(62U]X22A@*(G:
ML"<1AFHCP"!6!@(G./$IL]H/'!ID:K12RPB6*P^;^*:/+&U;&A[$TXP^SD5I
M8,IH %J[(-]W%NNUYH@N]9WRPL&!1N6"+E5WO__.:P?OEM6T]5;XBQEEU09!
M;1L(22 2'H'4%Q(&BBMBYONI'].!>F1MB#$UWE O63189ZQ-^,U(9'A0!W<;
M'NN"I:4%E;AOTO?J %QOU>UJ4Y2I]K@Z -<9G:T./6W:10-FOF "^22 B< (
MHC!ENJ5@"D5*F?#3)(V1VP!01X)/C6 W4_Y[%; =;<;-&'J*\S@PI[]=EOZ?
M+_M^D+5E-.&G%<OJ>$K>*C6^YXI716_]OLS_+I?J.[Y?ZAK"U;.7KR_7"]:V
M"D_4:D2C".IL5HA8+/0RI58M%'/?5SM]AA+C@-=3HTUM;5G)"U8"@TKB"UW=
M\B\6@9HG<>Y>')RC-S"CGP"N3VOQDPA:Q+FZ1'*D(->^KZ)=:*LI,)UQK2<?
M,EY0JZD^6Q&MQC?UVV&T54<O%WL]Q73/C?FR>,W%@_A6OE-J_'U&)0L93S!,
ML.)>E# "L<<9Y%Z 8^(E,0FLZ@C8#3\U1O[E]O;#[]>?/EV A[O+#U?@YO+7
MJ_L+<'GS =P^_,?5';B^>;B\^>7ZW:<K<'E_?_5P;[<9L)P<,Y-^.,@'IO%6
M\*H,XUYO1+ 6'ORAQ0>5_ [/A?H!Y]0TMA1A5 .W'SR[9FK/I[QQJX@[79C@
M5OY6-!?/HH"$RE(54.)4EPG GMHI<@R%#(,D\3!6/&ILJ XIZ=0HM9(/+B5\
M+433$^*-*OSOS:F!43R5F1J8B0>JV5_/_:V$2F=@$PDU_-R_43N'<]Z!/W?_
M!IMWX>T:-AR;G]$Z-.P)\.=LR7 ,Q\%Z,!P=L(<AT22FW(F79:Y/O7];D'GU
M#FI76ZY^J/YVU<1GS*BG4TJ8@%C0 *)()A!3$D-"O" -"?,#9!3.:CWRU!;Z
ME8!@^47D3X+89!I;06ZP;@\%Y-!'%;788"4WV! <K!&^LHH.LD?88G4<"NF1
M5CMGB-NM67U0ZUR#K!XXWIK21\^M-:+7 WIP_J]"-WHFB_9<0A+&HDC"*-3E
M-U J(/$X@8+[-"2*URG%QJR^_>RI\78KG067[(!EP,?](1B8<5O!^IP9[,!@
M09K]X1B)%D^^%'9T=UC?3D+;N64\RCHLZQ8I';FD;\I%2909S-O>J<W;%*0X
M$8P@B%-/,Q#5#B?/@RD.9"A#G"21D<.I>YBID=&/ETR]WZ]U>L '(3.6E3^!
M5O95<V+;!(N#")MYU\_';6 &VP-G@/*ZW2 XSILX.-3(V1)=ZN[G2'1>W3,S
M0M!R':)1U;0G 4U1XDN8)DSM-&420!(G!'I$1IX0B%)FE7JU/\34V$!+N!%T
MU:M#P $@S3[\\^ 9^*.W1,8^'>*H\FZ3(?:'&3<5XJB:>XD0QZ]T\8&ONS$Q
M01F)=3WJB*EUGRK0* Y"Z N"*4XP\R,Y^R)RNNSWG??JH[0YWG O=55I[:6M
MM"9U$Z,OG4V,K(#M\]5/L>G4SJ=_L='M:>/(?"@J&+8-T[&QWI 43K8H.G5Y
MSTHIR^?GK*S",R\7_/URH9T?8L$R<3!2A$@DO"BE,"&8*-L@""#VHA@F+$XQ
MYB(B/K*JH6(U_-3LAO>W-P_7-[]<W;R_OK*,T+'$W8Q4AD-S8*[9$+PZV=L2
M??@ G7ZXN:W>8B?"N'5=>L&S5_&EWU-ZYC^Q)\%?=77]2S4.SW0$Y!=1]0JI
M3O.NONGFZ8+K^G ZK/VU;&K(M9NKSR*OHMKKLHR$>U@FB;*3F-X2A55M-Q;!
M),6,>$E" ]^J^[E;\:9&BZUVNI;CIGY@K2!H-:R+.F[HJ&]:>1B4FG6Z3+^"
MG([? C,2?KNY'?K0\ VFU3Z!:1#TW:8IN15QW&2D0>#=2SD:9A2WI8K>?=_\
M3>7PX5&2AKXOH>]['D18_4%"@6$<2H_X41)+WTG1HOVAI[8$;%?>Z>-/LX#=
MU,$^!)B#.]TM<'16L.@X)*.4+CHP_"2*&!V'Q;2<4<<3SFKN6=46J$^;6!R*
M(.$(T@1)B)(0P50@ 1-*@L C(46AU0Y];X2I44U51>/3TC2PX#ARAN;=.7@,
M;:$U'3,KU]U@S2_W51^BH>7&*&_1I')?R2.-)P]<V.]3OEZP7)!"?!#U_Z\7
MEXPM7]5V^4XPD7VIMB"(AB%F20JC2/H0"3^!1 0(2BI\]9.$<!K.%N)1<XS9
M]VTRK-$KGM:O^.;@P[WIK8P@7PEI]_D;H6W&",X0'(<D6G'!CZW /^E*$BM$
M[TXC:LT<-A Y)1.C@4?E%QLH=BG'ZMZ>NYWM^/9;6L<<7"_4GNM)5WSXN,Q7
M9=H^:2':&/GO,TPHIT11DF0LA<C#/DQ1S"$C0<(\2:*0& 4S.I!E:D;*@>PT
M0-I<EM<%U\W(5B4'YUH5R]W2&=-FN'T:9S*&WD^U\[#*#@*M)IH$6UV 7.8;
M-2 K=5;I1M\=;L#.!]7MCNP,><;=HIT/W-Z>S<$C>V[BRB7[^YUX42_YDWKL
MYWSYF)/G.Z%KXJNQVGYDE4>KN'PMGY:YSEQZ6+X3Z[OX#$>^'[,HA#CEGH[H
M4#L_&890(C] DLL0>5:1G&[$FAH3ZV.H95MC35&M+)4-V:BD>TKE*]$;7BZ?
M!'A1CP _OKZH"WXZHT2;FWDVW*>./GM#;VZU0F M&VA4TCFC[?RM^WK6>H&U
M8GINJ=BXWV75-*=8N]U-NQ%MW"VX4SCW]NUNGSY@V,VJ,'\:\) BD< DI#I&
M/P@@34D,.:541@+Y*;<Z5[ :?8H$;A8KTK-/@MW<.(S,F6 '!9=@#Q.6,VAS
M!3L)IA>4<ZKM0K^']$A[7!G.UPNV?!:Z->,[H399XH,:][+*N"^RJJYD5;Y'
M/.;5B>Y*HE*W;LRXR)OL?1T&R70M96V*/Y+Y]?,+R?(J9'JQ3MB\K1/$<S[S
M0A1YD220,C^ B!,&TS04,.&Q"*, !S0@QGF6;ZS,] AY4>89K6K,J4VTAL0B
MN?&MWXQN_IZ"B!-:#M8ND1H*H+$ -1C@ U#B@TNP 4CUDPU(UNM'";9  5NH
M@ H6L,:E>LXZ27X%S9_H/;/(VOT3O6\CI0G_:=X[NW3EB4QT9W[T6\LX7D+V
M6VNZ8Z--2J:>+7BRA;B5VZT^5QOM=\L\7W[5S7Z(^NKU043D>X0$)(5IX'L0
M);H8!DH#F$0B]6*>4#^U<F#:#3\ULVHE("!?2#8_=?;@8@+,]K+#P3JP]:(%
MU[[!G::_FP[$->BM_ Z[\/3"S6WW'3L1QNVZTPN>O6X[_9[2C]]VPXW?D2)C
M,Q\C[DN/0.FS$"*UXX0D23PHDDAGD:0X2;D-C1T<96IL=2/*9N\'U))5GX\
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M1E+Z-$"*5'P/HI!K7[!B&QD2FOHQ]D5J=/9X>JBI&81*4MB("LA*5LLHO^/
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M,[O338,QI_;)WU_]\NO5S0/X</EP:9OL>!I@LZ_?,6P#$T(C+5B).WQ#1 N
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M]69Q=FMQN#S.7IH>9'+V:^'&Y>#;ALVFS]-U5^Y088$U_0-6F2/ %&6 2"0
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MD&LO3%4_HT46G^5Z4E6RE$)*0 21 '%$ $M3"203BM(<*@*%2X:P2'(Z,><
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M;N(15A_G^\],YWSZ8[:7U;!(<R8K;?>EJ:E. 5D.*(4,2%DQ28M<(9*[$%P
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M8QJQ><6/-DR*D*7\+N>KZ4_9E#_Y+-</ZI'^-2&<,5A)!?3F"P-4201PEA5
M9KBB3,F<E<@EXKVG+R?:&"#$_4#4UA/"C2WZ@+5CBT!P16:+0Z0.2B7=)<:-
M1)LT6N*[DVO!+W0IYP'/@"S@"LHG??T-RB<6BA_SB<TKGK[\5 \P79F(HCK5
MM"IAQJC$H.)(FQXX1X!FV@B115H@07-9$J=0\Z/VQV9N;,5S=,\_0LV.(&[
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MQ1R.WDNT*!T/=^46$[>#"[JH'?EMB;XL%UQ*L?J@(3E?ASN%I8GDU8MW458
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M%]3T=)5A4.O3$Z!C ]2W&;\%:)M:X-UTQ6>+U68I'^5?ZS=:L?^<<((@PZP
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M*2SH@4/%@X@V<'AY2#A/0]*#MNY9F7BQK"^)UUO/Z>T/N[12;99_EB/$*)5
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MC7A'8<>0_Z&&TXXQ7V.0 O-I1Z6HJ],L.FAEAJZKURQJ-)N9>E[[RHWYH-Z
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MD<!SW1X,_T+I1SJ'*8U>=?$ZQ="/U.LM?W[\*[]I:^(PJB.)QJ&/2)F2-"6
MQR4#L! (D*20>FT7%!&BHQM=INYY%U.;OO=G$KD H]TLO@^<P#.YPJ5)K#&X
M8V2_[H/.Z O=C#JK^]4\G=E7?NF;*N+G V.;YW6=O7BM_F2&.W950,1IB(Z$
MDE%$"8AYD:NYCQA 4E* 11GS#!<%S*TJPOH*,#5F^"QT6<;52]1J$1VIX9HC
MPG$\[$@D),J!*4:)WHOM;IRP*E_T!DX,X2C$R&DA_" Z3PKAV8X;_>VV^\5G
M[0UKRG5RD<>Q1 +0DBE3A*(4($&H]B0JB(P%I['5B>=1JU,C*KTI7.[V2WUB
M?Y26VZ'DZ3%LUZG'&XP1C \/'*Q)XZ+>UYA /=!A ?6O4P8X;G&4:7U1B6:N
M7O[2;_\QWQ(N'M:\VMA4,W^GU]3E#VV[5+-](7*4T9(F )6IFJ!(QV-D10)X
M3G NN"1J]KIL.JQZG=H$;N2,6D%GT5HX;C#L +?;50P.8^"I?P'!L!L')X &
MW2W8]3SJ%L$)C--]@=O#@Q=,_BCVBRP6*>9JEZ#H)@,P1A00(A(@2EX@F3/U
M@9/E<[V[J;%/9>DOVX*\I#;ZG1GH!LRQR/(2$0PH5N!"6!2 ZE#Y1):,Q 6%
M#$N7R-L!81ZIYN(CV6Y?3,:[)_V:#XJN';$/AUE@1K]5+?KCE9=SR+K0'53&
M*@.MNYQ*U>>.^@Y%GKM/^3'VN\V&_URN5HM4L@R6$((<2T4:.9> ,AVS'Z<%
M+I,4*9)>_!!;NK%EYZ9IEY>]VT&X=[Z1S(T7#E#9,8"/^H'G^DV]G2?TJ9*#
M3MU#XZ-.TE.53J?CV?>>]4WX?YYW^SKVJZF&)]2$?K]FFR>A"^#--Z[);ADG
M#(E4  $1 Q#3#! $M1]:%A<%3QFC3C?"(82<VK:LHZ,.E]PV6NIMF=JM:3WU
MY^O34LZ7LAD[%HH*\@[8L=-KCVQH._5X4 \*ZNU,5*G8%"S5)4HGD#PYY( ,
M6TPEA*#C%E8)"/59D960?7FZ(S0M?] %O!XWN_T"9FF9"8R!S @",!,2D(1
MP$J1YTADN$#$R1WAK(NIL7X[KU>F2)WXI;,Z6,8G7$'2CGWOPR<P=[;0&.EF
MD99O0(^$7MV']4@X[V9<CX1>-<\\$OI_Z5TZSQSN?2(O)ABJ/?/;/@M^(;U8
M'',%(BX!*]1F$28Y![34Q?(8*FF9E 2CV+%$GI, 4R.'PRGW7Y4")HR15-(W
M3.'HO.0\)I;;N(!(CW65\*D#<NT-54,=-F><+W9#EZ9S$V+L$G1>$%TH->?7
MCAL!JN;6BP>-]%QLGSYLR+H*U'CXMA7FBKJN(A['"&%8("!1(@!$(@>4I<I,
MQJJY%'$FN55)4,O^ID9O6N!(2QQID9M0HX/0=L1FB_5U'@N 8&#:N@'>[1KM
M7BCR#3.A!%5ZOA'1/.IX>J^D->D[0E-QO'Y($W<:9S5MVS8S"DL[ZM20LNMC
M?IO0.I?>)[+=O\RW9+W3IV2;]>[-<L=6&^TSU'I@4DE*G!<,I"E2?!P3 FB6
M"U!(DA%:2L&(4^DTA[ZGQLV?WWYXF+]]$WUZ^#S_,YI_?OCXY>%Q_OZ?'[^X
M[3==X+?;:@8"-3!=UU)'1NRH*W?4"AY]#>*[XH'8H'M+E_Y'W59Z '.ZH_1I
MXCYKNG65>5BM-C^)TO2/S;:B3G.,I[_J<%I.A"@0!E1RHO:8A4XFBP@@,BE3
M7N(L29T<[OS$F!J]?6'?!7]>F1#W@_PFO?&;S3/=R^=5XZGN:5\[CI*;E1T.
M^[%L[:[CXS'^]99+JU''%(9QZ+L/RR"VMZ,HKV*!^\'59X=[MN:;UD *9=7S
MZL9C3GZ]K4[0_B[60B[W"P+S3.80 \@P U P! @A$,@RQA@F-)5VE5TL^YL:
M)3;B'NZ:R2^_VXA;.-MQW8#H!2:U W#U?:Y.X5X+&_VM%K>_0J5'V@,K8 ;.
M?G"]SY&3(%@!<)X+P>XQ/W)YOU9[/<U?7\1^OQ)U&O>&W9K#](**F D4*YQU
M0B:=U1.1'(,8ED6!4)RG KI0C%6O4R.:@]#&Q^6'V+[H/VJ9W:C&#G4[PAD<
MR\"TT\+8$?AH8S7X38431(,2D%W/H]*0$QBG9.3VL&>6%K']L63"ZOS[XC,3
M>MEKN6Z?:KNG&;FD\;!91HYZ&#?)R"7ESG*,7/Q1WSO71?Z#^NOWWYI/U']T
MF9K??_L?4$L#!!0    ( &Y+I51\%>3]AX$  %/2!0 5    8V-R;BTR,#(R
M,#,S,5]P<F4N>&ULY+W9<EM)DB9\WT^1?\WM[Y6Q+V5=/4915!9ME*1:9'9-
MSPTL5@I=(* "0*743S\> +AO6$[@!'/,JI@4"9[CRQ<>[AX>[O_Z/[]?CG[Z
MEJ:SX63\US_1/Y,__93&81*'XXN__NFW\P]@_O0__^U?_N5?_S^ __WN\\>?
MWD_"U64:SW\ZG"8W3_&GWX?S+S_]/:;9/W[*T\GE3W^?3/\Q_.8 _FWQ1X>3
MKS^FPXLO\Y\88>SA;Z=_\5EYDI@ Q9T 88P&[ZP!IX5(/D1*C/C_+_YB$Y'1
M:P<J,PTB9 Y>Z02114:H,D(POGCH:#C^QU_*%^]FZ2=D;CQ;_/.O?_HRGW_]
MR\\___[[[W_^[J>C/T^F%S\S0OC/UY_^T^KCWQ]]_G>^^#2UUOZ\^.W-1V?#
MISZ(CZ4__^]?/YZ%+^G2P7 \F[MQ*"^8#?\R6_SPXR2X^4+FK]+UT[.?*/^"
MZX]!^1%0!IS^^?LL_NG?_N6GGY;BF$Y&Z7/*/Y7__O;Y^-XKPW0RFX7)U7@^
M_?$EN='\2W#3].<PN?RY?/SGPPF" PE?/&C^XVOZZY]FP\NOHW3]LR_3E/_Z
MIQ"F8R@:)GSY^O^Q_,.?;ZGX.DTS!,Z"ZX_X@]7?E[?L2E'Z/D_CF)8\7[]O
M- GW/C0J$I_<_.7(^31:_'00TW"P>.J!G\VG+LP'T0F=)'&@(_$@G$A@G3$@
M!5?&$<N%5/<%4!B8(0<+!<U2^//%Y-O/^&!4%*/_%.5;6'Z[D,ZC5RXEM1WM
MUVOR'#\[R-82YW!]"![PB]$"K(X*9.269*M$DF%GTN^^\3[E=[5\, T_3:8Q
M3=&P7+_23<,CC=\']>H3/W]%K8_G$+X,1_'ZKXN%Z4)G\TD'TENJ!LG]TT_(
M=4[3:8H?EYIYEKD%9W,TMVGQR2ZT_N]7;HI/'/WXG+Y.IO.!,L12&CE(GQP(
M&2U8CRP8H[+1,C%)9&< >/#RM;# VL?"+C)M!!:?TG0XB4?C^!ZWZ4&0M%#J
MP2JM0!!BP! JD)\8N6=""Y4[ \6]5Z\%"=X^)+:79R. .)^Z\6Q8!'\-ZL0H
M(5J"94JB3Z4\&.<<&)00S\G2E#O<*1Z\?2U8B/9AL9-4>T;&T7@^G*.)NQ@6
M88SG)^XR#1+20;BBX$@*(*B3X"AG8*C1*?I(B/,[H^*I-Z^%"-DN(G:69A-H
M.,;@;XI 7@C^#.6?#I>N^.$DI@%G!O^7,O!D4#8L,32 W(/'T A#-QF$9AV!
MXT5"UL**:ATKW<FZ">A\&([2R=6E3].!TSFY8!#QA!FDW60,URD%QI*7/(6L
M^>[NQL.WK@4*W3HHMI1B$P@X=]^/(\IJF(?+[,:*$9*-S(PC^9(2$,IY< [Q
M'#)E-&F=<B0=P>$9$M;"AFD=&UW(MPF@',2(*IBM_O-Q.$YTD-&@H>^D(#O<
M((5V#%PB%)*QS,4<G>L,)$^\?BV V-8!LJM<6P+'(7Y[.CV?_#X>&$45=5Z#
MB(:C%T5=R<IHH();1E L*L9NH7'[\O726^2-(&-+H;:$BX6C=#K]-)U\&XY#
M&B@?7 C1XK98_*0L%5B2<=.TGLF0G% I=0N.!Q2LAY"&,Z"=B;<EF'R:S.9N
M]'^&7Q?.M+"&>)4M$"N1]HRLF" =$!.<H,JR+#NV(/?>OQY$&DZ,=B3:G@%2
MK-_!-+DEW=Q1*8-$ITDAW3Y)L%&6;(W/TA@IK-O=W[C[QO5 T' J=&OQ]:SV
M<M8Z^O1E,KX.K'P4!DU7!F<8^LO11S!94PA)IZ1R\H[NGOE\^-;UU-]PRG,G
M,?8,@;,4KJ8(7\K\^7 ^2@/N3$9/AR#KR+^@";\S- /EB%V?,G*S.P0>OG4]
M"#2<X]Q)C#U#X'SJ2E7+V8]+/QD-G.59*YE!"2%!,*O!,Q' ,DLE-=0887?6
M_[U7KJ?\AI.6VPNPD<5_]#U\<>.+M,C,HSO+ X\!J#46A.$H!9(<<.V,5)9K
MDG;W")]Z\WHX:#A/N;,XFP@3#J^F15S+4[L":]3!U6R0:? TL@0N<71K-#.
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M)C>]+ED7Y=C610]9V02":Y1(] PHU]DF&:/D'=QI>N;MZ^&BX>1G)V)MY";
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MBY/XQ4TO2GV["E8F[0%W:;IJ1&*T0Q%E9:G!:-752H(]IJ;?2W=U#-#.4F\
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MO+@0<RVS9$AD3FB061@0BI:L+>>XR2>3J6:.V#I3SS:E=#W,O:G;2U65]8;
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M/IP-M&:6*:0^.^E ,)K1=> !(A,"?6A*8Z4,R8MD-8*H+?3]''1V%GX#2'K
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MI"F\[W+<94T2'8)%^;&<'8B B\8Y[8 8F;*T,>E*1W8;$-G:%:M>_,1ME=8
M'M>O;AID_+URQ$%(H<QH7BTR4.@1JS).5?-JA8UKTMBOH[C_JL<:JFM@X-PS
MG!V/OZ79,X)44N.ZY@F(U1J$Q)5MLBIMQ5Q"]UAP&^LT?=R<UD;:L>VISKLK
MI35@*]'#O;Z!'OYY-9PFY!47V_S'IY$;S]'Q+;=_OI:/#'P,F<HREB\;W&V2
M,N#1Q06)/+ID''6Q3G9G?1J;K!#O#"V3O:BNB6S/^J(<)&NB4=9#RB:#L$R6
M6;<,E,E2$=R#-*V3\UZ?QB:+O6O!LI+JVMW"/PS';AR>%F1@Z(A+;B$N?"&N
MD,.(@@S"<J]\DE'4N;.P.:W]^IG[WL*[4EH#6_CG]'6U$YSFLQ2ND(+WR<\'
M- 4KM+6@)#<H-<;!$J;!!I*22=S@NJZ"O6<(:G)S[@P'CSJ*[ZZ4)G;B3S=L
M%/I+TZY23'XXF<UG ZNRI4QE\,R75MDR@[,8D5F+WH907-^9JEK%(WR"J";W
MVEHHZTHYNR+MO+MX9#H)*<79!Q3MQ\GX I]\^7$X3LCB(1(UG ^RR,13(8$J
M$DJS[8"^K(AELB]/A%#C>)U;X*^2UF2FIAKT.E54$]=-[MKLIUF*1!"4BP)A
M'%IO[@58ECD@E\H09W7R=<9/O4I:OP=U/6ZNNRNJJ6WV<UH,M3F?G+OO?Q_.
MOY0>+"C #Y/I,_6^(G-"I0GE4KA;W3#$E0<J9(G>A<- KDY+IVTI[O>HKZ<-
MNJI:V]F][R[,D\G\MK@C4:N<2!ZR8;@>A0[@LB(0,F<Y2<&\JI,[?(ZB?L_X
M>K276ZNE'93==3VN%QBNI,7YY1,B'%#*'+6. 8FB-&;7O(1;%!3G(>;L9;)U
M:FXV)+3?NP8]^H]=*[&!I,SZTAP$;V/*) *E9=1T68G&4@^*!BL8RX)6:N6\
M/HW]WC+8,S(KJ:Z!!/91SBG,3_/1]_#%C2_29[3+IXO+LN7_Y;CHFQLMW164
MXS"@U2Z_.!C'^S^X\\F!,%9H[S1(8]'=9B@"[Q!K641MHR<NDSI9Q@K,]!M$
M54N!]ZWV!LSQ3LPNVZL_+IA:-<2\*]:EJ >92"XIJ@<- )H?'0(8R0)X;U30
M)@NAZG@<^^6SWU"NVGII&"P-;"*[V0TN>!1<('!3Z?7!LD0WSAAP*;K@A<^Y
M4KJB_L90+5IL$^@;J;*9>5<[[GK:>1U, J-*:B;@%R.$!VNYYDD:I62=F^GU
MT5LMKFP4O9NH\NVTIC[]_,O!R?'_.3@_/CTY.'G_[N#L^.STPZ?/1V=')^>+
MG][G:;V6U&L\M4(KZDUYZ:@%]>GTPHU7_?L.)^/99#2,;M7;[],=UD[S*B)T
MHQN(W[G$GC-G2DM<R#J!L(:!YSQB>.B89YIC;%AIZDP7Y._<U6,7(MX/9V$T
MF5U-TSFJ]!T^]Q\8;@2;M?3@9+DQ+7D&KZ4#7*6,9FN=976BS*XYZ;<(9O_8
M?M1 I$]D=!:(5K7A9[_]^NO!Y_\\_7!V_,O)\8?CPP,T=X>'I[^=G!^?_/+I
M]./QX?'15J,%UGQR!5N^#4\=V?/57<[%Y(K1,-S-$E(3@C.E.1P&7*5-' ,G
M:(9$-#>14!MB'7?N>9IV;N4UO!@/\S"4"O!'+[E=-43ZR-%#ARQ+*U!T>L#;
M8($3%H66T2M7:1#06O3UW&JX&\0\:MC5O6K^2 ;M6A+U#-O-&WHS<$_S6-_0
MX1Z]V)J!>*K*574*7@@&+$H7H@\TF3K+O9ZAN^<\+![^XW8-42&D\IZ""J&D
M)G3 L!+=@S*@3;KDB'%U^JB_1%6S1FT3=#P*PKM20P.'!._<;#@[S0\D]>,A
M5Y:6&8"&0BINIQ#<@I4^ Y="*2ZDH*8.N-:CK^<&Z75@5D$U#0#NMUDZS4>S
M^? 2(YS9@%HE(Y,2HZF,RR5C*&.$$)"X83$XK5BEG,%].GKN7EX'0#N(N@&@
MG$]=3#<=_1\UE%LN@P%10GH,>R$(5+-0Z#2:*'$QT$RE8\$H4Z<R?BWR>NY;
M7@=6W2NF ;0M[H\<S&:3,MTDQ5*O>O1].#^=OA_.ODYF;G1; 7,Z7638K\+\
M:HJRG3TTR#IQKV5*P+/0((@V8)PKXU"$3L002U2=^X_=\=!SQ_-:;ELO*FX
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M/IG^ UW;D,XFHZN%&?YE.KGZ>LN,8-D(23/H@-97>%PMSF4#06@M9)!.K7D
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M>3=+UV?>)!.7 CK^4N$7X?&+2Z5[)@DA"L6ULW4F%SX@I%EP[:[T27<:: !
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M4*LT[@$I;0%F&_T^JHO;1=@-H.7C<)Q.\]+SNMY>T>- 8CUHH7#'=HR!MT1
ME#ZY0%DBJ4XES&-:^MV8*N!E1W$W )B[_MCI_$N:KKZ_Z74=K<I)%W<])1"1
M2S!6$3 F,Y-D\CS52<.\0EB_U_TK0*E+132 J^6:^.#"<#2<_UCLY=8&GZA0
MH)A"4YJE1%.J2B\Y7##9!H9;?!4H/::E7_1T[2'O*.OFT+):33;(S!E%HDW4
M()BS8'F2J& 9+9I10G2=P_.GJ.G7U=E5PR\"9@MQ]YV8.4OCX62Z\M86][3>
MN1F2,''CE;DTB@:B?  694#Q< JNG*K$0"AR$K0*ZR7Q7GU52\C81I63:G)M
MP+#<-[4?;V?6)Y5X26,)71KI2T+ B9@AN1Q%5L'RA\T+JIP4?-RH2+Q:(YBZ
M1TS;2;TY\!R/\<EI-O_LYNDHYQ3FPV_I4YJ&HJF+-!"XYH0)#J0VZ*!E7ZHB
MN0"E#172)NT>'AM4@=0K9+9TXK E,%X$6Y=::AJ"B\N!\0YGP4OD1I=9L!X7
MK$\8>)89#E(P:8UE&('4JZY<C\:6$M.UP;>3?II#WJ&;3G\,QQ<'EZ64:F R
M[@K$&0@N9=P<,"*UI9>GDIH2;SV&IW4N>+]$54M!70UT[:"#!EJSOU^]]L-P
M[,8A'4YFJP[STLG@(_J25."R$&5^*I$9M(E"*)8IK=2(XAF"6O+$ND+1[I+?
M'$!V":!QNBAV\+S3H[3KFMK#JVD1ZD![9,6$ %YK@4M!8%#BLP7&&)4VIC(\
MJ]HYV@-B^NV.5P,_NTJ\B5DD=YDH,]%6?'"MK*>\C+9@MK3#0CX(ZEEZ*QGR
M&*73U9%S2T^__>QJ@V=+N;^E*Z*WU?^3W$$1_'./JU0(OQ;UE>^9BN!Y*5#,
M4N/.1+0"%R@%C?%:Z3L0(J'5/,O]%,/32&7,6H.FMJ3HN =#-(?(6+;2JVST
M/A(%[1;#;X*!=8KA-Q%X Y'7DX4P2:D4I/*0=4G'^7(Q/SD!Q$66F3-.ICI%
M'UL7F.VU('XC%:]38+:)O!O$S$VU9O3<)@?6NN+BHX ,"0*<2T3X[&.4^RE+
M;.$0;7<]KU=@MHG0&X#.XYJGP$P@/EA(ILPWUPQI9^5&$M&.:N^R,'7*$M]&
M@=E&^GVUP&P383> EH^/*YXL#4$Y1H#*S$#8I,N]V0B94)^84RR92D;F;128
M[8*7'<7= &!>JVOB)*1D%8=$0TEC!@_>"PZ>,/Y_VWNSYK:2'5WT_?X7Q,UY
M>#D1MLO>QW%<EH_MVOOV$P,YV8R623=)597[UU\D1<F:Q6$E5]*[7VQ)E-9"
M A^00"8&K>M@DMCF_.\4$\P.@=*0@N@ 5P\4MR459 FTER>>%:AB"P34#*+0
MTAL?8]!M#G/V+!D]:@G&(1[R@;SN#BTWZIE\1*]EL,!+7)]&\76;2P@F<<8$
M*N;;;%XG4S*ZDZ2W+1G=A>UC)YMM4=1(EC/XD#*(9!@Y<9HLM(T.D*N0#-GJ
MY+=K/'NR):,["73'DM%=N#LV6!XO<Q11%4:;-VA?IR=;6>]K$ZLE MQRQ='E
M9\^$3[)D=&]H#,/+#G:?!])WC2W9TR* .U6[KGH'7OD 6)B(Y&D5C6UB[%-(
MAC_$5SF0U]VA9:-$HN@Z9%V!K:/%%..$>$\*D+PHM!L7[4N;\]^32(;?2<+;
M),/OPNZQMYSGD[9E%,*6.AO RCKT*7L(VB<0'"TK(K+LY%9;SRDFP^\DRMV2
MX7?A:P>&Y;'[_1*-=,(*0&EI-XW$G)"8@YKHS6OK>!F/$3>_ZS<9?KC@>3^N
M=P">FXD<+W]L,@5^7-_9*I683^291^ZJ1Y;K=/<H:XUBT$+44ZIV]Y./T]53
MM+2GZ)](J#E0#IVAZF?VR<?\'7^L>[>>E0^+Z2Q.O^/YQUS-.0GLK+R9+B.>
MUR&7DR1<(1UT8&3-JL[<@ \V@^,R!)1DB'7[U+]]*!__:FLH%#T!T.8B/2T(
MOYV]SW^O/O^5S__,O\]GJZ_+2191*R<0<B #H#*2YVJ$@Q2LQQ"<,%Z-C=_[
M9(]_SS8^> \4YJDA=SV4_:_YQ EG7'8%4-<)(:)V<C,F@,_D36L=D[;M,V:W
MI7;\2[P><+J/Z$X2GH2W/"&'W$:+A!]1"@5ED9RKVE0W:%.KY(54IE&_F[WH
M'3?8Z0JB.XOO%$%Z.98]^V2D9N33D/XIJ3QI(L>:A,836A6Y:5-^OA>YXY:T
M] 31G84W]MG@ RO\\:+0PZ]78Y6T,4MR4F0F_B72-\^T A9LLD'Y:-.=BXA'
MS@:??=6XQ2T-8-2 PQU8M">+3A4+Z((HX).L,S** ^<X@^QY1)5<*>H81X5[
M%/[:$P+6X*(8K/ZW>0'5$]D !]92;?'D1F55NZZI\;@1%:(**E"0RA4H-)+,
MD4$@F4NEK4HEM6M]<YP**R%RC*%(B%Y3'&YL I0N0C2*25.RS^88K3#ZK;#:
M!0/;5%CMPO .MKB'*T$46AF<A.+7]M1K"$+[6M>L?5;%J$:S8$^CPFHG$6]5
M8;4#OSO$S.9VN116N'!$MA:1PE61P'.=($IG$JOC#'B[2.XT*JQVD?-V%5:[
M,+T#Z-PO^B':F=;9U4&$%I0/]21.($A#_$'ODI=MNNJ>1H753O)]ML)J%V9W
M@)8'4K#7XW833^ ,UNE@-<^D6 \Z)58DV6/9Z)+H% H;#MF8#N1U=VBYD77+
M&,6!61MP(=;^C9%T2/,(5M+77K'H\!@MNCHN;-A)TML6-NS"]K$/![=(O6>^
M>"N2A.P*!0H2:SU8T>"+2(SQHAB[DU[QJQ4V["30'0L;=N%NSV!Y\86^JGV^
M+H^FSLJ+\_,/\^5R2O;Y[2PN,BZORPQS-HQ9P6H?(0TJ2 5!U;ZR.EGC5;"9
M;9>+.A!!X\"N"4*V15\K<?4,T?6ZZA=X?O4;5^ZAS'5FAX<20P#%O "')9"^
M6QDQZ&CB=G4Y>[U^'']J5/@-(XH.?*]_XF):7=#:[G7M442!7M0HUX:,1+\H
MX)BRD- GFU#GW.AVY"XE_97T'.*E'\3GSG"R\2I4M$+:I !5%J 4!::(=1I\
M-DC!;=+8J.SX/BWC^EV'R?8)H.S!Z Z@\FX^2_/9NH]TP-E_GA6B(J>ZGG=O
M7YY]O&H!4I#KQ!5(5F=,^6#!I20@6V&UESP9U^S0\7GR^@'4/ABX?P(YL$ Z
M0-EC=0F2>>9T;2VC @>5K ,G@H$D77&T R/:?_.I&,,=-NW']>[ 4SVXB2MU
MKHQ$*(G"8U4R!^0B09')6B$LYG*,K)!*2T^G"'N*^.G[UEWYW1UBWF#<!)X3
M:9A,20G06//E*=* D+B (C2G'P>M7+MFKP]1U-/I=@OT[,G[[C#T$I?3Y2>B
M!=/9[.:.SR<F"92*:6 Q,K+0R"$4G2$I%[)-7NA&OM&V%/84F[7 V$"R&?LP
MZ?:BKM9Q<\++F_/Y?#%A55^T=% \!EJ38V2+HP5+G@+6ANE9W"DW>.3X:,L7
M]N03'0:?9FSNSEQ]R(OI/$WCA\N\\NND\DGVM4BL1@O2K7,X);B2(Y3"B](E
MH,EMNL!L1U^?LRR&,U6#R&4PM!TAMY;[>MHZ7$;M(\]KED>[#?UMLV>%=*:H
M3,Z2#^0V*4(&"DX(9$QX"O=]-*<TG^#=C?ZR5WU3+B-=1O%%4E9!BK0\5=OQ
M.QW(ZF9O#2D$>FR30_LH2>.'=@?BX:GFOOLSOX/=[H&.3"P5YGV=#<1UG1EC
M#*!"^E;H=3(62MTF_63/_F;M4MR&$?+S7<YVX7AWF-F<U,:2O)2I@-86:ZXH
M[;O6DI@C2SED(4*C+C(GT>5L)PEOT^5L%W:/'8\]WXW+A!R0B0C")'+:O+"D
M2D8"9\9)7UP=]KI5)':*7<YV$N5N7<YVX>O8*+EI;3]=A//IM^FFB[$,UH6J
M+,$7VJ>C #1<TW),Y#Q*9.BV L=C;QBY)<J@N\QPK.P1#QN-2;X.P$P28JDF
M5=,_: GE-O'BHC22(LN]$3'F#C*@])[#PQZL'!L1G_Z:SKY4Z[:\6L3&S%FG
M/'-^W>=<D@65-=<I1?J6$_W(@N=^N^WCD3=TAH9]9#<?FI&CHV&%LQ1^O,NK
M^L"[++IJ\XG:QZ03F=": ER'+#OC->B8N)$Q1\ZV="RV>-N("8%-4#(T@SL(
M7>[E+'&AH]%(FZJIAI5"?@A).C"I!!^"\RZTS^8:/^^O3:A[$+<[0\M&F\@A
MM]%&#MZI6#O(2/ I!%*IH WQ)+M&>3;=9__M)-OGL_]V870'4-E$86=_YL5L
M^N7KZG)B.VVS=4F?YF5Q_<G;6<I_?_H+O]=/KI+0LDR<PCQ(6'.3LJO]SR-"
M,3KEB-H*V6:2UD%D]P/ ?3#S</'I$038 5KK.<$-ZHUTTM%.#>3?&8HNR/=#
M)PQ4"Q_0NT@6OPG\;M,Q;AP^,)X.8'$' 'G('WAW?8W+7(H*B?J""LG48ZD^
M@8-L@V5>EZA;=0Q_BJR1VS$V\:"&DT.GH'K]]_?I8BVDRQO]"1,QF%@+E;RS
M]:0\@8N:%,^)Z(O(,F.CKLI;4-???=2>8-@"9@=)IE.T_8Y_3[]=?'LY7RSF
M]0SD%7ZG3U8_)JDDF[QAD$LH=5(>K3+("+ZV9#/,1QZ.=V7^&)7]G5.W0]\@
MDAK[B.KFPJX*=JOW&%8YS?)R28KU;;JB;U[^>.(NY_/\9;[D0TYO2"SK";"?
MYA>+F)<3[7.4R4A(#NO%HBO@>?$@;4)BN\M.[GX4WH;6_DXX#H-OCR+N"?%7
M7'XTJ_A%HM\B\>/YYFAQ_3O$F7F<TL?I7]/5UT]G;SY.N _"(C)@UM?2G1 !
M$YG3&)DQ-B1K[Q8;; 'RP<CKS^\<&-?C"+(G*%]O0U5C2:5CE? 7^GBMQLN)
M(S86RS6XPA(%BN0:8:C3=K5&$X5"SK?KM;+#2T=N[=T>=D,RO2<P7:O3S?6]
M^!.G]$?K#R84+6HI>(0<$[%/)P,A6PY:NJ!#B>9>G]==[-UCKQVYR?<1[=@@
MC.\LQ)D4'84,VH% K4"Q7-4ADW>,(C'%M7.^41/4&U2,W,_[*"'*3IS>&R5_
MYD68#X63VU>X9Q>K9;W;_=F07-.2BHH)DJC=6U)($)C.!'XM"_V(MN5&DX&>
MH6PK/+D3Q-.0$NG,$EUQZG)$7#6S]X)X&U%F8RT4AG*C08HC[>1.>1>2<K'1
MH)^=Z-P*??X$T==.6AU@<>N:5D$L-+40K80ZWZ'$"#Y*#3HK&4I1SN1C])H_
ML-Z8L],#8!,1=0"]ASCVQ^QBF=.5,KV:?_LV7:T+^O.-H&9";B;%Q,:#U[2\
MVIL2O)<<4O92$PNDSOIH%G$KDK<#YR]R&3*\$$^G]O3]?)4_X(^JE =6G3[P
MI$;UIL_1W'A.2T3&C+806;*@7##@DLH@7%9<UO8OC=)YCC>GA><4##,2@D_D
MGSJ,]%6IK=]40AVLS)H=8>_LM[IT%PQL,Z=E%X9WL!,^T+3;L*!SR&2)[;HC
M::[WQS(!MPH9KH>IM<D:V;,5_E%GM.PDWN=;X>_"Z^[0<J.%MQ6I*%ZUR-4)
M)!1[ !I:D=?9<!&%MZ5->O;)M,+?2=+;ML+?A>UC'ZV_QL5L?K&J._YRL^5O
M<NY0*UV2P'HM($ )FR!HU)!BL114Y*+OCFIYY!C]T5?TA(9]Q3<?G)<=&)27
M%\MIO7Y_$?_K8KI<7TZNM26XS+05 C#R0MI"RW!%.D"NF14E.R\:9;H^3%!/
M7>L.WXB&X'JGX*E?+O*5@KF,RD4F0?C:6E_7+HZQGHBI@B%A=$*T:9'Q+&GC
M6J1! + %J/:7QMB[U>\Y4:QP7: ?1>3)UDZ@N1[SAT*D.YE)[,E)8:UC.FZU
M1=U^;G\H.$!B\V'8UX%A>:PM6E&)H; .3!:D'ES6P4;<0Y0JI.(2[=?'B(RN
M">JIS^70X=%^7.\ /#>=LDG.3B0F%50ZB7;O(" M@'ABK":GW_(V?LQ-*GKR
M?O<4ZWP@'H^]K=PX[WQ_44WC6=ET1JPLPO/S^N5RDH6-VF@-5@9:4O((094$
M2.8S>VVBWK+/SG;OZ\F[/0P@K9C<(6YNKN4#3M.D#HNJIYD@;,Z@O&> M$<#
MHI>1*U?WWGU!<_=E/>T\;1!S$'L[V(8^YN^7F%^>E5OF4O(HY?JJ-M8L :,$
M.+*70/X8ELRC"KI->\W'*.JSW?(AV],@O#^-B\=WKU]\>OUIGXO&S5\VN%A\
MB*:!+A+?K0?W_;P\0E]*,!82!<8U3UY!H"T%M+$*DU$R-3JFNDW'X7F'RV7.
M9]]SK2.<?;E\^&=BV4OZK?^<U$D%M!<B^"@(M<IK\$EQ2#$(E62MC&YSA_@T
M72,7>>Z/A/M)AH.Q_Y2,QCIBW"M'X=;?-S,@#]'7QHPXDJ_7I0 J:^H]0(+@
M@@!AI-,J2V%%FRUY&#-R.8YR7>SQ8I;>32^S]*=YN4%RY>-/./,@8L(4@9F0
M:Y_5"*ZH.O^2 "V]DXJ+K=S4;=_8E9W81=2WQWVVX&\'?NI#QN]JB3]^Q]7%
MXJI!P\\ELF Q)5UOR\@8$M<BA"P4.%T,F4<F,K;2EYV)';D8_'#T'4M076"1
MUO1JOES=64:0S"3O$1CCD52J#K1GQ#O)*$#P/$=I&[IY]PD:N4)[2$P=SO!3
M<GE^%N"^G97YXMOZ)0<D:V[QU&;NT?9K:>,TH>.956=8NMJ.VWC"G=)^?76I
MN/6*8:M:J"%CK]L&]>VW[SA=K$\B2 83481!%0(8E1GIEO3@N:,U%IU9-BH&
MVR;R>HJJKORI75!PU_H,QOI3,D&?+KZ38;F<#?\2SW$6\Z>O.:^&-$@[O*.9
M>=IWG8TBO%H@4[@&;F*=82,(2.2G Z=MC9>DC6JDR"V-U<?:9?&L_+',Z^!D
M$HK)+&8+Y/:Q6@0DP'GE0,>,J)CV-ILC6*L[9'5EKG;!P=/FZA#F=^!J/Q)'
MO+I85*[2:I)DB47PY$N"LDI!X,* 06ZU4$6)N[,DFD#I+EU]!7.#8>D@]O<+
MIO?S6=PLR.4L4 D+QDI1LZ\=N0G$NJ)DHKT\!9O:G!@\2UI?L=SPD-I3"-VA
MZE^Y&MR<7OQ)/_V2K\NPUQ_6D>%\0DY0%"I(0)\Y<2_43&X?ZT6 XC&G*$*;
MSAZ[4CIR)ZQ6F!M81+U#L!:S52^X5F!OBELG7(B0F,B0,1A0Z.K(\9P!,^J$
M2?,;8^N/!\$'*!VY*]:1('BHB$XIL+S-B*L#X8-CR:<?VRQ\W&$U;2)&ZY,L
MAF"2A,TU]5J =U:"545C]C[$1@-/VJ<67/L&FZR\Y:6E3C7MZDU-&S__CXR+
M"3<<BU6T9%/[:2;D9+6CJ@.UO",=95PVZC"]-\U=Q9J[(&BGRY[AQ-;!%KO5
M2G^[R.])S3__E<__S+_/9ZNORXE'%C!K!"W7A>-(T1*J ((S[X7VC.E6Y\_[
M4=Q5\-H<G(>*[(2@6=7N\U_S24'N-"L%LE<%5$UM]LY[*#*H6LL5.!_18/XD
MM*N0]QA W$= IX8_ E2>. JB4EK/2Z[E/RP;"(P'B-XGQP-+V.Q.;D=2NPJ!
MCX;!G85T0BB<:*U2\<%#DBZ"LEG7XZ4$3J&G;SA:7D8%7U<Q[S$PMY-(]H?:
M?(7G[:'VQRQMHOF<7O\=:]WL90M0[HWS+ FPJ79Q<#J L]R#+4HAJW5%NDV1
M^5[DCMP]^D@@'$18NR/27R)REK_4=OJ?6U]P3!*+T02NR'9;5^< <PA1>R!7
M5I= 05AJU$OZ$8)&;BL]'+B&8'@'!NV9:SZII3)<<3!1$8><,^!R+6GCSE0&
M^<R/>BNVRRUKNV;2S5&T#_L/M45'NF>U*>D@G0>?(D78B )0I01>1VE+TBG=
MG>/=U3UKNQ[1S4&UIQ &['L_]AW#Y(ZR#';+,.$CW3/<7='U3</_.R13KY.P
MEP=?UMQ_5#/&/4-UFTL9@=9(4B(0$FL->,U@\#$ 1ZU=X2SD1OVD6J;Q705L
MDY@9ZG6I4*FYM$Y'\(J"-\&]DMKJI,0Q+H^OZ.GJ,F47R3]ML?=B=P?G,'<2
M#L\":=TLI[<SBJ^^XNQ+?C-?/.8V&V9$-$J#K,VD5"3?&>N0/)$YVA(*-[I-
M!_\#B.[JNN00^!U+<!U@]/8RZNXP"6AH"=F"+(J!2K5[&5<!2.=B1)5M8FUJ
MM^[3TM6]QW &;6<V=P"43U_GBU5-"?NY E:T8+P4T,S6@;7$"V1,T3*R)Q\Z
ML\C;)%S<IZ6KRXE#@'(@FSL RM68DYM(3TBA6P"'NM97<P<>HP+I0E$AHRB^
MC4&Y1TI7]PF'P.0P)I]&DMR;%V\__O/%NS]>_T[ARQ\?Z;_WG_?JF_/P@QK$
M65M0/%"4]0:GBW_B^47^.9_A)["B4DF8& '%>E@+2D!-__@0-:'!UG9,3?3M
M*:H.-2L//?MG^;/$X*2.A>".%I1"#CYI4@%F=.1&ZM HD>-)LL:-QP;#R%WC
M,YPH3M@0[=^+YZG''<LH->S4\R3LA,W*&"Q@N"#8F:0@Y)B!,0J-ZG987)OY
M02U-TZ?X-:>+\WQ6KM_R4.^9WVFOIM>FL]G'7 ^>+\?T3N]UHV&:"XN>-G+O
M06&=25BLI#5QP;GBZ%R;ELF#+J-CT[<+!N^YYZ.)N@//_GK)+W_<K __QV)^
M\9U6^'-=63J&/"*PXB-YMBF"DUQ 2CSF4F]L1)NRYFTI'/>DJADZFPCHA/?H
MU\O5]%N]R[UFS')>WDQGQ)DIGE\J+CZHN/,9WM;< RYZCD7:L7R'UEP]AA\B
MBS:B< JVA3&735"<3:1O@5Q57>LQ7&,+U3)$VG)+HE]X/Y\M[N]0%!U868K(
M$*W)H%(TX(0(Y,@SC4CNO62-PZE#E]"Q_[$+]AZU\$<5<5^^QWKIK\YQN;P<
M$V=,%,41FM835Z024/OD0> F>Y63":5-HYA'2>H$>\>%R..NR 'RZ@EXE^Q\
MS+/_8S8/R[SXLS+N[>S[Q8H^GL_JB.6UX&]R83,I*$O4EAQ]D**65A6R $[P
MR@SG!4IFK&[3L*75BCJ!_6& >]K>CB/]L4=I_+9YYZOYM^]YMEPO:3.F2F:?
M';H V>A $6RQM P?0'NO>?)D0>YVB7FD-?'C[^@$5J,"8#Z\-'HRK2]__,ST
MO5;;G'D(=20G]P%!J9(!"[- /V6!:>F9:',.]B19G9P<]+*W'RBWGD"XQ?'=
MLUI^FQT;34^Z]OF-"6S,HM[?:T">'3@EN:>=R930)@6R^=(Z,<V'P_ Q@'>!
MB8ZW_^"-DCYK( _+@=*,0MF@/ AZ!/E9F96D?HWMOP\D;.D'["*6GDSPRQ_7
M7_[O:5X045]_O,M_YO.U1M<,%B]4 BXU<8J3;J/4""(49 ZE1X^M'8(GZ!LW
M5[$[SV H2?:$SPT?U\GH]]>W46A5!R&FP$G;$@<EF -$2_IM4_8LF-)J]M-.
M9'9B5@?$R6-0'%QH/2%RO<\LUQSC&^,OM([H4)#^IGJ\K"*$XC-(YC+IMD_"
MM:EP?H*H3M V/!0> ]V!<ND)8@=L*.^N9T-*'11C#"$I%FGQR,"A<02EX#%A
M)IXTSOL98AGC9IEWML4?'1<=*,7EFA^XW9LXIR/+V@++G,)-4>=>T/<@K9)!
MFL*%;%.O]2A)G=C<X\-DWD)F'8!OEUCT+)Q/OZR%O9QD%[3%$BX'O2NI' 2;
M&.UJW$:#*1?5V/;N1O#I'[$. ]QCR/N$D[M>X6+QHPI@W::H9AP]F)CT:?IE
M-BW3B+/5=8[2S^G5JZ^X^BL3+N:K*];BZJ>M&#CIZX@D'RL9;"PI'"-)++ L
M4"@)43O:'Y(EC]TC@C5%)2F4LNJ$ZVC.OE= _-\+$LFT@N//6^4<EWZB-+J8
MVGVN-MY4F2CUQ16PVEC''8^I-#YQ>Y[(3MR<0_'SJ/$?6$P]^3%/'_Y8KUQ2
MD4'RKL;A0D!P.0 /R$P(VL74QJ,>\+BW/>Z&AL=^![J[R*HG!&YU(&0T"J?(
M@0IUA<I&#1YM!F9SDKZV9V\T5^#7.]#="2<''>CN(K2>$'GCX%!L#@Z]+T;6
M8A#+8VW R0R@EP%*-%%@,@5EX_R!^T1U@K;AH;#%@>X^<ND 8N_FLR_TM&^_
MY;#Z3'^S5DC%#5KF- 3C#!!_*%8L*4'(680D'2N->KT\1$TG@7_C+?5@.72(
MI8VF^:A,]+P "DYLT?6TP^5"7J\-R8ELHFLTL_5!>D9NAW:PG)\!SAY,'SN5
MZ#4N9O.+U?OY*B\_X(^J2QMC:G205N4Z4*SV(_"!C*E2'C@&YRW9[Q#N9'L^
MDDGTZ"OZ0L,^PIL/SLD.3,FG>HZ94^7+U0*R,49[VJ5+L=6X&@@AVCI*U>6D
M?62Y36'$/5)&;F@W'&2&878':'E%KYRNWF!<Y]&M3:K7*:!@!' 5;#UB1W#%
M.3"NV"R*2U:WV73NT]))"EAC!^9 &72'HBN]LBD:JP/XVI1/.>*&)[(A:B,3
M9L.5;9,W\Q UXVY6ATKX2<#LP>ZQW99/>3:=+S;&<WTO^!*71,(<KS)NL\S"
M8<D@-*,84UAB3R*_SB5A"Q>^J+MMCA]Q7YY]54_(V$>4\V9\[<"PW#@&NW$T
ML;ZA76N1L\ZLARD3NTHUNP*""A%*\"PFGU6.;9K]/T-8)XE-QSO,/E@Z/8'M
M)Y-JTL'F)G:CFYK[5"1QR0E5RPR%!,Q:U"NI>OA53-2-J^B>H*Z34\0AX/!\
MB[S#9-,!WC[,%VO1_+R9?V"5&[OMI&5)2P-28KWZC!P"SPA":N:UC@)UFZOS
M'8CL!'V#(61^''%U@,2KI)./^3LMDER'-=,>7YXP3J/"#,R3*Z%L\8"N)(B*
MPF4NG"(LM7'M=R.TDP/P5HAL*;8.4'F5^'2C-^#C:XO*%164 <ZT \5B6;=>
M!2M8#"R1TMDV#:AVH;*3\XQ6>&PFL [ ^/)B.9W5(8[QORZFR^E:9NLX7F)&
M3\@(R9-3HPPM(UD#*:JJ3I;KN^?L ^'N$8+&[<A^K,AC"&ET"JKZY2)?'4XK
MS;**@:3O:T<SH2,M+1@HWO# !5+LWB97YEG2QO7V!@' %J#:7QICG[']:[[X
MSS)?Q/QI?GZQ3F1?MRU].XL; VRC\<9:)!^@#M9):(E5R8)1W$@79 [A3C+J
M(T=LS[VI/Z0<(-5Y*Q:/C9=/^3S'51W*=$4]J0KMS<F "(J"&,\4\44QJ.,A
MC4#:I9W;"B#W'CVN7]X0$8<QL8,=:;L-_-UU/0ZQ(F:7$I12:BZ8"1"$J25?
M);!L$O.Q<2W4=H2..W/\Z >R#:37 3CK-?O/(I?KQ4Z2%LG+.L480P(EZQ0.
MKP.PDAUR;B/F-@F=CQ#4R4%8"Q#,AY?(@/-_#TC JSO"6;FZCKM?VQI"2K+F
MN\JL!"AC:$6R)&!!!>E=)IO>YLCK.<HZ.>,Z M@&E5$'YNS*#WDU_Q:FL[7(
M7LUG=:@A,9Z^6D[3>LAAK3*\FH:I),K 0H8LF0?%=8*@D==IF)RQ+'AT;?*+
M]R"VD].N(R"SM21/HZKXT^>S5__G?Y^]^^WUQT^O_^\?;S__QVWZMROT?> I
M#6IOGZ-UH'+8UQ16K'Y<%S"JI"QW,8,1%%RH&.NDFN+ ,%Y\%,$JT28EZC8=
MAX\N)5Y^G9\3J)>;)\_2^H?K=).K\=(_QZ.4E(PK-<4)0YW!(@5X92,(7VJ7
MOMI0K\WX@UTI'==S.P M]\>>-A31J9JC_4?,/?JLHYBFAL/E[D"N&*2-R"/8
MJ%P]/LT0&#>T,S$=O$[6\C9I!@,;J.NI8FO(APKYFVT]/V9ZS[0>U'Q:$?A)
M->[\Y(_9=+5\$<E9(*KN#!E3"K53QH(IUH J(1*/R&](6G.IBHG>MZFC;KFJ
MK@S?+BA\?*#<R*(_52/Y(J7UD6CM)U+FBV_K%Q[0N&7'-QS%H&Z_QC9FU@F)
MB9Q\D#%(4-XAA*(Y\!!]R2QJ%NSIF=F7=W7MQ6*!% *M/8V7/^YY'R_^PD6Z
M//1DPG//4ZV:P4"*Q1TI.\5& 85%D63)MLT)WF!+Z,J [H*O9PSHD83:P7',
M)Q+7>EF7S*QKGL_J*M<7RSP7GB+YQU[6$TU,!I!%5T^9N,;HI<MM+N*?)&M<
MU(T$E;N '4QN'8#PSAJN[B.#9UX2U12$A7HVM2Y6S%"8\2B*B@K;F,<'R1D9
M=,.)^V[ZVL&\[P! 1/ZW^6SMR6YNH(N2A>+Y "G%"(I'!MZQ!$'*FG(?(O)&
M]9QW2>EACSQ(O'?S;P_B=0=@^7".L_?X[;*5@G#K<<@((H5J@Z,"QZ('H5VT
MAC,?<YNX]B85X]YF];&A[2V5CA"UT2X2>)*V2"B8Z] @3(#*23"1PF;2%52-
MO*;;=(QK>/:7YR/ V(.Y8V>7G7V;3</%LJ[@JE&"T<*;6$?TJ/5]FP,*6RQ$
M3VR(*09F[APU/I)==N_1?4A['R'-!^/8B/)>+E:3C]5,7HX-H_U5R,#!8JPU
M)YI<LX :I!)*6&:"8EL===!3;V@_?7=7\V^]=MRKYW&WD?WYWP-HKB9N":6"
MUH&<L5H"+W,M42=OJD0TJK:<BV6KPN[M83.F[3A 9'>%O@?_1A;[[]/9]-O%
MMZN4:?3*%L/)JM5N2UH)<$%Z,+F(PGA1J+:JX]I*\+=>/;+H]Q'<? @NCBS^
MS]-5M91O9VGZYS1=X&5C4PK:B701@14R=TH+!^AK=HQWR-!'X\Q6>4Y;P>!!
M$L9MX3#^%G*X7'H#UK^FJZ\?\_GE5(>OT^^?YZ]K2MA5UQ4IO$7%UV:7=$9Q
M2SIC"PCCO'$9<]FN7]%^D'N:N/%LTP P> I4 \ID9+C]-EWD2!]?V7&CY+IF
M)"<*\<C)ISB/7/Y: 6*UTNBRWNK(=BLTW7YW1V 94KSS07C=P1G)VUF<?\O7
MY]COZA]<U2_F1!&A<058;8^BDK& FAP!1"FXTM)PVZ:AT1-$C5M2W,>9W% R
MZQ=^&Y6T*D9><UI,,:1!UGEPI= _7)@<74G:MDE->)*L<8]T!A/^=J#:0Q(=
MP.I3/J>/OOPCS_*"O(19>I&^44Q2,Q)JSOWKOZO&UH%;EQ<EEEN4$B&O%Y<I
MQ@TR(=3DKF)]+C&TJ1O<B<PN8;<//.ZUK6TEJPZ >&GQKQJ$"Y5YB PA,FUJ
M*HP'<D\+6!9B4999%]ILJ+?(&+?\M(\M='^Y= "J_1GW<]FS=.=N  ,C#]=H
MJ H+*MB:X,\DL(@F>QN:S4-KL9IQ;>4!X'JH<F),27> ]CLIT5=A%E-<"8/@
M?2%7)X0 /D@!QFFIE#:TPC:F]$%R1LY"&ATE\Z%%U@'N/N3%.AU[%O.:>5<>
MB*:07B<30:M20#'RKYT6!7),7'(DA2YMO,5'"!HY2Z4W[ TAM@[0]RQ?'V/K
MN^LBXH"NK&=AF<!IQ5HS<$PQT%$9F:4JF!KEL1],^U:8MK^VBWID!/2 ^;I9
M?,S?+Q;Q:UW4NAYJ-:TS32[J,&Q2[>G\LG!T.;$< X_:0]2:@Y*RMJ9A@92:
MRU*T$IFW&5^["Y6=^P4#(^A>+GPC<?8'U0^+^9<%?ON8Z_9%2WM_4?><C?U8
MOKA8?9TOIO^=T^?YRWR#(Q/:R)*O5^,Y%07*"0MH(P)*KVPP)7%L=/(T"/V=
MNQY'A?<Q(- !\&^DF;_"[],5GE\ND%S^O/@SIS?SQ9N+5>WFNUQ>5"=L$H7T
M(FH!N;;553IZ6.>41*ZBL=+I6-JDW>Y,ZLB)>N/"N:U@.T#NWOQ=__-/"FFO
M]RP^*<P%%Q(%)\F%RND H1 $<[3HI&04P+3IM#SD*D;.*AK9?(\%AU-6A<NR
MI9]-]I9GJZ]Y\?DKSBX;6RTK7VK'T4O&3%!GCYXB]R)2HOC'1L!H*1SB,2C#
MHF?8ID/8L58X<CK"B:I02QB-75S2CBDW3K9>K%;D9=;?HA_&"KDO>9**3UB3
MCLC@E%J74<";'$'6O9AGSB6[T]CJL1;)8RUAY)O)<;3IA%!SLKIU%8QMMNW*
M+CP_7_-KPF72+G+:NQUF4%AJ>]@Z+8D7Z1@WD=C15FV>H&[D@]!3U(BA9-V!
MG_;B?/T[.3W,C$UJS"1J(XPJ$J*N:5]19/#9)_"6!<](MV-IXV5M1]]6&':_
M&(8;BG#4'M6-=ZO;CM_[O)H4S4T0,4%(O!X,L]H30=5!YED&[TLB[H_LU=PC
M>BO$^U\,\5TCXU0;X-WM$+AI!3AH"[QGWG&4)GB[K+-1.^3H*,K,!"2N(BBC
M-_D!7F1F<A ZRS8G>KVVP8L"8^).@S6B%K($"X&M:T$5*N2FD/O4YNSFEVR#
MMPN^VK7!VT6H/3C MS(I%;=96")9BF#J55D"9(A0N!%.<:%+:-.Y>_?TZ1-H
M<[<3%)Y,G]Y%+AV JDG*FF>Y)(L*F'2\<E, )FLAT]J5$%$FTR@=Y1=/G]X)
M7,=(G]Y%TAV@_>%<7!D#1AT=!%N;1S-%NY&C+2EJU+I6ZV37YE+^WR5]>B>4
M;)4^O8O(.L#=8WFX07@=5$A@F:/0DM/>XPQ38#@W*K#(-;:9C?WODSY]"/:&
M$%L'Z!O@#,2IQ)*(6#O6>.*B][72D)"5C;,ZH8^L387)D=*G3Z!QY2$NZI$1
M<,J8?_;L[?U\]N?Z^.WC_/S\S7Q1_VC"B D<;00>N 55)*.=J6A"M<U8E!:I
MY1REHZVS<]]D8!0?+</C8$C]>RC<Y65FO:17&+,!(>O@9A<CN$S*H6ST0H1D
M1.YL+]IUB2>J9D? ^?%5<@_0[:V-WR^+0%:X6'6ND_^@1ZR6USEI+-E /HBO
M;70#.<2AMEGQQ**0A)?.ZVP;E6X<:86=!T;_#AIY .1^Z>WQ3GHH>3@<HY(@
M'*^%Y:R ]T%!-#Q&CTRG--+9ZS&SC/LK3/F55/$ R.VNBOY2%6?Y2\T<^GP"
M&DG"*WEZDT/)DL"X"""+)&,E4()SRH)W@N? LZ,?G9A2WEODB1;0_$IZ>1CP
M_AU4\ZY;KW440G )D=4A$#YX\B)X 1>50R$9<:C- 7Q?L61_13F_DEH> KH#
M8\G7LS2<1H;GF1/N,N<N"_Z5IU^^TO\O_LP+_)+73OUO9#W>X'3Q3SR_R-<Y
M0J9((W,J4,AV@8HHP-OBR'XYKKF7PKE&TYR/OM83C2X'/%;M%UJ_=.RX/>\F
MTB=EO6=@4TW94ZC J1+!<&NCB,;:T%F1]X"K[^! MF,-.?Y&.BQ<_^W.:Y]G
M7T:98I0"--8YU5DA8 D1*+97(B&WFO,3T_8=6=#!GOP_*M\6N+_TUG[[C&X;
M@^FTC8%#1$X&LU#4Y$WMF6]#RDFDJ'O+\!F:!1T<+/^/QK<%[B^M\9O3OPL"
M[O-<B\F@\M&!UG5D*08-P6A6RQN=\LALUFURGOM8?P>'U?^CZPTA^TLK^@YA
MD. F6,M)$>LQJ))HP1>?@:%PW*? HV GIN8#1^UMC[[_1\F;P770D_&VE>RO
M__'[Z_>??WOQ^<5>1>HW_KQ%_?ECU U46OXI?ZFP^)B_SQ>U!\TU6BUF8V22
M8+VJ(P%E *^L)$OB6(K,1A4:M61_A*+#!VW=?NYOTV4\GR]I=_M,O'Q)O_J?
M$\D%#\)35,IK]F"R!EQ"A.AYH$ UZ;3=],F#%_T <2.?<@Z!D_OSM(85R8FT
MSOBITNO:D?UZ8]Q[2%OC\Q"EK4V0-[2[>*E 9F%(]!1%.FG(PY36""ME-JI1
M2\Y&)NACCO-9G)Y/UY(Y*V>TV>&Z.>MB7J:K=R2--Z1YF]<O/\]?T08]/Y^F
MRP2.*Y70AA>KM"'*DP6E7+W/\PEJ^];$.&E&;L.78>COU)#M@K;[9;!'%^S)
MV;I#&@'=?TI;:]>RF<^C -1687&% 8I8<Z9%K86E@-ISVO 2YU*T.O3ITMRM
MRRHE9SH'D\%KSD"Y'(@GN@ /T6C&;6!RJ^'R1S9UX[?T&01EPYJYG07:PS'1
MU139EQ?+Z2POEU=K6S?\D-;:5*0#;FNJF$L:G(@:=$R16U.8\XWN89\B:US@
M'1LC]T:=#"6P47M7WE'C3;<$94LHTB1@OC:8J6=)+O(,5C'FE".6I4;YL#?)
M&-FP#2?@AZ/1/7@]?IO3]Q=D\>I ZO/S:>W%@J60RFT:8ACR79TK$4I !2IH
M5\>Z.D@:DT'A*&8OS[E@S[ZEB^UN']G-6[!Q?$1\^/IC.8U3G-U9A0A%"8:D
M$MQ0C($U"3NB!:Y0>$-+80&W L,C+Q@Y,V<8' S!O!Z\ESM.X/7>//M2,X/?
MS!=/[\ZW-^=WUPG%C(NB#;&AE%KB*0J'(+( QGB)VH7"&WGEC18T+F;']I@Z
M $D'NO(Q_YEG%[DNC-:SCI7^-5U]?76Q7,V_Y<7KO^/Y1:J!U'))3D=E_-\3
MBTXK"IF <R2VBQ3!R\P!<^!.6N_(-C2*3G<FMHO]>5R0W8MFVTI\[!$DUQQ]
M.XNTH,K1E[G,%_FWZN&\B/]U,5U.UP"8I;>S5?ZR6,.A\H+^B)A>63Y-^?+'
MZTY_%W&UGH?Z+G_!\[??ON-TL;YIGJ57\P6)EH1S1A[,UUS+O:SUEN640.B:
M^B60=E^,#H22/@J3DI;;>1HC+Z0+CZ8+S>E!&CO!:FP5O"N\/V9X-63C>F6;
MN1K+"8^2:Y8HH/"9O%7K,J#U&E()60>>6 QL*WW9Y:TCI]7V!NYF NO P_DM
MTYOCI9=)7Y_GC9*^^%;7^M_KGT\P">Z4YQ3?1@IR/6UPR+@&(V-4V47B7)LC
MIFVH&SDOM".P-I/IV!;ST?WC8SZ_U,+E:CD1L403"ZLUV@[J&L!;JX%+%117
M3E(PM)6IW.IU(V<J=@2[1B+JP#C>\D->?<7%%S+PR(04B<)J+3VM(60+024&
MSO@8'&-1E#:-TQZB9N2)DQVA<#"9=8"[&ERN?KJ\5ZLHV6;#48#+,5>V) C<
M.,C2<:FC1>2-YN0]2,_(LQT[Q-X <NL ?0_$<A/F L_,2&"6D5?K&0.OLX3@
M,1;KDB>GH0GT'B!FY'F,'>+N4(F=1MK8J[/WG]^^_\?K]Z_>OOZT3\;8[0<T
M2!9[@L*!\L1>S;]]FZXNK[;K0<CF^"1.\_)GGO1U6D]2DN50,L2:'*UR#( &
M%<10HF.<H1-MCJ)W(O-0>[75RV[D4U)HXSDG?IC:<"I4-R Z!.<H3(_9:E1M
M_+?=Z!SW:+X=SN[:KH;2.PVS]O;]J[/?7W]^\?_M9]1N_GD#D_8H=0,9M,L=
MZS/^_0"L0A3,*9NAJ$);F*%_O-0,. 8I:7-T4;;I;_ $48<:JP<>?0/<G@>6
M90!;C[*5K]GF'!W(6+1626AEVXRL?(JJ<0W14/BX:W8&D\/)&9D#4NX?>$I;
MD],RY?XI9"6?K7 "P2L2N^*\#NUCM,L8I61D)6G9)MQI:'E>EY+K6.)\_8Z/
M%(%<;K@7M.=N@@@*3B:LZ"1C'= F:%-7V4:*'5BH!R=1JUK9FQK-$MZ:QGZM
MTB[8N6N5&LEH[//[[9=UG5]1&;O(JTUPC#$XM%R!HJB6##*Y?J'.U$1>3;4)
M4I?MCO8/I63<:_^A87=\X71PO/7';)'C_,ML^M_K[)V7>9;+=+6<R)Q+2H:!
M-[&0&E&,X:,3D"US@O%DG&I3YOT(0>->PK>R<$-POU\0??Z*JW_-+\Y3/02.
MJVO5VBC5)&C#>5 )D@R1C#86P-HLPWKB&RVR64?6_>@=]VK]R! <4G;](I28
MNLBXS,N/>7EQ7L]:UJF.%XLJD<O^;?3;'^:75[G+2< D:U(\!)^J<;>25HT9
M?&&B>.>0\39C,(:A?]Q;^B,CN*5L3R/,_?CZW8O/KW_[\.+CY__X_/'%^T\O
M7GU^>_9^KX.U1Y_5(.3=CNZ! M]-1L8'7*Q^?%[@;$EPK'CXV9,J<)U*8>!"
MG=/%9(; 1<W7,,(8X="S5AD.3U-V>#['P\]_Z Q(652.V0+.4VBEN(Q0!SU
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M76/C)4/, _[VQ%7KOK!Z9%>VUDW@2 2J+3)#]Y6)TA#VI\R4E@!XF4$0#D^
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MW8H(=E8 9VA_4 ?N[%,!T1!#<LS*LL?2&9Z*E2U]>,7"EY[D=LAON 42 YP
MHCS  [HX2G&ZH\QX[#Q$C/S M:-448(4(OI(5#>L2@/BDQF,-U9%%SC1Q?]!
M[UL7@!MQ>KL6K,#6]#IT&50N-SQP0>A<;"5+K_*5E'KTKZ;P,87*VU-N/$?U
M-=%7BCD5];$6_*).KF[ TP5?FH/GM.YS6O>?D=:]BP)?8USX4.G4O\C'[<XI
M4X <50UOSJ,+T$_GPL KI0784K26$U ?M8"3DC@>.,E\C0F=-DW<B K"/EZ"
M'< E^+K,#NI!MYIPV8-EYQ#.&_8;7#T^*;A<?=\-CIQA9\V*O^OJN*&?3431
MP?%[$:.>U]COTI!_'*''AO?OY 24*#,%>,J(''@0'F)D$+EL2)&O<BHP6( 2
M2+2A@;$K-PD^$0*(M?A=Q)# C86R9?OFQ3:1OA+RICQ[_WAQ]@G1(VDXY966
M6\*K7#]0@NL@<A])@,O:(8G.EB!Z=.7[1TNBY6SZ>4$Q%CLQF'M!,>S%YV>\
MWPWOO_/(.2"DL01ZZ(.)61I*C^'=:S]3T]UE:YX1?C/"SR3<=RIL[]R'ZYUG
MP-\-\'"I-M@)5.5\\SZ<[S]S_FZ<?Z-2B7PNF;Z.>58UB56F)><R9DDYN!(
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M!'L#8OI8*DA$7=Z(3D_$"]\T.DW"6WB5E,7F :34/R/V6L%NP!+ILO= Z=I
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MI!1[,'!XW9X%>LBB(=C3AEQSJ$NW6X-]8@1?2 M*I-/?WOVPX3Q%]ZM0!$M
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M9&_()OV'&^A$F^E8"@"CBN&+3=%4\'L*RB&;\V'9YZ'^2'1^;/0DN%7[EW
ML87O>(*&5BSH;B<TJ^P538 Q))GUD!E8I 6VS( 06,E/I@HS6P_8%E3X+*!V
M>+NE-XCMJ0%KU.%WX8D.R/%'V!7$ZB$TRGRBU410?,SYJ#J)-Q4WBJQ0>B90
M.QWK0(A\#<  W!^2/#1W)W];/PLZO\FJ)(8 H3 -F%OQPHK!_,<YR+M0?#:0
MN3>:;W2^CBOZP#ZA"("DHAK%#QBJJV_OKUXU^^T^?7YW!O^3^<#5E_FF_S+?
M<LEF7:_9[9SNK&TWHYUUG^NUTVZVH]X?WFV_T^R^W-UTM=N6-T0P!LQM"YZ_
MKG5K\P85) >=XH%%\W4:K$LH?6SQ8.R_?NWZ*Q776 _K0:^:_#<^K_=\QD[K
M_A;+,YO9\5$/Y.*?C^\;K,UT3Y"V:<*UO:RSAVA%1DX7 \@R?T;)YC9YHI71
MR5<R\6.S#LWE!VS\)45:=GS4/3MG5V,ITK!MN7D0<4G'".RGD$&3_,F'<*C$
MU2.A\%I)OMCT6,OS]%,NB'S^3L:CZU2%#O?)!N&L>2(V+E@M7>E#1'O9A _A
MS]+M;K+K=M#.VUK5,]P=\[?8+O\/4$L#!!0    ( &Y+I52G_T6?(P@   \H
M   :    8V-R;C(P,C(P,S,Q+3$P<65X,S%X,BYH=&W=6FMSVS86_;Z_ I6G
MKC.C%_7P0W8\D]CNQ)T^LAGO9O=3!R) "6N08 %0LOKK>P"0>EC21FZ:1K9G
MHHC$Z^+>@W,/(%Q\<_W+U=U_W]^0L4TE>?^OMS_>7I%:H]7ZV+UJM:[OKLF[
MNY]^)+UF.R)WFF9&6*$R*ENMFY]KI#:V-A^T6M/IM#GM-I4>M>X^M%Q7O994
MRO FLZQV>>'>X)-3=OF/BV\:#7*MXB+EF26QYM1R1@HCLA'YR+BY)XU&6>M*
MY3,M1F-+.NU.AWQ4^EY,:"BWPDI^6?5ST0K/%RT_R,50L=GE!1,3(MCKFC@>
MMD_;_8C%9V?'/1XQ>L9ZM)\DO=/3*.J==7Z-8&0+U4,;8V>2OZZE(FN,N1M_
MT.LT3_JY/9\*9L>#J-W^MN:K7EXD*K,83Z-]^!JZ6>O,\@?;H%*,LH&?4BTT
MK8IC)94>'+3]W[DK:20T%7(V^.Y.I-R0G_F4?% IS;ZK&X2A8;@62:AHQ.\<
M-L$\_S@-)I^@'RDR7DTAZCBC;_[S[O;M[1WI1LW.JL6;;?U?8:Q(9E_<VMY&
M:P\/HN/V^2YVQ@ !UU_)J5=<PTDBIFYM/%NO?AUC;NODHY!2T)3\T"1O"YV9
M.HF]0V?$CJD]/.B?;C-VP\+[1-E\;5,]PO(>*FM5.CB&J3EE#!S4D#RQ@ZY[
MXP,F,@9H#1K1:?[EU^QF%T7-:AI__^BK;HG:S;YSPRT9TPDGFD\$GX*][5@8
M\EM!-=:@G.%]KK0E*B/?*YT&N$7MQC^)2LB55L: V8O,ZAEYQZFTXYAJ7B>W
M6=Q$L,^VK_?G%+3.W@7M+34(%8*2SLA]IJ:2LQ'<[F-71HPIF) II&6,0$5&
M:#8C+E(%QPR0J'W.1A0I2?&D!94DH3%>::)288E5H=Y:A8S'W!B*D*-*2N\Y
MQEWJT^ =@S$84OJ$CS%<A5AH)'A4R] <EC"NR70LXC$QA?M8M)]RS<M.W 12
M8224@!,54V''F*#)>>P-=/WF,$TQ3'."9HP,9\MN>#D@[#X?$'*2B QA=HA9
MA+4.!*(ZBO52N<@2\(K/MO@>RX*A3T!G*89UP$XX+LH1>0=:!V8I%Z@L 6$>
M#0W@,R]QZZY&(5$!4%3 BQ_.>'MB:L8DD6IJ*IQJ/A+&0A];0MW+8#>LK"_!
MS53&K%GK$4=>!.1Z>P>YNY7X'!Z<=J*3<U."JE0:CB=4 @F'5RYRMP0IR6,$
M,1=#R5TL"0<PAU*8L:ONJJ7@2,>3[ID)$TME"K1S[*F5#&#)M8HYPVM#CH -
MQ@&V (";AWA,LQ$G;T!,'PJ)&E&7-J+^$7_EFT9]%I["HW 2-PL@=?T3QUY+
MV U8<K;L/%"R,E""@=P\'R,:-5R^]TKL3Z/TI+-'**7[@]*HV3YQ?KCF!EL#
M!,QGMD^CJ>Z2;DP+LWL3E_V&',@H1PKY5!4:'8"B)L)XXD,MGOE^G/Y>4.8R
M[6HNJ8=:F5 7<*F7E.P*!>@3MA@E!?/;?%,,C6"":N$F($+:]XD@<ST5QJ5B
MOS*-S]N>)I7A, @;?-\HA\H4<2&I8W=,RQNQ2.EH$03"LJ[!MR%W%4' :,_9
M9Z7XO4+R<'^07/+M*I!W)JTU/.].=SO#&DMA(IA#*S4JHX[7J0'2G;QT$*::
M57 "P 4="BGLS"7Y3<.ZQ>61YT$5UL5*U25YZM/'0SFAO- Y0&V\*(ECI9DW
MP O5$<^@-22PC1*>NT7CJD"$!_QB<8D<#/YYDF&O(!SO#X0K,KZ94%EXQG(!
MYDD"J2@F"(W9(/GFDF('!@Z/FU6@ARP:@CU-T)I#5=CM%NR2(^B\-G=".OGT
M[H<,*XGN5R$/GH ] 7%N@!>!.K8_J*N(,\1S'1=N%UXJ.%^R$7Q/H$N7U54<
M%]I%?RF%;N@U5<;BO3M>15\F1D?E.0\YVM(D 8Q!9(]JEX9CZ\3] 8([6\B*
MN5VO@E5C:N9ZPU&@ASUG/C=X?Y2\/2-2W'-9GB8\JE__;!?-H1[.KM8_7\16
MK;]W*^#/;=7\622K%D]]06".3Y<!O. R!\$G*),UD3LWC4+H6J7-7 SX%^@R
M386UW&-]0[.A@M1P94S -M_!$2 .8C:.^/&_D]K5NN2_%0*F^S589+$_B'BU
M^5S\.3+Q'F[&WDBH-ZA)_ZL.;'*;Z5AP */,X?--T933>Y>4@YKS:=GK4'\D
M6AT;/0ENY?XE'$!LX#O*T-#P.=UMA6:I7M$$&(/(K =E8" +3)$"(?"2GTR9
M9C8>L,VI\$5 ;?]V2V^0VQ,-UJ@C[MP3'9#CC[!+B-5#:A391,D)=_DQHZ/R
M)%Z7W,C37*H91^ETK (ATA4  W!_B7AH;A=_>_K[IO7;O-*$(98!UPU8(FEN
M^*#Z<H[TD4LZ&XC,]^<;G:\BV_W^/W$Y"+*FG*>?<B@NKP:<G35/VB?N=H#5
M^,>J@<N+ TU_<:!EV7I9K]GM]+>6MIO1UK+_UVNGW6Q'O;^\VY-.LWN\O>ER
MMRWOB. ,N-OD-'M=Z]:J!N6B&'3R!Q)53!&\Z];)8X\'9__]P/(W/JZQ(E?3
M;CGY9SZOG^B,].O^DLT+F]GA00_TYC_7KAFL3'5'E+;=C&L[N6>'JB4;694/
M4)?X8U)2.>6);D8G7\G':WX=ZLN;!QX7[KR"_!M"G;S7T$0N^9/#@^[I.;D:
M"YX$FOZ^RC'A\9=2V7^!OZ/WX? ,Z>S-XD3-Z9^Y#:0<_M4Z-EH^)3SQELFC
MVV.Y"M?G!N'T?,+7[I,MD.%33GO1A X!C\)N;[+M,M36RVGE9[@JYR_M7?X!
M4$L#!!0    ( &Y+I51E*_U!=04  %43   :    8V-R;C(P,C(P,S,Q+3$P
M<65X,S)X,2YH=&W=6-MRVS80?>]7;.2I8\](I*B+=8UG'%F9J)/8CJU,VJ<.
M1( B&@A@ -"R^O5= )+CR%;K=)KFH@>.2.SE[&*Y>\#AD]/ST?2WBS'D=B'@
MXNWS5Y,15&IQ_*XYBN/3Z2F\G+Y^!:VHGL!4$VFXY4H2$<?CLPI4<FN+?APO
ME\MHV8R4GL?3R]B9:L5"*<,B:FGE>.B>X)41>OS3\$FM!J<J+1=,6D@U(Y91
M* V7<WA'F7D/M=I::J2*E>;SW$*CWFC .Z7?\VL2UBVW@AUO[ SC<#^,O9/A
M3-'5\9#R:^#T68633KO=/6K.6EF#MA)*>IW.;-8E7=9KS#JMM/E[@B!C% \Z
MQJX$>U99<%G+F?/?;S6B3KNP@R6G-N\G]?K/%2]Z/,R4M.A/HW[X&\S<,V;9
MC:T1P>>R[T.J!-7-<JJ$TOV]NO\-W$HM(PLN5OVG4[Y@!L[8$B[5@LBG58/;
M4#-,\RP(&OXG0TP(S]\N ^0.VA%<LDT(2<.!'O_Z<O)\,H5F(TH^1?PPUC]*
M8WFV^N)H6P^BW=]+CNJ#Q^!,L0B8_DI)'8TOIY,7D]')=')^AB_1Y=7;D[,I
M3,\AZ<+;Z"H:17 U'OG5I-FN_QB)YY)BTOO-H^++%_/#*"<24B4E2UU/@B6W
M.=B< 4E3M2B(7+F6\J8D&BM#K."2%4I;0,D72B]"A$F]]@94!B.MC,%^4TJK
M5_"2$6'SE&A6A8E,(SAP9D?!Z"%D2GL_'VY-%XA?46"8$0JOB4[S8+Z95'WK
MJ@8+^WO-UN#"R_)TC<<_.T0_5?A%Y1).(F? <FFJ<*&9X2[)0"2%4<Y9!N,;
MEI:67S,XSS*>,NW@WX%7A9QI-EL!+KD"@J+4IB1HPRHLQX!K4Y,A<^M48&%6
M@1@@5!6N)=]5_$2R5S_:.+TB>D8D,[7S&\%6<)):M]*HUS%DFQ.ONUC!>ZF6
M@M$Y\TI;&8"L%)A#MV>"8W'<[J-F'TJNF>OOQIG=@GM #@%W(FD?T,-;/)@<
MC2,*S8QOTIQ(=+D&E?2:+9_'@ N%N<2=7!!?/%A'EF"!47SZ,$C"_4[CEC@\
M52='A #41TDB$*TI$*"I>O6,2R)3]QPM4S\TO7.4*D4(1V'5>.=F:PNC[ZT_
M6#(3; -AIC1ENH9(!"D,ZV_^#"@WA2"K/I?>GE<:+(B>XYB=*6O5HN]&[+6K
MVY2(=9P^Y+"\GKZ]7M1M-]T MCAU+=TX7L_FR,_FV-+[:RT<XD<[5^M1LG/M
M[ZPFO:C7;?[G9CM)U#O:K7K7;.P3$9*!Z3981,\JS<I&H2"48BOL-XH;2###
M=ZI(L.Q>QD.R___"\J3J%%^G_;UV=[ U@=8I^,ZC>TU6T XCX0>+;'^OU1D8
M?]V>8Y]$^LA2K;N *X_*SB-$URW)JJ*/LF"4X!0V.?G,+*.1KY3B[;3BF>,C
M04 :T1T$BA#>G'L\P<D?7&B.4ZD@8DLHW*XE#^_O6.R[]9V)M//@\^VQQ!,P
MN'$XV14>O' LBS!N.3(-I J6202$7<<?1]>4@P(2J&W.4W5L0^&<UD WQU=2
MXKUT]8%;,D?ZE&ZHCK_=*"RY88%7.4KJ1KV#1&RI6: CI"@8T<:3CU6!_ATS
M\4QH34>80#1:220D6)#&T8E_&T6.'&_&4*'0ZIH[QHHD[1\(L*,N2XYT9^9H
MV9HIH?5'J&6EEMSDP<T61W/KMSP-V<^"FQ":!HXD"2/*,B@+?.)"8L9^=]3H
M6WTIIHZC*LWFRE5D."OX*L9<8TW=E@;V2H:TUQUY\#Q0*,,\6_5DW9^O;MFZ
M5S$;.OOY!X;=6[OU#09!>#[=UTP0U[SN?97YV/<]JZQ_5"$S#*BTNU5V?5+8
M^8EG?0T?G/RGK^._ %!+ P04    " !N2Z54M5QM58D%  #4$P  &@   &-C
M<FXR,#(R,#,S,2TQ,'%E>#,R>#(N:'1MW5A9<]LV$'[OK]C(4\>>D7CHL*PC
MGG%D9:),8CNV4K=/'8@$330@P0"@9?77=P&0BF-9K=-IFD,/')'8&Q]W/W#\
MY.1L,O_M? JISCB<OWO^>C:!1LOWKSH3WS^9G\#+^9O7T/6"$.:2Y(II)G+"
M?7]ZVH!&JG4Q]/WE<NDM.YZ0U_[\PC>FNCX70E$OUG'C:&R>X)62^.BG\9-6
M"TY$5&8TUQ!)2C2-H50LOX:KF*KWT&I54A-1K"2[3C6T@W8;KH1\SVZ(6]=,
M<WI4VQG[[G[L6R?CA8A71^.8W0"+GS788=!>=*)VK],_H%T:#@9AD,0#&@UH
MMW_0'X2_AQBDC^).1^D5I\\:&<M;*37^A]VVU^\5>K1DL4Z'81#\W+"B1^-$
MY!K]2=1W?YV9#6.:WNH6X>PZ']J4&DZU7HX$%W*X$]C?R*RT$I(QOAH^G;.,
M*CBE2[@0&<F?-A5N0TM1R1(GJ-B?%&/"\.SMTH7<1SN<Y;1.(6R;H*>_OIP]
MG\VAT_;:GT;\<*Q_E$JS9/7%H^T^&.WN3G@0C!X39X0@H/(K%74RO9C/7LPF
MQ_/9V2F^1!>7[XY/YS _@_ 0WGF7WL2#R^G$KH:=7O!C%)[E,19]V#DHOCR8
M'XYRED,D\IQ&IB?!DND4=$J!1)'("I*O3$MY6Q*)R. KN*"%D!I0\H60F<LP
M#%IO020PD4(I[#=EKN4*7E+"=1H129LPRR,/]HS9W9U.=S1QENW_?4B$M!X_
MK)T4F(F(@6)M8GA#9)0Z1YVP:9M8\XZM<RO+HBHR9Q,]-N&*<<Y(!J\\>%[*
M7#5A>DNC4K,;"K^PB,*YI(J9\@/)8YBDC";P@N4DCQCA<)8D*"1-8L99%7,3
M4BKI8@6X9* %12E52="&%@A4%V>-5E?3JD@(V280!206A6G6=Q4_D1P$![73
M2R(7)*>J=7;+Z0J.(VU6VD& )= IL;K9"M[G8LEI?$VMTKV*0%)RK*G93<X0
M-NL=EO1#R20UG5\9L_?"W2/[@#L3]O;B_74\6#^)PPO-3&^CE.3HL@HJ''2Z
MMHXN+A1F.>YL1BRL$&&:(/1B?/IPD(39G<<M,?$TC1SA'% ?)7$[<*'  %73
MJB?K;4++L1VGUCE*E=RE(Q!%UKFZMX7>]]8Y-%EP6H>P$#*FLH61<%(H.JS_
MC&*F"DY60Y9;>U9IE!%YC0-X(;06V= ,WQN#VXCP*D^;LENNYO)@X/6#OAG-
M&N>QCFO'U=3V[-3V=;RYUO4Z[=[6U< +MZ[]G=5V@+2I^Y^;[;>]SL%VU;MF
M?5L(5PPLMT(0/6MT&K5"0>(8F^2P7=Q"B!6^@R).DXV*NV+__\"R=.L$7Z?=
MG=[AQZE4)?^=Y_6&K*#GAL,/EMGN3K<_4O:Z,=$^2?61* U,QHU'E><1HE4W
MTJ(8HBPHP5D,=5$^L\QHY"O5>*.N>!+9RA6081R.'%MP;7I-&=QMS1N^P&_O
M7#+T5.#8.T9ZACS+D#,S]S9HR_XF-GP[$NZ,O:WGKF^/I!Z#0H@@?1!X[L-<
MN9OI#.D,\A%-<PP(6YL]#5>\)@9D:?>)5=-0&H%D0$)<GYY)B?>Y0:(I)W*T
MJ.93]K966#)%'7DS13=\PH1$="FIXSRD*"B1RC*<58'^#?VQ=*OB/)1C-%+D
MR'H0^LIPEG^;18I$<D%1H9#BAAF:C$SP'_BWP<D2D8Z*:+VB8VC]$6H)OA5,
MI<[-/2)HUM=D$"E6QI1+30)#)H89)0F4!3XQ*5&EOSO^]:V^%'-#A(6DU\(@
MTAU(+(JQUHBI-32P*U/DUN:<A8>.0BAJ*;$]$=CCW?I(8%54S9D__U2R?6OO
M?0+"("QI'TK*B>FR&Q^%/DX82UV#CRID@0F5>KO*MB\:6[\P55?WO<M^>3OZ
M"U!+ 0(4 Q0    ( &Y+I53HYF?C_Y<! &>>$0 1              "  0
M  !C8W)N+3(P,C(P,S,Q+FAT;5!+ 0(4 Q0    ( &Y+I51J6 Z4A1$  !>Q
M   1              "  2Z8 0!C8W)N+3(P,C(P,S,Q+GAS9%!+ 0(4 Q0
M   ( &Y+I50Z!%)F:1\  *A  0 5              "  >*I 0!C8W)N+3(P
M,C(P,S,Q7V-A;"YX;6Q02P$"% ,4    " !N2Z54;(>%?KU+  !G3P, %0
M            @ %^R0$ 8V-R;BTR,#(R,#,S,5]D968N>&UL4$L! A0#%
M  @ ;DNE5$2XH!3F2@4 O[0& !0              ( !;A4" &-C<FXM,C R
M,C S,S%?9S$N:G!G4$L! A0#%     @ ;DNE5'4,6O2CR   %W8( !4
M         ( !AF ' &-C<FXM,C R,C S,S%?;&%B+GAM;%!+ 0(4 Q0    (
M &Y+I51\%>3]AX$  %/2!0 5              "  5PI" !C8W)N+3(P,C(P
M,S,Q7W!R92YX;6Q02P$"% ,4    " !N2Z54N&Y1EL$+   K.0  &@
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A<65X,S)X,BYH=&U02P4&      P #  T P  )=,(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
